RESEARCH OPPORTUNITIES ALERT!

Issue 24: Volume 1b
GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (NIH)

(QUARTER: JANUARY – MARCH, 2016)

A Compilation by the
Research Services Unit
Office of Research, Innovation and Development (ORID)

December 2015
# TABLE OF CONTENT

## OPPORTUNITIES FOR JANUARY 2016

<table>
<thead>
<tr>
<th>Grant Type</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>R03</td>
<td>SMALL GRANTS PROGRAMME FOR CANCER RESEARCH: AIDS-RELATED</td>
<td>36</td>
</tr>
<tr>
<td>R01</td>
<td>GLOBAL BRAIN AND NERVOUS SYSTEM DISORDERS RESEARCH ACROSS THE LIFESPAN</td>
<td>37</td>
</tr>
<tr>
<td>R01</td>
<td>GLOBAL BRAIN AND NERVOUS SYSTEM DISORDERS RESEARCH ACROSS THE LIFESPAN</td>
<td>38</td>
</tr>
<tr>
<td>R03</td>
<td>BRAIN INITIATIVE: TECHNOLOGY SHARING AND PROPAGATION</td>
<td>39</td>
</tr>
<tr>
<td>R21</td>
<td>BRAIN INITIATIVE: FOUNDATIONS OF NON-INVASIVE FUNCTIONAL HUMAN BRAIN IMAGING AND RECORDING - BRIDGING SCALES AND MODALITIES</td>
<td>40</td>
</tr>
<tr>
<td>R01</td>
<td>RESEARCH ON ALCOHOL AND HIV/AIDS</td>
<td>41</td>
</tr>
<tr>
<td>R01</td>
<td>DRUG ABUSE ASPECTS OF HIV/AIDS</td>
<td>42</td>
</tr>
<tr>
<td>R01</td>
<td>HIV INFECTION OF THE CENTRAL NERVOUS SYSTEM</td>
<td>43</td>
</tr>
<tr>
<td>R21</td>
<td>STRUCTURAL INTERVENTIONS, ALCOHOL USE AND RISK OF HIV/AIDS</td>
<td>44</td>
</tr>
<tr>
<td>R01</td>
<td>RESEARCH ON MALIGNANCIES IN THE CONTEXT OF HIV/AIDS</td>
<td>45</td>
</tr>
<tr>
<td>R01</td>
<td>DRUG ABUSE PREVENTION INTERVENTION RESEARCH</td>
<td>46</td>
</tr>
<tr>
<td>R01</td>
<td>HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE</td>
<td>47</td>
</tr>
<tr>
<td>R01</td>
<td>INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH</td>
<td>48</td>
</tr>
<tr>
<td>R21</td>
<td>DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH</td>
<td>50</td>
</tr>
<tr>
<td>R03</td>
<td>IMAGING – SCIENCE TRACK AWARD FOR RESEARCH TRANSITION</td>
<td>51</td>
</tr>
<tr>
<td>R01</td>
<td>HEALTH DISPARITIES IN NIDDK DISEASES</td>
<td>51</td>
</tr>
<tr>
<td>R03</td>
<td>SMALL RESEARCH GRANT PROGRAMME (PARENT R03): AIDS-RELATED</td>
<td>52</td>
</tr>
<tr>
<td>R21</td>
<td>EXPLORATORY/DEVELOPMENTAL RESEARCH GRANT PROGRAMME (PARENT R21): AIDS-RELATED</td>
<td>53</td>
</tr>
<tr>
<td>R21</td>
<td>DRUG ABUSE ASPECTS OF HIV/AIDS (R21)</td>
<td>54</td>
</tr>
<tr>
<td>R03</td>
<td>DRUG ABUSE ASPECTS OF HIV/AIDS (R03)</td>
<td>55</td>
</tr>
<tr>
<td>R21</td>
<td>DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R21): AIDS-RELATED</td>
<td>56</td>
</tr>
<tr>
<td>DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R03): AIDS-RELATED</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>RESEARCH ON MALIGNANCIES IN THE CONTEXT OF HIV/AIDS (R21)</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>BIOLOGY OF MANUAL THERAPIES (R21): AIDS-RELATED</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td>NEI RESEARCH GRANT FOR SECONDARY DATA ANALYSIS (R21): AIDS-RELATED</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>PRESCRIPTION DRUG ABUSE (R21): AIDS-RELATED</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R21): AIDS-RELATED</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R03): AIDS-RELATED</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>PILOT AND FEASIBILITY CLINICAL TRIALS IN DIABETES, AND ENDOCRINE AND METABOLIC DISEASES (R21): AIDS-RELATED</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>EXPLORATORY/DEVELOPMENTAL BIOENGINEERING RESEARCH GRANTS (R21): AIDS-RELATED</td>
<td>65</td>
<td></td>
</tr>
<tr>
<td>BIOENGINEERING RESEARCH GRANTS (R01): AIDS-RELATED</td>
<td>66</td>
<td></td>
</tr>
<tr>
<td>BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R01): AIDS-RELATED</td>
<td>67</td>
<td></td>
</tr>
<tr>
<td>BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R03): AIDS-RELATED</td>
<td>68</td>
<td></td>
</tr>
<tr>
<td>MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R21): AIDS-RELATED</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R03): AIDS-RELATED</td>
<td>71</td>
<td></td>
</tr>
<tr>
<td>MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R01): AIDS-RELATED</td>
<td>72</td>
<td></td>
</tr>
<tr>
<td>RESEARCH PROJECT GRANT (PARENT R01): AIDS-RELATED</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td>RESEARCH ON ALCOHOL AND HIV/AIDS (R21)</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td>RESEARCH ON ALCOHOL AND HIV/AIDS (R03)</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>MOLECULAR GENETICS OF DRUG ADDICTION AND RELATED CO-MORBIDITIES (R01): AIDS-RELATED</td>
<td>76</td>
<td></td>
</tr>
<tr>
<td>PRESCRIPTION DRUG ABUSE (R01): AIDS-RELATED</td>
<td>77</td>
<td></td>
</tr>
<tr>
<td>FUNCTIONAL GENETICS, EPIGENETICS AND NON-CODING RNAs IN DRUG ADDICTION (R21): AIDS-RELATED</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R21): AIDS-RELATED</td>
<td>79</td>
<td></td>
</tr>
<tr>
<td>Topic</td>
<td>Page</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td>INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td>RESEARCH (R03): AIDS-RELATED</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R21)</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R03)</td>
<td>82</td>
<td></td>
</tr>
<tr>
<td>NEUROSCIENCE RESEARCH ON DRUG ABUSE (R01): AIDS-RELATED</td>
<td>83</td>
<td></td>
</tr>
<tr>
<td>NEUROSCIENCE RESEARCH ON DRUG ABUSE (R21): AIDS-RELATED</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td>NEUROSCIENCE RESEARCH ON DRUG ABUSE (R03): AIDS-RELATED</td>
<td>85</td>
<td></td>
</tr>
<tr>
<td>DEVELOPMENT OF ASSAYS FOR HIGH-THROUGHPUT DRUG SCREENING FOR USE IN</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td>PROBE AND PRE-THERAPEUTIC DISCOVERY (R01): AIDS-RELATED</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEVELOPMENT OF ANIMAL MODELS AND RELATED BIOLOGICAL MATERIALS FOR</td>
<td>87</td>
<td></td>
</tr>
<tr>
<td>RESEARCH (R21): AIDS-RELATED</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIDS-SCIENCE TRACK AWARD FOR RESEARCH TRANSITION (R03)</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>BIOENGINEERING RESEARCH PARTNERSHIPS (R01): AIDS-RELATED</td>
<td>89</td>
<td></td>
</tr>
<tr>
<td>BIOLOGY OF MANUAL THERAPIES (R01): AIDS-RELATED</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R01): AIDS-RELATED</td>
<td>91</td>
<td></td>
</tr>
<tr>
<td>NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R03): AIDS-RELATED</td>
<td>92</td>
<td></td>
</tr>
<tr>
<td>NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R21): AIDS-RELATED</td>
<td>93</td>
<td></td>
</tr>
<tr>
<td>SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG</td>
<td>94</td>
<td></td>
</tr>
<tr>
<td>ADULT POPULATIONS (R01): AIDS-RELATED</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG</td>
<td>94</td>
<td></td>
</tr>
<tr>
<td>ADULT POPULATIONS (R21): AIDS-RELATED</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>ADULT POPULATIONS (R03): AIDS-RELATED</td>
<td></td>
<td></td>
</tr>
<tr>
<td>THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R01): AIDS-</td>
<td>96</td>
<td></td>
</tr>
<tr>
<td>RELATED</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R01): AIDS-</td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>RELATED</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GENETIC EPIDEMIOLOGY OF SUBSTANCE USE DISORDERS (R03): AIDS-RELATED</td>
<td>98</td>
<td></td>
</tr>
<tr>
<td>GENETIC EPIDEMIOLOGY OF SUBSTANCE USE DISORDERS (R21): AIDS-RELATED</td>
<td>99</td>
<td></td>
</tr>
<tr>
<td>NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH SMALL GRANT</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>PROGRAMME FOR NEW INVESTIGATORS (R03): AIDS-RELATED</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R21): AIDS-</td>
<td>101</td>
<td></td>
</tr>
<tr>
<td>RELATED</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program</td>
<td>Page</td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td>Health Promotion Among Racial and Ethnic Minority Males (R01)</td>
<td>102</td>
<td></td>
</tr>
<tr>
<td>Epidemiology and Prevention in Alcohol Research (R01)</td>
<td>103</td>
<td></td>
</tr>
<tr>
<td>Epidemiology and Prevention in Alcohol Research (R21)</td>
<td>104</td>
<td></td>
</tr>
<tr>
<td>International Research Collaboration on Alcohol and Alcoholism (U01)</td>
<td>105</td>
<td></td>
</tr>
<tr>
<td>Alcohol Use Disorders: Treatment, Services and Recovery Research (R21)</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td>Programme for Extramural/Intramural Alcohol Research Collaborations (U01)</td>
<td>107</td>
<td></td>
</tr>
<tr>
<td>NLM Express Research Grants in Biomedical Informatics (R01)</td>
<td>107</td>
<td></td>
</tr>
<tr>
<td>Epidemiology of Drug Abuse (R01)</td>
<td>108</td>
<td></td>
</tr>
<tr>
<td>Epidemiology of Drug Abuse (R03)</td>
<td>110</td>
<td></td>
</tr>
<tr>
<td>Secondary Analyses of Existing Alcohol Epidemiology Data (R03)</td>
<td>111</td>
<td></td>
</tr>
<tr>
<td>Secondary Analyses of Existing Alcohol Epidemiology Data (R01)</td>
<td>112</td>
<td></td>
</tr>
<tr>
<td>Behavioural or Social Intervention Clinical Planning Grant (R34)</td>
<td>113</td>
<td></td>
</tr>
<tr>
<td>Research to Advance Vaccine Safety (R01)</td>
<td>114</td>
<td></td>
</tr>
<tr>
<td>Research to Advance Vaccine Safety (R21)</td>
<td>115</td>
<td></td>
</tr>
<tr>
<td>Pilot and Feasibility Clinical Research Grants in Urologic Disorders (R21)</td>
<td>116</td>
<td></td>
</tr>
<tr>
<td>Secondary Analyses in Obesity, Diabetes, Digestive and Kidney Diseases (R21)</td>
<td>117</td>
<td></td>
</tr>
<tr>
<td>Pilot and Feasibility Studies in Preparation for Drug Abuse Prevention Trials (R34)</td>
<td>118</td>
<td></td>
</tr>
<tr>
<td>Renal Function and Chronic Kidney Disease in Ageing (R21)</td>
<td>119</td>
<td></td>
</tr>
<tr>
<td>Pain in Ageing (R21)</td>
<td>120</td>
<td></td>
</tr>
<tr>
<td>Pain in Ageing (R03)</td>
<td>121</td>
<td></td>
</tr>
<tr>
<td>Pain in Ageing (R01)</td>
<td>122</td>
<td></td>
</tr>
</tbody>
</table>
ANCILLARY STUDIES OF ACUTE KIDNEY INJURY, CHRONIC KIDNEY DISEASE AND END STAGE RENAL DISEASE ACCESSING INFORMATION FROM CLINICAL TRIALS, EPIDEMIOLOGICAL STUDIES AND DATABASES (R01): AIDS-RELATED ........................................ 123
SECONDARY ANALYSES OF EXISTING DATA SETS AND STORED BIOSPECIMENS TO ADDRESS CLINICAL AGEING RESEARCH QUESTIONS (R01): AIDS-RELATED ...................... 124
DRUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R21): AIDS-RELATED .......... 125
DRUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R01): AIDS-RELATED .......... 126
BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R34): AIDS-RELATED ........................................................................................................... 127
DEVELOPMENT AND CHARACTERISATION OF ANIMAL MODELS FOR AGEING RESEARCH (R01): AIDS-RELATED ...................................................................................... 129
NEI CLINICAL STUDY PLANNING GRANT PROGRAMME (R34): AIDS-RELATED .......... 129
ACCELERATING THE PACE OF DRUG ABUSE RESEARCH USING EXISTING DATA (R01): AIDS-RELATED ........................................................................................................ 130
OBESITY POLICY EVALUATION RESEARCH (R01): AIDS-RELATED ................................ 131
NIDCR SMALL RESEARCH GRANTS FOR DATA ANALYSIS AND STATISTICAL METHODOLOGY APPLIED TO GENOME-WIDE DATA (R03): AIDS-RELATED ................... 132
STIMULATING HAEMATOLOGY INVESTIGATION: NEW ENDEAVOURS (SHINE) (R01): AIDS-RELATED ........................................................................................................... 133
STRUCTURAL INTERVENTIONS, ALCOHOL USE AND RISK OF HIV/AIDS (R01) ....... 134
CALCIUM OXALATE STONE DISEASES (R01): AIDS-RELATED ........................................ 135
UNDERSTANDING AND PROMOTING HEALTH LITERACY (R01): AIDS-RELATED ......... 135
UNDERSTANDING AND PROMOTING HEALTH LITERACY (R03): AIDS-RELATED .......... 136
UNDERSTANDING AND PROMOTING HEALTH LITERACY (R21): AIDS-RELATED ........... 137
ALCOHOL USE DISORDERS: TREATMENT, SERVICES AND RECOVERY RESEARCH (R03): AIDS-RELATED ........................................................................................................ 138
ALCOHOL USE DISORDERS: TREATMENT, SERVICES AND RECOVERY RESEARCH (R01): AIDS-RELATED ........................................................................................................ 139
NINDS PHASE III INVESTIGATOR-INITIATED EFFICACY TRIALS (U01): AIDS-RELATED ................................................................................................................................. 140
NINDS EXPLORATORY CLINICAL TRIALS (R01): AIDS-RELATED .................................. 141
COLLABORATIVE CLINICAL VISION RESEARCH PROJECT GRANT (U10): AIDS-RELATED ................................................................................................................................. 142
FUNCTIONAL GENETICS, EPIGENETICS AND NON-CODING RNAs IN DRUG ADDICTION (R01): AIDS-RELATED ................................................................. 143

FAMILY AND INTERPERSONAL RELATIONSHIPS IN AN AGEING CONTEXT (R01): AIDS-RELATED .................................................................................................................. 144

PREDICTIVE MULTISCALE MODELS FOR BIOMEDICAL, BIOLOGICAL, BEHAVIORAL, ENVIRONMENTAL AND CLINICAL RESEARCH (INTERAGENCY U01): AIDS-RELATED ................................................................. 145

SPATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R01) AIDS-RELATED .................................................................................................................. 146

SPATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R21) AIDS-RELATED .................................................................................................................. 147

SPATIAL UNCERTAINTY: DATA, MODELLING AND COMMUNICATION (R03) AIDS-RELATED .................................................................................................................. 148

MECHANISTIC STUDIES OF PAIN AND ALCOHOL DEPENDENCE (R01): AIDS-RELATED .................................................................................................................. 149

TARGETED BASIC BEHAVIOURAL AND SOCIAL SCIENCE AND INTERVENTION DEVELOPMENT FOR HIV PREVENTION AND CARE (R01) .................................................................................................................. 150

TARGETED BASIC BEHAVIOURAL AND SOCIAL SCIENCE AND INTERVENTION DEVELOPMENT FOR HIV PREVENTION AND CARE (R21) .................................................................................................................. 151

SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIOURAL AND SOCIAL SCIENCES (R01): AIDS-RELATED .................................................................................................................. 152

SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIOURAL AND SOCIAL SCIENCES (R21): AIDS-RELATED .................................................................................................................. 153

BUILDING GENETICS AND GENOMIC KNOWLEDGE ABOUT DENTAL, ORAL AND CRANIOFACIAL DISEASES AND DISORDERS (R01): AIDS-RELATED .................................................................................................................. 154

HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIOURS IN CHILDREN AND ADOLESCENTS (R01): AIDS-RELATED .................................................................................................................. 155

HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIOURS IN CHILDREN AND ADOLESCENTS (R21): AIDS-RELATED .................................................................................................................. 156

ALCOHOL IMPAIRMENT OF IMMUNE FUNCTION, HOST DEFENSE AND TISSUE HOMEOSTASIS (R01): AIDS-RELATED .................................................................................................................. 157

HIGH THROUGHPUT SCREENING TO DISCOVER CHEMICAL PROBES (R01): AIDS-RELATED .................................................................................................................. 158

THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R03): AIDS-RELATED .................................................................................................................. 159
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Health of Sexual and Gender Minority Populations (R21): AIDS-Related</td>
<td>160</td>
</tr>
<tr>
<td>Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol and Tobacco Abuse (R34): AIDS-Related</td>
<td>161</td>
</tr>
<tr>
<td>Environmental Exposures and Health: Exploration of Non-Traditional Settings (R01): AIDS-Related</td>
<td>162</td>
</tr>
<tr>
<td>Environmental Exposures and Health: Exploration of Non-Traditional Settings (R21): AIDS-Related</td>
<td>163</td>
</tr>
<tr>
<td>Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Programme Implementation (R34)</td>
<td>164</td>
</tr>
<tr>
<td>Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01): AIDS-Related</td>
<td>165</td>
</tr>
<tr>
<td>Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21): AIDS-Related</td>
<td>166</td>
</tr>
<tr>
<td>Development of Minimally Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R21): AIDS-Related</td>
<td>167</td>
</tr>
<tr>
<td>Ethical Issues in Research on HIV/AIDS and its Co-Morbidities (R21)</td>
<td>169</td>
</tr>
<tr>
<td>Ethical Issues in Research on HIV/AIDS and its Co-Morbidities (R01)</td>
<td>170</td>
</tr>
<tr>
<td>Lymphatics in Health and Disease in the Digestive System, Kidney and Urinary Tract (R01): AIDS-Related</td>
<td>171</td>
</tr>
<tr>
<td>Examination of Survivorship Care Planning Efficacy and Impact (R01): AIDS-Related</td>
<td>172</td>
</tr>
<tr>
<td>Effects of In Utero Alcohol Exposure on Adult Health and Disease (R21): AIDS-Related</td>
<td>173</td>
</tr>
<tr>
<td>Effects of In Utero Alcohol Exposure on Adult Health and Disease (R01): AIDS-Related</td>
<td>174</td>
</tr>
<tr>
<td>Epigenetic Inheritance and Transgenerational Effects of Alcohol (R21): AIDS-Related</td>
<td>175</td>
</tr>
<tr>
<td>Epigenetic Inheritance and Transgenerational Effects of Alcohol (R01): AIDS-Related</td>
<td>176</td>
</tr>
<tr>
<td>Selected Topics in Transfusion Medicine (R21): AIDS-Related</td>
<td>176</td>
</tr>
<tr>
<td>Selected Topics in Transfusion Medicine (R01): AIDS-Related</td>
<td>177</td>
</tr>
<tr>
<td>Topic</td>
<td>Page</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>ERYTHROPOIESIS: COMPONENTS AND MECHANISMS (R01): AIDS-RELATED</td>
<td>178</td>
</tr>
<tr>
<td>DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R01): AIDS-RELATED</td>
<td>179</td>
</tr>
<tr>
<td>DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R03): AIDS-RELATED</td>
<td>180</td>
</tr>
<tr>
<td>SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIOURS AND WEIGHT OUTCOMES (R21): AIDS-RELATED</td>
<td>181</td>
</tr>
<tr>
<td>SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIOURS AND WEIGHT OUTCOMES (R03): AIDS-RELATED</td>
<td>182</td>
</tr>
<tr>
<td>SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIOURS AND WEIGHT OUTCOMES (R01): AIDS-RELATED</td>
<td>184</td>
</tr>
<tr>
<td>REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R21): AIDS-RELATED</td>
<td>185</td>
</tr>
<tr>
<td>REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R03): AIDS-RELATED</td>
<td>185</td>
</tr>
<tr>
<td>REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R01): AIDS-RELATED</td>
<td>186</td>
</tr>
<tr>
<td>ACUTE KIDNEY INJURY IN OLDER ADULTS (R03) AIDS-RELATED</td>
<td>187</td>
</tr>
<tr>
<td>ACUTE KIDNEY INJURY IN OLDER ADULTS (R21) AIDS-RELATED</td>
<td>188</td>
</tr>
<tr>
<td>ACUTE KIDNEY INJURY IN OLDER ADULTS (R01) AIDS-RELATED</td>
<td>189</td>
</tr>
<tr>
<td>THE ROLE OF EXTRACELLULAR RNA IN MEDIATING THE HEALTH EFFECTS OF ALCOHOL (R21): AIDS-RELATED</td>
<td>189</td>
</tr>
<tr>
<td>THE EFFECTS OF MODULATING CHRONIC LOW GRADE INFLAMMATION ON GERIATRIC CONDITIONS - SECONDARY DATA OR BIOSPECIMEN ANALYSES AND ANCILLARY STUDIES IN ONGOING OR COMPLETED CLINICAL TRIALS (R01) AIDS-RELATED</td>
<td>190</td>
</tr>
<tr>
<td>RESEARCH GRANTS USING THE RESOURCES FROM THE OSTEOARTHRITIS INITIATIVE (R21): AIDS-RELATED</td>
<td>191</td>
</tr>
<tr>
<td>RESEARCH TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R03): AIDS-RELATED</td>
<td>192</td>
</tr>
<tr>
<td>RESEARCH TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R21): AIDS-RELATED</td>
<td>193</td>
</tr>
<tr>
<td>RESEARCH TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R01): AIDS-RELATED</td>
<td>194</td>
</tr>
</tbody>
</table>
SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R21): AIDS-RELATED ......................................................................................................................... 195
SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R03): AIDS-RELATED ......................................................................................................................... 196
IMPLICATIONS OF NEW DIGITAL MEDIA USE FOR UNDERAGE DRINKING, DRINKING-RELATED BEHAVIOURS AND PREVENTION RESEARCH (R21): AIDS-RELATED .......... 197
SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R01): AIDS-RELATED ......................................................................................................................... 198
IMPLICATIONS OF NEW DIGITAL MEDIA USE FOR UNDERAGE DRINKING, DRINKING-RELATED BEHAVIOURS AND PREVENTION RESEARCH (R01): AIDS-RELATED .......... 199
SYNERGISING OMIC AND SYMPTOM SCIENCE (R01): AIDS-RELATED ....................................................... 200
SYSTEMIC AMYLOIDOSIS: BASIC, TRANSLATIONAL AND CLINICAL RESEARCH (R01): AIDS-RELATED ........................................................................................................... 201
BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R21): AIDS-RELATED ......................................................................................................................... 202
BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R03): AIDS-RELATED ......................................................................................................................... 203
THE ROLE OF THE CYTOSKELETON IN CELLULAR AGEING (R21/R33): AIDS-RELATED ......................................................................................................................... 204
BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R01): AIDS-RELATED ......................................................................................................................... 205
BEHAVIOURAL AND SOCIAL SCIENCE RESEARCH ON UNDERSTANDING AND REDUCING HEALTH DISPARITIES (R21): AIDS-RELATED ......................................................................................................................... 206
BEHAVIOURAL AND SOCIAL SCIENCE RESEARCH ON UNDERSTANDING AND REDUCING HEALTH DISPARITIES (R01): AIDS-RELATED ......................................................................................................................... 207
GUT MICROBIOTA-DERIVED FACTORS IN THE INTEGRATED PHYSIOLOGY AND PATHOPHYSIOLOGY OF DISEASES WITHIN NIDDK’S MISSION (R01): AIDS-RELATED ......................................................................................................................... 208
METHODS FOR PREVENTION PACKAGES PROGRAMME III (R01) ......................................................................................................................... 208
INCREASED KNOWLEDGE AND INNOVATIVE STRATEGIES TO REDUCE HIV INCIDENCE (R01) ......................................................................................................................... 209
AUDACIOUS GOALS INITIATIVE HIGH PRIORITY RESEARCH AREA – INTERSECTION OF AGEING AND BIOLOGICAL MECHANISMS OF EYE DISEASE (R01): AIDS-RELATED ......................................................................................................................... 210
MECHANISMS OF ALCOHOL AND STIMULANT CO-ADDICTION (R21): AIDS-RELATED ......................................................................................................................... 211
MECHANISMS OF ALCOHOL AND STIMULANT CO-ADDICTION (R01): AIDS-RELATED .................................................................................................................................................................. 212
EXPLORATORY/DEVELOPMENTAL CLINICAL RESEARCH GRANTS IN OBESITY (R21): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 213
DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R03): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 214
DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R21): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 215
DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R01): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 216
EARLY-CAREER AWARD IN CHEMISTRY OF DRUG ABUSE AND ADDICTION (R21/R33): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 217
SUSTAINED RELEASE OF ANTIVIRALS FOR TREATMENT OR PREVENTION OF HIV (R01) .................................................................................................................................................................................................................................................................................................................................................................. 218
ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R03): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 218
ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R21): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 220
ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R01): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 221
MODELLING SOCIAL BEHAVIOUR (R01): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 222
NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (COLLABORATIVE R01): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 223
NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (R01): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 224
PUBLIC HEALTH IMPACT OF THE CHANGING POLICY/LEGAL ENVIRONMENT FOR MARIJUANA (R01): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 225
NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R21): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 226
NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R01): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 227
SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R01): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 228
ERADICATION OF HIV-1 FROM CENTRAL NERVOUS SYSTEM RESERVOIRS (R01) .................................................................................................................................................................................................................................................................................................................................................................. 229
CLINICAL VISION RESEARCH: RESOURCE CENTRE GRANT (UG1): AIDS-RELATED .................................................................................................................................................................................................................................................................................................................................................................. 230
CLINICAL VISION RESEARCH: CHAIR’S GRANT (UG1): AIDS-RELATED .......................231
CLINICAL VISION RESEARCH: CLINICAL CENTRE GRANT (UG1): AIDS-RELATED ....232
CLINICAL VISION RESEARCH: COORDINATING CENTRE GRANT (UG1): AIDS-RELATED .................................................................................................................................................................. 233
SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT
THEIR DELETERIOUS EFFECTS (R03): AIDS-RELATED ..................................................233
SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT
THEIR DELETERIOUS EFFECTS (R21): AIDS-RELATED ..................................................234
SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT
THEIR DELETERIOUS EFFECTS (R01): AIDS-RELATED ..................................................235
FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R01): AIDS-
RELATED.......................................................................................................................... 236
FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R21): AIDS-
RELATED.......................................................................................................................... 237
DESIGN AND DEVELOPMENT OF NOVEL TECHNOLOGIES FOR HEALTHY
INDEPENDENT LIVING (R21): AIDS-RELATED.............................................................. 238
TECHNOLOGIES FOR HEALTHY INDEPENDENT LIVING (R01): AIDS-RELATED .........239
ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R21): AIDS-RELATED
............................................................................................................................................. 240
ADVANCING STRUCTURAL LEVEL INTERVENTIONS THROUGH ENHANCED
UNDERSTANDING OF SOCIAL DETERMINANTS IN HIV PREVENTION AND CARE (R21)
............................................................................................................................................... 241
IMPROVING DELIVERY OF HIV PREVENTION AND TREATMENT THROUGH
IMPLEMENTATION SCIENCE AND TRANSLATIONAL RESEARCH (R21) ..................... 242
STRENGTHENING ADHERENCE TO ANTIRETROVIRAL-BASED HIV TREATMENT AND
PREVENTION (R21).............................................................................................................. 243
ACCELERATING IMPROVEMENTS IN THE HIV CARE CONTINUUM (R21)............... 244
ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R01): AIDS-RELATED
............................................................................................................................................. 244
ADVANCING STRUCTURAL LEVEL INTERVENTIONS THROUGH ENHANCED
UNDERSTANDING OF SOCIAL DETERMINANTS IN HIV PREVENTION AND CARE (R01)
............................................................................................................................................... 245
IMPROVING DELIVERY OF HIV PREVENTION AND TREATMENT THROUGH
IMPLEMENTATION SCIENCE AND TRANSLATIONAL RESEARCH (R01) ..................... 246
STRENGTHENING ADHERENCE TO ANTIRETROVIRAL-BASED HIV TREATMENT AND PREVENTION (R01) .............................................................................................................................. 247
ACCELERATING IMPROVEMENTS IN THE HIV CARE CONTINUUM (R01) ................. 248
PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R34): AIDS-RELATED ........................................................... 249
.................................................................................................................................................................. 250
PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R21): AIDS-RELATED ........................................................... 250
NEUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R21): AIDS- RELATED ................................................................................................................................................ 251
PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R01): AIDS-RELATED ........................................................... 252
NEUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R01): AIDS- RELATED ................................................................................................................................................ 253
COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R21): AIDS-RELATED ....... 254
COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R01): AIDS-RELATED ....... 255
ESTABLISHING BEHAVIOURAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R21): AIDS-RELATED . 256
ESTABLISHING BEHAVIOURAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R01): AIDS-RELATED . 257
EARLY STAGE DEVELOPMENT OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01): AIDS-RELATED ......................................................... 258
EXTENDED DEVELOPMENT, HARDENING AND DISSEMINATION OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01): AIDS-RELATED ................................................................................................................................................ 259
TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R21): AIDS-RELATED ......................................................... 260
TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R01): AIDS-RELATED ......................................................... 261
EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R21): AIDS-RELATED ..................................................................................................................................... 262
EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R03): AIDS-RELATED ..................................................................................................................................... 263
EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R01): AIDS-RELATED ..................................................................................................................................... 264
CLINICAL TRIAL PLANNING GRANT FOR INTERVENTIONS AND SERVICES TO IMPROVE TREATMENT AND PREVENTION OF HIV/AIDS (R34) .......................................................... 265

MHEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R21): AIDS-RELATED .......................................................... 266

MHEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R01) AIDS-RELATED .......................................................... 267

EXPLORATORY CLINICAL TRIALS OF MIND AND BODY INTERVENTIONS FOR NCCAM HIGH PRIORITY RESEARCH TOPICS (R34) AIDS-RELATED ................................................ 267

UNCONVENTIONAL ROLES OF ETHANOL METABOLISING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R01): AIDS-RELATED ................................................ 269

NK CELLS TO INDUCE IMMUNOLOGICAL MEMORY TO PREVENT HIV INFECTION (R01) .......................................................................................................................... 270

FC RECEPTOR AND ANTIBODY EFFECTOR FUNCTION IN HIV VACCINE DISCOVERY (R01) .......................................................................................................................... 270

HIV VACCINE VECTOR-HOST INTERACTIONS: UNDERSTANDING THE BIOLOGY AND IMMUNOLOGY (R21) .......................................................................................................................... 271

HIV VACCINE VECTOR-HOST INTERACTIONS: UNDERSTANDING THE BIOLOGY AND IMMUNOLOGY (R01) .......................................................................................................................... 272

CLINICAL EVALUATION OF ADJUNCTS TO OPIOID THERAPIES FOR THE TREATMENT OF CHRONIC PAIN (R01) AIDS-RELATED .......................................................... 273

ADVANCING RESEARCH IN VOICE DISORDERS (R21) AIDS-RELATED .......................................................... 274

ADVANCING RESEARCH IN VOICE DISORDERS (R01) AIDS-RELATED .......................................................... 275

BASIC RESEARCH ON HIV PERSISTENCE (R21): AIDS-RELATED .......................................................... 276

MULTIDISCIPLINARY STUDIES OF HIV AND VIRAL HEPATITIS CO-INFECTION (R21) .......................................................... 277

MULTIDISCIPLINARY STUDIES OF HIV AND VIRAL HEPATITIS CO-INFECTION (R01) .......................................................... 278

ARTS-BASED APPROACHES IN PALLIATIVE CARE FOR SYMPTOM MANAGEMENT (R01): AIDS-RELATED .......................................................... 279

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R03) AIDS-RELATED .......................................................... 280

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL, AND PAEDIATRIC CARE (R21): AIDS-RELATED .......................................................... 281

MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R21): AIDS-RELATED .......................................................... 282
MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R01): AIDS-RELATED ............................................................ 283
PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R01) AIDS-RELATED ............................................................ 284
ROLE OF THE MICROBIOME IN HIV-1 VACCINE RESPONSES (R21) ............................................................ 285
SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R21): AIDS-RELATED ................................................................................ 288
SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R21): AIDS-RELATED ............................................................ 289
NIDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY PLANNING GRANT (R34): AIDS-RELATED ........................................................................... 290
SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R01): AIDS-RELATED ............................................................ 291
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R21): AIDS-RELATED ............................................................ 291
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R03): AIDS-RELATED ............................................................ 292
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R01): AIDS-RELATED ............................................................ 294
BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R21): AIDS-RELATED ........................................................................... 295
BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R01): AIDS-RELATED ........................................................................... 296
BIOBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R21): AIDS-RELATED ........................................................................... 297
BIOBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R01): AIDS-RELATED ........................................................................... 298
PROMOTING RESEARCH IN BASIC NEUROSCIENCE (R01): AIDS-RELATED ........................................................................... 299
DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R21): AIDS-RELATED ........................................................................... 300
DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R03): AIDS-RELATED ........................................................................... 301
DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R01): AIDS-RELATED ........................................................................... 302
UNDERACTIVE BLADDER IN AGEING (R03): AIDS-RELATED ........................................................................... 303
UNDERACTIVE BLADDER IN AGEING (R21): AIDS-RELATED ........................................................................... 304
UNCONVENTIONAL ROLES OF ETHANOL METABOLISING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R21): AIDS-RELATED

NIDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY COOPERATIVE AGREEMENT (U01): AIDS-RELATED

BUILDING ON HIGH IMPACT BASIC NEUROBIOLOGY THROUGH ASSAY DEVELOPMENT: ADVANCING TOOLS FOR THERAPEUTIC DISCOVERY (R01): AIDS-RELATED

INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): ASSAY DEVELOPMENT AND THERAPEUTIC AGENT IDENTIFICATION AND CHARACTERISATION TO SUPPORT THERAPEUTIC DISCOVERY (R21/R33): AIDS-RELATED

INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): PHARMACODYNAMICS AND IN VIVO EFFICACY STUDIES FOR SMALL MOLECULES AND BIOLOGICS/BIOTECHNOLOGY PRODUCTS (R21/R33): AIDS-RELATED

ACADEMIC-INDUSTRIAL PARTNERSHIPS FOR TRANSLATION OF TECHNOLOGIES FOR CANCER DIAGNOSIS AND TREATMENT (R01): AIDS-RELATED

PREVENTION RESEARCH IN MID-LIFE ADULTS (R21): AIDS-RELATED

PREVENTION RESEARCH IN MID-LIFE ADULTS (R01): AIDS RELATED

REDUCTIONS IN ILLICIT DRUG USE AND FUNCTIONAL OUTCOMES (R21/R33): AIDS-RELATED

MATERNAL NUTRITION AND PRE-PREGNANCY OBESITY: EFFECTS ON MOTHERS, INFANTS AND CHILDREN (R01): AIDS-RELATED

ROLE OF EXOSOMES IN HIV PATHOGENESIS (R21)

EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R03): AIDS-RELATED

EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R21): AIDS-RELATED

ADVANCING TRANSLATIONAL AND CLINICAL PROBIOTIC OR PREBIOTIC AND HUMAN MICROBIOME RESEARCH (R01): AIDS-RELATED

EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R01): AIDS-RELATED

FUNCTIONAL WELLNESS IN HIV – MAXIMISING THE TREATMENT CASCADE (R21)

FUNCTIONAL WELLNESS IN HIV – MAXIMISING THE TREATMENT CASCADE (R01)
PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN KIDNEY DISEASES (R21): AIDS-RELATED ................................................................. 323
IMPROVING DIET AND PHYSICAL ACTIVITY ASSESSMENT (R21): AIDS-RELATED .... 324
DIET AND PHYSICAL ACTIVITY ASSESSMENT METHODOLOGY (R01): AIDS-RELATED 325
IMMUNE SYSTEM PLASTICITY IN THE PATHOGENESIS AND TREATMENT OF COMPLEX
DENTAL, ORAL, AND CRANIOFACIAL DISEASES (R21) – AIDS-RELATED ........... 326
IMMUNE SYSTEM PLASTICITY IN THE PATHOGENESIS AND TREATMENT OF COMPLEX
DENTAL, ORAL, AND CRANIOFACIAL DISEASES (R01) – AIDS-RELATED ............. 327
DEVELOPING THE THERAPEUTIC POTENTIAL OF THE ENDOCANNABINOID SYSTEM
FOR PAIN TREATMENT (R01): AIDS-RELATED .................................................. 328
STUDIES AT PERIVIABLE GESTATION (R03) – AIDS-RELATED............................ 329
STUDIES AT PERIVIABLE GESTATION (R21) – AIDS-RELATED............................ 330
STUDIES AT PERIVIABLE GESTATION (R01) – AIDS-RELATED............................ 331
HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE
DISORDER (R03) – AIDS-RELATED ................................................................. 332
HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE
DISORDER (R21) – AIDS-RELATED ................................................................. 333
HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE
DISORDER (R01) – AIDS-RELATED ................................................................. 334
EXPLOITING RNA AS A TARGET FOR HIV INTERVENTIONS (R21) ....................... 335
UNDERSTANDING HIV PERSISTENCE IN INFANTS (R01) .................................... 335
HARNESSING BIG DATA TO HALT HIV (R01) ...................................................... 336
BIOENGINEERING RESEARCH PARTNERSHIP – NON- OR MINIMALLY-INVASIVE
METHODS TO MEASURE BIOCHEMICAL SUBSTANCES DURING NEONATAL AND
PERINATAL PATIENT CARE AND RESEARCH (R01): AIDS-RELATED .................. 337
END-OF-LIFE AND PALLIATIVE NEEDS OF ADOLESCENTS AND YOUNG ADULTS WITH
SERIOUS ILLNESSES (R01) AIDS-RELATED ...................................................... 338
ETHICAL, LEGAL AND POLICY ISSUES IN HIV RESEARCH WITH KEY POPULATIONS
(R21) .................................................................................................................. 339
ETHICAL, LEGAL AND POLICY ISSUES IN HIV RESEARCH WITH KEY POPULATIONS
(R21) AIDS-RELATED .......................................................................................... 340
ETHICAL, LEGAL AND POLICY ISSUES IN HIV RESEARCH WITH KEY POPULATIONS
(R01) .................................................................................................................. 341
<table>
<thead>
<tr>
<th>Issue 24: Volume 1b – Grants from NIH (January – March, 2016)</th>
</tr>
</thead>
</table>

| ETHICAL, LEGAL AND POLICY ISSUES IN HIV RESEARCH WITH KEY POPULATIONS (R01) AIDS-RELATED | 342 |
| SMALL RESEARCH GRANTS FOR ORAL HEALTH DATA ANALYSIS AND STATISTICAL METHODOLOGY DEVELOPMENT AIDS-RELATED (R03) | 343 |
| RESEARCH ON THE MECHANISMS AND BEHAVIOURAL OUTCOMES OF MULTISENSORY PROCESSING (R01) AIDS-RELATED | 344 |
| PERSONALISED STRATEGIES TO MANAGE SYMPTOMS OF CHRONIC ILLNESS (R01) AIDS-RELATED | 345 |
| EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R21) AIDS-RELATED | 346 |
| HIV AND AIDS HIGH PRIORITY DRUG ABUSE RESEARCH (R01) | 347 |
| INNOVATIVE QUESTIONS IN SYMPTOM SCIENCE AND GENOMICS (R01): AIDS-RELATED | 348 |
| EXTENDED DEADLINE: DEVELOPMENT OF MINIMALLY INVASIVE BIOASSAYS TO SUPPORT OUTPATIENT CLINICAL TRIALS OF THERAPEUTICS FOR SUBSTANCE USE DISORDERS (R21) | 349 |
| CHARACTERISATION OF MYCOBACTERIAL INDUCED IMMUNITY IN HIV-INFECTED AND UNINFECTED INDIVIDUALS (R21) | 350 |
| NIAID CLINICAL TRIAL PLANNING GRANTS (R34) | 351 |
| NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01) | 352 |
| NIAID CLINICAL TRIAL IMPLEMENTATION GRANT (R01) | 353 |
| HIV-INFECTED ADOLESCENTS – TRANSITIONING FROM THE PAEDIATRIC TO THE ADULT CARE SETTING (R21) | 354 |
| HIV-INFECTED ADOLESCENTS – TRANSITIONING FROM THE PAEDIATRIC TO THE ADULT CARE SETTING (R01) | 355 |
| MINOR USE MINOR SPECIES DEVELOPMENT OF DRUGS RESEARCH PROJECT GRANT (R01) | 356 |
| ADMINISTRATIVE SUPPLEMENTS FOR RESEARCH ON DIETARY SUPPLEMENTS (ADMIN SUPP) | 357 |
| NEI AUDACIOUS GOAL INITIATIVE: DISCOVERY-BASED SCIENCE TO IDENTIFY FACTORS INFLUENCING NEURAL REGENERATION IN THE VISUAL SYSTEM (U01) | 358 |
| GENOMIC DATA ANALYSIS NETWORK: PROCESSING GENOMIC DATA CENTRE (U24) | 359 |
| GENOMIC DATA ANALYSIS NETWORK: SPECIALISED GENOMIC DATA CENTRE (U24) | 360 |
GENOMIC DATA ANALYSIS NETWORK: VISUALISATION GENOMIC DATA CENTRE (U24).....................................................................................................................................................................361
PREDICTIVE MULTISCALE MODELS FOR BIOMEDICAL, BIOLOGICAL, BEHAVIOURAL, ENVIRONMENTAL AND CLINICAL RESEARCH (INTERAGENCY U01)........................................................................362
ADAPTATION AND OPTIMISATION OF TECHNOLOGY TO SUPPORT SOCIAL FUNCTIONING (R21)........................................................................................................................................................................363
PARKINSON’S DISEASE BIOMARKER PROGRAMME DISCOVERY PROJECTS (U01)...........364
DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R01).........................364
GENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R01)....................365
MOLECULAR GENETICS OF DRUG ADDICTION AND RELATED CO-MORBILITIES (R01) ......................................................................................................................................................................366
THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R01)....................367
PRESCRIPTION DRUG ABUSE (R01)..................................................................................369

OPPORTUNITIES FOR FEBRUARY 2016..............................................................................363
HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R01)................................................370
INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R01)..................................................................................................................................................371
BIOENGINEERING RESEARCH GRANTS (R01)..................................................................372
BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R01) .............................................................................................................................................................................373
ANCILLARY STUDIES OF ACUTE KIDNEY INJURY, CHRONIC KIDNEY DISEASE AND END STAGE RENAL DISEASE ACCESSING INFORMATION FROM CLINICAL TRIALS, EPIDEMIOLOGICAL STUDIES AND DATABASES (R01)..........................................................................................................................................................374
ERYTHROPOIESIS: COMPONENTS AND MECHANISMS (R01)........................................375
LEGAL, ETHICAL AND SOCIAL IMPLICATIONS OF GENOMIC RESEARCH REGULAR RESEARCH PROGRAMME (R01)................................................................................................................376
DEVELOPMENT OF ASSAYS FOR HIGH-THROUGHPUT DRUG SCREENING FOR USE IN PROBE AND PRE-THERAPEUTIC DISCOVERY (R01)................................................................................................................................................377
EXTENDED DEADLINE: ANCILLARY STUDIES TO MAJOR ONGOING CLINICAL RESEARCH STUDIES TO ADVANCE AREAS OF SCIENTIFIC INTEREST WITHIN THE MISSION OF THE NIDDK (R01)............................................................................................................................................................................378
UNDERSTANDING AND PROMOTING HEALTH LITERACY (R01).................................379
<table>
<thead>
<tr>
<th>Grant Category</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALZHEIMER’S DISEASE PILOT CLINICAL TRIALS (R01)</td>
<td>380</td>
</tr>
<tr>
<td>CALCIUM OXALATE STONE DISEASES (R01)</td>
<td>380</td>
</tr>
<tr>
<td>HEALTH DISPARITIES IN NIDDK DISEASES (R01)</td>
<td>381</td>
</tr>
<tr>
<td>MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R01)</td>
<td>382</td>
</tr>
<tr>
<td>RESEARCH PROJECT GRANT (PARENT R01)</td>
<td>383</td>
</tr>
<tr>
<td>FUNCTIONAL GENETICS, EPIGENETICS AND NON-CODING RNAs IN DRUG ADDICTION (R01)</td>
<td>384</td>
</tr>
<tr>
<td>SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R01)</td>
<td>385</td>
</tr>
<tr>
<td>ACADEMIC-INDUSTRIAL PARTNERSHIPS FOR TRANSLATION OF IN VIVO IMAGING SYSTEMS FOR CANCER INVESTIGATIONS (R01)</td>
<td>386</td>
</tr>
<tr>
<td>NEUROSCIENCE RESEARCH ON DRUG ABUSE (R01)</td>
<td>387</td>
</tr>
<tr>
<td>BEHAVIOURAL AND SOCIAL SCIENCE RESEARCH ON UNDERSTANDING AND REDUCING HEALTH DISPARITIES (R01)</td>
<td>388</td>
</tr>
<tr>
<td>BIOLOGY OF MANUAL THERAPIES (R01)</td>
<td>389</td>
</tr>
<tr>
<td>NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R01)</td>
<td>390</td>
</tr>
<tr>
<td>SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R01)</td>
<td>391</td>
</tr>
<tr>
<td>HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R01)</td>
<td>392</td>
</tr>
<tr>
<td>EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R01)</td>
<td>393</td>
</tr>
<tr>
<td>GENETIC SUSCEPTIBILITY AND VARIABILITY OF HUMAN STRUCTURAL BIRTH DEFECTS (R01)</td>
<td>394</td>
</tr>
<tr>
<td>NLM EXPRESS RESEARCH GRANTS IN BIOMEDICAL INFORMATICS (R01)</td>
<td>395</td>
</tr>
<tr>
<td>EPIDEMIOLOGY OF DRUG ABUSE (R01)</td>
<td>396</td>
</tr>
<tr>
<td>SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R01)</td>
<td>397</td>
</tr>
<tr>
<td>INVESTIGATIONS ON PRIMARY IMMUNODEFICIENCY DISEASES (R01)</td>
<td>398</td>
</tr>
<tr>
<td>DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R01)</td>
<td>399</td>
</tr>
<tr>
<td>QUANTITATIVE IMAGING FOR EVALUATION OF RESPONSES TO CANCER THERAPIES (U01)</td>
<td>400</td>
</tr>
<tr>
<td>RESEARCH TO ADVANCE VACCINE SAFETY (R01)</td>
<td>401</td>
</tr>
<tr>
<td>MECHANISMS OF ALCOHOL AND NICOTINE CO-DEPENDENCE (R01)</td>
<td>402</td>
</tr>
<tr>
<td>PAIN IN AGEING (R01)</td>
<td>402</td>
</tr>
</tbody>
</table>
SECONDARY ANALYSES OF EXISTING DATA SETS AND STORED BIOSPECIMENS TO ADDRESS CLINICAL AGEING RESEARCH QUESTIONS (R01) ................................................................. 404
DRUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R01) ................................................................. 404
DEVELOPMENT AND CHARACTERISATION OF ANIMAL MODELS FOR AGEING RESEARCH (R01) ................................................................................................................................... 406
ACCELERATING THE PACE OF DRUG ABUSE RESEARCH USING EXISTING DATA (R01) ........................................................................................................................................... 407
OBESITY POLICY EVALUATION RESEARCH (R01) ......................................................................................... 407
SELECTED TOPICS IN TRANSFUSION MEDICINE (R01) .................................................................................. 408
STIMULATING HAEMATOLOGY INVESTIGATION: NEW ENDEAVOURS (SHINE) (R01) 409
ADVANCES IN POLYCYSTIC KIDNEY DISEASE (R01) ........................................................................................... 410
RESEARCH ON AUTISM SPECTRUM DISORDERS (R01) ........................................................................................ 411
ALCOHOL USE DISORDERS: TREATMENT, SERVICES AND RECOVERY RESEARCH (R01) .............................................................................................................................................. 412
HOME AND FAMILY BASED APPROACHES FOR THE PREVENTION OR MANAGEMENT OF OVERWEIGHT OR OBESITY IN EARLY CHILDHOOD (R01) .................................................. 413
NINDS EXPLORATORY CLINICAL TRIALS (R01) ................................................................................................. 414
NINDS PHASE III INVESTIGATOR-INITIATED EFFICACY CLINICAL TRIALS (U01) ... 414
REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R01) ............................................................................................................................. 415
RESEARCH ON HEARING HEALTHCARE (R01) ......................................................................................................... 416
NEUROBIOLOGY OF MIGRAINE (R01) ......................................................................................................................... 417
PRECLINICAL RESEARCH ON MODEL ORGANISMS TO PREDICT TREATMENT OUTCOMES FOR DISORDERS ASSOCIATED WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (R01) .............................................................................................................................................. 418
OUTCOME MEASURES FOR USE IN TREATMENT TRIALS FOR INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (R01) .............................................................................................................................................. 419
ANCILLARY STUDIES TO THE NIDDK INTESTINAL STEM CELL CONSORTIUM (R01) ... 420
FAMILY AND INTERPERSONAL RELATIONSHIPS IN AN AGEING CONTEXT (R01).............. 421
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R01) ................................................................. 422
SPATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R01) ................................. 423
OBESITY AND ASTHMA: AWARENESS AND SELF-MANAGEMENT (R01) ................................................................. 424
PREGNANCY IN WOMEN WITH DISABILITIES (R01) .............................................................................................. 425
MECHANISTIC STUDIES OF PAIN AND ALCOHOL DEPENDENCE (R01) ................................................................. 426
MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R01) ........................................... 427
DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R01) .............................................................................................................. 428
SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIOURAL AND SOCIAL SCIENCES (R01) .......................................................... 429
BUILDING GENETICS AND GENOMIC KNOWLEDGE ABOUT DENTAL, ORAL AND CRANIOFACIAL DISEASES AND DISORDERS (R01) .................................................................................................................................................. 430
BUILDING ON HIGH IMPACT BASIC NEUROBIOLOGY THROUGH ASSAY DEVELOPMENT: ADVANCING TOOLS FOR THERAPEUTIC DISCOVERY (R01) ................................................................. 431
HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIOURS IN CHILDREN AND ADOLESCENTS (R01) .................................................................................................................................................. 432
BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R01) .......................................................... 433
MHEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R01) .................................................................................................................................................. 434
ALCOHOL IMPAIRMENT OF IMMUNE FUNCTION, HOST DEFENSE AND TISSUE HOMEOSTASIS (R01) .......................................................... 435
DISCOVERY OF IN VIVO CHEMICAL PROBES (R01) .............................................................................................................. 435
HIGH THROUGHPUT SCREENING TO DISCOVER CHEMICAL PROBES (R01) .......................................................... 436
MATERNAL NUTRITION AND PRE-PREGNANCY OBESITY: EFFECTS ON MOTHERS, INFANTS AND CHILDREN (R01) .................................................................................................................................................. 437
ENVIRONMENTAL EXPOSURES AND HEALTH: EXPLORATION OF NON-TRADITIONAL SETTINGS (R01) .................................................................................................................................................. 438
PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS: EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R01) .................................................................................................................................................. 439
UNCONVENTIONAL ROLES OF ETHANOL METABOLISING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R01) .................................................................................................................................................. 440
LYMPHATICS IN HEALTH AND DISEASE IN THE DIGESTIVE SYSTEM, KIDNEY AND URINARY TRACT (R01) .................................................................................................................................................. 441
EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R01) .......................................................... 442
EFFECTS OF IN UTERO ALCOHOL EXPOSURE ON ADULT HEALTH AND DISEASE (R01) .......................................................... 443
<table>
<thead>
<tr>
<th>Issue 24: Volume 1b – Grants from NIH (January – March, 2016)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPIGENETIC INHERITANCE AND TRANSGENERATIONAL EFFECTS OF ALCOHOL (R01)</strong></td>
</tr>
<tr>
<td>SOLID ORGAN TRANSPLANTATION: OLDER DONORS AND RECIPIENTS (R01)</td>
</tr>
<tr>
<td>DIFFERENTIATION AND INTEGRATION OF STEM CELLS (EMBRYONIC AND INDUCED-PLURIPOTENT) INTO DEVELOPING OR DAMAGED TISSUES (R01)</td>
</tr>
<tr>
<td>SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIOURS AND WEIGHT OUTCOMES (R01)</td>
</tr>
<tr>
<td>MECHANISTIC INSIGHTS FROM BIRTH COHORTS (R01)</td>
</tr>
<tr>
<td>IMPROVEMENT OF ANIMAL MODELS FOR STEM-CELL-BASED REGENERATIVE MEDICINE (R01)</td>
</tr>
<tr>
<td>ACUTE KIDNEY INJURY IN OLDER ADULTS (R01)</td>
</tr>
<tr>
<td>THE EFFECTS OF MODULATING CHRONIC LOW GRADE INFLAMMATION ON GERIATRIC CONDITIONS - SECONDARY DATA OR BIOSPECIMEN ANALYSES AND ANCILLARY STUDIES IN ONGOING OR COMPLETED CLINICAL TRIALS (R01)</td>
</tr>
<tr>
<td>BIOMARKERS FOR DIABETES, DIGESTIVE, KIDNEY AND UROLOGIC DISEASES USING BIOSAMPLES FROM THE NIDDK REPOSITORY (R01)</td>
</tr>
<tr>
<td>PHENOTYPING EMBRYONIC LETHAL KNOCKOUT MICE (R01)</td>
</tr>
<tr>
<td>RESEARCH GRANTS USING THE RESOURCES FROM THE OSTEOARTHRITIS INITIATIVE (R01)</td>
</tr>
<tr>
<td>RESEARCH TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R01)</td>
</tr>
<tr>
<td>SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R01)</td>
</tr>
<tr>
<td>IMPLICATIONS OF NEW DIGITAL MEDIA USE FOR UNDERAGE DRINKING, DRINKING-RELATED BEHAVIOURS AND PREVENTION RESEARCH (R01)</td>
</tr>
<tr>
<td>SYNERGISING OMIC AND SYMPTOM SCIENCE (R01)</td>
</tr>
<tr>
<td>NEI AUDACIOUS GOALS INITIATIVE IN VISION RESEARCH HIGH-PRIORITY RESEARCH AREA: MOLECULAR THERAPIES FOR EYE DISEASE (R01)</td>
</tr>
<tr>
<td>SYSTEMIC AMYLOIDOSIS: BASIC, TRANSLATIONAL AND CLINICAL RESEARCH (R01)</td>
</tr>
<tr>
<td>GUT MICROBIOTA-DERIVED FACTORS IN THE INTEGRATED PHYSIOLOGY AND PATHOPHYSIOLOGY OF DISEASES WITHIN NIDDK’S MISSION (R01)</td>
</tr>
<tr>
<td>DEVELOPMENTAL PHARMACOLOGY AND TOXICOLOGY: ROLE OF ONTOGENY (R01)</td>
</tr>
<tr>
<td>AUDACIOUS GOALS INITIATIVE HIGH PRIORITY RESEARCH AREA: INTERSECTION OF AGEING AND BIOLOGICAL MECHANISMS OF EYE DISEASE (R01)</td>
</tr>
<tr>
<td>MECHANISMS OF ALCOHOL AND STIMULANT CO-ADDICTION (R01)</td>
</tr>
</tbody>
</table>
EARLY-STAGE PHARMACOLOGICAL VALIDATION OF NOVEL TARGETS AND ACCOMPANYING PRE-THERAPEUTIC LEADS FOR DISEASES OF INTEREST TO THE NIDDK (R01) .............................................................. 463
ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R01).................. 464
MODELLING SOCIAL BEHAVIOUR (R01) .................................................................. 465
NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (COLLABORATIVE R01) .......................................................................................... 466
NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (R01) .......... 467
PUBLIC HEALTH IMPACT OF THE CHANGING POLICY/LEGAL ENVIRONMENT FOR MARIJUANA (R01) .......................................................... 468
NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R01) .................................................................................................................. 469
SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R01) ............................................................... 470
FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R01) ........ 471
ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R01) ............. 472
PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R01) ................................................................. 473
NEUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R01) ........ 474
COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R01)............................. 475
ESTABLISHING BEHAVIOURAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R01) ................. 476
EARLY STAGE DEVELOPMENT OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01) ................................................................. 477
EXTENDED DEVELOPMENT, HARDENING AND DISSEMINATION OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01) ........................................ 478
TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R01) .................................................. 479
EFFECTS OF CANNABIS USE AND CANNABINOIDs ON THE DEVELOPING BRAIN (R01) .......................................................................................................................... 480
CLINICAL STUDIES OF MENTAL ILLNESS NOT INVOLVING TREATMENT DEVELOPMENT, EFFICACY OR EFFECTIVENESS TRIALS (COLLABORATIVE R01) ........ 481
NIH STROKENET CLINICAL TRIALS AND BIOMARKER STUDIES FOR STROKE TREATMENT, RECOVERY AND PREVENTION (U01) .......................................................... 482

CLINICAL EVALUATION OF ADJUNCTS TO OPIOID THERAPIES FOR THE TREATMENT OF CHRONIC PAIN (R01) ........................................................................................................ 482

ADVANCING RESEARCH IN VOICE DISORDERS (R01) .................................................. 483

COLLABORATIVE RESEARCH PROJECTS TO ENHANCE APPLICABILITY OF MOUSE MODELS FOR TRANSLATIONAL RESEARCH (COLLABORATIVE R01) ........................................ 484

RESEARCH PROJECTS TO ENHANCE APPLICABILITY OF MOUSE MODELS FOR TRANSLATIONAL RESEARCH (R01) ................................................................................................................... 485

ARTS-BASED APPROACHES IN PALLIATIVE CARE FOR SYMPTOM MANAGEMENT (R01) .......................................................................................................................... 486

SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R01) ....................... 487

BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R01) .... 488

BIOBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R01) .................................................................................................................. 489

PROMOTING RESEARCH IN BASIC NEUROSCIENCE (R01) ......................................... 490

RESEARCH ON EOSINOPHIL ASSOCIATED DISORDERS (R01) .................................... 491

DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R01) ..................... 492

NIDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY COOPERATIVE AGREEMENT (U01) ........................................................................................................ 493

ACADEMIC-INDUSTRIAL PARTNERSHIPS FOR TRANSLATION OF TECHNOLOGIES FOR CANCER DIAGNOSIS AND TREATMENT (R01) ................................................................. 495

PREVENTION RESEARCH IN MID-LIFE ADULTS (R01) ............................................. 496

ADVANCING TRANSLATIONAL AND CLINICAL PROBIOTIC OR PREBIOTIC AND HUMAN MICROBIOME RESEARCH (R01) .................................................................................. 497

EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R01) .................. 498

FUNCTIONAL WELLNESS IN HIV – MAXIMISING THE TREATMENT CASCADE (R01) ... 499

IMMUNE SYSTEM PLASTICITY IN THE PATHOGENESIS AND TREATMENT OF COMPLEX DENTAL, ORAL, AND CRANIOFACIAL DISEASES (R01) ................................................................. 500

DEVELOPING THE THERAPEUTIC POTENTIAL OF THE ENDOCANNABINOID SYSTEM FOR PAIN TREATMENT (R01) .......................................................................................................... 501

STUDIES AT PERIVIABLE GESTATION (R01) .................................................................... 502
HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R01) ............................................................ 503

BIOENGINEERING RESEARCH PARTNERSHIP - NON- OR MINIMALLY-INVASIVE METHODS TO MEASURE BIOCHEMICAL SUBSTANCES DURING NEONATAL AND PERINATAL PATIENT CARE AND RESEARCH (R01) ............................................................ 504

END-OF-LIFE AND PALLIATIVE NEEDS OF ADOLESCENTS AND YOUNG ADULTS WITH SERIOUS ILLNESSES (R01) ............................................................ 505

RESEARCH ON THE MECHANISMS OR BEHAVIOURAL OUTCOMES OF MULTISENSORY PROCESSING (R01) ............................................................ 506

PERSONALISED STRATEGIES TO MANAGE SYMPTOMS OF CHRONIC ILLNESS (R01) ... 507

INNOVATIVE QUESTIONS IN SYMPTOM SCIENCE AND GENOMICS (R01) ...................... 508

NINDS CREATE BIO DISCOVERY TRACK: OPTIMISATION IN PREPARATION FOR DEVELOPMENT OF BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (U01) .............. 509

NINDS CREATE BIO DEVELOPMENT TRACK: PRECLINICAL AND EARLY-PHASE CLINICAL DEVELOPMENT FOR BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (UH2/UH3) ............................................................................................................................ 510

BLUEPRINT NEUROTHERAPEUTICS NETWORK: SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT FOR DISORDERS OF THE NERVOUS SYSTEM (UH2/UH3) ........... 511

METABOLOMICS DATA ANALYSIS (R03) ..................................................................................... 512

COLLABORATIVE ACTIVITIES TO PROMOTE METABOLOMICS RESEARCH - ADMINISTRATIVE SUPPLEMENTS ............................................................................................................. 513

NEI RESEARCH GRANT FOR SECONDARY DATA ANALYSIS (R21) .............................................. 514

IMAGING - SCIENCE TRACK AWARD FOR RESEARCH TRANSITION (R03) ................................. 515

EXPLORATORY/DEVELOPMENTAL RESEARCH GRANT PROGRAMME (PARENT R21) 516

PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN UROLOGIC DISORDERS (R21) ............................................................................................................................ 517

DEVELOPMENT AND APPLICATION OF PET AND SPECT IMAGING LIGANDS AS BIOMARKERS FOR DRUG DISCOVERY AND FOR PATHOPHYSIOLOGICAL STUDIES OF CNS DISORDERS (R21) ............................................................................................................................ 518

SECONDARY ANALYSES IN OBESITY, DIABETES, DIGESTIVE AND KIDNEY DISEASES (R21) ............................................................................................................................ 519

HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R21) ............... 520

LEGAL, ETHICAL AND SOCIAL IMPLICATIONS OF GENOMIC RESEARCH SMALL RESEARCH GRANT PROGRAMME (R03) ............................................................................................................................ 521
EXPLORATORY/DEVELOPMENTAL CLINICAL RESEARCH GRANTS IN OBESITY (R21) 522
SMALL RESEARCH GRANTS FOR ORAL HEALTH DATA ANALYSIS AND STATISTICAL METHODOLOGY DEVELOPMENT (R03) .................................................................................................................. 522
UNDERSTANDING AND PROMOTING HEALTH LITERACY (R03) ............................... 523
DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R21) ......................... 524
SMALL RESEARCH GRANT PROGRAMME (PARENT R03) ............................................. 525
HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R21) ............................................................. 526
HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R03) ................................................................. 527
DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R21) ................................. 528
DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R03) ................................. 529
BIOL OGY OF MANUAL THERAPIES (R21) ........................................................................ 530
PRESCRIPTION DRUG ABUSE (R21) ................................................................................ 531
RESEARCH ON AUTISM SPECTRUM DISORDERS (R03) ............................................... 532
RESEARCH ON AUTISM SPECTRUM DISORDERS (R21) ............................................... 533
PILOT AND FEASIBILITY CLINICAL TRIALS IN DIABETES, AND ENDOCRINE AND METABOLIC DISEASES (R21) .................................................................................................................. 534
EXPLORATORY/DEVELOPMENTAL BIOENGINEERING RESEARCH GRANTS (R21) ... 535
BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R03) ........................................................................................................................................ 536
DEVELOPMENT AND APPLICATION OF PET AND SPECT IMAGING LIGANDS AS BIOMARKERS FOR DRUG DISCOVERY AND FOR PATHOPHYSIOLOGICAL STUDIES OF CNS DISORDERS [PHASED INNOVATION (R21/R33)] ................................................................................................................ 537
MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R21) ................................................................................................................................. 538
MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R03) ................................................................................................................................. 539
UNDERSTANDING AND PROMOTING HEALTH LITERACY (R21) ................................. 540
DRUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R21) ................................. 541
FUNCTIONAL GENETICS, EPIGENETICS AND NON-CODING RNAS IN DRUG ADDICTION (R21) ................................................................................................................................. 542
<table>
<thead>
<tr>
<th>Research Area</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R21)</td>
<td>543</td>
</tr>
<tr>
<td>INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R03)</td>
<td>544</td>
</tr>
<tr>
<td>NEUROSCIENCE RESEARCH ON DRUG ABUSE (R21)</td>
<td>545</td>
</tr>
<tr>
<td>NEUROSCIENCE RESEARCH ON DRUG ABUSE (R03)</td>
<td>546</td>
</tr>
<tr>
<td>ALCOHOL USE DISORDERS: TREATMENT, SERVICES AND RECOVERY RESEARCH (R03)</td>
<td>547</td>
</tr>
<tr>
<td>DEVELOPMENT OF ANIMAL MODELS AND RELATED BIOLOGICAL MATERIALS FOR RESEARCH (R21)</td>
<td>548</td>
</tr>
<tr>
<td>BEHAVIOURAL AND SOCIAL SCIENCE RESEARCH ON UNDERSTANDING AND REDUCING HEALTH DISPARITIES (R21)</td>
<td>549</td>
</tr>
<tr>
<td>NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R03)</td>
<td>550</td>
</tr>
<tr>
<td>NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R21)</td>
<td>551</td>
</tr>
<tr>
<td>SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R21)</td>
<td>552</td>
</tr>
<tr>
<td>SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R03)</td>
<td>553</td>
</tr>
<tr>
<td>GENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R03)</td>
<td>554</td>
</tr>
<tr>
<td>GENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R21)</td>
<td>555</td>
</tr>
<tr>
<td>NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH SMALL GRANT PROGRAMME FOR NEW INVESTIGATORS (R03)</td>
<td>556</td>
</tr>
<tr>
<td>EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R21)</td>
<td>556</td>
</tr>
<tr>
<td>ALCOHOL USE DISORDERS: TREATMENT, SERVICES AND RECOVERY RESEARCH (R21)</td>
<td>557</td>
</tr>
<tr>
<td>EPIDEMIOLOGY OF DRUG ABUSE (R03)</td>
<td>558</td>
</tr>
<tr>
<td>SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R03)</td>
<td>560</td>
</tr>
<tr>
<td>BEHAVIOURAL OR SOCIAL INTERVENTION CLINICAL PLANNING GRANT (R34)</td>
<td>561</td>
</tr>
<tr>
<td>RESEARCH TO ADVANCE VACCINE SAFETY (R21)</td>
<td>562</td>
</tr>
<tr>
<td>MECHANISMS OF ALCOHOL AND NICOTINE CO-DEPENDENCE (R21)</td>
<td>563</td>
</tr>
<tr>
<td>PILOT AND FEASIBILITY STUDIES IN PREPARATION FOR DRUG AND ALCOHOL ABUSE PREVENTION TRIALS (R34)</td>
<td>563</td>
</tr>
<tr>
<td>RENAL FUNCTION AND CHRONIC KIDNEY DISEASE IN AGEING (R21)</td>
<td>564</td>
</tr>
</tbody>
</table>
PAIN IN AGEING (R21) ................................................................. 565
PAIN IN AGEING (R03) ................................................................. 566
BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R34) ................................................................. 568
NEI CLINICAL STUDY PLANNING GRANT PROGRAMME (R34) ................................................................. 569
NIDCR SMALL RESEARCH GRANTS FOR DATA ANALYSIS AND STATISTICAL METHODOLOGY APPLIED TO GENOME-WIDE DATA (R03) ........................................................................................................ 570
SELECTED TOPICS IN TRANSFUSION MEDICINE (R21) ........................................................................................................ 571
HOME AND FAMILY BASED APPROACHES FOR THE PREVENTION OR MANAGEMENT OF OVERWEIGHT OR OBESITY IN EARLY CHILDHOOD (R21) ........................................................................................................ 572
RESEARCH ON HEARING HEALTHCARE (R21) ........................................................................................................ 573
NEUROBIOLOGY OF MIGRAINE (R21) ........................................................................................................ 574
EARLY-CAREER AWARD IN CHEMISTRY OF DRUG ABUSE AND ADDICTION (R21/R33) ........................................................................................................ 574
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R03) ........................................................................................................ 575
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R21) ........................................................................................................ 576
PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL, AND PAEDIATRIC CARE (R21) ........................................................................................................ 577
SPATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R21) ........................................................................................................ 578
SPATIAL UNCERTAINTY: DATA, MODELLING AND COMMUNICATION (R03) ........................................................................................................ 579
LEGAL, ETHICAL AND SOCIAL IMPLICATIONS OF GENOMIC RESEARCH EXPLORATORY/DEVELOPMENTAL RESEARCH PROGRAMME (R21) ........................................................................................................ 580
PREGNANCY IN WOMEN WITH DISABILITIES (R21) ........................................................................................................ 581
MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R21) ........................................................................................................ 582
DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R03) ........................................................................................................ 584
DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R21) ........................................................................................................ 585
SYSTEMS SCIENCE AND HEALTH IN BEHAVIOURAL AND SOCIAL SCIENCES (R21) ........................................................................................................ 586
HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIOURS IN CHILDREN AND ADOLESCENTS (R21) ........................................................................................................ 587
BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R21) ........................................................................................................ 588
BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R03) ........................................................................................................ 589
MHEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R21) ........................................................................................................... 590
THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R03).................... 591
THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R21).................... 592
PILOT HEALTH SERVICES AND ECONOMIC RESEARCH ON THE TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R34) ........................................................................................................ 593
ENVIRONMENTAL EXPOSURES AND HEALTH: EXPLORATION OF NON-TRADITIONAL SETTINGS (R21) ........................................................................................................... 594
PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS: EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R21) .......... 595
UNCONVENTIONAL ROLES OF ETHANOL METABOLISING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R21) ........................................................................ 596
EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R21)... 597
EFFECTS OF IN UTERO ALCOHOL EXPOSURE ON ADULT HEALTH AND DISEASE (R21) ........................................................................................................................................ 598
EPGENETIC INHERITANCE AND TRANSGENERATIONAL EFFECTS OF ALCOHOL (R21) ........................................................................................................... 599
SHARK TANK COMPETITION AWARD ......................................................................... 600
SOLID ORGAN TRANSPLANTATION: OLDER DONORS AND RECIPIENTS (R03)......... 601
SOLID ORGAN TRANSPLANTATION: OLDER DONORS AND RECIPIENTS (R21)......... 602
DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R03)............... 603
DIFFERENTIATION AND INTEGRATION OF STEM CELLS (EMBRYONIC AND INDUCED-PLURIPOTENT) INTO DEVELOPING OR DAMAGED TISSUES (R21) ................................. 604
SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIOURS AND WEIGHT OUTCOMES (R21) .............................................................................................. 605
SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIOURS AND WEIGHT OUTCOMES (R03) .............................................................................................. 606
IMPROVEMENT OF ANIMAL MODELS FOR STEM-CELL-BASED REGENERATIVE MEDICINE (R21) ........................................................................................................... 607
REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R21) ........................................................................................................... 608
REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R03) ........................................................................................................... 609
ACUTE KIDNEY INJURY IN OLDER ADULTS (R03) ................................................................. 610
ACUTE KIDNEY INJURY IN OLDER ADULTS (R21) .............................................................. 611
NIDCR SMALL RESEARCH GRANTS FOR SECONDARY ANALYSIS OF FACEBASE DATA (R03) ........................................................................................................... 612
RESEARCH GRANTS USING THE RESOURCES FROM THE OSTEOARTHRITIS INITIATIVE (R21) ........................................................................................................... 613
RESEARCH TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R03) ... 613
RESEARCH TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R21) ... 614
SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R21) ...................... 616
SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R03) ...................... 616
IMPLICATIONS OF NEW DIGITAL MEDIA USE FOR UNDERAGE DRINKING, DRINKING-RELATED BEHAVIOURS AND PREVENTION RESEARCH (R21) ......................... 617
THE ROLE OF THE CYTOSKELETON IN CELLULAR AGEING (R21/R33) ......................... 618
DEVELOPMENTAL PHARMACOLOGY AND TOXICOLOGY: ROLE OF ONTOGENY (R03) ........................................................................................................... 619
DEVELOPMENTAL PHARMACOLOGY AND TOXICOLOGY: ROLE OF ONTOGENY (R21) ........................................................................................................... 620
MECHANISMS OF ALCOHOL AND STIMULANT CO-ADDICTION (R21) ....................... 621
ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R21) ......................... 622
ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R03) ......................... 623
SECONDARY DATA ANALYSES TO EXPLORE THE NATIONAL INSTITUTE OF MENTAL HEALTH RESEARCH DOMAIN CRITERIA (R03) ................................................. 624
NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R21) ........................................................................................................... 625
SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R03) .................................................. 626
SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R21) .................................................. 627
ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R21) .................... 628
PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R34) ................................................................. 629
PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R21) ................................................................. 630
<table>
<thead>
<tr>
<th>Project Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R21)</td>
<td>631</td>
</tr>
<tr>
<td>COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R21)</td>
<td>632</td>
</tr>
<tr>
<td>ESTABLISHING BEHAVIOURAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R21)</td>
<td>633</td>
</tr>
<tr>
<td>TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R21)</td>
<td>634</td>
</tr>
<tr>
<td>EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R21)</td>
<td>635</td>
</tr>
<tr>
<td>EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R03)</td>
<td>636</td>
</tr>
<tr>
<td>ADVANCING RESEARCH IN VOICE DISORDERS (R21)</td>
<td>637</td>
</tr>
<tr>
<td>HIGH THROUGHPUT SCREENING (HTS) TO DISCOVER CHEMICAL PROBES (R21)</td>
<td>637</td>
</tr>
<tr>
<td>PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R03)</td>
<td>638</td>
</tr>
<tr>
<td>SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R21)</td>
<td>640</td>
</tr>
<tr>
<td>SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R21)</td>
<td>641</td>
</tr>
<tr>
<td>NIDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY PLANNING GRANT (R34)</td>
<td>642</td>
</tr>
<tr>
<td>BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R21)</td>
<td>643</td>
</tr>
<tr>
<td>BIOBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R21)</td>
<td>644</td>
</tr>
<tr>
<td>RESEARCH ON EOSINOPHIL ASSOCIATED DISORDERS (R21)</td>
<td>645</td>
</tr>
<tr>
<td>DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R03)</td>
<td>646</td>
</tr>
<tr>
<td>DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R21)</td>
<td>647</td>
</tr>
<tr>
<td>INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): PHARMACODYNAMICS AND IN VIVO Efficacy STUDIES FOR SMALL MOLECULES AND BIOLOGICS/BIOเทคโนโลยี PRODUCTS (R21/R33)</td>
<td>648</td>
</tr>
<tr>
<td>INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): ASSAY DEVELOPMENT AND THERAPEUTIC AGENT IDENTIFICATION AND CHARACTERISATION TO SUPPORT THERAPEUTIC DISCOVERY (R21/R33)</td>
<td>649</td>
</tr>
<tr>
<td>PREVENTION RESEARCH IN MID-LIFE ADULTS (R21)</td>
<td>650</td>
</tr>
<tr>
<td>REDUCTIONS IN ILLICIT DRUG USE AND FUNCTIONAL OUTCOMES (R21/R33)</td>
<td>651</td>
</tr>
<tr>
<td>Grant Title</td>
<td>Page</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>NOVEL BIOMARKERS FOR THE DEVELOPMENT OF HIV INCIDENCE ASSAYS WITH IMPROVED SPECIFICITY (R21)</td>
<td>652</td>
</tr>
<tr>
<td>EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R03)</td>
<td>653</td>
</tr>
<tr>
<td>EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R21)</td>
<td>654</td>
</tr>
<tr>
<td>FUNCTIONAL WELLNESS IN HIV - MAXIMISING THE TREATMENT CASCADE (R21)</td>
<td>655</td>
</tr>
<tr>
<td>PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN KIDNEY DISEASES (R21)</td>
<td>656</td>
</tr>
<tr>
<td>IMMUNE SYSTEM PLASTICITY IN THE PATHOGENESIS AND TREATMENT OF COMPLEX DENTAL, ORAL, AND CRANIOFACIAL DISEASES (R21)</td>
<td>657</td>
</tr>
<tr>
<td>STUDIES AT PERIVIABLE GESTATION (R03)</td>
<td>658</td>
</tr>
<tr>
<td>STUDIES AT PERIVIABLE GESTATION (R21)</td>
<td>659</td>
</tr>
<tr>
<td>HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R03)</td>
<td>660</td>
</tr>
<tr>
<td>HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R21)</td>
<td>661</td>
</tr>
<tr>
<td>PILOT SERVICES RESEARCH GRANTS NOT INVOLVING INTERVENTIONS (R34)</td>
<td>662</td>
</tr>
<tr>
<td>END-OF-LIFE AND PALLIATIVE NEEDS OF ADOLESCENTS AND YOUNG ADULTS WITH SERIOUS ILLNESSES (R21)</td>
<td>663</td>
</tr>
<tr>
<td>PERSONALISED STRATEGIES TO MANAGE SYMPTOMS OF CHRONIC ILLNESS (R21)</td>
<td>664</td>
</tr>
<tr>
<td>INNOVATIVE QUESTIONS IN SYMPTOM SCIENCE AND GENOMICS (R21)</td>
<td>665</td>
</tr>
<tr>
<td>APPLYING METABOLOMICS TO DRIVE BIOMARKER DISCOVERY IN SYMPTOM SCIENCE (R21)</td>
<td>666</td>
</tr>
<tr>
<td>ADVancing understanding, prevention and management of infections transmitted from women to their infants (R21)</td>
<td>667</td>
</tr>
<tr>
<td>UTILISING THE PLCO BIOSPECIMENS RESOURCE TO BRIDGE GAPS IN CANCER AETIOLOGY AND EARLY-DETECTION RESEARCH (U01)</td>
<td>668</td>
</tr>
<tr>
<td>EXPLORATORY CLINICAL TRIALS OF NOVEL INTERVENTIONS FOR MENTAL DISORDERS (R61/R33)</td>
<td>669</td>
</tr>
<tr>
<td>EXPLORATORY CLINICAL TRIALS OF NOVEL INTERVENTIONS FOR MENTAL DISORDERS (R33)</td>
<td>670</td>
</tr>
<tr>
<td>CLINICAL TRIALS TO TEST THE EFFECTIVENESS OF TREATMENT, PREVENTIVE AND SERVICES INTERVENTIONS (R01)</td>
<td>671</td>
</tr>
<tr>
<td>CLINICAL TRIALS TO TEST THE EFFECTIVENESS OF TREATMENT, PREVENTIVE AND SERVICES INTERVENTIONS (COLLABORATIVE R01)</td>
<td>672</td>
</tr>
</tbody>
</table>
PILOT EFFECTIVENESS TRIALS FOR TREATMENT, PREVENTIVE AND SERVICES INTERVENTIONS (R34) .................................................................................................................................................. 673

CONFIRMATORY EFFICACY CLINICAL TRIALS OF NON-PHARMACOLOGICAL INTERVENTIONS FOR MENTAL DISORDERS (R01) ................................................................................................. 674

MECHANISMS UNDERLYING THE CONTRIBUTION OF TYPE 1 DIABETES RISK-ASSOCIATED VARIANTS (DP3) .......................................................................................................................... 675

CLINICAL TRIAL READINESS FOR RARE NEUROLOGICAL AND NEUROMUSCULAR DISEASES (U01) ................................................................................................................................. 676

INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS – DEVELOPMENT AND VALIDATION OF MODEL SYSTEMS AND PHARMACODYNAMIC MARKERS TO FACILITATE THE DISCOVERY OF NEUROTHERAPEUTICS (R21/R33) .................. 677

SMALL GRANTS PROGRAMME FOR CANCER RESEARCH (R03) ........................................................................................................................................ 678

SICKLE CELL DISEASE IN SUB-SAHARAN AFRICA: DATA COORDINATING CENTRE (U24) ......................................................................................................................................................... 679

SICKLE CELL DISEASE IN SUB-SAHARAN AFRICA: COLLABORATIVE CONSORTIUM (U24) ......................................................................................................................................................... 680

OPPORTUNITIES FOR MARCH 2016 ........................................................................ 681

IDENTIFICATION OF GENETIC AND GENOMIC VARIANTS BY NEXT-GEN SEQUENCING IN NON-HUMAN ANIMAL MODELS (U01) ........................................................................................................... 681

ROLE OF THE MICROFLORA IN THE AETIOLOGY OF GASTROINTESTINAL CANCER (R01) ......................................................................................................................................................... 682

IMPACT OF THE USE OF GLUCOSE MONITORING AND CONTROL TECHNOLOGIES ON HEALTH OUTCOMES AND QUALITY OF LIFE IN OLDER ADULTS WITH TYPE 1 DIABETES (T1D) (DP3) .......................................................................................................................... 683

RESEARCH USING BIOSAMPLES AND SUBJECTS FROM TYPE 1 DIABETES CLINICAL STUDIES – COMPLICATIONS (DP3) ......................................................................................................................................... 683

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R01) ......................................................................................................................................................... 684

INTEGRATED PRECLINICAL AND CLINICAL AIDS VACCINE DEVELOPMENT PROGRAMME (U19) ......................................................................................................................................................... 685

ADVANCED CLINICAL TRIALS TO TEST ARTIFICIAL PANCREAS DEVICE SYSTEMS IN TYPE 1 DIABETES (UC4) ........................................................................................................................................ 686

EXPLORATION OF THE ROLES OF BROWN AND BEIGE ADIPOSE TISSUE IN HUMANS (R01) ......................................................................................................................................................... 688
INTEGRATIVE NEUROSCIENCE INITIATIVE ON ALCOHOLISM (INIA) CONSORTIA (COLLABORATIVE U01) ................................................................. 688
INTEGRATIVE NEUROSCIENCE INITIATIVE ON ALCOHOLISM CONSORTIA (COLLABORATIVE U01) ................................................................. 689
B CELL IMMUNOLOGY PROGRAMME FOR HIV-1 VACCINE DEVELOPMENT (R01)........ 690
GRAND OPPORTUNITY IN MEDICATIONS DEVELOPMENT FOR SUBSTANCE-USE DISORDERS (U01) .................................................................................................................................................................................................................................................. 691
STRATEGIC ALLIANCES FOR MEDICATIONS DEVELOPMENT TO TREAT SUBSTANCE USE DISORDERS (R01) ........................................................................................................................................................................................................................................................................... 692
FAST-TRACK DEVELOPMENT OF MEDICATIONS TO TREAT CANNABIS USE DISORDERS (UG3/UH3) ......................................................................................................................................................................................................................................................................................... 693
SMALL GRANTS PROGRAMME FOR CANCER RESEARCH (R03): AIDS-RELATED
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its Aids-related small grants programme for cancer research (R03). This Aids-related R03 funding opportunity announcement supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology and development of new research technology.

This funding opportunity will use the small grant programme (R03) mechanism, and runs in parallel with an FOA of identical scientific scope, PAR-13-146, which solicits applications under the exploratory/developmental (R21) award mechanism.

Applicants may request direct costs of up to US$50,000 per year over a two-year project period. Domestic and foreign for-profit or non-profit organisations and public or private institutions are eligible to apply.

Ref: PAR-14-007 (replaces PAR-12-144).

Closing date: 05 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Posted date: 22 Nov 13

Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Website:
Application form:
http://www.grants.gov/web/grants/applicant/download-application-package.html#download=true&oppNum=PAR-14-007

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Ovarian & Cervical Cancers; Project Management & Resource Allocation; Clinical Medicine; Breast Cancer; Cancer Immunology; Economics & Econometrics; Brain Cancer; Lung Cancer; Computer Science & Informatics; Oncology Nursing; Cancer Cell Biology; Melanoma & Other Skin Cancers; Prostate & Testicular Cancers; Carcinogenesis; HIV/AIDS; Physiology; Colorectal, Pancreatic & Stomach Cancers; Diagnostic Sciences; Nursing; Medical Research of Selected Fields; Leukaemia & Other Blood Cancers; Cancer Studies & Oncology; Non-cancerous Tumours; Data Analysis; Human Biological Sciences; Molecularly Targeted Therapy

Contact Details
---------------------------------------------------------------
NCI
6120 Executive Boulevard
Bethesda, MD 20892-7150
Tel: +1 301 496 7800
GLOBAL BRAIN AND NERVOUS SYSTEM DISORDERS RESEARCH ACROSS THE LIFESPAN (R21)
NIH: Fogarty International Center

Description:
A total of 10 participating institutes and centres of the National Institutes of Health invite applications for their global brain and nervous system disorders research across the lifespan (R21) grants. This R21 funding opportunity announcement encourages the development of innovative, collaborative research projects on brain and other nervous system function and disorders throughout life, relevant to low- and middle-income countries. Types of research relevant to this announcement include basic research and epidemiology, as well as translational research, research on diagnostics, early interventions, clinical treatment, prevention, and health services that are culturally appropriate, feasible, and acceptable for implementation within the LMIC.

At least one institution in the US or an upper-middle-income country, and at least one institution in a LMIC must be involved as partners in the grant application. This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PAR-14-332, which solicits applications under the NIH research project (R01) grant mechanism.

Application budgets are limited to US$125,000 per year in direct costs for up to two years.

Ref: PAR-14-331 (replaces PAR-11-031).

Closing date: 05 Jan 16
Posted date: 08 Sep 14

Award type: Directed grants to institutions, research groups etc
Award amount max: $250,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-331.html

Application form: http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PAR-14-331

Eligibility profile
Country of applicant institution: Any

Disciplines
----------------------------------------------
Aetiology; Psychology; Neurology; Cancer Genetics; HIV/Aids; Endocrine & Neuroendocrine Cancers; Sociology; Mental Illness; Biomedical Engineering; Depression & Other Mood Disorders; Post Traumatic Stress Disorder; Stress, Psychological; Neuropharmacology; Automated Clinical Analysis; Genetic Diseases; Epilepsy & Seizures; Neurostimulation; Medical Sociology ; Electrophysiology; Eating Disorders; Neuroscience; Neurosurgery; Personality Disorders; Diagnostic Sciences; Clinical Medicine; Medical & Diagnostic Tests; Traumatology, Accidents & Injury; Physics; Neuroendocrinology; Central Nervous System; Pharmaceutical Drugs; Psychiatry; Public Health, Health Services & Primary Care; Sensory Systems; Neuropsychology; Sensory Perception; Clinical Psychology; Cognitive Processes; Mental Health; Attention Deficit Hyperactivity Disorder (ADHD); Adolescent Paediatrics; Neurotransmitters; Biological Markers & Sensor Mechanisms; Social Aspects of Mental Health; Pharmacy & Pharmacology;
GLOBAL BRAIN AND NERVOUS SYSTEM DISORDERS RESEARCH ACROSS THE LIFESPAN (R01)
NIH: Fogarty International Center

Description:
A total of 10 participating institutes and centres of the National Institutes of Health invite applications for their global brain and nervous system disorders research across the lifespan (R01) grants. The purpose of this R01 funding opportunity announcement is to support innovative, collaborative research projects between US and low- and middle-income country scientists, on brain and other nervous system function and disorders throughout life, relevant to low- and middle-income countries. Relevant research topics for this FOA are related to nervous system function or impairment from birth to advanced age and across generations. Applicants are especially encouraged to propose research on co-morbidities and conditions that affect nervous system function at different life stages, as well as across the lifespan. Relevant research for these applications may range from basic science to epidemiological, clinical, health services and translational and implementation research. Applicants may propose a research and capacity building programme on some aspect of nervous system function or impairment at any stage of life.

Contact Details

----------------------------------------------
Fogarty International Center
Office of Communications
Building 31
31 Center Drive MSC 2220
Bethesda, MD 20892-2220
Tel: +1 301 496 1653
Email: brainfic@nih.gov

Description:
A total of 10 participating institutes and centres of the National Institutes of Health invite applications for their global brain and nervous system disorders research across the lifespan (R01) grants. The purpose of this R01 funding opportunity announcement is to support innovative, collaborative research projects between US and low- and middle-income country scientists, on brain and other nervous system function and disorders throughout life, relevant to low- and middle-income countries. Relevant research topics for this FOA are related to nervous system function or impairment from birth to advanced age and across generations. Applicants are especially encouraged to propose research on co-morbidities and conditions that affect nervous system function at different life stages, as well as across the lifespan. Relevant research for these applications may range from basic science to epidemiological, clinical, health services and translational and implementation research. Applicants may propose a research and capacity building programme on some aspect of nervous system function or impairment at any stage of life.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PAR-14-331 which solicits applications under the NIH exploratory/developmental (R21) grant mechanism.

Application budgets are not limited, but need to reflect actual needs of proposed project. The maximum project period is five years.

Ref: PAR-14-332 (replaces PAR-11-030).

Closing date: 05 Jan 16
Posted date: 08 Sep 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:

Application form:
http://www.grants.gov/web/grants/applicant-package.html#download=true&oppNum=PAR-14-332

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Post Traumatic Stress Disorder; Genetic Diseases; Sociology; Sensory Perception; HIV/AIDS; Neuroendocrinology; Physics; Psychology; Diagnostic Sciences; Aetiology; Neurobiology; Cognitive Processes; Public Health, Health Services & Primary Care; Neuroscience; Neuroimaging; Child & Adolescent Psychiatry; Automated Clinical Analysis; Traumatology, Accidents & Injury; Epilepsy & Seizures; Biological Sciences; Mental Illness; Bipolar Disorder; Mind-Body Dualism; Sensory Systems; Attention Deficit Hyperactivity Disorder (ADHD); Muscle Diseases; Psychiatry; Neurology; Primary Care; Personality Disorders; Social Aspects of Mental Health; Electrical & Electronic Engineering; Epidemiology; Neurotransmitters; Depression & Other Mood Disorders; Neurosurgery; Biomedical Engineering; Biological Markers & Sensor Mechanisms; Motor Neurone Disease; Plasma Physics & Fusion; Medical Genetics; Stress, Psychological; Medical & Diagnostic Tests; Cancer Genetics; Stroke & Cerebrovascular Disorders; Clinical Psychology; Adolescent Paediatrics; Prosthetic & Orthotic Devices; Neuropharmacology; Neurostimulation; Medical Sociology; Anxiety Disorders; Sleep & Sleep Disorders; Allied Health Professions; Neuroanatomy; Central Nervous System; Neuropsychology; Clinical Medicine; Endocrine & Neuroendocrine Cancers; Electrophysiology; Pharmaceutical Drugs; Mental Health; Pharmacy & Pharmacology; Eating Disorders

Contact Details
----------------------------------------------
Fogarty International Center
Office of Communications
Building 31
31 Center Drive MSC 2220
Bethesda, MD 20892-2220
Tel: +1 301 496 1653
Email: brainfic@nih.gov

RAIN INITIATIVE: TECHNOLOGY SHARING AND PROPAGATION (R03)
NIH: National Institute of Mental Health

Description:
A total of ten offices and institutes of the National Institutes of Health invite applications for their brain initiative: technology sharing and propagation (R03) funding opportunity announcement. This announcement aims to encourage the transfer of new technologies and new data analysis techniques into a research laboratory. One of the key goals of the Brain Research through Advancing Innovative Neurotechnologies initiative is to develop new technologies to improve our understanding of the brain. This funding opportunity announcement seeks applications from investigators who can identify new technologies which if introduced
into their laboratory will enable or promote new research activities that further the aims of the BRAIN initiative.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

The BRAIN initiative intends to commit approximately US$1 million in fiscal year 2016 to fund an estimate of more than 10 awards. Application budgets are limited to US$100,000 with US$50,000 in direct costs reserved for the purchase or lease of equipment or purchase or licensing of software. The budget needs to reflect the actual needs of the proposed project. The maximum project period is one year.

Ref: RFA-MH-16-725

Closing date: 06 Jan 16
Deadline information: Applications open on 6 December and are due by 5pm local time of applicant organisation on 6 January 2016.

BRAIN INITIATIVE: FOUNDATIONS OF NON-INVASIVE FUNCTIONAL HUMAN BRAIN IMAGING AND RECORDING – BRIDGING SCALES AND MODALITIES (R01)
NIH: National Institute of Mental Health

Description:
A total number of 10 institutes institutes and offices of the National Institutes of Health invite applications for their BRAIN initiative: foundations of non-invasive functional human brain imaging and recording – bridging scales and modalities (R01) funding opportunity. This announcement aims to support transformative discoveries that will lead to breakthroughs in understanding human brain function. The research objective is to advance our ability to accurately and precisely infer microscopic details of underlying anatomy and physiology in the human brain from the more limited data available from non-invasive functional brain mapping methods.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

The initiative intends to commit a total estimated budget of US$12 million in fiscal year 2016 to fund 12 to 15 awards. Projects are limited to US$700,000 in direct costs in any project year. The maximum project period is five years.
Ref: RFA-MH-16-750.

Closing date: 06 Jan 16
Deadline information: Applications open 6 December 2015 and are due by 5pm local time of the applicant organisation on 6 January 2016.
Posted date: 28 Sep 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $3,500,000
Award budget total: $12,000,000


Eligibility profile
Country of applicant institution: Any

Disciplines
Neuroimaging; Central Nervous System; Neurology

Contact Details
Tel: +1 301 443 3621
Email: churchillj@mail.nih.gov

RESEARCH ON ALCOHOL AND HIV/AIDS (R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites R01 applications for its research on alcohol and HIV/AIDS programme.

This supports small research projects that aim to:

- characterise the relative importance of reducing alcohol misuse in the prevention of acquisition and transmission of HIV, in order to identify and apply appropriate alcohol and HIV interventions as public health measures;
- more fully understand and prevent the progression of HIV in the presence of continued alcohol exposure;
- develop operational research frameworks for addressing the occurrence and persistence of infections in high-risk populations, such as minority women and gay men, and translate findings into effective, culturally appropriate preventive and treatment interventions for these targeted populations.

This funding opportunity announcement will utilise the R01 grant mechanism and runs in parallel with two funding opportunity announcements of identical scientific scope that solicit applications under the R03 and R21 mechanisms.

Application budgets are not limited but need to reflect the actual needs of the proposed project. Funding is available for up to five years.
Applications may be submitted by domestic and foreign for-profit and non-profit organisations and public or private institutions.

PA-13-121.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time every 7 January, 7 May, 7 September until 8 May 2016.
Posted date: 22 Feb 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Public Health; Psychology; Preventive Medicine; Disadvantaged & Minority Groups; Medical Sociology; Allied Health Professions; Epidemiology; Drug & Substance Abuse; Biomedical Engineering; Health Disparities; Pathogenesis; Public Health, Health Services & Primary Care; Social Work & Social Policy; Women’s Health; Economic & Social Environment; Sociology; Gender Roles & Sexuality; Lesbian, Gay, Bisexual & Transgender Studies; Alcoholism; Disease Control; Behavioural Medicine; HIV/Aids; Diagnostic Sciences

Contact Details
----------------------------------------------
Tel: +1 301 403 9289
Email: kbryant@mail.nih.gov

RUG ABUSE ASPECTS OF HIV/AIDS (R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its drug abuse aspects of HIV/Aids (R01) programme. This R01 funding opportunity announcement seeks to examine the drug abuse aspects of HIV/Aids, including research on drug-related risk behaviours, addiction and HIV disease, and drug use and HIV-related co-morbidities and consequences. Applications are needed for the following areas:

- to identify and predict changes in the epidemiology of HIV/Aids among the following groups among injection and non-injection drug users and among their sexual partners;
- to develop and test interventions for primary and secondary HIV prevention, including drug treatment interventions;
- to improve HIV testing, counselling and treatment services for those living with HIV/Aids;
- to address basic mechanisms involved in HIV infection and Aids pathogenesis in the context of drug abuse and addiction.

This FOA will use the R01 award mechanism and runs in parallel with two FOAs of
identical scientific scope, PA-12-294 that solicits applications under the R03 mechanism and PA-12-295 that solicits applications under the R21 mechanism. The maximum project period is five years. Application budgets are not limited, but must reflect the actual needs of the project. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-12-293 (replaces PA-10-129).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 26 Sep 12
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-293.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-293

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Social Behaviour & Attitudes; Psychology; Biochemical Markers; Addiction; Health Disparities; Disease Control; Medical Sociology; General Practice; Diagnostic Sciences; HIV/AIDS; Neurology; Physiology; Epidemiology; Neuroscience; Pharmacy & Pharmacology; Population Studies, Medical; Virology; Venereology & Sexually Transmitted Diseases; Preventive Medicine; Infection Agents & Pathogens; Public Health, Health Services & Primary Care; Biomedical Engineering; Clinical Medicine; Infectious Diseases; Gender Roles & Sexuality; Allied Health Professions; Biological Markers & Sensor Mechanisms; Sociology; Economic & Social Environment; Cognitive Processes; Behavioural Medicine; Aetiology; Drug & Substance Abuse

Contact Details
----------------------------------------------
Division of Basic Neuroscience and Behavioral Research
NIDA
Neuroscience Center, Room 4279
6001 Executive Boulevard
Bethesda, MD 20892-9555
Tel: +1 301 496 8804
Fax: +1 301 594 6043
Email: aavila@nida.nih.gov

HIV INFECTION OF THE CENTRAL NERVOUS SYSTEM (R01)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Allergy and Infectious Disease, the National Institute on Drug Abuse and the National Institute of Neurological Disorders and Stroke invite research applications for their HIV infection of the central nervous system (R01) grants. This R01 funding opportunity announcement focuses on defining the pathogenic mechanisms involved in human immunodeficiency virus-1 associated neurocognitive disorders and identifying
therapeutic strategies to treat and prevent the neurobehavioral and neurological effects of HIV-1 on the CNS. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PA-14-094 (replaces PA-11-014).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 12 Feb 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: -


Additional Information:

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Psychology; Nucleus & Organelles; Public Health, Health Services & Primary Care; Primary Care; Cellular Interactions ; Human Biological Sciences; Physiology; Infectious Diseases; Molecular Genetics; Clinical Medicine; Virology; Diagnostic Sciences; Neuropsychology; Infection Agents & Pathogens; Neurobiology; Neurology; Medical & Diagnostic Tests; Neuroimaging; Pathogenesis; HIV/Aids; General Practice; Preventive Medicine; Biological Sciences; Proteomics & Molecular Interactions; Central Nervous System

**Contact Details**

NIMH
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 443 6100
Email: jjeymoha@mail.nih.gov

---

**TRUCTURAL INTERVENTIONS, ALCOHOL USE AND RISK OF HIV/AIDS (R21)**

**NIH: National Institute on Alcohol Abuse and Alcoholism**

**Description:**

The National Institute on Alcohol Abuse and Alcoholism invites proposals for its structural interventions, alcohol use and risk of HIV/Aids (R21) programme. This R21 funding opportunity announcement solicits applications from institutions and organisations that propose to investigate the effectiveness of structural interventions that reduce the risk of HIV/Aids transmission by changing the environment of alcohol use.
This FOA will use the research project grant R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-191, which solicits applications under the R01 research project grant mechanism. Applications budgets are limited to US$275,000 over a two-year period, with no more than US$200,000 in any year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-192 (replaces PA-10-243).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 20 May 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-192

Eligibility profile
Country of applicant institution: Any

Disciplines
Diagnostic Sciences; Health Disparities; Behavioural Medicine; HIV/Aids; Gender Roles & Sexuality; Education; Public Health, Health Services & Primary Care; Biomedical Engineering; Health Systems Policy; Preventive Medicine; Mental Illness; Alcoholism; Psychology; Social Work & Social Policy; Primary Care

Contact Details
NIHAA
5635 Fishers Lane, Room 2073
Bethesda , MD 20892-9304
Tel: +1 301 443 8820
Email: rfreeman@mail.nih.gov

Research on Malignancies in the Context of HIV/AIDS (R01)
NIH: National Cancer Institute

Description:
The National Cancer Institute and the National Institute of Dental and Craniofacial Research invite applications for their research on malignancies in the context of HIV/AIDS (R01) grants. The purpose of this R01 funding opportunity announcement is to advance understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency infection or acquired immune deficiency syndrome. NCI and NIDCR seek to encourage research in areas such as the study of the aetiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both Aids-defining and non-Aids-defining malignancies in diverse populations in the context of an underlying HIV infection. This FOA invites research efforts that will: provide information on the clinical outcomes of such cancers in the HIV-infected population; and identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers.
This FOA will use the research project grant (R01) award mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-378, which solicits applications under the R21 exploratory/developmental grant mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PA-13-377 (replaces PA-10-290).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 23 Oct 13
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -

Eligibility profile
Country of applicant institution: Any

Disciplines
Molecularly Targeted Therapy; Breast Cancer; Diagnostic Sciences; HIV/AIDS; Colorectal, Pancreatic & Stomach Cancers; Ovarian & Cervical Cancers; Physiology; Immunopathology; Non-cancerous Tumours; Cancer Immunology; Oncology Nursing; General Practice; Nursing; Health Systems, Risk Management; Medical & Diagnostic Tests; Brain Cancer; Chemotherapy; Carcinogenesis; Melanoma & Other Skin Cancers; Leukaemia & Other Blood Cancers; Cancer Studies & Oncology; Public Health, Health Services & Primary Care; Lung Cancer; Pathology; Prostate & Testicular Cancers; Human Biological Sciences; Aetiology; Clinical Medicine; Cancer Cell Biology; Primary Care

Contact Details
NCI
9609 Medical Center Drive
Rockville, MD 20850
Tel: +1 301 276 6226
Email: bconnole@mail.nih.gov

DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its drug abuse prevention intervention research (R01) funding opportunity announcement. This Aids-related announcement aims to support research that will employ rigourous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan. This FOA encourages investigations of cognitive, behavioural, and social processes as they relate to:
• development of novel prevention approaches;
• efficacy and effectiveness of prevention interventions or programmes;
• processes that optimise the selection, integration, implementation and sustainability of science-based prevention, including systems-level and health economic factors;
• methodologies appropriate for studying complex aspects of prevention science.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This FOA uses the research project grant (R01) funding mechanism and runs in parallel with two opportunities of identical scientific scope, PA-15-080 and PA-15-081 which respectively use the exploratory/developmental grant (R21) and the small grant programme (R03) funding mechanism.

Application budgets are not limited, but should reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-15-082 (reissue of PA-11-311).

Closing date: 07 Jan 16
Deadline information: Applications open on 5 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 12 Jan 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
--------------------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------------------------------------------
Smoking & Tobacco; HIV/AIDS; Alcoholism; Drug & Substance Abuse

Contact Details
--------------------------------------------------------------------------------
Prevention Research Branch
Division of Epidemiology, Services and Prevention Research
NIDA
6001 Executive Blvd, Suite 5160
Bethesda, MD 20892-9589
Tel: +1 301 443 6504
Fax: +1 301 443 2636
Email: pconway@nida.nih.gov

HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite proposals for their health services and economic research on the prevention and treatment of drug, alcohol and
tobacco abuse (R01) funding opportunity announcement. This AIDS-related announcement supports rigorous health services and economic research to maximise the delivery of efficient, high-quality drug, tobacco and alcohol prevention, treatment and recovery support services. The following subjects are of specific interest to the NIDA and NIAAA:

- clinical quality improvement;
- quality improvement in service organisation and management;
- implementation research;
- economic research;
- implications of policy change for service quality;
- methods, technology and other tools.

Applicants are strongly encouraged to contact scientific staff prior to submitting an application.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with several of identical scientific scope, PA-15-252, PA-15-253 and PA-15-250, which solicit applications under the NIH small grant programme (R03), the NIH exploratory/developmental (R21) and the NIH planning (R34) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but should reflect the actual costs of the proposed project. The maximum project period is five years.

Ref: PA-15-251 (reissue of PA-12-127).

Closing date: 07 Jan 16
Deadline information: Applications are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 11 May 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276470

Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism; Smoking & Tobacco; Access to Health Care; Quality of Care; Social Services Delivery; Standards of Care; HIV/Aids; Health Economics; Drug & Substance Abuse

Contact Details

Tel: +1 301 443 4715
Email: djones1@nida.nih.gov
INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its international research collaboration on drug abuse and addiction research (R01) research opportunity announcement. This Aids-related announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Special opportunities include access to unusual talent, resources, populations or environmental conditions in other countries that will speed scientific discovery. Projects must have relevance to the mission of NIDA and where feasible should address NIDA’s scientific priority areas. Priority areas include: linkages between HIV/AIDS and drug abuse; prevention, initiation and treatment of nicotine and tobacco use; the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact.

This funding opportunity uses the NIH research project grant programme (R01) mechanism and runs in parallel with two of identical scientific scope, PA-15-141 and PA-15-143 which respectively solicit applications under the NIH small grant programme (R03) mechanism and the NIH exploratory/developmental grant (R21) mechanism.

Research must be conducted by US investigators in collaboration with non-US based investigators. Projects must include significant contributions of resources by each participant. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Application budgets are not limited but must reflect the actual needs of the proposed project. The maximum project period is five years. Applicants requesting US$500,000 or more for direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. Ref: PA-15-142 (reissue of PA-12-040).

Closing date: 07 Jan 16
Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 18 Mar 15
Award type: Directed grants to institutions, research groups etc,
Networking/collaboration
Award budget total: -
Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275229

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Drug & Substance Abuse; Smoking & Tobacco; Alcoholism; HIV/Aids

Contact Details
----------------------------------------------
National Institute on Drug Abuse
NSC BG Room 4274
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6480
Email: ipdirector@nida.nih.gov
DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R21): AIDS-RELATED
NIH: National Institute of Mental Health

Description:
A total of 13 participating institutes and centres of the National Institutes of Health invite applications for their Aids-related dissemination and implementation research in health (R21) grants. This Aids-related R21 funding opportunity announcement encourages investigators to submit applications that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures, and strategies to disseminate and implement research-tested health behaviour change interventions, evidence-based prevention, early detection, diagnostic, treatment and management, and quality of life improvement services, and data monitoring and surveillance reporting tools into public health and clinical practice settings that focus on patient outcomes.

This FOA will use the R21 exploratory/developmental award mechanism, and runs in parallel with two FOAs of identical scientific scope, PAR-13-055, which encourages applications under the R01 research project grant mechanism, and PAR-13-056, which encourages applications under the R03 small grant programme mechanism.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. PAR-13-054 (replaces PAR-10-040).

Closing date: 07 Jan 16

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-054

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Health Systems, Administration; Behavioural Medicine; Psychology; Medical & Diagnostic Tests; Psychiatry; Medical Sociology; HIV/Aids; Mental Illness; Economic & Social Environment; Public Health; Health Promotion; General Practice; Mental Health; Health Systems; Sociology; Preventive Medicine; Biomedical Engineering; Public Health, Health Services & Primary Care

Contact Details
-----------------------------------------------
Division of Services and Intervention Research
NIMH
6001 Executive Boulevard, Room 7133, MSC 9631
Bethesda, MD 20892-9631
Tel: +1 301 443 3747
Fax: +1 301 443 4045
Email: dchamber@mail.nih.gov
IMAGING – SCIENCE TRACK AWARD FOR RESEARCH TRANSITION (R03) AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse and the National Institute of Biomedical Imaging and Bioengineering invite applications for their imaging – science track award for research transition (R03) funding opportunity announcement. This Aids-related announcement facilitates the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programmes, to enable them to conduct small proof of concept studies. Funding covers research that deals with any area of brain imaging and drug abuse.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

The award covers direct costs of up to US$150,000 for a maximum project period of one year.

Ref: PAR-15-326 (replaces PAR-12-066).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 September 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.
Posted date: 10 Aug 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $150,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Drug & Substance Abuse; Neuroimaging; HIV/Aids

Contact Details
----------------------------------------------
Tel: +1 301 443 4877
Email: sgrant@nida.nih.gov

HEALTH DISPARITIES IN NIDDK DISEASES (R01): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites Aids-related applications for its health disparities in NIDDK diseases (R01) programme.

This R01 funding opportunity announcement supports Aids-related research which aims to improve understanding of the causes of high priority diseases in the US, and to develop and test more effective interventions for reducing and eliminating health disparities.
Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity announcement will utilise the R01 mechanism. Application budgets are not limited, but must reflect the actual needs of the proposed project. Funding is available for up to five years. PA-13-183 (replaces PA-09-262).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, 7 January, 7 May and 7 September annually until 8 May 2016.
Posted date: 28 Aug 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Application form: http://www.grants.gov

Eligibility profile
Country of applicant institution: Any

Disciplines
Nutrition & Dietetics; Diabetes; Hepatology; Diagnostic Sciences; HIV/AIDS; Obesity; Allied Health Professions; Chronic Care; Clinical Medicine; Gastroenterology; Nephrology & Kidneys; Hormones & Endocrinology

Contact Details
Tel: +1 301 594 9652
Email: mcbrydekd@mail.nih.gov

MALL RESEARCH GRANT PROGRAMME (PARENT R03): AIDS-RELATED
NIH: National Human Genome Research Institute

Description:
Participating institutes of the National Institutes of Health invite applications for its Aids-related small research grant programme (parent R03). This Aids-related R03 funding opportunity supports small research projects that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Direct costs are limited to US$100,000 direct costs over the R03 two year period, with no more than US$50,000 in direct costs allowed in a single year.

Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. PA-13-304 (replaces PA-11-262)

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 06 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Business & Management Studies; HIV/AIDS; Physiology; Health Counselling; Nursing; Dentistry; Allied Health Professions; Clinical Medicine; Social Work & Social Policy; Medical Research of Selected Fields; Primary Care; Blood Tests; Public Health, Health Services & Primary Care; Pharmacy & Pharmacology; Human Biological Sciences; Medicine & Health; Diagnostic Sciences; Employment & Unemployment Studies

EXPLORATORY/DEVELOPMENTAL RESEARCH GRANT PROGRAMME (PARENT R21):
AIDS-RELATED
NIH: National Institutes of Health

Description:
Participating institutes and centres of the National Institutes of Health invite AIDS-related applications under the exploratory/developmental research grant programme (parent R21). This AIDS-related funding opportunity announcement encourages exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioural or clinical research.

Applicants may request direct costs of up US$275,000 for a two-year period, with no more than US$200,000 in any year. Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. PA-13-303 (replaces PA-11-261).

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 06 Aug 13

Award type: Directed grants to institutions, research groups etc

Award amount max: $275,000


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Medicine & Health; Physiology; Allied Health Professions; Dentistry; Pharmacy & Pharmacology; Primary Care; Nursing; Public Health, Health Services & Primary Care; Human Biological Sciences; Clinical Medicine; HIV/AIDS; Diagnostic Sciences
Drug Abuse Aspects of HIV/AIDS (R21)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its drug abuse aspects of HIV/AIDS (R21) programme. This R21 funding opportunity announcement seeks to examine the drug abuse aspects of HIV/AIDS, including research on drug-related risk behaviours, addiction and HIV disease, and drug use and HIV-related co-morbidities and consequences. Applications are needed for the following areas:

- to identify and predict changes in the epidemiology of HIV/AIDS among the following groups among injection and non-injection drug users and among their sexual partners;
- to develop and test interventions for primary and secondary HIV prevention, including drug treatment interventions;
- to improve HIV testing, counselling and treatment services for those living with HIV/AIDS;
- to address basic mechanisms involved in HIV infection and AIDS pathogenesis in the context of drug abuse and addiction.

This FOA will use the R21 award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-12-293 that solicits applications under the R01 mechanism and PA-12-294 that solicits applications under the R03 mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-12-295 (replaces PA-10-130).

Closing date: 07 Jan 16

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 26 Sep 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa- files/PA-12-295.html

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-295

Eligibility profile
Country of applicant institution: Any

Disciplines
Drug & Substance Abuse; Public Health, Health Services & Primary Care; Immunisation Programmes & Vaccination; Virology; Pharmacy & Pharmacology; Venereology & Sexually Transmitted Diseases; Biological Markers & Sensor Mechanisms; Medical Sociology; Sociology; Infection Agents & Pathogens; Disease Control; Social Behaviour & Attitudes; Epidemiology; Preventive Medicine; Psychology; Neuroscience; Clinical Medicine; Infectious Diseases; Economic & Social Environment; Health Disparities; Allied Health Professions; Addiction; Biomedical Engineering; General Practice; Diagnostic Sciences; Aetiology; Gender Roles & Sexuality; Population Studies, Medical; Cognitive Processes; Physiology; Disadvantaged & Minority Groups; Drug Design; Neurology; Tuberculosis; Behavioural Medicine; Biochemical Markers; HIV/AIDS
DRUG ABUSE ASPECTS OF HIV/AIDS (R03)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its drug abuse aspects of HIV/AIDS (R03) programme. This R03 funding opportunity announcement seeks to examine the drug abuse aspects of HIV/AIDS, including research on drug-related risk behaviours, addiction and HIV disease, and drug use and HIV-related co-morbidities and consequences. Applications are needed for the following areas:

- to identify and predict changes in the epidemiology of HIV/AIDS among the following groups among injection and non-injection drug users and among their sexual partners;
- to develop and test interventions for primary and secondary HIV prevention, including drug treatment interventions;
- to improve HIV testing, counselling and treatment services for those living with HIV/AIDS;
- to address basic mechanisms involved in HIV infection and Aids pathogenesis in the context of drug abuse and addiction.

This FOA will use the NIH small research grant (R03) award mechanism and PA-12-295 that solicits applications under the R01 mechanism and PA-12-295 that solicits applications under the R21 mechanism. Budgets for direct costs of up to US$50,000 per year and a project duration of up to two years may be requested for a maximum of US$100,000 direct costs over a two-year project period. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-12-294 (replaces PA-10-131).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 26 Sep 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-294.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?option=PA-12-294

Eligibility profile
Country of applicant institution: Any

Disciplines

Contact Details
--------------------------------------------------
Division of Basic Neuroscience and
Behavioral Research
NIDA
Neuroscience Center, Room 4279
6001 Executive Boulevard
Bethesda, MD 20892-9555
Tel: +1 301 496 8804
Fax: +1 301 594 6043
Email: aavila@nida.nih.gov
D
RUG ABUSE PREVENTION INTERVENTION RESEARCH (R21): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its drug abuse prevention intervention research (R21) funding opportunity announcement. This Aids-related announcement aims to support research that will employ rigorous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan.

This FOA encourages investigations of cognitive, behavioral, and social processes as they relate to:

- development of novel prevention approaches;
- efficacy and effectiveness of prevention interventions or programmes;
- processes that optimise the selection, integration, implementation and sustainability of science-based prevention, including systems-level and health economic factors;
- methodologies appropriate for studying complex aspects of prevention science.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This FOA uses the exploratory/developmental grant (R21) funding mechanism and runs in parallel with two opportunities of identical scientific scope, PA-15-081 and PA-15-082 which respectively use the small grant programme (R03) and the research project grant (R01) funding mechanism.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year.
Ref: PA-15-080 (reissue of PA-11-312).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 12 Jan 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000

---

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Drug & Substance Abuse; Alcoholism; Smoking & Tobacco; HIV/Aids

**Contact Details**

NIDA
NSC BG Room 5171
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6504
Email: hperl@mail.nih.gov

---

**Drug Abuse Prevention Intervention Research (R03): AIDS-RELATED**

NIH: National Institute on Drug Abuse

**Description:**

The National Institute on Drug Abuse invites applications for its drug abuse prevention intervention research (R03) funding opportunity announcement. This Aids-related announcement aims to support research that will employ rigorous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings across the lifespan.

This FOA encourages investigations of cognitive, behavioural, and social processes as they relate to:

- development of novel prevention approaches;
- efficacy and effectiveness of prevention interventions or programmes;
- processes that optimise the selection, integration, implementation and sustainability of science-based prevention, including systems-level and health economic factors;
- methodologies appropriate for studying complex aspects of prevention science.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This FOA uses the small grant programme (R03)
funding mechanism and runs in parallel with two opportunities of identical scientific scope, PA-15-080 and PA-15-082 which respectively use the exploratory/developmental grant (R21) and the research project grant (R01) funding mechanism.

Direct costs of up to US$50,000 per year and a project duration of up to two years may be requested. 
Ref: PA-15-081 (reissue of PA-11-313).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 12 Jan 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Award amount min: -


Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/Aids; Smoking & Tobacco; Drug & Substance Abuse; Alcoholism

Contact Details
NIDA
NSC BG Room 5171
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6504
Email: hperl@mail.nih.gov

Description:
The National Cancer Institute and the National Institute of Dental and Craniofacial Research invite applications for their research on malignancies in the context of HIV/AIDS (R21) grants. The purpose of this R21 funding opportunity announcement is to advance understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency infection or acquired immune deficiency syndrome. NCI and NIDCR seek to encourage research in areas such as the study of the aetiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both Aids-defining and non-Aids defining malignancies in diverse populations in the context of an underlying HIV infection. This FOA invites research efforts that will: provide information on the clinical outcomes of such cancers in the HIV-infected population; and identify specific contributions resulting from HIV infection and its potential interaction with other
pathogens for the development and pathogenesis of these cancers.

This FOA will use the exploratory/developmental grant (R21) mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-377, which solicits applications under the research project R01 research project grant mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Ref: PA-13-378 (replaces PA-10-291).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 23 Oct 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Application form: http://apply07.grants.gov/apply(GetGrantFromFedgrants?opportunity=PA-13-378

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Prostate & Testicular Cancers; Lung Cancer; Cancer Studies & Oncology; Human Biological Sciences; Cancer Cell Biology; Carcinogenesis; Nursing; Brain Cancer; Public Health, Health Services & Primary Care; Aetiology; Chemotherapy; Non-cancerous Tumours; Leukaemia & Other Blood Cancers; Colorectal, Pancreatic & Stomach Cancers; Health Systems, Risk Management; Medical & Diagnostic Tests; Oncology Nursing; General Practice; Molecularly Targeted Therapy; Clinical Medicine; Immunopathology; HIV/Aids; Breast Cancer; Primary Care; Cancer Immunology; Melanoma & Other Skin Cancers; Physiology; Diagnostic Sciences; Ovarian & Cervical Cancers; Pathology

Contact Details
----------------------------------------------
NCI
9609 Medical Center Drive
Rockville, MD 20850
Tel: +1 301 276 6226
Email: bconnole@mail.nih.gov

BIOLOGY OF MANUAL THERAPIES (R21): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Center for Complementary and Alternative Medicine invites Aids-related applications for its call on biology of manual therapies (R21). This Aids-related R21 funding opportunity announcement supports studies of the basic science and mechanisms of action underlying the neurophysiological, immunological, endocrinological or biomechanical consequences of manual therapies such as spinal manipulation, mobilisation and massage therapy.
This FOA uses the R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-168, which solicits applications under the R01 mechanism.

Eligible institutions include domestic and foreign for-profit and non-profit organisations and public or private institutions.

Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PA-14-167 (replaces PA-10-210).

Closing date: 07 Jan 16
Deadline information: Deadlines by 5pm proposer’s local time every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 31 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-167.html
Application form: http://www.grants.gov/web/grants/applicants/download-application-

Eligibility profile

Country of applicant institution: Any

Disciplines

Folk, Complementary & Alternative Medicine; Mechanical Engineering; Traumatology, Accidents & Injury; Physiology; Aerospace Engineering & Avionics; Electrophysiology; Medical Research of Selected Fields; Endocrine & Neuroendocrine Cancers; Hormones & Endocrinology; Growth & Growth Factors; Cancer Cell Biology; HIV/Aids; Biomechanics; Manufacturing & Industrial Engineering; Human Biological Sciences; Central Nervous System; Clinical Medicine; Diagostic Sciences; Immunology; Therapy Evaluation

Contact Details

NCCAM
6707 Democracy Blvd, Suite 401
Bethesda, MD 20892
Tel: +1 301 594 3462
Fax: +1 301 401 1587
Email: patrap.khalsa@nih.gov

NIH RESEARCH GRANT FOR SECONDARY DATA ANALYSIS (R21): AIDS-RELATED

NIH: National Eye Institute

Description:
The National Eye Institute invites applications for its research grant for its Aids-related secondary data analysis (R21) programme. The purpose of this Aids-related R21 funding opportunity announcement is to conduct secondary analyses using existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports and extensive portfolio of clinical trials and large-scale epidemiologic research projects, wherein numerous data collection activities are required. Data are not limited to those
collected under NEI support, but such data are of the highest programmatic interest. The R21 grant may be used to develop new statistical methodologies or to test hypotheses using existing data, but this FOA may not be used to support the collection of new data.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to submit applications. PAR-13-035 (replaces PAR-09-252).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September 7 until until 8 May 2016.
Posted date: 06 Dec 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000


Eligibility profile
Country of applicant institution: Any

Disciplines
Clinical Medicine; Sensory Systems; Vision Science; Data Analysis; Eye Diseases; Ophthalmology; Physiology; HIV/Aids; Diagnostic Sciences

Contact Details
Division of Extramural Research
NEI
5635 Fishers Lane, Suite 1300, MSC 9300
Bethesda, MD 20892-9300
Tel: +1 301 451 2020
Fax: +1 301 402 0528
Email: everettd@mail.nih.gov

PRESRIPTION DRUG ABUSE (R21): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related prescription drug abuse research programme. The purpose of this Aids-related R21 funding opportunity announcement is to encourage a broad range of research strategies to address the problem of prescription drug abuse. Across proposed research strategies, there is an interest in stimulating the development and integration of novel technologies to observe and understand the aetiology and biological and behavioural mechanisms associated with prescription drug abuse. The specific areas of interest include:

- basic preclinical and clinical research;
- epidemiology and prevention research;
- treatment and health systems research.

This FOA will use the NIH exploratory/developmental (R21) award
mechanism and runs in parallel an FOA of identical scientific scope, PA-13-015, which solicits applications under the research project grant (R01) mechanism. Application budgets are limited to US$275,000 over a two-year period, with no more than US$200,000 in any year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-016 (replaces PA-08-128).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 05 Nov 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Public Health, Health Services & Primary Care; Psychology; Cognitive & Behavioural Therapies; Pharmacy & Pharmacology; Drug & Substance Abuse; Compulsive Behaviour; Addiction; Pharmaceutical Drugs; Preventive Medicine; General Practice; Economic & Social Environment; Allied Health Professions; Psychiatry; Anxiety Disorders; Diagnostic Sciences; HIV/Aids; Primary Care

Contact Details
----------------------------------------------
Division of Epidemiology, Services and Prevention Research
National Institute on Drug Abuse, NIH.
DHHS
6001 Executive Boulevard, Room 5193
Bethesda, Maryland 20892
Tel: +1 301 594 4371
Email: deniscor@nida.nih.gov
Applicants are strongly encouraged to contact scientific staff prior to submitting an application.

This funding opportunity uses the NIH exploratory/developmental (R21) mechanism and runs in parallel with several of identical scientific scope, PA-15-251, PA-15-252 and PA-15-250 which solicit applications under the NIH research project (R01), the NIH small grant programme (R03) and the NIH planning (R34) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs with up to US$200,000 in direct costs per year.

The maximum project period is two years.

Ref: PA-15-253 (reissue of PA-12-128).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 11 May 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276474

Eligibility profile

----------------------------------------------
Country of applicant institution: Any

Disciplines

----------------------------------------------
Social Services Delivery; Access to Health Care; Standards of Care; Quality of Care; Health Economics; HIV/AIDS; Smoking & Tobacco; Drug & Substance Abuse; Alcoholism

Contact Details

----------------------------------------------
Tel: +1 301 443 4715
Email: djones1@nida.nih.gov

HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R03): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite proposals for their health services and economic research on the prevention and treatment of drug, alcohol and tobacco abuse (R03) funding opportunity announcement. This Aids-related announcement supports rigourous health services and economic research to maximise the delivery of efficient, high-quality drug, tobacco and alcohol prevention, treatment and recovery support services. The following subjects are of specific interest to the NIDA and NIAAA:

• clinical quality improvement;
• quality improvement in service organisation and management;
• implementation research;
• economic research;
• implications of policy change for service quality;
• methods, technology and other tools.

Applicants are strongly encouraged to contact scientific staff prior to submitting an application.

This funding opportunity uses the NIH small grant programme (R03) grant mechanism and runs in parallel with several of identical scientific scope, PA-15-251, PA-15-253 and PA-15-250 which solicit applications under the NIH exploratory/developmental (R21) and the NIH planning (R34) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Application budgets are limited to US$50,000 in direct costs per year. The maximum project period is two years.

Ref: PA-15-252 (reissue of PA-12-129).

Closing date: 07 Jan 16

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 11 May 15

Award type: Directed grants to institutions, research groups etc

Award amount max: $100,000


Eligibility profile

----------------------------------------------

Country of applicant institution: Any

Disciplines

----------------------------------------------

Smoking & Tobacco; Social Services Delivery; Alcoholism; HIV/Aids; Quality of Care; Drug & Substance Abuse; Standards of Care; Health Economics; Access to Health Care

Contact Details

----------------------------------------------

Tel: +1 301 443 4715
Email: djones1@nida.nih.gov

Pilot and Feasibility Clinical Trials in Diabetes, and Endocrine and Metabolic Diseases (R21): AIDS-Related

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its pilot and feasibility clinical trials in diabetes, and endocrine and metabolic diseases (R21) funding opportunity announcement. This Aids-related announcement supports pilot and feasibility trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention or treatment of diabetes or selected endocrine and genetic metabolic diseases.

US and foreign for-profit and non-profit organisations and public and private
organisations are eligible to apply. Foreign applications must reflect special opportunities, and must be applicable to US healthcare systems to be considered for funding.

Application budgets are limited to a total of US$275,000 in direct costs, with a maximum of US$200,000 in direct costs per year. The maximum project period is two years. Ref: PA-15-176 (reissue of PA-12-157).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 07 Apr 15
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award amount max: $275,000


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Human Metabolism; Diabetes; Hormones & Endocrinology; Genetic Diseases; HIV/Aids

Contact Details
----------------------------------------------
NIDDK
BG 2DEM Room 687
6707 Democracy Boulevard
Bethesda, MD 20892
Tel: +1 301 594 7733
Email: marteylk@mail.nih.gov

EXPORATORY/DEVELOPMENTAL BIOENGINEERING RESEARCH GRANTS (R21): AIDS-RELATED
NIH: National Institute of Biomedical Imaging and Bioengineering

Description:
The National Institute of Biomedical Imaging and Bioengineering and 10 other participating institutes of the National Institutes of Health invite applications for their Aids-related exploratory/developmental bioengineering research (R21) grants. The purpose of this Aids-related R21 funding opportunity announcement is to establish the feasibility of technologies, techniques or methods that: explore a unique multidisciplinary approach to a biomedical challenge, are high-risk but have a considerable payoff, and develop data leading to significant future research. Applications may propose hypothesis-driven, developmental or design-directed research and is appropriate for evaluating unproven approaches for which there is minimal or no preliminary data.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible organisations include domestic and foreign for-profit and non-profit organisations and public or private institutions. PA-12-284 (replaces PA-10-010).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 May, 7 September and 7 January until 8 January 2016.
Posted date: 12 Sep 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-284.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-284

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
General Practice; Medicine & Health; Preventive Medicine; Behavioural Medicine; Biomedical Engineering; Radiology & Medical Imaging; Assistive Technology; Psychology; HIV/Aids; Medical & Diagnostic Tests; Medical Research of Selected Fields; Bioengineering; Clinical Medicine

Contact Details
----------------------------------------------
Division of Discovery Science and Technology
NIBIB
6707 Democracy Boulevard, Suite 200
Bethesda, MD 20892-5477
Tel: +1 301 451 4778
Fax: +1 301 480 1614
Email: kelleyc@mail.nih.gov

BIOENGINEERING RESEARCH GRANTS (R01): AIDS-RELATED
NIH: National Institute of Biomedical Imaging and Bioengineering

Description:
Participating institutes and centres of the National Institutes of Health invite Aids-related applications for their R01 bioengineering research grants. Grants are provided for Aids-related basic and or applied multidisciplinary research that can increase understanding and solve problems in biological, clinical or translational science. This programme intends to support Aids-related participating institutes and centres of the National Institutes of Health invite applications for their R01 bioengineering research grants.

This FOA will use the NIH R01 research project grant (R01) award mechanism and runs in parallel with two FOAs of similar scientific scope, PA-12-284 that solicits applications under the R21 mechanism and R01 opportunity PAR-10-234. Proposed projects may not exceed five years. Applications are welcome from domestic and foreign for-profit and non-profit organisations and public or private institutions. PAR-13-137 (replaces PA-10-009)

Closing date: 07 Jan 16
Deadline information:
Posted date: 11 Mar 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine; Human Biological Sciences; Bioengineering; Biomedical Engineering; Mechanical Engineering; Pharmacy & Pharmacology; Public Health, Health Services & Primary Care; Blood Tests; General Practice; Manufacturing & Industrial Engineering; Physiology; Medical Instrumentation; Medical Research of Selected Fields; Diagnostic Sciences; Medical & Diagnostic Tests; Pharmaceutical Drugs; Aerospace Engineering & Avionics; Primary Care; HIV/Aids; Allied Health Professions; Preventive Medicine; Dentistry; Nursing; Assistive Technology; Medicine & Health

Contact Details

NIBIB
Division of Discovery Science and Technology
6707 Democracy Blvd, Suite 200
MS 5477 – Room 225
Bethesda, MD 20892-2077
Tel: +1 301 451 4778
Fax: +1 301 480 1614
Email: kelleyc@mail.nih.gov

BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME
(R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the Office of Behavioral and Social Sciences Research invite applications for their Aids-related behavioural and integrative treatment development (R01) grants. The aim of this Aids-related R01 programme is to develop and test behavioural and integrative treatments for drug and alcohol abuse and dependence. Research will test efficacy, conduct clinical trials, examine mechanisms of behaviour change, determine dose-response, optimise combinations, or ascertain best sequencing of behavioural, combined, sequential, or integrated behavioural and pharmacological treatments in the following circumstances:

- drug abuse treatment interventions in diverse settings;
- drug abuse treatment and adherence interventions for use in primary care;
- drug abuse treatment and adherence interventions that use technologies to boost effects and increase implementability;
- interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment;
- interventions to promote adherence to drug abuse treatment, HIV and addiction medications;
- interventions to treat chronic pain.

Research of interest includes but is not limited to Stage II and Stage III efficacy research.

This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-079, which solicits applications under the R03 small grant programme mechanism, and PA-13-078, which solicits
applications under the R34 clinical trial planning grant programme. mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions. Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years. PA-13-077 (replaces PA-10-012).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-077

Eligibility profile
Country of applicant institution: Any

Disciplines
Counselling & Therapy; Public Health, Health Services & Primary Care; Behavioural Medicine; Biological Sciences; Neurobiology; General Practice; Drug & Substance Abuse; HIV/AIDS; Cognitive Processes; Mental Illness; Physiology; Psychology; Medical Sociology; Allied Health Professions; Population Studies, Medical; Primary Care; Diagnostic Sciences; Sociology; Cognitive & Behavioural Therapies; Molecular Genetics; Neuroscience

Contact Details
Division of Clinical Neuroscience and Behavioural Research
NIDA
6001 Executive Boulevard, Room 3172, MSC 9593
Bethesda, MD 20892-9593
Tel: +1 301 443 2235
Email: lisa_onken@nih.gov

BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R03): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the Office of Behavioral and Social Sciences Research invite applications for their Aids-related behavioural and integrative treatment development (R03) grants. The aim of this Aids-related R03 programme is to develop and test behavioural and integrative treatments for drug and alcohol abuse and dependence. Research will test efficacy, conduct clinical trials, examine mechanisms of behaviour change, determine dose-response, optimise combinations, or ascertain best sequencing of behavioural, combined, sequential, or integrated behavioural and pharmacological treatments in the following circumstances:

• drug abuse treatment interventions in diverse settings;
• drug abuse treatment and adherence interventions for use in primary care;
• drug abuse treatment and adherence interventions that use technologies to boost effects and increase implementability;
• interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment;
• interventions to promote adherence to drug abuse treatment, HIV and addiction medications;
• interventions to treat chronic pain.

Research of interest includes but is not limited to Stage II and Stage III efficacy research.

This funding opportunity announcement will use the NIH small research grant (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-077, which solicits applications under the R01 research project grant mechanism, and PA-13-078, which solicits applications under the R34 clinical trial planning grant programme.

Direct costs are limited to US$100,000 over a two-year period, with no more than US$50,000 in direct costs allowed in any single year. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. PAR-13-079 (replaces PAR-10-011).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.

Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-079

Eligibility profile
---------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------
Medical Sociology; Neuroscience; Cognitive Processes; Mental Illness; Sociology; General Practice; Public Health, Health Services & Primary Care; Population Studies, Medical; Molecular Genetics; Diagnostic Sciences; Biological Sciences; HIV/Aids; Psychology; Infection Agents & Pathogens; Primary Care; Cognitive & Behavioural Therapies; Infectious Diseases; Alcoholism; Allied Health Professions; Physiology; Behavioural Medicine; Counselling & Therapy; Neurobiology; Drug & Substance Abuse

Contact Details
---------------------------------------------
Division of Clinical Neuroscience and Behavioural Research
NIDA
6001 Executive Boulevard, Room 3172, MSC 9593
Bethesda, MD 20892-9593
Tel: +1 301 443 2235
Email: lisa_onken@nih.gov
MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R21): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
Participating institutes and centres of the National Institutes of Health invite AIDS-related applications for research into the mechanisms, models, measurement and management in pain research. The purpose of this funding opportunity announcement is to inform the scientific community of the pain research interests of the various institutes and centres at the NIH and to stimulate and foster a wide range of AIDS-related basic, clinical, and translational R21 studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioural and social sciences. Research may address: molecular and cellular mechanisms of pain; genetics of pain; biobehavioural pain; models of pain; diagnosis and assessment of pain; pain management; epidemiology of pain; health disparities; translational pain research. Research conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

This FOA will use the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-119, that utilises the R01 mechanism and PA-13-117, that utilises the R03 mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible organisations include for-profit and non-profit organisations, and public or private institutions. PA-13-119 (replaces PA-10-007).

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm applicant’s local time, every 7 May, 7 September and 7 January until 8 May 2016.
Posted date: 18 Feb 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile

Country of applicant institution: Any
Disciplines

Osteoporosis & Other Bone Diseases; Health Disparities; Chronic Pain; Ethology; HIV/AIDS; Primary Care; Traumatology; Accidents & Injury; Behavioural Medicine; Dermatology; Diagnostic Sciences; Chemotherapy; Muscle Diseases; Biological Sciences; Allied Health Professions; Pharmacy & Pharmacology; Cardiovascular Diseases; Oncology Nursing; Nursing; Gene Therapy; Clinical Medicine; Biochemistry & Molecular Biology; Palliative Nursing; Geriatric Nursing; Neuropharmacology; Pain Management; Medical & Diagnostic Tests; Molecular Genetics; Cognitive & Behavioural Therapies; Cell & Developmental Biology; Public Health, Health Services & Primary Care; Epidemiology

Contact Details

National Institute of Nursing Research, NIH
6701 Democracy Blvd., Suite 710
One Democracy Plaza
Bethesda, MD 20892-4870
Tel: +1 301 496 9623
Email: mardens@mail.nih.gov
MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R03): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
Participating institutes and centres of the National Institutes of Health invite AIDS-related applications for research into the mechanisms, models, measurement and management in pain research. The purpose of this funding opportunity announcement is to inform the scientific community of the pain research interests of the various institutes and centres at the NIH and to stimulate and foster a wide range of basic, clinical, and translational R03 studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioural and social sciences. Research may address: molecular and cellular mechanisms of pain; genetics of pain; biobehavioural pain; models of pain; diagnosis and assessment of pain; pain management; epidemiology of pain; health disparities; translational pain research. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

This FOA will use the NIH small research grant (R03) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-119, that utilises the R01 mechanism and PA-13-118, that utilises the R21 mechanism. Budgets for direct costs of up to US$50,000 per year and a project duration of up to two years may be requested for a maximum of US$100,000 direct costs over a two-year project period. Eligible organisations include for-profit and non-profit organisations, and public or private institutions. PA-13-117 (replaces PA-10-008).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm applicant’s local time, every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 18 Feb 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Medical & Diagnostic Tests; Osteoporosis & Other Bone Diseases; Cognitive & Behavioural Therapies; Ethology; Gene Therapy; Cardiovascular Diseases; Biochemistry & Molecular Biology; Behavioural Medicine; Oncology Nursing; Primary Care; Dermatology; Pharmacy & Pharmacology; Pain Management; Chemotherapy; Nursing; Allied Health Professions; Muscle Diseases; Cell & Developmental Biology; Chronic Pain; Palliative Nursing; Traumatology, Accidents & Injury; Epidemiology; Molecular Genetics; Health Disparities; Diagnostic Sciences; Biological Sciences; Public Health, Health Services & Primary Care; Neuropharmacology; Clinical Medicine; Geriatric Nursing; HIV/Aids

Contact Details
National Institute of Nursing Research, NIH
6701 Democracy Blvd., Suite 710
One Democracy Plaza
Bethesda, MD 20892-4870
Tel: +1 301 496 9623
Email: mardens@mail.nih.gov
MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R01): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
Participating institutes and centres of the National Institutes of Health invite AIDS-related R01 applications for research into the mechanisms, models, measurement and management in pain research. The purpose of this R01 funding opportunity announcement is to inform the scientific community of the pain research interests of the various institutes and centres at the NIH and to stimulate and foster a wide range of basic, clinical, and translational R01 studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioural and social sciences. Research may address: molecular and cellular mechanisms of pain; genetics of pain; biobehavioural pain; models of pain; diagnosis and assessment of pain; pain management; epidemiology of pain; health disparities; translational pain research. Research conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

This FOA will use the R01 grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-119, that solicits applications under the R21 mechanism, and PA-13-117, that solicits applications under the R03 mechanism. Eligible organisations include for-profit and non-profit organisations, and public or private institutions. PA-13-118 (replaces PA-10-006).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm applicant’s local time, every 7 May, 7 September and 7 January until 8 May 2016.

Posted date: 18 Feb 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile

Country of applicant institution: Any

Disciplines

Health Disparities; Allied Health Professions; Epidemiology; Medical & Diagnostic Tests; Chemotherapy; Molecular Genetics; Nursing; Public Health, Health Services & Primary Care; Traumatology, Accidents & Injury; Oncology Nursing; Osteoporosis & Other Bone Diseases; Diagnostic Sciences; Dermatology; Biochemistry & Molecular Biology; Behavioural Medicine; Clinical Medicine; Cell & Developmental Biology; Primary Care; Muscle Diseases; Chronic Pain; Palliative Nursing; Pharmacy & Pharmacology; Cognitive & Behavioural Therapies; HIV/AIDS; Cardiovascular Diseases; Biological Sciences; Pain Management; Gene Therapy; Geriatric Nursing; Ethology; Neuropharmacology

Contact Details

Office of Extramural Activities
National Institute of Nursing Research, NIH
6701 Democracy Blvd., Suite 710
One Democracy Plaza
Bethesda, MD 20892-4870
Tel: +1 301 496 9623
Email: mardens@mail.nih.gov
Description:
Participating institutes and centres of the National Institutes of Health invite Aids-related applications for under the research project grant parent R01 funding opportunity announcement. The research project grant (R01) supports a discrete, specified, circumscribed project to be performed by the named investigators in areas representing the specific interests and competencies of the investigators. The proposed project must be related to the stated programme interests of one or more of the NIH institutes and centres based on descriptions of their programmes. Research grant applications are assigned to an NIH institutes and centres based on receipt and referral guidelines and many applications are assigned to multiple ICs with related research interests.

This FOA will use the NIH research project grant (R01) award mechanism. Application budgets are not limited, but should reflect the actual needs of the projects. A project duration of up to five years may be requested. Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. PA-13-302 (replaces PA-11-260)

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 05 Aug 13

Award type: Directed grants to institutions, research groups etc

Award budget total: -


Eligibility profile

Country of applicant institution: Any

Disciplines

Human Biological Sciences; Biological Sciences; Physiology; Primary Care; Allied Health Professions; HIV/AIDS; Nursing; Public Health, Health Services & Primary Care; Dentistry; Pharmacy & Pharmacology; Diagnostic Sciences; Clinical Medicine; Medicine & Health

Research on Alcohol and HIV/AIDS (R21)

Description:
The National Institute on Alcohol Abuse and Alcoholism invites R21 applications for its research on alcohol and HIV/AIDS programme.
This supports small research projects that aim to:

- characterise the relative importance of reducing alcohol misuse in the prevention of acquisition and transmission of HIV, in order to identify and apply appropriate alcohol and HIV interventions as public health measures;
- more fully understand and prevent the progression of HIV in the presence of continued alcohol exposure;
- develop operational research frameworks for addressing the occurrence and persistence of infections in high-risk populations, such as minority women and gay men, and translate findings into effective, culturally appropriate preventive and treatment interventions for these targeted populations.

This funding opportunity announcement will utilise the R21 grant mechanism and runs in parallel with two funding opportunity announcements of identical scientific scope that solicit applications under the R01 and R03 mechanisms.

Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Applications may be submitted by domestic and foreign for-profit and non-profit organisations and public or private institutions.

PA-13-122.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time every 7 January, 7 May, 7 September until 8 May 2016.
Posted date: 22 Feb 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-10-105.html

Eligibility profile

Country of applicant institution: Any

Disciplines

Medical Sociology; Health Disparities; Diagnostic Sciences; HIV/AIDS; Sociology; Drug & Substance Abuse; Disease Control; Pathogenesis; Disadvantaged & Minority Groups; Economic & Social Environment; Social Work & Social Policy; Epidemiology; Psychology; Public Health; Behavioural Medicine; Lesbian, Gay, Bisexual & Transgender Studies; Gender Roles & Sexuality; Preventive Medicine; Alcoholism; Allied Health Professions; Public Health, Health Services & Primary Care; Women’s Health; Biomedical Engineering

Contact Details

Tel: +1 301 403 9289
Email: kbryant@mail.nih.gov
Research on Alcohol and HIV/AIDS (R03)
NIH: National Institute on Alcohol Abuse and Alcoholism

**Description:**
The National Institute on Alcohol Abuse and Alcoholism invites R03 applications for its research on alcohol and HIV/AIDS programme.

This supports small research projects that aim to:
- characterise the relative importance of reducing alcohol misuse in the prevention of acquisition and transmission of HIV, in order to identify and apply appropriate alcohol and HIV interventions as public health measures;
- more fully understand and prevent the progression of HIV in the presence of continued alcohol exposure;
- develop operational research frameworks for addressing the occurrence and persistence of infections in high-risk populations, such as minority women and gay men, and translate findings into effective, culturally appropriate preventive and treatment interventions for these targeted populations.

The R03 grant mechanism is intended to support small research projects that can be carried out in a short period of time with limited resources.

This funding opportunity announcement will utilise the R03 grant mechanism and runs in parallel with two funding opportunity announcements of identical scientific scope that solicit applications under the R01 and R21 mechanisms. Projects may request direct costs of US$50,000 over a maximum of two years.

Applications may be submitted by domestic and foreign for-profit and non-profit organisations and public or private institutions.

**Closing date:** 07 Jan 16
**Deadline information:** Applications due by 5pm proposer’s local time every 7 January, 7 May, 7 September until 8 May 2016.
**Posted date:** 22 Feb 13
**Award type:** Directed grants to institutions, research groups etc
**Award amount max:** $50,000

**Eligibility profile**
-----------------------------------------------
**Country of applicant institution:** Any

**Disciplines**
-----------------------------------------------
- Allied Health Professions; Drug & Substance Abuse; Lesbian, Gay, Bisexual & Transgender Studies; Women’s Health; Social Work & Social Policy; Behavioural Medicine; Pathogenesis; Public Health; Gender Roles & Sexuality; Biomedical Engineering; Health Disparities; Epidemiology; Alcoholism; Psychology; Medical Sociology ; Economic & Social Environment; Diagnostic Sciences; Disadvantaged & Minority Groups; HIV/AIDS; Preventive Medicine; Sociology; Disease Control; Public Health, Health Services & Primary Care

**Contact Details**
-----------------------------------------------
**Tel:** +1 301 403 9289
**Email:** kbryant@mail.nih.gov
MOLECULAR GENETICS OF DRUG ADDICTION AND RELATED CO-MORBIDITIES (R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for research into molecular genetics of drug addiction and related co-morbidities (R01) call. This Aids-related R01 funding opportunity announcement will support projects that identify or validate chromosomal loci and variations in genes that are associated with vulnerability to addiction and that inform the likelihood of responsiveness to treatment. Applications that propose to examine intermediate phenotypes or endophenotypes to assess the molecular genetics of drug addiction, addiction vulnerability or their associated co-morbidities and how they are related to drug addiction are especially encouraged. Also encouraged are genetic as well as computational and large-scale genomic approaches.

Application budgets are not limited, but must reflect the needs of the project. The maximum period is five years. Domestic and foreign for-profit and non-profit organisations and private or public institutions are eligible to apply.

Ref: PA-14-025 (replaces PA-11-026).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 12 Dec 13
Award type: Directed grants to institutions, research groups etc

Award budget total: -
Website:

Application form:
http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-025

Eligibility profile

Country of applicant institution: Any

Disciplines

Pharmacy & Pharmacology; Depression & Other Mood Disorders; Allied Health Professions; Public Health, Health Services & Primary Care; Biochemical Markers; Schizophrenia & Other Psychotic Disorders; Psychology; Disease Models; Biological Sciences; Primary Care; Population Studies, Medical; Biological Markers & Sensor Mechanisms; Genomics; Diagnostic Sciences; Drug & Substance Abuse; Molecular Genetics; Smoking & Tobacco; Mental Illness; Pharmacotherapy; Addiction; HIV/Aids

Contact Details

NIDA
6001 Executive Boulevard
Bethesda MD 20852
Tel: +1 301 445 1309
Email: mail@nih.gov
PRESCRIPTION DRUG ABUSE (R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related prescription drug abuse research programme. The purpose of this Aids-related R01 funding opportunity announcement is to encourage a broad range of research strategies to address the problem of prescription drug abuse. Across proposed research strategies, there is an interest in stimulating the development and integration of novel technologies to observe and understand the aetiology and biological and behavioural mechanisms associated with prescription drug abuse. The specific areas of interest include:

- basic preclinical and clinical research;
- epidemiology and prevention research;
- treatment and health systems research.

This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-016, which solicits applications under the exploratory/developmental grant (R21) mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-015 (replaces PA-08-127).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.

Posted date: 05 Nov 12
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-015

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Psychology; Addiction; Cognitive &Behavioural Therapies; Diagnostic Sciences;Economic & Social Environment; AnxietyDisorders; Pharmaceutical Drugs; Drug &Substance Abuse; General Practice;Compulsive Behaviour; Preventive Medicine;Public Health, Health Services & PrimaryCare; Psychiatry; HIV/AIDS; Pharmacy &Pharmacology; Allied Health Professions

Contact Details
----------------------------------------------
Division of Epidemiology, Services andPrevention Research
NIDA
6001 Executive Boulevard, Room 5193
Bethesda, MD 20892-9589
Tel: +1 301 594 4371
Email: deniscor@nida.nih.gov
FUNCTIONAL GENETICS, EPIGENETICS AND NON-CODING RNAs IN DRUG ADDICTION (R21): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related functional genetics, epigenetics and non-coding RNAs in drug addiction (R21) programme. This Aids-related R21 funding opportunity announcement encourages basic functional genomic research in two areas: functional validation to determine which candidate genes or variants have an authentic role in addictive processes, and detailed elucidation of the molecular pathways and processes modulated by candidate genes or variants, particularly for those genes with an unanticipated role in addiction.

This FOA will use the R21 exploratory/developmental research grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-014, which encourages applications under the R01 research project grant mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Applications budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Ref: PA-14-013 (reissue of PA-11-034).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation,
every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 06 Dec 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-14-013

Eligibility profile

Country of applicant institution: Any

Disciplines

Epigenetics; Psychology; Biological Markers & Sensor Mechanisms; Proteomics & Molecular Interactions; Biochemical Markers; Molecular Genetics; Neuroimaging; Diagnostic Sciences; Disease Models; Ribonucleic Acid, RNA; Drug & Substance Abuse; Biological Sciences; Physiology; HIV/AIDS; Pharmacokinetics; Primary Care; Neurotransmitters; Public Health, Health Services & Primary Care; Behavioural Medicine; Immunological & Bioassay Methods; Electrophysiology; Addiction; Genomics

Contact Details

NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 435 1020
Email: satterleej@nida.nih.gov
INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R21): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its international research collaboration on drug abuse and addiction research (R01) research opportunity announcement. This AIDS-related announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Special opportunities include access to unusual talent, resources, populations or environmental conditions in other countries that will speed scientific discovery. Projects must have relevance to the mission of NIDA and where feasible should address NIDA’s scientific priority areas. Priority areas include: linkages between HIV/AIDS and drug abuse; prevention, initiation and treatment of nicotine and tobacco use; the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact.

This funding opportunity uses the NIH exploratory research project grant (R21) mechanism and runs in parallel with two of identical scientific scope, PA-15-141 and PA-15-142 which respectively solicit applications under the NIH small grant programme (R03) mechanism and the NIH research project grant (R01) mechanism.

Research must be conducted by US investigators in collaboration with non-US based investigators. Projects must include significant contributions of resources by each participant. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to US$275,000 with a maximum of US$200,000 in indirect costs per year. The maximum project period is two years.

Ref: PA-15-143 (reissue of PA-12-041).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 18 Mar 15
Award type: Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration
Award amount max: $275,000
Website:
Application form:
http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275245

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Alcoholism; Drug & Substance Abuse; HIV/AIDS; Smoking & Tobacco

Contact Details
----------------------------------------------
National Institute on Drug Abuse
NSC BG Room 4274
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6480
Email: ipdirector@nida.nih.gov
INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R03): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its international research collaboration on drug abuse and addiction research (R03) research opportunity announcement. This Aids-related announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Special opportunities include access to unusual talent, resources, populations or environmental conditions in other countries that will speed scientific discovery. Projects must have relevance to the mission of NIDA and where feasible should address NIDA’s scientific priority areas. Priority areas include: linkages between HIV/Aids and drug abuse; prevention, initiation and treatment of nicotine and tobacco use; the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact.

This funding opportunity uses the NIH small grant programme (R03) mechanism and runs in parallel with two of identical scientific scope, PA-15-142 and PA-15-143 which respectively solicit applications under the NIH research project grant programme (R01) mechanism and the NIH exploratory/developmental grant (R21) mechanism.

Research must be conducted by US investigators in collaboration with non-US based investigators. Projects must include significant contributions of resources by each participant. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited US$50,000 per year over a maximum project period of two years.

Ref: PA-15-141 (reissue of PA-12-042).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 May and are due by 5 pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 18 Mar 15
Award type: Directed grants to institutions, research groups etc,
Networking/collaboration
Award amount max: $100,000
Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275228

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Smoking & Tobacco; HIV/Aids; Alcoholism; Drug & Substance Abuse

Contact Details
---------------------------------------------------------------
National Institute on Drug Abuse
NSC BG Room 4274
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6480
Email: ipdirector@nida.nih.gov
SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R21)
NIH: National Institute on Drug Abuse

Description:
The NIH's National Institute on Drug Abuse invites applications for its drug abuse, risky decision making and HIV/AIDS funding opportunity announcement.

This R21 call encourages applications to study cognitive, motivational or emotional mechanisms and brain neuroendocrine and reinforcement systems that relate to HIV-risk behaviours or treatment non-compliance. Interdisciplinary studies that incorporate approaches from psychology, economics, anthropology, sociology, decision sciences, neuroscience and computational modelling are encouraged.

The total project period for an application submitted in response to this funding opportunity announcement may not exceed two years. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

This FOA will use the NIH exploratory/developmental (R21) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-14-061, that encourages applications under the R01 and PA-14-063, that encourages applications under the R03 mechanism.

PA-14-062 (reissue of PA-11-007).

Closing date: 07 Jan 16

Deadline information: Aids-related applications due every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 19 Feb 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-062.html

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Political Risk Factors & Analysis; Chemistry; Economic & Social Environment; Clinical Psychology; Public Health, Health Services & Primary Care; Neuropsychology; Physiology; Decision Science; Pharmacokinetics; Neuropharmacology; Diagnostic Sciences; Toxicology; Computer Science & Informatics; Gender Roles & Sexuality; Pharmacy & Pharmacology; Psychology; Social Work & Social Policy; Drug & Substance Abuse; HIV/Aids; Built Environment & Spatial Planning; Medical Sociology ; Addiction; Sociology; Biological Sciences; Neurobiology

Contact Details
---------------------------------------------------------------
NIDA
6001 Executive Boulevard, Rm 3173
Bethesda, MD 20892-9593
Tel: +1 301 435 1318
Email: vlin1@nida.nih.gov
SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R03)
NIH: National Institute on Drug Abuse

Description:
The NIH's National Institute on Drug Abuse invites applications for its substance use and abuse, risky decision making and HIV/AIDS funding opportunity announcement. This R03 program is intended to stimulate research that will increase understanding of the way people make decisions about engaging in behaviours that impact the risk of acquiring or transmitting HIV, or to adhere to treatments for HIV. Decision making processes may contribute to both substance use/abuse and other HIV acquisition or transmission risks.

This FOA encourages applications to study cognitive, motivational or emotional mechanisms and brain neuroendocrine and reinforcement systems that relate to HIV-risk behaviours or treatment non-compliance. Interdisciplinary studies that incorporate approaches from psychology, economics, anthropology, sociology, decision sciences, neuroscience and computational modelling are encouraged.

This FOA for R03 applications is intended to support pilot and feasibility studies, small, self-contained research projects, development of research methodology, and development of new research technology that can be carried out in a short period of time with limited resources.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Budgets for direct costs of up to US$50,000 per year and a project duration of up to two years may be requested for a maximum of US$100,000 direct costs over a two-year project period.

This FOA will utilise the NIH small research grant (R03) mechanism and runs in parallel with FOAs of identical scientific scope, PA-14-061, that encourages applications under the R01 mechanism and PA-14-062 that encourages applications under the R21 mechanism. PA-14-063 (reissue of PA-11-008)

Closing date: 07 Jan 16
Deadline information: Standard applications due every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 19 Feb 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Website:
Application form:
http://www.grants.gov/web/grants/applicantpackage.html#download=true&oppNum=PA-14-063

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Contact Details
---------------------------------------------------------------
HIV/AIDS; Pharmacokinetics; Neurobiology; Economic & Social Environment; Decision Science; Neuropharmacology; Diagnostic Sciences; Medical Sociology; Toxicology; Pharmacy & Pharmacology; Psychology; Physiology; Political Risk Factors & Analysis; Primary Care; Drug & Substance Abuse; Sociology; Gender Roles & Sexuality; Biological Sciences; Chemistry; Public Health, Health Services & Primary Care; Addiction; Social Work & Social Policy; Neuropsychology; Clinical Psychology
Euroscience Research on Drug Abuse (R01): AIDS-Related

**NIH: National Institute on Drug Abuse**

**Description:**
The National Institute on Drug Abuse invites Aids-related applications for its neuroscience research on drug abuse (R01) grants. This Aids-related R01 funding opportunity announcement aims to understand the neurobiological mechanisms underlying drug abuse and addiction, with emphasis on changes that occur during chronic drug use, withdrawal and relapse. In vivo and in vitro model systems, as well as human studies, are appropriate.

This FOA will use the R01 grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-337, which encourages applications under the R21 exploratory/developmental grants mechanism, and PA-13-336, which encourages applications under the R03 small grant programme mechanism. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. Public and private, non-profit and for-profit, and domestic and foreign organisations are eligible. PA-13-338 (replaces PA-10-268).

**Closing date:** 07 Jan 16
**Deadline information:** Deadlines every 7 January, 7 May and 7 September until 8 January 2017.
**Posted date:** 27 Aug 13

**Award type:** Directed grants to institutions, research groups etc
**Award budget total:** -
**Application form:** [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-338](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-338)

**Eligibility profile**
----------------------------------------------
Country of applicant institution: Any

**Disciplines**
----------------------------------------------
HIV/AIDS; Cognitive & Behavioural Therapies; Biological Sciences; Diagnostic Sciences; Public Health, Health Services & Primary Care; Psychology; Drug & Substance Abuse; Pharmacy & Pharmacology; Social Work & Social Policy; Addiction; Physiology; Primary Care; Neuroscience; Allied Health Professions; Neurobiology; Behavioural Medicine

**Contact Details**
----------------------------------------------
Division of Clinical Neurosciences and Behavior Research
NIDA
6001 Executive Boulevard, Rm 3173

Rockville, MD 20852-9555
Tel: +1 301 435 1318
Fax: +1 301 594 6043
Email: ylin1@nida.nih.gov
EUROSCIENCE RESEARCH ON DRUG ABUSE (R21): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its neuroscience research on drug abuse (R21) grants. This Aids-related R21 funding opportunity announcement aims to understand the neurobiological mechanisms underlying drug abuse and addiction, with emphasis on changes that occur during chronic drug use, withdrawal and relapse. In vivo and in vitro model systems, as well as human studies, are appropriate.

This FOA will use the NIH exploratory/developmental (R21) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-338, which encourages applications under the R01 research project grant mechanism, and PA-13-336, which encourages applications under the R03 small grant programme mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in any year. Public and private, non-profit and for-profit, and domestic and foreign organisations are eligible. PA-13-337 (replaces PA-10-269).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 27 Aug 13
Award type: Directed grants to institutions, research groups etc

Award amount max: $275,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Neuroscience; Drug & Substance Abuse; Behavioural Medicine; Social Work & Social Policy; Physiology; Biological Sciences; Addiction; Pharmacy & Pharmacology; Public Health, Health Services & Primary Care; Allied Health Professions; Psychology; Diagnostic Sciences; Primary Care; Cognitive & Behavioural Therapies; HIV/Aids; Neurobiology

Contact Details
Division of Basic Neuroscience and Behavioral Research
NIDA
Neuroscience Center
6001 Executive Blvd, Rm 4282, MSC 9555
Bethesda, MD 20892-9555
Tel: +1 301 435 1317
Email: npilotte@nih.gov
EUROSCIENCE RESEARCH ON DRUG ABUSE (R03): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites Aids-related applications for its neuroscience research on drug abuse (R03) grants. This Aids-related R03 funding opportunity announcement aims to understand the neurobiological mechanisms underlying drug abuse and addiction, with emphasis on changes that occur during chronic drug use, withdrawal and relapse. In vivo and in vitro model systems, as well as human studies, are appropriate.

This FOA will use the NIH small research grant (R03) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-337, which encourages applications under the R21 exploratory/developmental grant mechanism, and PA-13-338, which encourages applications under the R01 research project grant mechanism. Direct costs are worth a maximum of US$100,000 over two years, with no more than US$50,000 in any year. Public and private, non-profit and for-profit, and domestic and foreign organisations are eligible. PA-13-336 (replaces PA-10-270).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 27 Aug 13
Award type: Directed grants to institutions, research groups etc

Award amount max: $100,000

Eligibility profile
--------------------------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------------------------
Behavioural Medicine; Physiology; Diagnostic Sciences; Pharmacy & Pharmacology; Allied Health Professions; Public Health, Health Services & Primary Care; Primary Care; Psychology; Drug & Substance Abuse; Cognitive & Behavioural Therapies; Social Work & Social Policy; Neurobiology; Neuroscience; HIV/Aids; Addiction; Biological Sciences

Contact Details
--------------------------------------------------------------
Division of Basic Neuroscience and Behavioral Research
NIDA
Neuroscience Center
6001 Executive Blvd, Rm 4282, MSC 9555
Bethesda, MD 20892-9555
Tel: +1 301 435 1317
Email: npilotte@nih.gov
DEVELOPMENT OF ASSAYS FOR HIGH-THROUGHPUT DRUG SCREENING FOR USE IN PROBE AND PRE-THERAPEUTIC DISCOVERY (R01): AIDS-RELATED

NIH: National Institute of Mental Health

Description:
Participating components of the National Institutes of Health invite applications for their Aids-related development of assays for high-throughput drug screening for use in probe and pre-therapeutic discover (R01). This Aids-related R01 funding opportunity announcement aims to stimulate research in the following areas:

- developing assays for specific biological targets and disease mechanisms to screen for small molecule compounds that show potential as probes for use in advancing knowledge about the known targets, identifying new targets or as pre-therapeutic leads;
- establishing collaboration with screening centres that have the requisite expertise and experience needed in implementation of HTS assays for the discovery and development of small molecule chemical probes.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is three years. Domestic and foreign for-profit and non-profit organisations and public and private institutions are eligible to apply. PAR-13-364 (replaces PA-10-213).

Closing date: 07 Jan 16

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 30 Sep 13

Award type: Directed grants to institutions, research groups etc

Award budget total: -


Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care; Pharmacy & Pharmacology; Clinical Medicine; Nursing; Screening for Diseases; HIV/Aids; Pharmacotherapy; Diagnostic Sciences; Public Health, Health Services & Primary Care; Blood Tests; Immunological & Bioassay Methods; Deoxyribonucleic Acid, DNA

Contact Details

NIDDK
6707 Democracy Boulevard
Bethesda MD 20892
Tel: +1 301 443 1421
Email: ili1@mail.nih.gov
DEVELOPMENT OF ANIMAL MODELS AND RELATED BIOLOGICAL MATERIALS FOR RESEARCH (R21): AIDS-RELATED
NIH: Office of the Director

Description:
The NIH Office of the Director invites AIDS-related applications for its development of animal models and related biological materials for research programme (R21).

This AIDS-related R21 announcement solicits proposals to develop, characterise or improve animal models for human disease, or to improve diagnosis and control diseases of laboratory animals that may interfere with research. Topics include:

- disease models;
- genetically-modified animals and preservation of important disease models;
- fundamental biology of animal model systems;
- disease biomarkers;
- genetically encoded reporters;
- biological molecule interactive and functional networks;
- animal models for human rare disease conditions;
- complementary approaches to use of animal models;
- animal diseases.

Domestic and foreign for-profit and non-profit organisations and public or private institutions may apply.

Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

PA-13-145 (replaces PA-10-138).

Closing date: 07 Jan 16
Deadline information: Proposals due 5pm applicant’s local time, every 7 January, 7 May and 7 September until 8 May 2016.
Description:
The National Institute on Drug Abuse invites applications for its AIDS-science track award for research transition (R03) funding opportunity announcement. This announcement seeks to facilitate the entry of both newly independent and early-career investigators to the area of drug abuse research on HIV and AIDS related to the following areas of interest:

- prevention of HIV acquisition and transmission;
- HIV treatment, including toward a cure research;
- co-morbidities, co-infections and complications;
- behavioural and social science research to advance treatment and prevention, and especially to address the continuum of care.

Applications are welcomed from all areas of HIV and AIDS research that NIDA supports.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Projects may receive up to US$100,000 per year for a maximum period of two years.

Ref: PA-15-290 (replaces PAR-12-282).

Closing date: 07 Jan 16
Deadline information: Applications open on 7 December 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.
Posted date: 10 Sep 15
Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc
Award amount max: $200,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Drug & Substance Abuse; HIV/AIDS

Contact Details
Tel: +1 301 443 3207
Email: aklinwm@mail.nih.gov
**BIOENGINEERING RESEARCH PARTNERSHIPS (R01): AIDS-RELATED**
NIH: National Institute of Biomedical Imaging and Bioengineering

**Description:**
10 participating institutes and centres of the National Institutes of Health invite applications for their Aids-related bioengineering research partnerships (R01). This Aids-related R01 funding opportunity announcement aims to accelerate the development and adoption of promising tools and technologies that can address important biomedical research problems. The objectives are to establish these tools and technologies as robust, well-characterised solutions that fulfil an unmet need and are capable of enhancing understanding of life science processes or the practice of medicine. Multidisciplinary teams should apply an integrative, quantitative bioengineering approach and engage biomedical researchers and clinicians throughout the project.

This FOA will use the NIH R01 research project grant (R01) award mechanism and runs in parallel with two FOAs of similar scientific scope, PA-12-284, which solicits applications under the R21 exploratory/developmental research grant mechanism and PAR-13-137, which also solicits applications under the R01 mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-092 (replaces PAR-10-234).

**Closing date:** 07 Jan 16
**Deadline information:** Applications due by 5pm proposer’s local time. Deadlines on: 7 September 2014, 7 January 2015, 7 September 2015, 7 January 2016.
**Posted date:** 07 Feb 14
**Award type:** Directed grants to institutions, research groups etc.
**Networking/collaboration**
**Award budget total:** -

**Application form:** [http://www.grants.gov/web/grants/applicant-download-application-package.html#download=true&oppNum=PAR-14-092](http://www.grants.gov/web/grants/applicant-download-application-package.html#download=true&oppNum=PAR-14-092)

**Eligibility profile**
----------------------------------------------
Country of applicant institution: Any

**Disciplines**
----------------------------------------------
Medical Research of Selected Fields; Bioengineering; Preventive Medicine; Medical & Diagnostic Tests; Public Health, Health Services & Primary Care; Medical Devices; Behavioural Medicine; HIV/AIDS; Translational Medicine; Radiology & Medical Imaging; Biomedical Engineering; Materials Sciences; Health Informatics; Biomaterials; Medicine & Health; Bioinformatics; Medical Physics; Clinical Medicine; Metallurgy; Computer Science & Informatics; Primary Care; General Practice
Biology of Manual Therapies (R01): AIDS-Related
NIH: National Center for Complementary and Integrative Health

Description:
The National Center for Complementary and Alternative Medicine invites Aids-related applications for its call on biology of manual therapies (R01). This AIDS-related R01 funding opportunity announcement supports studies of the basic science and mechanisms of action underlying the neurophysiological, immunological, endocrinological or biomechanical consequences of manual therapies such as spinal manipulation, mobilisation and massage therapy.

This FOA uses the NIH research project grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-167, which solicits applications under the R21 mechanism.

Eligible institutions include domestic and foreign for-profit and non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PA-14-168 (replaces PA-10-209).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 31 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -
Website:
Application form:
http://www.grants.gov/web/grants/applicant-package.html#download=true&oppNum=PA-14-168

Eligibility profile

Country of applicant institution: Any

Disciplines

Aerospace Engineering & Avionics; Human Biological Sciences; Folk, Complementary & Alternative Medicine; Physiology; Biomechanics; Clinical Medicine; Hormones & Endocrinology; Electrophysiology; Central Nervous System; Traumatology, Accidents & Injury; HIV/Aids; Diagnostic Sciences; Manufacturing & Industrial Engineering; Endocrine & Neuroendocrine Cancers; Therapy Evaluation; Mechanical Engineering; Growth & Growth Factors; Immunology

Contact Details

NCCAM
6707 Democracy Blvd, Suite 401
Bethesda, MD 20892
Tel: +1 301 594 3462
Fax: +1 301 401 1587
Email: patrap.khalsa@nih.gov
NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism and the Office of Dietary Supplements invite applications for their Aids-related nutrition and alcohol-related health outcomes (R01) grants. This Aids-related R01 funding opportunity announcement supports research to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this R01 funding opportunity announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease.

This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-360 and PA-13-361, which use the R03 small grant programme and the R21 exploratory/developmental grant mechanisms, respectively. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-359 (replaces PA-10-239)

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2017
Posted date: 24 Sep 13

Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-359

Eligibility profile
Country of applicant institution: Any
Disciplines
Allied Health Professions; Epidemiology; HIV/Aids; Psychology; Preventive Medicine; Diagnostic Sciences; Nutrition & Dietetics; General Practice; Disease Models; Alcoholism; Pathophysiology; Addiction; Primary Care; Cognitive Processes; Public Health, Health Services & Primary Care; Clinical Medicine

Contact Details
Division of Epidemiology and Prevention Research
NIAAA
5635 Fishers Lane, Room 2081, MSC 9304
Bethesda, MD 20892-9304
Tel: +1 301 594 6231
Fax: +1 301 443 8614
Email: rbreslow@mail.nih.gov
Description:
The National Institute on Alcohol Abuse and Alcoholism and the Office of Dietary Supplements invite applications for their Aids-related nutrition and alcohol-related health outcomes (R03) grants. This Aids-related R03 funding opportunity announcement supports research to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this R01 funding opportunity announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease.

This FOA will use the small grant programme (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-359 and PA-13-361, which use the R01 research project grant and the R21 exploratory/developmental grant mechanisms, respectively. Budgets for direct costs of limited to US$50,000 per year over a maximum two year project period. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-360 (replaces PA-10-240)

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017
Posted date: 24 Sep 13

Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Award amount min: -
Award budget total: -

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Allied Health Professions; Pathophysiology; Epidemiology; Disease Models; Clinical Medicine; Cognitive Processes; HIV/Aids; Psychology; Foetal Health & Prenatal Development; Preventive Medicine; Addiction; Primary Care; Nutrition & Dietetics; Alcoholism; Public Health, Health Services & Primary Care; General Practice; Maternal Health

Contact Details
----------------------------------------------
Division of Epidemiology and Prevention Research
NIAAA
5635 Fishers Lane, Room 2081, MSC 9304
Bethesda, MD 20892-9304
Tel: +1 301 594 6231
Fax: +1 301 443 8614
Email: rbreslow@mail.nih.gov
NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism and the Office of Dietary Supplements invite applications for their Aids-related nutrition and alcohol-related health outcomes (R21) grants. This Aids-related R21 funding opportunity announcement supports research to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this R01 funding opportunity announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease.

This FOA will use the exploratory/developmental research grant (R21) mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-359 and PA-13-360, which use the R01 research project grant and the R03 small grant programme mechanisms, respectively. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-361 (replaces PA-10-241).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017
Posted date: 24 Sep 13

Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: -


Eligibility profile
-------------------------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Addiction; HIV/Aids; Preventive Medicine; Primary Care; Psychology; Cognitive Processes; Alcoholism; Epidemiology; General Practice; Clinical Medicine; Allied Health Professions; Nutrition & Dietetics; Maternal Health; Foetal Health & Prenatal Development; Public Health, Health Services & Primary Care; Disease Models; Pathophysiology

Contact Details
-----------------------------------------------
Division of Epidemiology and Prevention Research
NIAAA
5635 Fishers Lane, Room 2081, MSC 9304
Bethesda, MD 20892-9304
Tel: +1 301 594 6231
Fax: +1 301 443 8614
Email: rbreslow@mail.nih.gov
SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites research grant applications on screening and brief interventions to prevent or reduce alcohol use and its adverse consequences. This Aids-related R01 funding opportunity announcement encourages research on screening and brief interventions to prevent and reduce alcohol use and alcohol related harms among underage and young adult populations.

This FOA will utilise the NIH research project grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-15-294 and PA-15-296, that solicit applications under the small research grant (R21) and exploratory/developmental (R03) award mechanisms, respectively. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-15-295 (replaces PA-12-031)

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September, until 8 May, 2018.
Posted date: 13 Jul 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:
Application form:
http://apply.grants.gov/apply/GetGrantFromFedgrants?cfda=&opportunity=PA-07-406&competitionid=

Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism; HIV/Aids; Screening of Drugs & Agents

Contact Details

Tel: +1 301 402 9389
Fax: +1 301 443 8614
Email: shirleym@mail.nih.gov

SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites research grant applications on screening and brief interventions to prevent or reduce alcohol use and its adverse consequences. This Aids-related R21 funding
opportunity announcement is designed to stimulate a developmentally grounded program of Aids-related research on screening and brief interventions to prevent or reduce underage drinking and hazardous young adult drinking.

This FOA will utilise the NIH exploratory/developmental grant (R21) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-15-95 and PA-15-296, that solicit applications under the R01 and R03 mechanisms, respectively. Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

PA-15-294 (replaces PA-12-030).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September, until 8 May, 2018.

**SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R03): AIDS-RELATED**

**NIH: National Institute on Alcohol Abuse and Alcoholism**

**Description:**
The National Institute on Alcohol Abuse and Alcoholism invites applications for its screening and brief alcohol interventions in underage and young adult populations funding opportunity announcement. This Aids-related R03 funding announcement encourages research on screening and brief interventions to prevent and reduce alcohol use and alcohol related harms among underage and young adult populations.

This FOA will utilise the NIH small research grant (R03) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-15-294 and PA-15-295, that solicit applications under the R01 and R21 mechanisms, respectively. Budgets for direct costs are limited up to US$50,000 per year for a project period of up to two years. Domestic and foreign for-profit and non-profit
organisations and public or private institutions are eligible to apply. PA-15-296.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May, 2018.
Posted date: 13 Jul 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Website:
Application form:
http://apply.grants.gov/apply/GetGrantFromFedgrants?cfda=&opportunity=PA-07-408&competitionid=

Eligibility profile
Country of applicant institution: Any

Disciplines
Alcoholism; Screening of Drugs & Agents; HIV/AIDS

Contact Details
Email: +1 301 402 9389
Fax: +1 301 443 8614
Email: shirleym@mail.nih.gov

THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R01): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of 10 institutes and offices of the National Institutes of Health invite applications for their health of sexual and gender minority populations (R01) funding opportunity announcement. This Aids-related announcement encourages research that describes the biological, clinical, behavioural and social processes that affect the health and development of sexual and gender minority populations and individuals, as well as their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that enhance the health and development of these populations. The research must focus on clearly defined health outcomes. The following types of research are prioritised:

- basic social and behavioural science studies addressing the processes involved as individuals discover, uncover, address or adapt to their sexual orientation and claim or do not claim identity as SGM, and how these processes affect the mental and physical health of the individual;
- research leading to interventions to ameliorate health disparities in SGM populations;
- large-scale design, implementation and evaluation of preventive or treatment interventions addressing health issues in SGM populations;
- research on how family structures and processes—including both families of origin and families of choice—affect the health of SGM individuals and their family members, including whether and how being raised in a family headed by SGM individuals affects the health, development and wellbeing of children.
This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-262 and PA-15-263, which solicit applications under the NIH small grant programme (R03) grant mechanism and the NIH exploratory/developmental (R21) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the actual costs of the proposed project. The maximum project period is five years.

Ref: PA-15-261 (reissue of PA-12-111).

Closing date: 07 Jan 16
Deadline information: Applications open on 5 September 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018. Applicants requesting US$500,000 or more in direct costs in any year must contact a research contact at least six weeks before submitting the application.

G
ENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their gene-environment interplay in substance use disorders (R01) funding opportunity announcement.

This Aids-related announcement seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course and outcomes of substance and alcohol use disorders. Collaborations to combine data and enhance power are strongly encouraged. Proposals are expected to focus on the interplay of genetics and environment. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.
This FOA uses the research project (R01) grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-111, which solicits applications under the small grant programme (R03) and PA-15-112, which solicits applications under the exploratory/developmental (R21) grant mechanism.

Application budgets are not limited, but should reflect the needs of the project. The maximum project period is five years.


Closing date: 07 Jan 16
Deadline information: Applications open on 5 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 06 Feb 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Website:

Application form:
http://www.grants.gov/web/grants/applicant
download-application-package.html#download=true?oppNum=PA-15-110

Eligibility profile
Country of applicant institution: Any

Disciplines
Medical Genetics; HIV/Aids; Drug & Substance Abuse; Alcoholism

Contact Details
NIDA
NSC BG Room 5150
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 402 1908
Email: nw46w@nih.gov

ENETIC EPIDEMIOLOGY OF SUBSTANCE USE DISORDERS (R03): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their gene-environment interplay in substance use disorders (R03) funding opportunity announcement.

This Aids-related announcement seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course and outcomes of substance and alcohol use disorders. Collaborations to combine data and enhance power are strongly encouraged. Proposals are expected to focus on the interplay of genetics and environment.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

This FOA uses the small grant programme (R03) and runs in parallel with two FOAs of identical scientific scope, PA-15-110, which solicits applications under the research project
(R01) grant mechanism and PA-15-112, which solicits applications under the exploratory/developmental (R21) grant mechanism.

Direct costs are limited to US$50,000 per year with a maximum project period of two years. Ref: PA-15-111 (reissue of PA-11-237).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 06 Feb 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Award amount min: -
Award budget total: -

Application form:

Eligibility profile
Country of applicant institution: Any

Disciplines
Medical Genetics; Alcoholism; Drug & Substance Abuse; HIV/AIDS

Contact Details
NIDA
NSC BG Room 5150
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 402 1908
Email: nw46w@nih.gov

GENETIC EPIDEMIOLOGY OF SUBSTANCE USE DISORDERS (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their gene-environment interplay in substance use disorders (R21) funding opportunity announcement.

This Aids-related announcement seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course and outcomes of substance and alcohol use disorders. Collaborations to combine data and enhance power are strongly encouraged. Proposals are expected to focus on the interplay of genetics and environment.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

This FOA uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-110, which solicits applications under the research project (R01) grant mechanism and PA-15-111, which solicits applications under the small grant programme (R03) mechanism.
Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PA-15-112 (reissue of PA-11-236).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Website:
Application form:
http://www.grants.gov/web/grants/applicant

Eligibility profile
Country of applicant institution: Any
Disciplines
HIV/Aids; Drug & Substance Abuse; Alcoholism; Medical Genetics

Contact Details
NIDA
NSC BG Room 5150
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 402 1908
Email: nw46w@nih.gov

THE NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH SMALL GRANT PROGRAMME FOR NEW INVESTIGATORS (R03): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its small grant programme for new investigators (R03): Aids-related. This Aids-related R03 funding opportunity announcement supports pilot and developmental research with the intention of facilitating subsequent submission of an Individual research project grant (R01) application.

Budgets for direct costs of up to US$150,000 over a two-year period may be requested. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-348 (replaces PAR-10-275).

Closing date: 07 Jan 16
Deadline information: Submissions due by 5pm proposers’s local time, every 7 January, 7 May and 7 September until 8 September 2016.

Award type: Directed grants to institutions, research groups etc
Award amount max: $150,000
Website:
HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R21): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for health promotion among racial and ethnic minority males (R21): AIDS-related. This AIDS-related R21 funding opportunity announcement aims to stimulate and expand research in the health of minority men. Specifically, this initiative is intended to: enhance understanding of the numerous factors influencing the health promoting behaviours of racial and ethnic minority males and their sub populations across the life cycle; and solicit applications focusing on the development and testing of culturally and linguistically appropriate health-promoting interventions designed to reduce health disparities among racially and ethnically diverse males and their sub populations aged 21 and older.

This FOA will use the exploratory/developmental (R21) grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-328 that solicits applications under the R01 mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-331 (replaces PA-10-237).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 15 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-10-237

Disciplines
----------------------------------------------
Nursing; Medicine & Health; Disadvantaged & Minority Groups; Urology; Public Health, Health Services & Primary Care; Health Promotion; Medical Sociology; Pharmaceutical Drugs; Health Systems, Risk Management; Population Studies, Medical; Sociology; Psychology; Diagnostic Sciences; Economic & Social Environment; HIV/AIDS; Biomedical Engineering; Behavioural Medicine; Health Disparities

Eligibility profile
Country of applicant institution: Any

Country of applicant institution: Any

Disciplines
----------------------------------------------
Oral Medicine; Diagnostic Sciences; Craniofacial Disorders; HIV/Aids; Dentistry; Oral & Maxillofacial Surgery; Dental Health & Hygiene

Eligibility profile

Disciplines
----------------------------------------------
Oral Medicine; Diagnostic Sciences; Craniofacial Disorders; HIV/Aids; Dentistry; Oral & Maxillofacial Surgery; Dental Health & Hygiene

Eligibility profile

Country of applicant institution: Any

Eligibility profile

Disciplines
----------------------------------------------
Oral Medicine; Diagnostic Sciences; Craniofacial Disorders; HIV/Aids; Dentistry; Oral & Maxillofacial Surgery; Dental Health & Hygiene

Eligibility profile

Country of applicant institution: Any

Eligibility profile

Country of applicant institution: Any

Eligibility profile

Disciplines
----------------------------------------------
Oral Medicine; Diagnostic Sciences; Craniofacial Disorders; HIV/Aids; Dentistry; Oral & Maxillofacial Surgery; Dental Health & Hygiene

Eligibility profile

Country of applicant institution: Any
HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R01): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research and the National Institute of Diabetes and Digestive and Kidney Diseases invite applications for health promotion among racial and ethnic minority males (R01): Aids-related. This Aids-related R01 funding opportunity announcement aims to stimulate and expand research in the health of minority men. Specifically, this initiative is intended to: enhance understanding of the numerous factors influencing the health promoting behaviours of racial and ethnic minority males and their sub populations across the life cycle; and solicit applications focusing on the development and testing of culturally and linguistically appropriate health-promoting interventions designed to reduce health disparities among racially and ethnically diverse males and their sub populations aged 21 and older.

This FOA will use the R01 research project grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-331, which solicits applications under the R21 mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-328 (replaces PA-10-236).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 15 Aug 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-328

Eligibility profile
Country of applicant institution: Any

Disciplines
Medicine & Health; Psychology; Behavioural Medicine; Biomedical Engineering; Health Disparities; Public Health, Health Services & Primary Care; Nursing; Pharmaceutical Drugs; Sociology; Urology; Economic & Social Environment; Medical Sociology ; Health Promotion; Population Studies, Medical; Diagnostic Sciences; Disadvantaged & Minority Groups; HIV/Aids

Contact Details
Office of Extramural Programs
EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its epidemiology and prevention in alcohol research programme. The goal of this R01 Aids-related funding opportunity is to encourage the submission of investigator-initiated research grant applications to support research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms, and alcohol use disorders.

This funding opportunity announcement will utilise the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-188, which solicits applications under the 21 exploratory of developmental grant mechanism, and PA-14-189, which solicits applications under the R03 small grant programme mechanism.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-14-190.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 May, 7 September and 7 January until 8 September 2017.

Posted date: 28 Apr 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-190.html
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Psychology; Biomedical Engineering; Diagnostic Sciences; Addiction; Economic & Social Environment; Public Health, Health Services & Primary Care; Sociology; Preventive Medicine; Population Studies, Medical; HIV/AIDS; Epidemiology; Allied Health Professions; Behavioural Medicine; Alcoholism; Medical Sociology ; Patient Care & Education

Contact Details
NIAA
Building 5635FL, Room 2083
5635 Fishers Lane
Rockville MD 20852
Tel: +1 301 402 6328
Email: mscott@mail.nih.gov
EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its epidemiology and prevention in alcohol research grants. The goal of this AIDS-related R21 funding opportunity is to encourage the submission of investigator-initiated research grant applications to support research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms, and alcohol use disorders. This mechanism will support investigation of novel scientific ideas or new model systems, tools or technologies that have the potential for significant impact on biomedical or biobehavioural research.

This funding opportunity announcement will utilise the NIH exploratory/developmental (R21) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-190, which solicits applications under the R01 research project grant mechanism, and PA-14-189, which solicits applications under the R03 small grant programme mechanism.

Direct costs are limited to US$275,000 over a maximum period of two years, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-14-188 (replaces PA-11-018).

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 May, 7 September and 7 January until 8 September 2017.

Posted date: 28 Apr 14

Award type: Directed grants to institutions, research groups etc

Award amount max: $275,000

Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-188.html

Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile

Country of applicant institution: Any

Disciplines

Behavioural Medicine; Public Health, Health Services & Primary Care; Sociology; Medical Sociology; Allied Health Professions; HIV/AIDS; Biomedical Engineering; Patient Care & Education; Alcoholism; Preventive Medicine; Epidemiology; Psychology; Economic & Social Environment; Addiction; Population Studies, Medical; Diagnostic Sciences

Contact Details

NIAAA
Building 5635FL, Room 2083
5635 Fishers Lane
Rockville MD 20852
Tel: +1 301 402 6328
Email: mscott@mail.nih.gov
INTERNATIONAL RESEARCH COLLABORATION ON ALCOHOL AND ALCOHOLISM (U01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related international research collaboration on alcohol and alcoholism (U01) grants. The purpose of this Aids-related U01 funding opportunity is to foster international collaborations between alcohol research investigators within the US and investigators located at non-US laboratories and performance sites, for the mutual advancement of the understanding of alcohol problems and of clinical and public health approaches to their solutions. The programme provides funds for research activities to be undertaken jointly between the US and a non-US laboratory that expands the research direction of both laboratories in a collaborative manner.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Grants are worth up to US$250,000 per year for direct costs. The maximum project period is five years.

Ref: PAR-14-268 (replaces PAR-11-282).

Closing date: 07 Jan 16
Deadline information: Applications are welcomed between 5 September 2014 and 5pm local time of applicant organisation on every 7 September, 7 January and 7 May until 8 September 2017.
Posted date: 02 Jul 14

Award type: Directed grants to institutions, research groups etc,
Networking/collaboration
Award amount max: -
Award amount min: -
Award budget total: -

Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Psychology; Pathophysiology; Behavioural Medicine; Alcoholism; Behavioural Studies & Social Problems; Primary Care; Sociology; Addiction; Epidemiology; Allied Health Professions; Public Health; HIV/Aids; Molecular Genetics; Public Health, Health Services & Primary Care; Diagnostic Sciences; Social Behaviour & Attitudes

Contact Details
NIAAIA
5635 Fishers Lane, MSC 9304
Bethesda MD 20892-9304
Tel: +1 301 443 2594
Email: pmurray@mail.nih.gov
ALCOHOL USE DISORDERS: TREATMENT, SERVICES AND RECOVERY RESEARCH (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its AIDS-related alcohol use disorders: treatment, services and recovery research (R21) programme. This AIDS-related R21 funding opportunity announcement supports research on behavioural and pharmacological treatment for alcohol use disorders; organisational, financial and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; or the phenomenon of recovery from alcohol use disorders.

Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. The total project period may not exceed two years. Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year. This programme will use the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with two programs of identical scientific scope: PA-13-160, which solicits applications under the R01 mechanism, and PA-13-161, which solicits applications under the R03 mechanism. PA-13-162 (replaces PA-10-102)

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.

Posted date: 02 Apr 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-161

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
HIV/Aids; Public Health, Health Services & Primary Care; Cognitive & Behavioural Therapies; Alcoholism; Primary Care; Psychology; Pharmacy & Pharmacology; Health Systems, Administration; Allied Health Professions; Experimental Psychology; General Practice; Drug & Substance Abuse

Contact Details
----------------------------------------------
NIAAA
6000 Executive Boulevard
Bethesda, MD 20892-7003
Tel: +1 301 443 0788
Email: falkde@mail.nih.gov
PROGRAMME FOR EXTRAMURAL/INTRAMURAL ALCOHOL RESEARCH COLLABORATIONS (U01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites Aids-related applications for its programme for extramural/intramural alcohol research collaborations (U01). The purpose of this Aids-related U01 funding opportunity is to bring together the research expertise that, as a functioning collaborative unit, will address key alcohol-based research questions that would not otherwise be possible by the same individuals working towards similar goals in isolation. The goal proposed by the collaborating investigators should address questions that advance alcohol research with respect to issues surrounding alcohol use disorders including dependence and the effects of alcohol on health.

The NIH U01 cooperative agreement award mechanism will be used. Applicants may request direct costs of up to US$250,000 per year. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-133 (replaces PAR-11-189).

Closing date: 07 Jan 16
Deadline information: Proposals due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2016.

Posted date: 07 Mar 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $1,250,000
Website: http://grants.nih.gov/grants/guide/notice-files/PAR-13-133.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-133

Eligibility profile
Country of applicant institution: Any

Disciplines
Electrophysiology; Epidemiology; Addiction; HIV/AIDS; Behavioural Medicine; Alcoholism; General Practice; Molecular Genetics; Diagnostic Sciences; Allied Health Professions; Neuroscience; Psychology; Physiology; Human Metabolism

Contact Details
Intramural Programme
NIAAA
5635 Fishers Lane, Room 3001
Bethesda, MD 20892-9304
Tel: +1 301 402 6966
Email: psilverm@mail.nih.gov

LM EXPRESS RESEARCH GRANTS IN BIOMEDICAL INFORMATICS (R01): AIDS-RELATED
NIH: National Library of Medicine

Description:
The National Library of Medicine invites applications for its Aids-related express research grants in biomedical informatics (R01). This Aids-related R01 funding
opportunity aims to advance the sciences of biomedical informatics.

The scope of NLM's interest in the research domain of informatics is interdisciplinary, encompassing informatics problem areas in the application domains of health care, public health, basic biomedical research, bioinformatics, biological modelling, translational research and health information management in disasters. NLM defines biomedical informatics as the science of optimal organisation, management, presentation and utilisation of information relevant to human health and biology. Informatics research produces concepts, tools and approaches that advance what is known in the field and have the capacity to improve human health.

Applicants may request funding over up to US$250,000 per year for a period of four years.

Eligible applicants include domestic public and private non-profit and for-profit organisations. PAR-13-300 (PAR-11-208).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 02 Aug 13

Award type: Directed grants to institutions, research groups etc
Award amount max: $1,000,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-300

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Health Informatics; Clinical Medicine; Bioinformatics; Administrative Big Data & Informatics; HIV/AIDS; Business Big Data & Informatics; Libraries & Information Science; Informatics & Big Data; Health Systems; Translational Medicine; Computer Science & Informatics; Public Health; Public Health, Health Services & Primary Care

Contact Details
----------------------------------------------
NLM Extramural Programmes
6705 Rockledge Drive
Rockledge 1, Suite 301
Bethesda, MD 20892
Tel: +1 301 594 4882
Email: simh@mail.nih.gov

Description:
The National Institute on Drug Abuse invites applications for its AIDS-related epidemiology of drug abuse grants. These R01 grants support AIDS-related projects that enhance understanding of the nature, extent, distribution, aetiology, comorbidities and consequences of drug use, abuse and addiction across individuals, families, communities and diverse population groups. Projects should aim to fill knowledge gaps related to changing patterns in drug use,
associated factors and consequences in populations, including the following:

- individual, familial and environmental factors associated with drug use;
- interplay of factors that exacerbate or mitigate risk for drug initiation, addiction, desistence, recovery and relapse;
- co-occurring psychiatric conditions, behaviours and associated problems;
- indicators and mechanisms of risk, vulnerability and health disparities among and between subpopulations;
- developmental and life course trajectories related to the aetiology and natural history of drug use;
- need for, access to and utilisation of drug abuse prevention and treatment services and the social, community and organisational factors that influence intervention development, availability and effectiveness.

- public health impacts of the attitudes, availability, behaviours and products, resulting from the shifting marijuana policy environment.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This funding opportunity announcement utilises the NIH research project grant (R01) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-15-001 that encourages applications under the NIH exploratory or developmental (R21) and PA-15-002 that encourages applications under the NIH small research grant R03 mechanism.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.


Closing date: 07 Jan 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 06 Oct 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Application form:
http://www.grants.gov/web/grants/applicant\s/download-application-package.html#download=true?oppNum=PA-15-003

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Social Psychology; Public Health; Epidemiology; Addiction; Health Psychology; Social Aspects of Mental Health; Health Systems, Risk Management; Psychology; Sexual Risk Taking; Social Exclusion & Isolation; Aetiology; Public Health, Health Services & Primary Care; Compulsive Behaviour; Prognosis & Natural History of Disease; Social Work & Social Policy; Education; Poverty in Developing Countries; HIV/Aids; Equal Educational Opportunity; Primary Care; Drug & Substance Abuse

Contact Details
----------------------------------------------
NIDA
6001 Executive Boulevard
Room 5213
Bethesda, MD 20892-9561
Tel: +1 301 443 6504
Email: lopezmar@nida.nih.gov
Description:
The National Institute on Drug Abuse invites applications for its AIDS-related epidemiology of drug abuse grants. This AIDS-related R03 funding opportunity announcement supports projects that enhance understanding of the nature, extent, distribution, aetiology, comorbidities and consequences of drug use, abuse and addiction across individuals, families, communities, and diverse population groups. Projects should aim to fill knowledge gaps related to changing patterns in drug use, associated factors and consequences in populations, including, but not limited to:

- individual, familial, and environmental factors associated with drug use;
- interplay of factors that exacerbate or mitigate risk for drug initiation, addiction, desistence, recovery, and relapse;
- co-occurring psychiatric conditions, behaviours and associated problems;
- indicators and mechanisms of risk, vulnerability, and health disparities among and between sub-populations;
- developmental and life course trajectories related to the aetiology and natural history of drug use;
- need for, access to, and utilisation of drug abuse prevention and treatment services, and the social, community, and organisational factors that influence intervention development, availability, and effectiveness.
- public health impacts of the attitudes, availability, behaviours, and products, resulting from the shifting marijuana policy environment.

US and foreign for-profit and non-profit organisations are eligible to apply. This funding opportunity announcement uses the NIH small research grant (R03) award mechanism and runs in parallel with opportunities of identical scientific scope: PA-15-001, which solicits applications under the NIH exploratory and developmental (R21) mechanism, and PA-15-003, which solicits applications under the NIH research project grant (R01) mechanism.

Funding is worth up to US$50,000 per year for a maximum project period of two years.


Closing date: 07 Jan 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 06 Oct 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Website:
Application form:

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Health Psychology; Social Psychology; Public Health, Health Services & Primary Care;
Secondary Analyses of Existing Alcohol Epidemiology Data (R03): AIDS-Related

**NIH: National Institute on Alcohol Abuse and Alcoholism**

**Description:**
The National Institute on Alcohol Abuse and Alcoholism invites applications for its AIDS-related secondary analyses of existing alcohol epidemiology data (R03) grants. These R03 grants support AIDS-related, investigator-initiated research projects that either analyse previously collected data in order to address key issues that have emerged from recent findings in alcohol epidemiology and prevention research, or develop new analytic techniques for conducting studies in alcohol epidemiology and prevention research. The goal is to enhance understanding of patterns of alcohol consumption and the epidemiology of alcohol-related problems.

This funding opportunity announcement uses the small grant programme (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-338 that encourages applications under the research project grant (R01) mechanism and PA-14-336 that encourages applications under the exploratory/developmental (R21) mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Grants are worth up to US$50,000 per year for direct costs over a maximum period of two years.

Ref: PA-14-337 (replaces PA-11-309).

**Closing date:** 07 Jan 16

**Deadline information:** Applications open on 24 September 2014 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September 2015 until 8 September 2017.

**Posted date:** 10 Sep 14

**Award type:** Directed grants to institutions, research groups etc

**Award amount max:** $100,000

**Website:**

**Application form:**
http://www.grants.gov/web/grants/applicantss/download-application-package.html#download=true&oppNum=PA-14-337

---

**Contact Details**

DESPR
National Institute on Drug Abuse, NIH/DHHS
6001 Executive Boulevard, Room 5185, MSC 9589
Bethesda, MD 20892-9589
Tel: +1 301 443 6504
Email: lopezmar@nida.nih.gov
Eligibility profile

Country of applicant institution: Any

Disciplines

Ethnic Groups; Social Work & Social Policy; Economic & Social Environment; Population Studies, Medical; Epidemiology; Allied Health Professions; HIV/Aids; Traumatology, Accidents & Injury; Primary Care; Data Analysis; Diagnostic Sciences; Alcoholism; Public Health, Health Services & Primary Care; Aetiology

Contact Details

NIAAA
6000 Executive Boulevard
Willco Building
Bethesda, MD 20892-7003
Tel: +1 301 443 0633
Email: zhaw@mail.nih.gov

SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its AIDS-related secondary analyses of existing alcohol epidemiology data (R01) grants. These R01 grants support AIDS-related, investigator-initiated research projects that either analyse previously collected data in order to address key issues that have emerged from recent findings in alcohol epidemiology and prevention research, or develop new analytic techniques for conducting studies in alcohol epidemiology and prevention research. The goal is to enhance understanding of patterns of alcohol consumption and the epidemiology of alcohol-related problems.

This funding opportunity announcement uses the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-337 that encourages applications under the small grant (R01) mechanism and PA-14-336 that encourages applications under the exploratory/developmental (R21) mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-338 (replaces PA-11-308).

Closing date: 07 Jan 16
Deadline information: Applications open on 24 September 2014 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September 2015 until 8 September 2017.

Posted date: 10 Sep 14
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-338.html
Application form:

http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PAR-14-338

Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism; Public Health, Health Services & Primary Care; HIV/Aids; Social Work & Social Policy; Data Analysis; Economic & Social Environment; Primary Care; Aetiology; Ethnic Groups; Population Studies, Medical; Allied Health Professions; Diagnostic Sciences; Traumatology, Accidents & Injury; Epidemiology

Contact Details

NIAAA
6000 Executive Boulevard
Willco Building
Bethesda, MD 20892-7003
Tel: +1 301 443 0633
Email: zhaw@mail.nih.gov

BEHAVIOURAL OR SOCIAL INTERVENTION CLINICAL PLANNING GRANT (R34):
AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its Aids-related NIDCR behavioural or social intervention clinical planning grant (R34). These R34 Aids-related grants support activities that include:

- the development of the behavioural or social intervention manual and procedures for training interventionists;
- development of the clinical protocol that will guide a subsequent clinical trial;
- the tools for data management, participant safety and operational oversight;
- other activities to prepare for a subsequent clinical trial.

R34 applications preparing for a behavioural or social intervention study may involve human subjects as part of small-scale testing of the feasibility and acceptability of the interventions, measures, methods and training approaches.

Eligible applicants include domestic and foreign public or private institutions and non-profit or for-profit organisations.

Grants are worth up to US$150,000 for a period of maximum of one year.

PAR-14-342 (replaces PAR-11-338)

Closing date: 07 Jan 16
Deadline information: Applications open on 21 October 2014 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 22 Sep 14
Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $150,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Oral Medicine; Drug Design; Biochemical Markers; Biological Markers & Sensor Mechanisms; Dental Health & Hygiene; Diagnostic Sciences; Clinical Medicine; HIV/AIDS; Dentistry; Clinical Chemistry

Contact Details

National Institute of Dental and Craniofacial Research
1DEM, Room 634, MSC 4878
6701 Democracy Boulevard
Bethesda, MD 20892-4878
Tel: +1 301 594 4814
Email: dclark2@nidcr.nih.gov

RESEARCH TO ADVANCE VACCINE SAFETY (R01): AIDS-RELATED

NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institutes of Allergy and infectious Diseases, and the Centres for Disease Control invite applications for their research to advance vaccine safety (R01) funding opportunity announcement. This Aids-related announcement supports research that will contribute to the overall understanding of vaccine safety. Studies should address scientific areas potentially relevant to vaccine safety such as:

- physiological and immunological responses to vaccines and vaccine components;
- how genetic variations affect immune or physiological responses that may impact vaccine safety;
- identification of risk factors biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines;

- creation or evaluation of statistical methodologies for analysing data on vaccine safety, including data available from existing data sources such as passive reporting systems;
- the application of genomic or molecular technologies to improve knowledge of vaccine safety.

This funding opportunity will use the NIH research project grant (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-313, which encourages applications under the NIH exploratory/developmental (R21) grant mechanism.

Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions.

Budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years.
Ref: PA-15-312 (replaces PA-12-037).

Closing date: 07 Jan 16
Deadline information: Applications open on 5 September, 2015 and are due by 5pm local time of applicant organisation every January 7, May 7, September 7 until 8 September, 2018.
Posted date: 29 Jul 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:

Application form:
http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
Country of applicant institution: Any
Disciplines
Immunology; Immunisation Programmes & Vaccination; HIV/Aids
Contact Details
Tel: +1 240 627 3322
Email: bmulach@niaid.nih.gov

RESEARCH TO ADVANCE VACCINE SAFETY (R21): AIDS-RELATED
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases, and Centres for Disease Control and Prevention invite applications for their research to advance vaccine safety (R21) funding opportunity announcement. This Aids-related announcement supports research that will contribute to the overall understanding of vaccine safety. Studies should address scientific areas potentially relevant to vaccine safety such as:

- physiological and immunological responses to vaccines and vaccine components;
- how genetic variations affect immune or physiological responses that may impact vaccine safety;
- identification of risk factors biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines;
- creation or evaluation of statistical methodologies for analysing data on vaccine safety, including data available from existing data sources such as passive reporting systems;
- the application of genomic or molecular technologies to improve knowledge of vaccine safety.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-312, which solicits applications under the NIH research project grant (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Direct costs are limited to US$275,000 over a two-year period, and no more than US$200,000 may be requested in any year.
Pilots and Feasibility Clinical Research Grants in Urologic Disorders (R21): AIDS-Related

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its AIDS-related pilot and feasibility clinical research grants in urologic disorders (R21) funding opportunity announcement. This AIDS-related announcement supports small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic disorders research.

Studies should address important clinical and translational questions that are potentially of high clinical and public health impact.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-161, which also solicits applications under the R21 mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs with a maximum of US$200,00 in direct costs per year. The maximum project period is two years.


Closing date: 07 Jan 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 30 Mar 15
Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275480

Eligibility profile
Country of applicant institution: Any

Disciplines
Urology; HIV/Aids

Contact Details
NIDDK
BG 2DEM Room 627
6707 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 77717
Email: ziya.kirkali@nih.gov

SECONDARY ANALYSES IN OBESITY, DIABETES, DIGESTIVE AND KIDNEY DISEASES (R21): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its secondary analyses in obesity, diabetes and digestive and kidney diseases (R21) funding opportunity announcement. This announcement supports the secondary analysis of existing data sets relevant to the following: diabetes and endocrine and metabolic diseases; genetic metabolic diseases; obesity, liver diseases; alimentary gastrointestinal tract diseases and nutrition; kidney, urologic and haematologic diseases. Innovative and high-risk applications with a likelihood for high impact are particularly encouraged.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs, with up to US$200,000 available for direct costs per year. The maximum project period is two years.

PA-15-169 (reissue of PA-12-125).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 02 Apr 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Award amount min: -
Award budget total: -

Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275615

Eligibility profile
Country of applicant institution: Any
Disciplines
----------------------------------------------
Diabetes; Gastroenterology; HIV/Aids; Hormones & Endocrinology; Nephrology & Kidneys; Metabolomics; Nutrition & Dietetics; Hepatology; Haematology; Obesity

Contact Details
----------------------------------------------
NIDDK
BG 2DEM Room 659
6707 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 8879
Email: aynur.unalp-arida@nih.gov

PILOT AND FEASIBILITY STUDIES IN PREPARATION FOR DRUG ABUSE PREVENTION TRIALS (R34): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their pilot and feasibility studies in preparation for drug and alcohol abuse prevention trials (R34) funding opportunity announcement. This Aids-related announcement supports pilot and feasibility testing of innovative new, revised or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings. It also supports pre-trial feasibility testing for prevention services and systems research. Of particular interest are prevention interventions targeting the healthcare system.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$450,000 in direct costs with up to US$225,000 in direct costs per year.

The maximum project period is three years.
Ref: PA-15-177 (reissue of PA-12-171).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 08 Apr 15
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award amount max: $450,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
RENAL FUNCTION AND CHRONIC KIDNEY DISEASE IN AGEING (R21): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites grant applications for renal function and chronic kidney disease in ageing. This Aids-related R21 funding opportunity announcement funds basic, clinical and translational research on chronic kidney disease and its consequences in ageing and in older persons. Applications should focus on:

- biology and pathophysiology of CKD in animal models;
- aetiology and pathophysiology of CKD in older adults;
- epidemiology and risk factors for the development of CKD with advancing age;
- diagnosis, medical management and clinical outcomes of CKD in this population.

This funding opportunity announcement will use the exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-211, which encourages applications under the NIH research project grant (R01) mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in any year. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PA-12-210 (replaces PA-09-166).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 14 Jun 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Application form: [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-210](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-210)

Eligibility profile
Country of applicant institution: Any

Disciplines
Hormones & Endocrinology; Osteoporosis & Other Bone Diseases; Blood Diseases; Biological Markers & Sensor Mechanisms; Nephrology & Kidneys; Aetiology; Geriatrics & Gerontology; Primary Care; Pathophysiology; Medical & Diagnostic Tests; Public Health, Health Services & Primary Care
PAIN IN AGEING (R21): AIDS-RELATED

NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications under its pain in ageing programme. This Aids-related funding opportunity announcement encourages exploratory and developmental research grant (R21) applications from institutions and organisations that propose to study pain from an ageing perspective, including studies of older populations, studies of age differences and age-related changes in pain processes and experiences, and studies of pain treatment and management in older adults. This FOA particularly encourages studies on:

- mechanisms and predictors of pain experience in ageing;
- development and evaluation of pain assessment tools for older adults or older model organisms;
- development and evaluation of pain management strategies in older adults, with particular attention to the challenges associated with treating pain in patients with multiple morbidities.

This FOA will use the NIH exploratory/developmental research grant (R21) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-058, that encourages applications under the research project grant (R01) grant mechanism, and PA-13-060, that encourages applications under the R03 small research grants mechanism. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PA-13-059 (replaces PA-09-194)

Closing date: 07 Jan 16
Deadline information: Applications are due every January 7, May 7 and September 7 until January 8, 2016.
Posted date: 27 Dec 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-059
Issue 24: Volume 1b – Grants from NIH (January – March, 2016)

Eligibility profile

Country of applicant institution: Any

Disciplines

Behavioural Medicine; Clinical Medicine; Primary Care; HIV/AIDS; Geriatrics & Gerontology; Pain Management; Medical Effectiveness & Patient Outcomes; Public Health, Health Services & Primary Care; Radiology & Medical Imaging; Biochemical Markers; Neurobiology; Diagnostic Sciences; Biological Sciences; Human Physiology; Chronic Pain; Biochemistry & Molecular Biology

Contact Details

NIA
Building 31, Room 5C27
31 Center Drive, MSC 2292
Bethesda, MD 20892
Tel: +1 301 496 9350
Email: chenw@nia.nih.gov

PAIN IN AGING (R03): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications under its pain in ageing programme. This Aids-related funding opportunity announcement encourages small grant (R03) applications from institutions and organisations that propose to study pain from an ageing perspective, including studies of older populations, studies of age differences and age-related changes in pain processes and experiences, and studies of pain treatment and management in older adults. This FOA particularly encourages studies on:

- mechanisms and predictors of pain experience in ageing;
- development and evaluation of pain assessment tools for older adults or older model organisms;
- development and evaluation of pain management strategies in older adults, with particular attention to the challenges associated with treating pain in patients with multiple morbidities.

This FOA will use the NIH R03 small research grants award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-058, that encourages applications under the R21 exploratory/developmental grant mechanism, and PA-13-059, that encourages applications under the research project grant (R01) mechanism. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Direct costs are limited to US$50,000 per year for a maximum of US$100,000 direct costs over a two-year project period. The maximum project period is two years. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations.

PA-13-060 (replaces PA-09-195)

Closing date: 07 Jan 16
Deadline information: Applications are due every January 7, May 7 and September 7 until January 8, 2016.
Posted date: 27 Dec 12
PAIN IN AGEING (R01): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications under its pain in ageing programme. This Aids-related funding opportunity announcement encourages research project grant (R01) applications from institutions and organisations that propose to study pain from an ageing perspective, including studies of older populations, studies of age differences and age-related changes in pain processes and experiences, and studies of pain treatment and management in older adults. This FOA particularly encourages studies on:

- mechanisms and predictors of pain experience in ageing;
- development and evaluation of pain assessment tools for older adults or older model organisms;
- development and evaluation of pain management strategies in older adults, with particular attention to the challenges associated with treating pain in patients with multiple morbidities.

This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-059, that encourages applications under the R21 exploratory/developmental grant mechanism, and PA-13-060, that encourages applications under the R03 small research grants mechanism. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. Eligible
organisations include domestic and foreign public and private non-profit organisations and for-profit organisations.
PA-13-058 (replaces PA-09-193)

Closing date: 07 Jan 16
Deadline information: Applications are due every January 7, May 7 and September 7 until January 8, 2016.
Posted date: 27 Dec 12
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

**Disciplines**
----------------------------------------------
Medical Effectiveness & Patient Outcomes; Primary Care; Clinical Medicine; Behavioural Medicine; Diagnostic Sciences; Psychology; Biochemical Markers; Geriatrics & Gerontology; Radiology & Medical Imaging; Psychology of Ageing; Biochemistry & Molecular Biology; Neurobiology; Public Health, Health Services & Primary Care; Chronic Pain; Pain Management; Biological Sciences; HIV/AIDS

**Contact Details**
----------------------------------------------
NIA
Building 31, Room 5C27
31 Center Drive, MSC 2292
Bethesda, MD 20892
Tel: +1 301 496 9350
Email: chenw@nia.nih.gov

ANCILLARY STUDIES OF ACUTE KIDNEY INJURY, CHRONIC KIDNEY DISEASE AND END STAGE RENAL DISEASE ACCESSING INFORMATION FROM CLINICAL TRIALS, EPIDEMIOLOGICAL STUDIES AND DATABASES (R01): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

**Description:**
The National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung, and Blood Institute invite applications for their Aids-related ancillary studies of acute kidney injury, chronic kidney disease and end stage renal disease accessing information from clinical trials, epidemiological studies and databases (R01) grants. This Aids-related R01 funding opportunity announcement encourages investigator-initiated ancillary studies to ongoing or completed clinical trials, existing epidemiological studies of kidney disease as well as clinical trials and epidemiological studies for other diseases or populations that lend themselves to the study of acute kidney injury and chronic kidney disease. The goal of these studies should be to extend understanding of risk factors for developing kidney disease and associated co-morbid illnesses, factors associated with rapid decline in kidney function among persons with chronic kidney disease, and the impact of these diseases on quality of life and mental and physical functioning. Investigations of acute kidney injury, including biomarkers, are also appropriate topics of investigation.
Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public and private institutions are eligible to apply. PA-12-299 (replaces PA-09-196).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 01 Oct 12
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-299.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-299

Eligibility profile
Country of applicant institution: Any

Disciplines
Drug Design; Biological Markers & Sensor Mechanisms; Population Studies, Medical; Public Health, Health Services & Primary Care; Biochemical Markers; Pathogenesis; Primary Care; Epidemiology; Diagnostic Sciences; HIV/AIDS; Nephrology & Kidneys; Data Analysis; Health Systems, Risk Management; Clinical Medicine

Contact Details
Division of Kidney, Urologic and Hematologic Diseases
NIDDK
6707 Democracy Boulevard, Room 617
Bethesda, MD 20892
Tel: +1 301 594 7735
Email: kusekj@extra.niddk.nih.gov

SECONDARY ANALYSES OF EXISTING DATA SETS AND STORED BIOSPECIMENS TO ADDRESS CLINICAL AGEING RESEARCH QUESTIONS (R01): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute of Aging invites applications for its Aids-related secondary analyses of existing data sets and stored biospecimens to address clinical ageing research questions (R01) programme. This Aids-related R01 funding opportunity announcement will address clinically related issues on ageing changes influencing health across the life span or on diseases and disabilities in older persons.

This FOA will support activities addressing specific hypotheses in clinical ageing research, or informing the design and implementation of future epidemiologic or human intervention studies, or current geriatric practice in maintenance of health, management of disease, and prevention of disability.

Application budgets are not limited, but must reflect the actual needs of the project. Projects may not exceed five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-168 (replaces PA-09-265).
Drug Discovery for Nervous System Disorders (R21): AIDS-Related

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health, the National Institute on Aging, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute on Drug Abuse invite applications for their drug discovery for nervous system disorders funding opportunity. This Aids-related R21 funding opportunity announcement encourages research grant applications directed toward the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders. The goal is to advance new, innovative and effective therapies for the prevention and treatment of nervous system disorders. Studies aimed at the development and testing of compounds for novel targets are encouraged, however projects designed for target identification are not covered under this announcement.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

This FOA will use the R21 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-13-048, that solicits applications under the R01 mechanism. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to US$275,000 direct costs over a two-year period, with no more than US$200,000 in direct costs allowed in any single year. PAR-13-049 (replaces PAR-10-002).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.
Posted date: 19 Dec 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-049

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Central Nervous System; Pharmacogenomics;
Endocrine & Neuroendocrine Cancers;
Human Biological Sciences; Prosthetic & Orthotic Devices; Cellular Interactions;
Diagnostic Sciences; Neurosurgery;
Toxicology; Neuroanatomy;
Pharmacokinetics; Neuroscience; Stress,
Psychological; HIV/Aids; Immunological & Bioassay Methods; Pharmacy & Pharmacology; Weapons of Mass Destruction;
Pharmaceutical Drugs; Medicinal Chemistry;
Neurostimulation; Neuropsychology;
Neuropharmacology; General Practice;
Screening of Drugs & Agents; Disease Models;
Neuroimaging; Psychology; Biochemical Markers; Pharmacotherapy; Biological Sciences; Methods of Drug Delivery;
Neurobiology; Clinical Pharmacy & Pharmacology; Drug Design; Muscle Diseases;
Neurology; Clinical Medicine; Chemistry; Clinical Chemistry; Electrophysiology;
Pharmacology; Neuroscience; Screening of Drugs & Agents; Disease Models;
Pharmaceutical Drugs; Medicinal Chemistry; Pharmacology; General Practice;
Screening of Drugs & Agents; Disease Models; Neuroimaging; Psychology; Biochemical Markers; Pharmacotherapy; Biological Sciences; Methods of Drug Delivery; Neurobiology; Clinical Pharmacy & Pharmacology; Drug Design; Muscle Diseases; Neurology; Clinical Medicine; Chemistry; Clinical Chemistry; Electrophysiology;

Contact Details
----------------------------------------------
NIMH
6001 Executive Boulevard, Room 7189
Rockville, MD 20852
Tel: +1 301 443 5288
Email: jdrisco1@mail.nih.gov

**DRUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R01): AIDS-RELATED**

**NIH: National Institute of Mental Health**

**Description:**
The National Institute of Mental Health, the National Institute on Aging, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute on Drug Abuse invite applications for their drug discovery for nervous system disorders funding opportunity. This Aids-related R01 funding opportunity announcement encourages research grant applications directed toward the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders. The goal is to advance new, innovative and effective therapies for the prevention and treatment of nervous system disorders. Studies aimed at the development and testing of compounds for novel targets are encouraged, however projects designed for target identification are not covered under this announcement.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.
This FOA will use the R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-13-049, that solicits applications under the R21 mechanism. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. PAR-13-048 (replaces PAR-10-001).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.
Posted date: 19 Dec 12
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-048

Disciplines

Electrophysiology; General Practice; Pharmacotherapy; Neuroimaging; Prosthetic & Orthotic Devices; HIV/AIDS; Neuroendocrinology; Clinical Pharmacy & Pharmacology; Neuroscience; Cellular Interactions; Endocrine & Neuroendocrine Cancers; Immunological & Bioassay Methods; Toxicology; Neuroanatomy; Biological Sciences; Disease Models; Biochemical Markers; Screening of Drugs & Agents; Stress, Psychological; Central Nervous System; Neurosurgery; Pharmacogenomics; Chemistry; Neurotransmitters; Clinical Chemistry; Pharmacokinetics; Methods of Drug Delivery; Neuropharmacology; Clinical Medicine; Neurostimulation; Pharmacy & Pharmacology; Weapons of Mass Destruction; Diagnostic Sciences; Medicinal Chemistry; Neurobiology; Psychology; Drug Design; Human Biological Sciences; Neuropsychology; Neurology; Muscle Diseases; Pharmaceutical Drugs

Contact Details

NIMH
6001 Executive Boulevard, Room 7189
Rockville, MD 20852
Tel: +1 301 443 5288
Email: jdrisco1@mail.nih.gov

BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R34): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the Office of Behavioral and Social Sciences Research invite applications for their Aids-related behavioural and integrative treatment development (R34) grants. The aim of this Aids-related R34 programme is to develop and test behavioural and integrative treatments for drug and
alcohol abuse and dependence. Research will test efficacy, conduct clinical trials, examine mechanisms of behaviour change, determine dose-response, optimise combinations, or ascertain best sequencing of behavioural, combined, sequential, or integrated behavioural and pharmacological treatments in the following circumstances:

- drug abuse treatment interventions in diverse settings;
- drug abuse treatment and adherence interventions for use in primary care;
- drug abuse treatment and adherence interventions that use technologies to boost effects and increase implementability;
- interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment;
- interventions to promote adherence to drug abuse treatment, HIV and addiction medications;
- interventions to treat chronic pain.

Research of interest includes but is not limited to Stage II and Stage III efficacy research. This funding opportunity announcement will use the R34 award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-079, which solicits applications under the R03 small grant mechanism, and PA-13-077, that solicits applications under the R01 research project grant mechanism.

Direct costs are limited to US$450,000 over three years, with no more than US$225,000 in direct costs allowed in any single year. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. PA-13-078 (replaces PA-10-013).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
-------------------------------
Country of applicant institution: Any

Disciplines
-------------------------
Counselling & Therapy; Psychology; Infection Agents & Pathogens; Drug & Substance Abuse; Cognitive & Behavioural Therapies; Biological Sciences; Population Studies, Medical; Molecular Genetics; Physiology; Allied Health Professions; Alcoholism; Neurobiology; General Practice; Mental Illness; Cognitive Processes; Behavioural Medicine; Neuroscience; HIV/Aids; Infectious Diseases; Diagnostic Sciences

Contact Details
---------------------------------------
Division of Clinical Neuroscience and Behavioural Research
NIDA
6001 Executive Boulevard, Room 3172, MSC 9593
Bethesda, MD 20892-9593
Tel: +1 301 443 2235
Email: lisa_onken@nih.gov
DEVELOPMENT AND CHARACTERISATION OF ANIMAL MODELS FOR AGEING RESEARCH (R01): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites Aids-related R01 applications for its development and characterisation of animal models for ageing research programme. The institute aims to promote Aids-related research under the R01 mechanism that develops, characterises, refines and enhances model systems for research on ageing. Studies that develop new model systems or refine existing models to maximise their value for ageing research will contribute to the understanding of normal changes in physiology and function with age and the onset, progression, therapeutics and prevention of age associated diseases. The objective of this programme is to enhance the biological resources and tools available to the research community for the study of biology of ageing.

This funding opportunity announcement will utilise the R01 award mechanism and runs in parallel with another FOA of identical scope, PA-13-156 that solicits applications under the R21 mechanism. Application budgets are not limited, and the maximum project period is five years. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PA-13-155 (replaces PA-10-014).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation.

Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.
Posted date: 25 Mar 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-155

Eligibility profile
----------------------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------------------
Geriatrics & Gerontology; Animal Models; Biological Sciences; Biomolecular Modelling; Diagnostic Sciences; HIV/Aids; Human Physiology; Cell Lines; Physiology; Biochemical Markers

Contact Details
----------------------------------------------------------
Division of Aging Biology (DAB)
National Institute on Aging
7201 Wisconsin Avenue, GWY BG Room 2C231
Bethesda, MD 20892-9205
Tel: +1 301 402 7749
Email: mmurthy@mail.nih.gov
NEI CLINICAL STUDY PLANNING GRANT PROGRAMME (R34): AIDS-RELATED
NIH: National Eye Institute

Description:
The National Eye Institute invites applications for its Aids-related clinical study planning grant programme (R34). This Aids-related R34 funding opportunity announcement will facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed manual of procedures (MOP) for a large-scale clinical trial or epidemiologic study. Funding may support the development of an MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential.
Direct costs are limited to US$150,000 per year and projects may not exceed two years. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PAR-13-073 (replaces PAR-10-017).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 07 Jan 13
Award type: Directed grants to institutions, research groups etc

CCELERATING THE PACE OF DRUG ABUSE RESEARCH USING EXISTING DATA (R01): AIDS-RELATED
NIH: National Cancer Institute

Description:
The National Institute of Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the National Cancer Institute invite applications for their Aids-related accelerating the pace of drug abuse research using existing data programme. This Aids-related R01 funding opportunity announcement will support the innovative analysis of existing social science,
behavioural, administrative and neuroimaging data to study the aetiology and epidemiology of drug-using behaviours and related disorders, associated HIV risk behaviours, prevention of drug use and HIV, and health service use.

Direct costs are limited to US$450,000 direct costs over three years, with no more than US$150,000 in any year. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply. PAR-13-080 (replaces PAR-10-018).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $450,000


Eligibility profile
Country of applicant institution: Any
Disciplines
Alcoholism; HIV/AIDS; Aetiology; Psychology; Drug & Substance Abuse; Diagnostic Sciences; Smoking & Tobacco; Cognitive & Behavioural Therapies; Epidemiology; Behavioural Medicine; Behavioural Studies & Social Problems

Contact Details
Division of Epidemiology, Services, and Prevention Research
NIDA
6001 Executive Boulevard, Room 5144, MCS 9589
Bethesda, MD 20892-9589
Tel: +1 301 443 6504
Email: lopezmar@nida.nih.gov

OBEISITY POLICY EVALUATION RESEARCH (R01): AIDS-RELATED
NIH: National Cancer Institute

Description:
Six organisations of the National Institutes of Health invite applications for their AIDS-related obesity policy evaluation research (R01) grants. This AIDS-related R01 funding opportunity announcement encourages evaluations of large scale policies or programmes that are expected to influence obesity-related behaviours or weight outcomes in an effort to prevent or reduce obesity.

Applications budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PA-13-110 (replaces PA-10-027).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 07 Feb 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-10-027.html

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-110

Eligibility profile
Country of applicant institution: Any

Disciplines
Carcinogenesis; Diagnostic Sciences; Education; Primary Care; Nutrition & Dietetics; HIV/AIDS; Exercise Physiology; Food Consumption; Public Health, Health Services & Primary Care; Malnutrition; Obesity; Food Science; Sports & Exercise Studies; Cancer Cell Biology; Cancer Studies & Oncology; Physical & Sports Education; Dietary Guidelines

Contact Details
NIDDK
6707 Democracy Boulevard, Room 605
Bethesda, MD 20817
Tel: +1 301 594 4728
Email: ch514c@nih.gov

IDCR SMALL RESEARCH GRANTS FOR DATA ANALYSIS AND STATISTICAL METHODOLOGY APPLIED TO GENOME-WIDE DATA (R03): AIDS-RELATED
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites Aids-related proposals for its small research grants for data analysis and statistical methodology applied to genome-wide data. This Aids-related R03 funding opportunity announcement will support meritorious research projects that involve secondary data analyses or development of statistical methodology using existing genome-wide data, relevant to human dental or craniofacial conditions or traits. Development of statistical methodology appropriate for analysing genome-wide data, relevant to human dental or craniofacial conditions or traits, may also be proposed.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

Up to US$200,000 is available per year for direct costs, given that the total project budget does not exceed US$300,000 over a maximum project period of two years. PAR-13-044 (replaces PAR-10-041).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on deadline dates. Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.
Posted date: 09 Jan 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $300,000
TIMULATING HAEMATOLOGY INVESTIGATION: NEW ENDEAVOURS (SHINE) (R01): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its Aids-related stimulating haematology investigation: new endeavours (SHINE) programme. This Aids-related programme will support innovative, high-quality haematology research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases. Investigator-initiated research project grant applications are requested in specific areas of basic and translational haematology research where needs and opportunities for progress are particularly timely.

NIH intends to provide US$1 million to fund two to four awards in fiscal year 2013. Application budgets are not limited, but must reflect the actual needs of the project. Projects may request up to five years of support. Domestic and foreign public and private non-profit organisations and for-profit organisations are eligible to apply. PAS-13-031 (replaces PAS-10-046).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September 7 until 8 January 2016.
Posted date: 04 Dec 12
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PAS-10-046.html

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAS-13-031

Eligibility profile
Country of applicant institution: Any
TRIUCTURAL INTERVENTIONS, ALCOHOL USE AND RISK OF HIV/AIDS (R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites proposals for its structural interventions, alcohol use and risk of HIV/AIDS (R01) programme. This R01 funding opportunity announcement solicits applications from institutions and organisations that propose to investigate the effectiveness of structural interventions that reduce the risk of HIV/AIDS transmission by changing the environment of alcohol use.

This FOA will use the research project grant R01 mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-192, which solicits applications under the R21 exploratory/developmental grant mechanism. Applications budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-191 (replaces PA-10-242).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 12 Apr 13
Award type: Directed grants to institutions, research groups etc

Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-191

Eligibility profile
Country of applicant institution: Any
Disciplines
Gender Roles & Sexuality; Education; Social Work & Social Policy; Mental Illness; Biomedical Engineering; Diagnostic Sciences; Health Systems Policy; Alcoholism; Psychology; Behavioural Medicine; HIV/AIDS; Public Health, Health Services & Primary Care; Health Disparities; Primary Care; Preventive Medicine

Contact Details
NIH: National Institute on Alcohol Abuse and Alcoholism
6707 Democracy Boulevard, Room 619
Bethesda, MD 20817
Tel: +1 301 594 7726
Fax: tb232j@nih.gov
**CALCIUM OXALATE STONE DISEASES (R01): AIDS-RELATED**

**NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

**Description:**
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for research into calcium oxalate stone diseases. This Aids-related funding opportunity announcement R01 aims to increase investigator interest in research into oxalate metabolism, transport and homeostasis, and oxalate stone diseases. This initiative encourages basic, clinical or epidemiological studies that utilise new and innovative approaches to study the diagnosis, treatment and prevention of these disorders.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. PA-13-043 (replaces PA-09-213).

**Closing date:** 07 Jan 16
**Deadline information:** Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.
**Posted date:** 17 Dec 12
**Award type:** Directed grants to institutions, research groups etc
**Award budget total:** -


**Application form:** [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-043](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-043)

**Eligibility profile**
Country of applicant institution: Any

**Disciplines**
Primary Care; HIV/AIDS; Public Health, Health Services & Primary Care; Pathogenesis; Diagnostic Sciences; Aetiology; General Practice; Molecular Genetics; Medical & Diagnostic Tests; Urology; Clinical Medicine; Nephrology & Kidneys; Preventive Medicine

**Contact Details**
Division of Kidney, Urologic, and Hematologic Diseases
NIDDK
6707 Democracy Blvd, Room 643
Bethesda, MD 20892-5458
Tel: +1 301 594 6007
Fax: +1 301 480 3510
Email: rebekah.rasooly@nih.gov

---

**UNDERSTANDING AND PROMOTING HEALTH LITERACY (R01): AIDS-RELATED**

**NIH: Office of the Director**

**Description:**
A total of 11 institutes and offices of the National Institutes of Health invite proposals for the Aids-related understanding and promoting health literacy (R01) programme. The goal of this Aids-related R01 funding
opportunity announcement is to encourage methodological, intervention and dissemination research for understanding and promoting health literacy. Health literacy is defined as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.

This call will use the NIH R01 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-131, which uses the R03 grant mechanism, and PAR-13-132, which uses the R21 grant mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited, but must reflect the actual needs of the project. The total project period may not exceed five years. PAR-13-130 (replaces PAR-10-133).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until May 8, 2016.
Posted date: 04 Mar 13

Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-130

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Health Systems; Patient Care & Education; Education; Health & Safety Education & Instruction; Primary Care; Health Promotion; Diagnostic Sciences; Health Education; Public Health; Clinical Medicine; HIV/Aids

Contact Details
----------------------------------------------
OBSSR
NIH
31 Centre Drive, Room B1C19
Bethesda, MD 20814
Email: +1 301 401 0116
Email: elwoodwi@od.nih.gov

UNDERSTANDING AND PROMOTING HEALTH LITERACY (R03): AIDS-RELATED
NIH: Office of the Director

Description:
A total of eight institutes and offices of the National Institutes of Health invite proposals for the AIDS-related understanding and promoting health literacy (R03) programme. The goal of this AIDS-related R03 funding opportunity announcement is to encourage methodological, intervention and dissemination research for understanding and promoting health literacy. Health literacy is defined as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.

This call will use the NIH R03 award mechanism and runs in parallel with FOAs of
identical scientific scope, PAR-13-130, which uses the R01 grant mechanism, and PAR-13-132, which uses the R21 grant mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Direct costs are limited to US$100,000 over two years with no more than US$50,000 in any year. PAR-13-132 (replaces PAR-10-134).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 04 Mar 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Eligibility profile

Country of applicant institution: Any

Disciplines

- Health & Safety Education & Instruction
- Diagnostic Sciences
- Patient Care & Education
- Public Health
- Health Systems
- Health Promotion
- Education
- Health Education
- Clinical Medicine
- HIV/AIDS
- Primary Care

Contact Details

- OBSSR
- NIH
- 31 Centre Drive, Room B1C19
- Bethesda, MD 20814
- Tel: +1 301 401 0116
- Email: elwoodwi@od.nih.gov

UNDERSTANDING AND PROMOTING HEALTH LITERACY (R21): AIDS-RELATED

NIH: Office of the Director

Description:

A total of nine institutes and offices of the National Institutes of Health invite proposals for the Aids-related understanding and promoting health literacy (R21) programme. The goal of this Aids-related R21 funding opportunity announcement is to encourage methodological, intervention and dissemination research for understanding and promoting health literacy. Health literacy is defined as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.

This call will use the NIH R21 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-130, which uses the R01 grant mechanism, and PAR-13-131, which uses the R03 grant mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Direct costs are limited to US$275,000 over two years with no more than US$200,000 available in any year. PAR-13-132 (replaces PAR-10-135).
Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant institution on every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 04 Mar 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000


Eligibility profile
-----------------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------------
Primary Care; Diagnostic Sciences; Public Health; Health & Safety Education & Instruction; Health Education; Health Promotion; Patient Care & Education; Education; Health Systems; Clinical Medicine; HIV/AIDS

Contact Details
-----------------------------------------------------
OBSSR
NIH
31 Centre Drive, Room B1C19
Bethesda, MD 20814
Tel: +1 301 401 0116
Email: elwoodwi@od.nih.gov

ALCOHOL USE DISORDERS: TREATMENT, SERVICES AND RECOVERY RESEARCH (R03): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its Aids-related alcohol use disorders: treatment, services and recovery research (R03) programme. This Aids-related R03 funding opportunity announcement supports research on behavioural and pharmacological treatment for alcohol use disorders; organisational, financial and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; or the phenomenon of recovery from alcohol use disorders.

Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. The total project period may not exceed two years. Direct costs are limited to US$100,000 over a two-year period, with no more than US$50,000 in direct costs allowed in any single year. This programme will use the NIH R03 grant mechanism and runs in parallel with two programmes of identical scientific scope: PA-13-160, which solicits applications under the R01 mechanism, and PA-13-162, which solicits applications under the R21 mechanism. PA-13-161 (replaces PA-10-101)

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 02 Apr 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000  
Award amount min: -  
Award budget total: -  
Eligibility profile  
Country of applicant institution: Any  
Disciplines  
Health Systems, Administration; Cognitive & Behavioural Therapies; Alcoholism; Pharmacy & Pharmacology; HIV/AIDS; Drug & Substance Abuse; Experimental Psychology; Psychology; Public Health, Health Services & Primary Care; Allied Health Professions; General Practice; Primary Care  

Contact Details  
NIAAA  
6000 Executive Boulevard  
Bethesda, MD 20892-7003  
Tel: +1 301 443 4715  
Fax: +1 301 443 0788  

ALCOHOL USE DISORDERS: TREATMENT, SERVICES AND RECOVERY RESEARCH (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its Aids-related alcohol use disorders: treatment, services and recovery research (R01) programme. This Aids-related R01 funding opportunity announcement supports research on behavioural and pharmacological treatment for alcohol use disorders; organisational, financial and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; or the phenomenon of recovery from alcohol use disorders.

Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. Application budgets are not limited, but must reflect the needs of the project. The total project period may not exceed five years. This programme will use the NIH R01 grant mechanism and runs in parallel with two programmes of identical scientific scope: PA-13-161, which solicits applications under the R21 mechanism, and PA-162, which solicits applications under the R03 mechanism. PA-13-160 (replaces PA-10-100).

Closing date: 07 Jan 16  
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.  
Posted date: 02 Apr 13  
Award type: Directed grants to institutions, research groups etc  
Award budget total: -  
**NINDS PHASE III INVESTIGATOR-INITIATED EFFICACY TRIALS (U01): AIDS-RELATED**

**NIH: National Institute of Neurological Disorders and Stroke**

**Description:**
The National Institute of Neurological Disorders and Stroke invites U01 applications for its Aids-related NINDS phase III investigator-initiated efficacy clinical trials. This Aids-related U01 funding opportunity will support investigator-initiated multi-site phase III randomised, controlled clinical trials which address research questions related to the mission and goals of NINDS. The clinical trials may evaluate an experimental intervention in comparison with a standard or control intervention, or compare two or more existing treatments. The programme supports drugs, biologics and devices, as well as surgical, behavioural and rehabilitation therapies. Trials should recruit study subjects from two or more geographically distinct enrolment sites, or centres.

Application budgets are not limited, but need to reflect the actual needs of the project. The maximum project period is five years. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations and academic institutions.

PAR-13-278 (previously PAR-11-173).

**Closing date:** 07 Jan 16
**Deadline information:** Deadlines every 7 January, 7 May and 7 September until 8 September 2016.
**Posted date:** 23 Jul 13
**Award type:** Clinical trials
**Award budget total:** -
**Website:**

**Application form:**

**Eligibility profile**

Country of applicant institution: Any
INDS EXPLORATORY CLINICAL TRIALS (R01): AIDS-RELATED
NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its NINDS exploratory clinical trials (R01). This R01 funding opportunity will support exploratory clinical trials that address research questions related to the mission and goals of NINDS. The clinical trials may evaluate drugs, biologics, devices, or surgical, behavioural or rehabilitation therapies.

Domestic and foreign public and private non-profit organisations and for-profit organisations may apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PAR-13-281 (replaces PAR-10-199).

Closing date: 07 Jan 16
Deadline information: Application due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 24 Jul 13
Award type: Clinical trials
Award budget total: -

Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-10-199

Eligibility profile
Country of applicant institution: Any

Disciplines
Medical Devices; Cognitive & Behavioural Therapies; Drug Design; Neuroscience; Neurobiology; HIV/AIDS; Neuropharmacology; Public Health, Health Services & Primary Care; Electrophysiology; Neurosurgery; Primary Care; Neurology; Muscle Diseases; Behavioural Medicine; Neuroimaging; Clinical Medicine; Diagnostic Sciences; Stroke & Cerebrovascular Disorders; Medicine & Health; Pharmacy & Pharmacology; Counselling & Therapy; Biological Sciences

Contact Details
NINDS
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 496 9135
Email: phase3trial@ninds.nih.gov
Description:
The National Eye Institute invites AIDS-related applications for its collaborative clinical vision research project grant (U10). This AIDS-related U10 funding opportunity announcement supports investigator-initiated clinical vision research projects, including multi-centre clinical trials and other complex or high-risk clinical vision research studies.

This funding opportunity announcement will use the U10 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-097, PAR-14-098, PAR-14-099 and PAR-14-100, each of which invites applications under the UG1 mechanism.

US and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-096 (replaces PAR-10-207).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 13 Feb 14
Award type: Research centres, Clinical trials, Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Epidemiology; Diagnostic Sciences; Optometry; Drug Design; Eye Diseases; Vision Science; Sensory Systems; HIV/AIDS

Contact Details
---------------------------------------------------------------
NEI
5635 Fishers Lane
Bethesda, MD 20892-9300
Tel: +1 301 451 2020
Email: everettd@mail.nih.gov
FUNCTIONAL GENETICS, EPIGENETICS AND NON-CODING RNAs IN DRUG ADDICTION (R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related functional genetics, epigenetics and non-coding RNAs in drug addiction (R01) programme. This Aids-related R01 funding opportunity announcement encourages basic functional genomic research in two areas: functional validation to determine which candidate genes or variants have an authentic role in addictive processes, and detailed elucidation of the molecular pathways and processes modulated by candidate genes or variants, particularly for those genes with an unanticipated role in addiction.

This FOA will use the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-013, which encourages applications under the R21 exploratory/developmental grant mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Applications budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.
Ref: PA-14-014 (reissue of PA-11-033).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 06 Dec 13

Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-014.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-14-014

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Drug & Substance Abuse; Molecular Genetics; Disease Models; Psychology; Addiction; Electrophysiology; Genomics; Ribonucleic Acid, RNA; Proteomics & Molecular Interactions; HIV/Aids; Physiology; Neurotransmitters; Epigenetics; Neuroimaging; Primary Care; Behavioural Medicine; Biochemical Markers; Public Health, Health Services & Primary Care; Diagnostic Sciences; Biological Markers & Sensor Mechanisms; Pharmacokinetics; Biological Sciences; Immunological & Bioassay Methods

Contact Details
----------------------------------------------
NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 435 1020
Email: satterleej@nida.nih.gov
FAMILY AND INTERPERSONAL RELATIONSHIPS IN AN AGING CONTEXT (R01): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its family and interpersonal relationships in an ageing context (R01) grants. This AIDS-related R01 funding opportunity announcement encourages innovative, hypothesis-driven research that can expand understanding of the role and impact of families and interpersonal relationships on health and well-being in midlife and older age. This FOA encourages research that takes a life span perspective, including studies which focus on early life influences on later life outcomes and on processes in midlife that impact subsequent trajectories of health and function. NIA is particularly interested in research that can inform the design of interventions that target the maintenance and improvement of aging-relevant outcomes for the following: satisfying, high quality intimate relationships, compliance and adherence to healthy behaviours; adaptive caregiving relationships, shared decision-making and economic security.

Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants requesting US$500,000 or more in direct costs in any year most contact NIH programme staff at least six weeks before submitting the application. The maximum project period is five years.

Ref: PA-15-042 (reissue of PA-11-128).

Closing date: 07 Jan 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 21 Nov 14
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award budget total: -

Eligibility profile
Country of applicant institution: Any

Disciplines
Psychology of Ageing; HIV/Aids; Geriatrics & Gerontology

Contact Details
National Institute on Aging
NIH
GWY BG Room 533
7201 Wisconsin Avenue
Bethesda MD 20814
Tel: +1 301 402 4156
Email: melissa.gerald@nih.gov
PREDICTIVE MULTISCALE MODELS FOR BIOMEDICAL, BIOLOGICAL, BEHAVIORAL, ENVIRONMENTAL AND CLINICAL RESEARCH (INTERAGENCY U01): AIDS-RELATED

NIH: National Institute of Biomedical Imaging and Bioengineering

Description:
A total of 23 participating institutes and centres of the National Institutes of Health, the US Army Research Office, the Department of Energy, the US Food and Drug Administration, the National Aeronautics and Space Administration, the National Science Foundation and the Office of Naval Research invite applications for their predictive multi scale models for biomedical, biological, behavioural, environmental and clinical research (interagency U01) grants. This AIDS-related funding opportunity aims to support the development of multi scale models to accelerate biological, biomedical, behavioural, environmental and clinical research. This FOA supports the development of non-standard modelling methods and experimental approaches to facilitate multi scale modelling and active participation in community-driven activities through the Multiscale Modeling Consortium.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Direct costs are limited to US$500,000 per year and the maximum project period is five years.

Ref: PAR-15-085 (Reissue of PAR-11-203)

Closing date: 07 Jan 16
Deadline information: Applications open on 9 February 2015 and are due by 5 pm local applicant’s time every 7 January, 7 May and 7 September till 8 January 2018.
Posted date: 09 Jan 15
Award type: Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration
Award amount max: $2,500,000


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Computer Simulation & Modelling; Medical Models, Mathematical; Disease Models; Computational Biology; Biomolecular Modelling; HIV/Aids; Data Analysis

Contact Details
----------------------------------------------
NIBIB
BG 2 Dem Room 200
6707 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 451 4778
Email: grace.peng@nih.gov
PATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R01) AIDS-RELATED
NIH: National Cancer Institute

Description:
The National Cancer Institute and the National Institute of Environmental Health Sciences invite applications for their AIDS-related spatial uncertainty: data, modeling and communication (R01) grants. This AIDS-related R01 funding opportunity announcement supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualise the nature and consequences of spatial uncertainty.

This FOA uses the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-009 and PA-15-011, that solicit applications under the exploratory and developmental grant (R21) and the small grant award (R03) mechanisms, respectively. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-15-010 (replaces PA-11-238).
Closing date: 07 Jan 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation every, 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 13 Oct 14

Award type: Directed grants to institutions, research groups etc
Award budget total: -

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-15-010

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Preventive Medicine; Prognosis & Natural History of Disease; Clinical Medicine; Health Informatics; HIV/AIDS; Disease Control; Public Health, Health Services & Primary Care; Health Systems, Risk Management; Social Work & Social Policy; Population Studies, Medical; Blood Tests; Demography; Computer Science & Informatics; Diagnostic Sciences; Libraries & Information Science; Informatics & Big Data; Epidemiology; Bioinformatics; Primary Care

Contact Details
----------------------------------------------
NCI
6116 Executive Boulevard, Room 504
Bethesda, MD 20852
Tel: +1 240 276 6851
Email: li.zhu@nih.gov
Patial uncertainty: data, modeling and communication (R21) AIDS-related

NIH: National Cancer Institute

Description:
The National Cancer Institute and the National Institute of Environmental Health Sciences invite applications for their AIDS-related spatial uncertainty: data, modeling and communication (R21) grants. This AIDS-related R21 funding opportunity announcement supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualise the nature and consequences of spatial uncertainty.

This FOA uses the NIH exploratory and developmental grant (R21) mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-010 and PA-15-011, that solicit applications under the research project grant (R01) award and the small grant (R03) award mechanisms, respectively. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Funding is worth up to US$275,000 over a maximum two-year project period.

Closing date: 07 Jan 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 13 Oct 14

Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Application form:

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Clinical Medicine; Health Systems, Risk Management; Blood Tests; Health Informatics; Informatics & Big Data; Bioinformatics; Demography; Disease Control; Computer Science & Informatics; Diagnostic Sciences; Population Studies, Medical; Epidemiology; Prognosis & Natural History of Disease; Primary Care; Libraries & Information Science; Social Work & Social Policy; HIV/AIDS; Public Health, Health Services & Primary Care; Preventive Medicine

Contact Details
----------------------------------------------
NCI
6116 Executive Boulevard, Room 504
Bethesda, MD 20852
Tel: +1 240 276 6851
Email: li.zhu@nih.gov
S

Patial Uncertainty: Data, Modelling and Communication (R03) AIDS-Related
NIH: National Cancer Institute

Description:
The National Cancer Institute and the National Institute of Environmental Health Sciences invite applications for their AIDS-related spatial uncertainty: data, modelling and communication (R03) grants. This AIDS-related R03 funding opportunity announcement supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualise the nature and consequences of spatial uncertainty.

This FOA uses the NIH small grant (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-009 and PA-15-010, that solicit applications under the exploratory and developmental grant (R21) and the research project grant (R01) award mechanisms, respectively. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Funding is worth up to US$50,000 per year over a maximum two-year project period.


Closing date: 07 Jan 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September annually until 8 January 2018.

Posted date: 13 Oct 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Health Informatics; Preventive Medicine; Libraries & Information Science; Prognosis & Natural History of Disease; Epidemiology; Primary Care; Demography; Disease Control; HIV/AIDS; Public Health, Health Services & Primary Care; Computer Science & Informatics; Population Studies, Medical; Informatics & Big Data; Health Systems, Risk Management; Bioinformatics; Social Work & Social Policy

Contact Details
----------------------------------------------
NCI
6116 Executive Boulevard, Room 504
Bethesda, MD 20852
Tel: +1 240 276 6851
Email: li.zhu@nih.gov
MECHANISTIC STUDIES OF PAIN AND ALCOHOL DEPENDENCE (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their AIDS-related mechanistic studies of pain and alcohol dependence (R01) research project grant. This AIDS-related R01 funding opportunity announcement supports research in the mechanistic studies on the relationship between excessive alcohol drinking, alcohol dependence and pain with the aim of understanding genetic, pharmacological and learning mechanisms underlying the association between the propensity to drink alcohol excessively and pain responses. Application budgets are not limited, but need to reflect the actual needs of the project. The maximum project period is five years. Applicants requesting US$500,000 or more in direct costs in any year, excluding consortium facilities and administrative costs, must contact NIH programme staff at least six weeks before submitting the application.

Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions.


Closing date: 07 Jan 16
Deadline information: Applications are invited between 5 January and 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 13 Nov 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Pain Management; Chronic Pain; Alcoholism

Contact Details

NIAA
BG 5635FL RM 2052
5635 Fishers Ln
Rockville, MD 20852
+1 301 443 1192
Email: regunathans@mail.nih.gov
TARGETED BASIC BEHAVIOURAL AND SOCIAL SCIENCE AND INTERVENTION DEVELOPMENT FOR HIV PREVENTION AND CARE (R01)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their targeted basic behavioural and social science and intervention development for HIV prevention and care (R01) grants. This R01 funding opportunity announcement aims to provide a global outline of areas for innovative, targeted basic behavioural and social science research and intervention development research to reduce the number of new HIV infections and improve the overall health of those living with HIV and encourage research grant applications in these areas.

This FOA encourages research designed to:
- conduct basic behavioural and social science research that is needed to advance the development of HIV prevention and care interventions;
- translate and operationalise the findings from these basic studies to develop interventions and assess their feasibility;
- conduct tests of the efficacy of HIV prevention and care interventions.

This FOA uses the NIH research (R01) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-128, that encourages applications under the NIH exploratory/developmental (R21) grant mechanism. Application budgets are not limited but need to reflect the actual needs of the project. The total project period may not exceed five years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. Ref: PA-14-127 (replaces PA-11-275).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:

Application form:
http://www.grants.gov/web/grants/applicant-package.html#download=true&oppNum=PA-14-127

Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/Aids; Psychology; Behavioural Medicine; Health Counselling; Public Health, Health Services & Primary Care; Health Systems; Biomedical Engineering; Pharmaceutical Drugs; Clinical Medicine; Primary Care; Social Work & Social Policy; Preventive Medicine; Diagnostic Sciences

Contact Details
NIMH
NSC BG
Room 6118
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 433 6100
Email: ebrouwer@mail.nih.gov
TARGETED BASIC BEHAVIOURAL AND SOCIAL SCIENCE AND INTERVENTION DEVELOPMENT FOR HIV PREVENTION AND CARE (R21)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their targeted basic behavioural and social science and intervention development for HIV prevention and care (R21) grants. This R21 funding opportunity announcement aims to provide a global outline of areas for innovative, targeted basic behavioural and social science research and intervention development research to reduce the number of new HIV infections and improve the overall health of those living with HIV and encourage research grant applications in these areas.

This FOA encourages research designed to:

- conduct basic behavioural and social science research that is needed to advance the development of HIV prevention and care interventions;
- translate and operationalise the findings from these basic studies to develop interventions and assess their feasibility;
- conduct tests of the efficacy of HIV prevention and care interventions.

This FOA uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-127, that encourages applications under the NIH research project (R01) grant mechanism. Direct costs are limited to US$275,000 over a two year project period, with no more than US$200,000 allowed in any single year. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions.

Ref: PA-14-128 (replaces PA-11-277).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-128.html


Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/AIDS; Public Health, Health Services & Primary Care; Biomedical Engineering; Clinical Medicine; Preventive Medicine; Social Work & Social Policy; Psychology; Health Systems; Pharmaceutical Drugs; Behavioural Medicine; Primary Care; Diagnostic Sciences; Health Counselling

Contact Details
NIMH
NSC BG
Room 6118
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 433 6100
Email: ebrouwer@mail.nih.gov
SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIOURAL AND SOCIAL SCIENCES (R01): AIDS-RELATED

NIH: Office of the Director

Description:
A total of 11 participating institutes of the National Institutes for Health invite applications for their systems science and health in the behavioural and social sciences (R01) grants. This Aids-related R01 funding opportunity announcement seeks to increase the breadth and scope of topics that can be addressed with systems science methodologies. This FOA calls for research projects that are applied or basic in nature, including methodological and measurement development, have a human behavioural or social science focus and employ methodologies suited to addressing the complexity inherent in behavioural and social phenomena, referred to as systems science methodologies. Additionally, this FOA seeks to promote interdisciplinary collaboration among health researchers and experts in computational approaches to further the development of modelling- and simulation-based systems science methodologies and their application to important public health challenges. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity announcement uses the NIH research project R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-15-047 that solicits applications under the exploratory/developmental research grant award (R21) mechanism. Application budgets are not limited but need to reflect actual needs of the proposed project. Applicants requesting US$500,000 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. The maximum project period is five years.

Closing date: 07 Jan 16
Deadline information: Applications are invited between 5 January and 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 24 Nov 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
Country of applicant institution: Any
Disciplines
Behavioural Studies & Social Problems; HIV/AIDS; Social Sciences; Research Methods in Sociology

Contact Details
NCI
BG 9609 Room 3E602
9609 Medical Centre DR
Rockville, MD 20850
Tel: +1 301 402 1146
Email: wireley@mail.nih.gov
SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIOURAL AND SOCIAL SCIENCES (R21): AIDS-RELATED
NIH: Office of the Director

Description:
A total of 11 participating institutes of the National Institutes for Health invite applications for their systems science and health in the behavioural and social sciences (R21) grants. This Aids-related R21 funding opportunity announcement seeks to increase the breadth and scope of topics that can be addressed with systems science methodologies. This FOA calls for research projects that are applied or basic in nature, including methodological and measurement development, have a human behavioural or social science focus and employ methodologies suited to addressing the complexity inherent in behavioural and social phenomena, referred to as systems science methodologies. Additionally, this FOA seeks to promote interdisciplinary collaboration among health researchers and experts in computational approaches to further the development of modelling- and simulation-based systems science methodologies and their application to important public health challenges. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. This funding opportunity announcement uses the NIH exploratory/developmental R21 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-15-048 that solicits applications under the research project grant award (R01) mechanism. Application budgets are limited to US$275,000 over the two-year R21 period, with no more than US$200,000 in any year. The maximum project period is two years.


Closing date: 07 Jan 16
Deadline information: Applications are invited between 16 January and 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 24 Nov 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:

Application form:

Eligibility profile
Country of applicant institution: Any
Disciplines
HIV/Aids; Social Sciences; Research Methods in Sociology; Behavioural Studies & Social Problems

Contact Details
NCI
BG 9609 Room 3E602
9609 Medical Centre DR
Rockville MD 20850
Tel: +1 301 402 1146
Email: wireley@mail.nih.gov
BUILDING GENETICS AND GENOMIC KNOWLEDGE ABOUT DENTAL, ORAL AND CRANIOFACIAL DISEASES AND DISORDERS (R01): AIDS-RELATED
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its building a genetic and genomic knowledge base in dental, oral and craniofacial diseases and disorders (R01) grants. This Aids-related R01 funding opportunity announcement encourages research into dental, oral, and craniofacial diseases and disorders for which there is evidence for genetic heritability but for which there is no strong understanding of the genetics or genomics of the disease or disorder.

Research areas may include identification of promising areas of the genome, and characterisation and elucidation of the functions of genetic variants that affect disease risk in humans. The goal is to drive development of effective diagnostic, therapeutic, and preventive approaches. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

The maximum project period is five years.
Ref: PA-14-347 (replaces PA-11-317).

Closing date: 07 Jan 16
Deadline information: Applications open on 28 October 2014 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 23 Sep 14
Award type: Directed grants to institutions, research groups etc

Award amount max: -
Award budget total: -
Website:
Application form:
http://www.grants.gov/web/grants/applicant-package.html#download=true&oppNum=PA-14-347

Eligibility profile
--------------------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------------------------------------------
Medical Genetics; Special Needs Dentistry; Diagnostic Sciences; Public Health, Health Services & Primary Care; Genomics; Genetics & Systems Biology; Allied Health Professions; Genetic Diseases; Primary Care; Dentistry; Clinical Medicine; Craniofacial Disorders; Medicine & Health; Population & Ecological Genetics; Quantitative Genetics; Human Genome; Cancer Genetics; Preventive Medicine; Biological Sciences; Oral Medicine; Preventive Dentistry; HIV/AIDS

Contact Details
--------------------------------------------------------------------------------
NIDCR
Public Information and Liaison Branch
45 Center Drive, MSC 6400
Bethesda, MD 20892-6400
Tel: +1 301 594 4846
Email: emily.harris@nih.gov
HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIOURS IN CHILDREN AND ADOLESCENTS (R01): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
A total of two institutes and offices of the NIH invite applications for their Aids-related healthy habits: timing for developing sustainable healthy behaviours in children and adolescents (R01) grants. This R01 funding opportunity announcement encourages applications that employ innovative research to identify mechanisms of influence and promote positive sustainable health behaviour in children and youth up to the age of 21. Applications to promote positive health behaviour should target social and cultural factors, including schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and mass media. Topics to be addressed in this announcement include:

- effective, sustainable processes for influencing young people to make healthy behaviour choices;
- identification of the appropriate stage of influence for learning sustainable lifelong health behaviours;
- the role of technology and new media in promoting healthy behaviour;
- identification of factors that support healthy behaviour development in vulnerable populations, identification of barriers to healthy behaviours;
- identification of mechanisms and mediators that are common to the development of a range of habitual health behaviours.

Given the many factors involved in developing sustainable health behaviours, applications from multidisciplinary teams are strongly encouraged. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PA-14-177 (Reissue of PA-11-327).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 May, 7 September and 7 January until 8 May 2017.
Posted date: 22 Apr 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-177.html

Eligibility profile
---------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------
Education; Social Work & Social Policy; Health Education; Health Promotion; Dentistry; Psychology; Maternal Health; Social Programmes; Health Psychology; Child Development; Public Health; Primary Care; Communication & Media Studies; Media Studies; Computer, Internet & Mobile Gaming; Group Dynamics & Collective Behaviour; Mental Health; Food Science; Child Protection & Welfare; Behavioural Studies & Social Problems; Communication Studies; Medical Education; Social Psychology; Public Health, Health Services & Primary Care; Social Aspects of Mental Health; Popular Culture; Adolescent Paediatrics; Malnutrition; HIV/Aids; Sociology; Children’s Literature; Behavioural Medicine; Social Behaviour & Attitudes
HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIOURS IN CHILDREN AND ADOLESCENTS (R21): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
A total of two institutes and offices of the NIH invite applications for their Aids-related healthy habits: timing for developing sustainable healthy behaviours in children and adolescents (R21) grants. This AIDS-related R21 funding opportunity announcement encourages applications that employ innovative research to identify mechanisms of influence and promote positive sustainable health behaviour in children and youth up to the age of 21. Applications to promote positive health behaviour should target social and cultural factors, including schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and mass media. Topics to be addressed in this announcement include:

- effective, sustainable processes for influencing young people to make healthy behaviour choices;
- identification of the appropriate stage of influence for learning sustainable lifelong health behaviours;
- the role of technology and new media in promoting healthy behaviour;
- identification of factors that support healthy behaviour development in vulnerable populations, identification of barriers to healthy behaviours;
- identification of mechanisms and mediators that are common to the development of a range of habitual health behaviours.

Given the many factors involved in developing sustainable health behaviours, applications from multidisciplinary teams are strongly encouraged. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.
Ref: PA-14-176 (Reissue of PA-11-329).

Closing date: 07 Jan 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 May 2017.
Posted date: 22 Apr 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
Country of applicant institution: Any

Disciplines
Health Psychology; Popular Culture; Communication Studies; Behavioural Studies
A

LCOHOL IMPAIRMENT OF IMMUNE FUNCTION, HOST DEFENSE AND TISSUE HOMEOSTASIS (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its alcohol impairment of immune function, host defense and tissue homeostasis (R01) funding opportunity announcement. This Aids-related announcement invites applications from researchers with broad expertise to study the consequences of alcohol consumption on immune function, with the goal of improving the outcome of patients who abuse alcohol.

This FOA also aims to attract research applications that utilise comprehensive approaches and cutting edge technology to address mechanistic questions about alcohol’s effect on human health. In view of the complexity of the interactions within the immune system and among immune, neural and endocrine networks, systems approaches are encouraged.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is five years.
Ref: PA-15-159 (reissue of PA-12-025).

Closing date: 07 Jan 16
Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 27 Mar 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:

Application form:
http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275459

Eligibility profile
--------------------------------------------------
Country of applicant institution: Any
HIGH THROUGHPUT SCREENING TO DISCOVER CHEMICAL PROBES (R01): AIDS-RELATED
NIH: National Institute of Mental Health

Description:
A total of 11 components of the National Institutes of Health invites applications for their solicitation of high throughput screening to discover chemical probes (R01) grants. This Aids-related R01 funding opportunity announcement encourages investigators to form collaborations with an established academic, non-profit or commercial high throughput screening facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Through this FOA, NIH wishes to stimulate research in:

- discovery and development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH institutes;
- discovery or validation of novel, biological targets that will inform studies of disease mechanisms.

Emphasis will be placed on assays that provide new insight into important disease targets and processes.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed three years. Ref: PAR-14-284 (replaces PAR-12-058).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation every 7 September, 7 January and 7 July until 8 September 2017.
Posted date: 18 Jul 14
Award type: Directed grants to institutions, research groups etc,
Networking/collaboration
Award budget total: -

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Translational Medicine; Disease Models; Pharmacy & Pharmacology; Nursing; Clinical
THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R03): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of eight institutes and offices of the National Institutes of Health invite applications for their health of sexual and gender minority populations (R03) funding opportunity announcement. This Aids-related announcement encourages research that describes the biological, clinical, behavioural and social processes that affect the health and development of sexual and gender minority populations and individuals, as well as their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that enhance the health and development of these populations. The research must focus on clearly defined health outcomes. The following types of research are prioritised:

- basic social and behavioural science studies addressing the processes involved as individuals discover, uncover, address or adapt to their sexual orientation and claim or do not claim identity as SGM, and how these processes affect the mental and physical health of the individual;
- research leading to interventions to ameliorate health disparities in SGM populations;
- large-scale design, implementation and evaluation of preventive or treatment interventions addressing health issues in SGM populations;
- research on how family structures and processes-including both families of origin and families of choice—affect the health of SGM individuals and their family members, including whether and how being raised in a family headed by SGM individuals affects the health, development and well-being of children.

This funding opportunity uses the NIH small grant programme (R03) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-261 and PA-15-263, which solicit applications under the NIH research project (R01) grant mechanism and the NIH research project (R01) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Contact Details
----------------------------------------------
National Institute of Mental Health
Division of Neuroscience and Basic Behavior Science
6001 Executive Boulevard, Room 7175, MSC 9641
Bethesda, MD 20892-9641
Tel: +1 301 443 6102
Email: yyao@mail.nih.gov
Application budgets are limited to US$100,000 over a two-year project period, with no more than US$50,000 in direct costs allowed in any year. Ref: PA-15-262 (reissue of PA-12-112).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 September 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 19 May 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Website:

Application form:

Eligibility profile
Country of applicant institution: Any

Disciplines
Health of Minority Groups; Lesbian, Gay, Bisexual & Transgender Studies; Gender Roles & Sexuality; HIV/AIDS

Contact Details
Eunice Kennedy Shriver NICHD
BG 6100 Room 8B05L
6100 Executive Boulevard
Rockville MD 20852
Tel: +1 301 435 6981
Email: newcomers@mail.nih.gov

THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R21): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of nine institutes and offices of the National Institutes of Health invite applications for their health of sexual and gender minority populations (R21) funding opportunity announcement. This Aids-related announcement encourages research that describes the biological, clinical, behavioural and social processes that affect the health and development of sexual and gender minority populations and individuals, as well as their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that enhance the health and development of these populations. The research must focus on clearly defined health outcomes. The following types of research are prioritised:

- basic social and behavioural science studies addressing the processes involved as individuals discover, uncover, address or adapt to their sexual orientation and claim or do not claim identity as SGM, and how these processes affect the mental and physical health of the individual;
• research leading to interventions to ameliorate health disparities in SGM populations;
• large-scale design, implementation and evaluation of preventive or treatment interventions addressing health issues in SGM populations;
• research on how family structures and processes—including both families of origin and families of choice—affect the health of SGM individuals and their family members, including whether and how being raised in a family headed by SGM individuals affects the health, development and wellbeing of children.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-261 and PA-15-262, which solicit applications under the NIH research project (R01) grant mechanism and the NIH small grant programme (R03) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any year.
Ref: PA-15-263 (reissue of PA-12-113).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 September 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 19 May 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000

Eligibility profile
-------------------------------------------------------------
Country of applicant institution: Any

Disciplines
-------------------------------------------------------------
Gender Roles & Sexuality; Lesbian, Gay, Bisexual & Transgender Studies; HIV/Aids; Health of Minority Groups

Contact Details
-------------------------------------------------------------
Eunice Kennedy Shriver NICHD
BG 6100 Room 8B05L
6100 Executive Boulevard
Rockville MD 20852
Tel: +1 301 435 6981
Email: newcomes@mail.nih.gov

PILOT HEALTH SERVICES AND ECONOMIC RESEARCH ON THE TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R34): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their pilot health services and economic research on the treatment of drug, alcohol and tobacco abuse
(R34) funding opportunity announcement. This AIDS-related announcement encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials into the quality, effectiveness, affordability and utilisation of drug, tobacco or alcohol use disorder treatments.

This funding opportunity uses the NIH planning (R34) grant mechanism and runs in parallel with several of identical scientific scope, PA-15-251, PA-15-252 and PA-15-253 which solicit applications under the NIH research project (R01), the NIH small grant programme (R03) and the NIH exploratory/developmental (R21) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$450,000 in direct costs with up to US$225,000 in direct costs per year.

The maximum project period is three years.
Ref: PA-15-250 (Reissue of PA-12-130).

Closing date: 07 Jan 16

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 11 May 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $450,000

Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276467

Eligibility profile
Country of applicant institution: Any

Disciplines
Smoking & Tobacco; Drug & Substance Abuse; HIV/AIDS; Access to Health Care; Social Services Delivery

Contact Details
Tel: +1 301 443 4715
Email: duffys@nida.nih.gov

ENVIRONMENTAL EXPOSURES AND HEALTH: EXPLORATION OF NON-TRADITIONAL SETTINGS (R01): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research and the National Institute of Environmental Health Research invite applications for their AIDS-related environmental exposures and health: exploration of non-traditional settings (R01) grants. The purpose of this AIDS-related R01 funding opportunity announcement is to encourage interdisciplinary research aimed at promoting health, limiting symptoms and disease, and reducing health disparities in children and older adults living or spending time in non-traditional settings. These settings result in exposure to environmental pollutants and toxins that result in health risks, symptoms and other health conditions
including lower respiratory diseases, chronic obstructive pulmonary disease and cardiovascular diseases. Risk identification and symptom management include prevention and behaviour changes and actions to maintain health and prevent disease with an emphasis on the individual, family and community which will advance nursing science.

This funding opportunity announcement will use the NIH research project grant (R01) mechanism and runs in parallel with an FOA of identical scientific scope: PA-12-134 that solicits applications under the exploratory/developmental grant (R34) mechanism. Application budgets are not limited, but must reflect the actual needs of the project. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-12-133.

Closing date: 07 Jan 16
Deadline information: Deadline: every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 26 Mar 12
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Website:
http://grants.nih.gov/grants/guide/pa-files/PA-12-133.html

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-133

Eligibility profile

Country of applicant institution: Any

Disciplines

Public Health, Health Services & Primary Care; HIV/Aids; Environmental & Occupational Health & Safety; Medicine & Health; Respiratory Medicine; Environmental Medicine; Nursing; Preventive Medicine; Cardiovascular Diseases; Economic & Social Environment; Health Disparities; Clinical Medicine; Primary Care; Chronic Care

Contact Details

Office of Extramural Activities
NINR
Tel: +1 301 594 5970
Email: hussk@mail.nih.gov

ENVIRONMENTAL EXPOSURES AND HEALTH: EXPLORATION OF NON-TRADITIONAL SETTINGS (R21): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research and the National Institute of Environmental Health Research invite applications for their Aids-related environmental exposures and health: exploration of non-traditional settings (R21) grants. The purpose of this Aids-related R21 funding opportunity announcement is to encourage interdisciplinary research aimed at promoting health, limiting symptoms and disease, and reducing health disparities in children and older adults living or spending time in non-traditional settings. These settings result in exposure to environmental pollutants and toxins that result in health risks, symptoms and other health conditions including lower respiratory diseases, chronic obstructive pulmonary disease and
cardiovascular diseases. Risk identification and symptom management include prevention and behaviour changes and actions to maintain health and prevent disease with an emphasis on the individual, family and community which will advance nursing science.

This funding opportunity announcement will use the NIH exploratory/developmental grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope: PA-12-133 that solicits applications under the research project grant (R01) mechanism. Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-12-134.

Closing date: 07 Jan 16
Deadline information: Deadline: every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 26 Mar 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -

EVELOPMENT AND TESTING OF NOVEL INTERVENTIONS TO IMPROVE HIV PREVENTION, CARE, AND PROGRAMME IMPLEMENTATION (R34)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse, the National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their development and testing of novel interventions to improve HIV prevention, care and programme implementation (R34) funding opportunity announcement. This announcement supports pilot or feasibility studies of new or adapted interventions to prevent HIV infection among populations where substance use may be a contributing factor; pilot or feasibility studies of new or adapted interventions to improve the care of HIV infection among populations where substance use is prevalent, including interventions that integrate treatment for

Award budget total: -
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-12-134.html
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-134

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Respiratory Medicine; Clinical Medicine; HIV/AIDS; Economic & Social Environment; Medicine & Health; Preventive Medicine; Health Disparities; Primary Care; Chronic Care; Cardiovascular Diseases; Environmental & Occupational Health & Safety; Public Health, Health Services & Primary Care; Environmental Medicine; Nursing

Contact Details
-----------------------------------------------
Office of Extramural Activities
NINR
Tel: +1 301 594 5970
Email: hussk@mail.nih.gov
substance use disorders and HIV infection; or pilot or feasibility studies to increase the scale, uptake, delivery or quality of HIV prevention or care interventions with established evidence of efficacy. Both primary and secondary prevention will be supported. The full range of substance use will be considered including problematic episodic use and substance use disorders, as well as a full range of substances and modes of administration. The most important consideration is that substance use may affect transmission directly as in the case of injection drug use or may affect transmission risk behaviour. Domestic and overseas populations will be considered, with particular attention to populations with disproportionate burden of HIV infection and those where HIV infection or drug use are emergent.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Direct costs are limited to US$450,000 over a three-year period, with no more than US$225,000 direct costs allowed in any single year.
Ref: PA-15-268 (reissue of PA-12-231).

Closing date: 07 Jan 16
Deadline information: Applications open on 7 August and are due by 5pm local time of applicant organisation on every 7 January, 7 September and 7 May until 8 May 2018.
Posted date: 29 May 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $450,000

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Drug & Substance Abuse

Contact Details

Tel: +1 301 443 1923
Email: jenkinsri@mail.nih.gov

---

**PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS: EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R01): AIDS-RELATED**

**NIH: National Cancer Institute**

**Description:**

The National Cancer Institute invites applications for its Aids-related physical activity and weight control interventions among cancer survivors: effects on biomarkers of prognosis and survival (R01) grants. This Aids-related R01 funding opportunity announcement encourages transdisciplinary and translational research that will identify specific biological or biobehavioural pathways through which physical activity or weight control may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control, on biomarkers of cancer prognosis.
among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Biomarkers may include but are not limited to intervention-induced changes in sex hormones, insulin-like growth factors or their binding proteins, leptin and other adipokines, immunologic or inflammatory factors, oxidative stress and DNA damage or repair capacity, angiogenesis, or prostaglandins.

This FOA will use the R01 award mechanism and runs in parallel with an FOA of identical scientific scope, PA-15-310, which solicits proposals under the exploratory/developmental grant (R21) mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions.

Ref: PA-15-311 (replaces PAR-12-228).

Closing date: 07 Jan 16

Deadline information: Applications open on 5 September 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.

Posted date: 27 Jul 15

Award type: Directed grants to institutions, research groups etc


Eligibility profile

Country of applicant institution: Any

Disciplines

Obesity; Cancer Studies & Oncology; Diagnostic Sciences; Human Metabolism; Cancer Cell Biology; HIV/Aids

Contact Details

Tel: +1 240 276 6782
Fax: +1 301 594 5070
Email: pernafm@mail.nih.gov

PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS: EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R21): AIDS-RELATED

NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its physical activity and weight control interventions among cancer survivors: effects on biomarkers of prognosis and survival (R21) grants. This Aids-related R21 funding opportunity announcement encourages transdisciplinary and translational research that will identify specific biological or biobehavioural pathways through which physical activity or weight control may affect cancer prognosis and survival. Research
applications should test the effects of physical activity, alone or in combination with weight control on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin or glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Biomarkers may include but are not limited to intervention-induced changes in sex hormones, insulin-like growth factors or their binding proteins, leptin and other adipokines, immunologic or inflammatory factors, oxidative stress and DNA damage or repair capacity, angiogenesis, or prostaglandins.

This FOA will use the explorator or developmental (R21) grant mechanism, and runs in parallel with an FOA of identical scientific scope, PA-15-311, which solicits applications under the research project grant (R01) mechanism.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions.

Ref: PA-15-310 (replaces PAR-12-229).
Closing date: 07 Jan 16
Deadline information: Applications open on 16 September 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.
Posted date: 27 Jul 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Application form: http://grants.nih.gov/grants/guide/ApplyButtomSplash.cfm

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Obesity; Cancer Studies & Oncology; Cancer Cell Biology; Human Metabolism; HIV/Aids

Contact Details
----------------------------------------------
Tel: +1 240 276 6782
Email: pernafm@mail.nih.gov

DEVELOPMENT OF MINIMALLY INVASIVE BIOASSAYS TO SUPPORT OUTPATIENT CLINICAL TRIALS OF THERAPEUTICS FOR SUBSTANCE USE DISORDERS (R21): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related development of minimally invasive bioassays to support outpatient clinical trials of therapeutics for substance use disorders (R21) grants. This Aids-related R21 funding opportunity announcement solicits proposals that seek to develop non-invasive or minimally invasive methods to support outpatient clinical trials of pharmacotherapies for substance use disorders. The announcement has two main aims:
• to encourage the development of devices or techniques that will improve estimations of a subject’s consumption of an abused drug during an outpatient clinical trial. Such a system would allow objective assessment of whether a medication reduces drug abuse, even if abstinence is not achieve. Proposed solutions should be able to assess systematic drug levels and be safe, portable, affordable and simple enough for subjects to take multiple samples at home and return them to the clinic for batch analysis;

• to develop new, improved markers to evaluate a subject’s adherence to the study medication. The goal is for investigators to be able to determine the level of systematic medication exposure throughout a study. Assays should be applicable to one of the following situations – assessment of medication adherence in a manner suitable for use in a clinical setting; or the quantitative assessment of medication adherence throughout an outpatient clinical trial.

This FOA will utilise the NIH exploratory/developmental grant (R21) award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-12-239, that solicits applications under the research project grant (R01)award mechanism. NIDA intends to commit up to US$2 million to fund both mechanisms in fiscal year 2013, and will fund up to seven R21 awards.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-12-238.

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 17 Jul 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-12-238.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-238

Eligibility profile
---------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------
Drug Design; HIV/Aids; Public Health, Health Services & Primary Care; Psychology; Primary Care; Medical Devices; Pharmacotherapy; Clinical Medicine; Biological Markers & Sensor Mechanisms; Immunological & Bioassay Methods; Drug & Substance Abuse; General Practice; Nursing; Biochemical Markers; Addiction; Community Health Services; Pharmacy & Pharmacology

Contact Details
---------------------------------------------------------
Medications Research Grants Branch
NIDA
NIH
6001 Executive Boulevard
Rockville, MD 20852
Tel: +1 301 443 8039
Fax: +1 301 443 9649
Email: aidan.hampson@nih.gov
ETHICAL ISSUES IN RESEARCH ON HIV/AIDS AND ITS CO-MORBIDITIES (R21)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Disease, the National Cancer Institute and the National Institute of Mental Health invite applications for the ethical issues in research on HIV/Aids and its co-morbidities (R21) funding opportunity announcement. This supports projects that address ethical issues relevant to research on HIV and associated co-morbidities, including research with populations living with, or at high risk of, HIV acquisition.

Projects may include conceptual work in bioethics or empirical work gathering and analysing relevant ethical issues in research, or a combination of the two. Empirical projects may include quantitative or qualitative methods in data collection, and bioethics projects should focus on at least one of the following goals:

- development of the empirical knowledge base for human subjects protection and ethical standards in HIV/Aids research;
- development of conceptual bioethics approaches to advance scholarship on difficult ethical challenges in HIV/Aids research;
- supporting the integration of bioethics work with ongoing research in HIV/Aids.

This announcement uses the R21 exploratory or developmental grant mechanism and runs in parallel with an opportunity of a similar scientific scope, PAR-15-274, which solicits applications under the R01 research project grant mechanism.

Each award covers direct costs of up to US$275,000 over a maximum period of two years. The maximum award budget for direct costs for any single year is US$200,000.

Ref: PAR-15-275 (replaces PAR-12-243).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on deadline dates until 9 January 2018.
Posted date: 09 Jun 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000


Eligibility profile
---------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------------
Research Ethics & Misconduct; HIV/Aids; Bioethics & Neuroethics; Patient Care & Education

Contact Details
---------------------------------------------------------------------
Tel: +1 240 627 3210
Email: dawsonl@niaid.nih.gov
ETHICAL ISSUES IN RESEARCH ON HIV/AIDS AND ITS CO-MORBIDITIES (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Disease, the National Cancer Institute and the National Institute of Mental Health invite applications for the ethical issues in research on HIV/AIDS and its co-morbidities (R01) funding opportunity announcement. This supports projects that address ethical issues relevant to research on HIV and associated co-morbidities, including research with populations living with, or at high risk of, HIV acquisition.

Projects may include conceptual work in bioethics or empirical work gathering and analysing relevant ethical issues in research, or a combination of the two. Empirical projects may include quantitative or qualitative methods in data collection, and bioethics projects should focus on at least one of the following goals:

- development of the empirical knowledge base for human subjects protection and ethical standards in HIV/Aids research;
- development of conceptual bioethics approaches to advance scholarship on difficult ethical challenges in HIV/Aids research;
- supporting the integration of bioethics work with ongoing research in HIV/Aids.

This announcement uses the R01 research project grant mechanism and runs in parallel with an opportunity of a similar scientific scope, PAR-15-275, which solicits applications under the R21 exploratory or developmental grant mechanism.

Applicants may be from US and foreign for-profit and non-profit organisations or public and private organisations.

Application budgets must reflect the actual needs of the proposed project. The maximum award period is five years.

Ref: PAR-15-274 (replaces PAR-12-244).

Closing date: 07 Jan 16
Posted date: 09 Jun 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:
Application form:

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Bioethics & Neuroethics; Patient Care & Education; HIV/Aids; Research Ethics & Misconduct

Contact Details
----------------------------------------------
Tel: +1 240 627 3210
Email: dawsonl@niaid.nih.gov
LYMPHATICS IN HEALTH AND DISEASE IN THE DIGESTIVE SYSTEM, KIDNEY AND URINARY TRACT (R01): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Kidney Diseases invites applications for its lymphatics in health and disease in the digestive system, kidney and urinary tract (R01): Aids-related. This R01 funding opportunity announcement supports research into aspects of lymphatic vessel physiology, development and pathophysiology related to health and diseases of digestive system, kidney and urinary tract organs. Studies to understand the factors that control local lymphatic vessel functional anatomy and physiology and development during health or disease in these organs and systems, and the mechanisms by which alterations of lymphatic vessel function affect organ function, are of interest. Studies with a major focus on immune mechanisms are not encouraged. This FOA will use the R01 research project grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions.

Application budgets are limited to US$250,000 in direct costs per year. The maximum project period is five years. Ref: PAR-15-306 (replaces PAR-12-259).

Closing date: 07 Jan 16

Deadline information: Applications open on 5 September 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2015.

Posted date: 27 Jul 15

Award type: Directed grants to institutions, research groups etc

Award amount max: $1,250,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Lymphatic System; Gastroenterology; HIV/Aids; Urology; Nephrology & Kidneys

Contact Details

NIDDK
BG 2Dem Room 661
6707 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 402 0671
Email: carringj@mail.nih.gov
EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R01)
AIDS-RELATED
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its examination of survivorship care planning efficacy and impact (R01) AIDS-related funding opportunity announcement. This AIDS-related announcement aims to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy, with the goal to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors. Specifically, this call aims to stimulate research that will:

• develop and test metrics for evaluating the impact of survivorship care planning;
• evaluate the impact of survivorship care planning on cancer survivors morbidity, self-management and adherence to care recommendations, utilisation of follow-up care;
• evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organisations implementing the care planning;
• identify models and processes of care that promote effective survivorship care planning.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-011, which solicits applications under the NIH exploratory or developmental (R21) grant mechanism.

US and foreign for-profit and non-profit organisations, and public or private institutions may apply.

Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-16-012 (replaces PA-12-275).

Closing date: 07 Jan 16
Deadline information: Applications open on 5 January 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.
Posted date: 26 Oct 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/notice-files/PA-16-012.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Quality of Care; Life Expectancy & Quality of Life; Rehabilitation Engineering; Cancer Studies & Oncology; HIV/AIDS; Emotional Rehabilitation

Contact Details
----------------------------------------------
Tel: +1 240 276 6947
Email: taplins@mail.nih.gov
EFFECTS OF IN UTERO ALCOHOL EXPOSURE ON ADULT HEALTH AND DISEASE (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its effects of in utero alcohol exposure on adult health and disease (R21): Aids-related grants. This Aids-related R21 funding opportunity announcement will support novel research on how prenatal alcohol exposure may contribute to the aetiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease concept which suggest that foetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adulthood disease. The goal of this FOA is to stimulate a broad range of research to:

- leverage existing prospective birth cohorts to define the role of maternal alcohol consumption in the DOHaD process;
- investigate the biological, cellular and molecular mechanisms by which prenatal alcohol exposure may impact disease outcomes later in life;
- identify biomarkers associated with gestational alcohol exposure that may predict adult disease susceptibility in exposed offspring.

Studies supported by this FOA will provide fundamental insights into a possible foetal-basis to adult disease that is influenced by maternal alcohol use.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-291, that solicits applications under the R01 research project grant mechanism. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PA-12-291.

Closing date: 07 Jan 16
Deadline information: Deadline every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 01 Oct 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-292.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-292

Eligibility profile
Country of applicant institution: Any

Disciplines
Medicine & Health; Aetiology; Psychology; Disease Models; Biological Sciences; Cell & Developmental Biology; Cognitive Processes; Alcoholism; Reproduction & Fertility; Foetal Health & Prenatal Development; Growth & Growth Factors; Reproductive Medicine; Biochemistry & Molecular Biology; Diagnostic Sciences; Child Development; HIV/Aids; Pregnancy & Birth

Contact Details
Division of Metabolism and Health Effects
NIAAA
5635 Flishers Lane, Room 2120
Bethesda, MD 20892-7003
Tel: +1 301 443 7351
Email: duntyw@mail.nih.gov
EFFECTS OF IN UTERO ALCOHOL EXPOSURE ON ADULT HEALTH AND DISEASE (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its effects of in utero alcohol exposure on adult health and disease (R01): Aids-related grants. This Aids-related R01 funding opportunity announcement will support novel research on how prenatal alcohol exposure may contribute to the aetiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease concept which suggest that foetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adulthood disease. The goal of this FOA is to stimulate a broad range of research to:

- leverage existing prospective birth cohorts to define the role of maternal alcohol consumption in the DOHaD process;
- investigate the biological, cellular and molecular mechanisms by which prenatal alcohol exposure may impact disease outcomes later in life;
- identify biomarkers associated with gestational alcohol exposure that may predict adult disease susceptibility in exposed offspring.

Studies supported by this FOA will provide fundamental insights into a possible foetal-basis to adult disease that is influenced by maternal alcohol use.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-292, that solicits applications under the R21 exploratory/developmental grant mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PA-12-291.

Closing date: 07 Jan 16
Deadline information: Deadline every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 01 Oct 12
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-­files/PA-12-291.html

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-291

Eligibility profile
="/-----------------------------------------------
Country of applicant institution: Any
Disciplines
("-----------------------------------------------
Aetiology; Pregnancy & Birth; Disease Models; Cell & Developmental Biology; Cognitive Processes; HIV/Aids; Biological Sciences; Foetal Health & Prenatal Development; Reproduction & Fertility; Child Development; Growth & Growth Factors; Alcoholism; Diagnostic Sciences; Reproductive Medicine; Medicine & Health; Biochemistry & Molecular Biology; Psychology
Contact Details
="/-----------------------------------------------
Division of Metabolism and Health Effects
NIAAA
5635 Flishers Lane, Room 2120
EPGENETIC INHERITANCE AND TRANSGENERATIONAL EFFECTS OF ALCOHOL (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its epigenetic inheritance and transgenerational effects of Aids-related alcohol (R21) grants. This Aids-related R21 funding opportunity announcement will support research proposing to conduct mechanistic studies in human and animal models on alcohol-induced transgenerational effects and the role of epigenetic inheritance in these effects.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-003, that solicits applications under the R01 research project grant mechanism. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PA-13-004.

Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-004

Eligibility profile
Country of applicant institution: Any

Disciplines
Alcoholism; Reproductive Medicine; Diagnostic Sciences; Biological Sciences; Pharmaceutical Drugs; Epigenetics; HIV/Aids; Reproduction & Fertility; Quantitative Genetics

Contact Details
Divison of Neuroscience and Behavior
NIAAA
6000 Executive Boulevard
Bethesda, MD 20892-7003
Tel: +1 301 594 6228
Email: reillymt@mail.nih.gov

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.

Posted date: 04 Oct 12
PIGENETIC INHERITANCE AND TRANSGENERATIONAL EFFECTS OF ALCOHOL (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its epigenetic inheritance and transgenerational effects of Aids-related alcohol (R01) grants. This Aids-related R01 funding opportunity announcement will support research proposing to conduct mechanistic studies in human and animal models on alcohol-induced transgenerational effects and the role of epigenetic inheritance in these effects.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-004, that solicits applications under the R21 exploratory/developmental grant mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PA-13-003.

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 04 Oct 12

Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-0files/PA-13-003.html

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-003

Eligibility profile
Country of applicant institution: Any

Disciplines
Quantitative Genetics; Epigenetics; Biological Sciences; Alcoholism; Reproduction & Fertility; HIV/Aids; Reproductive Medicine; Pharmaceutical Drugs; Diagnostic Sciences

Contact Details
Divison of Neuroscience and Behavior
NIAAA
6000 Executive Boulevard
Bethesda, MD 20892-7003
Tel: +1 301 594 6228
Email: reillymt@mail.nih.gov

ELECTED TOPICS IN TRANSFUSION MEDICINE (R21): AIDS-RELATED
NIH: National Heart, Lung and Blood Institute

Description:
The National Heart, Lung and Blood Institute invites applications for its Aids-related selected topics in transfusion medicine (R21) programme. This Aids-related R21 funding opportunity announcement will study topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Specifically, research
focused on improving blood donor health, the safety and availability of blood products and improving the practice of transfusion medicine is critical to public health. Research designed to better understand the determinants of transfusion-associated adverse events and how to best minimise transfusion risks is also important. Research is also needed to maintain an adequate blood supply by minimising risks associated with the donation process and developing enhanced recruitment and retention programmes.

This FOA will use the NIH exploratory/developmental R21 grant mechanism and runs in parallel with an FOA of identical scope, PAR-13-026, that encourages applications under the R01 mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,00 in direct costs allowed in any single year. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PAR-13-025 (replaces PAR-10-033).

Closing date: 07 Jan 16
Deadline information: Applications due every 7 May and 7 January until 8 January 2017.

Selected Topics in Transfusion Medicine (R01): AIDS-Related

NIH: National Heart, Lung and Blood Institute

Description:
The National Heart, Lung and Blood Institute invites applications for its Aids-related selected topics in transfusion medicine (R01) programme. This Aids-related R01 funding opportunity announcement will study topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Specifically, research focused on improving blood donor health, the safety and availability of blood products and improving the practice of transfusion medicine is critical to public health. Research

Posted date: 26 Nov 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-025

Eligibility profile

Country of applicant institution: Any

Disciplines

Blood, Blood Products & Transfusions; Clinical Medicine; HIV/Aids

Contact Details

Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Rockledge II, MSC 7950
6701 Rockledge Drive
Bethesda, MD 20892-7950
Tel: +1 301 435 0065
Fax: +1 301 480 0867
Email: zousn@nhlbi.nih.gov
designed to better understand the determinants of transfusion-associated adverse events and how to best minimise transfusion risks is also important. Research is also needed to maintain an adequate blood supply by minimising risks associated with the donation process and developing enhanced recruitment and retention programmes.

This FOA will use the NIH research project R01 grant mechanism and runs in parallel with an FOA of identical scope, PAR-13-025, that encourages applications under the R21 mechanism. Application budgets are not limited, but must reflect the actual needs of the project. Projects may not last longer than five years. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PAR-13-023 (replaces PAR-10-034).

Closing date: 07 Jan 16
Deadline information: Applications due every 7 May and 7 January until 8 January 2017.
Posted date: 26 Nov 12

Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-026

Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/Aids; Blood, Blood Products & Transfusions; Clinical Medicine

Contact Details
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Rockledge II, MSC 7950
6701 Rockledge Drive
Bethesda, MD 20892-7950
Tel: +1 301 435 0065
Fax: +1 301 480 0867
Email: zousn@nhlbi.nih.gov

Erythropoiesis: Components and Mechanisms (R01): AIDS-Related
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung, and Blood, Institute invite applications for their Aids-related erythropoiesis: components and mechanisms (R01) grants. This Aids-related R01 funding opportunity announcement aims to support research efforts towards a complete description of the molecular and cellular components of erythropoiesis and how these components contribute to erythropoiesis. Components include genes that are expressed in erythroid cells, either during development or during differentiation, and the proteins that are translated in erythroid cells, especially with post-translational modifications or sub-cellular localisations that are unique to erythroid cells. A long range goal of this program is to generate a concise description
of erythropoiesis that unifies genetics, molecular processes and cytokine determinants in the erythroid lineages so that new therapeutics may be developed to measure and combat anaemia.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. PA-13-034 (replaces PA-09-255).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 06 Dec 12
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-034

Eligibility profile
Country of applicant institution: Any

Disciplines
Protein Synthesis, Modification & Turnover;
Characteristics, Biological Macromolecules;
HIV/AIDS; Epigenetics; Molecular Genetics;
Diagnostic Sciences; Biological Sciences;
Haematology; Cell & Developmental Biology;
Proteomics & Molecular Interactions

Contact Details
Division of Kidney, Urologic, and Hematologic Diseases
NIDDK
6707 Democracy Boulevard
Room 619
Bethesda, MD 20817
Tel: +1 301 594 7726
Fax: tb232j@nih.gov

DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R01): AIDS-RELATED
NIH: National Institute of Mental Health

Description:
A total of 15 participating institutes and centres of the National Institutes of Health invite applications for their Aids-related dissemination and implementation research in health (R01) grants. This Aids-related R01 funding opportunity announcement encourages investigators to submit applications that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures, and strategies to disseminate and implement research-tested health behaviour change interventions, evidence-based prevention, early detection, diagnostic, treatment and management, and quality of life improvement services, and data monitoring and surveillance reporting tools into public health and clinical practice settings that focus on patient outcomes.

This FOA will use the R01 research project grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PAR-
13-054, which encourages applications under the R21 exploratory/developmental award mechanism, and PAR-13-056, which encourages applications under the R03 small grant programme mechanism.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PAR-13-055 (replaces PAR-10-038).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile

Country of applicant institution: Any

Disciplines

Economic & Social Environment; Psychiatry; Primary Care; HIV/Aids; Health Systems; Medical & Diagnostic Tests; Medical Sociology; Mental Health; Psychology; Public Health; Health Promotion; Public Health, Health Services & Primary Care; Mental Illness; General Practice; Sociology; Health Systems, Administration; Preventive Medicine; Biomedical Engineering

Contact Details

Division of Services and Intervention Research
NIMH
6001 Executive Boulevard, Room 7133, MSC 9631
Bethesda, MD 20892-9631
Tel: +1 301 443 3747
Fax: +1 301 443 4045
Email: dchamber@mail.nih.gov

**Dissemination and Implementation Research in Health (R03): AIDS-Related**

**NIH: National Institute of Mental Health**

**Description:**
A total of nine participating institutes and centres of the National Institutes of Health invite applications for their Aids-related dissemination and implementation research in health (R03) grants. This Aids-related R03 funding opportunity announcement encourages investigators to submit applications that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures, and strategies to disseminate and implement research-tested health behaviour change interventions, evidence-based prevention, early detection, diagnostic, treatment and management, and quality of life improvement services, and data monitoring and surveillance reporting tools into public health and clinical practice settings that focus on patient outcomes.
This FOA will use the R03 small grant programme mechanism, and runs in parallel with two FOAs of identical scientific scope, PAR-13-055, which encourages applications under the research project grant mechanism, and PAR-13-054, which encourages applications under the R21 exploratory/developmental award mechanism.

Direct costs are limited to US$100,000 over a two-year period, with no more than US$50,000 in direct costs allowed in any single year. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. PAR-13-056 (replaces PAR-10-039).

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-056

Eligibility profile
Country of applicant institution: Any

Disciplines
Economic & Social Environment; HIV/AIDS; Health Promotion; Sociology; Public Health; Health Systems; Primary Care; Psychiatry; Psychology; Public Health, Health Services & Primary Care; Medical & Diagnostic Tests; Mental Illness; Medical Sociology; Biomedical Engineering; Health Systems, Administration; Preventive Medicine; General Practice; Mental Health

Contact Details
Division of Services and Intervention Research
NIMH
6001 Executive Boulevard, Room 7133, MSC 9631
Bethesda, MD 20892-9631
Tel: +1 301 443 3747
Fax: +1 301 443 4045
Email: dchamber@mail.nih.gov

SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIOURS AND WEIGHT OUTCOMES (R21): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of four institutes and offices of the National Institutes of Health invites applications for their Aids-related school nutrition and physical activity policies, obesogenic behaviours and weight outcomes (R21) grants. The objectives of this Aids-related R21 funding opportunity announcement are to understand how school-related policies impact the school and home environment, promote positive nutrition and physical activity behaviours and decrease childhood obesity. Applications should propose to:
• foster multidisciplinary research that will evaluate how policies can influence school physical activity and nutrition environments, youths’ obesogenic behaviours and weight outcomes;
• understand how schools are implementing these policies and examine multi-level influences on adoption and implementation at various levels;
• understand the synergistic or counteractive effect of school nutrition and physical activity policies on the home and community environment and body weight.

This FOA will use the R21 exploratory/developmental research grant mechanism and runs in parallel with two FOAs of identical scope, PAR-13-099, which uses the R03 small grant programme mechanism, and PAR-13-100, which uses the R01 research project grant mechanism.

Application budgets are limited to US$275000 over a two-year project period, with no more than US$200,000 in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-13-098.

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.

SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIOURS AND WEIGHT OUTCOMES (R03): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of three institutes and offices of the National Institutes of Health invites applications for their Aids-related school nutrition and physical activity policies, obesogenic behaviours and weight outcomes (R03) grants. The objectives of this Aids-related R03 funding opportunity
announcement are to understand how school-related policies impact the school and home environment, promote positive nutrition and physical activity behaviours and decrease childhood obesity. Applications should propose to:

- foster multidisciplinary research that will evaluate how policies can influence school physical activity and nutrition environments, youths’ obesogenic behaviours and weight outcomes;
- understand how schools are implementing these policies and examine multi-level influences on adoption and implementation at various levels;
- understand the synergistic or counteractive effect of school nutrition and physical activity policies on the home and community environment and body weight.

This FOA will use the R03 small grant programme mechanism and runs in parallel with two FOAs of identical scope, PAR-13-098, which uses the R21 exploratory/developmental research grant mechanism, and PAR-13-100, which uses the R01 research project grant mechanism.

Application budgets are limited to US$50,000 per year over a two-year project period. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-13-099.

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 04 Feb 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-099

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Human Nutrient Requirements; HIV/Aids; Schools Policy & Politics; Behavioural Medicine; Obesity; Health Education; Sports & Exercise Studies; Physical & Sports Education; Diagnostic Sciences; Primary Care; Education; Psychology; Nutrition & Dietetics; Social Work & Social Policy; Public Health, Health Services & Primary Care

Contact Details
----------------------------------------------
NICHD
6100 Executive Boulevard, Room 4B05
Rockville, MD 20852
Tel: +1 301 435 6888
Email: espositl@mail.nih.gov
SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIOURS AND WEIGHT OUTCOMES (R01): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of four institutes and offices of the National Institutes of Health invites applications for their Aids-related school nutrition and physical activity policies, obesogenic behaviours and weight outcomes (R01) grants. The objectives of this Aids-related R01 funding opportunity announcement are to understand how school-related policies impact the school and home environment, promote positive nutrition and physical activity behaviours and decrease childhood obesity. Applications should propose to:

- foster multidisciplinary research that will evaluate how policies can influence school physical activity and nutrition environments, youths' obesogenic behaviours and weight outcomes;
- understand how schools are implementing these policies and examine multi-level influences on adoption and implementation at various levels;
- understand the synergistic or counteractive effect of school nutrition and physical activity policies on the home and community environment and body weight.

This FOA will use the R01 research project grant mechanism and runs in parallel with two FOAs of identical scope, PAR-13-098, the R21 exploratory/developmental research grant mechanism, and PAR-13-099, which uses the R03 small grant programme mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-13-100.

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 04 Feb 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-13-100.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-100

Eligibility profile
--------------------------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------------------------
Social Work & Social Policy; Primary Care; Public Health, Health Services & Primary Care; Behavioural Medicine; Education; Sports & Exercise Studies; Physical & Sports Education; Health Education; Nutrition & Dietetics; HIV/AIDS; Obesity; Schools Policy & Politics; Human Nutrient Requirements; Psychology; Diagnostic Sciences

Contact Details
--------------------------------------------------------------
NICHD
6100 Executive Boulevard, Room 4B05
Rockville, MD 20852
Tel: +1 301 435 6888
Email: espositl@mail.nih.gov
REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R21): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites R21 Aids-related applications for its regional and international differences in health and longevity at older ages grants.

Aids-related applications are sought from organisations proposing to advance knowledge on the reasons behind the divergent trends that have been observed in health and longevity at older ages, both across industrialised nations and across geographical areas in the United States.

This FOA will utilise the R21 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

The combined budget for direct costs may not exceed US$275,000 over two years, no more than US$200,000 per year may be requested.

PA-13-124.

Closing date: 07 Jan 16
Deadline information: Applications due 5pm proposer’s local time, 7 January, 7 May and 7 September annually until 8 September 2016.
Posted date: 22 Feb 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
--------------------------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------------------------
Psychology; Population Studies, Medical; Primary Care; Health Disparities; HIV/AIDS; Geriatrics & Gerontology; Psychology of Ageing; Social Work & Social Policy; International Health; Social & Income Inequality; Public Health, Health Services & Primary Care; Life Expectancy & Quality of Life

Contact Details
--------------------------------------------------------------
Tel: +1 301 496 3138
Email: patmiosg@nia.nih.gov

REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R03): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites R03 Aids-related applications for its regional and international differences in health and longevity at older ages grants.

Aids-related applications are sought from organisations proposing to advance knowledge on the reasons behind the divergent trends that have been observed in health and longevity at older ages, both across
This FOA will utilise the R03 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

The combined budget for direct costs may not exceed US$100,000 over two years, no more than US$50,000 per year may be requested.

PA-13-123.

Closing date: 07 Jan 16
Deadline information: Applications due 5pm proposer’s local time, 7 January, 7 May and 7 September annually until 8 September 2016.

Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Regional and International Differences in Health and Longevity at Older Ages (R01): AIDS-RELATED

NIH: National Institute on Aging

Description:
The National Institute on Aging invites R01 Aids-related applications for its regional and international differences in health and longevity at older ages grants.

Aids-related applications are sought from organisations proposing to advance knowledge on the reasons behind the divergent trends that have been observed in health and longevity at older ages, both across industrialised nations and across geographical areas in the United States.

This FOA will utilise the R01 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited but must reflect the actual needs of the proposed project. Funding is available for up to five years.

PA-13-125.

Closing date: 07 Jan 16
Deadline information: Applications due 5pm proposer’s local time, 7 January, 7 May and 7 September annually until 8 September 2016.

Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
AWARD TYPE: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-13-125.html#_Section_IV_Application_1

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Social & Income Inequality; Public Health, Health Services & Primary Care; Geriatrics & Gerontology; International Health; Life Expectancy & Quality of Life; Population Studies, Medical; Social Work & Social Policy; HIV/AIDS; Primary Care; Psychology of Ageing; Health Disparities; Psychology.

Contact Details
----------------------------------------------
Tel: +1 301 496 3138
Email: patmiosg@nia.nih.gov

CUTE KIDNEY INJURY IN OLDER ADULTS (R03) AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites R03 Aid-related applications for its acute kidney injury in older adults grants.

Applications should propose basic, clinical, translational and outcomes research on kidney injury in older adults. Applications may focus on: the epidemiology, etiology and risk factors for AKI in older adults; pathophysiology of AKI in the ageing kidney and its impact on chronic kidney disease (CKD) and other organ disease; early detection, diagnosis and monitoring of AKI; prevention, treatment and management strategies of AKI in older patients with the goal of improving short- and long-term outcomes, including morbidity, mortality, progression of CKD, functional independence and quality of life.

This Aids-related programme announcement will utilise the R03 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

Funding for direct costs may not exceed US$100,000 over two years, and no more than US$50,000 may be requested in any single year.
PA-13-142.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 15 Mar 13

Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Diabetes; HIV/AIDS; Nephrology & Kidneys; Primary Care; Clinical Medicine; Geriatrics &
CUTE KIDNEY INJURY IN OLDER ADULTS (R21) AIDS-RELATED

NIH: National Institute on Aging

Description:
The National Institute on Aging invites R21 Aids-related applications for its acute kidney injury in older adults grants.

Applications should propose basic, clinical, translational and outcomes research on kidney injury in older adults. Applications may focus on: the epidemiology, etiology and risk factors for AKI in older adults; pathophysiology of AKI in the ageing kidney and its impact on chronic kidney disease (CKD) and other organ disease; early detection, diagnosis and monitoring of AKI; prevention, treatment and management strategies of AKI in older patients with the goal of improving short- and long-term outcomes, including morbidity, mortality, progression of CKD, functional independence and quality of life.

This Aids-related programme announcement will utilise the R21 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

Funding for direct costs may not exceed US$275,000 over two years, and no more than US$200,000 may be requested in any single year.

PA-13-143.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 15 Mar 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-13-143.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Nephrology & Kidneys; Public Health, Health Services & Primary Care; Diagnostic Sciences; Prosthetic & Orthotic Devices; HIV/Aids; Geriatrics & Gerontology; Traumatology, Accidents & Injury; Diabetes; Blood Tests; Clinical Medicine; Primary Care

Contact Details
Tel: +1 301 496 6761
Email: susan.zieman@nih.gov
CUTE KIDNEY INJURY IN OLDER ADULTS (R01) AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites R01 Aids-related applications for its acute kidney injury in older adults grants.

Applications should propose basic, clinical, translational and outcomes research on kidney injury in older adults. Applications may focus on: the epidemiology, etiology and risk factors for AKI in older adults; pathophysiology of AKI in the ageing kidney and its impact on chronic kidney disease (CKD) and other organ disease; early detection, diagnosis and monitoring of AKI; prevention, treatment and management strategies of AKI in older patients with the goal of improving short- and long-term outcomes, including morbidity, mortality, progression of CKD, functional independence and quality of life.

This Aids-related programme announcement will utilise the R01 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited but must reflect the actual needs of the proposed project. Funding is available for up to five years.

PA-13-141.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 15 Mar 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Primary Care; Diabetes; Public Health, Health Services & Primary Care; Prosthetic & Orthotic Devices; Geriatrics & Gerontology; Diagnostic Sciences; Blood Tests; HIV/AIDS; Traumatology, Accidents & Injury; Clinical Medicine; Nephrology & Kidneys

Contact Details
----------------------------------------------
Tel: +1 301 496 6761
Email: susan.zieman@nih.gov

THE ROLE OF EXTRACELLULAR RNA IN MEDIATING THE HEALTH EFFECTS OF ALCOHOL (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for the Aids-related role of extracellular RNA in mediating the health effects of alcohol grant. This Aids-
related R21 funding opportunity announcement supports innovative research into the role of extracellular RNA in the development of alcohol-related diseases and end-organ injuries. It is anticipated that this announcement will generate data that may lead to breakthroughs in the understanding of the role of.exRNA communication in the initiation, progression and maintenance of diverse medical disorders caused by excessive, long-term alcohol consumption. Supported research may also provide information on the mechanistic basis of the health benefits of moderate alcohol consumption.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Foreign components are also allowed. Grants may not exceed US$275,000 in direct costs over a two-year period. PA-13-197.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 16 Apr 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

THE EFFECTS OF MODULATING CHRONIC LOW GRADE INFLAMMATION ON GERIATRIC CONDITIONS - SECONDARY DATA OR BIOSPECIMEN ANALYSES AND ANCILLARY STUDIES IN ONGOING OR COMPLETED CLINICAL TRIALS (R01) AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites Aids-related R01 proposals on the effects of modulating chronic low grade inflammation on geriatric conditions - secondary data or biospecimen analyses and ancillary studies in ongoing or completed clinical trials.

This Aids-related R01 opportunity supports ancillary studies and secondary analyses of
data or biospecimens from ongoing or completed studies of the effects of inflammation or anti-inflammatory agents on geriatric conditions, such as functional decline, mobility disability, fatigue, falls, cognitive decline and dementia, and chronic pain.

Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited but must reflect the actual needs of the proposed project. Funding is available for up to five years.
PA-13-221.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time.
Posted date: 08 May 13
Award type: Directed grants to institutions, research groups etc

Research Grants Using the Resources from the Osteoarthritis Initiative (R21): AIDS-Related
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Center for Complementary and Alternative Medicine and the National Institute on Aging invite applications for their Aids-related research grants using the resources from the osteoarthritis initiative (R21). This R21 funding opportunity announcement encourages research focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community.

Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

Direct costs may not exceed US$275,000 over a two-year project period, with no more than US$200,000 in any year. PA-13-237.

Closing date: 07 Jan 16
Deadline information: Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.
Posted date: 03 Jun 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
-------------------------------------------------------------------------------------
Country of applicant institution: Any

---

**Disciplines**
-------------------------------------------------------------------------------------
Rheumatology & Arthritis; Diagnostic Sciences; HIV/Aids; Clinical Medicine; Osteoporosis & Other Bone Diseases; Bone Cancers

**Contact Details**
-------------------------------------------------------------------------------------
NIAMS
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 594 3511
Email: lester1@mail.nih.gov

---

**RESEARCH TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH**
(R03): AIDS-RELATED
NIH: National Institute on Aging

**Description:**
A total of six institutes of the NIH invite applications for grants for research to characterise and reduce stigma to improve health. This Aids-related R03 funding opportunity announcement encourages research grant applications to characterise the role of stigma in health, life course development, and ageing, both in the US and globally, and to test interventions to prevent or reduce the impact of stigma at the individual, community, healthcare system, and policy levels. The goal is to promote research addressing the health-related aspects of stigma, including the aetiology and perpetuation of it; its impact on physical and mental health, well-being, life course development, and ageing; its influence on health behaviours and on use, access to, and quality of received healthcare services; its contribution to health disparities affecting vulnerable demographic groups; and intervention strategies to reduce health-related stigma or the negative health and life course developmental impacts of stigma.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

This funding opportunity uses the R03 small grant programme mechanism and runs in parallel with two of identical scientific scope, PA-13-246, which solicits applications under the NIH exploratory/developmental grant mechanism, and PA-13-248, which uses the R03 research project grant mechanism.

The combined budget for direct costs over the two-year maximum period may not exceed US$100,000. No more than US$50,000 in direct costs may be requested in any single year. PA-13-247.

**Closing date: 07 Jan 16**
Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September, 2016.
Posted date: 17 Jun 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $50,000
Award amount min: -
Award budget total: -
Application form:

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Economic & Social Environment; Behavioural Medicine; Social Services Delivery; Public Health, Health Services & Primary Care; Primary Care; Psychology of Ageing; Medical Sociology; Sociology; Health Systems, Administration; Social Work & Social Policy; Health Disparities; Health Education; Mental Health; Psychology; HIV/Aids; Geriatrics & Gerontology; Education; Allied Health Professions

Contact Details
----------------------------------------------
NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: +1 301 402 4156
Email: nielsenli@nia.nih.gov

**RESEARCH TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R21): AIDS-RELATED**

**NIH: National Institute on Aging**

**Description:**
A total of six institutes of the NIH invite applications for grants for research to characterise and reduce stigma to improve health. This Aids-related R21 funding opportunity announcement encourages research grant applications to characterise the role of stigma in health, life course development, and ageing, both in the US and globally, and to test interventions to prevent or reduce the impact of stigma at the individual, community, healthcare system, and policy levels. The goal is to promote research addressing the health-related aspects of stigma, including the aetiology and perpetuation of it; its impact on physical and mental health, well-being, life course development, and ageing; its influence on health behaviours and on use, access to, and quality of received healthcare services; its contribution to health disparities affecting vulnerable demographic groups; and intervention strategies to reduce health-related stigma or the negative health and life course developmental impacts of stigma.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

This funding opportunity uses the R21 exploratory/developmental research grant mechanism, and runs in parallel with two of identical scope, PA-13-248, which solicits
applications under the R01 research project grant mechanism, and PA-13-247, which uses the R03 small grant mechanism.

The combined budget for direct costs over the two-year maximum period may not exceed US$275,000. No more than US$200,000 in direct costs may be requested in any single year.

PA-13-246.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September, 2016.
Posted date: 17 Jun 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:

Application form:

Eligibility profile
Country of applicant institution: Any

Disciplines
Psychology of Ageing; Education; Psychology; Public Health, Health Services & Primary Care; Allied Health Professions; Sociology; Behavioural Medicine; Primary Care; Medical Sociology; HIV/Aids; Mental Health; Economic & Social Environment; Health Education; Geriatrics & Gerontology; Health Disparities; Health Systems, Administration; Social Services Delivery; Social Work & Social Policy

Contact Details
NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: +1 301 402 4156
Email: nielsenl@nia.nih.gov

Research to Characterise and Reduce Stigma to Improve Health (R01): AIDS-RELATED
NIH: National Institute on Aging

Description:
A total of six institutes of the NIH invite applications for grants for research to characterise and reduce stigma to improve health. This Aids-related R01 funding opportunity announcement encourages research grant applications to characterise the role of stigma in health, life course development, and ageing, both in the US and globally, and to test interventions to prevent or reduce the impact of stigma at the individual, community, healthcare system, and policy levels. The goal is to promote research addressing the health-related aspects of stigma, including the aetiology and perpetuation of it; its impact on physical and mental health, well-being, life course development, and ageing; its influence on health behaviours and on use, access to, and quality of received healthcare services; its contribution to health disparities affecting vulnerable demographic groups; and intervention strategies to reduce health-
related stigma or the negative health and life course developmental impacts of stigma.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

This funding opportunity uses the NIH exploratory/developmental (R01) research project grant mechanism and runs in parallel with two of identical scientific scope, PA-13-246, which solicits applications under the NIH exploratory/developmental grant mechanism, and PA-13-247, which utilises the R03 small grant programme mechanism.

Application budgets are not limited, but need to reflect the actual needs of the proposed project. The scope of the project should determine the project period; the maximum period is five years. PA-13-248.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September, 2016.
Posted date: 17 Jun 13
Award type: Directed grants to institutions, research groups etc

ECONOMICAL ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its Aids-related secondary analyses of alcohol and chronic disease (R21) grants. This Aids-related R21 funding opportunity announcement aims to support secondary analyses of alcohol related to chronic disease aetiology and epidemiology. The goal of this programme is to facilitate cost-effective exploratory or novel studies that break new ground or extend previous discoveries towards new directions or applications.

This funding opportunity announcement will use the NIH exploratory/developmental
research grant (R21) mechanism and runs in parallel with two FOA of identical scientific scope, PA-13-261, which solicits applications under the R03 small grant programme mechanism, and PA-13-260, which solicits applications under the R01 research project grant mechanism.

Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Domestic and foreign for-profit and nonprofit organisations and public or private institutions may apply. PA-13-251

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 09 Jul 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: -

Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its Aids-related secondary analyses of alcohol and chronic disease (R03) grants. This Aids-related R03 funding opportunity announcement aims to support secondary analyses of alcohol related to chronic disease aetiology and epidemiology. The goal of this programme is to facilitate innovative yet cost-effective research using previously collected data.

This funding opportunity announcement will use the NIH small grant programme (R03) mechanism and runs in parallel with two FOA of identical scientific scope, PA-13-260, which solicits applications under the R01 research project grant mechanism, and PA-13-251, which solicits applications under the R21 exploratory/developmental research grant mechanism.

Direct costs are limited to US$100,000 over a two-year project period, with no more than US$50,000 in any year. Domestic and foreign for-profit and nonprofit organisations and public or private institutions may apply. PA-13-261.
IMPLICATIONS OF NEW DIGITAL MEDIA USE FOR UNDERAGE DRINKING, DRINKING-RELATED BEHAVIOURS AND PREVENTION RESEARCH (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related implications of new digital media use for underage drinking, drinking-related behaviours and prevention research (R21) grants. This Aids-related R21 funding opportunity announcement aims to investigate whether, and how, heaving involvement in new digital media use, particularly social media and social networking sites, may influence adolescent alcohol use and drinking patterns, as well as drinking-related problems. The FOA also encourages studies exploring the ways new digital media may be use as platforms for preventative interventions aimed at underage drinking and related problems.

This funding opportunity announcement will use the NIH exploratorydevelopment research grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-262, which solicits applications under the R01 research project grant mechanism.

Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Domestic and foreign for-profit and non-profit organisations and public or private institutions may apply. PA-13-263.

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 09 Jul 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

**Description:**
The National Institute of Alcohol Abuse and Alcoholism invites applications for its Aids-related secondary analyses of alcohol and chronic disease (R01) grants. This Aids-related R01 funding opportunity announcement aims to support secondary analyses of alcohol related to chronic disease aetiology and epidemiology. The goal of this programme is to facilitate innovative yet cost-effective research using previously collected data.

This funding opportunity announcement will use the NIH research project grant (R01) mechanism and runs in parallel with two FOA of identical scientific scope, PA-13-261, which solicits applications under the R03 small grant programme mechanism and PA-13-251, which solicits applications under the R21 exploratory/developmental research grant mechanism.

Direct costs are not limited, but must reflect the needs of the project. The maximum project period is five years. Domestic and foreign for-profit and nonprofit organisations and public or private institutions may apply. PA-13-260.

**Closing date:** 07 Jan 16
**Deadline information:** Applications due by 5pm every 7 January, 7 May and 7 September until 8 September 2016.
**Posted date:** 09 Jul 13
**Award type:** Directed grants to institutions, research groups etc
**Award budget total:** -
**Website:**

**Application form:**

**Eligibility profile**
----------------------------------------------
Country of applicant institution: Any

**Disciplines**
----------------------------------------------
Social Behaviour & Attitudes; Sociology; Public Health, Health Services & Primary Care; Primary Care; Communication & Media Studies; Alcoholism; Business & Management Studies; Communication Studies; Social Networks; Networking Protocols; HIV/Aids; Media Studies

**Contact Details**
----------------------------------------------
NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 443 8820
Email: rfreeman@mail.nih.gov
IMPLICATIONS OF NEW DIGITAL MEDIA USE FOR UNDERAGE DRINKING, DRINKING-RELATED BEHAVIOURS AND PREVENTION RESEARCH (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its AIDS-related implications of new digital media use for underage drinking, drinking-related behaviours and prevention research (R01) grants. This AIDS-related R01 funding opportunity announcement aims to investigate whether, and how, having involvement in new digital media use, particularly social media and social networking sites, may influence adolescent alcohol use and drinking patterns, as well as drinking-related problems. The FOA also encourages studies exploring the ways new digital media may be used as platforms for preventative interventions aimed at underage drinking and related problems.

This funding opportunity announcement will use the NIH research project grant (R01) mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-263, which solicits applications under the R21 exploratory/developmental research grant mechanism.

Direct costs are not limited, but must reflect the needs of the project. The maximum project period is five years. Domestic and foreign for-profit and nonprofit organisations and public or private institutions may apply. PA-13-262.

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 09 Jul 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-262

Eligibility profile

Country of applicant institution: Any

Disciplines

Communication & Media Studies; Media Studies; Networking Protocols; Public Health, Health Services & Primary Care; Social Networks; Primary Care; Sociology; Social Behaviour & Attitudes; Alcoholism; Communication Studies; Business & Management Studies; HIV/AIDS
SYNERGISING OMIC AND SYMPTOM SCIENCE (R01): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for its Aids-related synergising omic and symptom science (R01) grants. This Aids-related R01 funding opportunity announcement aims to promote integration of diverse information from molecular and biological processes with patient-reported outcomes.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.
PA-13-264.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 10 Jul 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
Country of applicant institution: Any

Disciplines
Biological Sciences; HIV/Aids; Genomics; Carbohydrates; Medical Effectiveness & Patient Outcomes; Pharmacogenomics; Proteomics & Molecular Interactions; Pharmacy & Pharmacology; Diagnostic Sciences; Epigenetics

Contact Details
NINR
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: + 301 496 9623
Email: mardens@mail.nih.gov
SYSTEMIC AMYLOIDOSIS: BASIC, TRANSLATIONAL AND CLINICAL RESEARCH (R01): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Disease, the National Cancer Institute and the National Institute on Aging invite applications for their Aids-related systemic amyloidosis: basic, translational and clinical research (R01) grants. This Aids-related R01 funding opportunity announcement will support basic and clinical research projects that advance understanding of pathogenic mechanisms underlying systemic amyloidosis, develop improved techniques for the clinical detection and diagnosis of systemic amyloid diseases, develop novel cellular and in vivo models to identify candidate therapeutic agents with, and evaluate the clinical efficacy of novel therapies designed to prevent, arrest and reverse the morbid and lethal progression of these diseases.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. PA-13-286.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 29 Jul 13

Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-286

Eligibility profile
Country of applicant institution: Any

Disciplines
Biological Sciences; Medical & Diagnostic Tests; HIV/AIDS; Chemistry; Protein Synthesis, Modification & Turnover; Pharmacotherapy; Primary Care; Diagnostic Sciences; Structural Biology; Public Health, Health Services & Primary Care; Cell Physiology & Metabolism; Protein Trafficking; Pharmacy & Pharmacology; Nursing; Clinical Medicine; Pathogenesis; Non-Communicable Diseases; Characteristics, Biological Macromolecules

Contact Details
NIDDK
6707 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 594 6007
Email: rasoolyr@mail.nih.gov
BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R21): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for Aids-related its biomarkers: bridging paediatric and adult therapeutics (R21) grants. This Aids-related R21 funding opportunity announcement invites applications that propose adapting adult biomarkers to children. This would include the application and validation of biomarkers developed in adults to paediatric diagnosis, prognosis, and estimation of disease progression, toxicity and response to therapy. Projects supported will be confined to those biomarkers that correlate with a clinical observation, have been extensively studied in adults, and for which there is solid evidence that they have paediatric applications. Discovery of new biomarkers for use in new drug development or in preclinical studies are not part of this FOA.

This funding opportunity announcement will use the NIH exploratory/developmental research grant award (R21) mechanism and runs in parallel with two FOAs of identical scientific scope: PAR-13-299, which solicits applications under the small grants programme (R03) mechanism and PAR-13-296, which solicits applications under the research project grant (R01) mechanism.

Direct costs are limited to US$275,000 over two years, with no more than US$200,000 in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-295 (replaces PAR-11-324).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 02 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Application form:

Eligibility profile
Country of applicant institution: Any

Disciplines
Clinical Medicine; Medical Instrumentation; Biochemical Markers; Biological Markers & Sensor Mechanisms; Diagnostic Sciences; Drug Design; Medical & Diagnostic Tests; Paediatrics; HIV/AIDS

Contact Details
Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
6100 Executive Boulevard, Room 4A01C, MSC 7510
Bethesda, MD 20892
Tel: +1 301 496 5589
Email: gg65m@nih.gov
Biomarkers: Bridging Paediatric and Adult Therapeutics (R03): AIDS-Related
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for its AIDS-related biomarkers: bridging paediatric and adult therapeutics (R03) grants. This AIDS-related R03 funding opportunity announcement invites applications that propose adapting adult biomarkers to children. This would include the application and validation of biomarkers developed in adults to paediatric diagnosis, prognosis, and estimation of disease progression, toxicity and response to therapy. Projects supported will be confined to those biomarkers that correlate with a clinical observation, have been extensively studied in adults, and for which there is solid evidence that they have paediatric applications. Discovery of new biomarkers for use in new drug development or in preclinical studies are not part of this FOA.

This funding opportunity announcement will use the NIH small grants programme (R03) mechanism and runs in parallel with two FOAs of identical scientific scope: PA-13-296, which solicits applications under the research project grants (R01) mechanism and PA-13-295, which solicits applications under the exploratory/developmental grant (R21) mechanism. Applicants may request up to US$50,000 per year in direct costs for a maximum of two years.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-299 (replaces PAR-11-323).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 02 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-299

Eligibility profile
Country of applicant institution: Any

Disciplines
Drug Design; Biochemical Markers; Biological Markers & Sensor Mechanisms; Medical Instrumentation; Paediatrics; HIV/AIDS; Diagnostic Sciences; Clinical Medicine; Medical & Diagnostic Tests

Contact Details
Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
6100 Executive Boulevard, Room 4A01C, MSC 7510
Bethesda, MD 20892
Tel: +1 301 496 5589
Email: gg65m@nih.gov
THE ROLE OF THE CYTOSKELETON IN CELLULAR AGEING (R21/R33): AIDS-RELATED

NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its AIDS-related role of the cytoskeleton in cellular ageing (R21/R33) grants. This AIDS-related R21/R33 funding opportunity announcement aims to stimulate the development of innovative research strategies to increase understanding of the molecular and cellular changes in the cytoskeleton that occur during the ageing process. Applications considering the effect of age on factors such as cytoskeleton structure and function, the impact of the cytoskeleton on intracellular organelle interactions, and the signalling or regulatory molecules controlling cellular architecture are encouraged. There is also interest in studying the role of the cytoskeleton in nuclear-cytoplasmic communications and in spatio-temporal relationships during the ageing process and in age-related diseases.

The total project period for the combined R21/R33 application submitted in response to this FOA may not exceed five years and total direct costs are limited to $1.18 million. The R21 phase may not exceed two years or $275,000 in direct costs. The R33 phase may not exceed three years or $900,000 in direct costs.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-301.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 02 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $1,175,000

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-301

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Cell & Developmental Biology; HIV/Aids; Biological Sciences; Biochemistry & Molecular Biology; Geriatrics & Gerontology; Diagnostic Sciences; Cell Physiology & Metabolism

Contact Details
----------------------------------------------
NIA
7201 Wisconsin Avenue
Bethesda, MD 20814
Tel: +1 301 496 6428
Email: jvelazqu@mail.nih.gov
BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R01): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for its Aids-related biomarkers: bridging paediatric and adult therapeutics (R01) grants. This Aids-related R01 funding opportunity announcement invites applications that propose adapting adult biomarkers to children. This would include the application and validation of biomarkers developed in adults to paediatric diagnosis, prognosis, and estimation of disease progression, toxicity and response to therapy. Projects supported will be confined to those biomarkers that correlate with a clinical observation, have been extensively studied in adults, and for which there is solid evidence that they have paediatric applications. Discovery of new biomarkers for use in new drug development or in preclinical studies are not part of this FOA.

This funding opportunity announcement will use the NIH research project grant (R01) mechanism and runs in parallel with two FOAs of identical scientific scope: PAR-13-299, which solicits applications under small grants programme (R03) mechanism and PAR-13-295, which solicits applications under the exploratory/developmental grant (R21) programme. Application budgets are not limited, but must reflect actual needs of the project. The project period is a maximum of five years.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-296 (replaces PAR-11-322).

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016. Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.

Posted date: 02 Aug 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
Country of applicant institution: Any

Disciplines
Diagnostic Sciences; HIV/AIDS; Paediatrics; Clinical Medicine; Biochemical Markers; Medical Instrumentation; Biological Markers & Sensor Mechanisms; Drug Design; Medical & Diagnostic Tests

Contact Details
Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
6100 Executive Boulevard, Room 4A01C, MSC 7510
Bethesda, MD 20892
Tel: +1 301 496 5589
Email: gg65m@nih.gov
BEHAVIOURAL AND SOCIAL SCIENCE RESEARCH ON UNDERSTANDING AND REDUCING HEALTH DISPARITIES (R21): AIDS-RELATED

NIH: Office of the Director

Description:
Participating institutes and centres of the National Institutes of Health invite applications for Aids-related behavioural and social science research on understanding and reducing health disparities (R21) grants. This R21 funding opportunity announcement supports behavioural and social science research on the causes and solutions to health and disabilities disparities in the US population. Emphasis is placed on research in and among three broad areas of action:

- public policy;
- healthcare;
- disease and disability prevention.

Particular attention is given to reducing health gaps among groups. Proposals that use an interdisciplinary approach, investigate multiple levels of analysis, incorporate a life-course perspective, or employ innovative methods such as system science or community-based participatory research are particularly encouraged.

This FOA will utilise the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PAR13-292, which solicits applications under the R01 mechanism. Direct costs are limited to US$275,000 over an R21 two year period, with no more than US$200,000 in direct costs allowed in any single year.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-288 (replaces PAR-10-137).

Closing date: 07 Jan 16
Deadline information: Deadlines by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 05 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile

Country of applicant institution: Any

Disciplines

Health Systems Policy; Primary Care; Behavioural Medicine; HIV/Aids; Preventive Medicine; Health Disparities; Care for Disabled People; Population Studies, Medical; Allied Health Professions; Medical Sociology; Public Health, Health Services & Primary Care; Clinical Medicine; Economic & Social Environment; Sociology; Psychology; Social Work & Social Policy; Public Health; Rural Health; Disadvantaged & Minority Groups; Health Systems

Contact Details

OBSSR
31 Center Drive
Building 31, Room B1C19
Bethesda, MD 20892-2027
Tel: +1 301 451 4286
Email: michael.spittel@mail.nih.gov
BEHAVIOURAL AND SOCIAL SCIENCE RESEARCH ON UNDERSTANDING AND REDUCING HEALTH DISPARITIES (R01): AIDS-RELATED

NIH: Office of the Director

Description:
Participating institutes and centres of the National Institutes of Health invite applications for Aids-related behavioural and social science research on understanding and reducing health disparities (R01) grants. This Aids-related R01 funding opportunity announcement supports behavioural and social science research on the causes and solutions to health and disabilities disparities in the US population. Emphasis is placed on research in and among three broad areas of action:

- public policy;
- healthcare;
- disease and disability prevention.

Particular attention is given to reducing health gaps among groups. Proposals that use an interdisciplinary approach, investigate multiple levels of analysis, incorporate a life-course perspective, or employ innovative methods such as system science or community-based participatory research are particularly encouraged.

This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-288, which solicits applications under the R21 mechanism. Projects may last up to five years.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-292 (replaces PAR-10-136).

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 05 Aug 13

Award type: Directed grants to institutions, research groups etc

Award budget total: -

Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-292

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Social Work & Social Policy; Sociology; Medical Sociology; Economic & Social Environment; Psychology; Health Systems; Rural Health; HIV/AIDS; Health Systems Policy; Population Studies, Medical; Health Disparities; Behavioural Medicine; Clinical Medicine; Public Health; Care for Disabled People; Public Health, Health Services & Primary Care; Preventive Medicine; Disadvantaged & Minority Groups; Primary Care; Allied Health Professions

Contact Details
---------------------------------------------------------------
OBSSR
31 Center Drive
Building 31, Room B1C19
Bethesda, MD 20892-2027
Tel: +1 301 451 4286
Email: michael.spittel@mail.nih.gov
UT MICROBIOTA-DERIVED FACTORS IN THE INTEGRATED PHYSIOLOGY AND PATHOPHYSIOLOGY OF DISEASES WITHIN NIDDK’S MISSION (R01): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Kidney Diseases invites applications for its Aids-related gut microbiota-derived factors in the integrated physiology and pathophysiology of diseases within NIDDK’s mission (R01) grants. This Aids-related R01 funding opportunity announcement supports research to define interactions between the host and the gut microbiota that regulate normal physiology and pathopathology of diseases within NIDDK’s mission. The goal is to discover specific human gut microbiota-derived factors that affect or are affected by host physiology, homeostasis and disease pathophysiology. Projects will also define the specific factors and pathway microbiota-derived factors use to affect host processes within the gut or distant organ sites.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. PAR-13-293.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 05 Aug 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-293

Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/Aids; Biological Sciences; Gastroenterology; Waste Recycling, Reduction & Recovery; Diagnostic Sciences; Microbial Ecology

Contact Details
Division of Digestive Diseases and Nutrition
NIDDK
6707 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 451 3759
Email: greymj@mail.nih.gov

METHODS FOR PREVENTION PACKAGES PROGRAMME III (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their methods for prevention packages programme
III (R01) grants. This R01 funding opportunity announcement encourages collaborations to develop new research strategies and methodologies that will facilitate the design and testing of combination HIV prevention interventions. The call addresses the following two objectives:

- to devise optimal HIV prevention packages for specific populations;
- to perform feasibility and acceptability studies to demonstrate that the proposed prevention package is acceptable to the target population and the study is appropriate and feasible.

This FOA encourages collaboration between behavioural and biomedical clinical specialists, epidemiologists, mathematical modellers, and clinical research specialists.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is four years.

Domestic and foreign public and private non-profit organisations and for-profit organisations may apply. PAR-13-322

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, 7 January annually until 8 January 2016.
Posted date: 09 Aug 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
Country of applicant institution: Any

Disciplines
Primary Care; Preventive Medicine; Public Health, Health Services & Primary Care; Diagnostic Sciences; HIV/AIDS

Contact Details
NIH NIAID
6700B Rockledge Drive
Bethesda MD 20817
Tel: +1 301 827 0845
Email: elharrava@mail.nih.gov

**Increased Knowledge and Innovative Strategies to Reduce HIV Incidence (R01)**

*NIH: National Institute of Allergy and Infectious Diseases*

**Description:**
The National Institute of Allergy and Infectious Diseases, the National Institute on Drug Abuse and the National Institute of Mental Health invites applications for their increased knowledge and innovative strategies to reduce HIV incidence (R01) grants. This R01 funding opportunity announcement aims to promote innovative research to improve the identification of populations that are both at high risk of HIV-1 infection and have a high proportion of persons that are unaware of their HIV status, and to successfully link them to HIV testing, effective prevention interventions, and, if HIV-positive, care and treatment.
Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years.

Domestic and foreign public and private non-profit organisations and for-profit organisations may apply. PAR-13-323.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, 7 January annually until 8 January 2016.
Posted date: 09 Aug 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-323

Eligibility profile
Country of applicant institution: Any

Disciplines
Primary Care; Diagnostic Sciences; HIV/AIDS; Preventive Medicine; Public Health, Health Services & Primary Care

Contact Details
NIAID
6700 Rockledge Drive
Bethesda MD 20817
Tel: +1 301 435 8896
Email: burnsda@niaid.nih.gov

UDACIOUS GOALS INITIATIVE HIGH PRIORITY RESEARCH AREA – INTERSECTION OF AGEING AND BIOLOGICAL MECHANISMS OF EYE DISEASE (R01): AIDS-RELATED

NIH: National Eye Institute

Description:
The National Eye Institute and the National Institute on Aging invites applications for its audacious goals initiative high priority research area: intersection of ageing and biological mechanisms of eye disease (R01): Aids-related grants. This Aids-related R01 funding opportunity announcement aims to improve understanding of the intersection between ageing and the biological mechanism of eye disease. The following research areas are of interest:

- understanding how the biology of ageing contributes to disease;
- valuating how the failure of homeostatic processes causes or allows the transition from aging to early disease;
- defining the biological staging of disease to understand pathophysiology, identify biomarkers and explore therapy; distinguishing normal ocular changes associated with aging from pathophysiologic changes;
- investigate the diverse cellular, molecular, genetic, and neural circuitry mechanisms underlying age-related changes in the eye;
- ascertain the impact of age-related changes in the eye on the progression of visual function as well as associated brain or behavioral functions for the aged and the utility of such changes as
early biomarkers for pathological processes for the aged;
• identify and evaluate interventions that will modify age-related changes to alter the course of pathological development.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PA-13-332.

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 15 Aug 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-332

Eligibility profile
Country of applicant institution: Any
Disciplines
Clinical Medicine; Diagnostic Sciences; Biochemical Markers; Pathophysiology; Geriatrics & Gerontology; Eye Diseases; Biological Markers & Sensor Mechanisms; HIV/Aids

Contact Details
NEI
5635 Fishers Lane
Rockville MD, 20852
Tel: +1 301 451 2020
Email: mckiegeo@nei.nih.gov

M ECHANISMS OF ALCOHOL AND STIMULANT CO-ADDICTION (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their AIDS-related mechanisms of alcohol and stimulant co-addiction (R21) grants. This AIDS-related R21 funding opportunity announcement promotes research on neurobiological and behavioural mechanisms that might explain how alcohol and stimulants interact at genetic, epigenetic, cellular, neurocircuitry and behavioural levels to promote co-addiction.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PAR-13-339, which solicits applications under the R01 research project grant mechanism. Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-340.
Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 29 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
-------------------------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
-------------------------------------------------------------------------------------
Addiction; Behavioural Medicine; Psychology; Public Health, Health Services & Primary Care; Drug & Substance Abuse; Biological Sciences; Neurobiology; Diagnostic Sciences; Primary Care; HIV/AIDS; Alcoholism

Contact Details
-------------------------------------------------------------------------------------
NIAAA
6000 Executive Boulevard
Bethesda, MD 20892-7003
Tel: +1 301 443 7600
Email: igrakalic@mail.nih.gov

MECHANISMS OF ALCOHOL AND STIMULANT CO-ADDICTION (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their Aids-related mechanisms of alcohol and stimulant co-addiction (R01) grants. This Aids-related R01 funding opportunity announcement promotes research on neurobiological and behavioural mechanisms that might explain how alcohol and stimulants interact at genetic, epigenetic, cellular, neurocircuitry and behavioural levels to promote co-addiction.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PAR-13-340, which solicits applications under the R21 exploratory/developmental grant mechanism. Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-339.

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 29 Aug 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form:  

Eligibility profile  
--------------------------------------------------------------------
Country of applicant institution: Any

Disciplines  
--------------------------------------------------------------------
Alcoholism; Drug & Substance Abuse; HIV/Aids; Public Health, Health Services & Primary Care; Behavioural Medicine; Psychology; Addiction; Biological Sciences; Neurobiology; Diagnostic Sciences; Primary Care

Contact Details  
--------------------------------------------------------------------
NIAAA  
6000 Executive Boulevard  
Bethesda, MD 20892-7003  
Tel: +1 301 443 7600  
Email: igrakalic@mail.nih.gov

---

**EXPLORATORY/DEVELOPMENTAL CLINICAL RESEARCH GRANTS IN OBESITY (R21): AIDS-RELATED**  
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

**Description:**  
The National Institute of Diabetes and Digestive and Kidney Diseases, the National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and the Office of Dietary Supplements invite applications for their exploratory/developmental clinical research grants in obesity (R21) funding opportunity announcement. This Aids-related announcement supports exploratory and developmental clinical studies that accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and children. Exploratory epidemiological research with a goal of informing translational and clinical research may also be supported.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs with up to US$200,00,00 in direct costs per year. The maximum project period is two years.

Ref: PA-15-163 (reissue of PA-12-179).

Closing date: 07 Jan 16  
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 30 Mar 15  
Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants

Award amount max: $275,000

Website:  

Eligibility profile  
--------------------------------------------------------------------
Country of applicant institution: Any

Disciplines  
--------------------------------------------------------------------
HIV/Aids; Obesity
DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND
PAEDIATRIC DRUG DELIVERY SYSTEMS (R03): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and the Office of Rare Diseases invite applications for the development of appropriate formulations and paediatric drug delivery systems (R03): Aids-related grants. This Aids-related R03 funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Development and testing of novel paediatric drug delivery systems is also part of this initiative. This FOA also encourages development of novel drug delivery systems in the paediatric population. Investigators are encouraged to explore approaches and concepts new to the area of paediatric formulation development, testing and use of newly developed techniques superior to the ones currently used in the field.

This funding opportunity announcement will use the NIH research project R03 grant mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-325, which solicits applications under the research project grant (R01) mechanism and PAR-13-326, which solicits applications under the exploratory/developmental research grant award (R21) mechanism.

Application budgets are limited to US$100,000 over a two-year project period, with no more than US$50,000 in direct costs per year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-344 (replaces PAR-11-302).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 05 Sep 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-344

Eligibility profile
Country of applicant institution: Any

Disciplines
Paediatrics; Allied Health Professions; Drug Design; Methods of Drug Delivery; Pharmacy & Pharmacology; Clinical Medicine; Diagnostic Sciences

Contact Details
NICHD

Contact Details
----------------------------------------------
NIDDK
BG 2DEM Room 673
6707 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 451 8354
Email: kuczmarskir@mail.nih.gov

A compilation of the Research Services of the Office of Research, Innovation & Development (ORID)
DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R21): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and the National Institute on Deafness and Other Communication Disorders invite applications for the development of appropriate formulations and paediatric drug delivery systems (R21): Aids-related grants. This Aids-related R21 funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Development and testing of novel paediatric drug delivery systems is also part of this initiative.

This funding opportunity announcement will use the NIH research project R21 grant mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-325, which solicits applications under the research project grant (R01) mechanism and PAR-13-344, which solicits applications under the small grant award (R03) mechanism.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs per year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-326 (replaces PAR-11-303)

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 05 Sep 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000


Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Clinical Medicine; Diagnostic Sciences; Drug Design; Allied Health Professions; Paediatrics; Pharmacy & Pharmacology; Methods of Drug Delivery

Contact Details
---------------------------------------------------------------
NICHD
Obstetric and Paediatric Pharmacology and Therapeutics Branch
6100 Executive Boulevard, ROom 4A01C, MSC 7510
Bethesda, MD 20852

Description:
The National Institute of Child Health and the National Institute on Deafness and Other Communication Disorders invite applications for the development of appropriate formulations and paediatric drug delivery systems (R21): Aids-related grants. This Aids-related R21 funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Development and testing of novel paediatric drug delivery systems is also part of this initiative.

This funding opportunity announcement will use the NIH research project R21 grant mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-325, which solicits applications under the research project grant (R01) mechanism and PAR-13-344, which solicits applications under the small grant award (R03) mechanism.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs per year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-326 (replaces PAR-11-303)

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 05 Sep 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000


Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Clinical Medicine; Diagnostic Sciences; Drug Design; Allied Health Professions; Paediatrics; Pharmacy & Pharmacology; Methods of Drug Delivery

Contact Details
---------------------------------------------------------------
NICHD
Obstetric and Paediatric Pharmacology and Therapeutics Branch
6100 Executive Boulevard, ROom 4A01C, MSC 7510
Bethesda, MD 20852
DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R01): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and the National Institute on Deafness and Other Communication Disorders invite applications for the development of appropriate formulations and paediatric drug delivery systems (R01): Aids-related grants. This Aids-related R01 funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Development and testing of novel paediatric drug delivery systems is also part of this initiative.

This funding opportunity announcement will use the NIH research project R01 grant mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-344, which solicits applications under the small grant (R03) mechanism and PAR-13-326, which solicits applications under the exploratory/developmental research grant award (R21) mechanism.

Application budgets are not limited, but should reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-325 (replaces PAR-11-301).

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 05 Sep 13

Award type: Directed grants to institutions, research groups etc

Award budget total: -


Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-325

Eligibility profile

Country of applicant institution: Any

Disciplines

Paediatrics; Clinical Medicine; Methods of Drug Delivery; Pharmacy & Pharmacology; Allied Health Professions; Drug Design; Diagnostic Sciences

Contact Details

NICHD
Obstetric and Paediatric Pharmacology and Therapeutics Branch
6100 Executive Boulevard, ROom 4A01C, MSC 7510
Bethesda, MD 20852
Tel: +1 301 496 5589
Email: gg65m@nih.gov
EARLY-CAREER AWARD IN CHEMISTRY OF DRUG ABUSE AND ADDICTION (R21/R33): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related early-career award in chemistry of drug abuse and addiction (R21/R33). This Aids-related R21/R33 funding opportunity announcement seeks to facilitate the entry of new-to-NIH investigators into basic chemistry research applied to drug abuse and addiction.

Direct costs are limited to US$250,000 over a R21 two-year period, with a maximum of US$200,000 allowed in any single year. The R33 award phase will be limited to US$250,000 in direct costs per year. The total project period for an application submitted in response to this funding opportunity may not exceed four years. Awards will support milestone driven exploratory/feasibility proof of concept studies (R21 phase, up to two years), with possible rapid transition to expedited development (R33 phase, up to three years, depending upon the requested period for the R21 phase). Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PAR-13-350 (replaces PAS-10-274).

Closing date: 07 Jan 16
Deadline information: Submissions due by 5pm proposers’s local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 12 Sep 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $1,000,000


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Primary Care; Psychology; Drug & Substance Abuse; Alcoholism; Clinical Chemistry; Public Health, Health Services & Primary Care; Biological Sciences; Neurobiology; Addiction; HIV/AIDS

Contact Details
----------------------------------------------
Division of Basic Neuroscience and Behavioral Research
NIDA
6001 Executive Boulevard
Bethesda, MD 20892-9555
Tel: +1 301 443 9800
Email: boughk@mail.nih.gov
SUSTAINED RELEASE OF ANTIVIRALS FOR TREATMENT OR PREVENTION OF HIV (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases, the National Institute of Child and Maternal Health and the National Institute of Mental Health invite applications for their Sustained release of antivirals for treatment or prevention of HIV (R01) call. This R01 funding opportunity announcement will support proposed treatment or prevention products delivered using sustained release platforms, such as oral, injection, implant or direct delivery to HIV target mucosa, that will provide a minimum of one week or one month’s efficacy or protection.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply. PAR-13-349.

Closing date: 07 Jan 16
Deadline information: Deadlines on 7 January annually until 8 January 2016.
Posted date: 12 Sep 13
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -

Award budget total: -
Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-349

Eligibility profile
----------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------
Social Work & Social Policy; Primary Care; Public Health, Health Services & Primary Care; HIV/AIDS; Disease Control; Poverty in Developing Countries; Methods of Drug Delivery; General Practice; Preventive Medicine; Virology; Diagnostic Sciences; Antivirals

Contact Details
----------------------------------
Division of AIDS
NIAID
6700B Rockledge Drive
Bethesda, MD 20817
Fax: +1 301 435 3771
Email: sturk@niaid.nih.gov

ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R03): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging and the the National Center for Complementary and Alternative Medicine invite applications for their grants for advancing the science of geriatric palliative care. This Aids-related R03 funding opportunity announcement encourages research grant applications
focused on palliative care in geriatric populations. This FOA emphasises studies in a variety of settings including ambulatory care, hospitals, assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programmes. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients' disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.

This FOA uses the R03 small grant programme mechanism and runs in parallel with two of identical scientific scope: PA-13-354, which solicits applications under the R01 research project grant mechanism, and PA-13-355, which solicits applications under the R21 exploratory/developmental grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritoripus applications. The total project period may not exceed two years; direct costs are limited to US$50,000 per year. PA-13-356.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.
Posted date: 20 Sep 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Eligibility profile

Country of applicant institution: Any

Disciplines

Social Work & Social Policy; Geriatrics & Gerontology; Palliative Nursing; Nursing; Primary Care; Public Health, Health Services & Primary Care; Pharmaceutical Drugs; Health Counselling; Geriatric Nursing; Hospice & Palliative Care; Health Systems; HIV/Aids; Pain Management; Clinical Medicine; Chronic Pain; Hospitalisation; Clinical Pharmacy & Pharmacology; Blood Tests; Pharmacy & Pharmacology

Contact Details

NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Fax: +1 301 496 6761
Email: basil.eldadah@nih.gov
ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R21): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging and the National Center for Complementary and Alternative Medicine invite applications for their grants for advancing the science of geriatric palliative care. This Aids-related R21 funding opportunity announcement encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasises studies in a variety of settings including ambulatory care, hospitals, assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programmes. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients' disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with two of identical scientific scope: PA-13-356, which solicits applications under the R03 small grant programme mechanism, and PA-13-354, which solicits applications under the R01 research project grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The total project period may not exceed two years; the combined budget for direct costs over this period may not exceed US$275,000. No more than US$200,000 may be requested in any single year. PA-13-355.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.
Posted date: 20 Sep 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Geriatrics & Gerontology; Nursing; Pain Management; Health Counselling; Pharmacy & Pharmacology; Public Health, Health Services & Primary Care; HIV/AIDS; Hospitalisation; Geriatric Nursing; Health Systems; Pharmaceutical Drugs; Clinical Pharmacy & Pharmacology; Primary Care; Blood Tests; Chronic Pain; Hospice & Palliative Care; Clinical Medicine; Palliative Nursing; Social Work & Social Policy

Contact Details
NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R01): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging and the National Center for Complementary and Alternative Medicine invite applications for their grants for advancing the science of geriatric palliative care. This AIDS-related R01 funding opportunity announcement encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasises studies in a variety of settings including ambulatory care, hospitals, assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programmes. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients' disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years. PA-13-354.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.
Posted date: 20 Sep 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:
Application form:

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Clinical Pharmacy & Pharmacology; Health Systems; Chronic Pain; Pharmacy &
**MODELLING SOCIAL BEHAVIOUR (R01): AIDS-RELATED**

NIH: National Institute of General Medical Sciences

**Description:**
A total of 10 institutes and offices of the National Institutes of Health invites applications for their Aids-related modelling social behaviour (R01) call. This Aids-related R01 funding opportunity announcement aims to develop and test innovative theories and computational, mathematical or engineering approaches to deepen understanding of complex social behaviour. This research will examine phenomena at multiple scales to address the emergence of collective behaviours that arise from individual elements or parts of a system working together.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. Transdisciplinary teams are encouraged, including at minimum researchers with expertise in the behavioural or social sciences as well as those in computational and systems modelling.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years for new and early-stage investigators, and four years for established investigators.

Ref: PAR-13-374.

**Closing date:** 07 Jan 16

**Deadline information:** Applications due by 5pm, local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2017.

**Posted date:** 18 Oct 13

**Award type:** Directed grants to institutions, research groups etc

**Award budget total:** -


**Eligibility profile**

**Country of applicant institution:** Any

**Disciplines**

Social Behaviour & Attitudes; Computer Simulation & Modelling; Computer Science & Informatics; HIV/Aids; Sociology

**Contact Details**

NIGMS
45 Center Drive
Bethesda, MD 20814
Tel: +1 301 594 2987
Email: marcusst@mail.nih.gov
NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (COLLABORATIVE R01): AIDS-RELATED

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its new computational methods for understanding the functional role of DNA variants that are associated with mental disorders (collaborative R01): Aids-related grants. The aim of this collaborative R01 funding opportunity announcement is to support Aids-related development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex aetiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness, This should take into account the added complexities and nuances of brain diseases, and ultimately inform the identification and validation of potential targets for novel treatment development.

This FOA is suitable when two or more sites are needed to complete the study. Each site must have its own programme director or principal investigator. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

MIMH will invest US$3 million in fiscal year 2015 to fund this and a companion FOA. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is three years.

Ref: PAR-13-391.

Closing date: 07 Jan 16

Deadline information: Deadlines 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 14 Nov 13

Award type: Directed grants to institutions, research groups etc, Networking/collaboration

Award budget total: -


Eligibility profile

Country of applicant institution: Any

Disciplines

Computer Science & Informatics; Aetiology; Diagnostic Sciences; Mental Health; Medical Informatics & Telemedicine; Bioinformatics; Psychology; Structural Biology; Human Genome; Health Informatics; Systematics; Deoxyribonucleic Acid, DNA ; Biostatistics; Mental Illness

Contact Details

NIMH
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6653
Email: anjene.addington@nih.gov
NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (R01): AIDS-RELATED

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its new computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01): Aids-related grants. The aim of this R01 funding opportunity announcement is to support Aids-related development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex aetiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness. This should take into account the added complexities and nuances of brain diseases, and ultimately inform the identification and validation of potential targets for novel treatment development.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

MIMH will invest US$3 million in fiscal year 2015 to fund this and a companion FOA. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is three years.
Ref: PAR-13-391.

Closing date: 07 Jan 16
Deadline information: Deadlines 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 14 Nov 13
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total:
Website:

Application form:
http://www.grants.gov/web/grants/applicant
s/download-application-
package.html#download=true&oppNum=PAR-13-392

Eligibility profile
Country of applicant institution: Any
Disciplines
Mental Illness; Psychology; Aetiology; Biostatistics; Medical Informatics & Telemedicine; Systematics; Mental Health; Health Informatics; HIV/AIDS; Structural Biology; Computer Science & Informatics; Diagnostic Sciences; Deoxyribonucleic Acid, DNA ; Bioinformatics; Human Genome

Contact Details
NIMH
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6653
Email: anjene.addington@nih.gov
PUBLIC HEALTH IMPACT OF THE CHANGING POLICY/LEGAL ENVIRONMENT FOR MARIJUANA (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related public health impact of the changing policy/legal environment for marijuana (R01) grants. This Aids-related R01 funding opportunity announcement encourages research on the impact of changing marijuana policies and laws on public health outcomes. This includes:

- marijuana exposure among children, adolescents and adults;
- other licit and illicit drug use;
- education and professional achievement;
- social development;
- risky behaviours;
- mental health;
- HIV.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

NIH will invites US$3 million in fiscal year 2014 to fund six to ten awards. Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is three years.

Ref: PAS-14-020.

Closing date: 07 Jan 16
Deadline information: Submissions due by 5pm proposers’s local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 09 Dec 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PAS-14-020.html

Eligibility profile

Country of applicant institution: Any

Disciplines

Addiction; Drug & Substance Abuse; Social Behaviour & Attitudes; Pharmacokinetics; Medical Effectiveness & Patient Outcomes; Cognitive & Behavioural Therapies; Primary Care; Health Systems Policy; Public Health; Mental Health; Child Development; Sociology; Social Work & Social Policy; Clinical Medicine; Educational Evaluation & Assessment; Behavioural Medicine; Psychology; Public Health, Health Services & Primary Care; Diagnostic Sciences; HIV/Aids; Blood Tests; Education

Contact Details

NIDA
6001 Executive Boulevard
Rockville, MD 20852
Tel: +1 301 443 6504
Email: lopezmar@mail.nih.gov
NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R21): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites Aids-related applications for its grants on neuroimmune signalling and function in substance abuse disorders (R21). This Aids-related R21 funding opportunity announcement aims to examine the molecular, cellular, circuit and behavioural responses to neuroimmune signalling within the central nervous system. Research should pertain to the initiation, escalation and maintenance of the neurological consequences resulting from substance use disorders and to abstinence, withdrawal and relapse. The goal is to determine the extent to which neuroimmune responses contribute to or protect against the risk and consequences of SUDs.

This FOA will use the R21 exploratory/developmental research grant mechanism, and runs in parallel with an FOA of identical scientific scope, PA-14-084, which encourages applications under the R01 research project grant mechanism.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Ref: PAR-14-083.

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm proposers’s local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 05 Feb 14

Award type: Directed grants to institutions, research groups etc

Award amount max: $275,000

Website:

Application form:
http://www.grants.gov/web/grants/applicant
s/download-application-package.html#download=true&oppNum=PA-14-083

Eligibility profile

Country of applicant institution: Any

Disciplines

Public Health, Health Services & Primary Care; Primary Care; Cell & Developmental Biology; Pathology; Neurosciences; Biological Sciences; Behavioural Medicine; Psychology; Ethology; HIV/AIDS; Diagnostic Sciences; Drug & Substance Abuse; Biochemistry & Molecular Biology; Cytopathology

Contact Details

NIDA
6001 Executive Boulevard
Bethesda, MD 20892-9561
Tel: +1 301 443 3205
Email: rsorense@mail.nih.gov
NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites Aids-related applications for its grants on neuroimmune signalling and function in substance abuse disorders (R01). This Aids-related R01 funding opportunity announcement aims to examine the molecular, cellular, circuit and behavioural responses to neuroimmune signalling within the central nervous system. Research should pertain to the initiation, escalation and maintenance of the neurological consequences resulting from substance use disorders and to abstinence, withdrawal and relapse. The goal is to determine the extent to which neuroimmune responses contribute to or protect against the risk and consequences of SUDs.

This FOA will use the R01 research project grant mechanism, and runs in parallel with an FOA of identical scientific scope, PA-14-083, which encourages applications under the R21 exploratory/developmental research grant mechanism.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-084.

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 05 Feb 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care; Cell & Developmental Biology; Neuroscience; HIV/AIDS; Cytopathology; Biological Sciences; Psychology; Drug & Substance Abuse; Ethology; Public Health, Health Services & Primary Care; Pathology; Behavioural Medicine; Biochemistry & Molecular Biology; Diagnostic Sciences

Contact Details

NIDA
6001 Executive Boulevard
Bethesda, MD 20892-9561
Tel: +1 301 443 3205
Email: rsorense@mail.nih.gov
SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:
The NIH's National Institute on Drug Abuse invites applications for its drug abuse, risky decision making and HIV/AIDS funding opportunity announcement. This AIDS-related R01 funding opportunity announcement intends to stimulate model driven research that will increase understanding of the way people make decisions about engaging in behaviours that impact the risk of acquiring or transmitting HIV, or to adhere to treatments for HIV. Decision making processes may contribute to both substance use and abuse and other HIV acquisition or transmission risks.

This announcement encourages applications to study cognitive, motivational or emotional mechanisms and brain neuroendocrine and reinforcement systems that relate to HIV-risk behaviors or treatment non-compliance. Interdisciplinary studies that incorporate approaches from psychology, economics, anthropology, sociology, decision sciences, neuroscience and computational modelling are encouraged.

The total project period for an application submitted in response to this funding opportunity announcement may not exceed five years. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. This FOA utilises the NIH R01 research project grant award mechanism and runs in parallel with FOAs of identical scientific scope, PA-14-062, that solicits applications under the R21 mechanism and PA-14-063 that solicits applications under the R03 mechanism.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum funding period is five years.

Ref: PA-14-061 (reissue of PA-11-006)

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 19 Feb 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-061.html

Application form: http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-061

Eligibility profile

Country of applicant institution: Any

Disciplines

Public Health, Health Services & Primary Care; Addiction; Gender Roles & Sexuality; Chemistry; Biological Sciences; Sociology; Psychology; Computer Science & Informatics; Political Risk Factors & Analysis; Toxicology; Pharmacokinetics; Computer Simulation & Modelling; Pharmacy & Pharmacology; Social Work & Social Policy; Drug & Substance Abuse; Neurobiology; Decision Science; Economic & Social Environment; Physiology; Diagnostic Sciences; Clinical Psychology; Neuropharmacology; Medical Sociology; HIV/AIDS

Contact Details

Division of Clinical Neurosciences and Behavior Research
NIDA
RADICATION OF HIV-1 FROM CENTRAL NERVOUS SYSTEM RESERVOIRS (R01)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health, the National Institute of Allergy and Infectious Disease, the National Institute on Drug Abuse and the National Institute of Neurological Disorders and Stroke invite research applications for their eradication of HIV infection of central nervous system reservoirs (R01) grants. This R01 programme announcement aims to address the problem of HIV-1 persistence focused solely on the CNS of persons treated with highly active anti-retroviral therapy. This FOA will support research in the following areas:

- basic research to identify and characterise persistent HIV-1 in CNS derived cells such as macrophages, microglia or astrocytes in the setting of suppressive anti-retroviral therapy, with or without substance use;
- basic research to determine the mechanisms involved in the temporal establishment, maintenance and resurgence of persistent HIV-1 in the CNS in relationship to the timing of antiretroviral therapy;
- development of physiologically relevant animal models and CNS-based cellular assays that recapitulate HIV-1 persistence and latency in the presence of effective HAART including effects of chronic substance use;
- assessment of current and emerging eradication approaches on whether or how well they have successfully reactivated persistent HIV from CNS-derived cells such as macrophages, microglia and astrocytes;
- assessment of CNS toxicity and adverse impacts of current and emerging eradication strategies.

Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PA-14-095.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 12 Feb 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-095.html
Application form:
http://www.grants.gov/web/grants/applicant
s/download-application-
package.html#download=true?oppNum=PA
-14-095

Eligibility profile
Country of applicant institution: Any

Disciplines
Central Nervous System; Neuropsychology; Infectious Diseases; Neurobiology; Preventive Medicine; Cellular Interactions; HIV/AIDS; Neuroimaging; Medical & Diagnostic Tests; Psychology; Nucleus & Organelles;

Pathogenesis; Primary Care; Proteomics & Molecular Interactions; Antivirals; Virology; Human Biological Sciences; Neurology; Biological Sciences; Clinical Medicine; General Practice; Diagnostic Sciences; Public Health, Health Services & Primary Care; Infection Agents & Pathogens; Physiology; Molecular Genetics

Contact Details
NIMH
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 443 6100
Email: jjeymoha@mail.nih.gov

C

LINICAL VISION RESEARCH: RESOURCE CENTRE GRANT (UG1): AIDS-RELATED

NIH: National Eye Institute

Description:
The National Eye Institute invites Aids-related applications for its clinical vision research: resource centre grant (UG1). This Aids-related UG1 funding opportunity announcement supports single component resource centres to provide imaging, laboratory or other requisite services for a multi-centre clinical trial or other complex or high-risk clinical vision research study.

This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-096, which invites applications under the U10 mechanism, and PAR-14-098, PAR-14-099 and PAR-14-100, each of which invites applications under the UG1 mechanism.

US and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-097.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 13 Feb 14
Award type: Research centres, Clinical trials, Directed grants to institutions, research groups etc
Award budget total: -
Clinical Vision Research: Chair's Grant (UG1): AIDS-Related
NIH: National Eye Institute

Description:
The National Eye Institute invites AIDS-related applications for its clinical vision research: chair’s grant (UG1). This AIDS-related UGI funding opportunity announcement supports the scientific rationale, study aims and significance of the research project.

This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-096, which invites applications under the U10 mechanism, and PAR-14-097, PAR-14-099 and PAR-14-100, each of which invites applications under the UGI mechanism.

US and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Ref: PAR-14-098.

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 13 Feb 14
Award type: Research centres, Clinical trials, Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-098.html

Eligibility profile
Country of applicant institution: Any
Disciplines
Optometry; Epidemiology; Diagnostic Sciences; Sensory Systems; Vision Science; Eye Diseases; HIV/Aids; Drug Design; Eye Diseases
CLINICAL VISION RESEARCH: CLINICAL CENTRE GRANT (UG1): AIDS-RELATED
NIH: National Eye Institute

Description:
The National Eye Institute invites AIDS-related applications for its clinical vision research: clinical centre grant (UG1). This AIDS-related UG1 funding opportunity announcement supports the organisation and operations of the clinical centre responsible for recruitment and retention of study participants and implementation of the study protocol.

This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-096, which invites applications under the U10 mechanism, and PAR-14-097, PAR-14-098 and PAR-14-100, each of which invites applications under the UG1 mechanism.

US and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.
Ref: PAR-14-099.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 13 Feb 14
Award type: Research centres, Clinical trials, Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-099.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Epidemiology; Diagnostic Sciences; HIV/Aids; Optometry; Vision Science; Eye Diseases; Sensory Systems; Drug Design

Contact Details
NEI
5635 Fishers Lane
Bethesda, MD 20892-9300
Tel: +1 301 451 2020
Email: everettd@mail.nih.gov
CLINICAL VISION RESEARCH: COORDINATING CENTRE GRANT (UG1): AIDS-RELATED
NIH: National Eye Institute

Description:
The National Eye Institute invites Aids-related applications for its clinical vision research: coordinating centre grant (UG1). This Aids-related UG1 funding opportunity announcement supports the provision of details of the coordinating centre's responsibilities and operations.

This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-096, which invites applications under the U10 mechanism, and PAR-14-097, PAR-14-098 and PAR-14-099, each of which invites applications under the UG1 mechanism.

US and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-100.

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 13 Feb 14

Award type: Research centres, Clinical trials, Directed grants to institutions, research groups etc

Award budget total: -

Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-100.html

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug Design; HIV/Aids; Diagnostic Sciences; Eye Diseases; Vision Science; Optometry; Sensory Systems; Epidemiology

Contact Details

NEI
5635 Fishers Lane
Bethesda, MD 20892-9300
Tel: +1 301 451 2020
Email: everettd@mail.nih.gov

SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO
COUNTERACT THEIR DELETERIOUS EFFECTS (R03): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related call on synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R03). This Aids-related R03 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as
develop prevention strategies and treatment strategies.

This FOA uses the R03 small grant programme grant mechanism and runs in parallel with two FOAs of identical scientific scope, PAR-14-105 and PAR-14-106 which use the R21 exploratory/developmental and R01 research project grant mechanisms respectively.

The combined budget for direct costs for the maximum two year project period may not exceed US$100,000. No more than US$50,000 in direct costs may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.
Ref: PAR-14-014.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 21 Feb 14
Award type: Directed grants to institutions, research groups etc

Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-104.html
Application form: http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-104

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any
Disciplines
---------------------------------------------------------------
HIV/Aids; Diagnostic Sciences; Drug Design; Public Health, Health Services & Primary Care; Psychology; General Practice; Chemistry; Drug & Substance Abuse; Pharmacokinetics; Primary Care; Behavioural Medicine; Clinical Medicine; Methods of Drug Delivery

Contact Details
---------------------------------------------------------------
Tel: +1 301 435 1304
Email: rrapaka@nida.nih.gov

SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R21): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related call on synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R21). This Aids-related R21 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-104 and PA-14-106 which use the R03 small grant and R01 research project grant mechanisms respectively.
The combined budget for direct costs for the maximum two year project period may not exceed US$275,000. No more than US$200,000 may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.

Ref: PA-14-105.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 21 Feb 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000


Eligibility profile
---------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------------
Pharmacokinetics; Primary Care; Public Health, Health Services & Primary Care; Drug Design; HIV/Aids; Chemistry; Methods of Drug Delivery; Drug & Substance Abuse; Behavioural Medicine; Psychology; Clinical Medicine; General Practice; Diagnostic Sciences

Contact Details
---------------------------------------------------------------------
Tel: +1 301 435 1304
Email: rrapaka@nida.nih.gov

SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related call on synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R01). This Aids-related R01 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies.

This FOA uses the R01 research project grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-105 and PA-14-106 which use the R21 exploratory/developmental and R03 small grant mechanisms respectively.

Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.

Ref: PA-14-106.
FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R01): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for its Aids-related call on family-centred self-management of chronic conditions (R01). This Aids-related R01 funding opportunity announcement seeks to build on the science of family-centred self-management in chronic conditions.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-113, which uses the R21 exploratory/developmental research grant mechanism.

Foreign or US for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-14-112.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 25 Feb 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-112.html
Eligibility profile

Country of applicant institution: Any

Disciplines

Social Programmes; Social Work & Social Policy; HIV/Aids; Public Health, Health Services & Primary Care; Chronic Care; Primary Care; Community Health Services

Contact Details

Tel: +1 301 594 5970
Email: hussk@mail.nih.gov

FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R21): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for its Aids-related call on family-centred self-management of chronic conditions (R21). This Aids-related R21 funding opportunity announcement seeks to build on the science of family-centred self-management in chronic conditions.

This FOA uses the R21 exploratory/developmental research grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-112, which uses the R01 research project grant mechanism.

Foreign or US for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-14-113.

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 25 Feb 14

Award type: Directed grants to institutions, research groups etc

Award budget total: -

Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-113.html

Eligibility profile

Country of applicant institution: Any

Disciplines

Social Programmes; Social Work & Social Policy; HIV/Aids; Chronic Care; Public Health, Health Services & Primary Care; Chronic Care; Primary Care; Community Health Services

Contact Details

Tel: +1 301 594 5970
Email: hussk@mail.nih.gov
DESIGN AND DEVELOPMENT OF NOVEL TECHNOLOGIES FOR HEALTHY INDEPENDENT LIVING (R21): AIDS-RELATED
NIH: National Institute of Biomedical Imaging and Bioengineering

Description:
A total of six institutes and offices of the National Institutes of Health invite Aids-related applications for their design and development of novel technologies for healthy independent living (R21) grants. This Aids-related R21 funding opportunity announcement supports the design and development of novel technologies to monitor health or deliver care in a real-time, accessible, effective and minimally obtrusive way. Systems may be novel sensor or monitoring systems, home-use point-of-care devices, home or mobile therapy or rehabilitation tools, or information systems. Systems should also have the goal of fostering healthy and independent living.

This funding opportunity announcement will use the NIH R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-118, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Ref: PAR-14-119 (replaces PAR-11-021).

Closing date: 07 Jan 16
Posted date: 27 Feb 14
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000

Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-119.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Engineering Standards & Specifications; Home Health Care Services; Health Systems, Administration; Scientific Instrumentation; Biological Sciences; Diagnostic Sciences; Innovation & Technology Management; Community Health Services; Assistive Technology; Biotechnology; Health Systems, Consumer Choice ; Biological Markers & Sensor Mechanisms; HIV/Aids; Research Management

Contact Details
----------------------------------------------
NIBIB
Tel: +1 301 402 1337
Email: rodgersmm@mail.nih.gov
TECHNOLOGIES FOR HEALTHY INDEPENDENT LIVING (R01): AIDS-RELATED
NIH: National Institute of Biomedical Imaging and Bioengineering

Description:
A total of six institutes and offices of the National Institutes of Health invite Aids-related applications for their technologies for healthy independent living (R01) grants. This Aids-related R01 funding opportunity announcement supports research and development of technologies to monitor and deliver healthcare in a real-time, accessible, effective and minimally obtrusive way. Systems should integrate, process, analyse communicate and present data in order to engage individuals and empower them in their own healthcare.

This funding opportunity announcement will use the NIH R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-119, which solicits applications under the R21 exploratory/developmental research grant award mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years. Ref: PAR-14-118 (replaces PAR-11-020).

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm proposer’s local time. Deadlines on: 7 January 2015, 7 January 2016, 7 January 2017. Posted date: 27 Feb 14

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award budget total: -

Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-118.html

Eligibility profile

Country of applicant institution: Any

Disciplines

Health Systems, Consumer Choice; Engineering Standards & Specifications; Biological Markers & Sensor Mechanisms; Home Health Care Services; Biotechnology; Diagnostic Sciences; HIV/Aids; Biological Sciences; Community Health Services; Scientific Instrumentation; Innovation & Technology Management; Assistive Technology; Research Management; Health Systems, Administration

Contact Details

NIBIB
Tel: +1 301 402 1337
Email: rodgersmm@mail.nih.gov
Description:
The National Institute on Alcohol Abuse and Alcoholism invites AIDS-related applications for its alcohol-induced effects on tissue injury and repair (R21) grants. This AIDS-related R21 funding opportunity announcement supports the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. The NIAAA is especially interested in integrative research that elucidates alcohol’s effects on complex mechanisms of injury and repair that are either common or specific to each organ system. The call also encourages the study of alcohol’s effect on stem cells, embryonic development and regeneration, as well as the studies on molecular and cellular actions of moderate alcohol consumption.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-123, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PA-14-124.

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: $275,000

Website:

Application form:

Eligibility profile

Country of applicant institution: Any

Disciplines

Pathophysiology; Regenerative Medicine; Diagnostic Sciences; Stem Cell; Stem Cell Genomics; Cytopathology; Biological Sciences; Traumatology, Accidents & Injury; Embryonic Stem Cells; HIV/AIDS; Pathology; Alcoholism; Cellular Interactions; Stem Cell Therapy; Foetal Health & Prenatal Development; Induced Pluripotent Stem Cells

Contact Details

Tel: +1 301 443 7351
Email: duntyw@mail.nih.gov
Advancing Structural Level Interventions Through Enhanced Understanding of Social Determinants in HIV Prevention and Care (R21)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Disease invite applications for their advancing structural level interventions through enhanced understanding of social determinants in HIV prevention and care (R21) grants. This R21 funding opportunity announcement aims to understand and address social determinants associated with the prevention and treatment of HIV. This FOA supports two research endeavours:

- characterising the social determinants that are most relevant to HIV prevention and treatment outcomes, particularly in association with inequities in HIV risk or outcomes;
- developing and testing structural interventions aimed at reducing the negative impact or maximising positive aspects of social determinants.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-133, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PA-14-134.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm, local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-134.html
Application form: http://www.grants.gov/web/grants/applicant/s/download-application-package.html#download=true&oppNum=PA-14-134

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Biomedical Engineering; HIV/AIDS; Primary Care; Public Health, Health Services & Primary Care; Diagnostic Sciences; Health Disparities; Preventive Medicine

Contact Details
---------------------------------------------------------------
NIMH
NSC BG RM 6117
6001 Executive Blvd
Rockville MD 20852
Tel: +1 301 443 8962
Email: grossmanc@mail.nih.gov
IMPROVING DELIVERY OF HIV PREVENTION AND TREATMENT THROUGH IMPLEMENTATION SCIENCE AND TRANSLATIONAL RESEARCH (R21)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their improving delivery of HIV prevention and treatment through implementation science and translational research (R21) grant. This R21 funding opportunity announcement encourages research designed to increase the public health impact of efficacious HIV/Aids-related interventions for prevention and treatment.

The goals of this scientific agenda are to learn how best to deliver interventions more efficiently and effectively in real-world communities and clinics, to more readily transfer interventions from one setting or population to another, and to make better informed choices for combination intervention packages.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-131, which solicits applications under the R01 research project grant mechanism.

Direct costs are limited to US$275,000 over a two year project period, with no more than US$200,000 allowed in any single year. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions.

Ref: PA-14-129.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-129.html


Eligibility profile

Country of applicant institution: Any

Disciplines
HIV/Aids; Primary Care; Pharmaceutical Drugs; Health Counselling; Public Health; Psychology; Diagnostic Sciences; Preventive Medicine; Clinical Medicine; Social Work & Social Policy; Population Studies, Medical; Public Health, Health Services & Primary Care; Biomedical Engineering; General Practice

Contact Details
NIMH
NSC BG
Room 6106
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 1613
Email: cgordon1@mail.nih.gov
STRENGTHENING ADHERENCE TO ANTIRETROVIRAL-BASED HIV TREATMENT AND PREVENTION (R21)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their strengthening adherence to antiretroviral-based HIV treatment and prevention (R21) grant. This R21 funding opportunity announcement supports research to understand and promote adherence to antiretroviral regimens for HIV treatment and prevention. Studies addressing pre-exposure prophylaxis and antiretroviral therapy are the foci of this FOA. The emphasis is on the development of feasible interventions to improve and sustain PrEP or ART adherence, which could be rapidly implemented to improve HIV treatment and prevention outcomes.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-126, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PA-14-125.

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm, local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: $275,000

Website:

Application form:
http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-125

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine; Virology; Preventive Medicine; HIV/AIDS; Public Health, Health Services & Primary Care; Diagnostic Sciences; Primary Care; Antivirals; General Practice

Contact Details

NIMH
NSC BG
Room 6116
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6802
Email: stirrattm@mail.nih.gov
A

ACCELERATING IMPROVEMENTS IN THE HIV CARE CONTINUUM (R21)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their strengthening adherence to antiretroviral-based HIV treatment and prevention (R21) grant. This R21 funding opportunity announcement supports innovative studies to address gaps in HIV care continuum research. Research should focus on less-studies aspects of entering and remaining in HIV care.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-132, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PA-14-130.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm, local time of applicant organisation,
every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-130.html
Application form: http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-130

Eligibility profile
Country of applicant institution: Any

Disciplines
Standards of Care; Access to Health Care; Diagnostic Sciences; HIV/Aids; Quality of Care; Primary Care; Public Health, Health Services & Primary Care; Health Systems, Consumer Choice ; Clinical Medicine; Blood Tests

Contact Details
Tel: +1 301 443 1613
Email: cgordon1@mail.nih.gov

A

ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites Aids-related applications for its alcohol-induced effects on tissue injury and repair (R01) grants. This Aids-related R01 funding opportunity announcement supports


the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. The NIAAA is especially interested in integrative research that elucidates alcohol’s effects on complex mechanisms of injury and repair that are either common or specific to each organ system. The call also encourages the study of alcohol’s effect on stem cells, embryonic development and regeneration, as well as the studies on molecular and cellular actions of moderate alcohol consumption.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-124, which solicits applications under the R21 exploratory/developmental grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.
Ref: PA-14-123.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-123.html

Application form: http://www.grants.gov/web/grants/applicant s/download-application-package.html#download=true&oppNum=PA-14-123

Eligibility profile

Country of applicant institution: Any

Disciplines

Traumatology, Accidents & Injury; Diagnostic Sciences; Induced Pluripotent Stem Cells; Cellular Interactions; Stem Cell Therapy; Pathology; Regenerative Medicine; Alcoholism; Cytopathology; Biological Sciences; Stem Cell; Pathophysiology; HIV/Aids; Embryonic Stem Cells; Stem Cell Genomics; Foetal Health & Prenatal Development

Contact Details

Tel: +1 301 443 7351
Email: dunityw@mail.nih.gov

ADVANCING STRUCTURAL LEVEL INTERVENTIONS THROUGH ENHANCED UNDERSTANDING OF SOCIAL DETERMINANTS IN HIV PREVENTION AND CARE (R01)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Disease invite applications for their advancing structural level interventions through enhanced understanding of social determinants in HIV prevention and care (R01) grants. This R01 funding opportunity announcement aims to understand and address social determinants associated with
the prevention and treatment of HIV. This FOA supports two research endeavours:

- characterising the social determinants that are most relevant to HIV prevention and treatment outcomes, particularly in association with inequities in HIV risk or outcomes;
- developing and testing structural interventions aimed at reducing the negative impact or maximising positive aspects of social determinants.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-134, which solicits applications under the R21 exploratory/developmental grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Ref: PA-14-133.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm, local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2017.

IMPROVING DELIVERY OF HIV PREVENTION AND TREATMENT THROUGH IMPLEMENTATION SCIENCE AND TRANSLATIONAL RESEARCH (R01)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their improving delivery of HIV prevention and treatment through implementation science and translational research (R01) grant. This R01 funding opportunity announcement

Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Preventive Medicine; Primary Care; Diagnostic Sciences; Public Health, Health Services & Primary Care; Biomedical Engineering; Health Disparities; HIV/AIDS

Contact Details
----------------------------------------------
NIMH
NSC BG RM 6117
6001 Executive Blvd
Rockville MD 20852
Tel: +1 301 443 8962
Email: grossmanc@mail.nih.gov
encourages research designed to increase the public health impact of efficacious HIV/AIDS-related interventions for prevention and treatment.

The goals of this scientific agenda are to learn how best to deliver interventions more efficiently and effectively in real-world communities and clinics, to more readily transfer interventions from one setting or population to another, and to make better informed choices for combination intervention packages.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-129, which solicits applications under the R21 exploratory/developmental grant mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions.

Ref: PA-14-131.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 03 Mar 14

TRENGTHENING ADHERENCE TO ANTIRETROVIRAL-BASED HIV TREATMENT AND PREVENTION (R01)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their strengthening adherence to antiretroviral-based HIV treatment and

Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://www.grants.gov/web/grants/applicant/download-application-package.html#download=true&oppNum=PA-14-131

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Biomedical Engineering; Clinical Medicine; HIV/Aids; Population Studies, Medical; Psychology; Public Health; General Practice; Diagnostic Sciences; Health Counselling; Primary Care; Public Health, Health Services & Primary Care; Pharmaceutical Drugs; Preventive Medicine; Social Work & Social Policy

Contact Details
----------------------------------------------
NIMH
NSC BG
Room 6106
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 1613
Email: cgordon1@mail.nih.gov
A compilation of the Research Services of the Office of Research, Innovation & Development (ORID)
focus on less-studies aspects of entering and remaining in HIV care.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-130, which solicits applications under the R21 exploratory/developmental grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Ref: PA-14-132.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc

Award budget total: -
Website: http://grants.nih.gov/grants/guide/px- files/PA-14-132.html

Application form: http://www.grants.gov/web/grants/applicant s/download-application- package.html#download=true&oppNum=PA-14-132

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
HIV/Aids; Primary Care; Health Systems, Consumer Choice; Diagnostic Sciences; Quality of Care; Clinical Medicine; Access to Health Care; Public Health, Health Services & Primary Care; Standards of Care; Blood Tests

Contact Details
----------------------------------------------
Tel: +1 301 443 1613
Email: cgordon1@mail.nih.gov

PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R34): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related grants on the prevention and treatment of substance using populations with or at risk for hepatitis C virus (R34). This Aids-related R34 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing infections more effectively. This FOA supports the initial development of a clinical trial or research project focused on HCV for at-risk substance using populations, including those with or at risk for HIV.

This FOA uses the R34 planning grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-136 and PA-14-137, which use the R21 exploratory/developmental grant mechanism and the R01 research project grant mechanisms respectively.
The combined budget for direct costs for the maximum three year project period may not exceed US$450,000. No more than US$225,000 may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations. Ref: PA-14-135.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 04 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $450,000
Website:
Application form:
http://www.grants.gov/web/grants/applicant-s/download-application-

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Primary Care; Infection Agents & Pathogens; Drug & Substance Abuse; Public Health, Health Services & Primary Care; Diagnostic Sciences; HIV/AIDS; General Practice; Drug Design; Infectious Diseases; Preventive Medicine; Hepatology

Contact Details
----------------------------------------------
NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 443 3207
Email: aklinwm@nida.nih.gov

PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R21): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related grants on the prevention and treatment of substance using populations with or at risk for hepatitis C virus (R21). This Aids-related R21 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing infections more effectively. This FOA supports the initial development of a clinical trial or research project focused on HCV for at-risk substance using populations, including those with or at risk for HIV.

This FOA uses the R21 exploratory/developmental grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-135 and PA-14-137, which use the R34 planning grant mechanism and the R01 research project grant mechanisms respectively.

The combined budget for direct costs for the maximum two year project period may not exceed US$275,000. No more than US$200,000 may be requested in any single year.
Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.

Ref: PA-14-136.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 04 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care; Public Health, Health Services & Primary Care; Drug & Substance Abuse; Preventive Medicine; Hepatology; Infection Agents & Pathogens; Diagnostic Sciences; HIV/Aids; Drug Design; General Practice; Infectious Diseases

Contact Details

NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 443 3207
Email: aklinwm@nida.nih.gov

EUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites Aids-related applications for its grants on neuroimmune mechanisms of alcohol-related disorders (R21). This Aids-related R21 funding opportunity announcement seeks studies to address the role of neuroimmune modulation in response to and in the neuroadaptation of the brain to acute and chronic alcohol exposure, and alcohol dependence and withdrawal. The goal is to achieve fundamental insights of neuroimmune mechanisms underlying brain functional and behavioural changes induced by alcohol.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-139 which uses the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.
Ref: PA-14-138.
Description:
The National Institute on Drug Abuse invites applications for its Aids-related grants on the prevention and treatment of substance using populations with or at risk for hepatitis C virus (R01). This Aids-related R01 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing infections more effectively. This FOA supports the initial development of a clinical trial or research project focused on HCV for at-risk substance using populations, including those with or at risk for HIV.

This FOA uses the R01 research project grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-135 and PA-14-136, which use the R34 planning grant mechanism and the R21 exploratory/developmental grant mechanisms respectively.

Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.

Ref: PA-14-137.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 04 Mar 14

Disciplines

- Neurology; Clinical Medicine; HIV/AIDS;
- Immunology; Biological Sciences; Behavioural Medicine; Neuroscience; Neuropsychology;
- Neuroendocrinology; Psychology;
- Neurobiology; Alcoholism; Endocrine & Neuroendocrine Cancers; Diagnostic Sciences;
- Ethology

Contact Details

NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 443 1678
Email: changhai.cui@nih.gov

PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-137.html

Application form: http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-137

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Public Health, Health Services & Primary Care; Drug Design; Infectious Diseases; Hepatology; Drug & Substance Abuse; HIV/AIDS; Preventive Medicine; Diagnostic Sciences; Infection Agents & Pathogens; Primary Care; General Practice

Contact Details
----------------------------------------------
NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 443 3207
Email: aklinwm@nida.nih.gov

EUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites Aids-related applications for its grants on neuroimmune mechanisms of alcohol-related disorders (R01). This Aids-related R01 funding opportunity announcement seeks studies to address the role of neuroimmune modulation in response to and in the neuroadaptation of the brain to acute and chronic alcohol exposure, and alcohol dependence and withdrawal. The goal is to achieve fundamental insights of neuroimmune mechanisms underlying brain functional and behavioural changes induced by alcohol.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Ref: PA-14-139 (re-issue of PA-11-064).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 04 Mar 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-139.html
C O M M U N I T Y  P A R T N E R S H I P S  T O  A D V A N C E  R E S E A R C H  ( R 2 1 ) :  A I D S - R E L A T E D

NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites Aids-related applications for its community partnerships to advance research (R21). This Aids-related R21 funding opportunity announcement encourages researchers to partner with communities using community engaged research methodologies that will enhance relationships leading to better interventions and positive health outcomes.

This funding opportunity announcement will use the NIH R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-142, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Ref: PAR-14-141.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 05 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:

Application form:
http://www.grants.gov/web/grants/applicant
s/download-application-package.html#download=true&oppNum=P A-14-141
COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R01): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites Aids-related applications for its community partnerships to advance research (R01). This Aids-related R01 funding opportunity announcement encourages researchers to partner with communities using community engaged research methodologies that will enhance relationships leading to better interventions and positive health outcomes.

This funding opportunity announcement will use the NIH R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-141, which solicits applications under the R21 exploratory/developmental research grant award mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-142.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 05 Mar 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Website: http://grants.nih.gov/grants/guide/announcements/PA-14-142.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Translational Medicine; Medical Research of Selected Fields; Clinical Medicine; Nursing;
E
STABLISHING BEHAVIOURAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R21): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites Aids-related applications for its grants on establishing behavioural and social measures for causal pathway research in dental, oral and craniofacial health (R21). This Aids-related R21 funding opportunity announcement aims to establish measures of specific behavioural or social phenomena to test causal hypotheses about behavioural and social contributors to dental, oral or craniofacial diseases. This announcement encourages the development and testing of two types of measures:

- measures of the health behaviours, social interactions, community characteristics, built environments, targeted by behavioural or social interventions to improve oral health;
- measures of the hypothesised moderators and mediators of a behavioural or social intervention's effect.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-143, which uses the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions may apply.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Ref: PAR-14-144.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 06 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-144.html
Application form: http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=P AR-14-144

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
E
S
T
A
B
L
I
S
H
I
N
G
B
E
H
A
V
I
O
R
U
A
L
A
N
D
S
O
C
A
L
M
E
A
S
U
R
E
S
F
O
R
C
A
U
S
A
L
P
A
T
H
W
A
Y
R
E
S
E
A
R
C
H
I
N
D
T
A
N,
O
R
A
L
A
N
D
C
R
A
N
I
O
F
A
C
C
A
L
H
E
A
L
T
H
R
E
A
P
S
I
O
N
G
R
0
1:
A
I
D
S-
R
E
L
A
R
E
D
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites Aids-related applications for its grants on establishing behavioural and social measures for causal pathway research in dental, oral and craniofacial health (R01). This Aids-related R01 funding opportunity announcement aims to establish measures of specific behavioural or social phenomena to test causal hypotheses about behavioural and social contributors to dental, oral or craniofacial diseases. This announcement encourages the development and testing of two types of measures:

- measures of the health behaviours, social interactions, community characteristics, built environments, targeted by behavioural or social interventions to improve oral health;
- measures of the hypothesised moderators and mediators of a behavioural or social intervention’s effect.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-144, which uses the R21 exploratory/developmental grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.
Ref: PAR-14-143.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 06 Mar 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/ps-files/PAR-14-143.html

Application form: http://www.grants.gov/web/grants/applicants/download-application-
R01:

**ARLY STAGE DEVELOPMENT OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01): AIDS-RELATED**

**NIH: National Institute of General Medical Sciences**

**Description:**

A total of 12 institutes and offices of the National Institutes of Health invite applications for their Aids-related grants on early stage development of technologies in biomedical computing, informatics and big data science (R01). This Aids-related R01 funding opportunity announcement aims to promote a broad base of research and development of technologies in biomedical computing, informatics and big data science that will support rapid progress in areas of scientific opportunity in biomedical research. Applications should develop enabling technologies that could apply to the interests of most NIH institutes and centres and range from basic biomedicine and including research to all relevant organ systems and diseases.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

Application budgets may not exceed US$300,000 direct costs per year, over a maximum project period of three years.

Ref: PA-14-155.

**Closing date: 07 Jan 16**

**Deadline information:** Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.

**Posted date:** 17 Mar 14

**Award type:** Prototypes and demonstrations, Directed grants to institutions, research groups etc

**Award amount max:** $900,000

**Website:**


**Application form:**

http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-155

**Contact Details**

NIDCR
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 451 3888
Email: riddleme@mail.nih.gov

Country of applicant institution: Any

**Disciplines**

Psychology; Preventive Dentistry; HIV/Aids; Medical Education; Behavioural Medicine; Oral & Maxillofacial Surgery; Restorative Dentistry; Dentistry; Oral Medicine; Craniofacial Disorders; Public Health, Health Services & Primary Care; Paediatric Dentistry; Dental Health & Hygiene; Special Needs Dentistry; Primary Care
EXTENDED DEVELOPMENT, HARDENING AND DISSEMINATION OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01): AIDS-RELATED

NIH: National Institute of General Medical Sciences

Description:
A total of 12 institutes and offices of the National Institutes of Health invite applications for their AIDS-related grants on extended development, hardening and dissemination of technologies in biomedical computing, informatics and big data science (R01). This AIDS-related R01 funding opportunity announcement supports the extended development, maintenance, testing, evaluation, hardening and dissemination of existing biomedical software. The scheme aims to promote a broad base of research and development of technologies in biomedical computing, informatics and big data science that will support rapid progress in areas of scientific opportunity in biomedical research. Applications should develop enabling technologies that could apply to the interests of most NIH institutes and centres and range from basic biomedicine and including research to all relevant organ systems and diseases.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-14-156.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 17 Mar 14
Award type: Technology innovation/development, Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-156.html

Application form:
http://www.grants.gov/web/grants/applicant/package.html#download=true&oppNum=PA-14-156
Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Biotechnology; Health Informatics; HIV/Aids; Computer Science & Informatics; Research Management; Engineering Standards & Specifications; Bioinformatics; Innovation & Technology Management; Biomolecular Modelling; Therapy Evaluation; Diagnostic Sciences; Biological Sciences; Informatics & Big Data; Disease Control

Contact Details
----------------------------------------------
NIGMS
45 Center Drive
Bethesda, MD 20814
Tel: +1 301 451 6446
Fax: lysterp@mail.nih.gov

TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R21): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering invite applications for their Aids-related call on translational research to help older adults maintain their health and independence in the community (R21). This Aids-related R21 funding opportunity announcement supports translational research collaborations between academic research centres and community-based organisations with expertise in serving or engaging older adults to develop tools, techniques, programmes or policies to respond to the needs of the ageing population.

This FOA uses the R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-161, which solicits applications under the R01 research project grant mechanism.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Ref: PAR-14-159 (replaces PAR-11-124).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 21 Mar 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: £275,000
Website:

Application form:
http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true?oppNum=PA-14-159
Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Geriatrics & Gerontology; Home Health Care Services; HIV/AIDS; Social Programmes; Psychology of Ageing; Social Work & Social Policy; Public Health, Health Services & Primary Care; Accessibility for Disabled People; Primary Care; Psychology; Access to Health Care; Health Systems Policy

Contact Details
----------------------------------------------
NIA
7201 Wisconsin Avenue
Bethesda, MD 20814
Tel: +1 301 402 4156
Email: kingjo@nia.nih.gov

TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R01): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering invite applications for their Aids-related call on translational research to help older adults maintain their health and independence in the community (R01). This Aids-related R01 funding opportunity announcement supports translational research collaborations between academic research centres and community-based organisations with expertise in serving or engaging older adults to develop tools, techniques, programmes or policies to respond to the needs of the ageing population.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-159, which solicits applications under the R21 exploratory/developmental research grant award mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-161 (replaces PAR-11-123).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 21 Mar 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-161.html
Application form: http://www.grants.gov/web/grants/applicantpackage.html#download=true?oppNum=PA-14-161

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R21): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related call on the effects of cannabis use and cannabinoids on the developing brain (R21). This Aids-related R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans.

This FOA uses the R21 exploratory/developmental grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-163 and PA-14-164, which use the R01 research project grant mechanism and the R03 small research grant mechanism respectively.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Ref: PA-14-162.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 27 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-162.html


Eligibility profile
Country of applicant institution: Any

Disciplines
Pharmacokinetics; Cognitive Processes; Drug & Substance Abuse; Neuroscience; Neurology; Psychology; Primary Care; Diagnostic Sciences; HIV/Aids; Public Health, Health Services & Primary Care; Central Nervous System
EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R03): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related call on the effects of cannabis use and cannabinoids on the developing brain (R03). This Aids-related R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans.

This FOA uses the R03 small research grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-162 and PA-14-163, which use the R21 exploratory/developmental grant mechanism and the R01 research project grant mechanism respectively.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Direct costs are limited to US$100,000 over a two-year project period, with no more than US$50,000 in any year.
Ref: PA-14-164.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 27 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/px- files/PA-14-164.html


Eligibility profile
Country of applicant institution: Any

Disciplines
Central Nervous System; Cognitive Processes; Psychology; Pharmacokinetics; HIV/AIDS; Neuroscience; Public Health, Health Services & Primary Care; Diagnostic Sciences; Neurology; Primary Care; Drug & Substance Abuse

Contact Details
NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 435 4649
Email: wudy@mail.nih.gov
EFFECTS OF CANNABIS USE AND CANNABINOIDs ON THE DEVELOPING BRAIN (R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related call on the effects of cannabis use and cannabinoids on the developing brain (R01). This Aids-related R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans.

This FOA uses the R01 research project grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-162 and PA-14-164, which use the R21 exploratory/developmental grant mechanism and the R03 small research grant mechanism respectively.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. Ref: PA-14-163.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 27 Mar 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-163.html


Eligibility profile
Country of applicant institution: Any

Disciplines
Diagnostic Sciences; Psychology; Drug & Substance Abuse; HIV/Aids; Neuroscience; Neurology; Cognitive Processes; Central Nervous System; Primary Care; Public Health, Health Services & Primary Care; Pharmacokinetics

Contact Details
NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 435 4649
Email: wudy@mail.nih.gov
CLINICAL TRIAL PLANNING GRANT FOR INTERVENTIONS AND SERVICES TO IMPROVE TREATMENT AND PREVENTION OF HIV/AIDS (R34)

NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their clinical trial planning grant for interventions and services to improve treatment and prevention of HIV/AIDS. This R34 funding opportunity supports efforts to prevent acquisition and transmission of HIV infection, or to improve treatment and care for persons who are HIV infected, or both. Priority areas and potential research topics include:

- research to develop and test the feasibility and acceptability of integrated prevention and/or treatment strategies to improve clinical outcomes within target populations;
- novel approaches to maximise HIV testing, linkage to care, retention, and durable viral suppression;
- behavioural or service interventions that initiate, sustain, and restore adherence to recommended HIV care or regimens;
- studies that elucidate information about barriers and needs of populations who have difficulty engaging in and sustaining treatment and prevention care;
- interventions that promote effective utilisation of health services;
- acceptability or feasibility studies that inform drug development or that complement an ongoing efficacy or effectiveness trial of an experimental strategy or intervention;
- challenges and the implementation of multiple prevention methods;
- approaches that sustain engagement in care among people living with HIV and other serious co-morbidities or co-infections.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Direct costs are limited to US$450,000 over the project period, with no more than US$225,000 available in any single year. The maximum project period is three years.
Ref: PA-14-179.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time every 7 May, 7 September and 7 January until 8 January 2017.
Posted date: 23 Apr 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $450,000
Website: http://grants.nih.gov/grants/guide/ann-files/PA-14-179.html#_Section_VII_Agency

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
HIV/Aids; Public Health; Biomedical Engineering; Diagnostic Sciences; Blood Tests; Preventive Medicine; Public Health, Health Services & Primary Care; Patient Care & Education; Pharmaceutical Drugs; Clinical Medicine

Contact Details
----------------------------------------------
NIH: National Institutes of Health
6701 Rockledge Drive, Room 1040 - MSC 7710
Bethesda, MD 20892-7710
Tel: +1 301 451 7324
HEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R21): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
A total of two institutes and offices of the NIH invite AIDS-related applications for their mHealth tools to promote effective patient-provider communication, adherence to treatment and self-management of chronic diseases in underserved populations R21 grants. The purpose of this R21 AIDS-related funding opportunity announcement is to stimulate research utilizing mobile health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases in underserved populations.

This funding opportunity announcement will utilise the NIH research project grant R21 mechanism and runs in parallel with another FOA of identical scientific scope: PA-14-180 that solicits applications under the research project grant (R01) funding mechanism. The combined budget for direct costs for the two year project period may not exceed US$275,000 and no more than US$200,000 may be requested in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-14-181 (Reissue of PA-11-332).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 23 Apr 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Assistive Technology; Medical & Diagnostic Tests; Patient Care & Education; Primary Care; Public Health, Health Services & Primary Care; Social Work & Social Policy; Clinical Medicine; 5G, Wireless & Mobile Networks; Health Economics; Chronic Care; Rural Health; HIV/AIDS; Social Programmes; Pharmaceutical Drugs; Computer Science & Informatics

Contact Details
----------------------------------------------
Tel: +1 301 594 5971
Email: mccloskd@mail.nih.gov
HEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R01) AIDS-RELATED

NIH: National Institute of Nursing Research

Description:
A total of two institutes and offices of the NIH invite applications for their Aids-related mHealth tools for individuals with chronic conditions to promote effective patient-provider communication, adherence to treatment and self-management (R01) grants. The purpose of this Aids-related R01 funding opportunity announcement is to stimulate research utilising mobile health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases in underserved populations.

This funding opportunity announcement will utilise the NIH research project grant R01 mechanism and runs in parallel with another FOA of identical scientific scope: PA-14-181 that solicits applications under the exploratory/developmental grant (R21) funding mechanism. Application budgets are not limited, but need to reflect actual needs of the proposed project. The total project period is a maximum of five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-14-180 (Reissue of PA-11-330).

Closing date: 07 Jan 16

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 23 Apr 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/PA-14-180.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Pharmaceutical Drugs; Primary Care; Medical & Diagnostic Tests; Information Systems; Clinical Medicine; Electrical & Electronic Engineering; Screening for Diseases; Health Economics; Chronic Care; HIV/AIDS; 5G, Wireless & Mobile Networks; Patient Care & Education; Computer Science & Informatics; Public Health, Health Services & Primary Care; Assistive Technology; Rural Health

Contact Details
Tel: +1 301 594 5971
Email: mccloskd@mail.nih.gov

EXPORATORY CLINICAL TRIALS OF MIND AND BODY INTERVENTIONS FOR NCCAM HIGH PRIORITY RESEARCH TOPICS (R34) AIDS-RELATED

NIH: National Center for Complementary and Integrative Health

Description:
The National Center for Complementary and Alternative Medicine (NCCAM) invites Aids-related applications for its exploratory clinical trials of mind and body interventions for NCCAM high priority research topics (R34).
The goal of this R34 Aids-related funding opportunity is to support early phase clinical trials of mind and body approaches for conditions that have been identified by NCCAM as high priority research topics.

Priority areas include:

- the mind and body or integrated approach, including spinal manipulation, mobilisation, massage, tai chi, qi gong, yoga, acupuncture, hypnosis, guided imagery, light therapy, breathing activity, progressive relaxation, meditation, biofeedback, or mindfulness techniques;
- symptom management for chronic pain syndromes, reduction of prescription drug use or abuse in patients with chronic pain, medication adherence, post-traumatic stress, traumatic brain injury, sleep disorders or disturbances, anxiety, depression, promotion of psychological resilience, weight loss and weight loss maintenance, smoking cessation and promotion of healthy eating and physical activity.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Proposals may request up to $450,000 over a maximum of three years.
Ref: PA-14-182.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm applicant’s local time. Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.

Posted date: 23 Apr 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $450,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-182.html#_Section_III._Eligibility

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse; Anxiety Disorders; Exercise Physiology; Experimental Psychology; Clinical Medicine; Pharmacy & Pharmacology; Psychology; Post Traumatic Stress Disorder; Health Counselling; Chronic Pain; Sports & Exercise Studies; Stress, Psychological; Smoking & Tobacco; Clinical Pharmacy & Pharmacology; Psychobiology; Traumatology, Accidents & Injury; Nutrition & Dietetics; HIV/AIDS; Chronic Care; Cognitive & Behavioural Therapies; Social Work & Social Policy; Folk, Complementary & Alternative Medicine; Health Promotion; Mental Health; Allied Health Professions; Public Health, Health Services & Primary Care; Pharmaceutical Drugs; Stress, Biological; Addiction; Depression & Other Mood Disorders; Sports Psychology; Sleep & Sleep Disorders; Diagnostic Sciences; Pain Management

Contact Details

Tel: +1 301 402 1272
Email: weberwj@mail.nih.gov
UNCONVENTIONAL ROLES OF ETHANOL METABOLISING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its AIDS-related unconventional roles of ethanol metabolising enzymes, metabolites and cofactors in health and disease (R01) funding opportunity announcement. This AIDS-related announcement provides support for integrated, innovative research on the novel and unconventional contributions of ethanol metabolising pathways, their metabolites, cofactors and interactions with synergising biological pathways in the development of alcohol-induced diseases and end organ injuries.

The aim is to generate data that leads to breakthroughs in identification and understanding of key cellular and molecular components in the initiation, progression and maintenance of the diverse medical disorders caused by excessive or long term alcohol consumption. The generated knowledge should enable clinicians to improve disease outcomes and consequently, public health. Research areas include the following: ethanol and NAD+; ethanol and acetate; ethanol and SAM; ethanol and zinc; endogenous substrates and functions of alcohol metabolising pathways - regulation of growth, development and disease.

This announcement uses the R01 research project grant mechanism and runs in parallel with one of identical scientific scope, PA-15-057, which encourages applications under the R21 exploratory or developmental grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years.
Ref: PA-15-058 (reissue of PA-14-198).

Closing date: 07 Jan 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 09 Dec 14
Award type: Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration
Award budget total: -

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Alcoholic Beverages; Alcoholism; HIV/Aids; Cell Physiology & Metabolism; Addiction; Hepatology

Contact Details
----------------------------------------------
NIAAA
Building 5635FL, Room 2119
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 443 2193
Email: orosza@mail.nih.gov
NK CELLS TO INDUCE IMMUNOLOGICAL MEMORY TO PREVENT HIV INFECTION (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites application for its natural killer cells to induce immunological memory to prevent HIV infection (R01) grants. The purpose of this R01 funding opportunity is to support multidisciplinary, hypothesis-driven research on NK cells, leading to the discovery of pathways relevant for early immune responses and immune regulation impacting the potential protective immunity to be induced by HIV vaccination. Secondary objectives include the development of novel technologies to allow for more definitive studies of human immune monitoring in the context of vaccine clinical trials and the recruitment of innate immunologists to the HIV vaccine field.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PA-14-217

Closing date: 07 Jan 16

Deadline information: Deadlines every 7 September, 7 January and 7 May until 8 January 2017.
Posted date: 13 May 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-217.html

Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Virology; Immunology; Clinical Medicine; HIV/AIDS; Immunisation Programmes & Vaccination; Diagnostic Sciences

Contact Details
Tel: +1 240 627 3038
Email: cesar.boggiano@nih.gov

Fc RECEPTOR AND ANTIBODY EFFECTOR FUNCTION IN HIV VACCINE DISCOVERY (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites application for its Fc Receptor and antibody effector function in HIV vaccine discovery (R01) grants. The purpose of this R01 funding opportunity is to stimulate and support investigator driven collaborative research to probe how vaccine
elicited antibodies protect against viral acquisition via Fc receptor mediated mechanisms and also benchmark functional profiles of vaccines that protect against viral infections to inform advancement of HIV vaccine candidates. Areas of interest include, but are not limited to:

- identification of Fc receptor binding profiles that correlate with protective antibody responses;
- use of animal models to understand mechanisms of antibody dependent protective immune responses to broadly neutralising antibodies and or candidate vaccines in vivo;
- examination of adjuvants in both modulating Fc receptor binding profiles and in their influence on immune effector function and/or antibody effector function;
- investigations of antibody glycosylation and Fc receptor-mediated activity and function;
- passive administration studies of BNAbs and or non-neutralising antibodies in pre-clinical animal models to understand Fc-related mechanisms of immune protection;
- examination of Fc Receptor binding and effector function of vaccine-elicited IgA antibodies.

Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PA-14-218.

Closing date: 07 Jan 16
Deadline information: Deadlines every 7 September, 7 January and 7 May until 8 January 2017.
Posted date: 13 May 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/notice-files/PA-14-218.html
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
--------------------------------------------------------
Country of applicant institution: Any
Disciplines
--------------------------------------------------------
Immunology; Virology; Genetics & Systems Biology; Clinical Medicine; Medical Genetics; HIV/Aids; Immunisation Programmes & Vaccination; Diagnostic Sciences

Contact Details
--------------------------------------------------------
Tel: +1 240 627 3031
Email: thandi.onami@nih.gov

HIV VACCINE VECTOR-HOST INTERACTIONS: UNDERSTANDING THE BIOLOGY AND IMMUNOLOGY (R21)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites application for its HIV vaccine vector-host interactions: understanding the biology and immunology (R21) grants. The purpose of this R21 funding opportunity is to support increased understanding of the biology and
immunology of natural viral infections and HIV vaccine vectors. This initiative is intended to advance understanding of the following:

- the biology and immune response to live attenuated or replication-defective viral vectors developed from adenoviridae, poxviridae, adeno-associated viruses and herpesviridae families in humans and non-human primates;
- the development of animal models that could better evaluate the potential for increased HIV acquisition following vaccination.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PA-14-214.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm, local time of applicant organisation, on every 7 September, 7 January and 7 May until 8 January 2017.

HIV VACCINE VECTOR-HOST INTERACTIONS: UNDERSTANDING THE BIOLOGY AND IMMUNOLOGY (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites application for its HIV vaccine vector-host interactions: understanding the biology and immunology (R21) grants. The purpose of this R01 funding opportunity is to support increased understanding of the biology and immunology of natural viral infections and HIV vaccine vectors. This initiative is intended to advance understanding of the following:
- the biology and immune response to live attenuated or replication-defective viral vectors developed from adenoviridae, poxviridae, adenov-associated viruses and herpesviridae families in humans and non-human primates;
- the development of animal models that could better evaluate the potential for increased HIV acquisition following vaccination.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-14-215

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm, local time of applicant institution, on every 7 September, 7 January and 7 May until 8 January 2017.
Posted date: 14 May 14

Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
Country of applicant institution: Any

Contact Details
NIAID
Office of Communications and Public Liaison
Building 31, Room 7A-50
31 Center Drive MSC 2520
Bethesda, MD 20892-2520
Tel: +1 301 435 3749
Email: mpensiero@niaid.nih.gov

Disciplines
Clinical Medicine; Medical Genetics; Genetics & Systems Biology; Diagnostic Sciences; Immunology; HIV/AIDS; Immunisation Programmes & Vaccination; Virology

Clinical Evaluation of Adjuncts to Opioid Therapies for the Treatment of Chronic Pain (R01) AIDS-Related
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse and the National Center for Complementary and Alternative Medicine invite applications for their clinical evaluation of adjuncts to opioid therapies for the treatment of chronic pain (R01) Aids-related grants. The purpose of this R01 Aids-related funding opportunity is to support meritorious clinical studies that seek to characterise opioid and pharmaceutical adjunct combinations that safely improve analgesia in chronic pain patients. As a secondary objective, this opportunity aims to disseminate the results of these studies as widely as possible to the healthcare providers who regularly prescribe opioids to the patient population. This will ensure that standard clinical practices are influenced by the
findings of the proposed studies. In the population proposed to be studied, the subjects should be etiologically homogenous and symptomatically well-defined. Examples of such chronic pain populations in which opioids are often prescribed include patients with radicular cervical pain, metastatic bone pain or peripheral neuropathies. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period is three years.

Ref: PAR-14-225

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017
Posted date: 16 May 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -

**DVANCING RESEARCH IN VOICE DISORDERS (R21) AIDS-RELATED**
**NIH: National Institute on Deafness and other Communication Disorders**

**Description:**
The National Institute on Deafness and Other Communication Disorders invites applications for its advancing research in voice disorders (R21) Aids-related grants. The purpose of this R21 Aids-related funding opportunity is to focus on advancing the scientific knowledge of the human larynx and human voice production in health and disease and optimal ways to prevent, evaluate, diagnose and clinically manage voice disorders. This is to support to support the development of novel ideas, technologies, or methodologies at an early stage of development which have the potential to break new ground or extend toward new directions or applications. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. The combined budget for direct

**Application form:**

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Opiates; Pharmacy & Pharmacology; Molecular Genetics; Drug & Substance Abuse; HIV/Aids; Neurobiology; Chronic Pain; Cognitive & Behavioural Therapies; Pain Management; Epidemiology; Mental Health; Public Health, Health Services & Primary Care; Preventive Medicine; Physiology; Neuroscience; Biological Sciences; General Practice; Diagnostic Sciences; Primary Care

**Contact Details**

NIDA
6001 Executive Boulevard
Room 5213
Bethesda, MD 20892-9561
Tel: +1 301 443 8039
Email: aidan.hampson@nih.gov
costs for the two year project period may not exceed US$275,000. No more than US$200,000 may be requested in any single year. The total project period may not exceed two years.

Ref: PA-14-235.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 22 May 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/notice-files/PA-14-235.html
Application form:
http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Speech Pathology & Disorders; Public Health, Health Services & Primary Care; HIV/AIDS; Physiology; Clinical Medicine; Prosthetic & Orthotic Devices; Primary Care; Allied Health Professions; Speech & Language Therapy

Contact Details
NIDCD
Division of Extramural Research
Executive Plaza South, Room 400C
6120 Executive Boulevard, MSC 7180
Rockville, MD 20892-7180
Tel: +1 301 496 5061
Email: shekiml@nidcd.nih.gov

DVANCING RESEARCH IN VOICE DISORDERS (R01) AIDS-RELATED
NIH: National Institute on Deafness and other Communication Disorders

Description:
The National Institute on Deafness and Other Communication Disorders invites applications for its advancing research in voice disorders (R01) AIDS-related grants. The purpose of this R01 AIDS-related funding opportunity is to focus on advancing the scientific knowledge of the human larynx and human voice production in health and disease and optimal ways to prevent, evaluate, diagnose and clinically manage voice disorders. Furthermore it encourages a range of research inclusive of basic, clinical, and translational. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.
Ref: PA-14-236

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 22 May 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:
ASIC RESEARCH ON HIV PERSISTENCE (R21): AIDS-RELATED

NIH: National Institutes of Health

Description:
The National Institute of Mental Health invites applications for its basic research on HIV persistence (R21) AIDS-related. This AIDS-related R21 announcement will support basic research in aspects of the persistence of HIV or Simian immunodeficiency virus infection in individuals or animals receiving highly active anti-retroviral therapy. It is expected that applications will involve at least one of the following areas of study: cellular, structural or systems biology, host or viral genetics, immunology, or virology. The emphasis of this initiative is on the development of new ideas and approaches in HIV-1 persistence including model and assay development that may directly inform future studies on the design of therapeutic strategies to achieve long term remission without treatment or a complete eradication of residual virus and complete cure for HIV infection and AIDS.

Higher education institutions, non-profits other than institutions of higher education, for-profit organisations, governments and foreign institutions are eligible to apply.

Approximately eight awards are available, worth up to US$275,000 each for two years. Ref: PAR-14-428.

Closing date: 07 Jan 16
Deadline information: Application are due by 5pm local time of applicant organisation, every 7 September, 7 January and 7 May until 8 January 2017.
Posted date: 05 Jun 14
Award type: Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration
Award amount max: $275,000
Award amount min: -
Award budget total: $2,000,000
Website:
Application form:
http://www.grants.gov/web/grants/applicant s/download-application-
MULTIDISCIPLINARY STUDIES OF HIV AND VIRAL HEPATITIS CO-INFECTION
(R21)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its multidisciplinary studies of HIV and viral hepatitis co-infection (R21) grant. The purpose of this R21 funding opportunity is to fill gaps in our understanding of the pathogenic interactions between HIV and hepatitis viruses, co-morbidities associated with HIV/hepatitis virus co-infection, and the effectiveness of interferon-free direct-acting antiviral drug regimens to treat HIV and HCV co-infection.

Research should focus on HIV-infected adults, pregnant or postpartum women, adolescents, children, infants and sub-populations at highest risk for HBV or HCV co-infection. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. The combined budget for direct costs for the two year project period may not exceed $275,000. No more than US$200,000 may be requested in any single year.

Ref: PAR-14-254.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 11 Jun 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-254.html
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Infectious Diseases; Primary Care; Diagnostic Sciences; Clinical Medicine; Hepatology; Infection Agents & Pathogens; Public Health, Health Services & Primary Care; Virology; Blood Tests; HIV/Aids; Disease Control
MULTIDISCIPLINARY STUDIES OF HIV AND VIRAL HEPATITIS CO-INFECTION (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its multidisciplinary studies of HIV and viral hepatitis co-infection (R01) grant. The purpose of this R01 funding opportunity is to fill gaps in our understanding of the pathogenic interactions between HIV and hepatitis viruses, co-morbidities associated with HIV and hepatitis virus co-infection, and the effectiveness of interferon-free direct-acting antiviral drug regimens to treat HIV or HCV co-infection. Research should focus on HIV-infected adults, pregnant or postpartum women, adolescents, children, infants and sub-populations at highest risk for HBV or HCV co-infection. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-255.

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
ARTS-BASED APPROACHES IN PALLIATIVE CARE FOR SYMPTOM MANAGEMENT (R01): AIDS-RELATED
NIH: National Center for Complementary and Integrative Health

Description:
A total of four participating institutes and centres of the National Institutes of Health invite applications for their arts-based approaches in palliative care for symptom management (R01) grants. The purpose of this AIDS-related R01 funding opportunity announcement is to foster research on the potential for arts-based approaches to enhance palliative care for individuals living with multiple symptoms related to serious chronic or terminal illness. This FOA is intended to support mechanistic clinical studies to provide an evidence base for the use of the arts in palliative care for symptom management. The objective is to understand the biological, physiological, neurological, psychological, or sociological mechanisms by which the arts exert their effects on symptom management during and throughout the palliative care continuum. The term “arts” refers not only to artistic activities, but also to creative activities, such as literature, rituals, oral histories and storytelling.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Applicants may request up to US$300,000 in direct costs per year. The maximum project period is three years.

Closing date: 07 Jan 16
Deadline information: Applications open on 5 September and are due by 5pm local time of applicant organisation every 7 September, 7 January and 7 May until 8 September 2017.
Posted date: 25 Jul 14

Award type: Directed grants to institutions, research groups etc
Award amount max: $900,000
Application form: http://www.grants.gov/web/grants/applicant-package.html#download=true&oppNum=PAR-14-294

Eligibility profile
Country of applicant institution: Any

Disciplines
Health Systems, Administration; HIV/Aids; Psychology; Death & Mortality; Music Therapy; Hospice & Palliative Care; Oral History; Social Work & Social Policy; Art Therapies; Palliative Nursing; Clinical Medicine; Primary Care; Public Health, Health Services & Primary Care; Performing Arts; Theatre Studies; Allied Health Professions; Nursing; Visual Arts; Literature, Drama; Paediatrics; Customs & Traditions; Art & Design: History, Practice & Theory

Contact Details
NIH: National Center for Complementary and Alternative Medicine
31 Center Drive, MSC 2182
Bethesda, MD 20892-2182
Tel: +1 301 443 8374
Email: lee.alekel@nih.gov
PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R03) AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institutes of Health invites applications for their patient safety in the context of perinatal, neonatal and paediatric care programme. This Aids-related R03 funding opportunity announcement encourages collaborative research projects related to patient safety in the context of perinatal, neonatal and paediatric care both in routine hospital settings and in the intensive care units. Proposals may address:

- the epidemiology of errors and adverse events in neonatal and paediatric care hospital units;
- medication errors;
- diagnostic errors;
- procedure-related errors;
- human factor and fatigue;
- promotion of a safety culture;
- other working conditions and systems issues;
- risk reduction and disclosure practices.

Eligibility is unrestricted. This funding opportunity uses the NIH small grant (R03) mechanism and runs in parallel with one of identical scientific scope, PA-14-312, which solicits applications under the NIH research project grant (R01) mechanism.

Funding is worth up to US$50,000 per year for a maximum project period of two years.

Ref: PA-14-313 (replaces PAR-11-226).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 September 2014 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.
PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL, AND PAEDIATRIC CARE (R21): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for its patient safety in the context of perinatal, neonatal, and paediatric care (R21) grants. The purpose of this Aids-related R21 funding opportunity announcement is to encourage a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and paediatric care both in routine hospital settings and in the intensive care units. The FOA welcomes applications related to the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional levels to help reduce and eliminate medical errors.

It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness.

This FOA will utilise the R21 mechanism and runs in parallel with two FOAs of identical scientific scope, PAR-14-312 that encourages applications under the R01 research grant programme mechanism and PAR-14-313 that encourages applications under the R03 small grant programme mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are limited to direct costs of up $275,000 over a two-year project period and no more than $200,000 may be requested in any one year.

Ref: PA-14-311 (replaces PAR-11-227).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 07 Aug 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $275,000


Eligibility profile
-------------------------------------------------------------
Country of applicant institution: Any
Molecular and Cellular Substrates of Complex Brain Disorders (R21): AIDS-Related
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its molecular and cellular substrates of complex brain disorders (R21) grants. This AIDS-related funding opportunity announcement uses the R21 mechanism to encourage new research activities directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. By using the R21 activity code, this funding opportunity seeks to foster the introduction of novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential to advance research at the interface between cellular and molecular mechanisms and that address gaps in understanding the biological mechanisms behind putative disease associated processes with the goal of accelerating progress in emerging research areas relevant to complex brain disorders.

This FOA uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-309 that encourages applications under the NIH research project (R01) grant mechanism. Direct costs are limited to US$275,000 over a two year period, with no more than US$200,000 in direct costs in any one year. The total project period may not exceed two years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PAR-14-310 (replaces PAR-11-300).

Closing date: 07 Jan 16 (Forecast)
Deadline information: !! Call has not yet been announced by funder, but this is the approximate deadline we expect.
Applications open on 16 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 07 Aug 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:
Application form:
http://www.grants.gov/web/grants/applicant/download-application-
Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Diagnostic Sciences; Central Nervous System; Biological Sciences; Neuroendocrinology; Electrophysiology; HIV/AIDS; Public Health, Health Services & Primary Care; Psychology; Neuropharmacology; Cognitive Processes; Mental Illness; Allied Health Professions; Pharmacy & Pharmacology; Neuroscience; Neuroanatomy; Cell & Developmental Biology; Nucleus & Organelles; Neurobiology; Clinical Medicine; Primary Care; Muscle Diseases; Intellectual Disabilities; Neurology; Biochemistry & Molecular Biology; Endocrine & Neuroendocrine Cancers

Contact Details
----------------------------------------------
NIMH
6001 Executive Blvd
Room 8184 MSC 9663
Bethesda, Maryland 20892
Tel: +1 301 443 5288
Email: casanuma@mail.nih.gov

MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R01): AIDS-RELATED
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its molecular and cellular substrates of complex brain disorders (R01) grants. This Aids-related R01 funding opportunity announcement encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. This FOA seeks to encourage innovative leads at the interface between cellular and molecular mechanisms, and that address gaps in understanding the biological mechanisms behind putative disease and associated processes with the goal of accelerating progress in emerging research areas relevant to complex brain disorders. Proposals should be hypothesis-driven and propose discovery-based studies with an emphasis on exploring neurobiological mechanisms at the molecular, cellular and circuit levels.

This FOA uses the NIH research project (R01) grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-310 that encourages applications under the NIH exploratory/developmental (R21) grant mechanism. Application budgets are not limited but must reflect the actual needs of the proposed project. The total project period may not exceed five years. Applicants that request US$500,000 or more in direct costs in any year must contact the NIH six weeks prior to applying.

US and foreign for-profit and non-profit organisations, higher education institutions and public and private organisations may apply.
Ref: PAR-14-309 (replaces PAR-11-299).
PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R01) AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institutes of Health invites applications for their patient safety in the context of perinatal, neonatal and paediatric care programme. This Aids-related R01 funding opportunity announcement encourages collaborative research projects related to patient safety in the context of perinatal, neonatal and paediatric care both in routine hospital settings and in the intensive care units. Proposals may address:

- the epidemiology of errors and adverse events in neonatal and paediatric care hospital units;
- medication errors;
- diagnostic errors;
- procedure-related errors;
- human factor and fatigue;
- promotion of a safety culture;
- other working conditions and systems issues;
- risk reduction and disclosure practices.

Eligibility is unrestricted. This funding opportunity uses the NIH research project grant (R01) mechanism and runs in parallel with one of identical scientific scope, PA-14-
A compilation of the Research Services of the Office of Research, Innovation & Development (ORID)

313, which solicits applications under the NIH small grant (R03) mechanism.

Applicants requesting US$500,000 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. The total project period may not exceed five years.

Ref: NIH PA-14-312 (replaces PAR-11-225).

Closing date: 07 Jan 16
Deadline information: Applications due by 5pm proposer’s local time every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 07 Aug 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-312.html
Application form: http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-312

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
HIV/Aids; Health Informatics; Health Psychology; Standards of Care; Medical Research of Selected Fields; Primary Care; Law; Hospitalisation; Paediatric Nursing; Maternal Health; Quality of Care; Diagnostic Sciences; Safety & Accident Investigation; Nursing; Allied Health Professions; Public Health & Medical Law; Psychology; Blood Tests; Clinical Medicine; Medical Effectiveness & Patient Outcomes; Business & Management Studies; Pregnancy & Birth; Medical Informatics & Telemedicine; Patient Care & Education; Health Systems, Risk Management; Health Professions; Clinical Decision-making & Analysis; Neonatal Disorders; Medical & Diagnostic Tests; Public Health, Health Services & Primary Care; Paediatrics

Contact Details
----------------------------------------------
NIH
Pregnancy and Perinatology Branch
Eunice Kennedy Shriver National Institute of Child and Human Development
6100 Executive Blvd, 4B03D
Bethesda MD 20892
Tel: +1 301 435 6873
Fax: +1 301 496 3790
Email: kosomari@mail.nih.gov

ROLE OF THE MICROBIOME IN HIV-1 VACCINE RESPONSES (R21)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its role of the microbiome in HIV-1 vaccine responses (R21) grants. The purpose of this

R21 funding opportunity announcement is to stimulate research focused on elucidating the role of the microbiome in shaping the host immune responses to HIV-1 transmission and vaccination in the gastrointestinal and genital
mucosa. The focus is on the microbiome’s role in immune responses within the context of HIV-1 transmission and prevention vaccines.

Applicants are expected to undertake multidisciplinary research in metagenomics, immunology, microbiology, HIV virology and host genetics. Projects may comprise the translation of existing critical knowledge and technologies from other fields for the benefit of HIV-1 vaccine research.

This funding opportunity uses the exploratory/developmental (R21) grant mechanism and runs in parallel with an opportunity of identical scientific scope, PAR-14-317, which solicits applications under the NIH research project (R01) grant mechanism.

Direct costs are limited to US$275,000 over two years. No more than US$200,000 may be requested in any single year.

Ref: PAR-14-318.

Closing date: 07 Jan 16
Deadline information: Applications open on 7 December 2014 and are due by 5pm local time of applicant organisation on every 7 January until 8 January 2017. Deadlines on: 7 January 2015, 7 January 2016, 7 January 2017.

Contact Details
NIH: NIAID
Office of Communications and Public Liaison
Building 31, Room 7A-50
31 Center Drive MSC 2520
Bethesda, MD 20892-2520
Tel: +1 240 292 6181
Email: qdang@niaid.nih.gov

ROLE OF THE MICROBIOME IN HIV-1 VACCINE RESPONSES (R01)

NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its role of the microbiome in HIV-1 vaccine responses (R01) grants. The purpose of this R01 funding opportunity announcement is to
stimulate research focused on elucidating the role of the microbiome in shaping the host immune responses to HIV-1 transmission and vaccination in the gastrointestinal and genital mucosa. The focus is on the microbiome’s role in immune responses within the context of HIV-1 transmission and prevention vaccines.

Applicants are expected to undertake multidisciplinary research in metagenomics, immunology, microbiology, HIV virology and host genetics. Projects may comprise the translation of existing critical knowledge and technologies from other fields for the benefit of HIV-1 vaccine research.

This FOA uses the research project grant (R01) award mechanism and runs in parallel with an opportunity of identical scientific scope, PAR-14-318, which solicits proposals under the exploratory/developmental (R21) award mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-317.

Closing date: 07 Jan 16
Deadline information: Applications open on 7 December 2014 and are due by 5pm local time of applicant organisation on every 7 January until 8 January 2017. Deadlines on: 7 January 2015, 7 January 2016, 7 January 2017.

Posted date: 12 Aug 14
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -

Eligibility profile
---------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------------
Medicinal Chemistry; Bacterial Diseases; Biochemistry & Molecular Biology; Microbial Ecology; Bacteriology; Chemistry; Human Genome; Pharmacokinetics; Microbiology; Genomics; Biological Sciences; HIV/Aids; Virology; Pharmacy & Pharmacology; Deoxyribonucleic Acid, DNA; Diagnostic Sciences; Immunisation Programmes & Vaccination

Contact Details
---------------------------------------------------------------------
NIH: NIAID
Office of Communications and Public Liaison
Building 31, Room 7A-50
31 Center Drive MSC 2520
Bethesda, MD 20892-2520
Tel: +1 240 292 6181
Email: qdang@niaid.nih.gov
SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its AIDS-related secondary analyses of existing alcohol epidemiology data (R21) grants. These R21 grants support AIDS-related, investigator-initiated research projects that either analyse previously collected data in order to address key issues that have emerged from recent findings in alcohol epidemiology and prevention research, or develop new analytic techniques for conducting studies in alcohol epidemiology and prevention research. The goal is to enhance understanding of patterns of alcohol consumption and the epidemiology of alcohol-related problems.

This funding opportunity announcement uses the NIH exploratory/developmental research grant (R21) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-338 that encourages applications under the research project grant (R01) mechanism and PA-14-337 that encourages applications under the small grant programme (R03) mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Grants are worth up to US$275,000 in direct costs over a maximum period of two years. No more than US$200,000 may be requested in any single year.

Ref: PA-14-336.

Closing date: 07 Jan 16
Deadline information: Applications open on 24 September 2014 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September 2015 until 8 September 2017. Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.

Posted date: 10 Sep 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-337.html

Application form:

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Traumatology; Accidents & Injury; Psychology; Clinical Medicine; Behavioural Studies & Social Problems; Chronic Care; Alcoholism; Primary Care; Addiction; Aetiology; Allied Health Professions; Public Health, Health Services & Primary Care; Epidemiology; Education; Economic & Social Environment

Contact Details
-----------------------------------------------
NIAAA
6000 Executive Boulevard
Willco Building
Bethesda, MD 20892-7003
Tel: +1 301 443 0633
Email: zhaw@mail.nih.gov
ELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R21): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
A total of three participating institutes and centres of the National Institutes of Health invite applications for their Aids-related self-management for health in chronic conditions (R21) grants. These Aids-related R21 grants support research in self-management focused across conditions. Projects should address the Institute of Medicine’s recommendation for crosscutting, coordinated public health actions for living well with chronic illness, by describing an initiative that focuses on self-management as a mainstream science in order to reduce the burden of chronic illnesses or conditions.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This FOA will use the NIH exploratory and developmental grant (R21) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-344 that encourages applications under the research project grant(R01) mechanism and PA-14-345 that encourages applications under the academic research enhancement award (R15) mechanism.

The combined budget for direct costs for the two-year project period may not exceed US$275,000. No more than US$200,000 in direct costs may be requested in any single year. The maximum project period is two years.
Ref: PA-14-343.

Closing date: 07 Jan 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 22 Sep 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-343.html
Application form: http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-343

Eligibility profile
Country of applicant institution: Any
Disciplines
General Practice; Medical Informatics & Telemedicine; Access to Health Care; Clinical Medicine; Clinical Decision-making & Analysis; Home Health Care Services; Primary Care; HIV/Aids; Social Work & Social Policy; Chronic Care; Economic & Social Environment; Libraries & Information Science; Medical Effectiveness & Patient Outcomes; Health Systems; Public Health, Health Services & Primary Care; Quality of Care; Health Systems Policy; Disease Control; Health Informatics; Standards of Care

Contact Details
NINR
NIH
31 Center Drive, Room 5B10
Bethesda MD 20892-2178
Tel: +1 301 594 5970
Email: hussk@mail.nih.gov
**NIDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY PLANNING GRANT (R34): AIDS-RELATED**

**NIH: National Institute of Dental and Craniofacial Research**

**Description:**
The National Institute of Dental and Craniofacial Research invites applications for its NIDCR clinical trial or biomarker clinical validation study planning grant (R34) AIDS-related call. This R34 AIDS-related call for funding supports activities to develop a draft clinical protocol, the clinical investigators brochure, tools for data and quality management, safety and operational oversight plans, recruitment and retention strategies, a study team and other essential documents.

US and foreign for-profit and non-profit organisations and public and private organisations may apply. This funding opportunity uses the NIH planning grant (R34) mechanism and runs in parallel with two opportunities of identical scientific scope, PAR-14-342, which solicits applications under the same mechanism (R34) and PAR-11-339, which solicits applications under the NIH research project cooperative agreement (U01) mechanism.

Direct costs may not exceed US$150,000 over a period of one year.
Ref: PAR-14-346 (replaces PAR-11-338).

**Closing date:** 07 Jan 16
**Deadline information:** Applications due by 5pm applicant’s local time. Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.
**Posted date:** 22 Sep 14
**Award type:** Directed grants to institutions, research groups etc
**Award amount max:** $150,000
**Application form:** [http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm](http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm)

**Eligibility profile**
---------------------------------------------------------------
Country of applicant institution: Any

**Disciplines**
---------------------------------------------------------------
Diagnostic Sciences; Drug Design; Oral Medicine; Craniofacial Disorders; Dental Health & Hygiene; Biochemical Markers; Clinical Medicine; HIV/AIDS; Biological Markers & Sensor Mechanisms; Dentistry

**Contact Details**
---------------------------------------------------------------
NIH NIDCR
Public Information and Liaison Branch
45 Center Drive, MSC 6400
Bethesda MD 20892-6400
Tel: +1 301 435 7908
Email: jatkinso@mail.nih.gov
ELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R01): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research, the National Institute on Ageing and the National Institute on Deafness and Other Communication Disorders invites applications for its AIDS-related self-management for health in chronic conditions grants. These R01 AIDS-related grants support activities that focus on self-management as a mainstream science in order to reduce the burden of chronic illnesses and conditions.

Eligible applicants include domestic and foreign public or private institutions and non-profit or for-profit organisations.

The maximum project period is five years.

PA-14-344

Closing date: 07 Jan 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May, 7 September until 8 January 2018.
Posted date: 22 Sep 14
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award budget total: -

Website:
Application form:
http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
Country of applicant institution: Any

Disciplines
Sociology; Public Health; HIV/AIDS; Social Work & Social Policy; Chronic Fatigue Syndrome; Combustion & Fuel Engineering; Public Health, Health Services & Primary Care; Avionics; Allied Health Professions; Clinical Medicine; Business & Management Studies; Chronic Care; Health Counselling; Primary Care; Assistive Technology; Employment & Unemployment Studies

Contact Details
National Institute of Nursing Research
31 Center Drive, Room 5B10
Bethesda MD 20892-2178
Tel: +1 301 594 5970
Email: hussk@mail.nih.gov

STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R21): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its AIDS-related studies in neonatal resuscitation (R21) grants. These AIDS-related R21 grants support collaborative research projects on a wide
range of topics related to neonatal resuscitation.

Projects should help develop strategies to deliver highest quality of healthcare to newborn infants and children with utmost safety and effectiveness. Projects may relate to the epidemiology of various domains of medical errors and consequent patient harm, assessing the factors at various levels that contribute to such errors, and intervention strategies at individual, systems and institutional-levels to help reduce and eliminate medical errors.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This Aids-related funding opportunity uses the R21 exploratory and developmental grant mechanism, and runs in parallel with two opportunities of identical scientific scope: PA-14-351, which solicits applications under the R03 small grant programme mechanism, and PA-14-350, which solicits applications under the R01 research project grant mechanism.

Application budgets are limited to US$275,000 over a maximum of two years, and no more than US$200,000 may be requested in a single year.
Ref: PA-14-349 (replaces PAR-11-224).

Closing date: 07 Jan 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant institution on every 7 May, 7 September and 7 January until 8 January 2018.

Ref: PA-14-349 (replaces PAR-11-224).

Closing date: 07 Jan 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant institution on every 7 May, 7 September and 7 January until 8 January 2018.
collaborative research projects on a wide range of topics related to neonatal resuscitation.

Projects should help develop strategies to deliver highest quality of healthcare to newborn infants and children with utmost safety and effectiveness. Projects may relate to the epidemiology of various domains of medical errors and consequent patient harm, assessing the factors at various levels that contribute to such errors, and intervention strategies at individual, systems and institutional-levels to help reduce and eliminate medical errors.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This Aids-related funding opportunity utilises the R03 mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-350 that encourages applications under the R01 research project grant mechanism and PA-14-349 that encourages applications under the R21 exploratory or developmental grant mechanism.

Application budgets are limited to US$50,000 in direct costs per year over a maximum period of two years.
Ref: PA-14-351 (replaces PAR-11-223).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 29 Sep 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-351.html

Application form: http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-351

Eligibility profile
Country of applicant institution: Any
Disciplines
Neonatal Disorders; Respiratory Medicine; Foetal Health & Prenatal Development; Obstetrics & Gynaecology; Clinical Medicine; Paediatrics; HIV/Aids; Cardiology; Allied Health Professions

Contact Details
NICHHD
Building 31, Room 2A32
MSC 2425
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 435 6873
Email: kosomari@mail.nih.gov
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R01): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its AIDS-related studies in neonatal resuscitation (R01) grants. These AIDS-related R01 grants support collaborative research projects on a wide range of topics related to neonatal resuscitation.

Projects should help develop strategies to deliver highest quality of healthcare to newborn infants and children with utmost safety and effectiveness. Projects may relate to the epidemiology of various domains of medical errors and consequent patient harm, assessing the factors at various levels that contribute to such errors, and intervention strategies at individual, systems and institutional-levels to help reduce and eliminate medical errors.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This AIDS-related funding opportunity uses the R01 research project mechanism, and runs in parallel with two opportunities of identical scientific scope: PA-14-35, which solicits applications under the R03 small grant programme mechanism, and PA-14-349, which solicits applications under the R21 exploratory and developmental grant mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The total project period may not exceed five years.

Ref: PA-14-350 (replaces PAR-11-222).

Closing date: 07 Jan 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 29 Sep 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-350.html
Application form: http://www.grants.gov/web/grants/applicant s/download-application-package.html#download=true&oppNum=PA-14-350

Eligibility profile
-------------------------------------------------------------
Country of applicant institution: Any

Disciplines
-------------------------------------------------------------
Respiratory Medicine; Paediatrics; Foetal Health & Prenatal Development; Obstetrics & Gynaecology; Cardiology; HIV/Aids; Neonatal Disorders; Allied Health Professions; Clinical Medicine

Contact Details
-------------------------------------------------------------
NIH: National Institute of Child Health and Human Development
Building 31, Room 2A32
MSC 2425
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 435 6873
Email: kosomari@mail.nih.gov
BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R21): AIDS-RELATED
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research and the National Institute of Biomedical Imaging and Bioengineering invite applications for their biology of the temporomandibular joint in health and disease (R21): Aids-related grants. This R21 Aids-related funding opportunity encourages research that advances understanding of the temporomandibular joint in health and disease, and aims to stimulate research focused on the biology of joint function and the tissues that make up the joint. Focus areas include:
- bone;
- muscle;
- cartilaginous and ligamentous tissues;
- vascularisation and innervation;
- models;
- measurement of joint health, disease and functions.

This Aids-related funding opportunity uses the NIH research project (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-14-358, which solicits applications under the NIH exploratory and developmental grant (R01) mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Funding is worth up to US$275,000 over two years, and projects may request no more than US$200,000 per year.
Ref: PA-14-359.

Closing date: 07 Jan 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 06 Oct 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-359.html


Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Musculoskeletal System; Clinical Medicine; Muscle Diseases; Orthopaedic Surgery; Physiology; Bone Cancers; Connective Tissue; Osteoporosis & Other Bone Diseases; HIV/Aids; Diagnostic Sciences; Movement Disorders; Cardiology; Disease Models; Human Biological Sciences; Primary Care; Human Physiology; Public Health, Health Services & Primary Care

Contact Details
---------------------------------------------------------------
NIH: National Institute of Dental and Craniofacial Research
Public Information and Liaison Branch
45 Center Drive, MSC 6400
Bethesda MD 20892-6400
Tel: +1 301 594 9898
Email: jasonwan@mail.nih.gov
BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R01):
AIDS-RELATED
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research and the National Institute of Biomedical Imaging and Bioengineering invite applications for their biology of the temporomandibular joint in health and disease (R01): Aids-related grants. This Aids-related R01 funding opportunity encourages research that advances understanding of the temporomandibular joint in health and disease, and aims to stimulate research focused on the biology of joint function and the tissues that make up the joint. Focus areas include:
- bone;
- muscle;
- cartalaginous and ligamentous tissues;
- vascularisation and innervation;
- models;
- measurement of joint health, disease and functions.

This Aids-related funding opportunity uses the NIH exploratory and developmental grant (R01) mechanism and runs in parallel with one of identical scientific scope, PA-14-359, which solicits applications under the NIH research project (R21) grant mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Budgets are not limited but must reflect the actual needs of the proposed project. The scope of the project should define its duration.

Ref: PA-14-358.

Closing date: 07 Jan 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 06 Oct 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:

Application form:

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any
Disciplines
---------------------------------------------------------------
Diagnostic Sciences; Primary Care; Disease Models; Musculoskeletal System; Movement Disorders; Orthopaedic Surgery; Human Physiology; Osteoporosis & Other Bone Diseases; Cardiology; Muscle Diseases; Bone Cancers; Clinical Medicine; Connective Tissue; Physiology; Human Biological Sciences; HIV/AIDS; Public Health, Health Services & Primary Care

Contact Details
---------------------------------------------------------------
NIH: National Institute of Dental and Craniofacial Research
Public Information and Liaison Branch
45 Center Drive, MSC 6400
Bethesda MD 20892-6400
Tel: +1 301 594 9898
Email: jasonwan@mail.nih.gov
BIΟBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R21): AIDS-RELATED

NIH: National Institutes of Health

Description:
The National Institutes of Health, under the National Institute of Nursing Research and the National Institute on Aging, invite applications for their AIDS-related biobehavioural and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia grants. These AIDS-related R21 grants aim to stimulate clinical research focused on biobehavioural or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment, or disease or age-related cognitive decline. Particular interest is on the following:

- interventions that can be implemented in community settings by the affected individual, informal caregivers or others in the community;
- research to inform the development of the type of interventions identified above;
- research that examines underlying mechanisms and biomarkers associated with response to interventions.

This funding opportunity uses the R21 exploratory or developmental grant mechanism that seeks to foster the introduction of novel scientific ideas, model systems, tools, agents, targets and technologies that have the potential to substantially advance biomedical research. The opportunity runs in parallel with two opportunities of identical scientific scope; PA-15-017, which solicits applications under the R01 research project grant mechanism, and PA-15-016, which solicits applications under the R15 academic research enhancement award mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

Grants cover direct costs up to a maximum of US$275,000 over a period of up to two years. Ref: PA-15-015.

Closing date: 07 Jan 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 15 Oct 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $275,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Public Health, Health Services & Primary Care; Clinical Medicine; Alzheimer’s Disease & Senile Dementia; Neuroscience; Health Economics; Primary Care; Psychology; Neurology; General Practice; Medical Effectiveness & Patient Outcomes; Cognitive Processes; Diagnostic Sciences; HIV/AIDS
BIOBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R01): AIDS-RELATED

NIH: National Institutes of Health

Description:
The National Institutes of Health, under the National Institute of Nursing Research and the National Institute on Aging, invite applications for their AIDS-related biobehavioural and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia grants. These AIDS-related R01 grants aim to stimulate clinical research focused on biobehavioural or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment, or disease or age-related cognitive decline. Particular interest is on the following:

- interventions that can be implemented in community settings by the affected individual, informal caregivers or others in the community;
- research to inform the development of the type of interventions identified above;
- research that examines underlying mechanisms and biomarkers associated with response to interventions.

This funding opportunity uses the R01 research project grant mechanism and runs in parallel with two opportunities of identical scientific scope; PA-15-016, which solicits applications under the R15 academic research enhancement award mechanism, and PA-15-015, which solicits applications under the R21 exploratory or developmental award mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

Grants are awarded for a maximum project period of five years.

Ref: PA-15-017.

Closing date: 07 Jan 16
Deadline information: Applications requesting US$500,000 or more in direct costs per year should contact NIH staff at least six weeks before applying. Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018. Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.

Posted date: 15 Oct 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: -
Website:

Application form:
http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Clinical Medicine; Health Economics; Diagnostic Sciences; Cognitive Processes; Public Health, Health Services & Primary Care; Primary Care; HIV/AIDS; Psychology; Neurology; General Practice; Alzheimer’s Disease & Senile Dementia; Medical Effectiveness & Patient Outcomes; Neuroscience

Contact Details
----------------------------------------------
NINR
Building 1DEM
Suite 713A
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 594 5968
Email: tullyla@mail.nih.gov

PROMOTING RESEARCH IN BASIC NEUROSCIENCE (R01): AIDS-RELATED

NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke, the National Institute on Aging, the National Institute on Drug Abuse and the National Institute of Mental Health invite applications for their AIDS-related promoting research in basic neuroscience (R01) grants. These AIDS-related R01 grants aim to stimulate research addressing fundamental questions in basic neuroscience.

Projects can address any area of neuroscience within the missions of the participating institutes and should focus on understanding the structure and/or function of the normal nervous system. Grants are not intended to stimulate research that is explicitly disease-related.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAS-15-029.

Closing date: 07 Jan 16
Deadline information: Applications requesting US$500,000 or more in direct costs per year should contact NIH staff at least six weeks before applying. Applications are invited between 5 January and 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018. Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.

Posted date: 05 Nov 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: -
DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R21): AIDS-RELATED

NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its diabetes and cardiovascular disease in older adults (R21) grants. These AIDS-related R21 grants encourage basic, clinical and epidemiological outcomes research on the impact of age on the development of, diagnosis and management of diabetes and cardiovascular disease complications in older persons or animal models. Research supported by this initiative is expected to elucidate the role of ageing mechanisms that underlie the increased vulnerability of older adults to DM and its CVD complications and to provide evidence-based guidance to improve more appropriate diagnostic criteria, risk stratification and intervention recommendations to prevent the onset, or improve short- and long-term outcomes, of DM and CVD in older persons.

This funding opportunity uses the R21 exploratory and developmental research grant mechanism and runs in parallel with two of identical scientific scope, PA-15-037, which solicits applications under the R01 research project grant mechanism and PA-15-039, which solicits applications under the R03 small grant programme mechanism. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US$275,000 for direct costs over a maximum project period of two years. No more than US$200,000 may be requested in any single year.

Ref: PA-15-038.

Closing date: 07 Jan 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 20 Nov 14
Award type: Directed grants to institutions, research groups etc, Innovation grants
DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R03): AIDS-RELATED

NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its diabetes and cardiovascular disease in older adults (R03) grants. These AIDS-related R03 grants encourage basic, clinical and epidemiological outcomes research on the impact of age on the development of, diagnosis and management of diabetes and cardiovascular disease complications in older persons or animal models. Research supported by this initiative is expected to elucidate the role of ageing mechanisms that underlie the increased vulnerability of older adults to DM and its CVD complications and to provide evidence-based guidance to improve more appropriate diagnostic criteria, risk stratification and intervention recommendations to prevent the onset, or improve short- and long-term outcomes, of DM and CVD in older persons.

This funding opportunity uses the R03 small grant programme mechanism and runs in parallel with two of identical scientific scope, PA-15-037, which solicits applications under the R01 research project grant mechanism and PA-15-038, which solicits applications under the R21 exploratory and developmental research grant mechanism. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Application budgets are limited to US$100,000 for direct costs over a maximum project period of two years. No more than US$50,000 may be requested in any single year.

Ref: PA-15-039.

Closing date: 07 Jan 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 20 Nov 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Website:
**Diabetes and Cardiovascular Disease in Older Adults (R01): AIDS-Related**  

*NIH: National Institute on Aging*

**Description:**
The National Institute on Aging invites applications for its diabetes and cardiovascular disease in older adults (R01) grants. These AIDS-related R01 grants encourage basic, clinical and epidemiological outcomes research on the impact of age on the development, diagnosis and management of diabetes and cardiovascular disease complications in older persons or animal models. Research supported by this initiative is expected to elucidate the role of ageing mechanisms that underlie the increased vulnerability of older adults to DM and its CVD complications and to provide evidence-based guidance to improve more appropriate diagnostic criteria, risk stratification and intervention recommendations to prevent the onset, or improve short- and long-term outcomes, of DM and CVD in older persons.

This funding opportunity uses the R01 research project grant mechanism and runs in parallel with two of identical scientific scope, PA-15-038, which solicits applications under the R21 exploratory and developmental grant mechanism and PA-15-039, which solicits applications under the R03 small grant programme mechanism. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-15-037.

**Closing date:** 07 Jan 16

**Deadline information:** Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

**Posted date:** 05 Jan 15

**Award type:** Directed grants to institutions, research groups etc

**Award budget total:** -

**Website:**  

**Application form:**  
http://www.grants.gov/web/grants/applicant
UNDERACTIVE BLADDER IN AGEING (R03): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its underactive bladder in ageing (R03) grants. This Aids-related R03 funding opportunity announcement invites applications that propose basic, clinical or translational research on underactive bladder and its consequences in ageing and in older persons. Applications should focus on the:

- biology, aetiology and pathophysiology of UAB in animal models and older adults;
- translation of basic or clinical research into clinical practice and health decision-making;
- diagnosis, prevention, management and clinical outcomes of UAB in older adults;
- epidemiology and risk factors for the development of UAB with advancing age.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. This FOA uses the NIH small grant (R03) mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-049 that solicits applications under the research project grant award (R01) mechanism and PA-15-051 that solicits applications under the exploratory/developmental (R21) mechanism. Application budgets are limited to US$100,000 over the two-year R03 period, with no more than US$50,000 in any year. The maximum project period is two years.

Ref: PA-15-050.

Closing date: 07 Jan 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 25 Nov 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Eligibility profile

Country of applicant institution: Any

Disciplines

Incontinence; Geriatrics & Gerontology; Urology; HIV/Aids

Contact Details

NIA
GWY BG Room 3C307
7201 Wisconsin Avenue
Bethesda MD 20814
Tel: +1 301 496 6761
Email: saliveme@mail.nih.gov

UNDERACTIVE BLADDER IN AGEING (R21): AIDS-RELATED

NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its underactive bladder in ageing (R21) grants. This Aids-related funding opportunity announcement invites applications that propose basic, clinical or translational research on underactive bladder and its consequences in ageing and in older persons. Applications should focus on the:

- biology, aetiology and pathophysiology of UAB in animal models and older adults;
- translation of basic or clinical research into clinical practice and health decision-making;
- diagnosis, prevention, management and clinical outcomes of UAB in older adults;
- epidemiology and risk factors for the development of UAB with advancing age.

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 25 Nov 14

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. This FOA uses the NIH exploratory/developmental R21 grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-049 that solicits applications under the research project grant award (R01) mechanism and PA-15-050 that solicits applications under the small grant programme (R03) mechanism.

Application budgets are limited to US$275,000 over the two-year R21 period, with no more than US$200,000 in any year.

Ref: PA-15-051.

Closing date: 07 Jan 16

Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Award amount min: -
Award budget total: -
Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related unconventional roles of ethanol metabolising enzymes, metabolites and cofactors in health and disease (R21) funding opportunity announcement. This Aids-related announcement provides support for integrated, innovative research on the novel and unconventional contributions of ethanol metabolising pathways, their metabolites, cofactors and interactions with synergising biological pathways in the development of alcohol-induced diseases and end organ injuries.

The aim is to generate data that leads to breakthroughs in identification and understanding of key cellular and molecular components in the initiation, progression and maintenance of the diverse medical disorders caused by excessive or long term alcohol consumption. The generated knowledge should enable clinicians to improve disease outcomes and consequently, public health.

Research areas include the following: ethanol and NAD+; ethanol and acetate; ethanol and SAM; ethanol and zinc; endogenous substrates and functions of alcohol metabolising pathways - regulation of growth, development and disease.

This announcement uses the R21 exploratory or developmental research grant mechanism and runs in parallel with one of identical scientific scope, PA-15-058, which encourages applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Grants cover direct costs up to a maximum of US$275,000 over a maximum period of two years. No more than US$200,000 may be requested in any single year.

Ref: PA-15-057 (reissue of PA-12-234).
Closing date: 07 Jan 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation, every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 09 Dec 14
Award type: Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration
Award amount max: $275,000

Eligibility profile

Country of applicant institution: Any

Disciplines

Addiction; Alcoholism; HIV/AIDS; Alcoholic Beverages; Cell Physiology & Metabolism; Hepatology

Contact Details

NIAAA
Building 5635FL, Room 2119
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 443 2193
Email: orosza@mail.nih.gov

**IDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY COOPERATIVE AGREEMENT (U01): AIDS-RELATED**

NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its AIDS-related clinical trial or biomarker validation study cooperative agreement (U01) funding opportunity announcement. This AIDS-related announcement supports investigator-initiated phase I, II, III or IV clinical trials, stage one to four behavioural or social intervention trials or biomarker validation studies that require prospective collection of clinical outcomes and clinical specimens through the funding mechanism. Eligible clinical trials may focus on the following:

- chemotherapeutic, pharmacologic or other interventions to prevent or treat periodontal diseases and various types of dental caries;
- testing new dental materials for restoration of carious lesions;
- testing non-opiate methods of reducing postoperative pain and swelling after dental surgery;
- preventing or treatment of HIV/AIDS, its associated oral complications, coinfections or malignancies, and dental diseases caused by bacteria, fungi or viruses;
- testing therapies to prevent or treat oral candidiasis, oral herpes virus infections and other pathogens with oral targets that commonly occur in those with congenital or acquired immune dysfunction;
- testing treatments for oral mucositis and other oral manifestations of systemic diseases;
- comparing therapies for oral diseases in medically complex patients;
- preventing or managing salivary dysfunction;
- testing treatments for temporomandibular dysfunction and other orofacial pain conditions;
- validation of biomarkers of oral or dental diseases through prospective collection of biospecimens and data on clinical outcomes;
- testing the efficacy or effectiveness and mechanisms of action of behavioural or social interventions to improve dental, oral or craniofacial health;
- adapting behavioural or social principles, methods or interventions from other areas of health to be applied and tested in dental, oral or craniofacial health, or in the dental setting;
- developing and testing algorithms for tailoring or targeting behavioural or social interventions for individuals, groups, communities or settings in which further testing is justified.

This announcement uses the NIH research (U01) grant mechanism and runs in parallel with two announcements of identical scientific scope, PAR-14-342 and PAR-14-346, both of which solicit applications under the NIH planning grant (R34) mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the needs of the project. The maximum project period is five years.


Closing date: 07 Jan 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018. Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.
Posted date: 09 Dec 14
Award type: Clinical trials, Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: -


Eligibility profile

Country of applicant institution: Any

Disciplines

Preventive Medicine; Dentistry; HIV/Aids; Infection Agents & Pathogens; Pain Management; Biochemical Markers

Contact Details

NIDCR
Building 1DEM, Room 634
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 435 7908
Email: jatkinso@mail.nih.gov
BUILDING ON HIGH IMPACT BASIC NEUROBIOLOGY THROUGH ASSAY DEVELOPMENT: ADVANCING TOOLS FOR THERAPEUTIC DISCOVERY (R01): AIDS-RELATED

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health, the National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their Aids-related building on high impact basic neurobiology through assay development: advancing tools for therapeutic discovery (R01) grants.

This Aids-related announcement encourages research to develop novel, robust assays to reveal changes in neuronal and glial function. The goal is to adapt state-of-the-art measures of basic cellular processes or molecular events that are key mediators of nervous system function with the intent to probe mechanisms or perturbations in an unbiased and efficient manner.

US and foreign for-profit and non-profit organisations and public and private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants requesting US$500,00 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. The maximum project period is four years.


Closing date: 07 Jan 16

Deadline information: Applications open on 23 January and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 11 Dec 14

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award budget total: -


Eligibility profile

Country of applicant institution: Any

Disciplines

Cellular Interactions; Neurobiology; HIV/AIDS

Contact Details

NSC BG Room 7189
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 5288
Email: jdrisco1@mail.nih.gov
INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): ASSAY DEVELOPMENT AND THERAPEUTIC AGENT IDENTIFICATION AND CHARACTERISATION TO SUPPORT THERAPEUTIC DISCOVERY (R21/R33): AIDS-RELATED

NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its innovation grants to nurture initial translational efforts (IGNITE): assay development and therapeutic agent identification and characterisation to support therapeutic discovery (R21/R33) funding opportunity announcement. This Aids-related announcement encourages research to develop in vitro or ex vivo assays and conduct iterative screening efforts to identify and characterise potential therapeutic agents for neurological disorders. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity uses the NIH phased innovation award (R21/R33) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-071, which also solicits applications under the NIH phased innovation award (R21/R33) grant mechanism.

Application budgets are limited to US$750,000 over the maximum combined project period of three years, with a maximum of US$250,000 for the R21 phase and US$500,000 for the R33 phase. The R21 and R33 cannot be awarded in the same fiscal year.

Ref: PAR-15-070.

Closing date: 07 Jan 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 15 Dec 14
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $750,000
Website:

Application form:

Eligibility profile

Country of applicant institution: Any

Contact Details

NSC BG Room 2106
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 496 1779
Email: amir.tamiz@nih.gov

Disciplines

Neurology; HIV/Aids
INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): PHARMACODYNAMICS AND IN VIVO EFFICACY STUDIES FOR SMALL MOLECULES AND BIOLOGICS/BIOTECHNOLOGY PRODUCTS (R21/R33): AIDS-RELATED

NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its innovation grants to nurture initial translational efforts (IGNITE): pharmacodynamics and in vivo efficacy studies for small molecules and biologics/biotechnology products (R21/R33) funding opportunity announcement. This Aids-related announcement provides funding to conduct pharmacodynamics, pharmacokinetics and in vivo efficacy studies to demonstrate that proposed therapeutic agents have sufficient biological activity to warrant further development to treat neurological disorders. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity uses the NIH phased innovation award(R21/R33) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-070, which also solicits applications under the NIH phased innovation award (R21/R33) grant mechanism.

Application budgets are limited to US$750,000 over the maximum combined project period of three years, with a maximum of US$250,000 for the R21 phase and US$500,000 for the R33 phase. The R21 and R33 cannot be awarded in the same fiscal year.

Ref: PAR-15-071.

Closing date: 07 Jan 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 15 Dec 14
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award budget total: -

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Neurology

Contact Details

NSC BG Room 2106
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 496 1779
Email: amir.tamiz@nih.gov
CADEMIC-INDUSTRIAL PARTNERSHIPS FOR TRANSLATION OF TECHNOLOGIES FOR CANCER DIAGNOSIS AND TREATMENT (R01): AIDS-RELATED

NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its Aids-related academic-industrial partnerships for translation of technologies for cancer diagnosis and treatment (R01) funding opportunity announcement. This Aids-related announcement enables academic and industrial investigators to form research partnerships and work together to accelerate the translation of technologies, methods, assays or devices, systems for preclinical or clinical molecular diagnosis or in vitro imaging designed to solve a targeted cancer problem.

The proposed systems may include molecular diagnosis, molecular imaging or related research resources. Clinical trials that test functionality, and optimise and validate the performance of the proposed translational work may also be funded.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the needs of the project. The maximum funding period is five years.

Ref: PAR-15-075.

Closing date: 07 Jan 16
Deadline information: Applications open on 6 February and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2017.
Posting date: 17 Dec 14
Award type: Clinical trials, Research calls for business, Directed grants to institutions, research groups etc, Academic-Industry links, Networking/collaboration
Award budget total: -

Eligibility profile

Country of applicant institution: Any

Disciplines

Oncology Nursing; Chemotherapy; Radiotherapy; Cancer Immunology; HIV/Aids; Molecularly Targeted Therapy; Cancer Diagnosis

Contact Details

NCI
Building 9609 Room 3W424
9609 Medical Center Drive
Rockville, MD 20850
Tel: +1 240 276 5714
Email: ossandom@mail.nih.gov
PREVENTION RESEARCH IN MID-LIFE ADULTS (R21): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute on Nursing Research and the National Institute on Ageing invite applications for their prevention research in mid-life adults (R21) funding opportunity announcement. This Aids-related announcement encourages research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimise health and wellness as individuals age and prevent illness and disability in later years. This FOA particularly encourages interventions that can be delivered in multiple settings. Studies in disparate groups, such as African American, Native American and Hispanic populations who have a greater prevalence of illness related to multiple chronic conditions, are especially needed. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-098, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The combined application budget is limited to US$275,000 in direct costs over a two year period. No more than US$200,000 may be requested in any single year.

Ref: PA-15-097.

Closing date: 07 Jan 16
Deadline information: Applications open on 16 May 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 23 Jan 15
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award amount max: $275,000


Eligibility profile
Country of applicant institution: Any
Disciplines
Geriatric Nursing; HIV/Aids; Preventive Medicine; Geriatrics & Gerontology; Health of Minority Groups

Contact Details
NINR
BG 1Dem Room 717
6701 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 2154
Email: mary.roary@nih.gov
PREVENTION RESEARCH IN MID-LIFE ADULTS (R01): AIDS RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute on Nursing Research and the National Institute on Aging invite applications for their prevention research in mid-life adults (R01)funding opportunity announcement. This Aids-related announcement encourages research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimise health and wellness as individuals age and prevent illness and disability in later years. This FOA particularly encourages interventions that can be delivered in multiple settings. Studies in disparate groups, such as African American, Native American and Hispanic populations who have a greater prevalence of illness related to multiple chronic conditions, are especially needed. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-097, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. Applicants requesting US$500,000 or more in direct costs in any year (excluding consortium F&A) must contact NIH program staff at least six weeks before submitting the application.

Ref: PA-15-098

Closing date: 07 Jan 16
Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 23 Jan 15
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
HIV/Aids; Geriatrics & Gerontology; Preventive Medicine; Geriatric Nursing; Health of Minority Groups

Contact Details
----------------------------------------------
NINR
BG 1Dem Room 717
6701 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 2154
Email: mary.roary@nih.gov
EDUCTIONS IN ILLICIT DRUG USE AND FUNCTIONAL OUTCOMES (R21/R33):
AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its reductions in illicit drug use and functional outcomes (R21/R33) funding opportunity announcement. This AIDS-related announcement encourages research that determines whether reductions in illicit drug use are associated with positive changes in health-related and other functional outcomes in individuals with substance use disorders. Functional outcomes include, for example, reductions in morbidity, mortality, criminal justice involvement and overall healthcare expenditures.

This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by possible transition to expanded research support (R33 phase). The transition to the R33 phase will be determined by NIH programme evaluation of successful achievement of the milestones set for the R21 phase.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The R21 phase may request up to two years of support for a maximum of US$275,000 in direct costs, with no more than US$200,000 requested in any single year. The R33 phase may request up to three years of support for a maximum of US$500,000 in direct costs per year, although requests for more than US$500,000 per year may also be considered.

Ref: PA-15-099.

Closing date: 07 Jan 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 26 Jan 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/AIDS; Health Promotion; Drug & Substance Abuse; Smoking & Tobacco; Alcoholism

Contact Details
NSC BG Room 4131
6001 Execuctive Boulevard
Rockville MD 20852
Email: imontoya@mail.nih.gov
MATERNAL NUTRITION AND PRE-PREGNANCY OBESITY: EFFECTS ON MOTHERS, INFANTS AND CHILDREN (R01): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research and Office of Dietary Supplements invite applications for their maternal nutrition and pre-pregnancy obesity: effects on mothers, infants and children (R01) funding opportunity announcement. This Aids-related announcement encourages projects to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited, but need to reflect actual needs of the proposed project. Applicants requesting US$500,000 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. The maximum project period is five years.

Ref: PA-15-100 (replaces PA-12-061).

Closing date: 07 Jan 16
Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
Country of applicant institution: Any

Disciplines
- Obesity; HIV/AIDS; Foetal Health & Prenatal Development; Pregnancy & Birth; Maternal Health; Reproduction & Fertility

Contact Details
- NINR
  Building 1Dem, Room 718
  6701 Democracy Boulevard
  Bethesda MD 20817
  Tel: +1 301 594 5976
  Email: hardylr@mail.nih.gov

ROLE OF EXOSOMES IN HIV PATHOGENESIS (R21)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases, together with the National Institute of Mental Health, invites applications for its role of exosomes in HIV pathogenesis (R21) funding opportunity

Posted date: 28 Jan 15
announcement. This announcement encourages new research on the potential role of exosomes in cell-to-cell communication relevant to HIV transmission, innate or adaptive immune responses to HIV or HIV pathogenesis. Studies looking at the function of exosomes in acute infection, or in chronic infection in individuals on fully suppressive antiretroviral regimens are encouraged.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The maximum budget for direct costs for the two-year project period is US$275,000. No more than US$200,000 may be requested in any single year.

The maximum project period is two years.


Closing date: 07 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2018.

**EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R03): AIDS-RELATED**

**NIH: National Cancer Institute**

**Description:**
The National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Environmental Health Sciences invite applications for their Aids-related early-life factors and cancer development in later life (R03) funding opportunity announcement. This Aids-related announcement stimulates research focused on the role of early-life factors in cancer development in later life. A better understanding is sought in the following areas:

- early-life factors that are associated with later cancer development, with early-life including maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and adult years;
• how early-life factors mediate biological processes relevant to carcinogenesis;
• whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies.

This announcement uses the R03 small grant programme mechanism, which supports pilot or feasibility studies, secondary analysis of existing data, small and self-contained research projects, the development of research methodology or the development of new research technology. The announcement also runs on parallel with two announcements of identical scientific scope; PA-15-126, which uses the R01 research project grant mechanism, and PA-15-125, which uses the R21 exploratory or developmental research grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. The principal investigator should attend an NCI-sponsored two-day meeting, generally held every second year in the Washington DC area.

Awards are worth up to US$100,000 each in direct costs over a maximum period of two years.


Closing date: 07 Jan 16

Deadline information: Applications open on 16 May 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 27 Feb 15

Award type: Technology innovation/development, Research calls for business, Directed grants to institutions, research groups etc, Innovation grants, Academic-Industry links, Networking/collaboration

Award amount max: $100,000


Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=274816

Eligibility profile

Country of applicant institution: Any

Disciplines

Cancer Studies & Oncology; HIV/Aids

Contact Details

NCI
Building 9609
Room 4E548
9609 Medical Center Drive
Rockville MD 20850
Tel: +1 240 276 6941
Email: mahabir@mail.nih.gov
EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R21): AIDS-RELATED
NIH: National Cancer Institute

Description:
The National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Environmental Health Sciences invite applications for their AIDS-related early-life factors and cancer development in later life (R21) funding opportunity announcement. This AIDS-related announcement stimulates research focused on the role of early-life factors in cancer development in later life. A better understanding is sought in the following areas:

- early-life factors that are associated with later cancer development, with early-life including maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and adult years;
- how early-life factors mediate biological processes relevant to carcinogenesis;
- whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies.

This announcement uses the R21 exploratory or developmental grant mechanism and runs on parallel with two announcements of identical scientific scope; PA-15-126, which uses the R01 research project grant mechanism, and PA-15-124, which uses the R03 small grant programme mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. The principal investigator should attend an NCI-sponsored two-day meeting, generally held every second year in the Washington DC area.

Awards are worth up to US$275,000 each in direct costs over a maximum period of two years.

Ref: PA-15-125.

Closing date: 07 Jan 16
Deadline information: Applications open on 16 May 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 27 Feb 15
Award type: Research calls for business, Directed grants to institutions, research groups etc, Academic-Industry links, Networking/collaboration
Award amount max: $275,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Cancer Studies & Oncology; HIV/AIDS

Contact Details

NCI
Building 9609
Room 4E548
9609 Medical Center Drive
Rockville MD 20850
Tel: +1 240 276 6941
Email: mahabir@mail.nih.gov
ADVANCING TRANSLATIONAL AND CLINICAL PROBIOTIC OR PREBIOTIC AND HUMAN MICROBIOME RESEARCH (R01): AIDS-RELATED
NIH: National Cancer Institute

Description:
The National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Drug Abuse, the National Center for Complementary and Integrative Health and the Office of Dietary Supplements invite applications for their AIDS-related advancing translational and clinical probiotic or prebiotic and human microbiome research (R01) funding opportunity announcement. This AIDS-related announcement supports interdisciplinary collaborations across scientific disciplines engaged in microbiome and probiotic or prebiotic research.

The aim is to accelerate translational and clinical phase I and II a/b safety and efficacy studies for substantial measurable functional benefits of probiotic or prebiotic components or their combinations, and to understand the underlying mechanisms of their actions and variability in responses to these interventions.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets must reflect the actual needs of the proposed projects. The maximum project period is five years.

Ref: PA-15-127.

Closing date: 07 Jan 16
Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 27 Feb 15
Award type: Clinical trials, Research calls for business, Directed grants to institutions, research groups etc, Innovation grants, Academic-Industry links, Networking/collaboration
Award budget total: -


Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/Aids; Medical Genetics; Microbial Genomics; Microbial Ecology; Population & Ecological Genetics

Contact Details
NCI
Building 9606
Room 5E568
9609 Medical Center Drive
Rockville MD 20850
Tel: +1 240 276 7118
Email: gabriela.riscuta@nih.gov
EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R01): AIDS-RELATED
NIH: National Cancer Institute

Description:
The National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Environmental Health Sciences invite applications for their Aids-related early-life factors and cancer development in later life (R01) funding opportunity announcement. This Aids-related announcement stimulates research focused on the role of early-life factors in cancer development in later life. A better understanding is sought in the following areas:

- early-life factors that are associated with later cancer development, with early-life including maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and adult years;
- how early-life factors mediate biological processes relevant to carcinogenesis;
- whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies.

This announcement uses the R01 research project grant mechanism and runs on parallel with two announcements of identical scientific scope; PA-15-125, which uses the R21 exploratory or developmental grant mechanism, and PA-15-124, which uses the R03 small grant programme mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. The principal investigator should attend an NCI-sponsored two-day meeting, generally held every second year in the Washington DC area.

Application budgets need to reflect the actual needs of the proposed projects. The maximum project period is five years.

Ref: PA-15-126.

Closing date: 07 Jan 16
Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 27 Feb 15
Award type: Research calls for business, Directed grants to institutions, research groups etc, Academic-Industry links, Networking/collaboration

Award budget total: -


Eligibility profile

Country of applicant institution: Any

Disciplines

Cancer Studies & Oncology; HIV/Aids

Contact Details

NCI
Building 9609
Room 4E548
9609 Medical Center Drive
Rockville MD 20850
Tel: +1 240 276 6941
Email: mahabir@mail.nih.gov
FUNCTIONAL WELLNESS IN HIV – MAXIMISING THE TREATMENT CASCADE (R21)
AIDS-RELATED
NIH: National Institutes of Health

Description:
The National Institute of Nursing Research and the Office of Behavioral and Social Sciences Research invite applications for their aids-related functional wellness in HIV – maximising the treatment cascade (R21) funding opportunity announcement. This aids-related announcement encourages the development of HIV interventions that target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV. Projects should include strategies and interventions that aim to:
- improve functional wellness and increase quality of life in HIV positive individuals;
- determine barriers and facilitators to entering and maintaining HIV care;
- validate the construct of functional wellness;
- develop and test methods to improve entrance and continuance in HIV care.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-133, which solicits applications under the NIH research project (R01) grant mechanism.

The combined budget for direct costs over the two-year project period may not exceed US$275,000, with no more than US$200,000 requested in any single year. The maximum project period is two years.

Ref: PA-15-134.

Closing date: 07 Jan 16
Deadline information: Applications open on 16 May 2015 and are due by 5pm local time of applicant organisation every 7 May, 7 September and 7 January until 8 May 2018.
Posted date: 06 Mar 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000


Eligibility profile
---------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------
HIV/Aids; Life Expectancy & Quality of Life; Quality of Care

Contact Details
---------------------------------------------
Tel: +1 301 594 5976
Email: lynda.hardy@nih.gov
FUNCTIONAL WELLNESS IN HIV - MAXIMISING THE TREATMENT CASCADE (R01)
AIDS-RELATED
NIH: National Institutes of Health

Description:
The National Institute of Nursing Research and the Office of Behavioral and Social Sciences Research invite applications for their aids-related functional wellness in HIV – maximising the treatment cascade (R01) funding opportunity announcement. This aids-related announcement encourages the development of HIV interventions that target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV. Projects should include strategies and interventions that aim to:

- improve functional wellness and increase quality of life in HIV positive individuals;
- determine barriers and facilitators to entering and maintaining HIV care;
- validate the construct of functional wellness;
- develop and test methods to improve entrance and continuance in HIV care.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-134, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

Application budgets are not limited but must reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-15-133.

Closing date: 07 Jan 16
Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation every 7 May, 7 September and 7 January until 8 May 2018.
Posted date: 06 Mar 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:

Application form:

Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/AIDS; Life Expectancy & Quality of Life; Quality of Care

Contact Details
Tel: +1 301 594 5976
Email: lynda.hardy@nih.gov
PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN KIDNEY DISEASES (R21): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its Aids-related pilot and feasibility clinical research grants in kidney diseases (R21) funding opportunity announcement. This Aids-related announcement supports small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney diseases research.

Studies should address important clinical and translational questions that are potentially of high clinical and public health impact.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-162, which also solicits applications under the R21 mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs with a maximum of US$200,00 per year. The maximum project period is two years.


Closing date: 07 Jan 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation on every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 30 Mar 15
Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000


Eligibility profile
Country of applicant institution: Any
Disciplines
Nephrology & Kidneys; HIV/Aids

Contact Details
BG 2DEM Room 633
6707 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 7717
Email: mm726k@nih.gov
**IMPROVING DIET AND PHYSICAL ACTIVITY ASSESSMENT (R21): AIDS-RELATED**

**NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

**Description:**
A total of seven participating institutes and centres of the National Institutes of Health invite applications for their diet and physical activity assessment methodology (R21) funding opportunity announcement. This Aids-related announcement supports innovative research to enhance the quality of measurements of dietary intake and physical activity.

This FOA uses the NIH exploratory/developmental grant (R21) award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-15-170, which solicits applications under the NIH research project grant (R01) award mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs, with up to US$200,000 available for direct costs per year. The maximum project period is two years.

PAR-15-171 (reissue of PAR-12-197).

**Closing date:** 07 Jan 16
**Deadline information:** Applications open on 16 September and are due by 5pm local time of applicant organisation on 7 January and 7 September 2016, 7 May 2017, and 7 January and 7 September 2018.
**Posted date:** 02 Apr 15
**Award type:** Directed grants to institutions, research groups etc, Innovation grants
**Award amount max:** $275,000


**Eligibility profile**

**Country of applicant institution:** Any

**Disciplines**

Nutrition & Dietetics; Behavioural Medicine; Obesity; HIV/Aids

**Contact Details**

NIDDK
BG 2DEM Room 681
6707 Democracy Boulevard
BETHESDA MD 20817
Tel: +1 301 594 4578
Email: evansmary@niddk.nih.gov
DIET AND PHYSICAL ACTIVITY ASSESSMENT METHODOLOGY (R01): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
A total of seven participating institutes and centres of the National Institutes of Health invite applications for their diet and physical activity assessment methodology (R01) Aids-related funding opportunity announcement. This Aids-related announcement supports innovative research to enhance the quality of measurements of dietary intake and physical activity.

This FOA uses the NIH research project grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-15-171, which solicits applications under the NIH exploratory/developmental grant (R21) award mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but need to reflect the actual costs of the proposed project. The maximum project period is five years.

PAR-15-170 (reissue of PAR-12-198).

Closing date: 07 Jan 16
Deadline information: Applications open on 5 September 2015 and are due by 5pm local time of applicant organisation on 7 January and 7 September 2016, 7 May 2017, and 7 January and 7 September 2018.
Posted date: 02 Apr 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award budget total: -

Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275619

Eligibility profile
-----------------------------
Country of applicant institution: Any

Disciplines
-----------------------------
Sports Medicine; Behavioural Medicine; Obesity; HIV/Aids; Exercise Physiology; Nutrition & Dietetics

Contact Details
-----------------------------
NIDDK
BG 2DEM Room 681
6707 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 4578
Email: evansmary@niddk.nih.gov
Description:
The National Institute of Dental and Craniofacial Research invites applications for its immune system plasticity in the pathogenesis and treatment of complex dental, oral, and craniofacial diseases (R21) funding opportunity announcement. This Aids-related announcement supports contemporary, systematic research to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral and craniofacial diseases as well as to develop novel tools and technologies to treat and prevent disease based on precise modulation of the immune system. Plasticity, for the purposes of this initiative, is defined as the ability of the immune system to undergo changes in both characteristics and functions in response to the environment.

Clinical trials are not supported.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-192, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs with up to US$200,000 in direct costs per year.

The maximum project period is two years.


Closing date: 07 Jan 16
Deadline information: Applications open on 16 September 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.

Posted date: 29 Apr 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Website:

Application form:
http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276222

Eligibility profile
Country of applicant institution: Any

Disciplines
Dental Health & Hygiene; Oral Medicine; Restorative Dentistry; Endodontics; Preventive Dentistry; HIV/AIDS; Dental Therapeutics & Pharmacology; Periodontics; Craniofacial Disorders

Contact Details
BG 1DEM Room 620
6701 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 9718
Email: amanda.melillo@mail.nih.gov
IMMUNE SYSTEM PLASTICITY IN THE PATHOGENESIS AND TREATMENT OF COMPLEX DENTAL, ORAL, AND CRANIOFACIAL DISEASES (R01) – AIDS-RELATED
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its immune system plasticity in the pathogenesis and treatment of complex dental, oral and craniofacial diseases (R21) funding opportunity announcement. This Aids-related announcement supports contemporary, systematic research to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral and craniofacial diseases as well as to develop novel tools and technologies to treat and prevent disease based on precise modulation of the immune system. Plasticity, for the purposes of this initiative, is defined as the ability of the immune system to undergo changes in both characteristics and functions in response to the environment.

Clinical trials are not supported.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-193, which solicits applications under the NIH exploratory/developmental (R21) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the actual needs of the proposed project.

The maximum project period is five years. Ref: PAR-15-192.

Closing date: 07 Jan 16

Deadline information: Applications open on 5 September 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018. Applicants requesting US$500,000 or more in direct costs in any year must contact a scientific contact at least six weeks before submitting the application. Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016.

Posted date: 29 Apr 15

Award type: Directed grants to institutions, research groups etc

Award budget total: -


Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276220

Eligibility profile

Country of applicant institution: Any

Disciplines

Endodontics; Oral Medicine; Preventive Dentistry; Dental Therapeutics & Pharmacology; Dental Health & Hygiene; Periodontics; Craniofacial Disorders; HIV/Aids; Restorative Dentistry

Contact Details

BG 1DEM Room 620
6701 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 9718
Email: amanda.melillo@mail.nih.gov
DEVELOPING THE THERAPEUTIC POTENTIAL OF THE ENDOCANNABINOID SYSTEM FOR PAIN TREATMENT (R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
A total of seven institutes and centres of the National Institutes of Health invite applications for their developing the therapeutic potential of the endocannabinoid system for pain treatment (R01) funding opportunity announcement. This Aids-related announcement supports projects that seek to elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain. Applications should consider the following points:

- if plant-derived cannabis material is proposed it should be well justified, with a statement on where the material or compounds will be obtained, and the stats of a schedule one license should be noted;
- explicit sex or gender analyses of effects are highly encouraged;
- role of cannabinoids in the modulation of HIV pain is also encouraged.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is four years.

Ref: PA-15-188.

Closing date: 07 Jan 16
Deadline information: Applications are accepted between 5 September 2015 and 5pm local time of applicant organisation on every 7 May, 7 September and 7 January until 8 September 2018.
Posted date: 29 Apr 15
Award type: Research calls for business, Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: -

Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276193

Eligibility profile
-----------------------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------------------
HIV/Aids; Chronic Pain; Pain Management

Contact Details
-----------------------------------------------------------
Tel: +1 301 435 1313
Email: dthomas1@nida.nih.gov
STUDIES AT PERIVIABLE GESTATION (R03) – AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its studies at periviable gestation (R03) funding opportunity announcement. This Aids-related announcement supports research that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants. The scope of this FOA includes the following areas:

- knowledge gaps in obstetrical care practices at periviable gestations;
- knowledge gaps in neonatal care at periviable gestations;
- research needs concerning family counseling.

This funding opportunity uses the NIH small grant programme (R03) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-198, which solicits applications under the NIH exploratory or developmental (R21) grant mechanism and PA-15-200, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$100,000 in direct costs with up to US$50,000 in direct costs per year.

The maximum project period is two years.

Ref: PA-15-199.

Closing date: 07 Jan 16
Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September, until 8 September 2018.
Posted date: 05 May 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276312

Eligibility profile

Country of applicant institution: Any

Disciplines

Obstetrics & Gynaecology; Family & Relationships Counselling; HIV/Aids; Foetal Health & Prenatal Development; Pregnancy & Birth

Contact Details

NICHD
BG 6100 RM 4B03B
6100 Executive Boulevard
Rockville MD 20852
Tel: +1 301 435 7909
Email: higginsr@mail.nih.gov
STUDIES AT PERIVIABLE GESTATION (R21) – AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its studies at periviable gestation (R21) funding opportunity announcement. This Aids-related announcement supports research that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants. The scope of this FOA includes the following areas:

- knowledge gaps in obstetrical care practices at periviable gestations;
- knowledge gaps in neonatal care at periviable gestations;
- research needs concerning family counseling.

This funding opportunity uses the NIH exploratory or developmental (R21) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-199, which solicits applications under the NIH small grant programme (R03) grant mechanism and PA-15-200, which solicits applications under the NIH research project ((R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs with up to US$200,000 in direct costs per year.

The maximum project period is two years.


Closing date: 07 Jan 16
Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September, until 8 September 2018.

Posted date: 05 May 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:

Application form:
http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276320

Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/AIDS; Foetal Health & Prenatal Development; Family & Relationships Counselling; Pregnancy & Birth; Obstetrics & Gynaecology

Contact Details
NICHD
BG 6100 RM 4B03B
6100 Executive Boulevard
Rockville MD 20852
Tel: +1 301 435 7909
Email: higginsr@mail.nih.gov
STUDIES AT PERIVIABLE GESTATION (R01) – AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its studies at periviable gestation (R01) funding opportunity announcement. This Aids-related announcement supports research that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants. The scope of this FOA includes the following areas:

- knowledge gaps in obstetrical care practices at periviable gestations;
- knowledge gaps in neonatal care at periviable gestations;
- research needs concerning family counseling.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-198, which solicits applications under the NIH exploratory or developmental (R21) grant mechanism and PA-15-199, which solicits applications under the NIH small grant programme (R03) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.


Closing date: 07 Jan 16
Deadline information: Applications open on 5 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September, until 8 September 2018. Applicants requesting US$500,000 or more in direct costs in any year must contact a scientific contact at least six weeks before submitting the application.

Posted date: 05 May 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276313

Eligibility profile
Country of applicant institution: Any

Disciplines
Pregnancy & Birth; Obstetrics & Gynaecology; HIV/AIDS; Family & Relationships Counselling; Foetal Health & Prenatal Development

Contact Details
NIHDC
BG 6100 RM 4B03B
6100 Executive Boulevard
Rockville MD 20852
Tel: +1 301 435 7909
Email: higginsr@mail.nih.gov
HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R03) – AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its human studies to evaluate promising medications to treat alcohol use disorder (R03) funding opportunity announcement. This Aids-related announcement encourages applications that use human laboratory paradigms or clinical trials to evaluate the safety and efficacy of novel or repurposed compounds, that bind to new targets, for treatment of alcohol use disorder or AUD with a comorbid post-traumatic stress disorder.

This funding opportunity uses the NIH small grant programme (R03) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-256 and PA-15-254, which solicit applications under the NIH research project (R01) grant mechanism and the NIH exploratory/developmental (R21) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$100,000 in direct costs with up to US$50,000 in direct costs per year.

The maximum project period is two years.

Ref: PA-15-255.

Closing date: 07 Jan 16
Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.
Posted date: 14 May 15
Awards type: Clinical trials, Directed grants to institutions, research groups etc
Award amount max: $100,000

Application form:

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Alcoholism; Post Traumatic Stress Disorder; HIV/AIDS

Contact Details
----------------------------------------------
BG 5635FL Room 2041
5635 Fishers Lane
Rockville MD 20852
Tel: +1 301 443 0636
Email: rlitten@mail.nih.gov
**Human Studies to Evaluate Promising Medications to Treat Alcohol Use Disorder (R21) - AIDS-Related**

**NIH: National Institute on Alcohol Abuse and Alcoholism**

**Description:**
The National Institute on Alcohol Abuse and Alcoholism invites applications for its human studies to evaluate promising medications to treat alcohol use disorder (R21) funding opportunity announcement. This Aids-related announcement encourages applications that use human laboratory paradigms or clinical trials to evaluate the safety and efficacy of novel or repurposed compounds, that bind to new targets, for treatment of alcohol use disorder or AUD with a comorbid post-traumatic stress disorder.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-255 and PA-15-256, which solicit applications under the NIH small grant programme (R03) grant mechanism and the NIH research project (R01) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs with up to US$200,000 in direct costs per year.

The maximum project period is two years.

Ref: PA-15-254.

**Closing date:** 07 Jan 16

Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018.

Posted date: 14 May 15

Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants

Award amount max: $275,000


**Eligibility profile**

-------------------------------
Country of applicant institution: Any

**Disciplines**

-----------------------------------
Alcoholism; Post Traumatic Stress Disorder; HIV/AIDS

**Contact Details**

-----------------------------------
BG 5635FL Room 2041
5635 Fishers Lane
Rockville MD 20852
Tel: +1 301 443 0636
Email: rlitten@mail.nih.gov
**Human Studies to Evaluate Promising Medications to Treat Alcohol Use Disorder (R01) – AIDS-Related**

**NIH: National Institute on Alcohol Abuse and Alcoholism**

**Description:**
The National Institute on Alcohol Abuse and Alcoholism invites applications for its human studies to evaluate promising medications to treat alcohol use disorder (R03) funding opportunity announcement. This AIDS-related announcement encourages applications that use human laboratory paradigms or clinical trials to evaluate the safety and efficacy of novel or repurposed compounds, that bind to new targets, for treatment of alcohol use disorder or AUD with a comorbid post-traumatic stress disorder.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-255 and PA-15-254, which solicit applications under the NIH small grant programme (R03) grant mechanism and the NIH exploratory/developmental (R21) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the actual costs of the proposed project.

The maximum project period is five years.

Ref: PA-15-256.

**Closing date: 07 Jan 16**

**Deadline information:** Applications open on 5 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 May 2018. Applicants requesting US$500,000 or more in direct costs in any year must contact scientific contact at least six weeks before submitting the application.

**Posted date:** 14 May 15

**Award type:** Clinical trials, Directed grants to institutions, research groups etc

**Award budget total:** -


**Application form:** [http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276559](http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276559)

**Eligibility profile**

---

**Country of applicant institution:** Any

**Disciplines**

---

Post Traumatic Stress Disorder; Alcoholism; HIV/Aids

**Contact Details**

---

BG 5635FL Room 2041
5635 Fishers Lane
Rockville MD 20852
Tel: +1 301 443 0636
Email: rlitten@mail.nih.gov
EXPLOITING RNA AS A TARGET FOR HIV INTERVENTIONS (R21)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Disease and the National Institute of Mental Health invite applications for their exploiting RNA as a target for HIV infections (R21) funding opportunity announcement. This aims to investigate the role of viral and cellular non-coding RNAs in the regulation of HIV replication, pathogenesis, latency, immunity and gene expression, exploit IncRNAs for the development of novel HIV interventions, and exploit advances in RNA structural biology to identify novel targets for HIV intervention and functional cure.

Applicants may be from US and foreign for-profit and non-profit organisations or public and private organisations.

Each award covers direct costs of up to US$275,000 over a maximum project period of two years. No more than US$200,000 may be requested in any single year.


Closing date: 07 Jan 16
Deadline information: Applications open on 7 August 2015 and are due by 5pm local time of applicant organisation on every 7 September, 7 January and 7 May until 8 May 2018.

Posted date: 08 Jun 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000


Eligibility profile
Country of applicant institution: Any

Disciplines
Pharmacy & Pharmacology; Immunology; HIV/AIDS; Ribonucleic Acid, RNA

Contact Details
Tel: +1 240 627 3209
Email: brigitte.sanders@nih.gov

UNDERSTANDING HIV PERSISTENCE IN INFANTS (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its understanding HIV persistence in infants (R01) funding opportunity announcement. This aims to stimulate research in the pathogenesis of perinatal HIV-1 infection by elucidating HIV-1 immune responses in the setting of the infant’s evolving immune system, and mechanisms of establishment and
maintenance of HIV-1 latent viral reservoirs. The goal is to gain knowledge to be used in the future development of strategies to induce HIV-1 remission.

Applicants may be from US and foreign for-profit and non-profit organisations or public and private organisations.

Application budgets must reflect the actual needs of the project. The maximum project period is five years.


Closing date: 07 Jan 16
Deadline information: Applications open on 7 August 2015 and are due by 5pm local time of applicant organisation on every 7 September, 7 January and 7 May until 8 January 2016.
Posted date: 08 Jun 15

Award type: Directed grants to institutions, research groups etc.
Award budget total: -

Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/Aids; Infant Paediatrics

Contact Details
Tel: +1 240 627 3096
Email: decarloe@niaid.nih.gov

HARNESSING BIG DATA TO HALT HIV (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases, the National Cancer Institute, the National Institute on Drug Abuse and the National Institute of Mental Health invite applications for their harnessing big data to halt HIV (R01) funding opportunity announcement. This promotes research that transforms understanding of HIV transmission, the HIV care continuum and HIV comorbidities using big data science.

Projects should identify gaps in rare, unseen and otherwise undiscovered biomedical, behavioural, social patterns and other social determinants that shed light on HIV acquisition, transmission and long-term control as in the HIV treatment continuum. Approaches should include projects to assemble big data sources, conduct robust and reproducible analyses, and create meaningful visualisation of big data.

Applicants may be from US and foreign for-profit and non-profit organisations or public and private organisations.

Application budgets must reflect the actual needs of the project. The maximum project period is five years.


Closing date: 07 Jan 16
Deadline information: Applications open on 7 August 2015 and are due by 5pm local time of applicant organisation on every 7 September, 7 January and 7 May until 8 May 2018.

Posted date: 08 Jun 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
Country of applicant institution: Any

Disciplines
Medical Informatics & Telemedicine; HIV/Aids; Health Informatics; Bioinformatics

Contact Details
Tel: +1 240 627 3214
Email: rm434n@nih.gov

**BIOENGINEERING RESEARCH PARTNERSHIP – NON- OR MINIMALLY-INVASIVE METHODS TO MEASURE BIOCHEMICAL SUBSTANCES DURING NEONATAL AND PERINATAL PATIENT CARE AND RESEARCH (R01): AIDS-RELATED**

**NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

**Description:**
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications, under the bioengineering research partnership, for its Aids-related non- or minimally-invasive methods to measure biochemical substances during neonatal and perinatal patient care and research (R01) funding opportunity announcement. Funding enables bioengineering and biomedical scientists to collaborate in developing non- and minimally-invasive methods for measuring biochemical substances in connection with the care of perinatal patient populations.

The developed methods should test analytes and physiological variables, and may include serum electrolytes, liver function tests, renal functions, biomarkers of infection and inflammation, metabolic by-products of drugs, concentrations of drugs used in clinical care or research and physiological variables affected by cardiopulmonary and metabolic systems. Sources for developing the noted monitoring could include trans-epidermal, transcutaneous using nano-sized electrodes, saliva and other fluids.

This announcement solicits applications under the R01 research project grant mechanism and runs in parallel with an opportunity of an identical scientific scope, RFA-HD-16-028, which solicits applications from US-based applicants using the R41 small business technology transfer grant mechanism for phase I projects.

Applicants may be from US and foreign for-profit and non-profit organisations or public and private organisations.

Application budgets must reflect the actual needs of the project. The maximum project period is five years.

ND-OF-LIFE AND PALLIATIVE NEEDS OF ADOLESCENTS AND YOUNG ADULTS WITH SERIOUS ILLNESSES (R01) AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research, the National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Office of Research on Women’s Health invite applications for their end-of-life and palliative needs of adolescents and young adults with serious illnesses (R01) funding opportunity announcement. This Aids-related announcement aims to foster research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses. Funding also supports research focused on specific end-of-life or palliative care models that support the physical, psychological, spiritual and social needs of AYA with serious illness as well as their families and caregivers. The objective is to encourage clinical studies aimed at:

- increasing this knowledge base;
- developing AYA-appropriate measurement tools;
- designing, testing and evaluating of AYA-specific EOLPC models of care and interventions that positively impact health-related quality of life for AYA with serious illness, and their family and caregivers. This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-325, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit, non-profit and public and private organisations may apply.
Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-15-324.

Closing date: 07 Jan 16

Deadline information: Applications open on 5 January 2016 and are due by 5pm local time of applicant organisation every 7 September, 7 January and 7 May until 8 January 2019.

Posted date: 10 Aug 15

Award type: Directed grants to institutions, research groups etc

Award budget total: -

Website:

Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/AIDS; Adolescent Paediatrics; Youth & Adolescents; Child & Adolescent Psychiatry

Contact Details
Tel: +1 301 594 8911
Email: lynn.adams@nih.gov

ETHICAL, LEGAL AND POLICY ISSUES IN HIV RESEARCH WITH KEY POPULATIONS (R21)

NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their ethical, legal and policy issues in HIV research with key populations (R21) funding opportunity announcement. This encourages applications to analyse and address ethical, legal or policy challenges to specific work with populations that experience high risk of HIV acquisition due to certain behaviours and risk exposures. Projects should focus on ethical, legal or policy challenges in relation to research studies or programme implementation for HIV or associated co-morbidities affecting one or more of the following key populations:

- men who have sex with men;
- people who inject drugs;
- people in prisons and other closed settings;
- sex workers;
- transgender people;
- adolescent girls and young women at high risk of HIV acquisition or who are living with HIV. Empirical and conceptual research projects addressing these topics are encouraged. This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scope, PAR-15-328, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are limited to US$275,000 for the maximum project period of two years.
No more than US$200,000 may be requested in any single year.

Ref: PAR-15-327

Closing date: 07 Jan 16

Deadline information: Applications open on 7 December, 2015 and are due 7 January and 7 September, 2016 and 2017 and on 8 January and 7 September, 2018 by 5pm local time of applicant organisation until 8 September, 2018. Deadlines on: 7 January 2016, 7 September 2016, 7 January 2017, 7 September 2017, 8 January 2018, 7 September 2018.

Posted date: 11 Aug 15

Award type: Directed grants to institutions, research groups etc

Award amount max: $275,000

Website:

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Health Systems Policy; HIV/Aids; Lesbian, Gay, Bisexual & Transgender Studies; Medical & Health Ethics; Legal Ethics; Prostitution; Women’s Health

Contact Details
----------------------------------------------
Tel: +1 240 627 3210
Email: dawsonl@niaid.nih.gov

---

ETHICAL, LEGAL AND POLICY ISSUES IN HIV RESEARCH WITH KEY POPULATIONS (R21) AIDS-RELATED

NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their ethical, legal and policy issues in HIV research with key populations (R21) funding opportunity announcement. This Aids-related announcement encourages applications to analyse and address ethical, legal or policy challenges to specific to work with populations that experience high risk of HIV acquisition due to certain behaviours and risk exposures. Projects should be focused on ethical, legal or policy challenges in relation to research studies or programme implantation for HIV or associated co-morbidities affecting one or more of the following key populations:

- men who have sex with men;
- people who inject drugs;
- people in prisons and other closed settings;
- sex workers;
- transgender people;
- adolescent girls and young women at high risk of HIV acquisition or who are living with HIV. Empirical and conceptual research projects addressing these topics are encouraged. This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scope, PAR-15-328, which solicits applications under the NIH research project (R01) grant mechanism.
US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are limited to US$275,000 for the maximum project period of two years. No more than US$200,000 may be requested in any single year.

Ref: PAR-15-327

Closing date: 07 Jan 16

Posted date: 11 Aug 15

Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Lesbian, Gay, Bisexual & Transgender Studies; Health Systems Policy; Medical & Health Ethics; Prostitution; HIV/Aids; Legal Ethics; Women’s Health

Contact Details
Tel: +1 240 627 3210
Email: dawsonl@niaid.nih.gov

ETHICAL, LEGAL AND POLICY ISSUES IN HIV RESEARCH WITH KEY POPULATIONS (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their ethical, legal and policy issues in HIV research with key populations (R01) funding opportunity announcement. This encourages applications to analyse and address ethical, legal or policy challenges to specific to work with populations that experience high risk of HIV acquisition due to certain behaviours and risk exposures. Projects should focus on ethical, legal or policy challenges in relation to research studies or programme implantation for HIV or associated co-morbidities affecting one or more of the following key populations:

- men who have sex with men;
- people who inject drugs;
- people in prisons and other closed settings;
- sex workers;
- transgender people;
- adolescent girls and young women at high risk of HIV acquisition or who are living with HIV.

Empirical and conceptual research projects addressing these topics are encouraged. This funding opportunity uses the NIH exploratory/developmental (R01) grant mechanism and runs in parallel with one of identical scope, PAR-15-327, which solicits
applications under the NIH research project (R21) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-15-328

Closing date: 07 Jan 16
Deadline information: Applications open on 7 December, 2015 and are due 7 January and 7 September, 2016 and 2017 and on 8 January and 7 September, 2018 by 5pm local time of applicant organisation until 9 September, 2018. Deadlines on: 7 January 2016, 7 September 2016, 7 January 2017, 7 September 2017, 8 January 2018, 7 September 2018.

Ethical, Legal and Policy Issues in HIV Research with Key Populations (R01) AIDS-RELATED

NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their ethical, legal and policy issues in HIV research with key populations (R01) funding opportunity announcement. This Aids-related announcement encourages applications to analyse and address ethical, legal or policy challenges to specific to work with populations that experience high risk of HIV acquisition due to certain behaviours and risk exposures. Projects should focus on ethical, legal or policy challenges in relation to research studies or programme implantation for HIV or associated co-morbidities affecting one or more of the following key populations:

- men who have sex with men;
- people who inject drugs;
- people in prisons and other closed settings;
- sex workers;
- transgender people;
- adolescent girls and young women at high risk of HIV acquisition or who are living with HIV. Empirical and conceptual research projects addressing these topics are encouraged. This funding opportunity uses the

Posted date: 11 Aug 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile

Country of applicant institution: Any

Disciplines

Legal Ethics; Medical & Health Ethics; Lesbian, Gay, Bisexual & Transgender Studies; Women’s Health; Prostitution; Health Systems Policy; HIV/Aids

Contact Details

+1 240 627 3210
Email: dawsonl@niaid.nih.gov
exploratory/developmental (R01) grant mechanism and runs in parallel with one of identical scope, PAR-15-327, which solicits applications under the NIH research project (R21) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-15-328

Closing date: 07 Jan 16

Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
Country of applicant institution: Any

Disciplines
Health Systems Policy; Medical & Health Ethics; Legal Ethics; Prostitution; HIV/AIDS; Lesbian, Gay, Bisexual & Transgender Studies; Women’s Health

Contact Details
Tel: +1 240 627 3210
Email: dawsonl@niaid.nih.gov

SMALL RESEARCH GRANTS FOR ORAL HEALTH DATA ANALYSIS AND STATISTICAL METHODOLOGY DEVELOPMENT AIDS-RELATED (R03)
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its small research grants for oral health data analysis and statistical methodology development (R03) funding opportunity announcement. This Aids-related announcement supports research projects that involve secondary data analyses of existing oral or craniofacial database resources, or aims to develop needed statistical methodology for analysing oral and craniofacial data using existing oral or craniofacial databases. This R03 grant mechanism supports research specifically limited in time and amount for studies in categorical programme areas.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Projects may receive up to US$100,000 per year for a maximum period of two years.

Ref: PAR-15-344 (replaces PAR-12-120).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.  
Posted date: 10 Sep 15  
Award type: Directed grants to institutions, research groups etc  
Award amount max: $200,000  

### Eligibility profile

Country of applicant institution: Any

### Disciplines

HIV/Aids; Data Analysis; Oral Medicine

### Contact Details

+1 301 594 4876  
Email: dena.fischer@nih.gov

---

**RESEARCH ON THE MECHANISMS AND BEHAVIOURAL OUTCOMES OF MULTISENSORY PROCESSING (R01) AIDS-RELATED**  
**NIH: National Institutes of Health**

**Description:**  
A total of eleven institutes and offices of the National Institutes of Health invite applications for their research on the mechanisms and behavioural outcomes of multisensory processing (R01) funding opportunity announcement. This Aids-related announcement supports basic, behavioural and clinical research projects examining the interactions between neural systems such as cognitive, affective or motor processes and multiple sensory modalitites. Innovative studies, using animal or human subjects examining two or more senses for the elucidation of mechanisms and behavioural outcomes of multisensory processing, are encouraged. The initiative supports the use of diverse methodologies including basic biochemical, molecular, cellular, genetic approaches, neuroimaging and neurophysiological analyses, experimental psychophysics, “real world” settings, immersive virtual technology and animal models.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants requesting US$500,000 or more in direct costs in any year must contact a scientific research contact at least six weeks before submitting the application. The maximum project period is five years.

Ref: PA-15-347.

**Closing date: 07 Jan 16**

Deadline information: Applications open on 5 January 2016 and due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.  
Declarations on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.  
Posted date: 18 Sep 15  
Award type: Clinical trials, Directed grants to institutions, research groups etc  
Award budget total: -
PERSONALISED STRATEGIES TO MANAGE SYMPTOMS OF CHRONIC ILLNESS (R01)
AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for its personalised strategies to manage symptoms of chronic illness (R01) Aids-related funding opportunity announcement. This Aids-related announcement aims to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life in persons with chronic illness through increasing knowledge of the biological mechanisms of symptoms and promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms. The research objectives are to:

- examine complex adaptive symptoms related to biobehavioural and environmental interactions that underlie symptom evolution to include change over time;
- identify and validate novel biomarkers and other patient risk factors to assess individual susceptibility to physical, cognitive and affective symptoms and serve as surrogate endpoints for evaluating clinical benefit of targeted interventions;
- develop computer-simulated dynamic models that result in strategies to address individual heterogeneity related symptoms, clusters and patterns;
- develop and test targeted scalable interventions to prevent and mitigate symptoms and clusters to include examination of omics and genetic factors that predict response to interventions;
- examine large databases and electronic health records to discover new biologic, clinical, psychosocial, behavioural and economic factors related to symptom burden and health-related quality of life experienced by persons with chronic illness and new patterns and trends that may translate to targeted interventions.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with two of identical scientific scope, PA-16-008 and PA-16-006, which solicits applications under the NIH exploratory and developmental (R21) grant mechanism and the NIH academic research (R15) enhancement award.
US and foreign for-profit and non-profit organisations and public and private organisations may apply. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-16-007.

Closing date: 07 Jan 16

Deadline information: Applications open on 5 January 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Deadlines on: 7 January 2016, 7 May 2016, 7 September 2016, and repeated annually.

Posted date: 19 Oct 15

Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration

XAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R21)

AIDS-RELATED

NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its examination of survivorship care planning efficacy and impact (R21) Aids-related funding opportunity announcement. This Aids-related announcement aims to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy, with the goal to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors. Specifically, this call aims to stimulate research that will:

- develop and test metrics for evaluating the impact of survivorship care planning;
- evaluate the impact of survivorship care planning on cancer survivors morbidity, self-management and adherence to care recommendations, utilisation of follow-up care;
- evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organisations implementing the care planning;
- identify models and processes of care that promote effective survivorship care planning.

Award budget total: -

Website: http://grants.nih.gov/grants/guide/pa-files/PA-16-007.html

Eligibility profile

Country of applicant institution: Any

Disciplines

Intensive Care & Life Support; Genomics; Biochemical Markers; Innovation & Technology Management; Life Expectancy & Quality of Life

Contact Details

Tel: +1 301 594 2775
Email: matocham@mail.nih.gov
This funding opportunity uses the NIH exploratory and developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-012, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Application budgets are limited to US$275,000 per year for a maximum project period of two years. No more than US$200,000 may be requested in any single year.

Ref: PA-16-011 (replaces PA-12-274).

Closing date: 07 Jan 16
Deadline information: Applications open on 16 January 2016 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

IV AND AIDS HIGH PRIORITY DRUG ABUSE RESEARCH (R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its HIV and Aids high priority drug abuse research (R01) funding opportunity announcement. This announcement aims to stimulate high priority research relevant to drug abuse and HIV and Aids. Populations of interest include urban and non-urban drug users, including those transitioning to injection drug use and populations where HIV is heavily concentrated such as men who have sex with men, especially men of young age from minority groups.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

NIDA intends to fund up to 34 awards and has set aside US$18 million for fiscal years 2016 to 2019. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAS-16-018.

Closing date: 07 Jan 16
Deadline information: Applications open on 7 December 2015 and are due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 September 2018.

Posted date: 28 Oct 15
Award type: Directed grants to institutions, research groups etc
Award budget total: $18,000,000

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse; Disadvantaged & Minority Groups; Health of Minority Groups; Lesbian, Gay, Bisexual & Transgender Studies; HIV/AIDS

Contact Details

Tel: +1 301 443 2261
Email: kahanas@mail.nih.gov

INNOVATIVE QUESTIONS IN SYMPTOM SCIENCE AND GENOMICS (R01): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for its innovative questions in symptom science and genomics (R01) Aids-related funding opportunity announcement. This Aids-related announcement seeks to optimise innovation, insight and cutting edge conceptual and technological breakthroughs by catalysing research that emanates from the identified questions in symptom and genomic nursing science. These innovative questions are reflective of broad domains from which more specific novel hypotheses or problems to be solved can be derived.

This funding opportunity uses the NIH research project grant (R21) mechanism and runs in parallel with two of identical scientific scope, PA-16-023 and PA-16-022, which solicit applications under the NIH exploratory or developmental grant (R01) mechanism and the NIH academic research enhancement award (R15) mechanism, respectively.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-16-024.

Closing date: 07 Jan 16
Deadline information: Applications open on 5 January 2016 and due by 5pm local time of applicant organisation every 7 January, 7 May and 7 September until 8 January 2019.

Posted date: 02 Nov 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award budget total: -
Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids; Nursing; Diagnostic Sciences; Genomics

Contact Details

Tel: +1 301 594 2775
Email: matocham@mail.nih.gov

EXTENDED DEADLINE: DEVELOPMENT OF MINIMALLY INVASIVE BIOASSAYS TO SUPPORT OUTPATIENT CLINICAL TRIALS OF THERAPEUTICS FOR SUBSTANCE USE DISORDERS (R21)

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse has extended the expiration date for its development of minimally invasive bioassays to support outpatient clinical trials of therapeutics for substance use disorders (R21) grants. The expiration date has been extended from 8 September 2015 to 8 January 2016. All other call details remain unchanged. ***

This R21 funding opportunity announcement solicits proposals that seek to develop non-invasive or minimally invasive methods to support outpatient clinical trials of pharmacotherapies for substance use disorders. The announcement has two main aims:

- to encourage the development of devices or techniques that will improve estimations of a subject’s consumption of an abused drug during an outpatient clinical trial. Such a system would allow objective assessment of whether a medication reduces drug abuse, even if abstinence is not achieve. Proposed solutions should be able to assess systematic drug levels and be safe, portable, affordable and simple enough for subjects to take multiple samples at home and return them to the clinic for batch analysis;

- to develop new, improved markers to evaluate a subject’s adherence to the study medication. The goal is for investigators to be able to determine the level of systematic medication exposure throughout a study. Assays should be applicable to one of the following situations - assessment of medication adherence in a manner suitable for use in a clinical setting; or the quantitative assessment of medication adherence throughout an outpatient clinical trial.

This FOA will utilise the NIH exploratory/developmental grant (R21) award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-12-239, that solicits applications under the research project grant (R01)award mechanism. NIDA intends to commit up to US$2 million to fund both mechanisms in fiscal year 2013, and will fund up to seven R21 awards.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Domestic and foreign for-profit and non-profit organisations...
and public or private institutions are eligible to apply. PAR-12-238.

Closing date: 08 Jan 16
Deadline information:
Posted date: 07 Aug 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: [http://grants.nih.gov/grants/guide/par-files/PAR-12-238.html](http://grants.nih.gov/grants/guide/par-files/PAR-12-238.html)

Application form: [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-238](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-238)

### Eligibility profile
- Country of applicant institution: Any

### Disciplines
- Drug Design; Drug & Substance Abuse

### Contact Details
- Medications Research Grants Branch
  - NIDA
  - NIH
  - 6001 Executive Boulevard
  - Rockville, MD 20852
  - Tel: +1 301 443 8039
  - Fax: +1 301 443 9649
  - Email: aidan.hampson@nih.gov

---

**CHARACTERISATION OF MYCOBACTERIAL INDUCED IMMUNITY IN HIV-INFECTED AND UNINFECTED INDIVIDUALS (R21)**

**NIH: National Institute of Allergy and Infectious Diseases**

**Description:**
The National Institute of Allergy and Infectious Diseases invites applications for its characterisation of mycobacterial induced immunity in HIV–infected and uninfected individuals (R21) funding opportunity announcement. This announcement aims to support hypothesis-generating research on innate and adaptive immune responses induced by mycobacterial infection, Bacillus Calmette–Guerin vaccine or other mycobacterium tuberculosis vaccinations. Studies that include evaluation of immune responses by anatomical location in HIV-infected or uninfected individuals are of particular interest. Applications that address the following areas are encouraged:

- characterisation of the timing, anatomical location and contribution to disease outcome of systemic and mucosal immune responses to mycobacterial infection and vaccination;
- development of new technologies and assays to compare key mycobacterial-specific mucosal and systemic immunological parameters and facilitate more sophisticated and comprehensive monitoring of human immune responses during vaccine clinical trials;
- monitoring of immune responses in appropriate animal models during preclinical studies and vaccine candidate selection.

The main objective is to provide novel data advancing new hypotheses that can contribute to the advancement of new tuberculosis vaccines.
US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are limited to US$275,000 in direct costs over a maximum period of two years. No more than US$200,000 can be requested in any single year.


Closing date: 11 Jan 16
Posted date: 01 Oct 15
Award type: Directed grants to institutions, research groups etc

NIAID CLINICAL TRIAL PLANNING GRANTS (R34)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its NIAID clinical trial planning grants. NIAID will support R34 applications that propose the complete planning, design and preparation of the documentation necessary for the implementation of investigator-initiated non-high-risk clinical trials. The trials must be hypothesis driven, milestone-driven, related to the research mission of the NIAID and considered a high priority by the institute. Sufficient preclinical data to support the planning of the clinical trial should be available prior to submission of the R34 grant application.

This funding opportunity announcement will utilise the NIH R34 grant mechanism and runs in parallel with two related FOAs, PAR-13-151, which solicits applications under the U01 grant mechanism, and PAR-13-149, which solicits applications under the R01 grant mechanism. Eligible applicants include domestic and foreign for-profit or nonprofit organisations and public or private institutions. Application budgets are limited to US$150,000 direct costs and the maximum project period is one year. PAR-13-150 (replaces PAR-10-185).

Closing date: 13 Jan 16
Deadline information: Applications open 4 May 2013; applications due by 5pm local time of the applicant organisation.
Deadlines on: 4 June 2013, 11 September 2013, 13 January 2014, 13 May 2014, 11
NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01)
NIH: National Institute of Allergy and Infectious Diseases

**Description:**
The National Institute of Allergy and Infectious Diseases invites applications for its clinical trial implementation cooperative agreements. These U01 grants will support cooperative agreement applications for implementation of investigator initiated high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. The trials must be hypothesis driven, milestone-driven, related to the research mission of the NIAID and considered a high priority by the institute.

This funding opportunity announcement will utilise the NIH U01 grant mechanism and runs in parallel with two related FOAs, PAR-13-149, which solicits applications under the R01 grant mechanism, and PAR-13-150, which solicits applications under the R34 grant mechanism. Eligible applicants include domestic and foreign for-profit or nonprofit organisations and public or private institutions. Application budgets are not limited, and the maximum project period is five years. PAR-13-151 (replaces PAR-11-234).

**Closing date:** 13 Jan 16


**Posted date:** 25 Mar 13

**Award type:** Clinical trials, Directed grants to institutions, research groups etc

**Contact Details**
---------------------------------------------------------------
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Diseases
Room 3138, MSC-7616
6700-B Rockledge Drive
Bethesda, MD 20892
Tel: +1 301 51 4414
Email: egoldmuntz@niaid.nih.gov

**Award type:** Clinical trials, Directed grants to institutions, research groups etc

**Pharmaceutical Drugs; Diagnostic Sciences; General Practice; Drug Design; Pharmacy & Pharmacology; Preventive Medicine; Infectious Diseases; Immunology; Medical & Diagnostic Tests; Clinical Pharmacy & Pharmacology; Infection Agents & Pathogens**
**IAID CLINICAL TRIAL IMPLEMENTATION GRANT (R01)**

**NIH: National Institute of Allergy and Infectious Diseases**

**Description:**
The National Institute of Allergy and Infectious Diseases invites applications for its NIAID clinical trial implementation grants. NIAID will support R01 applications that propose implementation of investigator-initiated non-high-risk clinical trials. The trials must be hypothesis driven, related to the research mission of the NIAID and considered a high priority by the institute. Applicants must propose a time-sensitive, milestone-driven clinical trial and describe the clinical trial stages, criteria for completion of the stages and contingency plans for each stage. The trial must have clear primary and secondary endpoints.

This funding opportunity announcement will utilise the NIH R01 grant mechanism and runs in parallel with two related FOAs, PAR-13-151, which solicits applications under the U01 grant mechanism, and PAR-13-150, which solicits applications under the R34 grant mechanism. Eligible applicants include domestic and foreign for-profit or nonprofit organisations and public or private institutions. Application budgets are not limited, and the maximum project period is five years. PAR-13-149 (replaces PAR-10-184).

**Closing date:** 13 Jan 16


**Posted date:** 25 Mar 13

**Award type:** Clinical trials, Directed grants to institutions, research groups etc

**Award budget total:** -
Website:  http://grants.nih.gov/grants/guide/pa-files/PAR-13-149.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-149

Eligibility profile
------------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Pharmaceutical Drugs; Drug Design; Pharmacy & Pharmacology; Preventive Medicine; Clinical Pharmacy & Pharmacology; Infection Agents & Pathogens; Infectious Diseases; Immunology; General Practice; Diagnostic Sciences; Medical & Diagnostic Tests

Contact Details
------------------------------------------------------------------------
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Diseases
Room 3138, MSC-7616
6700-B Rockledge Drive
Bethesda, MD 20892
Tel: +1 301 51 4414
Email: egoldmuntz@niaid.nih.gov

IV-INFECTED ADOLESCENTS – TRANSITIONING FROM THE PAEDIATRIC TO THE ADULT CARE SETTING (R21)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description: The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its HIV-infected adolescents – transitioning from the paediatric to the adult care setting (R21) funding opportunity announcement. This announcement encourages research on the assessment of programmes for the transition of HIV-infected adolescents to the adult healthcare setting both domestically and globally. The goal is to develop an evidence base to support guidelines applicable to low-, middle- and high-income countries. This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, RFA-HD-16-033, which solicits applications under the NIH exploratory or developmental research (R01) grant mechanism.

Any individual with the skills, knowledge and resources necessary to carry out the proposed research as the programme director or principal investigator is invited to apply. Eligible institutions include higher education institutions, non- and for-profit organisations as well as governments worldwide.

Aids-related projects that fall within the announcement’s research remit are also welcome.

The total budget for the fiscal year 2016 is US$500,000, to fund two awards. Each award is worth up to US$275,000 over a maximum period of two years. No more than US$200,000 is allowed in direct costs per year. Ref: RFA-HD-16-034.

Closing date: 14 Jan 16
Deadline information: Applications are invited between 14 December 2015 and 5pm local time of applicant organisation, 14 January 2016.
Posted date: 08 Jul 15
Award type: Research centres, Directed grants for individual investigators, Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-HD-16-034.html#_Section_VII._Agency
Application form: https://public.era.nih.gov/assist/public/login.do?TYPE=33554433&REALMOID=06-58b5535a-f2c3-40ec-b9ff-a06a3ed4ee18&GUID=&SMAUTHREASON=0&METHOD=GET&SMAGENTNAME=SM-

Eligibility profile
Country of applicant institution: Any
Disciplines
HIV/Aids; Adolescent Paediatrics; Infant Paediatrics
Contact Details
Tel: +1 301 435 6868
Email: hazrar@mail.nih.gov

IV-INFECTED ADOLESCENTS – TRANSITIONING FROM THE PAEDIATRIC TO THE ADULT CARE SETTING (R01)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its HIV-infected adolescents - transitioning from the paediatric the adult care setting (R01) funding opportunity announcement. This announcement encourages research on the assessment of programmers for the transition of HIV-infected adolescents to the adult healthcare setting both domestically and globally. The goal is to develop an evidence base to support guidelines applicable to low-, middle- and high-income countries. This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism.

Any individual with the skills, knowledge and resources necessary to carry out the proposed research as the programme director or principal investigator is invited to apply. Eligible institutions include higher education institutions, non- and for-profit organisations as well as governments worldwide. Aids-related projects that fall within the announcement’s research remit are also welcome.

The total budget for the fiscal year 2016 is US$1.5 million, to fund three to four awards. Each award is worth up to US$225,000 in direct costs per year. The maximum project period is five years.
INOR USE MINOR SPECIES DEVELOPMENT OF DRUGS RESEARCH PROJECT
GRANT (R01)
Food and Drug Administration

Description:
The Food and Drug Administration’s Center for Veterinary Medicine invites applications for its minor use minor species development of drugs research project grant (R01) funding opportunity announcement. This announcement supports the development of new animal drugs intended for minor use in major species or intended for use in minor species.

Only companies developing drugs for veterinary use or parties working as research partners with such companies are eligible for grants. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget is US$1 million in fiscal year 2015 and will fund up to ten grants. Smaller grants are limited to US$100,000 in total costs per year with a maximum project period of two years for any routine safety or effectiveness study supportive of new animal drug approval or conditional approval of the designated product for the designated intended use. Larger grants are limited to US$150,000 in total costs per year with a maximum project period of three years for necessary studies that are of unusual complexity, duration or size.

Ref: RFA-FD-15-004 (reissue of RFA-FD-12-003).

Closing date: 15 Jan 16
ADMIMISTRATIVE SUPPLEMENTS FOR RESEARCH ON DIETARY SUPPLEMENTS (ADMIN SUPP)
NIH: National Cancer Institute

Description:
A total of 12 institutes and offices of the National Institutes of Health invite applications for their administrative supplements administrative supplements for research on dietary supplements funding opportunity announcement. This announcement aims to support research in which the supplemental funding would investigate the role of dietary supplements or their ingredients in health maintenance and disease prevention. Parent awards need not be focused on dietary supplements; this FOA may provide support to include dietary supplements within the scope of relevant research projects. Applications that stimulate dietary supplement research where it is lacking or lagging, clarify gaps, opportunities and balance between benefits and risks where data are in conflict, target special population groups where additional science on dietary supplements is needed, and focus on the use of dietary supplements in improving or maintaining health and reducing the risk of chronic disease are preferred.

US and foreign for-profit and non-profit organisations and public and private organisations that already hold an eligible parent award may apply. The total available budget is US$3 million in fiscal year 2016 and will fund 30 awards. Application budgets are limited to US$100,000 and must not exceed the amount of the current parent award. The project and budget periods must be within the currently approved project period for the existing parent awards and should not exceed one year.

Ref: PA-15-258 (reissue of PA-14-201).
Closing date: 15 Jan 16
Deadline information: Applications open on 15 September and are due by 5pm local time of applicant organisation on 15 October 2015, 15 January and 15 April 2016.
Posted date: 15 May 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Award amount min: -
Award budget total: $3,000,000
Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276566

Eligibility profile
Country of applicant institution: Any
Disciplines
Dietary Guidelines; Nutrition & Dietetics

Contact Details
ODS
Building 6100, Room 3B01
6100 Executive Boulevard
Rockville MD 20852
Tel: +1 301 496 0168
Email: davisci@mail.nih.gov

NIH AUDACIOUS GOAL INITIATIVE: DISCOVERY-BASED SCIENCE TO IDENTIFY FACTORS INFLUENCING NEURAL REGENERATION IN THE VISUAL SYSTEM (U01)

NIH: National Eye Institute

Description:
The National Eye Institute invites applications for its NEI audacious goal initiative: discovery-based science to identify factors influencing neural regeneration in the visual system (U01) funding opportunity announcement. This announcement seeks applications proposing to use discovery-based approaches to identify unknown factors critical to the regeneration of neurons, guiding their axons to targets and making new functional connections. This funding opportunity announcement strongly encourages the establishment of investigative teams that are multidisciplinary with the complimentary expertise required for genetic screening and development of assays in appropriate species.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

The NEI intends to commit a total of US$3 million to US$5m in fiscal year 2016 to fund five to ten awards. Application budgets are limited to US$500,000 annual direct costs for the maximum project period of three years.

Ref: RFA-EY-15-002
Closing date: 15 Jan 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Posted date: 24 Aug 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $500,000

Eligibility profile
Country of applicant institution: Any
**Genomic Data Analysis Network: Processing Genomic Data Centre (U24)**

**NIH: National Cancer Institute**

**Description:**
The National Cancer Institute, under the genomic data analysis network, invites applications for its processing genomic data centre (U24) funding opportunity announcement. This announcement solicits applications for a processing genomic data centre that will be a part of the genomic data analysis network. The overall goal of CCG programmes is to help elucidate the mechanisms of cancer initiation and evolution as well as resistance to therapy by means of genomic characterisation of well-annoted and high quality tumour samples.

This funding opportunity uses the NIH resource-related research (U24) projects - cooperative agreements mechanism and runs in parallel with two of identical scientific scope, RFA-CA-15-019 and RFA-CA-15-020, which solicit applications under the same (U24) mechanism.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

The NCI intends to commit US$1 million in fiscal year 2016 to fund one award. Application budgets are limited to US$660,000 in direct costs per year for the maximum period of five years.

**Ref:** RFA-CA-15-018.

**Closing date:** 27 Jan 16

**Deadline information:** Applications are invited between 27 December 2015 and 5pm local time of applicant organisation, 27 January 2016.

**Posted date:** 23 Oct 15

**Award type:** Directed grants to institutions, research groups etc

**Award amount max:** $660,000

**Award amount min:** -

**Award budget total:** $1,000,000

**Website:**

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Genomics; Cancer Studies & Oncology; Preventive Medicine

**Contact Details**

Tel: +1 301 451 2144
Email: jz44m@nih.gov
GENOMIC DATA ANALYSIS NETWORK: SPECIALISED GENOMIC DATA CENTRE (U24)
NIH: National Cancer Institute

Description:
The National Cancer Institute, under its genomic data analysis network, invites applications for its specialised genomic data centre (U24) funding opportunity announcement. This announcement seeks intensive analysis of discrete sets of genomic platforms (core competencies) to facilitate the integration and analysis of data generated by the genome characterisation centres and other projects participants and deployment of innovative bioinformatic and computational tools and the implementation of advanced bioinformatic analyses. The overall goal of all centre for cancer genomic programmes is to help elucidate the mechanisms of cancer initiation and evolution as well as resistance to therapy by means of genomic characterisation of well-annoted and high quality tumour samples. This funding opportunity announcement solicits applications for a specialised genomic data centre that will be a part of the genomic data analysis network.

This funding opportunity uses the NIH resource-related research (U24) projects - co-operative agreements mechanism and runs in parallel with two of identical scientific scope, RFA-CA-15-018 and RFA-CA-15-019, which solicit applications under the same (U24) mechanism.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

The NCI intends to commit US$5.5 million in fiscal year 2016 to fund up to 11 awards. Application budgets are limited to US$330,000 in direct costs per year for the maximum period of five years.

Ref: RFA-CA-15-020.

Closing date: 27 Jan 16
Deadline information: Applications are invited between 27 December 2015 and 5pm local time of applicant organisation, 27 January 2016.
Posted date: 23 Oct 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $330,000
Award budget total: $5,500,000
Website:

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Cancer Studies & Oncology; Genomics; Preventive Medicine

Contact Details
----------------------------------------------
Tel: +1 301 451 2144
Email: jz44m@nih.gov
GENOMIC DATA ANALYSIS NETWORK: VISUALISATION GENOMIC DATA CENTRE (U24)

NIH: National Cancer Institute

Description:
The National Cancer Institute, under its genomic data analysis network, invites applications for its visualisation genomic data centre (U24) funding opportunity announcement. This announcement seeks applications for a visualisation genomic data centre that will be a part of the genomic data analysis network. The overall goal is to help elucidate the mechanisms of cancer initiation and evolution as well as resistance to therapy by means of genomic characterisation of well annotated and high quality tumour samples. This funding opportunity announcement is a part of the genomics programmes supported by the NCI and managed by its centre for cancer genomics. The visualisation type genomic data analysis centre is expected to focus on the following aspects:

- developing and implementing appropriate bioinformatic systems to create a user interface for the exploration of genome-wide datasets generated by the GCCs;
- create a biology-centric computational user interface for more advanced analyses and identify potential translational directions and outcomes from ‘omics data.

This funding opportunity uses the NIH resource-related research (U24) projects - cooperative agreements mechanism and runs in parallel with two of identical scientific scope, RFA-CA-15-018 and RFA-CA-15-020, which solicit applications under the same (U24) mechanism.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

The NCI intends to commit US$2 million in fiscal year 2016 to fund two awards. Application budgets are limited to US$660,000 in direct costs per year for the maximum period of five years.

Ref: RFA-CA-15-019.

Closing date: 27 Jan 16
Deadline information: Applications are invited between 27 December 2015 and 5pm local time of applicant organisation, 27 January 2016.
Posted date: 23 Oct 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $660,000
Award amount min: -
Award budget total: $2,000,000

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Cancer Studies & Oncology; Preventive Medicine; Genomics

Contact Details
-----------------------------------------------
Tel: +1 301 451 2144
Email: jz44m@nih.gov
PREDICTIVE MULTISCALE MODELS FOR BIOMEDICAL, BIOLOGICAL, BEHAVIOURAL, ENVIRONMENTAL AND CLINICAL RESEARCH (INTERAGENCY U01)
NIH: National Institute of Biomedical Imaging and Bioengineering

Description:
A total of 23 participating institutes and centres of the National Institutes of Health, the US Army Research Office, the Department of Energy, the US Food and Drug Administration, the National Aeronautics and Space Administration, the National Science Foundation and the Office of Naval Research invite applications for their predictive multiscale models for biomedical, biological, behavioural, environmental and clinical research (interagency U01) funding opportunity announcement. This announcement aims to support the development of multiscale models to accelerate biological, biomedical, behavioural, environmental and clinical research. Furthermore, funding supports the development of non-standard modelling methods and experimental approaches to facilitate multiscale modelling and active participation in community-driven activities through the Multiscale Modeling (MSM) Consortium.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Direct costs are limited to US$500,000 per year and the maximum project period is five years.


Closing date: 29 Jan 16

Posted date: 09 Jan 15
Award type: Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration
Award amount max: $2,500,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Disease Models; Biomolecular Modelling; Computer Simulation & Modelling; Computational Biology; Data Analysis; Medical Models, Mathematical

Contact Details
----------------------------------------------
NIBIB
BG 2 Dem Room 200
6707 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 451 4778
Email: grace.peng@nih.gov
ADAPTATION AND OPTIMISATION OF TECHNOLOGY TO SUPPORT SOCIAL FUNCTIONING (R21)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its call on adaptation and optimisation of technology to support social functioning. This announcement supports the development and testing and new, cutting-edge technologies to enhance functioning in individuals with social impairments. Projects will create social prosthetics – scalable technology or devices that would augment performance in this domain.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

NIMH intends to commit US$2.5 million in fiscal year 2017 to support eight to 10 awards under this call. Projects are limited to US$200,000 in direct costs in any project year, or no more than US$275,000 in total over the maximum project period of two years.

Ref: RFA-MH-17-150.

Closing date: 03 Feb 16

Deadline information: Applications due between 3 January and 5pm applicant’s local time, 3 February 2016.
Posted date: 23 Oct 15
Award type: Technology innovation/development, Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: $2,500,000
Website: https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-17-150.html

Application form: https://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
Country of applicant institution: Any
Disciplines
Behavioural Studies & Social Problems; Assistive Technology

Contact Details
Tel: +1 301 443 3825
Email: gilottyl@mail.nih.gov
**ARKINSON'S DISEASE BIOMARKER PROGRAMME DISCOVERY PROJECTS (U01)**

**NIH: National Institute of Neurological Disorders and Stroke**

**Description:**
The National Institute of Neurological Disorders and Stroke invites applications for its Parkinson's disease biomarker programme discovery projects (U01) grants. These U01 grants support up to three years of study towards the discovery, assay optimisation and replication stages required for the development of biological biomarkers for Parkinson’s disease.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are expected to be worth between US$200,000 to US$490,000 per year in direct costs. The project period is two to three years.

Ref: PAR-14-259.

**Closing date:** 04 Feb 16

**Deadline information:** Applications open on 4 August 2014 and are due by 5pm local time of applicant organisation on every 4 September, 4 February and 4 May until 5 May 2016.

**Posted date:** 17 Jun 14

**Award type:** Directed grants to institutions, research groups etc, Networking/collaboration

**Award amount max:** $450,000

**Award amount min:** $200,000

**Award budget total:** -


**Application form:** [http://www.grants.gov/applicants/apply-for-grants.html](http://www.grants.gov/applicants/apply-for-grants.html)

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Neurology; Public Health, Health Services & Primary Care; Central Nervous System; Clinical Medicine; Biological Markers & Sensor Mechanisms; Primary Care; Biochemical Markers; Parkinson’s Disease

**Contact Details**

NINDS
Division of Extramural Research
6001 Executive Boulevard Suite 3309
Bethesda, MD 20892-9531
Tel: +1 496 5680
Email: sutherlandm@ninds.nih.gov

---

**DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R01)**

**NIH: National Institute of Mental Health**

**Description:**
A total of 15 participating institutes and centres of the National Institutes of Health invite applications for their dissemination and implementation research in health (R01) grants. This R01 funding opportunity
announcement encourages investigators to submit applications that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures, and strategies to disseminate and implement research-tested health behaviour change interventions, evidence-based prevention, early detection, diagnostic, treatment and management, and quality of life improvement services, and data monitoring and surveillance reporting tools into public health and clinical practice settings that focus on patient outcomes.

This FOA will use the R01 research project grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PAR-13-054, which encourages applications under the R21 exploratory/developmental award mechanism, and PAR-13-056, which encourages applications under the R03 small grant programme mechanism.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PAR-13-055 (replaces PAR-10-038).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 January 2016.
Posted date: 10 Jan 13

Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-055

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Biomedical Engineering; Mental Illness; Economic & Social Environment; Preventive Medicine; Public Health, Health Services & Primary Care; Primary Care; Medical & Diagnostic Tests; Health Systems, Administration; Sociology; Health Promotion; General Practice; Health Systems; Psychiatry; Psychology; Medical Sociology ; Public Health; Mental Health

Contact Details
----------------------------------------------
Division of Services and Intervention Research
NIMH
6001 Executive Boulevard, Room 7133, MSC 9631
Bethesda, MD 20892-9631
Tel: +1 301 443 3747
Fax: +1 301 443 4045
Email: dchamber@mail.nih.gov

GENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their gene-environment interplay in substance use
This announcement seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course and outcomes of substance and alcohol use disorders. Collaborations to combine data and enhance power are strongly encouraged. Proposals are expected to focus on the interplay of genetics and environment.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

This FOA uses the research project (R01) grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-111, which solicits applications under the small grant programme (R03) and PA-15-112, which solicits applications under the exploratory/developmental (R21) grant mechanism.

Application budgets are not limited, but should reflect the needs of the project. The maximum project period is five years.


Closing date: 05 Feb 16
Deadline information: Applications open on 5 May and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 September 2017.

Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Medical Genetics; Drug & Substance Abuse; Alcoholism

Contact Details
----------------------------------------------
NIDA
NSC BG Room 5150
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 402 1908
Email: nw46w@nih.gov

MOLECULAR GENETICS OF DRUG ADDICTION AND RELATED CO-MORBIDITIES (R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for research into molecular genetics of drug addiction and related co-morbidities (R01) call. This R01 funding opportunity announcement will support projects that identify or validate chromosomal loci and variations in genes that are associated with vulnerability to addiction and that inform the likelihood of responsiveness to treatment. Applications that propose to examine intermediate phenotypes or
endophenotypes to assess the molecular genetics of drug addiction, addiction vulnerability or their associated co-morbidities and how they are related to drug addiction are especially encouraged. Also encouraged are genetic as well as computational and large-scale genomic approaches.

Application budgets are not limited, but must reflect the needs of the project. The maximum period is five years. Domestic and foreign for-profit and non-profit organisations and private or public institutions are eligible to apply.

Ref: PA-14-025 (replaces PA-11-026).

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 January 2017.
Posted date: 12 Dec 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-025.html
Application form: http://www.grants.gov/web/grants/applicant

Eligibility profile
Country of applicant institution: Any

Disciplines
Genomics; Drug & Substance Abuse; Biological Sciences; Pharmacy & Pharmacology; Primary Care; Addiction; Biological Markers & Sensor Mechanisms; Population Studies, Medical; Schizophrenia & Other Psychotic Disorders; Smoking & Tobacco; Psychology; Biochemical Markers; Disease Models; Public Health, Health Services & Primary Care; Pharmacotherapy; Molecular Genetics; Mental Illness; Depression & Other Mood Disorders; Allied Health Professions; Diagnostic Sciences

Contact Details
NIDA
6001 Executive Boulevard
Bethesda MD 20852
Tel: +1 301 445 1309
Email: jpollock@mail.nih.gov

THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R01)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of 10 institutes and offices of the National Institutes of Health invite applications for their health of sexual and gender minority populations (R01) funding opportunity announcement. This announcement encourages research that describes the biological, clinical, behavioural and social processes that affect the health and development of sexual and gender minority populations and individuals, as well as their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that enhance the health and development of these populations. The
research must focus on clearly defined health outcomes. The following types of research are prioritised:

- basic social and behavioural science studies addressing the processes involved as individuals discover, uncover, address or adapt to their sexual orientation and claim or do not claim identity as SGM, and how these processes affect the mental and physical health of the individual;
- research leading to interventions to ameliorate health disparities in SGM populations;
- large-scale design, implementation and evaluation of preventive or treatment interventions addressing health issues in SGM populations;
- research on how family structures and processes-including both families of origin and families of choice-affect the health of SGM individuals and their family members, including whether and how being raised in a family headed by SGM individuals affects the health, development and wellbeing of children.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-262 and PA-15-263, which solicit applications under the NIH small grant programme (R03) grant mechanism and the NIH exploratory/developmental (R21) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the actual costs of the proposed project. The maximum project period is five years.

Ref: PA-15-261 (reissue of PA-12-111).

Closing date: 05 Feb 16
Deadline information: Applications open on 5 September 2015 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 May 2015.
Applicants requesting US$500,000 or more in direct costs in any year must contact a research contact at least six weeks before submitting the application.
Posted date: 19 May 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276658

Eligibility profile
Country of applicant institution: Any

Disciplines
Health of Minority Groups; Gender Roles & Sexuality; Lesbian, Gay, Bisexual & Transgender Studies

Contact Details
Eunice Kennedy Shriver NICHD
BG 6100 Room 8B05L
6100 Executive Boulevard
Rockville MD 20852
Tel: +1 301 435 6981
Email: newcomes@nih.gov
Prescription Drug Abuse (R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its prescription drug abuse research programme. The purpose of this R01 funding opportunity announcement is to encourage a broad range of research strategies to address the problem of prescription drug abuse. Across proposed research strategies, there is an interest in stimulating the development and integration of novel technologies to observe and understand the aetiology and biological and behavioural mechanisms associated with prescription drug abuse. The specific areas of interest include:

- basic preclinical and clinical research;
- epidemiology and prevention research;
- treatment and health systems research.

This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-016, which solicits applications under the exploratory/developmental grant (R21) mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-015 (replaces PA-08-127).

Closing date: 05 Feb 16

Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 January 2016.
Posted date: 05 Nov 12
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-015

Eligibility profile
-------------------------------------------------------------
Country of applicant institution: Any

Disciplines
-------------------------------------------------------------
Cognitive & Behavioural Therapies; Economic & Social Environment; Pharmacy & Pharmacology; Compulsive Behaviour; General Practice; Psychology; Public Health, Health Services & Primary Care; Anxiety Disorders; Preventive Medicine; Addiction; Allied Health Professions; Drug & Substance Abuse; Psychiatry; Pharmaceutical Drugs

Contact Details
-------------------------------------------------------------
Division of Epidemiology, Services and Prevention Research
NIDA
6001 Executive Boulevard, Room 5193
Bethesda, MD 20892-9589
Tel: +1 301 594 4371
Email: deniscor@nida.nih.gov
HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite proposals for their health services and economic research on the prevention and treatment of drug, alcohol and tobacco abuse (R01) funding opportunity announcement. This announcement supports rigorous health services and economic research to maximise the delivery of efficient, high-quality drug, tobacco and alcohol prevention, treatment and recovery support services. The following subjects are of specific interest to the NIDA and NIAAA:

- clinical quality improvement;
- quality improvement in service organisation and management;
- implementation research;
- economic research;
- implications of policy change for service quality;
- methods, technology and other tools.

Applicants are strongly encouraged to contact scientific staff prior to submitting an application.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with several of identical scientific scope, PA-15-252, PA-15-253 and PA-15-250, which solicit applications under the NIH small grant programme (R03), the NIH exploratory/developmental (R21) and the NIH planning (R34) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but should reflect the actual costs of the proposed project. The maximum project period is five years.

Ref: PA-15-251 (reissue of PA-12-127).

Closing date: 05 Feb 16
Deadline information: Applications are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 May 2018. Applicants requesting US$500,000 or more in direct costs in any year must contact a scientific contact at least six weeks before submitting the application.

Posted date: 11 May 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile

----------------------------------------------
Country of applicant institution: Any

Disciplines

----------------------------------------------
Social Services Delivery; Alcoholism; Standards of Care; Drug & Substance Abuse; Health Economics; Quality of Care; Access to Health Care; Smoking & Tobacco

Contact Details

----------------------------------------------
Tel: +1 301 443 6504
Email: djones1@nida.nih.gov
INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its international research collaboration on drug abuse and addiction research (R01) research opportunity announcement. This announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US.

Special opportunities include access to unusual talent, resources, populations or environmental conditions in other countries that will speed scientific discovery. Projects must have relevance to the mission of NIDA and where feasible, address NIDA’s scientific priority areas. These include: linkages between HIV/AIDS and drug abuse; prevention, initiation and treatment of nicotine and tobacco use; the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact.

This funding opportunity uses the NIH research project grant programme (R01) mechanism and runs in parallel with two of identical scientific scope, PA-15-141 and PA-15-143 which respectively solicit applications under the NIH small grant programme (R03) mechanism and the NIH exploratory/developmental grant (R21) mechanism.

Research must be conducted by US investigators in collaboration with non-US based investigators. Projects must include significant contributions of resources by each participant. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the actual needs of the proposed project. The maximum project period is five years. Applicants requesting US$500,000 or more for direct costs in any year must contact NIH programme staff at least six weeks before submitting the application.

Ref: PA-15-142 (reissue of PA-12-040).

Closing date: 05 Feb 16
Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 May 2015.
Posted date: 18 Mar 15
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: -
Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275229

Eligibility profile
Country of applicant institution: Any
Disciplines
Alcoholism; Smoking & Tobacco; Drug & Substance Abuse

Contact Details
National Institute on Drug Abuse
NSC BG Room 4274
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6480
Email: ipdirector@nida.nih.gov
BIOENGINEERING RESEARCH GRANTS (R01)
NIH: National Institute of Biomedical Imaging and Bioengineering

Description:
Participating institutes and centres of the National Institutes of Health invite AIDS-related applications for their R01 bioengineering research grants. Grants are provided for basic and or applied multidisciplinary research that can increase understanding and solve problems in biological, clinical or translational science. This programme intends to support AIDS-related participating institutes and centres of the National Institutes of Health invite applications for their R01 bioengineering research grants.

This FOA will use the NIH R01 research project grant (R01) award mechanism and runs in parallel with two FOAs of similar scientific scope, PA-12-284 that solicits applications under the R21 mechanism and R01 opportunity PAR-10-234. Proposed projects may not exceed five years. Applications are welcome from domestic and foreign for-profit and non-profit organisations and public or private institutions. PAR-13-137 (replaces PA-10-009)

Closing date: 05 Feb 16
Deadline information: Applications due by 5 pm local time of applicant organisation.
Posted date: 11 Mar 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Website:

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Dentistry; Nursing; Bioengineering; Diagnostic Sciences; Physiology; Biomedical Engineering; Aerospace Engineering & Avionics; Primary Care; Mechanical Engineering; Medicine & Health; Pharmaceutical Drugs; Pharmacy & Pharmacology; Assistive Technology; Medical Instrumentation; Medical Research of Selected Fields; Preventive Medicine; Allied Health Professions; General Practice; Medical & Diagnostic Tests; Public Health, Health Services & Primary Care; Manufacturing & Industrial Engineering; Human Biological Sciences; Clinical Medicine

Contact Details
---------------------------------------------------------------
NIBIB
Division of Discovery Science and Technology
6707 Democracy Blvd, Suite 200
Bethesda, MD 20892-2077
Tel: +1 301 451 4778
Fax: +1 301 480 1614
Email: kelleyc@mail.nih.gov
BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME
(R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the Office of Behavioral and Social Sciences Research invite applications for their behavioural and integrative treatment development (R01) grants. The aim of this R01 programme is to develop and test behavioural and integrative treatments for drug and alcohol abuse and dependence. Research will test efficacy, conduct clinical trials, examine mechanisms of behaviour change, determine dose-response, optimise combinations, or ascertain best sequencing of behavioural, combined, sequential, or integrated behavioural and pharmacological treatments in the following circumstances:

- drug abuse treatment interventions in diverse settings;
- drug abuse treatment and adherence interventions for use in primary care;
- drug abuse treatment and adherence interventions that use technologies to boost effects and increase implementability;
- interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment;
- interventions to promote adherence to drug abuse treatment, HIV and addiction medications;
- interventions to treat chronic pain.

Research of interest includes but is not limited to Stage II and Stage III efficacy research.

This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-079, which solicits applications under the R03 small grant programme mechanism, and PA-13-078, which solicits applications under the R34 clinical trial planning grant programme. mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions. Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years.

PA-13-077 (replaces PA-10-012).

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 January 2016.

Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-077

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Physiology; Allied Health Professions; Cognitive & Behavioural Therapies; Mental Illness; Psychology; Behavioural Medicine; Population Studies, Medical; Counselling & Therapy; Neuroscience; Medical Sociology; Drug & Substance Abuse; Primary Care; Cognitive Processes; Public Health, Health Services & Primary Care; Sociology; Biological Sciences; Molecular Genetics; Alcoholism; General Practice; Neurobiology
ANCILLARY STUDIES OF ACUTE KIDNEY INJURY, CHRONIC KIDNEY DISEASE AND END STAGE RENAL DISEASE ACCESSING INFORMATION FROM CLINICAL TRIALS, EPIDEMIOLOGICAL STUDIES AND DATABASES (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung, and Blood Institute invite applications for their ancillary studies of acute kidney injury, chronic kidney disease and end stage renal disease accessing information from clinical trials, epidemiological studies and databases (R01) grants. This R01 funding opportunity announcement encourages investigator-initiated ancillary studies to ongoing or completed clinical trials, existing epidemiological studies of kidney disease as well as clinical trials and epidemiological studies for other diseases or populations that lend themselves to the study of acute kidney injury and chronic kidney disease. The goal of these studies should be to extend understanding of risk factors for developing kidney disease and associated co-morbid illnesses, factors associated with rapid decline in kidney function among persons with chronic kidney disease, and the impact of these diseases on quality of life and mental and physical functioning. Investigations of acute kidney injury, including biomarkers, are also appropriate topics of investigation.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public and private institutions are eligible to apply. PA-12-299 (replaces PA-09-196).

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 January 2016.
Posted date: 01 Oct 12
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-299.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-299

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Nephrology & Kidneys; Public Health, Health Services & Primary Care; Data Analysis; Clinical Medicine; Diagnostic Sciences; Population Studies, Medical; Pathogenesis; Biochemical Markers; Primary Care; Epidemiology; Biological Markers & Sensor Mechanisms; Health Systems, Risk Management; Drug Design
Erythropoiesis: Components and Mechanisms (R01)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung, and Blood Institute invite applications for their erythropoiesis: components and mechanisms (R01) grants. This R01 funding opportunity announcement aims to support research efforts towards a complete description of the molecular and cellular components of erythropoiesis and how these components contribute to erythropoiesis. Components include genes that are expressed in erythroid cells, either during development or during differentiation, and the proteins that are translated in erythroid cells, especially with post-translational modifications or sub-cellular localisations that are unique to erythroid cells. A long range goal of this program is to generate a concise description of erythropoiesis that unifies genetics, molecular processes and cytokine determinants in the erythroid lineages so that new therapeutics may be developed to measure and combat anaemia.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. PA-13-034 (replaces PA-09-255).

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 January 2016.
Posted date: 06 Dec 12
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-034

Eligibility profile
Country of applicant institution: Any

Disciplines
Proteomics & Molecular Interactions; Epigenetics; Biological Sciences; Molecular Genetics; Haematology; Diagnostic Sciences; Characteristics, Biological Macromolecules; Cell & Developmental Biology; Protein Synthesis, Modification & Turnover

Contact Details
---------------------------------------------------------------
Division of Kidney, Urologic, and Hematologic Diseases
NIDDK

Description:
A total of eight participating institutes and centres of the National Institutes of Health invite applications for their ethical, legal and social implications of genomic research regular research programme. The purpose of this R01 funding opportunity is to study the ethical, legal and social implications of human genome research.

The specific areas of interest for this FOA are:

- genomic research;
- genomic health care;
- broader societal issues;
- legal, regulatory and public policy issues.

This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-277, which encourages applications under the small research grant (R03) mechanism, and PA-14-278, which encourages applications under the exploratory/developmental research grant (R21) mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years, however many projects that are funded will be no more than three years in duration.

Ref: PA-14-276 (replaces PA-11-250).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 September 2017.
Posted date: 11 Jul 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/notice-files/PA-14-276.html

Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
-----------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------
Medical Sociology; Cancer Genetics; Human Genome; Public Health, Health Services & Primary Care; Genomics; Philosophy; Sociology; Research Ethics & Misconduct; Medical Genetics; Primary Care; Ethical Use of Technology; Law; Diagnostic Sciences; Medical & Health Ethics; Public Health & Medical Law; Biological Sciences; Professional Ethics
DEVELOPMENT OF ASSAYS FOR HIGH-THROUGHPUT DRUG SCREENING FOR USE IN PROBE AND PRE-THERAPEUTIC DISCOVERY (R01)

**NIH: National Institute of Mental Health**

**Description:**
Participating components of the National Institutes of Health invite applications for their development of assays for high-throughput drug screening for use in probe and pre-therapeutic discover (R01). This R01 funding opportunity announcement aims to stimulate research in the following areas:

- developing assays for specific biological targets and disease mechanisms to screen for small molecule compounds that show potential as probes for use in advancing knowledge about the known targets, identifying new targets or as pre-therapeutic leads;
- establishing collaboration with screening centres that have the requisite expertise and experience needed in implementation of HTS assays for the discovery and development of small molecule chemical probes.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is three years. Domestic and foreign for-profit and non-profit organisations and public and private institutions are eligible to apply. PAR-13-364 (replaces PA-10-213).

**Closing date: 05 Feb 16**

**Deadline information:** Deadlines every 5 February, 5 June and 5 October until 8 January 2017.

**Posted date:** 30 Sep 13

**Award type:** Directed grants to institutions, research groups etc

**Award budget total:** -

**Website:**

**Application form:**

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Clinical Medicine; Primary Care; Immunological & Bioassay Methods; Public Health, Health Services & Primary Care; Diagnostic Sciences; Pharmacy & Pharmacology; Nursing; Pharmacotherapy; Deoxyribonucleic Acid, DNA ; Screening for Diseases

**Contact Details**

NIDDK
6707 Democracy Boulevard
EXTENDED DEADLINE: ANCILLARY STUDIES TO MAJOR ONGOING CLINICAL RESEARCH STUDIES TO ADVANCE AREAS OF SCIENTIFIC INTEREST WITHIN THE MISSION OF THE NIDDK (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute on Drug Abuse has extended the expiry date for its ancillary studies to major ongoing clinical research studies to advance areas of scientific interest within the mission of the NIDDK (R01) funding opportunity announcement. The expiry date has been extended from 8 September 2015 to 1 January 2016, meaning that the final closing date is now 5 October instead of 5 June 2015. All other call details remain unchanged.

This announcement funds ancillary studies to major ongoing research studies, including clinical trials, epidemiological studies and disease databases supported by the NIDDK, other components of the National Institutes of Health, other government agencies and the private sector.

The proposed study must advance the scientific research mission of the NIDDK by focusing on diseases and areas of direct interest to the institute, including: diabetes, type 1 diabetes, digestive diseases, genetic metabolic diseases and gene therapy, haematological diseases, HIV/Aids research, immunological diseases, kidney diseases, liver diseases, obesity, pancreas, urological diseases, biotechnology, endocrinology, epidemiology, genetics and genomics, metabolic research and nutrition research.

The parent study must be ongoing, the subject of inquiry must be within the mission and interest of the NIDDK, the ancillary study must be approved by the parent study, and the proposed study will collect new information from enrolled study participants or assays of existing or biologic samples.

Eligible applicants include domestic and foreign for-profit and non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-12-265 (replaces PAR-09-247).

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 January 2016.
Posted date: 10 Jul 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-12-265.html

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-265

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
UNDERSTANDING AND PROMOTING HEALTH LITERACY (R01)
NIH: Office of the Director

Description:
A total of 11 institutes and offices of the National Institutes of Health invite proposals for the understanding and promoting health literacy (R01) programme. The goal of this R01 funding opportunity announcement is to encourage methodological, intervention and dissemination research for understanding and promoting health literacy. Health literacy is defined as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.

This call will use the NIH R01 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-131, which uses the R03 grant mechanism, and PAR-13-132, which uses the R21 grant mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited, but must reflect the actual needs of the project. The total project period may not exceed five years. PAR-13-130 (replaces PAR-10-133).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 May 2016.

Posted date: 04 Mar 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-130

Eligibility profile
Country of applicant institution: Any
Disciplines
Health Promotion; Health Systems; Health Education; Public Health; Primary Care; Clinical Medicine; Public Health, Health Services & Primary Care; Patient Care & Education; Health & Safety Education & Instruction

Contact Details
OBSSR
NIH
31 Centre Drive, Room B1C19
Bethesda, MD 20814
Tel: +1 301 401 0116
Email: elwoodwi@od.nih.gov
**LZHEIMER’S DISEASE PILOT CLINICAL TRIALS (R01)**  
**NIH: National Institute on Aging**

**Description:**
The National Institute on Aging invites applications for Alzheimer’s disease pilot clinical trials. In this R01 funding opportunity announcement aims to enable the clinical testing of promising pharmacological and non-pharmacological interventions in individuals across the Alzheimer’s disease spectrum from pre-symptomatic to more severe stages of disease, and to stimulate studies to enhance trial design and methods.

US and foreign for-profit or non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited, but must reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-089 (replaces PAR-11-100).

**Closing date:** 05 Feb 16  
**Deadline information:** Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 May 2017.  
**Posted date:** 06 Feb 14  
**Award type:** Directed grants to institutions, research groups etc  
**Award amount max:** -  
**Award amount min:** -  
**Award budget total:** -

**Website:**  

**Application form:**  

**Eligibility profile**  
Country of applicant institution: Any

**Disciplines**  
Drug Design; Pharmaceutical Drugs; Public Health, Health Services & Primary Care; Primary Care; Alzheimer’s Disease & Senile Dementia; General Practice; Cognitive Processes; Diagnostic Sciences; Geriatrics & Gerontology; Psychology; Clinical Medicine; Neurology

**Contact Details**  
National Institute on Aging  
7201 Wisconsin Avenue  
Bethesda, MD 20892  
Tel: +1 301 496 9350  
Fax: +1 301 496 1494  
Email: ryanl@nia.nih.gov

---

**CALCIUM OXALATE STONE DISEASES (R01)**  
**NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

**Description:**
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for research into calcium oxalate stone diseases. This R01 funding opportunity announcement aims to increase investigator...
interest in research into oxalate metabolism, transport and homeostasis and oxalate stone diseases. This initiative encourages basic, clinical or epidemiological studies that utilise new and innovative approaches to study the diagnosis, treatment and prevention of these disorders.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. PA-13-043 (replaces PA-09-213).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on deadline dates. Deadlines on: 5 February 2016, 5 June 2016, 5 October 2016, and repeated annually.
Posted date: 17 Dec 12
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -

Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-043

Eligibility profile
Country of applicant institution: Any

Disciplines
Pathogenesis; Aetiology; Nephrology & Kidneys; Molecular Genetics; Diagnostic Sciences; Primary Care; Public Health, Health Services & Primary Care; Clinical Medicine; General Practice; Medical & Diagnostic Tests; Urology; Preventive Medicine

Contact Details
Division of Kidney, Urologic, and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Blvd, Room 643
Bethesda, MD 20892-5460
Tel: +1 301 594 6007
Fax: +1 301 480 3510
Email: rebekah.rasooly@nih.gov

HEALTH DISPARITIES IN NIDDK DISEASES (R01)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its health disparities in NIDDK diseases (R01) programme.

This R01 funding opportunity announcement supports research which aims to improve understanding of the causes of high priority diseases in the US, and to develop and test more effective interventions for reducing and eliminating health disparities.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.
This funding opportunity announcement will utilise the R01 mechanism. Application budgets are not limited, but must reflect the actual needs of the proposed project. Funding is available for up to five years.

PA-13-183 (replaces PA-09-262).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, 5 February, 5 June and 5 October annually until 8 May 2016.
Posted date: 09 Apr 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/announcements/PA-13-183.html
Application form: http://www.grants.gov

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine; Hormones & Endocrinology; HIV/AIDS; Chronic Care; Gastroenterology; Hepatology; Allied Health Professions; Nephrology & Kidneys; Nutrition & Dietetics; Obesity; Diagnostic Sciences; Diabetes

Contact Details

Tel: +1 301 594 9652
Email: mcbrydekd@mail.nih.gov

M ECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R01)
NIH: National Institute of Nursing Research

Description:
Participating institutes and centres of the National Institutes of Health invite R01 applications for research into the mechanisms, models, measurement and management in pain research. The purpose of this R01 funding opportunity announcement is to inform the scientific community of the pain research interests of the various institutes and centres at the NIH and to stimulate and foster a wide range of basic, clinical, and translational R01 studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioural and social sciences. Research may address: molecular and cellular mechanisms of pain; genetics of pain; biobehavioural pain; models of pain; diagnosis and assessment of pain; pain management; epidemiology of pain; health disparities; translational pain research. Research conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

This FOA will use the R01 grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-119, that solicits applications under the R21 mechanism, and PA-13-117, that solicits applications under the R03 mechanism. Eligible organisations include for-profit and non-profit organisations, and public or private institutions. PA-13-118 (replaces PA-10-006).
Closing date: 05 Feb 16
Deadline information: Applications due by 5pm applicant’s local time, every 5 February, 5 June and 5 October until 8 May 2016.
Posted date: 18 Feb 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Cognitive & Behavioural Therapies; Gene Therapy; Public Health, Health Services & Primary Care; Dermatology; Palliative Nursing; Cell & Developmental Biology; Primary Care; Oncology Nursing; Medical & Diagnostic Tests; Pharmacy & Pharmacology; Muscle Diseases; Biological Sciences; Osteoporosis & Other Bone Diseases; Neuropharmacology; Epidemiology; Health Disparities; Geriatric Nursing; Molecular Genetics; Behavioural Medicine; Allied Health Professions; Diagnostic Sciences; Clinical Medicine; Traumatology, Accidents & Injury; Chemotherapy; Chronic Pain; Biochemistry & Molecular Biology; Pain Management; Nursing; Ethology; Cardiovascular Diseases

Contact Details
----------------------------------------------
Office of Extramural Activities
National Institute of Nursing Research, NIH
6701 Democracy Blvd., Suite 710
One Democracy Plaza
Bethesda, MD 20892-4870
Tel: +1 301 496 9623
Email: mardens@mail.nih.gov

RESEARCH PROJECT GRANT (PARENT R01)
NIH: National Institutes of Health

Description:
Participating institutes and centres of the National Institutes of Health invite applications under the research project grant parent R01 funding opportunity announcement. The research project grant (R01) supports a discrete, specified, circumscribed project to be performed by the named investigators in areas representing the specific interests and competencies of the investigators. The proposed project must be related to the stated programme interests of one or more of the NIH institutes and centres based on descriptions of their programmes. Research grant applications are assigned to an NIH institutes and centres based on receipt and referral guidelines and many applications are assigned to multiple ICs with related research interests.

This FOA will use the NIH research project grant (R01) award mechanism. A project duration of up to five years may be requested.

Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. PA-13-302 (replaces PA-11-260).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 September 2016. Posted date: 05 Aug 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
Country of applicant institution: Any

Disciplines
Diagnostic Sciences; Immunisation Programmes & Vaccination; Influenza; Medicine & Health; Public Health, Health Services & Primary Care

FUNCTIONAL GENETICS, EPIGENETICS AND NON-CODING RNAs IN DRUG ADDICTION (R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its functional genetics, epigenetics and non-coding RNAs in drug addiction (R01) programme. This R01 funding opportunity announcement encourages basic functional genomic research in two areas: functional validation to determine which candidate genes or variants have an authentic role in addictive processes, and detailed elucidation of the molecular pathways and processes modulated by candidate genes or variants, particularly for those genes with an unanticipated role in addiction.

This FOA will use the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-013, which encourages applications under the R21 exploratory/developmental grant mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Applications budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PA-14-014 (reissue of PA-11-033).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation, every 5 February, 5 June and 5 October until 8 January 2017.
Posted date: 06 Dec 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-014.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-14-014

Eligibility profile
Country of applicant institution: Any
Stimulate model driven research that will increase understanding of the way people make decisions about engaging in behaviours that impact the risk of acquiring or transmitting HIV, or to adhere to treatments for HIV. Decision making processes may contribute to both substance use and abuse and other HIV acquisition or transmission risks. This announcement encourages applications to study cognitive, motivational or emotional mechanisms and brain neuroendocrine and reinforcement systems that relate to HIV-risk behaviors or treatment non-compliance. Interdisciplinary studies that incorporate approaches from psychology, economics, anthropology, sociology, decision sciences, neuroscience and computational modelling are encouraged.

The total project period for an application submitted in response to this funding opportunity announcement may not exceed five years. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. This FOA utilises the NIH R01 research project grant award mechanism and runs in parallel with FOAs of identical scientific scope, PA-14-062, that solicits applications under the R21 mechanism and PA-14-063 that solicits applications under the R03 mechanism.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum funding period is five years.

Ref: PA-14-061 (reissue of PA-11-006)

Closing date: 05 Feb 16

Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 May 2017.

Posted date: 19 Feb 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-061.html

Application form: http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-061

Eligibility profile
Country of applicant institution: Any

Disciplines
Public Health, Health Services & Primary Care; Sociology; Political Risk Factors & Analysis; Neuropsychology; Decision Science; Chemistry; Computer Science & Informatics; Medical Sociology; Neuropsychology; Social Work & Social Policy; Clinical Psychology; Psychology; Pharmacy & Pharmacology; HIV/AIDS; Drug & Substance Abuse; Pharmacokinetics; Biological Sciences; Addiction; Toxicology; Economic & Social Environment; Computer Simulation & Modelling; Physiology; Neurobiology; Diagnostic Sciences; Gender Roles & Sexuality

Contact Details
Division of Clinical Neurosciences and Behavior Research
NIDA
6001 Executive Boulevard, Rm 3173
Rockville, MD 20852-9555
Tel: +1 301 435 1318
Fax: +1 301 594 6043
Email: ylin1@nida.nih.gov

CADEMIC-INDUSTRIAL PARTNERSHIPS FOR TRANSLATION OF IN VIVO IMAGING SYSTEMS FOR CANCER INVESTIGATIONS (R01)
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its academic-industrial partnerships for translation of in vivo imaging systems for cancer investigations. This supports research partnerships formed by academic and industrial investigators to accelerate the translation of either preclinical or clinical systems or methods designed to solve a targeted cancer problem.

Partnerships must include at least one lead academic and one lead industrial organisation. With that condition met, higher education institutes, non-profit and for-profit organisations and foreign organisations are eligible.

Application budgets are not limited, but must reflect the actual needs of the project. Funding is available for up to five years.

This programme will utilise the R01 award mechanism. PAR-13-169 (replaces PAR-10-169).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation every 5 June, 5 October and 5 February until 8 May, 2013.
Posted date: 09 Apr 13
Award type: Directed grants to institutions, research groups etc, Academic-Industry links, Networking/collaboration
Award amount max: -
Award amount min: -
Award budget total: -

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Cancer Studies & Oncology; Carcinogenesis; Diagnostic Sciences; Drug Design; Veterinary Medicine; Structural Chemistry & Spectroscopy; Animal Parasites & Pathogens; Clinical Medicine; Cancer Cell Biology; Radiology & Medical Imaging

Contact Details
----------------------------------------------
Tel: +1 240 276 5908
Fax: +1 240 276 7890
Email: bakerhou@mail.nih.gov

**EUROSCIENCE RESEARCH ON DRUG ABUSE (R01)**

**NIH: National Institute on Drug Abuse**

Description:
The National Institute on Drug Abuse invites applications for its neuroscience research on drug abuse (R01) grants. This R01 funding opportunity announcement aims to understand the neurobiological mechanisms underlying drug abuse and addiction, with emphasis on changes that occur during chronic drug use, withdrawal and relapse. In vivo and in vitro model systems, as well as human studies, are appropriate.

This FOA will use the R01 grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-337, which encourages applications under the R21 exploratory/developmental grants mechanism, and PA-13-336, which encourages applications under the R03 small grant programme mechanism. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. Public and private, non-profit and for-profit, and domestic and foreign organisations are eligible. PA-13-338 (replaces PA-10-268).

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 January 2017.
Posted date: 27 Aug 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Neuroscience; Drug & Substance Abuse; Psychology; Neurobiology; Social Work &
Social Policy; Cognitive & Behavioural Therapies; Physiology; Addiction; Diagnostic Sciences; Behavioural Medicine; Biological Sciences; Pharmacy & Pharmacology; Public Health, Health Services & Primary Care; Primary Care; Allied Health Professions

Contact Details
---------------------------------------------

BEHAVIOURAL AND SOCIAL SCIENCE RESEARCH ON UNDERSTANDING AND REDUCING HEALTH DISPARITIES (R01)
NIH: Office of the Director

Description:
Participating institutes and centres of the National Institutes of Health invite applications for behavioural and social science research on understanding and reducing health disparities (R01) grants. This R01 funding opportunity announcement supports behavioural and social science research on the causes and solutions to health and disabilities disparities in the US population. Emphasis is placed on research in and among three broad areas of action:

- public policy;
- healthcare;
- disease and disability prevention.

Particular attention is given to reducing health gaps among groups. Proposals that use an interdisciplinary approach, investigate multiple levels of analysis, incorporate a life-course perspective, or employ innovative methods such as system science or community-based participatory research are particularly encouraged.

This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-288, which solicits applications under the R21 mechanism. Projects may last up to five years.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-292 (replaces PAR-10-136).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm, proposer’s local time, every 5 February, 5 June and 5 October until 8 September 2016.

Posted date: 05 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-292

Eligibility profile
---------------------------------------------
Country of applicant institution: Any
Disciplines

Psychology; Sociology; Disadvantaged & Minority Groups; Primary Care; Economic & Social Environment; Public Health, Health Services & Primary Care; Allied Health Professions; Social Work & Social Policy; Behavioural Medicine; Health Disparities; Rural Health; Care for Disabled People; Medical Sociology; Public Health; Population Studies; Medical; Clinical Medicine; Preventive Medicine; Health Systems Policy; Health Systems

Contact Details

OBSSR
31 Center Drive
Building 31, Room B1C19
Bethesda, MD 20892-2027
Tel: +1 301 451 4286
Email: michael.spittel@mail.nih.gov

BIOLOGY OF MANUAL THERAPIES (R01)

NIH: National Center for Complementary and Integrative Health

Description:
The National Center for Complementary and Alternative Medicine invites applications for its call on biology of manual therapies (R01). This R01 funding opportunity announcement supports studies of the basic science and mechanisms of action underlying the neurophysiological, immunological, endocrinological or biomechanical consequences of manual therapies such as spinal manipulation, mobilisation and massage therapy.

This FOA uses the NIH research project grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-167, which solicits applications under the R21 mechanism.

Eligible institutions include domestic and foreign for-profit and non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PA-14-168 (replaces PA-10-209).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 May 2017.
Posted date: 31 Mar 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:
Application form:
http://www.grants.gov/web/grants/applicant-package.html#download=true&oppNum=P A-14-168

Eligibility profile

Country of applicant institution: Any

Disciplines

Mechanical Engineering; Growth & Growth Factors; Central Nervous System; Human Biological Sciences; Immunology; Hormones & Endocrinology; Folk, Complementary & Alternative Medicine; Electrophysiology;
NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism and the Office of Dietary Supplements invite applications for their nutrition and alcohol-related health outcomes (R01) grants. This R01 funding opportunity announcement supports research to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this R01 funding opportunity announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease.

This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-360 and PA-13-361, which use the R03 small grant programme and the R21 exploratory/developmental grant mechanisms, respectively. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 May 2017.
Posted date: 24 Sep 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
Country of applicant institution: Any

Disciplines
Alcoholism; Epidemiology; Cognitive Processes; Disease Models; Addiction; Preventive Medicine; Allied Health Professions; Public Health, Health Services & Primary Care; Psychology; Nutrition & Dietetics; Pathophysiology; General Practice; Primary Care; Clinical Medicine
SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its screening and brief interventions in underage and young adult populations (R01) funding opportunity announcement. This R01 announcement encourages research on screening and brief interventions to prevent and reduce alcohol use and alcohol related harms among underage and young adult populations.

This FOA will utilise the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-294 and PA-15-296, that solicit applications under the small research grant (R21) and exploratory/developmental (R03) award mechanisms, respectively. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

PA-15-295 (replaces PA-12-031).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October, until 8 May, 2018.
Posted date: 13 Jul 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-031

Eligibility profile

Country of applicant institution: Any

Disciplines

Alcoholism; Screening of Drugs & Agents

Contact Details

Tel: +1 301 402 9389
Email: shirleym@mail.nih.gov
HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R01)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research and the National Institute of Diabetes and Digestive and Kidney Diseases invite applications for health promotion among racial and ethnic minority males (R01). This R01 funding opportunity announcement aims to stimulate and expand research in the health of minority men. Specifically, this initiative is intended to: enhance understanding of the numerous factors influencing the health promoting behaviours of racial and ethnic minority males and their sub populations across the life cycle; and solicit applications focusing on the development and testing of culturally and linguistically appropriate health-promoting interventions designed to reduce health disparities among racially and ethnically diverse males and their sub populations aged 21 and older.

This FOA will use the R01 research project grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-331, which solicits applications under the R21 mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-328 (replaces PA-10-236).

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 September 2016.

Posted date: 15 Aug 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
Country of applicant institution: Any

Disciplines
Behavioural Medicine; Health Disparities; Health Promotion; Disadvantaged & Minority Groups; Medical Sociology; Risk Management; Biomedical Engineering; Sociology; Psychology; Public Health, Health Services & Primary Care; Economic & Social Environment; Population Studies, Medical; Nursing; Pharmaceutical Drugs; Urology; Medicine & Health

Contact Details
Office of Extramural Programs
NINR
6701 Democracy Blvd, Room 710, MSC 4870
Bethesda, MD 20892-4870
Tel: +1 301 402 6423
Email: cottonp@mail.nih.gov
Epidemiology and Prevention in Alcohol Research (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its epidemiology and prevention in alcohol research programme. The goal of this R01 funding opportunity is to encourage the submission of investigator-initiated research grant applications to support research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms and alcohol use disorders.

This funding opportunity announcement will utilise the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-188, which solicits applications under the 21 exploratory of developmental grant mechanism, and PA-14-189, which solicits applications under the R03 small grant programme mechanism.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-14-190 (replaces PA-11-016).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 5 June, 5 October and 5 February until 8 September, 2017. Deadlines on: 5 February 2016, 5 June 2016, 5 October 2016, and repeated annually.

Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile

Country of applicant institution: Any

Disciplines

Behavioural Medicine; Public Health, Health Services & Primary Care; Preventive Medicine; Epidemiology; Addiction; Alcoholism; Allied Health Professions; Sociology; Biomedical Engineering; Patient Care & Education; Medical Sociology; Economic & Social Environment; Population Studies, Medical; Psychology

Contact Details

NIAAA
Building 5635FL, Room 2083
5635 Fishers Lane
Rockville MD 20852
Tel: +1 301 402 6328
Email: mscott@mail.nih.gov
GENETIC SUSCEPTIBILITY AND VARIABILITY OF HUMAN STRUCTURAL BIRTH DEFECTS (R01)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of six institutes and centres of the National Institutes of Health invite applications for their genetic susceptibility and variability of human structural birth defects (R01) grants. This R01 funding opportunity announcement supports innovative studies using animal models in conjunction with translational and clinical approaches that take advantage of advances in genetics, biochemistry, molecular, and developmental biology to identify the specific genetic, epigenetic, environmental, or gene and environment interactions associated with the susceptibility to and variability of structural birth defects in human populations. Successful applicants will join the NICHD’s Birth Defects Working Group and participate in annual meetings designed to provide a forum to discuss research progress, exchange ideas, share resources, and foster collaborations.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. Domestic and foreign non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-14-056 (reissue of PA-11-085).

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 January 2017.
Posted date: 03 Jan 14

Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/announcements/PA-14-056.html

Application form:

Eligibility profile
Country of applicant institution: Any

Disciplines
Genetic Diseases; Clinical Medicine; Molecular Genetics; Environmental & Occupational Health & Safety; Population & Ecological Genetics; Epigenetics; Primary Care; Environmental Impact Assessment; Diagnostic Sciences; Cancer Genetics; Biochemistry & Molecular Biology; Public Health, Health Services & Primary Care; Evolutionary Biology; Biological Sciences; Birth & Congenital Defects; Medical Genetics

Contact Details
NICHD
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 496 5541
Email: javoisl@mail.nih.gov
NLM EXPRESS RESEARCH GRANTS IN BIOMEDICAL INFORMATICS (R01)

NIH: National Library of Medicine

Description:
The National Library of Medicine invites applications for its express research grants in biomedical informatics (R01). This R01 funding opportunity aims to advance the sciences of biomedical informatics.

The scope of NLM's interest in the research domain of informatics is interdisciplinary, encompassing informatics problem areas in the application domains of health care, public health, basic biomedical research, bioinformatics, biological modelling, translational research and health information management in disasters. NLM defines biomedical informatics as the science of optimal organisation, management, presentation and utilisation of information relevant to human health and biology. Informatics research produces concepts, tools and approaches that advance what is known in the field and have the capacity to improve human health.

Applicants may request funding over up to US$250,000 per year for a period of four years.

Eligible applicants include domestic public and private non-profit and for-profit organisations. PAR-13-300 (PAR-11-208).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm proposer's local time, every 5 February, 5 June and 5 October until 8 September 2016.

Posted date: 02 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $1,000,000

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-300

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Public Health, Health Services & Primary Care; Libraries & Information Science; Informatics & Big Data; Computer Science & Informatics; Administrative Big Data & Informatics; Bioinformatics; Business Big Data & Informatics; Clinical Medicine; Health Systems; Translational Medicine; Health Informatics; Public Health

Contact Details
----------------------------------------------
NLM Extramural Programmes
6705 Rockledge Drive
Rockledge 1, Suite 301
Bethesda, MD 20892
Tel: +1 301 594 4882
Email: simh@mail.nih.gov
Epidemiology of Drug Abuse (R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its epidemiology of drug abuse grants. These R01 grants support projects that enhance understanding of the nature, extent, distribution, aetiology, comorbidities and consequences of drug use, abuse and addiction across individuals, families, communities and diverse population groups. Projects should aim to fill knowledge gaps related to changing patterns in drug use, associated factors and consequences in populations, including the following:

- individual, familial and environmental factors associated with drug use;
- interplay of factors that exacerbate or mitigate risk for drug initiation, addiction, desistence, recovery and relapse;
- co-occurring psychiatric conditions, behaviours and associated problems;
- indicators and mechanisms of risk, vulnerability and health disparities among and between subpopulations;
- developmental and life course trajectories related to the aetiology and natural history of drug use;
- need for, access to and utilisation of drug abuse prevention and treatment services and the social, community and organisational factors that influence intervention development, availability and effectiveness.
- public health impacts of the attitudes, availability, behaviours and products, resulting from the shifting marijuana policy environment.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This funding opportunity announcement utilises the NIH research project grant (R01) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-15-001 that encourages applications under the NIH exploratory or developmental (R21) and PA-15-002 that encourages applications under the NIH small research grant R03 mechanism.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.


Closing date: 05 Feb 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 September 2017.
Posted date: 06 Oct 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
---------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------
Sexual Risk Taking; Aetiology; Public Health; Equal Educational Opportunity; Public Health, Health Services & Primary Care; Psychology; Prognosis & Natural History of
SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its secondary analyses of existing alcohol epidemiology data (R01) grants. These R01 grants support investigator-initiated research projects that either analyse previously collected data in order to address key issues that have emerged from recent findings in alcohol epidemiology and prevention research, or develop new analytic techniques for conducting studies in alcohol epidemiology and prevention research. The goal is to enhance understanding of patterns of alcohol consumption and the epidemiology of alcohol-related problems.

This funding opportunity announcement uses the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-337 that encourages applications under the small grant (R01) mechanism and PA-14-336 that encourages applications under the exploratory/developmental (R21) mechanism.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-338 (replaces PA-11-308).

Closing date: 05 Feb 16
Deadline information: Applications are invited on every 5 February, 5 June and 5 October until 8 September 2017. Deadlines on: 5 February 2016, 5 June 2016, 5 October 2016, and repeated annually.

Posted date: 10 Sep 14
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-338.html
Application form: http://www.grants.gov/web/grants/applicant-package.html#download=true&oppNum=PAR-14-338

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
INVESTIGATIONS ON PRIMARY IMMUNODEFICIENCY DISEASES (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its investigations on primary immunodeficiency diseases (R01) funding opportunity announcement. This announcement supports innovative investigations in primary immunodeficiency diseases. Of particular interest are the detection of primary immunodeficiency diseases, the identification of the molecular basis of these diseases and the design and pre-clinical development of innovative therapies for these diseases. Clinical trials will not be supported.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-15-130 (reissue of PAR-12-036).

Closing date: 05 Feb 16
Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 May 2015.

Posted date: 05 Mar 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=274939

Eligibility profile
Country of applicant institution: Any

Disciplines
Infectious Diseases

Contact Details
NIAID
BG 5601FL Room 7D44
5601 Fishers Lane
Rockville MD 20852
Tel: +1 240 627 3499
Email: drjohnson@niaid.nih.gov
**Drug Abuse Prevention Intervention Research (R01)**

**NIH: National Institute on Drug Abuse**

**Description:**
The National Institute on Drug Abuse invites applications for its drug abuse prevention intervention research (R01) funding opportunity announcement. This announcement aims to support research that will employ rigorous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan.

Investigations of cognitive, behavioural, and social processes are encouraged, provided that they relate to the following:

- development of novel prevention approaches;
- efficacy and effectiveness of prevention interventions or programmes;
- processes that optimise the selection, integration, implementation and sustainability of science-based prevention, including systems-level and health economic factors;
- methodologies appropriate for studying complex aspects of prevention science.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This FOA uses the research project grant (R01) funding mechanism and runs in parallel with two opportunities of identical scientific scope, PA-15-080 and PA-15-081, which respectively use the exploratory/developmental grant (R21) and the small grant programme (R03) funding mechanisms.

Application budgets are not limited, but should reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-15-082 (replaces PA-11-311).

**Closing date: 05 Feb 16**

**Deadline information:** Applications open on 5 May and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 September 2017.

**Posted date:** 12 Jan 15

**Award type:** Directed grants to institutions, research groups etc

**Award budget total:** -

**Website:**

**Application form:**

**Eligibility profile**
Country of applicant institution: Any

**Disciplines**
Drug & Substance Abuse; Alcoholism; Smoking & Tobacco

**Contact Details**
NIDA
NSC BG Room 5171
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6504
Email: hperl@mail.nih.gov
QUANTITATIVE IMAGING FOR EVALUATION OF RESPONSES TO CANCER THERAPIES (U01)
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its quantitative imaging for evaluation of responses to cancer therapies (U01) grants. This U01 funding opportunity announcement aims to enhance the value of quantitative imaging in clinical trials for prediction or measurement of response to cancer therapies. There are two avenues of enhancement:

- emphasising the development, optimisation and validation of state of the art QI methods and software tools for potential implementation in single site phase 1 or 2 clinical trials;
- addressing the challenges of integrating existing or new QI methods as required for multicentre phase 3 clinical trials.

It is anticipated that these research goals will require multidisciplinary efforts.
US and foreign non-profit or for-profit organisations and public or private institutions may apply.

Applicants may request direct costs of up to US$500,000 per year, over a maximum five-year project period.

Ref: PAR-14-116 (replaces PAR-11-150).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm, proposer’s local time every 5 February, 5 June and 5 October until 8 May 2017.
Posted date: 27 Feb 14

Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $2,500,000

Application form:

Eligibility profile
-------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------
Cancer Cell Biology; Physiology; Cancer Studies & Oncology; Diagnostic Sciences; Radiology & Medical Imaging; Prostate & Testicular Cancers; Carcinogenesis; Colorectal, Pancreatic & Stomach Cancers; Clinical Medicine; Leukaemia & Other Blood Cancers; Ovarian & Cervical Cancers; Breast Cancer; Lung Cancer; Human Biological Sciences

Contact Details
-----------------------------------
National Cancer Institute
6130 Executive Boulevard
Bethesda, MD 20892
Tel: +1 240 276 5934
Email: nordstrr@mail.nih.gov
RESEARCH TO ADVANCE VACCINE SAFETY (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases, and Centres for Disease Control and Prevention invite applications for their research to advance vaccine safety (R01) funding opportunity announcement. This announcement supports research that will contribute to the overall understanding of vaccine safety. Studies should address scientific areas potentially relevant to vaccine safety, such as:

- physiological and immunological responses to vaccines and vaccine components;
- how genetic variations affect immune or physiological responses that may impact vaccine safety;
- identification of risk factors biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines;
- creation or evaluation of statistical methodologies for analysing data on vaccine safety including data available from existing data sources such as passive reporting systems; the application of genomic or molecular technologies to improve knowledge of vaccine safety.

This funding opportunity uses the NIH research project grant (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-313, which solicits applications under the NIH exploratory/developmental (R21) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-15-312 (replaces PA-12-037)

Closing date: 05 Feb 16
Deadline information: Applications open on 5 September 2015 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 September 2018.
Posted date: 29 Jul 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Immunology; Immunisation Programmes & Vaccination
Contact Details
----------------------------------------------
Tel: +1 240 627 3322
Email: bmulach@niaid.nih.gov
ECHANISMS OF ALCOHOL AND NICOTINE CO-DEPENDENCE (R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its mechanisms of alcohol and nicotine co-dependence (R01) grants. This R01 funding opportunity announcement will support studies of neurobiological and behavioural mechanisms contributing to concurrent alcohol and nicotine co-addiction.

This FOA will use the R01 research project grants mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-193, which encourages applications under the R21 exploratory/developmental grant mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PA-13-194 (PA-09-099).

Closing date: 05 Feb 16
Deadline information: Deadlines by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 September 2016.

Posted date: 15 Apr 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-194

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Public Health, Health Services & Primary Care; Biochemistry & Molecular Biology; Biological Sciences; Smoking & Tobacco; Behavioural Medicine; Primary Care; Alcoholism; Psychology; Neurobiology; Allied Health Professions

Contact Details
----------------------------------------------
Tel: +1 301 443 7600
Email: igrakalic@mail.nih.gov

PAIN IN AGEING (R01)
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications under its pain in ageing programme. This funding opportunity announcement encourages research project grant (R01) applications from institutions and organisations that propose to study pain from an ageing perspective, including studies of older populations, studies of age differences and age-related changes in pain processes and experiences, and studies of pain treatment

Contact Details
----------------------------------------------
Tel: +1 301 443 7600
Email: igrakalic@mail.nih.gov
and management in older adults. This FOA particularly encourages studies on:

- mechanisms and predictors of pain experience in ageing;
- development and evaluation of pain assessment tools for older adults or older model organisms;
- development and evaluation of pain management strategies in older adults, with particular attention to the challenges associated with treating pain in patients with multiple morbidities.

This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-059, that encourages applications under the R21 exploratory/developmental grant mechanism, and PA-13-060, that encourages applications under the R03 small research grants mechanism. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PA-13-058 (replaces PA-09-193)

Closing date: 05 Feb 16
Deadline information: Applications are due every February 5, June 5 and October 5 until 8 January 2016.

Posted date: 27 Dec 12
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-058

Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care; Pain Management; Behavioural Medicine; Radiology & Medical Imaging; Neurobiology; Chronic Pain; Geriatrics & Gerontology; Clinical Medicine; Medical Effectiveness & Patient Outcomes; Psychology; Public Health, Health Services & Primary Care; Biochemistry & Molecular Biology; Biological Sciences; Psychology of Ageing; Physiology; Biochemical Markers

Contact Details

NIA
Building 31, Room 5C27
31 Center Drive, MSC 2292
Bethesda, MD 20892
Tel: +1 301 496 9350
Email: chenw@nia.nih.gov
SECONDARY ANALYSES OF EXISTING DATA SETS AND STORED BIOSPECIMENS TO ADDRESS CLINICAL AGEING RESEARCH QUESTIONS (R01)

NIH: National Institute on Aging

Description:
The National Institute of Aging invites applications for its secondary analyses of existing data sets and stored biospecimens to address clinical ageing research questions (R01) programme. This R01 funding opportunity announcement will address clinically related issues on ageing changes influencing health across the life span or on diseases and disabilities in older persons.

This FOA will support activities addressing specific hypotheses in clinical ageing research, or informing the design and implementation of future epidemiologic or human intervention studies, or current geriatric practice in maintenance of health, management of disease, and prevention of disability.

Application budgets are not limited, but must reflect the actual needs of the project. Projects may not exceed five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-168 (replaces PA-09-265).

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June 5 and 5 October until 8 May 2016.

RUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R01)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health, the National Institute on Aging, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute on Drug Abuse invite applications for their drug discovery for nervous system disorders funding opportunity. This R01 funding opportunity

Posted date: 02 Apr 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
Country of applicant institution: Any
Disciplines
Diagnostic Sciences; Care for Disabled People; Preventive Medicine; Primary Care; Nursing; Geriatric Nursing; Geriatrics & Gerontology; Pharmacy & Pharmacology; Data Analysis; Public Health, Health Services & Primary Care; Epidemiology; Biomedical Engineering

Contact Details
National Institute on Aging
7201 Wisconsin Ave, Suite 3C-307
Bethesda, MD 20892-9205
Tel: +1 301 435 3048
Email: duttac@mail.nih.gov
announcement encourages research grant applications directed toward the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders. The goal is to advance new, innovative and effective therapies for the prevention and treatment of nervous system disorders. Studies aimed at the development and testing of compounds for novel targets are encouraged, however projects designed for target identification are not covered under this announcement.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

This FOA will use the R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-13-049, that solicits applications under the R21 mechanism. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. PAR-13-048 (replaces PAR-10-001).

Closing date: 05 Feb 16
Deadline information: Applications due 5 February, 5 June and 5 October annually until 8 January 2016.
Posted date: 19 Dec 12
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/announcements/PAR-13-048.html

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-048

Eligibility profile
Country of applicant institution: Any

Disciplines
Pharmacotherapy; Endocrine & Neuroendocrine Cancers; Pharmaceutical Drugs; Stress, Psychological; Diagnostic Sciences; Drug Design; Electrophysiology; Pharmacokinetics; Neuroendocrinology; Neurostimulation; Methods of Drug Delivery; Neuroscience; Biological Sciences; Central Nervous System; Neuropeptides; Clinical Chemistry; Pharmacy & Pharmacology; General Practice; Screening of Drugs & Agents; Neuroanatomy; Weapons of Mass Destruction; Clinical Medicine; Human Biological Sciences; Neuroimaging; Neurology; Muscle Diseases; Cellular Interactions; Neurosurgery; Neurobiology; Toxicology; Disease Models; Medicinal Chemistry; Neuropharmacology; Chemistry; Neuropsychology; Pharmacogenomics; Immunological & Bioassay Methods; Biochemical Markers; Prosthetic & Orthotic Devices; Clinical Pharmacy & Pharmacology; Psychology

Contact Details
NIMH
6001 Executive Boulevard, Room 7189
Rockville, MD 20852
Tel: +1 301 443 5288
Email: jdrisco1@mail.nih.gov
DEVELOPMENT AND CHARACTERISATION OF ANIMAL MODELS FOR AGEING RESEARCH (R01)
NIH: National Institute on Aging

Description:
The National Institute on Aging invites R01 applications for its development and characterisation of animal models for ageing research programme. The institute aims to promote research under the R01 mechanism that develops, characterises, refines and enhances model systems for research on ageing. Studies that develop new model systems or refine existing models to maximise their value for ageing research will contribute to the understanding of normal changes in physiology and function with age and the onset, progression, therapeutics and prevention of age associated diseases. The objective of this programme is to enhance the biological resources and tools available to the research community for the study of biology of ageing.

This funding opportunity announcement will utilise the R01 award mechanism and runs in parallel with another FOA of identical scope, PA-13-156 that solicits applications under the R21 mechanism. Application budgets are not limited, and the maximum project period is five years. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PA-13-155 (replaces PA-10-014).

Closing date: 05 Feb 16
Deadlines on: 5 February 2016, 5 June 2016, 5 October 2016, and repeated annually.
Deadline information: Applications due by 5pm local time of applicant organisation.

Award: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-155

Eligibility profile
Country of applicant institution: Any
Disciplines
Physiology; Animal Models; Human Physiology; Cell Lines; Biological Sciences; Diagnostic Sciences; Geriatrics & Gerontology; Biochemical Markers; Biomolecular Modelling

Contact Details
Division of Aging Biology (DAB)
National Institute on Aging
7201 Wisconsin Avenue, GWY BG Room 2C231
Bethesda, MD 20892-9205
Tel: +1 301 402 7749
Email: mmurthy@mail.nih.gov
ACCELERATING THE PACE OF DRUG ABUSE RESEARCH USING EXISTING DATA (R01)
NIH: National Cancer Institute

Description:
The National Institute of Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the National Cancer Institute invite applications for their accelerating the pace of drug abuse research using existing data programme. This R01 funding opportunity announcement will support the innovative analysis of existing social science, behavioural, administrative and neuroimaging data to study the aetiology and epidemiology of drug-using behaviours and related disorders, associated HIV risk behaviours, prevention of drug use and HIV, and health service use.

Direct costs are limited to US$450,000 direct costs over three years, with no more than US$150,000 in any year. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply. PAR-13-080 (replaces PAR-10-018).

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 January 2016.
Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc

Award amount max: $450,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-080

Eligibility profile
Country of applicant institution: Any

Disciplines
Smoking & Tobacco; Drug & Substance Abuse; Aetiology; Behavioural Medicine; Epidemiology; Behavioural Studies & Social Problems; Cognitive & Behavioural Therapies; Diagnostic Sciences; Psychology; Alcoholism

Contact Details
Division of Epidemiology, Services, and Prevention Research
NIDA
6001 Executive Boulevard, Room 5144, MCS 9589
Bethesda, MD 20892-9589
Tel: +1 301 443 6504
Email: lopezmar@nida.nih.gov

OBESITY POLICY EVALUATION RESEARCH (R01)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
Six organisations of the National Institutes of Health invite applications for their obesity policy evaluation research (R01) grants. This R01 funding opportunity announcement encourages evaluations of large scale policies or programmes that are expected to influence obesity-related behaviours or weight...
outcomes in an effort to prevent or reduce obesity.

Applications budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PA-13-110 (replaces PA-10-027).

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 May 2016.
Posted date: 07 Feb 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-110

Eligibility profile

Country of applicant institution: Any

Disciplines

Food Consumption; Sports & Exercise Studies; Obesity; Primary Care; Dietary Guidelines; Cancer Studies & Oncology; Carcinogenesis; Physical & Sports Education; Exercise Physiology; Cancer Cell Biology; Education; Food Science; Nutrition & Dietetics; Public Health, Health Services & Primary Care; Diagnostic Sciences; Malnutrition

Contact Details

NIDDK
6707 Democracy Boulevard, Room 605
Bethesda, MD 20817
Tel: +1 301 594 4728
Email: ch514c@nih.gov

S

ELECTED TOPICS IN TRANSFUSION MEDICINE (R01)
NIH: National Heart, Lung and Blood Institute

Description:
The National Heart, Lung and Blood Institute invites applications for its selected topics in transfusion medicine (R01) programme. This R01 funding opportunity announcement will study topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Specifically, research focused on improving blood donor health, the safety and availability of blood products and improving the practice of transfusion medicine is critical to public health. Research designed to better understand the determinants of transfusion-associated adverse events and how to best minimise transfusion risks is also important. Research is also needed to maintain an adequate blood supply by minimising risks associated with the donation process and developing enhanced recruitment and retention programmes.

This FOA will use the NIH research project R01 grant mechanism and runs in parallel with an FOA of identical scope, PAR-13-025, that encourages applications under the R21 mechanism. Application budgets are not
Eligibility profile

Country of applicant institution: Any

Disciplines

Blood, Blood Products & Transfusions; Clinical Medicine

Contact Details

Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Rockledge II, MSC 7950
6701 Rockledge Drive
Bethesda, MD 20892-7950
Tel: +1 301 435 0065
Fax: +1 301 480 0867
Email: zousn@nhlbi.nih.gov

TIMULATING HAEMATOLOGY INVESTIGATION: NEW ENDEAVOURS (SHINE)

(R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its stimulating haematology investigation: new endeavours (SHINE) programme. This programme will support innovative, high-quality haematology research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases. Investigator-initiated research project grant applications are requested in specific areas of basic and translational haematology research where needs and opportunities for progress are particularly timely.

NIH intends to provide US$1 million to fund two to four awards in fiscal year 2013. Application budgets are not limited, but must reflect the actual needs of the project. Projects may request up to five years of support. Domestic and foreign public and private non-profit organisations and for-profit organisations are eligible to apply. PAS-13-031 (replaces PAS-10-046).

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 January 2016.
Posted date: 04 Dec 12
Award type: Directed grants to institutions, research groups etc
ADVANCES IN POLYCYSTIC KIDNEY DISEASE (R01)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for research under its advances in polycystic kidney disease programme. The purpose of this R01 funding opportunity announcement is to increase investigator interest in basic and applied investigations of the etiology and pathogenesis of polycystic kidney disease, in both its autosomal dominant and autosomal recessive forms. The ultimate aim is to facilitate PKD-related research studies, which will provide the basis for new therapeutic approaches.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. PA-13-064 (replaces PA-09-202).

Closing date: 05 Feb 16

Deadline information: Applications are due every February 5, June 5, and October 5 until January 8, 2016.
Posted date: 27 Dec 12
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: 
Application form: 
Eligibility profile
Country of applicant institution: Any
Disciplines
General Practice; Aetiology; Nucleus & Organelles; Pathogenesis; Disease Models; Molecular Genetics; Diagnostic Sciences; Clinical Medicine; Radiology & Medical Imaging; Nephrology & Kidneys
**Research on Autism Spectrum Disorders (R01)**

NIH: National Institute of Mental Health

**Description:**
Participating institutes of the National Institutes of Health invite applications for their research on autism spectrum disorders (R01) grants. The purpose of this R01 funding opportunity announcement is to encourage research designed to elucidate the aetiology, epidemiology, diagnosis, treatment and optimal means of service delivery in relation to autism spectrum disorders. Basic, clinical and applied studied are encouraged.

This FOA will use the NIH research project grant (R01) and will be run in parallel with two FOAs of identical scientific scope, PA-13-217 and PA-13-218, that will use the small research grant (R03) and the exploratory/developmental (R21) grant mechanisms, respectively. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible organisations include domestic and foreign for-profit and non-profit organisations and public or private institutions. PA-13-216 (replaces PA-10-158).

**Closing date:** 05 Feb 16  
**Deadline information:** Deadlines every 5 February, 5 June and 5 October until 8 May 2016  
**Posted date:** 02 May 13

**Award type:** Directed grants to institutions, research groups etc  
**Award budget total:** -  

**Eligibility profile**
Country of applicant institution: Any

**Disciplines**
Epidemiology; Cognitive Processes; Pharmacy & Pharmacology; Diagnostic Sciences; Public Health, Health Services & Primary Care; Psychiatry; General Practice; Biological Sciences; Neurobiology; Primary Care; Clinical Medicine; Neuroscience; Neuropsychology; Aetiology; Psychology; Cognitive & Behavioural Therapies; Neuropharmacology; Group Therapy; Compulsive Behaviour; Physiology; Medical & Diagnostic Tests; Allied Health Professions; Mental Illness; Autism Spectrum Disorders; Mental Health; Molecular Genetics

**Contact Details**
NIMH
A

LCOHOL USE DISORDERS: TREATMENT, SERVICES AND RECOVERY RESEARCH (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its alcohol use disorders: treatment, services and recovery research (R01) programme. This R01 funding opportunity announcement supports research on behavioural and pharmacological treatment for alcohol use disorders; organisational, financial and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; or the phenomenon of recovery from alcohol use disorders.

Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. Application budgets are not limited, but must reflect the needs of the project. The total project period may not exceed five years. This programme will use the NIH R01 grant mechanism and runs in parallel with two programmes of identical scientific scope: PA-13-161, which solicits applications under the R21 mechanism, and PA-162, which solicits applications under the R03 mechanism. PA-13-160 (replaces PA-10-100).

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 May 2016

Posted date: 02 Apr 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Public Health, Health Services & Primary Care; General Practice; Psychology; Experimental Psychology; Cognitive & Behavioural Therapies; Drug & Substance Abuse; Health Systems, Administration; Primary Care; Alcoholism; Allied Health Professions; Pharmacy & Pharmacology

Contact Details
----------------------------------------------
NIAAA
6000 Executive Boulevard
Bethesda, MD 20892-7003
Tel: +1 301 443 4715
Email: pchiapel@wilco.niaaa.nih.gov
HOME AND FAMILY BASED APPROACHES FOR THE PREVENTION OR MANAGEMENT OF OVERWEIGHT OR OBESITY IN EARLY CHILDHOOD (R01)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney, National Heart, Lung and Blood Institute and the Office of Behavioral and Social Sciences Research invite R01 applications for their home and family based approaches for the prevention or management of overweight or obesity in early childhood programme. This R01 funding opportunity announcement is for applications that propose randomised controlled clinical trials that test novel home or family based interventions for the prevention or management of overweight in infancy and early childhood. Tested interventions can use behavioural, environmental or other relevant approaches. Applications should focus on infants and young children and emphasise the role of home environment and the influence of family members and parents within that environment. The direct goal of this initiative is to fund research that will advance knowledge for innovative approaches to the prevention and management of overweight in children less than six years of age, with potential future translation to applications either in the home or linked to community settings.

This FOA will utilise the R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-154, that encourages applications under the R21 mechanism. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. Application budgets are not limited, and the maximum project period is five years. PA-13-153 (replaces PA-10-127).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Posted date: 25 Mar 13
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile

Country of applicant institution: Any

Disciplines

Obesity; Child Protection & Welfare; Social Programmes; Nutrition & Dietetics; Public Health, Health Services & Primary Care; Social Work & Social Policy; Maternal Health; Paediatrics; Primary Care

Contact Details

Division of Digestive Diseases and Nutrition
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Room 673
Bethesda, MD 20892-5450
Tel: +1 301 451 8354
Fax: +1 301 480 8300
Email: robert.kuczmaski@nih.gov
INDS EXPLORATORY CLINICAL TRIALS (R01)
NIH: National Institute of Neurological Disorders and Stroke

**Description:**
The National Institute of Neurological Disorders and Stroke invites applications for its NINDS exploratory clinical trials (R01). This R01 funding opportunity will support exploratory clinical trials that address research questions related to the mission and goals of NINDS. The clinical trials may evaluate drugs, biologics, devices, or surgical, behavioural or rehabilitation therapies.

Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PAR-13-281 (replaces PAR-10-199).

**Closing date:** 05 Feb 16
**Deadline information:** Applications due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 May 2016.
**Posted date:** 24 Jul 13
**Award type:** Clinical trials
**Award budget total:** -


**Eligibility profile**
----------------------------------------------
Country of applicant institution: Any

**Disciplines**
----------------------------------------------
Clinical Medicine; Behavioural Medicine; Neuroscience; Neurology; Cognitive & Behavioural Therapies; Muscle Diseases; Counselling & Therapy; Diagnostic Sciences; Neuroimaging; Medicine & Health; Drug Design; Public Health, Health Services & Primary Care; Medical Devices; Pharmacy & Pharmacology; Neuropharmacology; Biological Sciences; Stroke & Cerebrovascular Disorders; Primary Care; Electrophysiology; Neurosurgery; Neurobiology

**Contact Details**
----------------------------------------------
NINDS
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 496 0870
Email: exploratorytrial@ninds.nih.gov

INDS PHASE III INVESTIGATOR-INITIATED EFFICACY CLINICAL TRIALS (U01)
NIH: National Institute of Neurological Disorders and Stroke

**Description:**
The National Institute of Neurological Disorders and Stroke invites U01 applications for its NINDS phase III investigator-initiated efficacy clinical trials. This U01 funding opportunity will support investigator-initiated multi-site phase III randomised, controlled clinical trials which address...
research questions related to the mission and goals of NINDS. The clinical trials may evaluate an experimental intervention in comparison with a standard or control intervention, or compare two or more existing treatments. The programme supports drugs, biologics and devices, as well as surgical, behavioural and rehabilitation therapies. Trials should recruit study subjects from two or more geographically distinct enrolment sites, or centres.

Application budgets are not limited, but need to reflect the actual needs of the project. The maximum project period is five years. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations and academic institutions. PAR-13-278 (previously PAR-11-173).

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 September 2016.
Posted date: 23 Jul 13
Award type: Clinical trials
Award budget total: -

Website: 
Application form: 
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-278

Eligibility profile

Country of applicant institution: Any

Disciplines

Counselling & Therapy; Medical Devices; General Surgery; Public Health, Health Services & Primary Care; Pharmacotherapy; Pharmacy & Pharmacology; Drug Design; Methods of Drug Delivery; Behavioural Medicine; Clinical Medicine; Diagnostic Sciences; Ethology; Cognitive & Behavioural Therapies; Primary Care; Biological Sciences

Contact Details

NINDS
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 496 9135
Email: phase3trial@ninds.nih.gov

REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R01)
NIH: National Institute on Aging

Description:
The National Institute on Aging invites R01 applications for its regional and international differences in health and longevity at older ages grants.

Applications are sought from organisations proposing to advance knowledge on the reasons behind the divergent trends that have been observed in health and longevity at older ages, both across industrialised nations and across geographical areas in the United States.

This FOA will utilise the R01 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited but must reflect the actual needs of the proposed
project. Funding is available for up to five years.
PA-13-125.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm applicant's local time, every 5 February, 5 June and 5 October until 8 May 2016.
Posted date: 22 Feb 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Primary Care; Population Studies, Medical; Social Work & Social Policy; Geriatrics & Gerontology; Psychology of Ageing; Social & Income Inequality; Public Health, Health Services & Primary Care; International Health; Life Expectancy & Quality of Life; Psychology; Health Disparities

Contact Details
----------------------------------------------
Tel: +1 301 496 3138
Email: patmiosg@nia.nih.gov

RESEARCH ON HEARING HEALTHCARE (R01)
NIH: National Institute on Deafness and other Communication Disorders

Description:
The National Institute on Deafness and Other Communication Disorders invites applications for its research on hearing healthcare (R01) grants. This R01 funding opportunity announcement supports research leading to accessible and affordable hearing healthcare. The overarching emphasis is on the acquisition of knowledge that can be rapidly translated into new or enhanced approaches for access, assessment or interventions in order to deliver better hearing healthcare outcomes. Applications should seek quality approaches that are effective, affordable and deliverable to those who need them as well as implementable and sustainable in settings beyond the research environment.

This funding opportunity announcement will use the R01 research project grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-090, which encourages applications under the R21 exploratory/developmental grant mechanism.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.
Ref: PA-14-091 (replaces PA-10-253).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 May 2017.
Posted date: 06 Feb 14
A compilation of the Research Services of the Office of Research, Innovation & Development (ORID)

**Award type:** Directed grants to institutions, research groups etc
**Award amount max:** -
**Award amount min:** -
**Award budget total:** -

**Eligibility profile**
----------------------------------------------
Country of applicant institution: Any

**Disciplines**
----------------------------------------------
Quality of Care; Standards of Care; Health Systems Policy; Sensory Systems; Health Economics; Social Work & Social Policy; Clinical Decision-making & Analysis; Access to Health Care; Hearing & Otology; Economics & Econometrics; Health Systems, Consumer Choice ; Health Systems

**Contact Details**
----------------------------------------------
NIDCD
6120 Executive Boulevard
Bethesda MD 20892
Tel: +1 301 402 3458
Email: donahuea@nidcd.nih.gov

**EUROBIOLOGY OF MIGRAINE (R01)**
NIH: National Institute of Neurological Disorders and Stroke

**Description:**
A total of five institutes and offices of the NIH invite applications for their neurobiology of migraine grants. These R01 grants support research elucidating the mechanisms underlying migraine; expanding our current knowledge of the role of genetic, physiological, biopsychosocial and environmental influences in migraine susceptibility and progression; and exploring new therapeutic targets and therapies for acute migraine management and longer term prevention.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

This FOA utilises the R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-069, that encourages applications under the R21 mechanism. Applicants may request support for up to five years. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Ref: PA-14-068 (replaces PA-10-258).

**Closing date:** 05 Feb 16
**Deadline information:** Applications due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 May 2017.
**Posted date:** 14 Jan 14
**Award type:** Directed grants to institutions, research groups etc
**Award budget total:** -
Eligibility profile

Country of applicant institution: Any

Disciplines

Neurobiology; Headaches; Neurology; Physiology; Biological Sciences; Human Biological Sciences

Contact Details

Tel: +1 301 451 4460
Email: porterl@ninds.nih.gov

PRECLINICAL RESEARCH ON MODEL ORGANISMS TO PREDICT TREATMENT OUTCOMES FOR DISORDERS ASSOCIATED WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its preclinical research on model organisms to predict treatment outcomes for disorders associated with intellectual and developmental disabilities (R01) programme. This R01 funding opportunity announcement encourages research addressing preclinical research in model organisms of neurodevelopmental disorders. The goal of this FOA is to accelerate and improve the preclinical testing of candidate treatments and therapeutic compounds in order to move promising new drug therapies into clinical trials.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US$499,999 per year over a period of up to five years. PAR-13-195 (replaces PAR-11-038).

Closing date: 05 Feb 16

Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 May 2016.
Posted date: 26 Apr 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $2,500,000
Website:

Application form:

Eligibility profile

Country of applicant institution: Any

Disciplines

Neurology; Diagnostic Sciences; Clinical Medicine; Central Nervous System; Developmental Psychology; Human Biological Sciences; Cognitive Processes; Clinical Pharmacy & Pharmacology; Growth & Growth Factors; Child Development; Pharmacy & Pharmacology; Care for Disabled
OUTCOME MEASURES FOR USE IN TREATMENT TRIALS FOR INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (R01)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Mental Health invite applications for their outcome measures for use in treatment trials for individuals with intellectual and developmental disabilities (R01) programme. This R01 funding opportunity announcement encourages applications that propose to develop informative outcome measures for use in clinical trials for individuals with intellectual and developmental disabilities. This FOA will address a significant need in the field, one that is especially apparent in efforts to develop pharmacological treatments for these populations. This solicitation will focus ongoing clinical and translational research on a neglected area essential for therapy and pharmacological treatment development.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions.

Direct costs are limited to US$499,999 per year over a five-year period. PAR-13-213 (replaces PAR-11-045).

Closing date: 05 Feb 16

Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 May 2016.
Posted date: 26 Apr 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $2,500,000


Eligibility profile
Country of applicant institution: Any

Disciplines
Care for Disabled People; Primary Care; Child Development; Psychology; Mental Health; Drug Design; Clinical Pharmacy & Pharmacology; Cognitive Processes; Public Health, Health Services & Primary Care; Pharmacy & Pharmacology

Contact Details
NICHD
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 435 6880
Email: parisima@mail.nih.gov
ANCILLARY STUDIES TO THE NIDDK INTESTINAL STEM CELL CONSORTIUM (R01)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its ancillary studies to the NIDDK intestinal stem cell consortium grants. These R01 grants fund ancillary studies to the NIDDK intestinal stem cell consortium, and consist of research which will make use of consortium collaborations, techniques, and resources to accelerate research into intestinal stem cells. The proposed ancillary study must be designed to advance the scientific research mission of the NIDDK by focusing on diseases and areas of interest to the institute and commensurate with the interests and intent of the ISCC.

Application budgets are not limited, but should reflect actual needs of the proposed projects. The maximum period is five years. Eligible applicants include domestic and foreign public or private institutions and non-profit or for-profit organisations.

PAR-13-066 (replaces PAR-11-107).

Closing date: 05 Feb 16
Deadline information: Applications are due every February 5, June 5 and October 5 until January 8, 2016.
Posted date: 27 Dec 12

Award type: Directed grants to institutions, research groups etc,
Networking/collaboration
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-066

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Clinical Medicine; Stem Cell Genomics; Gastroenterology; Diagnostic Sciences; Embryonic Stem Cells; Stem Cell Therapy; Induced Pluripotent Stem Cells; Internal Medicine; Stem Cell

Contact Details
-----------------------------------------------
NIDDK
NIH
9000 Rockville Pike
Bethesda, MD 20892
Tel: +1 301 402 0671
Email: carringj@mail.nih.gov
FAMILY AND INTERPERSONAL RELATIONSHIPS IN AN AGEING CONTEXT (R01)
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its family and interpersonal relationships in an ageing context (R01) grants. This R01 funding opportunity announcement encourages innovative, hypothesis-driven research that can expand understanding of the role and impact of families and interpersonal relationships on health and well-being in midlife and older age. This FOA encourages research that takes a life span perspective, including studies which focus on early life influences on later life outcomes and on processes in midlife that impact subsequent trajectories of health and function. NIA is particularly interested in research that can inform the design of interventions that target the maintenance and improvement of ageing-relevant outcomes for the following: satisfying, high quality intimate relationships, compliance and adherence to healthy behaviours; adaptive caregiving relationships, shared decision-making and economic security.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants requesting US$500,000 or more in direct costs in any year most contact NIH programme staff at least six weeks before submitting the application. The maximum project period is five years.

Ref: PA-15-042 (reissue of PA-11-128).

Closing date: 05 Feb 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 January 2018.
Posted date: 21 Nov 14
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award budget total: -
Website:

Application form:

Eligibility profile
Country of applicant institution: Any

Disciplines
Psychology of Ageing; Geriatrics & Gerontology

Contact Details
National Institute on Aging
NIH
GWY BG Room 533
7201 Wisconsin Avenue
Bethesda MD 20814
Tel: +1 301 402 4156
Email: melissa.gerald@nih.gov
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R01)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its studies in neonatal resuscitation (R01) grants. These R01 grants support collaborative research projects on a wide range of topics related to neonatal resuscitation.

Projects should help develop strategies to deliver highest quality of healthcare to newborn infants and children with utmost safety and effectiveness. Projects may relate to the epidemiology of various domains of medical errors and consequent patient harm, assessing the factors at various levels that contribute to such errors, and intervention strategies at individual, systems and institutional-levels to help reduce and eliminate medical errors.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This funding opportunity uses the R01 research project mechanism, and runs in parallel with two opportunities of identical scientific scope: PA-14-35, which solicits applications under the R03 small grant programme mechanism, and PA-14-349, which solicits applications under the R21 exploratory and developmental grant mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The total project period may not exceed five years.

Ref: PA-14-350 (replaces PAR-11-222).

Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of the applicant organisation on every 5 February, 5 June and 5 October until 8 January 2018.

Posted date: 29 Sep 14
Award type: Directed grants to institutions, research groups etc

Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-350.html


Eligibility profile
Country of applicant institution: Any

Disciplines
Foetal Health & Prenatal Development; Cardiology; Allied Health Professions; Paediatrics; Respiratory Medicine; Obstetrics & Gynaecology; Neonatal Disorders; Clinical Medicine

Contact Details
NIH: National Institute of Child Health and Human Development
Building 31, Room 2A32
MSC 2425
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 435 6873
Email: kosomari@mail.nih.gov
SpatiaL Uncertainty: Data, Modeling and Communication (R01)
NIH: National Cancer Institute

Description:
The National Cancer Institute and the National Institute of Environmental Health Sciences invite applications for their spatial uncertainty: data, modeling and communication (R01) grants. This R01 funding opportunity announcement supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualise the nature and consequences of spatial uncertainty.

This FOA uses the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-009 and PA-15-011, that solicit applications under the exploratory and developmental grant (R21) and the small grant award (R03) mechanisms, respectively. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-15-010 (replaces PA-11-238).

Closing date: 05 Feb 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation every, 5 February, 5 June and 5 October until 8 January 2018.
OBESITY AND ASTHMA: AWARENESS AND SELF-MANAGEMENT (R01)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for its obesity and asthma: awareness and self-management (R01) grants. The purpose of this R01 funding opportunity announcement is to stimulate research to examine the relationship between asthma, obesity and self-management.

Studies should focus on the common exposures of obesity and asthma in early life and transition to adulthood. They may investigate the molecular pathways linking asthma and obesity, as long as the studies describe how these relate to self-management, or research interventions targeting asthma or obesity and their effects on each other, and possible mechanisms of action and effect on behaviour.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but should reflect the actual needs of the project. The maximum period is five years.

Ref: PA-14-316 (replaces PA-11-245).

Deadlines on: 5 February 2016, 5 June 2016, 5 October 2016, and repeated annually.
Posted date: 11 Aug 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-316.html

Application form: http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-316

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Adolescent Paediatrics; Asthma; Clinical Medicine; Primary Care; Home Health Care Services; Obesity; Paediatrics; Biological Sciences; Patient Compliance; Maternal Health; Diagnostic Sciences; Respiratory Medicine; Public Health, Health Services & Primary Care; Patient Care & Education; Epidemiology

Contact Details
----------------------------------------------
Tel: +1 301 594 5970
Email: hussk@mail.nih.gov
**PREGNANCY IN WOMEN WITH DISABILITIES (R01)**

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

**Description:**
The Eunice Kennedy Shriver National Institute of Child Health and Development invites applications for its pregnancy in women with disabilities (R01) grants. The purpose of this R01 funding opportunity announcement is to encourage research investigating the incidence, course and outcomes of pregnancy among women with disabilities. Areas of interest also include studies to inform preconceptional and antenatal counselling and strategies for addressing barriers to prenatal care, and management of pregnancy, the puerperium, and the transition to parenthood in order to optimise outcomes for women with physical, intellectual and developmental, or sensory disabilities and their families. Applicants are encouraged to include women with disabilities and members of the community in the design and conduct of their research.

This FOA will utilise the NIH research project grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-355 that solicits applications under the exploratory/developmental grant (R21) mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-354 (replaces PAR-11-258).

**Closing date:** 05 Feb 16

**Deadline information:** Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 January 2017.

**Posted date:** 02 Oct 14

**Award type:** Directed grants to institutions, research groups etc

**Award budget total:** -

**Website:**


**Application form:**


**Eligibility profile**

---------------------------------------------
Country of applicant institution: Any

**Disciplines**

---------------------------------------------
Sociology; Neonatal Disorders; Reproductive Medicine; Reproduction & Fertility; Care for Disabled People; Maternal Health; Public Health, Health Services & Primary Care; Allied Health Professions; Obstetrics & Gynaecology; Clinical Medicine; Pregnancy & Birth; Primary Care; Family Health; Women’s Health; Diagnostic Sciences

**Contact Details**

---------------------------------------------

NICHD
Building 31, Room 2A32
MSC 2425
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 435 7909
Email: higginsr@mail.nih.gov
**MECHANISTIC STUDIES OF PAIN AND ALCOHOL DEPENDENCE (R01)**

NIH: National Institute on Alcohol Abuse and Alcoholism

**Description:**
The National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their mechanistic studies of pain and alcohol dependence (R01) research project grant. This R01 funding opportunity announcement supports research in the mechanistic studies on the relationship between excessive alcohol drinking, alcohol dependence and pain with the aim of understanding genetic, pharmacological and learning mechanisms underlying the association between the propensity to drink alcohol excessively and pain responses.

Application budgets are not limited, but need to reflect the actual needs of the project. The maximum project period is five years. Applicants requesting US$500,000 or more in direct costs in any year, excluding consortium facilities and administrative costs, must contact NIH programme staff at least six weeks before submitting the application. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions.


Closing date: 05 Feb 16

Deadline information: Applications are invited between 5 January and 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 January 2018.

Posted date: 13 Nov 14

Award type: Directed grants to institutions, research groups etc

Award budget total: -


Eligibility profile

Country of applicant institution: Any

Disciplines

Chronic Pain; Pain Management; Alcoholism

Contact Details

NIAAA
BG 5635FL RM 2052
5635 Fishers Ln
Rockville, MD 20852
Tel: +1 301 443 1192
Email: regunathans@mail.nih.gov
Molecular and Cellular Substrates of Complex Brain Disorders (R01)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its molecular and cellular substrates of complex brain disorders grants (R01). This R01 funding opportunity announcement encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. This FOA seeks to encourage innovative leads at the interface between cellular and molecular mechanisms, and that address gaps in understanding the biological mechanisms behind putative disease and associated processes with the goal of accelerating progress in emerging research areas relevant to complex brain disorders. Proposals should be hypothesis-driven and propose discovery-based studies with an emphasis on exploring neurobiological mechanisms at the molecular, cellular and circuit levels.

This FOA uses the NIH research project (R01) grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-310 that encourages applications under the NIH exploratory/developmental (R21) grant mechanism. Application budgets are not limited but must reflect the actual needs of the proposed project. The total project period may not exceed five years. Applicants that request US$500,000 or more in direct costs in any year must contact the NIH six weeks prior to applying.

US and foreign for-profit and non-profit organisations, higher education institutions and public and private organisations may apply.

Ref: PAR-14-309 (replaces PAR-11-299).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm proposer’s local time every 5 February, 5 June and 5 October until September 8, 2017.
Posted date: 07 Aug 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/parfiles/PAR-14-309.html


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Electrophysiology; Public Health, Health Services & Primary Care; Neuroendocrinology; Cognitive Processes; Primary Care; Pharmacy & Pharmacology; Neurology; Neuroanatomy; Clinical Medicine; Neurobiology; Allied Health Professions; Psychology; Endocrine & Neuroendocrine Cancers; Cell & Developmental Biology; Neuropharmacology; Muscle Diseases; Neuroscience; Central Nervous System; Mental Illness; Intellectual Disabilities; Diagnostic Sciences; Biological Sciences; Biochemistry & Molecular Biology; Nucleus & Organelles

Contact Details
----------------------------------------------
NIMH
6001 Executive Blvd
DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R01)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and the National Institute on Deafness and Other Communication Disorders invite applications for the development of appropriate formulations and paediatric drug delivery systems (R01) grants. This R01 funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Development and testing of novel paediatric drug delivery systems is also part of this initiative.

This funding opportunity announcement will use the NIH research project R01 grant mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-344, which solicits applications under the small grant (R03) mechanism and PAR-13-326, which solicits applications under the exploratory/developmental research grant award (R21) mechanism.

Application budgets are not limited, but should reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-325 (replaces PAR-11-301).

Closing date: 05 Feb 16

Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 September 2016.
Posted date: 05 Sep 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-325

Eligibility profile
--------------------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------------------
Drug Design; Pharmacy & Pharmacology;
Methods of Drug Delivery; Diagnostic Sciences; Paediatrics; Allied Health Professions; Clinical Medicine

Contact Details
--------------------------------------------------------
NICHD
Obstetric and Paediatric Pharmacology and Therapeutics Branch
6100 Executive Boulevard, ROom 4A01C, MSC 7510
Bethesda, MD 20852
Tel: +1 301 496 5589
Fax: gg65m@nih.gov
SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIOURAL AND SOCIAL SCIENCES

(R01)

NIH: Office of the Director

Description:
A total of 11 participating institutes of the National Institutes for Health invite applications for their systems science and health in the behavioural and social sciences (R01) grants. This R01 funding opportunity announcement seeks to increase the breadth and scope of topics that can be addressed with systems science methodologies. This FOA calls for research projects that are applied or basic in nature, including methodological and measurement development, have a human behavioural or social science focus and employ methodologies suited to addressing the complexity inherent in behavioural and social phenomena, referred to as systems science methodologies. Additionally, this FOA seeks to promote interdisciplinary collaboration among health researchers and experts in computational approaches to further the development of modelling- and simulation-based systems science methodologies and their application to important public health challenges. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity announcement uses the NIH research project R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-15-047 that solicits applications under the exploratory/developmental research grant award (R21) mechanism. Application budgets are not limited but need to reflect actual needs of the proposed project. Applicants requesting US$500,000 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. The maximum project period is five years.


Closing date: 05 Feb 16
Deadline information: Applications are invited between 5 January and 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 January 2018.
Posted date: 24 Nov 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
Country of applicant institution: Any

Disciplines
Research Methods in Sociology; Social Sciences; Behavioural Studies & Social Problems

Contact Details
NCI
BG 9609 Room 3E602
9609 Medical Centre DR
Rockville, MD 20850
Tel: +1 301 402 1146
Email: wireley@mail.nih.gov
BUILDING GENETICS AND GENOMIC KNOWLEDGE ABOUT DENTAL, ORAL AND CRANIOFACIAL DISEASES AND DISORDERS (R01)
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its building a genetic and genomic knowledge base in dental, oral and craniofacial diseases and disorders (R01) grants. This R01 funding opportunity announcement encourages research into dental, oral, and craniofacial diseases and disorders for which there is evidence for genetic heritability but for which there is no strong understanding of the genetics or genomics of the disease or disorder.

Research areas may include identification of promising areas of the genome, and characterisation and elucidation of the functions of genetic variants that affect disease risk in humans. The goal is to drive development of effective diagnostic, therapeutic, and preventive approaches.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

The maximum project period is five years.
Ref: PA-14-347 (replaces PA-11-317).

Closing date: 05 Feb 16
Deadline information: Applications open on 28 October 2014 and are due by 5pm local time of applicant organisation on 28 November 2014 and then on every 5 February, 5 June and 5 October until 8 January 2018.
Posted date: 23 Sep 14

Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-347.html
Application form: http://www.grants.gov/web/grants/applicant-package.html#download=true&oppNum=PA-14-347

Eligibility profile
--------------------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------------------------------
Special Needs Dentistry; Oral Medicine; Biological Sciences; Clinical Medicine; Population & Ecological Genetics; Human Genome; Genetics & Systems Biology; Craniofacial Disorders; Quantitative Genetics; Preventive Dentistry; Cancer Genetics; Preventive Medicine; Allied Health Professions; Diagnostic Sciences; Genomics; Genetic Diseases; Medicine & Health; Medical Genetics; Dentistry

Contact Details
-----------------------------------------------------------------------
NIDCR
Public Information and Liaison Branch
45 Center Drive, MSC 6400
Bethesda, MD 20892-6400
Tel: +1 301 594 4846
Email: emily.harris@nih.gov
BUILDING ON HIGH IMPACT BASIC NEUROBIOLOGY THROUGH ASSAY DEVELOPMENT: ADVANCING TOOLS FOR THERAPEUTIC DISCOVERY (R01)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health, the National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their building on high impact basic neurobiology through assay development: advancing tools for therapeutic discovery (R01) grants.

This announcement encourages research proposals to develop novel, robust assays to reveal changes in neuronal and glial function. The goal is to adapt state-of-the-art measures of basic cellular processes or molecular events that are key mediators of nervous system function with the intent to probe mechanisms or perturbations in an unbiased and efficient manner.

US and foreign for-profit and non-profit organisations and public and private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants requesting US$500,00 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. The maximum project period is four years.


Closing date: 05 Feb 16

Deadline information: Applications open on 23 January and are due by 5pm local time of applicant organisation on 23 February and every 5 February, 5 June and 5 October after that until 8 January 2018.

Posted date: 11 Dec 14

Award type: Directed grants to institutions, research groups etc, Innovation grants

Award budget total: -

Website:

Application form:

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Cellular Interactions ; Neurobiology

Contact Details
----------------------------------------------
NSC BG Room 7189
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 5288
Email: jdrisco1@mail.nih.gov
HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIOURS IN CHILDREN AND ADOLESCENTS (R01)
NIH: National Institute of Nursing Research

Description:
A total of two institutes and offices of the NIH invite applications for their healthy habits: timing for developing sustainable healthy behaviours in children and adolescents (R01) grants. This R01 funding opportunity announcement encourages applications that employ innovative research to identify mechanisms of influence and promote positive sustainable health behaviour in children and youth up to the age of 21. Applications to promote positive health behaviour should target social and cultural factors, including schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and mass media. Topics to be addressed in this announcement include:

- effective, sustainable processes for influencing young people to make healthy behaviour choices;
- identification of the appropriate stage of influence for learning sustainable lifelong health behaviours;
- the role of technology and new media in promoting healthy behaviour;
- identification of factors that support healthy behaviour development in vulnerable populations, identification of barriers to healthy behaviours;
- identification of mechanisms and mediators that are common to the development of a range of habitual health behaviours.

Given the many factors involved in developing sustainable health behaviours, applications from multidisciplinary teams are strongly encouraged. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PA-14-177 (Reissue of PA-11-327).

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 May 2017.
Posted date: 22 Apr 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/notice-files/PA-14-177.html

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any
Disciplines
-----------------------------------------------
Sociology; Dentistry; Social Psychology; Behavioural Studies & Social Problems; Public Health, Health Services & Primary Care; Media Studies; Social Programmes; Mental Health; Communication & Media Studies; Children’s Literature; Health Education; Social Aspects of Mental Health; Public Health; Behavioural Medicine; Child Development; Child Protection & Welfare; Malnutrition; Psychology; Popular Culture; Adolescent Paediatrics; Computer, Internet & Mobile Gaming; Social Behaviour & Attitudes; Primary Care; Education; Health Promotion; Social Work & Social Policy; Food Science; Maternal Health; Medical Education; Health Psychology; Communication Studies; Group Dynamics & Collective Behaviour
Biomarkers: Bridging Paediatric and Adult Therapeutics (R01)
NIH: Eunice Kennedy Shriver National Institute Of Child Health And Human Development

Description:
The National Institute of Child Health and Human Development invites applications for its biomarkers: bridging paediatric and adult therapeutics (R01) grants. This R01 funding opportunity announcement invites applications that propose adapting adult biomarkers to children. This would include the application and validation of biomarkers developed in adults to paediatric diagnosis, prognosis, and estimation of disease progression, toxicity and response to therapy. Projects supported will be confined to those biomarkers that correlate with a clinical observation, have been extensively studied in adults, and for which there is solid evidence that they have paediatric applications. Discovery of new biomarkers for use in new drug development or in preclinical studies are not part of this FOA.

This funding opportunity announcement will use the NIH research project grant (R01) mechanism and runs in parallel with two FOAs of identical scientific scope: PAR-13-299, which solicits applications under small grants programme (R03) mechanism and PAR-13-295, which solicits applications under the exploratory/developmental grant (R21) programme. Application budgets are not limited, but must reflect actual needs of the project. The project period is a maximum of five years.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-296 (replaces PAR-11-322).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 September 2016.
Posted date: 02 Aug 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
Country of applicant institution: Any

Disciplines
Medical & Diagnostic Tests; Clinical Medicine; Diagnostic Sciences; Medical Instrumentation; Biochemical Markers; Biological Markers & Sensor Mechanisms; Drug Design; Paediatrics

Contact Details
Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
HEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R01)

NIH: National Institute of Nursing Research

Description:
A total of two institutes and offices of the NIH invite applications for their mHealth tools for individuals with chronic conditions to promote effective patient-provider communication, adherence to treatment and self-management (R01) grants. The purpose of this R01 funding opportunity announcement is to stimulate research utilising mobile health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases in underserved populations.

This funding opportunity announcement will utilise the NIH research project grant R01 mechanism and runs in parallel with another FOA of identical scientific scope: PA-14-181 that solicits applications under the exploratory/developmental grant (R21) funding mechanism. Application budgets are not limited, but need to reflect actual needs of the proposed project. The total project period is a maximum of five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-14-180 (Reissue of PA-11-330).

Closing date: 05 Feb 16

Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 May 2017.

Posted date: 23 Apr 14

Award type: Directed grants to institutions, research groups etc

Award budget total: -


Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Public Health, Health Services & Primary Care; Medical & Diagnostic Tests; Electrical & Electronic Engineering; Clinical Medicine; 5G, Wireless & Mobile Networks; Screening for Diseases; Pharmaceutical Drugs; Computer Science & Informatics; Rural Health; Primary Care; Assistive Technology; Patient Care & Education; Information Systems; Health Economics; Chronic Care

Contact Details
---------------------------------------------------------------
Tel: +1 301 594 5971
Email: mccloskd@mail.nih.gov
ALCOHOL IMPAIRMENT OF IMMUNE FUNCTION, HOST DEFENSE AND TISSUE HOMEOSTASIS (R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its alcohol impairment of immune function, host defense and tissue homeostasis (R01) funding opportunity announcement. This announcement invites applications from researchers with broad expertise to study the consequences of alcohol consumption on immune function, with the goal of improving the outcome of patients who abuse alcohol.

This FOA also aims to attract research applications that utilise comprehensive approaches and cutting edge technology to address mechanistic questions about alcohol’s effect on human health. In view of the complexity of the interactions within the immune system and among immune, neural and endocrine networks, systems approaches are encouraged.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is five years.
Ref: PA-15-159 (reissue of PA-12-025).

Closing date: 05 Feb 16
Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 May 2018.
Posted date: 27 Mar 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:
Application form:
http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275459

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Immunology; Alcoholism

Contact Details
---------------------------------------------------------------
NIAID
BG 5635FL Room 2021
5635 Fishers Lane
Rockville MD 20852
Tel: +1 301 443 8744
Email: jungma@mail.nih.gov

DISCOVERY OF IN VIVO CHEMICAL PROBES (R01)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health, in collaboration with eight other offices of the National Institutes of Health, invites proposals for its discovery of in vivo chemical...
probes grant (R01). This R01 funding opportunity supports research in the following fields:

- discovery and development of novel, small molecules for their potential use in studying disease treatment, relevant to the missions of the participating NIH institutes;
- discovery or validation of novel, biological targets that will inform studies of disease mechanisms.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. Projects may not exceed three years in length.

Ref: PAR-14-279 (replaces PAR-12-060).

Closing date: 05 Feb 16
Deadline information: Applications due every 5 February, 5 June and 5 October until 8 September, 2014.
Posted date: 14 Jul 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-279.html
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
- Country of applicant institution: Any

Disciplines
- Disease Models; Public Health, Health Services & Primary Care; Primary Care; Nucleus & Organelles; Molecular Probes; Diagnostic Sciences; Biochemistry & Molecular Biology; General Practice; Biological Sciences; Pathogenesis; Epidemiology; Immunological & Bioassay Methods

Contact Details
- NIH NIMH
6001 Executive Boulevard
Bethesda, MD 20892-9663
Tel: +1 301 443 5415
Email: michelottiel@mail.nih.gov

HIGH THROUGHPUT SCREENING TO DISCOVER CHEMICAL PROBES (R01)
NIH: National Institute of Mental Health

Description:
A total of 11 components of the National Institutes of Health invites applications for their solicitation of high throughput screening to discover chemical probes (R01) grants. This R01 funding opportunity announcement encourages investigators to form collaborations with an established academic, non-profit or commercial high throughput screening facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Through this FOA, NIH wishes to stimulate research in:

- discovery and development of novel, small molecules for their potential use
in studying disease treatments relevant to the missions of the participating NIH institutes;
- discovery or validation of novel, biological targets that will inform studies of disease mechanisms.

Emphasis will be placed on assays that provide new insight into important disease targets and processes.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed three years.

Ref: PAR-14-284 (replaces PAR-12-058).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 September 2017.
Posted date: 18 Jul 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-284.html

MATERNAL NUTRITION AND PRE-PREGNANCY OBESITY: EFFECTS ON MOTHERS, INFANTS AND CHILDREN (R01)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research and Office of Dietary Supplements invite applications for their maternal nutrition and pre-pregnancy obesity: effects on mothers, infants and children (R01) funding opportunity announcement. This announcement encourages projects to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity.
US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited, but need to reflect actual needs of the proposed project. Applicants requesting US$500,000 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. The maximum project period is five years.

Ref: PA-15-100 (replaces PA-12-061).

Closing date: 05 Feb 16
Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 May 2018.
Posted date: 28 Jan 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
Country of applicant institution: Any

Disciplines
Maternal Health; Obesity; Reproduction & Fertility; Pregnancy & Birth; Foetal Health & Prenatal Development

Contact Details
NINR
Building 1Dem, Room 718
6701 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 5976
Email: hardylr@mail.nih.gov

ENVIRONMENTAL EXPOSURES AND HEALTH: EXPLORATION OF NON-TRADITIONAL SETTINGS (R01)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research and the National Institute of Environmental Health Research invite applications for their environmental exposures and health: exploration of non-traditional settings (R01) grants. The purpose of this R01 funding opportunity announcement is to encourage interdisciplinary research aimed at promoting health, limiting symptoms and disease, and reducing health disparities in children and older adults living or spending time in non-traditional settings. These settings result in exposure to environmental pollutants and toxins that result in health risks, symptoms and other health conditions including lower respiratory diseases, chronic obstructive pulmonary disease and cardiovascular diseases. Risk identification and symptom management include prevention and behaviour changes and actions to maintain health and prevent disease with an emphasis on the individual, family and community which will advance nursing science.
This funding opportunity announcement will use the NIH research project grant (R01) mechanism and runs in parallel with an FOA of identical scientific scope: PA-12-134 that solicits applications under the exploratory/developmental grant (R34) mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-12-133.

Closing date: 05 Feb 16
Deadline information: Deadline: every 5 February, 5 June and 5 October until 8 January 2016.
Posted date: 26 Mar 12
Award type: Directed grants to institutions, research groups etc
Award budget total: -

**Application form:**
[http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-133](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-133)

**Eligibility profile**
---------------------------------------------
Country of applicant institution: Any

**Disciplines**
---------------------------------------------
Preventive Medicine; Environmental Medicine; Health Disparities; Economic & Social Environment; Public Health, Health Services & Primary Care; Medicine & Health; Primary Care; Chronic Care; Respiratory Medicine; Clinical Medicine; Nursing; Environmental & Occupational Health & Safety; Cardiovascular Diseases.

**Contact Details**
---------------------------------------------
Office of Extramural Activities
NINR
Tel: +1 301 594 5970
Email: hussk@mail.nih.gov

**PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS: EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R01)**

*NIH: National Cancer Institute*

**Description:**
The National Cancer Institute invites applications for its physical activity and weight control interventions among cancer survivors: effects on biomarkers of prognosis and survival (R01) grants. This R01 funding opportunity announcement encourages transdisciplinary and translational research that will identify specific biological or biobehavioural pathways through which physical activity or weight control may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control, on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Biomarkers may include but are not limited to intervention-induced changes in sex hormones, insulin-like growth factors or their binding proteins, leptin and other adipokines, immunologic or inflammatory factors, oxidative stress and DNA damage or repair capacity, angiogenesis, or prostaglandins.
This FOA will use the R01 award mechanism and runs in parallel with an FOA of identical scientific scope, PA-15-310, which solicits proposals under the exploratory/developmental grant (R21) mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions.

Ref: PA-15-311 (replaces PAR-12-228).

Closing date: 05 Feb 16
Deadline information: Applications open on 5 September 2015 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 September 2018.
Posted date: 27 Jul 15

Award type: Directed grants to institutions, research groups etc
Award budget total: -
Application form: http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
=================================================
Country of applicant institution: Any

Disciplines
=================================================
Diagnostic Sciences; Cancer Cell Biology; Human Metabolism; Obesity; Cancer Studies & Oncology

Contact Details
=================================================
Tel: +1 240 276 6782
Email: pernafm@mail.nih.gov

UNCONVENTIONAL ROLES OF ETHANOL METABOLISING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its unconventional roles of ethanol metabolising enzymes, metabolites and cofactors in health and disease (R01) funding opportunity announcement. This announcement provides support for integrated, innovative research on the novel and unconventional contributions of ethanol metabolising pathways, their metabolites, cofactors and interactions with synergising biological pathways in the development of alcohol-induced diseases and end organ injuries.

The aim is to generate data that leads to breakthroughs in identification and understanding of key cellular and molecular components in the initiation, progression and maintenance of the diverse medical disorders caused by excessive or long term alcohol consumption. The generated knowledge should enable clinicians to improve disease outcomes and consequently, public health. Research areas include the following: ethanol and NAD+; ethanol and acetate; ethanol and SAM; ethanol and zinc; endogenous substrates and functions of alcohol metabolising pathways – regulation of growth, development and disease.
This announcement uses the R01 research project grant mechanism and runs in parallel with one of identical scientific scope, PA-15-057, which encourages applications under the R21 exploratory or developmental grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-15-058 (reissue of PA-14-198).

Closing date: 05 Feb 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 January 2018.
Posted date: 09 Dec 14
Award type: Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration
Award budget total: -

Website:
Application form:

Eligibility profile
Country of applicant institution: Any
Disciplines
Addiction; Alcoholism; Alcoholic Beverages; Cell Physiology & Metabolism; Hepatology

Contact Details
NIAAA
Building 5635FL, Room 2119
5635 Fishers Lane
Rockville, MD 20852
+1 301 443 2193
Email: orosza@mail.nih.gov

LYMPHATICS IN HEALTH AND DISEASE IN THE DIGESTIVE SYSTEM, KIDNEY AND URINARY TRACT (R01)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Kidney Diseases invites applications for its lymphatics in health and disease in the digestive system, kidney and urinary tract (R01) grants. This R01 funding opportunity announcement supports research into aspects of lymphatic vessel physiology, development and pathophysiology related to health and diseases of the digestive system, kidney and urinary tract organs. Studies to understand the factors that control local lymphatic vessel functional anatomy and physiology and development during health or disease in these organs and systems, and the mechanisms by which alterations of lymphatic vessel function affect organ function, are of interest. Studies with a major focus on immune mechanisms are not encouraged. This FOA will use the R01 research project grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit
organisations and public or private institutions.

Application budgets are limited to US$250,000 in direct costs per year. The maximum project period is five years. Ref: PAR-15-306 (replaces PAR-12-259).

Closing date: 05 Feb 16
Deadline information: Applications open on 5 September 2015 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 September 2018.
Posted date: 27 Jul 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $1,250,000

Application form:
http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Lymphatic System; Nephrology & Kidneys; Gastroenterology; Urology

Contact Details
----------------------------------------------
NIDDK
BG 2Dem Room 661
6707 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 402 0671
Email: carringj@mail.nih.gov

EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R01)
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its examination of survivorship care planning efficacy and impact (R01) funding opportunity announcement. This announcement aims to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy, with the goal to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors. Specifically, this call aims to stimulate research that will:

• develop and test metrics for evaluating the impact of survivorship care planning;
• evaluate the impact of survivorship care planning on cancer survivors morbidity, self-management and adherence to care recommendations, utilisation of follow-up care;
• evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organisations implementing the care planning;
• identify models and processes of care that promote effective survivorship care planning.
This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-011, which solicits applications under the NIH exploratory or developmental (R21) grant mechanism.

US and foreign for-profit, non-profit organisations and public or private institutions, may apply.

Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-16-012 (replaces PA-12-275).

Closing date: 05 Feb 16
Deadline information: Applications open 5 January 2016 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 January 2019.

EFFECTS OF IN UTERO ALCOHOL EXPOSURE ON ADULT HEALTH AND DISEASE (R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its effects of in utero alcohol exposure on adult health and disease (R01) grants. This R01 funding opportunity announcement will support novel research on how prenatal alcohol exposure may contribute to the aetiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease concept which suggest that foetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adulthood disease. The goal of this FOA is to stimulate a broad range of research to:

- leverage existing prospective birth cohorts to define the role of maternal alcohol consumption in the DOHaD process;
- investigate the biological, cellular and molecular mechanisms by which prenatal alcohol exposure may impact disease outcomes later in life;
- identify biomarkers associated with gestational alcohol exposure that may predict adult disease susceptibility in exposed offspring.

Studies supported by this FOA will provide fundamental insights into a possible foetal-basis to adult disease that is influenced by maternal alcohol use.
This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-292, that solicits applications under the R21 exploratory/developmental grant mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PA-12-291.

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 May 2016.
Posted date: 01 Oct 12
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-291

Eligibility profile
Country of applicant institution: Any

Disciplines
Reproduction & Fertility; Reproductive Medicine; Medicine & Health; Cognitive Processes; Biological Sciences; Child Development; Biochemistry & Molecular Biology; Aetiology; Foetal Health & Prenatal Development; Alcoholism; Cell & Developmental Biology; Psychology; Pregnancy & Birth; Disease Models; Diagnostic Sciences; Growth & Growth Factors

Contact Details
Division of Metabolism and Health Effects
NIAAA
5635 Fishers Lane, Room 2120
Bethesda, MD 20892-7003
Tel: +1 301 443 7351
Fax: +1 301 594 0673
Email: duntyw@mail.nih.gov

EPIGENETIC INHERITANCE AND TRANSGENERATIONAL EFFECTS OF ALCOHOL
(R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its epigenetic inheritance and transgenerational effects of alcohol (R01) grants. This R01 funding opportunity announcement will support research proposing to conduct mechanistic studies in human and animal models on alcohol-induced transgenerational effects and the role of epigenetic inheritance in these effects.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-004, that solicits applications under the R21 exploratory/developmental grant mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PA-13-003.
Description:
The National Institute on Aging and the National Institute of Nursing Research invite applications for its solid organ transplantation: older donors and recipients (R01) grants. This R01 funding opportunity announcement will support basic, clinical translational, epidemiological and outcomes research on solid organ transplant in older persons. Research may focus on, but is not limited to, the following:

- appropriate selection of older SOT donors and recipients;
- improved management of older SOT recipients;
- immunology and immunosuppression pertaining to older SOT patients;
- healthcare disparities, utilisation and costs of SOT in older patients.

Supported research is expected to enhance knowledge of immunobiology in ageing and transplantation, and to provide evidence-based guidance to improve access to transplantation, organ allocation and utilisation, graft survival, and short- and long-term outcomes of SOT in older persons.

This FOA will use the R01 research project grant mechanism and runs in parallel with two FOAs of identical scope, PA-13-037, which uses the R03 small grant mechanism and PA-13-038, which uses the R21 exploratory developmental research grant mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Applications may be submitted by foreign or domestic for-profit and non-profit
DIFFERENTIATION AND INTEGRATION OF STEM CELLS (EMBRYONIC AND INDUCED-PLURIPOTENT) INTO DEVELOPING OR DAMAGED TISSUES (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Development invites applications for its differentiation and integration of stem cells (embryonic and induced-pluripotent) into developing or damaged tissues (R01) grants. This R01 funding opportunity announcement aims to promote in vivo studies of stem cells in animals models and humans to better understand how stem cells function within developing or damaged tissues. The areas of emphasis would include systematically profiling and cataloguing changes at genetic and epigenetic levels that take place in stem cells and their microenvironment. The study intends to gain in-depth knowledge of the mechanisms involved in:

- progressive differentiation of embryonic stem cells into embryonic lineages, progenitor cells and specialised cell types;
- adult stem cells or progenitor cells during tissue regeneration and wound healing;
- induced pluripotent stem cells at the site of injury during stem cell therapy.

This FOA will use the R01 research project grant mechanism and runs in parallel with an FOA of identical scope, PAR-13-095, which uses the R21 exploratory/developmental research grant mechanism.

Application budgets are limited to US$500,000 per year over a five-year project period. Applications may be submitted by foreign or
domestic for-profit and non-profit organisations and public or private institutions. PAR-13-094.

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 September 2016.
Posted date: 29 Jan 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $2,500,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Physiology; Regenerative Medicine; Embryonic Stem Cells; Public Health, Health Services & Primary Care; Diagnostic Sciences; Epigenetics; Molecular Genetics; Cancer Genetics; Stem Cell Genomics; Tissue Culture; Medical Genetics; Pharmacy & Pharmacology; Wound Healing; Gene Therapy; Nursing; Induced Pluripotent Stem Cells; Genetics & Systems Biology; Primary Care; Stem Cell; Human Biological Sciences; Clinical Medicine; Biological Sciences; Stem Cell Therapy; Pharmacotherapy

Contact Details
----------------------------------------------
Developmental Biology and Structural Variation Branch
NICHD
Building 31
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 435 6886
Email: mukhopam@mail.nih.gov

SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIOURS AND WEIGHT OUTCOMES (R01)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of four institutes and offices of the National Institutes of Health invites applications for their school nutrition and physical activity policies, obesogenic behaviours and weight outcomes (R01) grants. The objectives of this R01 funding opportunity announcement are to understand how school-related policies impact the school and home environment, promote positive nutrition and physical activity behaviours and decrease childhood obesity. Applications should propose to:

- foster multidisciplinary research that will evaluate how policies can influence school physical activity and nutrition environments, youths’ obesogenic behaviours and weight outcomes;
- understand how schools are implementing these policies and examine multi-level influences on adoption and implementation at various levels;
- understand the synergistic or counteractive effect of school nutrition and physical activity policies on the
home and community environment and body weight.

This FOA will use the R01 research project grant mechanism and runs in parallel with two FOAs of identical scope, PAR-13-098, the R21 exploratory/developmental research grant mechanism, and PAR-13-099, which uses the R03 small grant programme mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-13-100.

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 May 2016.
Posted date: 04 Feb 13
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -

Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-100

Eligibility profile
Country of applicant institution: Any

Disciplines
Public Health, Health Services & Primary Care; Schools Policy & Politics; Psychology; Health Education; Primary Care; Diagnostic Sciences; Nutrition & Dietetics; Social Work & Social Policy; Human Nutrient Requirements; Obesity; Behavioural Medicine; Education; Physical & Sports Education; Sports & Exercise Studies

Contact Details
NICHD
6100 Executive Boulevard, Room 4B05
Rockville, MD 20852
Tel: +1 301 435 6888
Email: espositl@mail.nih.gov

MECHANISTIC INSIGHTS FROM BIRTH COHORTS (R01)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases, the National Heart, Lung and Blood Institute and the National Institute of Child Health and Human Development invite applications for their mechanistic insights from birth cohorts (R01) grants. This R01 funding opportunity announcement supports novel research on how prenatal exposures contribute to the aetiology of chronic diseases and health conditions later in life. The goal is to stimulate research by leveraging existing birth cohorts to address targeted mechanistic questions regarding the normal and abnormal developmental origins of organ systems or diseases of interest to the participating institutes.
Application budgets are limited to less than US$500,000 in direct costs per year over five years. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. PAR-13-109.

Closing date: 05 Feb 16
Deadline information: Applications due every 5 February, 5 June and 5 October until 8 May 2016.
Posted date: 07 Feb 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $2,500,000

Eligibility profile

Country of applicant institution: Any

**Disciplines**

Primary Care; Pathophysiology; Preventive Medicine; Diagnostic Sciences; Chronic Care; Public Health, Health Services & Primary Care; Maternal Health; Clinical Medicine; Birth & Congenital Defects; Growth & Growth Factors; Aetiology; Non-Communicable Diseases

**Contact Details**

Division of Diabetes, Endocrinology and Metabolic Diseases
NIDDK
6707 Democracy Boulevard, Room 794
Bethesda, MD 20892-5460
Tel: +1 301 451 7335
Fax: +1 301 480 0475
Email: silvacm@mail.nih.gov

**IMPROVEMENT OF ANIMAL MODELS FOR STEM-CELL-BASED REGENERATIVE MEDICINE (R01)**

**NIH: Office of the Director**

**Description:**
The NIH Office of Research Infrastructure Programs, the National Heart, Lung and Blood Institute, the National Institute of Dental and Craniofacial Research, the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of General Medical Sciences invite applications for their improvement of animal models for stem-cell-based regenerative medicine (R01) grants. This R01 funding opportunity announcement aims to characterise animal stem cells and improve existing and create new animal models for human disease conditions. This initiative focuses on the following areas:
- comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems;
- development of new technologies for stem cell characterisation and transplantation;
- improvement of animal disease models for stem-cell-based therapeutic applications.
This FOA will use the R01 research project grant mechanism, and runs in parallel with an FOA of identical scientific scope, PAR-13-115, which encourages applications under the R21 exploratory/developmental award mechanism.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PAR-13-114.

Closing date: 05 Feb 16
Deadline information: Applications due every 5 February, 5 June and 5 October until 8 May 2016.
Posted date: 12 Feb 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -


**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Pharmacotherapy; Animal Models; Stem Cell Therapy; Clinical Medicine; Diagnostic Sciences; Regenerative Medicine; Embryonic Stem Cells; Disease Control; Pharmacy & Pharmacology; Stem Cell Genomics; Preventive Medicine; Induced Pluripotent Stem Cells; General Practice; Primary Care; Physiology; Public Health, Health Services & Primary Care; Nursing; Stem Cell; Biological Sciences

**Contact Details**

Division of Comparative Medicine
ORIP
Division of Programme Coordination, Planning and Strategic Initiatives
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 435 0744
Fax: +1 301 480 3819
Email: oleg.mirochnitchenko@nih.gov

**A CUTE KIDNEY INJURY IN OLDER ADULTS (R01)**

*NIH: National Institute on Aging*

**Description:**
The National Institute on Aging invites R01 applications for its acute kidney injury in older adults grants.

Applications should propose basic, clinical, translational and outcomes research on kidney injury in older adults. Applications may focus on: the epidemiology, etiology and risk factors for AKI in older adults; pathophysiology of AKI in the ageing kidney and its impact on chronic kidney disease (CKD) and other organ disease; early detection, diagnosis and monitoring of AKI; prevention, treatment and management strategies of AKI in older patients with the goal of improving short- and long-term outcomes, including morbidity, mortality, progression of CKD, functional independence and quality of life.
This programme announcement will utilise the R01 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited but must reflect the actual needs of the proposed project. Funding is available for up to five years.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 May 2016.

Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
Country of applicant institution: Any

Disciplines
Geriatrics & Gerontology; Primary Care; Traumatology, Accidents & Injury; Diagnostic Sciences; Nephrology & Kidneys; Diabetes; Public Health, Health Services & Primary Care; Clinical Medicine; Prosthetic & Orthotic Devices

Contact Details
Tel: +1 301 496 6761
Email: susan.zieman@nih.gov

THE EFFECTS OF MODULATING CHRONIC LOW GRADE INFLAMMATION ON GERIATRIC CONDITIONS - SECONDARY DATA OR BIOSPECIMEN ANALYSES AND ANCILLARY STUDIES IN ONGOING OR COMPLETED CLINICAL TRIALS (R01)

NIH: National Institute on Aging

Description:
The National Institute on Aging invites R01 proposals on the effects of modulating chronic low grade inflammation on geriatric conditions - secondary data or biospecimen analyses and ancillary studies in ongoing or completed clinical trials.

This R01 opportunity supports ancillary studies and secondary analyses of data or biospecimens from ongoing or completed studies of the effects of inflammation or anti-inflammatory agents on geriatric conditions, such as functional decline, mobility disability, fatigue, falls, cognitive decline and dementia, and chronic pain.

Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

Application budgets are not limited but must reflect the actual needs of the proposed project. Funding is available for up to five years.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm proposer’s local time.

Award type: Directed grants to institutions, research groups etc
Award budget total: -
IOMARKERS FOR DIABETES, DIGESTIVE, KIDNEY AND UROLOGIC DISEASES USING BIOSAMPLES FROM THE NIDDK REPOSITORY (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

**Description:**
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its biomarkers for diabetes, digestive, kidney and urologic diseases using biosamples from the NIDDK repository (R01) call. This R01 funding opportunity announcement will support assays and data analysis of repository-held samples for studies focused on a disease relevant to the institute. Studies should generate discoveries on disease mechanisms, pathogenic processes, disease progression or clinical responses. Projects that make good use of the associated data from clinical trials and studies, the original intent of the study or the trial are encouraged.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Application budgets are limited to US$250,000 in direct costs per year over a maximum of three years. PAR-13-228

**Deadline information:** Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 September 2016.
**Posted date:** 16 May 13
**Award type:** Directed grants to institutions, research groups etc
**Award amount max:** $750,000
**Website:**

**Eligibility profile**
Country of applicant institution: Any

**Disciplines**
Biochemical Markers; Urology; Biological Markers & Sensor Mechanisms; Diabetes; Diagnostic Sciences; Prognosis & Natural History of Disease; Clinical Medicine; Gastroenterology; Pathogenesis; Nephrology & Kidneys
HENOTYPING EMBRYONIC LETHAL KNOCKOUT MICE (R01)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development, the National Human Genome Research and the National Institute of Diabetes and Digestive and Kidney Diseases invite applications for their phenotyping embryonic lethal knockout mice (R01) grants. This R01 funding opportunity announcement aims to phenotype embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium. KO mouse phenotyping efforts will generate 20,000 mouse strains over the next decade of which about 30 per cent will be embryonic or perinatal lethal. A large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Budgets are limited to US$499,999 per year for up to five years. PAR-13-231.

Closing date: 05 Feb 16
Deadline information: Applications due every 5 February, 5 June and 5 October until 8 September 2016.
Posted date: 23 May 13

Award type: Directed grants to institutions, research groups etc
Award amount max: $2,500,000
Website:

Eligibility profile
Country of applicant institution: Any

Disciplines
Genetic Diseases; Human Physiology; Biological Sciences; Veterinary Medicine; Allied Health Professions; Morphology; Genetics & Systems Biology; Animal Physiology; Diagnostic Sciences; Vertebrate Biology; Molecular Genetics; Ethology; Medical Genetics; Biochemical Markers; Quantitative Genetics; Animal Breeding

Contact Details
NICHD
6100 Executive Boulevard, Room 4B01D
Rockville, MD 20852
Tel: +1 301 496 5541
Email: javoisl@mail.nih.gov
RESEARCH GRANTS USING THE RESOURCES FROM THE OSTEOARTHRITIS INITIATIVE (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Center for Complementary and Alternative Medicine and the National Institute on Aging invite applications for their research grants using the resources from the osteoarthritis initiative (R01). This R01 funding opportunity announcement encourages research focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community.

Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

Applications budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. PA-13-236

Closing date: 05 Feb 16

Deadline information: Deadlines every 5 June, 5 October and 5 February until 8 January 2016.
Posted date: 03 Jun 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
Country of applicant institution: Any

Disciplines
Diagnostic Sciences; Clinical Medicine; Rheumatology & Arthritis; Bone Cancers; Osteoporosis & Other Bone Diseases

Contact Details
NIAMS
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 594 3511
Email: lester1@mail.nih.gov

RESEARCH TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R01)
NIH: National Institute on Aging

Description:
A total of six institutes of the NIH invite applications for grants for research to characterise and reduce stigma to improve health. This R01 funding opportunity announcement encourages research grant applications to characterise the role of stigma in health, life course development, and ageing, both in the US and globally, and to test interventions to prevent or reduce the impact of stigma at the individual, community, healthcare system, and policy levels. The goal is to promote research addressing the health-related aspects of
stigma, including the aetiology and perpetuation of it; its impact on physical and mental health, well-being, life course development, and ageing; its influence on health behaviours and on use, access to, and quality of received healthcare services; its contribution to health disparities affecting vulnerable demographic groups; and intervention strategies to reduce health-related stigma or the negative health and life course developmental impacts of stigma.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

This funding opportunity uses the NIH exploratory/developmental (R01) research project grant mechanism and runs in parallel with two of identical scientific scope, PA-13-246, which solicits applications under the NIH exploratory/developmental grant mechanism, and PA-13-247, which utilises the R03 small grant programme mechanism.

Application budgets are not limited, but need to reflect the actual needs of the proposed project. The scope of the project should determine the project period; the maximum period is five years. PA-13-248.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 September, 2016.
Posted date: 17 Jun 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
-------------------------------
Country of applicant institution: Any

Disciplines
--------------------------
Geriatrics & Gerontology; Social Work & Social Policy; Psychology of Ageing; Education; Psychology; Health Disparities; Allied Health Professions; Mental Health; Medical Sociology; Public Health, Health Services & Primary Care; Health Systems, Administration; Behavioural Medicine; Sociology; Primary Care; Economic & Social Environment; Health Education; Social Services Delivery

Contact Details
-------------------------------
NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: +1 301 402 4156
Email: nielsenli@nih.gov

SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its secondary analyses of alcohol and chronic disease (R01) grants. This R01 funding opportunity announcement aims to support secondary analyses of alcohol related to chronic disease aetiology and epidemiology. The goal of this programme is to facilitate
innovative yet cost-effective research using previously collected data.

This funding opportunity announcement will use the NIH research project grant (R01) mechanism and runs in parallel with two FOA of identical scientific scope, PA-13-261, which solicits applications under the R03 small grant programme mechanism and PA-13-251, which solicits applications under the R21 exploratory/developmental research grant mechanism.

Direct costs are not limited, but must reflect the needs of the project. The maximum project period is five years. Domestic and foreign for-profit and nonprofit organisations and public or private institutions may apply. PA-13-251

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 September 2016.
Posted date: 09 Jul 13
Award type: Directed grants to institutions, research groups etc

Website:

Application form:

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Chronic Care; Clinical Medicine; Public Health, Health Services & Primary Care; Epidemiology; Primary Care; Alcoholism; Aetiology

Contact Details
----------------------------------------------
NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 594 6231
Email: rbreslow@mail.nih.gov

IMPLICATIONS OF NEW DIGITAL MEDIA USE FOR UNDERAGE DRINKING, DRINKING-RELATED BEHAVIOURS AND PREVENTION RESEARCH (R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its implications of new digital media use for underage drinking, drinking-related behaviours and prevention research (R01) grants. This R01 funding opportunity announcement aims to investigate whether, and how, having involvement in new digital media use, particularly social media and social networking sites, may influence adolescent alcohol use and drinking patterns, as well as drinking-related problems. The FOA also encourages studies exploring the ways new digital media may be use as platforms for preventative interventions aimed at underage drinking and related problems.

This funding opportunity announcement will use the NIH research project grant (R01) mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-263, which solicits applications under the R21 exploratory/developmental research grant mechanism.
Direct costs are not limited, but must reflect the needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions may apply. PA-13-262.

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 September 2016.
Posted date: 09 Jul 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Sociology; Public Health, Health Services & Primary Care; Primary Care; Communication Studies; Social Behaviour & Attitudes; Business & Management Studies; Networking Protocols; Alcoholism; Communication & Media Studies; Media Studies; Social Networks

Contact Details
----------------------------------------------
NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 443 8820
Email: rfreeman@mail.nih.gov

S YNERGISING OMIC AND SYMPTOM SCIENCE (R01)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for its synergising omic and symptom science (R01) grants. This R01 funding opportunity announcement aims to promote integration of diverse information from molecular and biological processes with patient-reported outcomes.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PA-13-264.

Closing date: 05 Feb 16

Deadline information: Applications due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 September 2016.
Posted date: 10 Jul 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Description:
The National Eye Institute invites applications for its audacious goals initiative in vision research high-priority research area: molecular therapies for eye disease (R01) grants. The purpose of this R01 funding opportunity announcement is to encourage submission of new, innovative projects that explore the use of molecular approaches to develop new treatments for eye disease. Treatments should aim to:

- control, modify and deliver genetic information;
- develop small molecules and optogenetic approaches to treat eye disease and restore sight.

Applications may address any portion of the visual system.

Budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Small, multidisciplinary teams are encouraged to apply. PA-13-283.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 5 October, 5 February and 5 June until 8 September 2016.

Posted date: 25 Jul 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
Country of applicant institution: Any

Disciplines
Cancer Genetics; Diagnostic Sciences; Molecular Genetics; Vision Science; Medical Genetics; Optometry; Eye Diseases; Sensory Systems

Contact Details
NEI
5635 Fishers Lane
Rockville MD 20852
Tel: +1 301 451 2020
Email: arajh@mail.nih.gov
SYSTEMIC AMYLOIDOSIS: BASIC, TRANSLATIONAL AND CLINICAL RESEARCH
(R01)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Disease, the National Cancer Institute and the National Institute on Aging invite applications for their systemic amyloidosis: basic, translational and clinical research (R01) grants. This R01 funding opportunity announcement will support basic and clinical research projects that advance understanding of pathogenic mechanisms underlying systemic amyloidosis, develop improved techniques for the clinical detection and diagnosis of systemic amyloid diseases, develop novel cellular and in vivo models to identify candidate therapeutic agents with, and evaluate the clinical efficacy of novel therapies designed to prevent, arrest and reverse the morbid and lethal progression of these diseases.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. PA-13-286.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 September 2016.
Posted date: 29 Jul 13
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -


Eligibility profile
Country of applicant institution: Any
Disciplines
Structural Biology; Non-Communicable Diseases; Pathogenesis; Chemistry; Pharmacy & Pharmacology; Public Health, Health Services & Primary Care; Characteristics, Biological Macromolecules; Medical & Diagnostic Tests; Diagnostic Sciences; Pharmacotherapy; Clinical Medicine; Primary Care; Biological Sciences; Cell Physiology & Metabolism; Protein Synthesis, Modification & Turnover; Protein Trafficking; Nursing

Contact Details
NIDDK
6707 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 594 6007
Email: rasoolyr@mail.nih.gov
UT MICROBIOTA-DERIVED FACTORS IN THE INTEGRATED PHYSIOLOGY AND PATHOPHYSIOLOGY OF DISEASES WITHIN NIDDK’S MISSION (R01)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Kidney Diseases invites applications for its gut microbiota-derived factors in the integrated physiology and pathophysiology of diseases within NIDDK’s mission (R01) grants. This R01 funding opportunity announcement supports research to define interactions between the host and the gut microbiota that regulate normal physiology and pathopathology of diseases within NIDDK’s mission. The goal is to discover specific human gut microbiota-derived factors that affect or are affected by host physiology, homeostasis and disease pathophysiology. Projects will also define the specific factors and pathway microbiota-derived factors use to affect host processes within the gut or distant organ sites.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. PAR-13-293.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 January 2017.

Posted date: 05 Aug 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-293

Eligibility profile
---------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------
Diagnostic Sciences; Waste Recycling, Reduction & Recovery; Biological Sciences; Gastroenterology; Microbial Ecology

Contact Details
---------------------------------------------
Division of Digestive Diseases and Nutrition NIDDK
6707 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 451 3759
Email: greymj@mail.nih.gov

EVELOPMENTAL PHARMACOLOGY AND TOXICOLOGY: ROLE OF ONTOGENY (R01)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development, the National Institute of Environmental Health Sciences and the National Institute of General Medical Sciences
invite applications for funding concerning the role of ontogeny in developmental pharmacology and toxicology. This R01 funding opportunity announcement encourages grant applications from institutions or organisations that propose multidisciplinary, investigator-initiated basic and translational research in developmental pharmacology and toxicology. Particular emphasis should be placed on the role of ontogeny on drug metabolizing enzymes, transporters, receptors and signaling pathways across developmental periods from fetal life to adolescence affecting drug action and toxicity.

This funding opportunity uses the NIH R01 research project grant mechanism and runs in parallel with two of identical scientific scope, PAR-13-307, which solicits applications under the R03 small grant mechanism and PAR-13-208, which solicits applications under the R21 exploratory/developmental grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

Application budgets are not limited, but need to reflect the actual needs of the proposed project. Total project periods may not exceed five years.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Posted date: 08 Aug 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
-----------------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------------
Clinical Pharmacy & Pharmacology; Pharmacokinetics; Foetal Health & Prenatal Development; Pharmacy & Pharmacology; Toxicology; Chemistry

Contact Details
-----------------------------------------------------
NICHD
MSC 2425
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 496 5589
Email: gg65m@mail.nih.gov

UDACIOUS GOALS INITIATIVE HIGH PRIORITY RESEARCH AREA:
INTERSECTION OF AGEING AND BIOLOGICAL MECHANISMS OF EYE DISEASE (R01)
NIH: National Eye Institute

Description:
The National Eye Institute and the National Institute on Aging invites applications for its audacious goals initiative high priority research area: intersection of ageing and biological mechanisms of eye disease (R01) grants. This R01 funding opportunity announcement aims to improve understanding of the intersection between ageing and the biological mechanism of eye disease. The following research areas are of interest:
understanding how the biology of ageing contributes to disease;
valuating how the failure of homeostatic processes causes or allows the transition from aging to early disease;
defining the biological staging of disease to understand pathophysiology, identify biomarkers and explore therapy;
distinguishing normal ocular changes associated with aging from pathophysiologic changes;
investigate the diverse cellular, molecular, genetic, and neural circuitry mechanisms underlying age-related changes in the eye;
ascertain the impact of age-related changes in the eye on the progression of visual function as well as associated brain or behavioral functions for the aged and the utility of such changes as early biomarkers for pathological processes for the aged;
identify and evaluate interventions that will modify age-related changes to alter the course of pathological development.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PA-13-332.

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 January 2017.
Posted date: 15 Aug 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-332

Eligibility profile
Country of applicant institution: Any

Disciplines
Diagnostic Sciences; Biochemical Markers; Pathophysiology; Biological Markers & Sensor Mechanisms; Eye Diseases; Clinical Medicine; Geriatrics & Gerontology

Contact Details
NEI
5635 Fishers Lane
Rockville MD, 20852
Tel: +1 301 451 2020
Email: mckiegeo@nei.nih.gov

MECHANISMS OF ALCOHOL AND STIMULANT CO-ADDSCTION (R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their mechanisms of alcohol and stimulant co-addction (R01) grants. This R01 funding
opportunity announcement promotes research on neurobiological and behavioural mechanisms that might explain how alcohol and stimulants interact at genetic, epigenetic, cellular, neurocircuitry and behavioural levels to promote co-addiction.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PAR-13-340, which solicits applications under the R21 exploratory/developmental grant mechanism. Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-339.

Closing date: 05 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 January 2017.
Posted date: 29 Aug 13
Award type: Directed grants to institutions, research groups etc

Award budget total: -

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Alcoholism; Biological Sciences; Drug & Substance Abuse; Behavioural Medicine; Psychology; Primary Care; Public Health, Health Services & Primary Care; Diagnostic Sciences; Neurobiology; Addiction

Contact Details
----------------------------------------------
NIAAA
6000 Executive Boulevard
Bethesda, MD 20892-7003
Tel: +1 301 443 7600
Email: igrakalic@mail.nih.gov

EARLY-STAGE PHARMACOLOGICAL VALIDATION OF NOVEL TARGETS AND ACCOMPANYING PRE-THERAPEUTIC LEADS FOR DISEASES OF INTEREST TO THE NIDDK (R01)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its early-stage pharmacological validation of novel targets and accompanying pre-therapeutic leads for diseases of interest to the NIDDK (R01) grants. This R21 funding opportunity announcement promotes translation of basic science research into knowledge and tools that can be used to provide strong justification for later-phase drug discovery and development efforts in areas relevant to the NIDDK. There should be novelty in the target, chemical scaffold or non-viral biologic itself, or in the approaches used to pursue further target validation.

Application budgets are limited to US$500,000 in direct costs per year over a maximum five-year period.
Eligible institutions include domestic and foreign for-profit and not-for-profit organisations and public or private institutions. PAR-13-007.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 March 2016.
Posted date: 29 Aug 13
Award type: Directed grants for individual investigators
Award amount max: $2,500,000

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-007

Eligibility profile
Country of applicant institution: Any

Disciplines
Diagnostic Sciences; Public Health, Health Services & Primary Care; Primary Care; Pharmacy & Pharmacology; Clinical Medicine; Nursing; Clinical Pharmacy & Pharmacology; Diabetes; Pharmacotherapy; Nephrology & Kidneys; Gastroenterology

Contact Details
Division of Diabetes, Endocrinology and Metabolic Diseases
NIDDK
6707 Democracy Boulevard, Room 788B
Bethesda, MD 20892
Tel: +1 301 451 7299
Email: pawlykac@mail.nih.gov

ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R01)
NIH: National Institute on Aging

Description:
The National Institute on Aging and the National Center for Complementary and Alternative Medicine invite applications for their grants for advancing the science of geriatric palliative care. This R01 funding opportunity announcement encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasises studies in a variety of settings including ambulatory care, hospitals, assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programmes. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients' disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.

This FOA uses the R01 research project grant mechanism and runs in parallel with two of identical scientific scope: PA-13-356, which solicits applications under the R03 small grant programme mechanism, and PA-13-355, which solicits applications under the R21 exploratory/developmental grant mechanism.
Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years. PA-13-354.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Deadlines on: 5 February 2016, 5 June 2016, 5 October 2016, and repeated annually.
Posted date: 20 Sep 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Application form:

Eligibility profile
--------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------
Geriatric Nursing; Pain Management; Chronic Pain; Primary Care; Health Systems; Clinical Pharmacy & Pharmacology; Hospice & Palliative Care; Clinical Medicine; Public Health, Health Services & Primary Care; Geriatrics & Gerontology; Nursing; Pharmacy & Pharmacology; Pharmaceutical Drugs; Hospitalisation; Palliative Nursing

Contact Details
--------------------------------------------
NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: +1 301 496 6761
Email: basil.eldadah@nih.gov

MODELLING SOCIAL BEHAVIOUR (R01)
NIH: National Institute of General Medical Sciences

Description:
A total of 10 institutes and offices of the National Institutes of Health invites applications for their modelling social behaviour (R01) call. This R01 funding opportunity announcement aims to develop and test innovative theories and computational, mathematical or engineering approaches to deepen understanding of complex social behaviour. This research will examine phenomena at multiple scales to address the emergence of collective behaviours that arise from individual elements or parts of a system working together.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. Transdisciplinary teams are encouraged, including at minimum researchers with expertise in the behavioural or social sciences as well as those in computational and systems modelling.
Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years for new and early-stage investigators, and four years for established investigators.

Ref: PAR-13-374.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm, local time of applicant organisation, every 5 February, 5 June and 5 October until 8 January 2017.
Posted date: 18 Oct 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-374

Eligibility profile
Country of applicant institution: Any

Disciplines
Computer Simulation & Modelling; Sociology; Computer Science & Informatics; Social Behaviour & Attitudes

Contact Details
NIGMS
45 Center Drive
Bethesda, MD 20814
Tel: +1 301 594 2987
Email: marcusst@mail.nih.gov

NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (COLLABORATIVE R01)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its new computational methods for understanding the functional role of DNA variants that are associated with mental disorders (collaborative R01) grants. The aim of this collaborative R01 funding opportunity announcement is to support the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex aetiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness. This should take into account the added complexities and nuances of brain diseases, and ultimately inform the identification and validation of potential targets for novel treatment development.

This FOA is suitable when two or more sites are needed to complete the study. Each site must have its own programme director or principal investigator. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

MIMH will invest US$3 million in fiscal year 2015 to fund this and a companion FOA.
Application budgets are not limited, but must
reflect the needs of the project. The maximum project period is three years.

Ref: PAR-13-391.

Closing date: 05 Feb 16
Deadline information: Deadlines 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 January 2017.
Posted date: 14 Nov 13
Award type: Directed grants to institutions, research groups etc,
Networking/collaboration
Award budget total: -

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Biostatistics; Medical Informatics & Telemedicine; Bioinformatics; Health Informatics; Mental Illness; Aetiology; Mental Health; Systematics; Diagnostic Sciences; Deoxyribonucleic Acid, DNA; Structural Biology; Human Genome; Psychology; Computer Science & Informatics

**Contact Details**

NIH
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6653
Email: anjene.addington@nih.gov

**NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (R01)**

**NIH: National Institute of Mental Health**

**Description:**
The National Institute of Mental Health invites applications for its new computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01) grants. The aim of this collaborative R01 funding opportunity announcement is to support the development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex aetiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness. This should take into account the added complexities and nuances of brain diseases, and ultimately inform the identification and validation of potential targets for novel treatment development.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

MIMH will invest US$3 million in fiscal year 2015 to fund this and a companion FOA. Application budgets are not limited, but must
reflect the needs of the project. The maximum project period is three years.

Ref: PAR-13-392.

Closing date: 05 Feb 16
Deadline information: Deadlines 5pm local time of applicant organisation every 5 February, 5 June and 5 September until 8 January 2017.
Posted date: 14 Nov 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -

PUBLIC HEALTH IMPACT OF THE CHANGING POLICY/LEGAL ENVIRONMENT FOR MARIJUANA (R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its public health impact of the changing policy/legal environment for marijuana (R01) grants. This R01 funding opportunity announcement encourages research on the impact of changing marijuana policies and laws on public health outcomes. This includes:

- marijuana exposure among children, adolescents and adults;
- other licit and illicit drug use;
- education and professional achievement;
- social development;
- risky behaviours;
- mental health;
- HIV.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

NIH will invites US$3 million in fiscal year 2014 to fund six to ten awards. Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is three years.

Ref: PAS-14-020.
EUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R01)

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its grants on neuroimmune signalling and function in substance abuse disorders (R01). This R01 funding opportunity announcement aims to examine the molecular, cellular, circuit and behavioural responses to neuroimmune signalling within the central nervous system. Research should pertain to the initiation, escalation and maintenance of the neurological consequences resulting from substance use disorders and to abstinence, withdrawal and relapse. The goal is to determine the extent to which neuroimmune responses contribute to or protect against the risk and consequences of SUDs.

This FOA will use the R01 research project grant mechanism, and runs in parallel with an FOA of identical scientific scope, PA-14-083, which encourages applications under the R21 exploratory/developmental research grant mechanism.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Ref: PAR-14-084.

Closing date: 05 Feb 16
SYNTHEtic PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETEROUS EFFECTS (R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its call on synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R01). This R01 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies.

This FOA uses the R01 research project grant mechanism and runs in parallel with two FOAs of identical scientific scope, PAR-14-105 and PAR-14-106 which use the R21 exploratory/developmental and R03 small grant mechanisms respectively.

Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations. Ref: PAR-14-106.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 May 2017.
Posted date: 21 Feb 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-106.html

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine; General Practice; Behavioural Medicine; Chemistry; Psychology; Diagnostic Sciences; Pharmacokinetics; Methods of Drug Delivery; Public Health, Health Services & Primary Care; Drug Design; Primary Care; Drug & Substance Abuse

Contact Details

Tel: +1 301 435 1304
Email: rrapaka@nida.nih.gov

FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R01)

NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for its call on family-centred self-management of chronic conditions (R01). This R01 funding opportunity announcement seeks to build on the science of family-centred self-management in chronic conditions.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-113, which uses the R21 exploratory/developmental research grant mechanism.

Foreign or US for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-14-112.

Closing date: 05 Feb 16

Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 May 2017.

Posted date: 25 Feb 14

Award type: Directed grants to institutions, research groups etc

Award budget total: -


Eligibility profile

Country of applicant institution: Any

Disciplines

Community Health Services; Public Health, Health Services & Primary Care; Chronic Care; Social Work & Social Policy; Social Programmes; Primary Care

Contact Details

Tel: +1 301 594 5970
Email: hussk@mail.nih.gov
Alcohol-Induced Effects on Tissue Injury and Repair (R01)

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its alcohol-induced effects on tissue injury and repair (R01) grants. This R01 funding opportunity announcement supports the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. The NIAAA is especially interested in integrative research that elucidates alcohol’s effects on complex mechanisms of injury and repair that are either common or specific to each organ system. The call also encourages the study of alcohol’s effect on stem cells, embryonic development and regeneration, as well as the studies on molecular and cellular actions of moderate alcohol consumption.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-124, which solicits applications under the R21 exploratory/developmental grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Ref: PA-14-123.

Closing date: 05 Feb 16

Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 May 2017.
Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-123.html

Application form: http://www.grants.gov/web/grants/applicant s/download-application-package.html#download=true&oppNum=PA-14-123

Eligibility profile

Country of applicant institution: Any

Disciplines

Traumatology, Accidents & Injury; Pathophysiology; Pathology; Cytopathology; Cellular Interactions; Stem Cell Genomics; Diagnostic Sciences; Foetal Health & Prenatal Development; Induced Pluripotent Stem Cells; Regenerative Medicine; Alcoholism; Biological Sciences; Embryonic Stem Cells; Stem Cell Therapy; Stem Cell

Contact Details

Tel: +1 301 443 7351
Email: duntyw@mail.nih.gov
Prevention and Treatment of Substance Using Populations With or At Risk for Hepatitis C Virus (R01)

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its grants on the prevention and treatment of substance using populations with or at risk for hepatitis C virus (R01). This R01 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing infections more effectively. This FOA supports the initial development of a clinical trial or research project focused on HCV for at-risk substance using populations, including those with or at risk for HIV.

This FOA uses the R01 research project grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-135 and PA-14-136, which use the R34 planning grant mechanism and the R21 exploratory/developmental grant mechanisms respectively.

Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations. Ref: PA-14-137.

Closing date: 05 Feb 16

Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 May 2017.

Posted date: 04 Mar 14

Award type: Directed grants to institutions, research groups etc

Award budget total: -


Eligibility profile

Country of applicant institution: Any

Disciplines

Hepatology; Infection Agents & Pathogens; Public Health, Health Services & Primary Care; Drug & Substance Abuse; Diagnostic Sciences; Primary Care; Infectious Diseases; Drug Design; General Practice; Preventive Medicine

Contact Details

NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 443 3207
Email: aklinwm@nida.nih.gov
EUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its grants on neuroimmune mechanisms of alcohol-related disorders (R01). This R01 funding opportunity announcement seeks studies to address the role of neuroimmune modulation in response to and in the neuroadaptation of the brain to acute and chronic alcohol exposure, and alcohol dependence and withdrawal. The goal is to achieve fundamental insights of neuroimmune mechanisms underlying brain functional and behavioural changes induced by alcohol.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-138 which uses the R21 exploratory/developmental grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Ref: PA-14-139 (re-issue of PA-11-064).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 May 2017.

Posted date: 04 Mar 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-139.html

Application form: http://www.grants.gov/web/grants/applicant/package.html#download=true&oppNum=PA-14-139

Eligibility profile
Country of applicant institution: Any

Disciplines
Clinical Medicine; Behavioural Medicine; Neuroendocrinology; Immunology; Ethology; Neurology; Biological Sciences; Diagnostic Sciences; Endocrine & Neuroendocrine Cancers; Neuropsychology; Alcoholism; Psychology; Neurobiology; Neuroscience

Contact Details
NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 443 1678
Email: changhai.cui@nih.gov
COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R01)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for its community partnerships to advance research (R01). This R01 funding opportunity announcement encourages researchers to partner with communities using community engaged research methodologies that will enhance relationships leading to better interventions and positive health outcomes.

This funding opportunity announcement will use the NIH R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-141, which solicits applications under the R21 exploratory/developmental research grant award mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-142.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 May 2017.
Posted date: 05 Mar 14

Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-142.html
Application form: http://www.grants.gov/web/grants/applicantss/download-application-package.html#download=true&oppNum=PA-14-142

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Public Health, Health Services & Primary Care; Pharmaceutical Drugs; Primary Care; Nursing; Biomedical Engineering; Medical Effectiveness & Patient Outcomes; Clinical Medicine; Translational Medicine; Medical Research of Selected Fields

Contact Details
----------------------------------------------
NINR
National Institutes of Health
31 Center Drive, Room 5B10
Bethesda MD 20892-2178
Tel: +1 301 594 5971
Email mccloskd@mail.nih.gov
Establishing Behavioural and Social Measures for Causal Pathway Research in Dental, Oral and Craniofacial Health (R01)

NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its grants on establishing behavioural and social measures for causal pathway research in dental, oral and craniofacial health (R01). This R01 funding opportunity announcement aims to establish measures of specific behavioural or social phenomena to test causal hypotheses about behavioural and social contributors to dental, oral or craniofacial diseases. This announcement encourages the development and testing of two types of measures:

- measures of the health behaviours, social interactions, community characteristics, built environments, targeted by behavioural or social interventions to improve oral health;
- measures of the hypothesised moderators and mediators of a behavioural or social intervention's effect.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-144, which uses the R21 exploratory/developmental grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-143.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 May 2017.

Posted date: 06 Mar 14
Award type: Directed grants to institutions, research groups etc

Award budget total: -


Eligibility profile

Country of applicant institution: Any

Disciplines

Preventive Dentistry; Special Needs Dentistry; Oral Medicine; Restorative Dentistry; Behavioural Medicine; Medical Education; Psychology; Craniofacial Disorders; Oral & Maxillofacial Surgery; Primary Care; Dentistry; Dental Health & Hygiene; Paediatric Dentistry; Public Health, Health Services & Primary Care

Contact Details

NIDCR
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 451 3888
Email: riddleme@mail.nih.gov
EARLY STAGE DEVELOPMENT OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01)
NIH: National Institute of General Medical Sciences

Description:
A total of 12 institutes and offices of the National Institutes of Health invite applications for their grants on early stage development of technologies in biomedical computing, informatics and big data science (R01). This R01 funding opportunity announcement aims to promote a broad base of research and development of technologies in biomedical computing, informatics and big data science that will support rapid progress in areas of scientific opportunity in biomedical research. Applications should develop enabling technologies that could apply to the interests of most NIH institutes and centres and range from basic biomedicine and including research to all relevant organ systems and diseases.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

Application budgets may not exceed US$300,000 direct costs per year, over a maximum project period of three years.

Ref: PA-14-155.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 May 2017.
Posted date: 17 Mar 14

Award type: Prototypes and demonstrations, Directed grants to institutions, research groups etc
Award amount max: $900,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-155.html

Application form: http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-155

Eligibility profile
Country of applicant institution: Any

Disciplines
Biological Sciences; Disease Control; Informatics & Big Data; Bioinformatics; Computer Science & Informatics; Innovation & Technology Management; Biomolecular Modelling; Health Informatics; Research Management; Diagnostic Sciences; Engineering Standards & Specifications; Therapy Evaluation; Biotechnology

Contact Details
NIGMS
45 Center Drive
Bethesda, MD 20814
Tel: +1 301 451 6446
Email: lysterp@mail.nih.gov
EXTENDED DEVELOPMENT, HARDENING AND DISSEMINATION OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01)

NIH: National Institute of General Medical Sciences

Description:
A total of 12 institutes and offices of the National Institutes of Health invite applications for their grants on extended development, hardening and dissemination of technologies in biomedical computing, informatics and big data science (R01). This R01 funding opportunity announcement supports the extended development, maintenance, testing, evaluation, hardening and dissemination of existing biomedical software. The scheme aims to promote a broad base of research and development of technologies in biomedical computing, informatics and big data science that will support rapid progress in areas of scientific opportunity in biomedical research. Applications should develop enabling technologies that could apply to the interests of most NIH institutes and centres and range from basic biomedicine and including research to all relevant organ systems and diseases.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.
Ref: PA-14-156.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 May 2017.
Posted date: 17 Mar 14

Award type: Technology innovation/development, Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-156.html

Application form: http://www.grants.gov/web/grants/applicant/download-application-package.html#download=true&oppNum=PA-14-156

Eligibility profile
Country of applicant institution: Any

Disciplines
Disease Control; Diagnostic Sciences; Bioinformatics; Biomolecular Modelling; Computer Science & Informatics; Biotechnology; Health Informatics; Engineering Standards & Specifications; Biological Sciences; Informatics & Big Data; Therapy Evaluation; Innovation & Technology Management; Research Management

Contact Details
NIGMS
45 Center Drive
Bethesda, MD 20814
Tel: +1 301 451 6446
Email: lysterp@mail.nih.gov
TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR
HEALTH AND INDEPENDENCE IN THE COMMUNITY (R01)

NIH: National Institute on Aging

Description:
The National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering invite applications for their call on translational research to help older adults maintain their health and independence in the community (R01). This R01 funding opportunity announcement supports translational research collaborations between academic research centres and community-based organisations with expertise in serving or engaging older adults to develop tools, techniques, programmes or policies to respond to the needs of the ageing population.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-159, which solicits applications under the R21 exploratory/developmental research grant award mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-161 (replaces PAR-11-123).

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 May 2017.

Posted date: 21 Mar 14
Award type: Directed grants to institutions, research groups etc,
Networking/collaboration
Award budget total: -

Website:

Application form:
http://www.grants.gov/web/grants/applicant
s/download-application-package.html#download=true?oppNum=PA
-14-161

Eligibility profile
---------------------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------------------------
Primary Care; Public Health, Health Services & Primary Care; Accessibility for Disabled People; Access to Health Care; Geriatrics & Gerontology; Social Work & Social Policy; Psychology; Psychology of Ageing; Health Systems Policy; Home Health Care Services; Social Programmes

Contact Details
---------------------------------------------------------------------------------
NIA
7201 Wisconsin Avenue
Bethesda, MD 20814
Tel: +1 301 402 4156
Email: kingjo@nia.nih.gov

NIA
7201 Wisconsin Avenue
Bethesda, MD 20814
Tel: +1 301 402 4156
Email: kingjo@nia.nih.gov
EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN
(R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its call on the effects of cannabis use and cannabinoids on the developing brain (R01). This R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans.

This FOA uses the R01 research project grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-162 and PA-14-164, which use the R21 exploratory/developmental grant mechanism and the R03 small research grant mechanism respectively.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.
Ref: PA-14-163.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 May 2017.

Posted date: 27 Mar 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-163.html


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Neurology; Drug & Substance Abuse; Psychology; Central Nervous System; Pharmacokinetics; Neuroscience; Primary Care; Public Health, Health Services & Primary Care; Diagnostic Sciences; Cognitive Processes

Contact Details
----------------------------------------------
NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 435 4649
Email: wudy@mail.nih.gov
Clinical Studies of Mental Illness Not Involving Treatment Development, Efficacy or Effectiveness Trials (Collaborative R01)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its call for clinical studies of mental illness not involving treatment development, efficacy or effectiveness trials (collaborative R01). This collaborative R01 funding opportunity announcement seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses such as psychopathology and neurodevelopmental trajectories of psychopathology. Applicants should respond to this FOA when two or more sites are needed to complete the study.

For a linked set of collaborative R01s, each site should have its own principal investigator and the programme should provide a mechanism for cross-site coordination, quality control, database management, statistical analysis, and reporting. US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-165.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 May 2017.

Posted date: 28 Mar 14
Award type: Clinical trials, Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-165.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Biological Markers & Sensor Mechanisms; Neurology; Mental Health; Diagnostic Sciences; Cognitive Processes; Psychology; Psychopathology; Medical Genetics; Biochemical Markers; Cancer Genetics; Mental Illness

Contact Details
----------------------------------------------
NIMH
6001 Executive Boulevard, MSC 9617
Bethesda, MD 20892
Tel: +1 301 443 8316
Email: avenevos@mail.nih.gov
NIH STROKENET CLINICAL TRIALS AND BIOMARKER STUDIES FOR STROKE TREATMENT, RECOVERY AND PREVENTION (U01)
NIH: National Institutes of Health

Description:
The National Institutes of Health invite applications for NIH StrokeNet clinical trials and biomarker studies for stroke treatment, recovery and prevention (U01). This U01 funding announcement encourages multi-site exploratory and confirmatory clinical trials focused on promising interventions, as well as biomarker-or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment and recovery. It is the intention that StrokeNet will maintain a balanced portfolio of studies in primary and secondary prevention stroke trials, emergent management or acute stroke treatment trials and neuro-recovery and rehabilitation stroke trials.

Any higher education institutions, non-profit organisations, businesses and governments are welcome to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. Projects are expected to last no longer than five years.
Ref: NIH: RFA-MH-14-220.

Closing date: 05 Feb 16
Deadline information: Submissions accepted from 15 June 2014; applications due by 5pm local time of applicant organisation.

Posted date: 15 May 14
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-220.html

Application form: http://www.grants.gov/web/grants/applicant\$download-application-package.html#download=true&oppNum=PAR-14-220

Eligibility profile
Country of applicant institution: Any

Disciplines
Primary Care; Drug Design; Diagnostic Sciences; Stroke & Cerebrovascular Disorders; Public Health, Health Services & Primary Care; Biological Markers & Sensor Mechanisms; Biochemical Markers; Clinical Medicine

Contact Details
Tel: +1 301 496 9135
Email: moyc@ninds.nih.gov

CLINICAL EVALUATION OF ADJUNCTS TO OPIOID THERAPIES FOR THE TREATMENT OF CHRONIC PAIN (R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse and the National Center for Complementary and Alternative Medicine invite applications for their clinical evaluation of adjuncts to opioid therapies for the treatment of chronic pain (R01) grants. The purpose of this R01 funding

opportunity is to support meritorious clinical studies that seek to characterise opioid and pharmaceutical adjunct combinations that safely improve analgesia in chronic pain patients. As a secondary objective, this opportunity aims to disseminate the results of these studies as widely as possible to the healthcare providers who regularly prescribe opioids to the patient population. This will ensure that standard clinical practices are influenced by the findings of the proposed studies. In the population proposed to be studied, the subjects should be etiologically homogenous and symptomatically well-defined. Examples of such chronic pain populations in which opioids are often prescribed include patients with radicular cervical pain, metastatic bone pain or peripheral neuropathies. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period is three years.

Ref: PAR-14-225.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation, every 5 February, 5 June and 5 October until 8 September 2017.
Posted date: 16 May 14

Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: 
Application form: 
http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Drug & Substance Abuse; Epidemiology; Diagnostic Sciences; Neuroscience; Chronic Pain; Biological Sciences; Cognitive & Behavioural Therapies; Public Health, Health Services & Primary Care; Molecular Genetics; General Practice; Physiology; Primary Care; Mental Health; Pain Management; Neurobiology; Preventive Medicine; Opiates; Pharmacy & Pharmacology

Contact Details
----------------------------------------------
NIH: National Institute on Drug Abuse
6001 Executive Boulevard
Room 5213
Bethesda, MD 20892-9561
Tel: +1 301 443 8039
Fax: +1 301 443 7397
Email: aidan.hampson@nih.gov

ADVANCING RESEARCH IN VOICE DISORDERS (R01)
NIH: National Institute on Deafness and other Communication Disorders

Description:
The National Institute on Deafness and Other Communication Disorders invites applications for its advancing research in voice disorders (R01) grants. The purpose of this R01 funding opportunity is focus on advancing the scientific knowledge of the human larynx and human voice production in

A
health and disease and optimal ways to prevent, evaluate, diagnose and clinically manage voice disorders. Furthermore it encourages a range of research inclusive of basic, clinical, and translational. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-14-236.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 September 2017.
Posted date: 22 May 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-236.html

Application form:
http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile

Country of applicant institution: Any

Disciplines

Prosthetic & Orthotic Devices; Allied Health Professions; Clinical Medicine; Public Health, Health Services & Primary Care; Primary Care; Speech Pathology & Disorders; Physiology; Speech & Language Therapy

Contact Details

NIDCD
Division of Extramural Research
Executive Plaza South, Room 400C
6120 Executive Boulevard, MSC 7180
Rockville, MD 20892-7180
Tel: +1 301 496 5061
Email: shekiml@nidcd.nih.gov

COLLABORATIVE RESEARCH PROJECTS TO ENHANCE APPLICABILITY OF MOUSE MODELS FOR TRANSLATIONAL RESEARCH (COLLABORATIVE R01)

NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its collaborative research projects to enhance applicability of mouse models for translational research (collaborative R01). This funding opportunity aims to support collaborative R01 projects from multidisciplinary teams to expand, improve, or transform the utility of mouse cancer and tumour models for translational research. The major goals of these projects include the following:

- to address the technical and experimental parameters that ensure effective translational use of mouse models;
- to identify and propose the means to address unmet translational requirements;
- to extend the range of crossdisciplinary insights and approaches that address translational oncology modelling needs, such as those cited above, and many others;
- to be active participants in the oncology models forum PAR-14-239.
Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are limited to US$450,000 direct costs per year. The maximum project period is three years.
Ref: PAR-14-240.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 5 June, 5 October and 5 February until 8 May 2017.
Posted date: 02 Jun 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $450,000
Website:
Application form:
http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Nursing; Animal Parasites & Pathogens; Cancer Cell Biology; Veterinary Immunology; Preventive Medicine; Lung Cancer; Leukaemia & Other Blood Cancers; Prostate & Testicular Cancers; General Practice; Cancer Studies & Oncology; Biological Sciences; Non-cancerous Tumours; Breast Cancer; Cancer Immunology; Animal Models; Ovarian & Cervical Cancers; Veterinary Medicine; Melanoma & Other Skin Cancers; Brain Cancer; Molecularly Targeted Therapy; Clinical Medicine; Colorectal, Pancreatic & Stomach Cancers; Human Biological Sciences; Chemotherapy; Carcinogenesis; Diagnostic Sciences; Oncology Nursing; Physiology

Contact Details
----------------------------------------------
NIH: NCI
6116 Executive Boulevard
Suite 300
Bethesda, MD 20892-8322
Tel: +31 240 276 6217
Email: marksc@mail.nih.gov

NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its research projects to enhance applicability of mouse models for translational research (R01). This R01 funding opportunity aims to support projects that expand and improve the utility of mouse cancer and tumour models for translational research. The major goals of these projects include the following:

• to address one or more of the technical and experimental parameters that ensure effective translational use of mouse models;
• to identify and propose the means to address unmet translational requirements;
• to take advantage of the oncology models forum PAR-14-239 NCIP hub platform to facilitate collaborations.
that require sharing large amounts of data or images or developing informatics tools.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are limited to US$450,000 direct costs per year. The maximum project period is three years.

Ref: PAR-14-241.

Closing date: 05 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 5 June, 5 October and 5 February until 8 May 2017.

Posted date: 02 Jun 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $450,000
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile

Disciplines

Country of applicant institution: Any

Breast Cancer; Chemotherapy; Cancer Studies & Oncology; Animal Parasites & Pathogens; Oncology Nursing; Lung Cancer; Carcinogenesis; Nursing; Melanoma & Other Skin Cancers; Diagnostic Sciences; Leukaemia & Other Blood Cancers; Veterinary Medicine; Brain Cancer; Animal Models; Cancer Cell Biology; Cancer Immunology; Preventive Medicine; Molecularly Targeted Therapy; Prostate & Testicular Cancers; General Practice; Colorectal, Pancreatic & Stomach Cancers; Human Biological Sciences; Physiology; Non-cancerous Tumours; Veterinary Immunology; Ovarian & Cervical Cancers; Clinical Medicine; Biological Sciences

Contact Details

NIH: NCI
6116 Executive Boulevard
Suite 300
Bethesda, MD 20892-8322
Tel: +31 240 276 6217
Email: marksc@mail.nih.gov

ARTS-BASED APPROACHES IN PALLIATIVE CARE FOR SYMPTOM MANAGEMENT (R01)

NIH: National Center for Complementary and Integrative Health

Description:
A total of four participating institutes and centres of the National Institutes of Health invite applications for their arts-based approaches in palliative care for symptom management (R01) grants. The purpose of this R01 funding opportunity announcement is to foster research on the potential for arts-based approaches to enhance palliative care for individuals living with multiple symptoms related to serious chronic or terminal illness. This FOA is intended to support mechanistic clinical studies to provide an evidence base for the use of the arts in palliative care for symptom management. The objective is to understand the biological, physiological, neurological, psychological, or sociological mechanisms by which the arts exert their
effects on symptom management during and throughout the palliative care continuum. The term arts refers not only to artistic activities, but also to creative activities, such as literature, rituals, oral histories and storytelling.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Applicants may request up to US$300,000 in direct costs per year. The maximum project period is three years.

Ref: PAR-14-294.

Closing date: 05 Feb 16
Deadline information: Applications open on 5 September and are due by 5pm local time of applicant organisation every 5 October, 5 February and 5 June until 8 September 2017.
Posted date: 25 Jul 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $900,000

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Care for Disabled People; Performing Arts; Theatre Studies; Life Expectancy & Quality of Life; Customs & Traditions; Clinical Medicine; Literature, Drama; Public Health, Health Services & Primary Care; Death & Mortality; Paediatrics; Palliative Nursing; Nursing; Oral History; Art Therapies; Medical Effectiveness & Patient Outcomes; Visual Arts; Music Therapy; Social Work & Social Policy; Standards of Care; Neurology; Primary Care; Hospice & Palliative Care; Quality of Care; Art & Design: History, Practice & Theory; Psychology; Allied Health Professions; Accessibility for Disabled People; Health Systems, Administration

Contact Details
-----------------------------------------------
NIH: National Center for Complementary and Alternative Medicine
31 Center Drive, MSC 2182
Bethesda, MD 20892-2182
Tel: +1 301 443 8374
Email: lee.alekel@nih.gov

SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R01)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research, the National Institute on Ageing and the National Institute on Deafness and Other Communication Disorders invites applications for its self-management for health in chronic conditions grants. These R01 grants support activities that focuses on self-management as a mainstream science in order to reduce the burden of chronic illnesses and conditions.
Eligible applicants include domestic and foreign public or private institutions and non-profit or for-profit organisations.

The maximum project period is five years.

PA-14-344

Closing date: 05 Feb 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation on every 5 February, 5 June, 5 October until 8 January 2018.
Posted date: 22 Sep 14
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-344.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Public Health, Health Services & Primary Care; Public Health; Primary Care; Chronic Care; Allied Health Professions; Clinical Medicine; Chronic Fatigue Syndrome

Contact Details
National Institute of Nursing Research
31 Center Drive, Room 5B10
Bethesda MD 20892-2178
Tel: +1 301 594 5970
Email: hussk@mail.nih.gov

BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R01)

NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research and the National Institute of Biomedical Imaging and Bioengineering invite applications for their biology of the temporomandibular joint in health and disease (R01) grants. This R01 funding opportunity encourages research that advances understanding of the temporomandibular joint in health and disease, and aims to stimulate research focused on the biology of joint function and the tissues that make up the joint. Focus areas include:

- bone;
- muscle;
- cartalaginous and ligamentous tissues;
- vascularisation and innervation;
- models;
- measurement of joint health, disease and functions.

This funding opportunity uses the NIH exploratory and developmental grant (R01) mechanism and runs in parallel with one of identical scientific scope, PA-14-359, which solicits applications under the NIH research project (R21) grant mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Budgets are not limited but must reflect the actual needs.
of the proposed project. The scope of the project should define its duration.

Ref: PA-14-358.

Closing date: 05 Feb 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation, every 5 February, 5 June and 5 October until 8 September 2017.
Posted date: 06 Oct 14
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Musculoskeletal System; Human Biological Sciences; Orthopaedic Surgery; Bone Cancers; Physiology; Muscle Diseases; Cardiology; Movement Disorders; Diagnostic Sciences; Primary Care; Clinical Medicine; Osteoporosis & Other Bone Diseases; Disease Models; Connective Tissue; Public Health, Health Services & Primary Care

Contact Details
----------------------------------------------
NIH: National Institute of Dental and Craniofacial Research
Public Information and Liaison Branch
45 Center Drive, MSC 6400
Bethesda MD 20892-6400
Tel: +1 301 594 9898
Email: jasonwan@mail.nih.gov

**IOBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R01)**

*NIH: National Institutes of Health*

**Description:**
The National Institutes of Health, under the National Institute of Nursing Research and the National Institute on Aging, invite applications for their biobehavioural and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia grants. These R01 grants aim to stimulate clinical research focused on biobehavioural or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment, or disease or age-related cognitive decline. Particular interest is on the following:

- interventions that can be implemented in community settings by the affected individual, informal caregivers or others in the community;
- research to inform the development of the type of interventions identified above;
- research that examines underlying mechanisms and biomarkers associated with response to interventions.
This funding opportunity uses the R01 research project grant mechanism and runs in parallel with two opportunities of identical scientific scope; PA-15-016, which solicits applications under the R15 academic research enhancement award mechanism, and PA-15-015, which solicits applications under the R21 exploratory or developmental award mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

Grants are awarded for a maximum project period of five years.

Ref: PA-15-017.

Closing date: 05 Feb 16
Deadline information: Applications requesting US$500,000 or more in direct costs per year should contact NIH staff at least six weeks before applying. Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 January 2018. Deadlines on: 5 February 2016, 5 June 2016, 5 October 2016, and repeated annually.
Posted date: 15 Oct 14

Award type: Directed grants to institutions, research groups etc,
Networking/collaboration
Award budget total: -
Website:
Application form:
http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Health Economics; General Practice; Public Health, Health Services & Primary Care; Alzheimer’s Disease & Senile Dementia; Diagnostic Sciences; Neurology; Primary Care; Cognitive Processes; Clinical Medicine; Neuroscience; Medical Effectiveness & Patient Outcomes; Psychology

Contact Details
----------------------------------------------
NINR
Building 1DEM
Suite 713A
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 594 5968
Email: tullyla@mail.nih.gov

PROMOTING RESEARCH IN BASIC NEUROSCIENCE (R01)
NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke, the National Institute on Aging, the National Institute on Drug Abuse and the National Institute of Mental Health invite applications for their promoting research in basic neuroscience (R01) grants. These R01 grants aim to stimulate research addressing fundamental questions in basic neuroscience.
Projects can address any area of neuroscience within the missions of the participating institutes and should focus on understanding the structure and/or function of the normal nervous system. Grants are not intended to stimulate research that is explicitly disease-related.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAS-15-029.

Closing date: 05 Feb 16
Deadline information: Applications requesting US$500,000 or more in direct costs per year should contact NIH staff at least six weeks before applying. Applications are invited between 5 January and 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 January 2018. Deadlines on: 5 February 2016, 5 June 2016, 5 October 2016, and repeated annually.
Posted date: 05 Nov 14

Research on Eosinophil Associated Disorders (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases, the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Diabetes and Digestive and Kidney Diseases invite applications for their research on eosinophil associated disorders grants

These R01 grants encourage research aimed at elucidating the pathophysiology of eosinophil-associated disorders and clarifying the cellular and molecular mechanisms

Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: -

Eligibility profile
Country of applicant institution: Any
Disciplines
Pharmacy & Pharmacology; Neuroendocrinology; Neuroimaging; Neurosurgery; Neuropsychology; Neuropharmacology; Neurotransmitters; Biological Sciences; Stroke & Cerebrovascular Disorders; Primary Care; Public Health, Health Services & Primary Care; Neurology; Muscle Diseases; Clinical Medicine; Diagnostic Sciences; Endocrine & Neuroendocrine Cancers; Neuroanatomy; Neurobiology; Neuroscience; Electrophysiology; Psychology
Contact Details
Tel: +1 301 496 5745
Email: rr260c@nih.gov
underlying the role of eosinophil leukocytes in these conditions.

This funding opportunity uses the R01 research project grant mechanism and runs in parallel with one of identical scientific scope, PA-15-028, which solicits applications under the R21 exploratory or developmental grant mechanism.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-15-027.

Closing date: 05 Feb 16
Deadline information: Applications are invited between 5 January and 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 May 2018. Deadlines on: 5 February 2016, 5 June 2016, 5 October 2016, and repeated annually.
Posted date: 12 Nov 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Biological Markers & Sensor Mechanisms; Blood Diseases; Cell & Developmental Biology; Biochemistry & Molecular Biology; Diagnostic Sciences; Pathology; Cytopathology; Pathophysiology; Biological Sciences

Contact Details
----------------------------------------------
NIAID
Building 5601FL
Room 6B59
5601 Fishers Lane
Rockville MD 20852
Tel: +1 240 627 3532
Email: minnicozzim@niaid.nih.gov

DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R01)
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its diabetes and cardiovascular disease in older adults (R01) funding opportunity announcement. This announcement encourages basic, clinical and epidemiological outcomes research on the impact of age on the development of, diagnosis and management of diabetes and CVD complications in older persons or animal models. Research supported by this initiative is expected to elucidate the role of ageing mechanisms that underlie the increased vulnerability of older adults to DM and its
CVD complications and to provide evidence-based guidance to improve more appropriate diagnostic criteria, risk stratification and intervention recommendations to prevent the onset, or improve short- and long-term outcomes, of DM and CVD in older persons.

This funding opportunity uses the R01 research project grant mechanism and runs in parallel with two of identical scientific scope, PA-15-038, which solicits applications under the R21 exploratory and developmental grant mechanism and PA-15-039, which solicits applications under the R03 small grant programme mechanism. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-15-037.

Closing date: 05 Feb 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 January 2018.
Posted date: 05 Jan 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Cardiovascular Diseases; Geriatrics & Gerontology; Diabetes

Contact Details
----------------------------------------------
GWY BG Room 3C307
7201 Wisconsin Avenue
Bethesda MD 20814
Tel: +1 301 496 6761
Email: susan.zieman@nih.gov

IDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY COOPERATIVE AGREEMENT (U01)
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its clinical trial or biomarker validation study cooperative agreement (U01) funding opportunity announcement. This announcement supports investigator-initiated phase I, II, III or IV clinical trials, stage one to four behavioural or social intervention trials or biomarker validation studies that require prospective collection of clinical outcomes and clinical specimens through the funding mechanism. Eligible clinical trials may focus on the following:
• chemotherapeutic, pharmacologic or other interventions to prevent or treat periodontal diseases and various types of dental caries;
• testing new dental materials for restoration of carious lesions;
• testing non-opiate methods of reducing postoperative pain and swelling after dental surgery;
• preventing or treatment of HIV/AIDS, its associated oral complications, coinfections or malignancies, and dental diseases caused by bacteria, fungi or viruses;
• testing therapies to prevent or treat oral candidiasis, oral herpes virus infections and other pathogens with oral targets that commonly occur in those with congenital or acquired immune dysfunction;
• testing treatments for oral mucositis and other oral manifestations of systemic diseases;
• comparing therapies for oral diseases in medically complex patients;
• preventing or managing salivary dysfunction;
• testing treatments for temporomandibular dysfunction and other orofacial pain conditions;
• validation of biomarkers of oral or dental diseases through prospective collection of biospecimens and data on clinical outcomes;
• testing the efficacy or effectiveness and mechanisms of action of behavioural or social interventions to improve dental, oral or craniofacial health;
• adapting behavioural or social principles, methods or interventions from other areas of health to be applied and tested in dental, oral or craniofacial health, or in the dental setting;
• developing and testing algorithms for tailoring or targeting behavioural or social interventions for individuals, groups, communities or settings in which further testing is justified.

This announcement uses the NIH research (U01) grant mechanism and runs in parallel with two announcements of identical scientific scope, PAR-14-342 and PAR-14-346, both of which solicit applications under the NIH planning grant (R34) mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the needs of the project. The maximum project period is five years.


Closing date: 05 Feb 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 January 2018. Deadlines on: 5 February 2016, 5 June 2016, 5 October 2016, and repeated annually.

Posted date: 09 Dec 14
Award type: Clinical trials, Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: -

Application form:
http://www.grants.gov/web/grants/applicant
s/download-application-package.html#download=true&oppNum=PAR-15-059

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
CADEMIC-INDUSTRIAL PARTNERSHIPS FOR TRANSLATION OF TECHNOLOGIES FOR CANCER DIAGNOSIS AND TREATMENT (R01)
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its academic-industrial partnerships for translation of technologies for cancer diagnosis and treatment (R01) funding opportunity announcement. This announcement enables academic and industrial investigators to form research partnerships and work together to accelerate the translation of technologies, methods, assays or devices, systems for preclinical or clinical molecular diagnosis or in vitro imaging designed to solve a targeted cancer problem.

The proposed systems may include molecular diagnosis, molecular imaging or related research resources. Clinical trials that test functionality, and optimise and validate the performance of the proposed translational work may also be funded.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the needs of the project. The maximum funding period is five years.

Ref: PAR-15-075.

Closing date: 05 Feb 16
Deadline information: Applications open on 6 February and are due by 5pm local time of applicant organisation on 6 March 2015. After this, applications are due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 January 2017.
Posted date: 17 Dec 14
Award type: Clinical trials, Research calls for business, Directed grants to institutions, research groups etc, Academic-Industry links, Networking/collaboration
Award budget total: -

Eligibility profile

Country of applicant institution: Any

Disciplines

Chemotherapy; Molecularly Targeted Therapy; Radiotherapy; Cancer Diagnosis; Cancer Immunology; Oncology Nursing
Description:
The National Institute on Nursing Research and the National Institute on Ageing invite applications for their prevention research in mid-life adults (R01) funding opportunity announcement. This announcement encourages research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimise health and wellness as individuals age and prevent illness and disability in later years. This FOA particularly encourages interventions that can be delivered in multiple settings. Studies in disparate groups, such as African American, Native American and Hispanic populations who have a greater prevalence of illness related to multiple chronic conditions, are especially needed. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-097, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. Applicants requesting US$500,000 or more in direct costs in any year (excluding consortium F&A) must contact NIH programme staff at least six weeks before submitting the application.

Ref: PA-15-098.

Closing date: 05 Feb 16
Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 May 2018.

Posted date: 23 Jan 15

Award type: Clinical trials, Directed grants to institutions, research groups etc

Award budget total: -


Eligibility profile
Country of applicant institution: Any
ADVANCING TRANSLATIONAL AND CLINICAL PROBIOTIC OR PREBIOTIC AND HUMAN MICROBIOME RESEARCH (R01)  
NIH: National Cancer Institute  

Description: 
The National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Drug Abuse, the National Center for Complementary and Integrative Health and the Office of Dietary Supplements invite applications for their advancing translational and clinical probiotic or prebiotic and human microbiome research (R01) funding opportunity announcement. This announcement supports interdisciplinary collaborations across scientific disciplines engaged in microbiome and probiotic or prebiotic research.  
The aim is to accelerate translational and clinical phase I and II a/b safety and efficacy studies for substantial measurable functional benefits of probiotic or prebiotic components or their combinations, and to understand the underlying mechanisms of their actions and variability in responses to these interventions. 

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. 

Application budgets must reflect the actual needs of the proposed projects. The maximum project period is five years.

Ref: PA-15-127. 

Closing date: 05 Feb 16 
Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 May 2018. Deadlines on: 5 February 2016, 5 June 2016, 5 October 2016, and repeated annually. 
Posted date: 27 Feb 15 
Award type: Clinical trials, Research calls for business, Directed grants to institutions, research groups etc, Innovation grants, Academic-Industry links, Networking/collaboration 
Award budget total: - 
Website: 

Application form: 

Eligibility profile 
Country of applicant institution: Any
EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R01)
NIH: National Cancer Institute

Description:
The National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Environmental Health Sciences invite applications for their early-life factors and cancer development in later life (R01) funding opportunity announcement. This announcement stimulates research focused on the role of early-life factors in cancer development in later life. A better understanding is sought in the following areas:

- early-life factors that are associated with later cancer development, with early-life including maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and adult years;
- how early-life factors mediate biological processes relevant to carcinogenesis; whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies.

This announcement uses the R01 research project grant mechanism and runs on parallel with two announcements of identical scientific scope; PA-15-125, which uses the R21 exploratory or developmental grant mechanism, and PA-15-124, which uses the R03 small grant programme mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. The principal investigator should attend an NCI-sponsored two-day meeting, generally held every second year in the Washington DC area.

Application budgets need to reflect the actual needs of the proposed projects. The maximum project period is five years.

Ref: PA-15-126.

Closing date: 05 Feb 16
Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 January 2018. Deadlines on: 5 February 2016, 5 June 2016, 5 October 2016, and repeated annually.

Posted date: 27 Feb 15
Award type: Research calls for business, Directed grants to institutions, research groups etc, Academic-Industry links, Networking/collaboration
The National Institute of Nursing Research and the Office of Behavioral and Social Sciences Research invite applications for their functional wellness in HIV – maximising the treatment cascade (R01) funding opportunity announcement. This announcement encourages the development of HIV interventions that target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV. Projects should include strategies and interventions that aim to:

- improve functional wellness and increase quality of life in HIV positive individuals;
- determine barriers and facilitators to entering and maintaining HIV care;
- validate the construct of functional wellness;
- develop and test methods to improve entrance and continuance in HIV care.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-134, which solicits applications under the NIH exploratory or developmental research (R21) grant mechanism.

Application budgets are not limited but must reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-15-133.

Closing date: 05 Feb 16
Deadline information: Applications open on 5 May 2015 and are due by 5pm local time of applicant organisation every 5 June, 5 October and 5 February until 8 May 2018.
Posted date: 06 Mar 15
Award type: Directed grants to institutions, research groups etc  
Award amount max: -  
Award amount min: -  
Award budget total: -  
Website:  

Application form:  

Eligibility profile  
Country of applicant institution: Any

Disciplines  
Quality of Care; HIV/Aids; Life Expectancy & Quality of Life

Contact Details  
Tel: +1 301 594 5976  
Email: lynda.hardy@nih.gov

Immunology: System plasticity in the pathogenesis and treatment of complex dental, oral, and craniofacial diseases (R01)  
NIH: National Institute of Dental and Craniofacial Research

Description:  
The National Institute of Dental and Craniofacial Research invites applications for its immune system plasticity in the pathogenesis and treatment of complex dental, oral and craniofacial diseases (R21) funding opportunity announcement. This announcement supports contemporary, systematic research to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral and craniofacial diseases as well as to develop novel tools and technologies to treat and prevent disease based on precise modulation of the immune system. Plasticity, for the purposes of this initiative, is defined as the ability of the immune system to undergo changes in both characteristics and functions in response to the environment.

Clinical trials are not supported.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-193, which solicits applications under the NIH exploratory/developmental (R21) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but must reflect the actual needs of the proposed project.

The maximum project period is five years.  

Closing date: 05 Feb 16  
Deadline information: Applications open on 5 September 2015 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 September 2018. Applicants requesting US$500,000 or more in direct costs in any year must contact a scientific contact at least six weeks before submitting the application. 
Posted date: 29 Apr 15
Award type: Directed grants to institutions, research groups etc  
Award amount max: -  
Award amount min: -  
Award budget total: -  
Website:  
Application form:  
http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276220  

Eligibility profile  
----------------------------------------------  
Country of applicant institution: Any  
Disciplines  
----------------------------------------------  
Restorative Dentistry; Craniofacial Disorders;  
Dental Health & Hygiene; Oral Medicine;  
Preventive Dentistry; Endodontics;  
Periodontics; Dental Therapeutics & Pharmacology  
Contact Details  
----------------------------------------------  
BG 1DEM Room 620  
6701 Democracy Boulevard  
Bethesda MD 20817  
Tel: +1 301 594 9718  
Email: amanda.melillo@mail.nih.gov  

DEVELOPING THE THERAPEUTIC POTENTIAL OF THE ENDOCANNABINOID SYSTEM FOR PAIN TREATMENT (R01)  
NIH: National Institute on Drug Abuse  

Description:  
A total of seven institutes and centres of the National Institutes of Health invite applications for their developing the therapeutic potential of the endocannabinoid system for pain treatment (R01) funding opportunity announcement. This announcement supports projects that seek to elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain. Applications should consider the following points:  

- if plant-derived cannabis material is proposed it should be well justified, with a statement on where the material or compounds will be obtained, and the stats of a schedule one license should be noted;  
- explicit sex or gender analyses of effects are highly encouraged;  
- role of cannabinoids in the modulation of HIV pain is also encouraged.  

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.  

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is four years.  

Ref: PA-15-188.  

Closing date: 05 Feb 16  
Deadline information: Applications are accepted between 5 September 2015 and 5pm local time of applicant organisation on every 5 February, 5 June and 5 October until 8 September 2018.  
Posted date: 29 Apr 15
Award type: Research calls for business, Directed grants to institutions, research groups etc, Networking/collaboration

Award budget total: -

Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276193

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug Design; Pain Management; Chronic Pain

Contact Details

NIDA
NSC BG RM 4277
6001 Executive Boulevard
Rockville, MD 20852
Tel: +1 301 594 5753
Email: vpurohit@nida.nih.gov

STUDIES AT PERIVIABLE GESTATION (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its studies at periviable gestation (R01) funding opportunity announcement. This announcement supports research that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants. The scope of this FOA includes the following areas:

- knowledge gaps in obstetrical care practices at periviable gestations;
- knowledge gaps in neonatal care at periviable gestations;
- research needs concerning family counseling.

This funding opportunity uses the NIH research project (R01) grant mechanism and PA-15-199, which solicits applications under the NIH small grant programme (R03) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.


Closing date: 05 Feb 16
Deadline information: Applications open on 5 September and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October, until 8 September 2018. Applicants requesting US$500,000 or more in direct costs in any year must contact a scientific contact at least six weeks before submitting the application.

Posted date: 05 May 15
**Award type:** Directed grants to institutions, research groups etc  
**Award amount max:** -  
**Award amount min:** -  
**Award budget total:** -  
**Website:**  
**Application form:**  
http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276313  
**Eligibility profile**  
Country of applicant institution: Any  
**Disciplines**  
----------------------------------------------  
Foetal Health & Prenatal Development; Obstetrics & Gynaecology; Pregnancy & Birth; Family & Relationships Counselling  
**Contact Details**  
----------------------------------------------  
NICHD  
BG 6100 RM 4B03B  
6100 Executive Boulevard  
Rockville MD 20852  
Tel: +1 301 435 7909  
Email: higginsr@mail.nih.gov  

**Human Studies to Evaluate Promising Medications to Treat Alcohol Use Disorder (R01)**  
NIH: National Institute on Alcohol Abuse and Alcoholism  

**Description:**  
The National Institute on Alcohol Abuse and Alcoholism invites applications for its human studies to evaluate promising medications to treat alcohol use disorder (R03) funding opportunity announcement. This announcement encourages applications that use human laboratory paradigms or clinical trials to evaluate the safety and efficacy of novel or repurposed compounds, that bind to new targets, for treatment of alcohol use disorder or AUD with a comorbid post-traumatic stress disorder.  

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-255 and PA-15-254, which solicit applications under the NIH small grant programme (R03) grant mechanism and the NIH exploratory/developmental (R21) grant mechanism respectively.  

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.  

Application budgets are not limited but must reflect the actual costs of the proposed project.  

The maximum project period is five years.  

Ref: PA-15-256.  

**Closing date:** 05 Feb 16  
**Deadline information:** Applications open on 5 September and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 May 2018. Applicants requesting US$500,000 or more in direct costs in any year must contact scientific contact at least six weeks before submitting the application.  
**Posted date:** 14 May 15  
**Award type:** Clinical trials, Directed grants to institutions, research groups etc  
**Award amount max:** -
BIOENGINEERING RESEARCH PARTNERSHIP – NON- OR MINIMALLY-INVASIVE METHODS TO MEASURE BIOCHEMICAL SUBSTANCES DURING NEONATAL AND PERINATAL PATIENT CARE AND RESEARCH (R01)

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications, under the bioengineering research partnership, for its non- or minimally-invasive methods to measure biochemical substances during neonatal and perinatal patient care and research (R01) funding opportunity announcement. Funding enables bioengineering and biomedical scientists to collaborate in developing non- and minimally-invasive methods for measuring biochemical substances in connection with the care of perinatal patient populations.

The developed methods should test analytes and physiological variables, and may include serum electrolytes, liver function tests, renal functions, biomarkers of infection and inflammation, metabolic by-products of drugs, concentrations of drugs used in clinical care or research and physiological variables affected by cardiopulmonary and metabolic systems. Sources for developing the noted monitoring could include trans-epidermal, transcutaneous using nano-sized electrodes, saliva and other fluids.

This announcement solicits applications under the R01 research project grant mechanism and runs in parallel with an opportunity of an identical scientific scope, RFA-HD-16-028, which solicits applications from US-based applicants using the R41 small business technology transfer grant mechanism for phase I projects.

Applicants may be from US and foreign for-profit and non-profit organisations or public and private organisations.

Application budgets must reflect the actual needs of the project. The maximum project period is five years.


Closing date: 05 Feb 16

Deadline information: Applications open on 5 September 2015 and are due by 5pm local time of applicant organisation on every 5 October, 5 February and 5 June until 8
END-OF-LIFE AND PALLIATIVE NEEDS OF ADOLESCENTS AND YOUNG ADULTS WITH SERIOUS ILLNESSES (R01)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research, the National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Office of Research on Women’s Health invite applications for their end-of-life and palliative needs of adolescents and young adults with serious illnesses (R01) funding opportunity announcement. This announcement aims to foster research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses. Funding also supports research focused on specific end-of-life or palliative care models that support the physical, psychological, spiritual and social needs of AYA with serious illness as well as their families and caregivers. The objective is to encourage clinical studies aimed at:

- increasing this knowledge base;
- developing AYA-appropriate measurement tools;
- designing, testing and evaluating of AYA-specific EOLPC models of care and interventions that positively impact health-related quality of life for AYA with serious illness, and their family and caregivers. This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-325, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit, non-profit and public and private organisations may apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-15-324.
RESEARCH ON THE MECHANISMS OR BEHAVIOURAL OUTCOMES OF MULTISENSORY PROCESSING (R01)

NIH: National Institutes of Health

Description:
A total of eleven institutes and offices of the National Institutes of Health invite applications for their research on the mechanisms and behavioural outcomes of multisensory processing (R01) funding opportunity announcement. This announcement supports basic, behavioural or clinical research projects examining the interactions between neural systems such as cognitive, affective or motor processes and multiple sensory modalities. Innovative studies, using animal or human subjects examining two or more senses for the elucidation of mechanisms and behavioural outcomes of multisensory processing, are encouraged. The initiative supports the use of diverse methodologies including basic biochemical, molecular, cellular, genetic approaches, neuroimaging and neurophysiological analyses, experimental psychophysics, “real world” settings, immersive virtual technology and animal models.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants requesting US$500,000 or more in direct costs in any year must contact a scientific research contact at least six weeks before submitting the application. The maximum project period is five years.

Ref: PA-15-347

Closing date: 05 Feb 16
Deadline information: Applications open on 5 January 2016 and due by 5pm local time of applicant organisation every 5 February, 5 June and 5 October until 8 January 2019.

Posted date: 18 Sep 15
Award type: Clinical trials, Directed grants to institutions, research groups etc

Contact Details
Tel: +1 301 594 8911
Email: lynn.adams@nih.gov
PERSONALISED STRATEGIES TO MANAGE SYMPTOMS OF CHRONIC ILLNESS (R01)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for its personalised strategies to manage symptoms of chronic illness (R01) funding opportunity announcement. This announcement aims to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life in persons with chronic illness through increasing knowledge of the biological mechanisms of symptoms and promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms. The research objectives are to:

- examine complex adaptive symptoms related to biobehavioural and environmental interactions that underlie symptom evolution to include change over time;
- identify and validate novel biomarkers and other patient risk factors to assess individual susceptibility to physical, cognitive and affective symptoms and serve as surrogate endpoints for evaluating clinical benefit of targeted interventions;
- develop computer-simulated dynamic models that result in strategies to address individual heterogeneity related symptoms, clusters and patterns;
- develop and test targeted scalable interventions to prevent and mitigate symptoms and clusters to include examination of omics and genetic factors that predict response to interventions;
- examine large databases and electronic health records to discover new biologic, clinical, psychosocial, behavioural and economic factors related to symptom burden and health-related quality of life experienced by persons with chronic illness and new patterns and trends that may translate to targeted interventions.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with two of identical scientific scope, PA-16-008 and PA-16-006, which solicits applications under the NIH exploratory and developmental (R21) grant
mechanism and the NIH academic research (R15) enhancement award.

US and foreign for-profit and non-profit organisations and public and private organisations may apply. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-16-007.

Closing date: 05 Feb 16
Deadline information: Applications open on 5 January 2016 and are due by 5pm local time of applicant organisation every 5 February, 5 June and 5 September until 8 January 2019. Deadlines on: 5 February 2016, 5 June 2016, 5 October 2016, and repeated annually. Posted date: 19 Oct 15

Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration
Award budget total: -

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Genomics; Life Expectancy & Quality of Life; Biochemical Markers; Innovation & Technology Management; Intensive Care & Life Support

Contact Details
----------------------------------------------
Tel: +1 301 594 2775
Email: matocham@mail.nih.gov

INNOVATIVE QUESTIONS IN SYMPTOM SCIENCE AND GENOMICS (R01)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for its innovative questions in symptom science and genomics (R01) funding opportunity announcement. This announcement seeks to optimise innovation, insight and cutting edge conceptual and technological breakthroughs by catalysing research that emanates from the identified innovative questions in symptom and genomic nursing science. These innovative questions are reflective of broad domains from which more specific novel hypotheses or problems to be solved can be derived.

This funding opportunity uses the NIH research project grant (R01) mechanism and runs in parallel with two of identical scientific scope, PA-16-023 and PA-16-022, which solicit applications under the NIH exploratory or developmental grant (R21) mechanism and the NIH academic research enhancement award (R15) mechanism, respectively.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposed
INDS CREATE BIO DISCOVERY TRACK: OPTIMISATION IN PREPARATION FOR DEVELOPMENT OF BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (U01)

NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its cooperative research to enable and advance translational enterprises for biotechnology products and biologics discovery track: optimisation in preparation for development of biotechnology products and biologics (U01) grants. The purpose of this U01 funding opportunity announcement is the discovery of therapeutic biotechnology products and biologics for disorders that fall under the NINDS mission. This FOA supports the optimisation of therapeutic leads showing convincing proof-of-concept. At the end of the funding period, projects that successfully advance through support from this programme will have identified an optimised candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy or target engagement, and other favourable properties that are consistent with the desired clinical application, and will be ready for entry into the CREATE bio development track for further development to enable filing for an investigational new drug. The NINDS CREATE bio programme is dedicated to biotechnology product and biologics-based therapies, which broadly include modalities such as peptides, proteins, oligonucleotides, gene therapies and cell therapies.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited but must reflect the actual needs of the proposed project. Budgets will normally remain under US$500,000 in direct costs in any given year. The project period is typically three years and may not exceed four years.

Ref: PAR-14-286.

Closing date: 11 Feb 16
Deadline information: Applications open on 21 September 2014 and are due by 5pm local time of applicant organisation on 21 October 2014, 11 February and 11 August 2015, 11 February and 11 August 2016, and 8 February 2017.

Posted date: 21 Jul 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-286.html

Disciplines
Protein Synthesis, Modification & Turnover;
Methods of Drug Delivery; Gene Therapy;
Neuropharmacology; Neurobiology;
Biological Sciences; Pharmacotherapy;
Clinical Medicine; Primary Care; Public Health, Health Services & Primary Care;
Toxicology; Pharmacokinetics; Cell Physiology & Metabolism; Clinical Pharmacy & Pharmacology; Neurology; Pharmacy & Pharmacology; Chemistry; Drug Design; Diagnostic Sciences

Contact Details
NIH/NINDS
Neuroscience Center, Room 2106
6001 Executive Blvd MSC
Bethesda MD 20892
Tel: +1 301 496 1779
Email: createnquiries@mail.nih.gov

INDS CREATE BIO DEVELOPMENT TRACK: PRECLINICAL AND EARLY-PHASE CLINICAL DEVELOPMENT FOR BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (UH2/UH3)

NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its NINDS cooperative research to enable and advance translational enterprises for biotechnology products and biologics development track: preclinical and early-phase clinical development for biotechnology products and biologics (UH2/UH3) grants. The purpose of this UH2/UH3 funding opportunity announcement is the development of therapeutic biotechnology products and biologics for disorders that fall under the NINDS mission. An identified candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy or target engagement, and other favourable properties that are consistent with the desired clinical application, is required for entry to the CREATE bio development track. The FOA supports investigational new drug-enabling studies for the candidate and early-phase clinical trials. At the end of the funding period, a successful project should have an IND application submitted to the US Food and Drug Administration, at a minimum. The NINDS CREATE bio programme is dedicated to biotechnology product and biologics- based therapies, which broadly include modalities such as peptides, proteins, oligonucleotides, gene therapies and cell therapies.

Domestic and foreign for-profit and non-profit organisations and public or private
institutions are eligible to apply. Applications should rarely exceed US$1 million in direct costs per year during the UH2 phase and US$1.5 million in direct costs per year during the UH3 phase. The proposed project period for the UH2 phase may not exceed two years and the UH3 phase may not exceed four and a half years. The total duration of UH2 and UH3 phases may not exceed five years.

Ref: PAR-14-288.

Closing date: 11 Feb 16
Deadline information: Applications open on 21 September 2014 and are due by 5pm local time of applicant organisation on 21 October 2014, 11 February and 11 August 2015, 11 February and 11 August 2016, and 8 February 2017.
Posted date: 21 Jul 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/ announcements/PAR-14-288.html
Application form: http://www.grants.gov/web/grants/applicants/download-application-

Eligibility profile
--------------------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------------------------------------------
Pharmacotherapy; Diagnostic Sciences; Cell Physiology & Metabolism; Methods of Drug Delivery; Gene Therapy; Protein Synthesis, Modification & Turnover; Neuropharmacology; Clinical Medicine; Drug Design; Pharmacokinetics; Neurology; Primary Care; Public Health, Health Services & Primary Care; Biological Sciences; Pharmacy & Pharmacology; Neurobiology; Clinical Pharmacy & Pharmacology; Toxicology; Chemistry

Contact Details
--------------------------------------------------------------------------------
NIH/NINDS
Neuroscience Center, Room 2106
6001 Executive Blvd MSC
Bethesda MD 20892
Tel: +1 301 496 1779
Email: createnquiries@mail.nih.gov

BLUEPRINT NEUROTHERAPEUTICS NETWORK: SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT FOR DISORDERS OF THE NERVOUS SYSTEM (UH2/UH3)

NIH: National Institute of Neurological Disorders and Stroke

Description:
A total of nine participating institutes and centres of the National Institutes of Health invite applications for their blueprint neurotherapeutics network: small molecule drug discovery and development for disorders of the nervous system (UH2/UH3) grants. The purpose of this UH2/UH3 funding opportunity announcement is to help neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organisations that specialise in medicinal chemistry, pharmacokinetics, toxicology, formulations development,
chemical synthesis under good manufacturing practices, and phase I clinical testing.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The combined duration of the UH2 and UH3 award cannot exceed five years.

Ref: PAR-14-293.

Closing date: 11 Feb 16
Deadline information: Applications open on 21 September 2014 and are due by 5pm local time of applicant organisation on 21 October 2014, 11 February and 11 August 2015, 11 February and 11 August 2016, and 8 February 2017.
Posted date: 23 Jul 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-293.html
Application form: http://www.grants.gov/web/grants/applicants/download-application-

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Central Nervous System; Chemistry; Biological Sciences; Neurobiology; Pharmacy & Pharmacology; Gene Therapy; Protein Synthesis, Modification & Turnover; Diagnostic Sciences; Neurology; Pharmacokinetics; Neuropharmacology; Toxicology; Drug Design; Methods of Drug Delivery; Clinical Medicine; Primary Care; Clinical Pharmacy & Pharmacology; Cell Physiology & Metabolism; Pharmacotherapy; Public Health, Health Services & Primary Care

Contact Details
----------------------------------------------
NIH: National Institute of Neurological Disorders and Stroke
Division of Extramural Research
6001 Executive Boulevard Suite 3309
Bethesda, MD 20892- 9531
Tel: +1 301 496 1779
Email: farkasr@ninds.nih.gov

METABOLOMICS DATA ANALYSIS (R03)
NIH: National Cancer Institute

Description:
The National Cancer Institute, on behalf of the Common Fund initiative, invites applications for its metabolomics data analysis (R03) funding opportunity announcement. This announcement seeks to foster collaboration between bioinformaticians, metabolomics experts and biomedical researchers in efforts to improve the ability to analyse metabolomics data to address biomedical questions. These grants are also intended to complement the current efforts of the Common Fund metabolomics programme and maximise the value of existing metabolomics databases and resources. Bidirectional collaborations, such that in-
depth appreciation of both the biology and informatics involved, are strongly encouraged. Specific areas of interest include:

- improved methods of processing raw data for compound identification from mass spectrometry and nuclear magnetic resonance spectroscopy peaks or features;
- integration of metabolite data acquired across different metabolomics technological platforms;
- metabolic modelling of known or unknown pathways with regard to a disease or disorder;
- novel data visualisations that better uncover relationships between diseases and metabolites;
- validation of new methods or statistical analyses to test a specific biomedical question;
- integration of metabolomics data with other ‘omics data to test specific biomedical questions.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

The Common Fund intends to commit US$1 million in fiscal year 2016 to fund six to seven awards. Application budgets are limited to US$100,000 in direct costs but need to reflect the actual needs of the proposed project. The maximum project period is one year.


Closing date: 11 Feb 16
Deadline information: Applications open on 11 January and are due by 5pm local time of applicant organisation, 11 February 2016.
Posted date: 02 Nov 15
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $100,000
Award amount min: -
Award budget total: $1,000,000

Eligibility profile

Country of applicant institution: Any

Disciplines

Bioinformatics; Metabolomics

Contact Details

Tel: +1 240 276 6230
Email: spalholb@mail.nih.gov

NIH: National Institutes of Health

Description:
The National Institutes of Health, via the National Cancer Institute, invites applications for its administrative supplements for collaborative activities to promote metabolomics research funding opportunity announcement, under the common fund metabolomics programme. This announcement supports supplemental funds to current NIH-funded research projects for
new interactive collaborations between basic or clinical researchers and metabolomics experts to add a metabolomics approach to the existing research strategy for the project.

In addition to enhancing the parent grant by adding metabolomics analyses, collaborative projects must include activities to increase the expertise of the biomedical research group in key aspects of metabolomics study design, analysis and data interpretation. Administrative supplements are only available for selected parent awards. An overview of the eligible activity codes is available on the NIH website.

US and foreign for-profit and non-profit organisations and public and private organisations that already hold an eligible parent award, may apply.

NIH intends to commit approximately US$2 million in fiscal year 2016 to fund between 12 and 14 awards. Application budgets are limited to up to US$100,000 in direct costs, exclusive of consortium or contractual facilities and administrative costs, and budgets must reflect the actual needs of the proposed project.

The project and budget period must be within the currently approved project period for the existing parent award. Parent awards must be funded through 30 June 2017 exclusive of any no cost extension.

Ref: PA-16-005 (replaces PA-15-030).

Closing date: 15 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Posted date: 12 Oct 15
Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-16-005.html

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Metabolomics

Contact Details
-----------------------------------------------
Tel: +1 240 276 6230
Email: witkinkeren@mail.nih.gov

NIH RESEARCH GRANT FOR SECONDARY DATA ANALYSIS (R21)
NIH: National Eye Institute

Description:
The National Eye Institute invites applications for its research grant for its secondary data analysis (R21) programme. The purpose of this R21 funding opportunity announcement is to conduct secondary analyses using existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports and extensive portfolio of clinical trials and large-scale epidemiologic research projects, wherein numerous data collection activities are required. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The R21 grant may be used to
develop new statistical methodologies or to test hypotheses using existing data, but this FOA may not be used to support the collection of new data.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to submit applications. PAR-13-035 (replaces PAR-09-252).

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 October, 16 February and 16 June until 8 May 2016.
Posted date: 06 Dec 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-035

Eligibility profile
Country of applicant institution: Any
Disciplines
Eye Diseases; Clinical Medicine; Ophthalmology; Sensory Systems; Vision Science; Physiology; Data Analysis

Contact Details
Division of Extramural Research
NEI
5635 Fishers Lane, Suite 1300, MSC 9300
Bethesda, MD 20892-9300
Tel: +1 301 451 2020
Fax: +1 301 402 0528
Email: everettd@mail.nih.gov

MAGING – SCIENCE TRACK AWARD FOR RESEARCH TRANSITION (R03)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse and the National Institute of Biomedical Imaging and Bioengineering invite applications for their imaging – science track award for research transition (R03) funding opportunity announcement. This announcement facilitates the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programmes, to enable them to conduct small proof of concept studies. Funding covers research that deals with any area of brain imaging and drug abuse.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

The award covers direct costs of up to US$150,000 for a maximum project period of one year.

Ref: PAR-15-326 (replaces PAR-12-066).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 September 2015 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2018.
Posted date: 10 Aug 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $150,000

Eligibility profile
Country of applicant institution: Any
Disciplines
Drug & Substance Abuse; Neuroimaging

Contact Details
Tel: +1 301 443 4877
Email: sgrant@nida.nih.gov

Exploratory/Developmental Research Grant Programme (Parent R21)
NIH: National Institutes of Health

Description:
Participating institutes and centres of the National Institutes of Health invite applications under the exploratory/developmental research grant programme (parent R21). This funding opportunity announcement encourages exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioural or clinical research.

Applications may request direct costs of up US$275,000 for a two-year period, with no more than US$200,000 in any year.

Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. PA-13-303 (replaces PA-11-261).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 16 February, 16 June and 16 October until 8 September 2016.
Posted date: 06 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000


Eligibility profile
Country of applicant institution: Any
Disciplines
Physiology; Dentistry; Primary Care; Pharmacy & Pharmacology; Clinical Medicine; Human Biological Sciences; Diagnostic Sciences; Nursing; Public Health,
PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN UROLOGIC DISORDERS (R21)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its pilot and feasibility clinical research grants in urologic disorders (R21) funding opportunity announcement. This announcement supports small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials, related to urologic disorders research.

Studies should address important clinical and translational questions that are potentially of high clinical and public health impact.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-161, which also solicits applications under the R21 mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs with a maximum of US$200,00 per year. The maximum project period is two years.


Closing date: 16 Feb 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation on every 16 February, 16 June and 16 October until 8 May 2018.
Posted date: 30 Mar 15
Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000

Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275480

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Urology

Contact Details
----------------------------------------------
NIDDK
BG 2DEM Room 627
6707 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 7717
Email: ziya.kirkali@nih.gov
DEVELOPMENT AND APPLICATION OF PET AND SPECT IMAGING LIGANDS AS BIOMARKERS FOR DRUG DISCOVERY AND FOR PATHOPHYSIOLOGICAL STUDIES OF CNS DISORDERS (R21)

NIH: National Institute of Mental Health

Description:
Participating institutes of the National Institutes of Health invite applications for the their development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and for pathophysiological studies of CNS disorders phased innovation award (R21). This R21 funding opportunity announcement aims to support the development of novel radioligands for positron emission tomography or single photon emission computed tomography imaging in the human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development or clinical studies.

This FOA will utilise the exploratory or developmental (R21) award mechanism, and runs in parallel with FOA PA-13-158, which solicits applications using the NIH exploratory or developmental phased innovation R21/R33 award mechanism.

Direct costs are limited to US$450,000 over a maximum of three years, with no more than US$175,000 available in direct costs in any single year.

Eligible institutions include domestic or foreign for-profit and non-profit organisations and public or private institutions.


Closing date: 16 Feb 16
Deadline information: Applications due by 5pm applicant’s local time, 16 February, 16 June and 16 October until 8 September 2016.

Posted date: 25 Jul 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $450,000


Eligibility profile
Country of applicant institution: Any

Disciplines
Chemistry; Human Biological Sciences; Mental Illness; Molecular Probes; Cellular Interactions; Clinical Psychology; Primary Care; Neuroscience; Radiation Sources & Isotopes; Neuroimaging; Biochemical Markers; Diagnostic Sciences; Physiology; Radiology & Medical Imaging; Public Health, Health Services & Primary Care; Nucleus & Organelles; Pathophysiology; Pharmacokinetics; Pharmacy & Pharmacology; Psychology; Neurology; Central Nervous System

Contact Details
NIMH
6001 Executive Boulevard
Rockville, MD 20852
Tel: +1 301 443 3563
Email: lbrady@mail.nih.gov
SECONDARY ANALYSES IN OBESITY, DIABETES, DIGESTIVE AND KIDNEY DISEASES (R21)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

**Description:**
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its secondary analyses in obesity, diabetes and digestive and kidney diseases (R21) funding opportunity announcement. This Aids-related announcement supports the secondary analysis of existing data sets relevant to the following: diabetes and endocrine and metabolic diseases; genetic metabolic diseases; obesity, liver diseases, alimentary gastrointestinal tract diseases and nutrition; kidney, urologic and haematologic diseases. Innovative and high-risk applications with a likelihood for high impact are particularly encouraged.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs, with up to US$200,000 available for direct costs per year. The maximum project period is two years.

PA-15-169 (reissue of PA-12-125).

**Closing date:** 16 Feb 16

**Deadline information:** Applications open on 16 May and are due by 5pm local time of applicant organisation, every 16 February 16 June and 16 October until 8 May 2018.

**Posted date:** 02 Apr 15

**Award type:** Directed grants to institutions, research groups etc, Innovation grants

**Award amount max:** $275,000

**Website:**

**Application form:**

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Nutrition & Dietetics; Haematology; Obesity; Metabolomics; Hepatology; Gastroenterology; Diabetes; Nephrology & Kidneys; Hormones & Endocrinology

**Contact Details**

NIDDK
BG 2DEM Room 659
6707 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 8879
Email: aynur.unalp-arida@nih.gov
HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R21)
NIH: National Institute of Nursing Research

**Description:**
The National Institute of Nursing Research invites applications for health promotion among racial and ethnic minority males (R21). This R21 funding opportunity announcement aims to stimulate and expand research in the health of minority men. Specifically, this initiative is intended to: enhance understanding of the numerous factors influencing the health promoting behaviours of racial and ethnic minority males and their sub populations across the life cycle; and solicit applications focusing on the development and testing of culturally and linguistically appropriate health-promoting interventions designed to reduce health disparities among racially and ethnically diverse males and their sub populations aged 21 and older.

This FOA will use the exploratory/developmental (R21) grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-328 that solicits applications under the R01 mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-331 (replaces PA-10-237)

**Closing date:** 16 Feb 16
**Deadline information:** Deadlines every 16 February, 16 June and 16 October until 8 September 2016.
**Posted date:** 15 Aug 13

**Award type:** Directed grants to institutions, research groups etc
**Award amount max:** $275,000
**Award amount min:** -
**Award budget total:** -
**Application form:** [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-331](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-331)

**Eligibility profile**
Country of applicant institution: Any

**Disciplines**
- Urology; Health Promotion; Nursing;
- Disadvantaged & Minority Groups;
- Population Studies, Medical; Public Health, Health Services & Primary Care;
- Pharmaceutical Drugs; Behavioural Medicine; Health Disparities; Biomedical Engineering; Medical Sociology; Economic & Social Environment; Sociology; Medicine & Health; Psychology; Health Systems, Risk Management

**Contact Details**
Office of Extramural Programs
NINR
6701 Democracy Blvd, Room 710, MSC 4870
Bethesda, MD 20892-4870
Tel: +1 301 402 6423
Email: cottonp@mail.nih.gov
LEGAL, ETHICAL AND SOCIAL IMPLICATIONS OF GENOMIC RESEARCH SMALL RESEARCH GRANT PROGRAMME (R03)
NIH: National Human Genome Research Institute

Description:
A total of eight participating institutes and centres of the National Institutes of Health invite applications for their ethical, legal and social implications of genomic research small research grant programme. The purpose of this R03 funding opportunity is to study the ELSI of human genome research. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues.

The specific areas of interest for this FOA are:

- genomic research;
- genomic health care;
- broader societal issues;
- legal, regulatory and public policy issues.

This FOA will use the NIH small research grant (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-276 that encourages applications under the regular research grant (R01) mechanism and PA-14-278 that encourages applications under the exploratory/developmental research grant (R21) mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are limited to no more than US$50,000 in direct costs per year. The maximum project period is two years.

Ref: PA-14-277 (replaces PA-11-249).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2017.

Posted date: 11 Jul 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $50,000
Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-277.html

Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Human Genome; Medical & Health Ethics; Medical Sociology; Philosophy; Sociology; Medical Genetics; Ethical Use of Technology; Diagnostic Sciences; Biological Sciences; Public Health, Health Services & Primary Care; Public Health & Medical Law; Professional Ethics; Genomics; Cancer Genetics; Law; Primary Care; Research Ethics & Misconduct

Contact Details
----------------------------------------------
National Human Genome Research Institute
National Institutes of Health
Building 31, Room 4B09
31 Center Drive MSC 2152
9000 Rockville Pike
Bethesda MD 20892 2152
Tel: +1 301 402 4997
Email: jb40m@nih.gov
**EXPLORATORY/DEVELOPMENTAL CLINICAL RESEARCH GRANTS IN OBESITY (R21)**
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

**Description:**
The National Institute of Diabetes and Digestive and Kidney Diseases, the National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and the Office of Dietary Supplements invite applications for their exploratory/developmental clinical research grants in obesity (R21) funding opportunity announcement. This announcement supports exploratory and developmental clinical studies that accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and children.

Exploratory epidemiological research with a goal of informing translational and clinical research may also be supported.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs with a maximum of US$200,000 in direct costs per year. The maximum project period is two years.

Ref: PA-15-163 (reissue of PA-12-179).

**Closing date:** 16 Feb 16
**Deadline information:** Applications open on 16 May and are due by 5pm local time of applicant organisation on every 16 February, 16 June and 16 October until 8 May 2018.
**Posted date:** 30 Mar 15
**Award type:** Clinical trials, Directed grants to institutions, research groups etc, Innovation grants
**Award amount max:** $275,000

**Eligibility profile**
-------------------------------------------------------------
Country of applicant institution: Any

**Disciplines**
-----------------------------------------------
Obesity

**Contact Details**
-----------------------------------------------
NIDDK
BG 2DEM Room 673
6707 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 451 8354
Email: kuczmarskir@mail.nih.gov

---

**MALL RESEARCH GRANTS FOR ORAL HEALTH DATA ANALYSIS AND STATISTICAL METHODOLOGY DEVELOPMENT (R03)**
NIH: National Institute of Dental and Craniofacial Research

**Description:**
The National Institute of Dental and Craniofacial Research invites applications for its small research grants for oral health data analysis and statistical methodology development (R03) funding opportunity announcement. This announcement supports
research projects that involve secondary data analyses of existing oral or craniofacial database resources, or aims to develop needed statistical methodology for analysing oral and craniofacial data using existing oral or craniofacial databases. This R03 grant mechanism supports research specifically limited in time and amount for studies in categorical programme areas.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Projects may receive up to US$100,000 per year for a maximum period of two years. Ref: PAR-15-344 (replaces PAR-12-120).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 September 2015 and are due by 5pm of applicant organisation every 16 October, 16 February and 16 June until 8 September 2018.

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Oral Medicine; Data Analysis

Contact Details
----------------------------------------------
Tel: +1 301 594 4876
Email: dena.fischer@nih.gov

UNDERSTANDING AND PROMOTING HEALTH LITERACY (R03)
NIH: Office of the Director

Description:
A total of eight institutes and offices of the National Institutes of Health invite proposals for the understanding and promoting health literacy (R03) programme. The goal of this R03 funding opportunity announcement is to encourage methodological, intervention and dissemination research for understanding and promoting health literacy. Health literacy is defined as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.

This call will use the NIH R03 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-130, which uses the R01 grant mechanism, and PAR-13-132, which uses the R21 grant mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Direct costs are limited to US$100,000 over two years with no more than US$50,000 in any year. PAR-13-132 (replaces PAR-10-134).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm local time of applicant institution every 16 February, 16 June and 16 October until 8 May 2016.

Posted date: 04 Mar 13
DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R21)

NIH: National Institute of Mental Health

Description:
A total of 13 participating institutes and centres of the National Institutes of Health invite applications for their dissemination and implementation research in health (R21) grants. This R21 funding opportunity announcement encourages investigators to submit applications that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures, and strategies to disseminate and implement research-tested health behaviour change interventions, evidence-based prevention, early detection, diagnostic, treatment and management, and quality of life improvement services, and data monitoring and surveillance reporting tools into public health and clinical practice settings that focus on patient outcomes.

This FOA will use the R21 exploratory/developmental award mechanism, and runs in parallel with two FOAs of identical scientific scope, PAR-13-055, which encourages applications under the R01 research project grant mechanism, and PAR-13-056, which encourages applications under the R03 small grant programme mechanism.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. PAR-13-054 (replaces PAR-10-040).

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 January 2016.
Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
MALL RESEARCH GRANT PROGRAMME (PARENT R03)
NIH: National Institute of Nursing Research

Description:
Participating institutes of the National Institutes of Health invite applications for their small research grant programme (parent R03). This R03 funding opportunity supports small research projects that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Direct costs are limited to US$100,000 direct costs over the R03 two year period, with no more than US$50,000 in direct costs allowed in a single year.

Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. PA-13-304 (replaces PA-11-262).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 16 February, 16 June and 16 October until 8 September 2016.
Posted date: 06 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite proposals for their health services and economic research on the prevention and treatment of drug, alcohol and tobacco abuse (R21) funding opportunity announcement. This announcement supports rigorous health services and economic research to maximise the delivery of efficient, high-quality drug, tobacco and alcohol prevention, treatment and recovery support services. The following subjects are of specific interest to the NIDA and NIAAA:

- clinical quality improvement;
- quality improvement in service organisation and management;
- implementation research;
- economic research;
- implications of policy change for service quality;
- methods, technology and other tools.

Applicants are strongly encouraged to contact scientific staff prior to submitting an application.

This funding opportunity uses the NIH exploratory/developmental (R21) mechanism and runs in parallel with several of identical scientific scope, PA-15-251, PA-15-252 and PA-15-250 which solicit applications under the NIH research project (R01), the NIH small grant programme (R03) and the NIH planning (R34) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs with up to US$200,000 in direct costs per year.

The maximum project period is two years.

Ref: PA-15-253 (reissue of PA-12-128).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 May 2018.
Posted date: 11 May 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-128
Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol and Tobacco Abuse (R03)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite proposals for their health services and economic research on the prevention and treatment of drug, alcohol and tobacco abuse (R03) funding opportunity announcement. This announcement supports rigorous health services and economic research to maximise the delivery of efficient, high-quality drug, tobacco and alcohol prevention, treatment and recovery support services. The following subjects are of specific interest to the NIDA and NIAAA:

- clinical quality improvement;
- quality improvement in service organisation and management;
- implementation research;
- economic research;
- implications of policy change for service quality;
- methods, technology and other tools.

Applicants are strongly encouraged to contact scientific staff prior to submitting an application.

This funding opportunity uses the NIH small grant programme (R03) grant mechanism and runs in parallel with several of identical scientific scope, PA-15-251, PA-15-253 and PA-15-250 which solicit applications under the NIH research project (R01), the NIH exploratory/developmental (R21) and the NIH planning (R34) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to US$50,000 in direct costs per year. The maximum project period is two years.

Ref: PA-15-252 (reissue of PA-12-129).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 May 2018.
Posted date: 11 May 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Award amount min: -
Award budget total: -
Drug Abuse Prevention Intervention Research (R21)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its drug abuse prevention intervention research (R21) funding opportunity announcement. This announcement aims to support research that will employ rigorous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan.

This FOA encourages investigations of cognitive, behavioural, and social processes as they relate to:

- development of novel prevention approaches;
- efficacy and effectiveness of prevention interventions or programmes;
- processes that optimise the selection, integration, implementation and sustainability of science-based prevention, including systems-level and health economic factors;
- methodologies appropriate for studying complex aspects of prevention science.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This FOA uses the exploratory/developmental grant (R21) funding mechanism and runs in parallel with two opportunities of identical scientific scope, PA-15-081 and PA-15-082 which respectively use the small grant programme (R03) and the research project grant (R01) funding mechanism.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PA-15-080 (reissue of PA-11-312).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 May and are due by 5pm local time of
applicant organisation every 16 February, 16
June and 16 October until 8 September 2017. Forced date: 12 Jan 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-
files/PA-15-080.html
Application form: http://www.grants.gov/web/grants/applicant
s/download-application-
package.html#download=true?oppNum=PA

Eligibility profile
Country of applicant institution: Any

Disciplines
Drug & Substance Abuse; Smoking & Tobacco; Alcoholism

Contact Details
NIDA
NSC BG Room 5171
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6504
Email: hperl@mail.nih.gov

D RUG ABUSE PREVENTION INTERVENTION RESEARCH (R03)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its drug abuse prevention intervention research (R03) funding opportunity announcement. This announcement aims to support research that will employ rigorous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan.

This FOA encourages investigations of cognitive, behavioural, and social processes as they relate to:

• development of novel prevention approaches;
• efficacy and effectiveness of prevention interventions or programmes;
• processes that optimise the selection, integration, implementation and sustainability of science-based prevention, including systems-level and health economic factors;
• methodologies appropriate for studying complex aspects of prevention science.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This FOA uses the small grant programme (R03) funding mechanism and runs in parallel with two opportunities of identical scientific scope, PA-15-080 and PA-15-082 which respectively use the exploratory/developmental grant (R21) and the research project grant (R01) funding mechanism.
Direct costs of up to US$50,000 per year and a project duration of up to two years may be requested.

Ref: PA-15-081 (reissue of PA-11-313).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2017.
Posted date: 12 Jan 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Award amount min: -
Award budget total: -
Application form: http://www.grants.gov/web/grants/applicant

**BIOLOGY OF MANUAL THERAPIES (R21)**
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Center for Complementary and Alternative Medicine invites applications for its call on biology of manual therapies (R21). This R21 funding opportunity announcement supports studies of the basic science and mechanisms of action underlying the neurophysiological, immunological, endocrinological or biomechanical consequences of manual therapies such as spinal manipulation, mobilisation and massage therapy.

This FOA uses the R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-168, which solicits applications under the R01 mechanism.

Eligible institutions include domestic and foreign for-profit and non-profit organisations and public or private institutions.

Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any single year.
Ref: PA-14-167 (replaces PA-10-210).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time every 16 February, 16 June and 16 October until 8 May 2017.
Precription Drug Abuse (R21)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its prescription drug abuse research programme. The purpose of this R21 funding opportunity announcement is to encourage a broad range of research strategies to address the problem of prescription drug abuse. Across proposed research strategies, there is an interest in stimulating the development and integration of novel technologies to observe and understand the aetiology and biological and behavioural mechanisms associated with prescription drug abuse. The specific areas of interest include:

- basic preclinical and clinical research;
- epidemiology and prevention research;
- treatment and health systems research.

This FOA will use the NIH exploratory/developmental (R21) award mechanism and runs in parallel an FOA of identical scientific scope, PA-13-015, which solicits applications under the research project grant (R01) mechanism. Application budgets are limited to US$275,000 over a two-year period, with no more than US$200,000 in any year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-016 (replaces PA-08-128).
Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 January 2016.
Posted date: 05 Nov 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Drug & Substance Abuse; Pharmacy & Pharmacology; Anxiety Disorders; Psychiatry; Allied Health Professions; Compulsive Behaviour; Economic & Social Environment; Addiction; Cognitive & Behavioural Therapies; Primary Care; Preventive Medicine; Pharmaceutical Drugs; Public Health, Health Services & Primary Care; Psychology; General Practice

Contact Details
----------------------------------------------
Division of Epidemiology, Services and Prevention Research
National Institute on Drug Abuse, NIH.
DHHS
6001 Executive Boulevard, Room 5193
Bethesda, Maryland 20892
Tel: +1 301 594 4371
Email: deniscor@nida.nih.gov

RESEARCH ON AUTISM SPECTRUM DISORDERS (R03)
NIH: National Institute of Mental Health

Description:
Participating institutes of the National Institutes of Health invite applications for their research on autism spectrum disorders (R03) grants. The purpose of this R03 funding opportunity announcement is to encourage research designed to elucidate the aetiology, epidemiology, diagnosis, treatment and optimal means of service delivery in relation to autism spectrum disorders. Basic, clinical and applied studied are encouraged.

This FOA will use the small research (R03) grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-217 and PA-13-216, that solicit applications under the exploratory/developmental research (R21) mechanism and the traditional research project grant (R01) mechanism. Direct costs are limited to US$100,000 over a two-year project period, with not more than US$50,000 in any year. Eligible organisations include domestic and foreign for-profit and nonprofit organisations and public or private institutions. PA-13-218 (replaces PA-10-159)

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 May 2016
Posted date: 02 May 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Award amount min: -
Award budget total: -
Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-218

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Psychiatry; Mental Health; Biological Sciences; Medical & Diagnostic Tests; Neuropsychology; Allied Health Professions; Autism Spectrum Disorders; Neuroscience; Molecular Genetics; Group Therapy; Diagnostic Sciences; Aetiology; Clinical Medicine; Mental Illness; Neuropharmacology; Cognitive & Behavioural Therapies; Physiology; Neurobiology; Psychology; Primary Care; Pharmacy & Pharmacology; General Practice; Compulsive Behaviour; Epidemiology; Public Health, Health Services & Primary Care; Cognitive Processes

Contact Details
----------------------------------------------
NIMH
6001 Executive Blvd, Room 6179, MSC 9617
Bethesda, MD 20892-9617
Tel: +1 301 443 3825
Email: gilottyl@mail.nih.gov

Research on Autism Spectrum Disorders (R21)
NIH: National Institute of Mental Health

Description:
Participating institutes of the National Institutes of Health invite applications for their research on autism spectrum disorders (R21) grants. The purpose of this R21 funding opportunity announcement is to encourage research designed to elucidate the aetiology, epidemiology, diagnosis, treatment and optimal means of service delivery in relation to autism spectrum disorders. Basic, clinical and applied studied are encouraged.

This FOA will use the exploratory/developmental (R21) grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-218 and PA-13-216, that solicit applications under the small research grant (R03) mechanism and the research project grant (R01) mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible organisations include domestic and foreign for-profit and nonprofit organisations and public or private institutions. PA-13-217 (replaces PA-10-160)

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 May 2016
Posted date: 02 May 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: -
Website:
PILOT AND FEASIBILITY CLINICAL TRIALS IN DIABETES, AND ENDOCRINE AND METABOLIC DISEASES (R21)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its pilot and feasibility clinical trials in diabetes, and endocrine and metabolic diseases (R21) funding opportunity announcement. This announcement supports pilot and feasibility trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention or treatment of diabetes or selected endocrine and genetic metabolic diseases.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Foreign applications must reflect special opportunities, and must be applicable to US healthcare systems to be considered for funding.

Application budgets are limited to a total of US$275,000 in direct costs, with a maximum of US$200,000 in direct costs per year. The maximum project period is two years.

Ref: PA-15-176 (reissue of PA-12-157).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 May 2018.
Posted date: 07 Apr 15
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:

Application form:
Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Human Metabolism; Genetic Diseases; Hormones & Endocrinology; Diabetes

Contact Details
----------------------------------------------
NIDDK
BG 2DEM Room 687
6707 Democracy Boulevard
Bethesda, MD 20892
Tel: +1 301 594 7733
Email: marteylk@mail.nih.gov

EXPLORATORY/DEVELOPMENTAL BIOENGINEERING RESEARCH GRANTS (R21)
NIH: National Institute of Biomedical Imaging and Bioengineering

Description:
The National Institute of Biomedical Imaging and Bioengineering and 10 other participating institutes of the National Institutes of Health invite applications for their exploratory/developmental bioengineering research (R21) grants. The purpose of this R21 funding opportunity announcement is to establish the feasibility of technologies, techniques or methods that: explore a unique multidisciplinary approach to a biomedical challenge, are high-risk but have a considerable payoff, and develop data leading to significant future research. Applications may propose hypothesis-driven, developmental or design-directed research and is appropriate for evaluating unproven approaches for which there is minimal or no preliminary data.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible organisations include domestic and foreign for-profit and non-profit organisations and public or private institutions. PA-12-284 (replaces PA-10-010).

Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 January 2016.
Posted date: 12 Sep 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-284.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-284

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Behavioural Medicine; Preventive Medicine; General Practice; Radiology & Medical Imaging; Psychology; Assistive Technology; Medicine & Health; Bioengineering; Biomedical Engineering; Medical Research of Selected Fields; Medical & Diagnostic Tests
EHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R03)

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the Office of Behavioral and Social Sciences Research invite applications for their behavioural and integrative treatment development (R03) grants. The aim of this R03 programme is to develop and test behavioural and integrative treatments for drug and alcohol abuse and dependence. Research will test efficacy, conduct clinical trials, examine mechanisms of behaviour change, determine dose-response, optimise combinations, or ascertain best sequencing of behavioural, combined, sequential, or integrated behavioural and pharmacological treatments in the following circumstances:

- drug abuse treatment interventions in diverse settings;
- drug abuse treatment and adherence interventions for use in primary care;
- drug abuse treatment and adherence interventions that use technologies to boost effects and increase implementability;
- interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment;
- interventions to promote adherence to drug abuse treatment, HIV and addiction medications;
- interventions to treat chronic pain.

Research of interest includes but is not limited to Stage II and Stage III efficacy research.

This funding opportunity announcement will use the NIH small research grant (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-077, which solicits applications under the R01 research project grant mechanism, and PA-13-078, which solicits applications under the R34 clinical trial planning grant programme.

Direct costs are limited to US$100,000 over a two-year period, with no more than US$50,000 in direct costs allowed in any single year. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. PAR-13-079 (replaces PAR-10-011).

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 January 2016.
Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Award amount min: -
Award budget total: -
DEVELOPMENT AND APPLICATION OF PET AND SPECT IMAGING LIGANDS AS BIOMARKERS FOR DRUG DISCOVERY AND FOR PATHOPHYSIOLOGICAL STUDIES OF CNS DISORDERS [PHASED INNOVATION (R21/R33)]

NIH: National Institute of Mental Health

Description:
Participating institutes of the National Institutes of Health request R21/R33 grant applications for the development and application of PET and SPECT imaging ligands as biomarkers for drug discovery and for pathophysiological studies of CNS disorders phased innovation award.

Phased innovation R21/R33 applications should propose the development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in the human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.

This FOA will utilise the exploratory/developmental grant phased innovation grant (R21/R33) award mechanism, and runs in parallel with FOA PA-13-157, which solicits applications using the NIH exploratory/developmental R21 award mechanism.

Direct costs are limited to US$175,000 per year for the R21 phase and US$500,000 per year for the R33 phase, and neither phase can last longer than three years. The combined R21/R33 award is limited to five years in duration. Eligible institutions include domestic or foreign for-profit and non-profit organisations and public or private institutions. PAR-13-158 (replaces PA-10-024).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm applicant’s local time, 16 February, 16 June and 16 October until 8 May 2016.
Posted date: 26 Mar 13
MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R21)
NIH: National Institute of Nursing Research

Description:
Participating institutes and centres of the National Institutes of Health invite applications for research into the mechanisms, models, measurement and management in pain research. The purpose of this funding opportunity announcement is to inform the scientific community of the pain research interests of the various institutes and centres at the NIH and to stimulate and foster a wide range of basic, clinical, and translational R21 studies on pain as they relate to the missions of these ICs. Research may address: molecular and cellular mechanisms of pain; genetics of pain; biobehavioural pain; models of pain; diagnosis and assessment of pain; pain management; epidemiology of pain; health disparities; translational pain research. Research conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

This FOA will use the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-118 that utilises the R01 mechanism and PA-13-117, that utilises the R03 mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible organisations include for-profit and non-profit organisations, and public or private institutions. PA-13-119 (replaces PA-10-007).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm applicant’s local time, 16 February, 16 June and 16 October until 8 May 2016.
Posted date: 18 Feb 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: -
Website:

Eligibility profile
--------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------
Nursing; Dermatology; Public Health, Health Services & Primary Care; Traumatology, Accidents & Injury; Behavioural Medicine; Cognitive & Behavioural Therapies; Gene Therapy; Diagnostic Sciences; Geriatric Nursing; Oncology Nursing; Clinical Medicine; Molecular Genetics; Ethology; Allied Health Professions; Chronic Pain; Neuropharmacology; Pharmacy & Pharmacology; Epidemiology; Osteoporosis & Other Bone Diseases; Pain Management; Primary Care; Cell & Developmental Biology; Chemotherapy; Biochemistry & Molecular Biology; Cardiovascular Diseases; Muscle Diseases; Medical & Diagnostic Tests; Biological Sciences; Palliative Nursing; Health Disparities

Contact Details
--------------------------------------------
National Institute of Nursing Research, NIH
6701 Democracy Blvd., Suite 710
One Democracy Plaza
Bethesda, MD 20892-4870
Tel: +1 301 496 9623
Email: mardens@mail.nih.gov

M ECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R03)
NIH: National Institute of Nursing Research

Description:
Participating institutes and centres of the National Institutes of Health invite applications for research into the mechanisms, models, measurement and management in pain research. The purpose of this funding opportunity announcement is to inform the scientific community of the pain research interests of the various institutes and centres at the NIH and to stimulate and foster a wide range of basic, clinical, and translational R03 studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioural and social sciences. Research may address: molecular and cellular mechanisms of pain; genetics of pain; biobehavioural pain; models of pain; diagnosis and assessment of pain; pain management; epidemiology of pain; health disparities; translational pain research.

Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

This FOA will use the NIH small research grant (R03) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-119, that utilises the R01 mechanism and PA-13-118, that utilises the R21 mechanism. Budgets for direct costs of up to US$50,000 per year and a project duration of up to two years may be requested for a maximum of US$100,000 direct costs over a two-year project period. Eligible organisations include for-profit and non-profit
organisations, and public or private institutions. PA-13-117 (replaces PA-10-008).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm applicant’s local time, 16 February, 16 June and 16 October until 8 May 2016.
Posted date: 18 Feb 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Eligibility profile

Country of applicant institution: Any

Disciplines

Chronic Pain; Gene Therapy; Allied Health Professions; Cognitive & Behavioural Therapies; Pharmacy & Pharmacology; Chemotherapy; Nursing; Biological Sciences; Pain Management; Muscle Diseases; Cardiovascular Diseases; Cell & Developmental Biology; Dermatology; Public Health, Health Services & Primary Care; Health Disparities; Geriatric Nursing; Medical & Diagnostic Tests; Primary Care; Osteoporosis & Other Bone Diseases; Neuropharmacology; Traumatology, Accidents & Injury; Oncology Nursing; Clinical Medicine; Epidemiology; Ethology; Molecular Genetics; Diagnostic Sciences; Biochemistry & Molecular Biology; Behavioural Medicine; Palliative Nursing

Contact Details

National Institute of Nursing Research, NIH
6701 Democracy Blvd., Suite 710
One Democracy Plaza
Bethesda, MD 20892-4870
Tel: +1 301 496 9623
Email: mardens@mail.nih.gov

UNDERSTANDING AND PROMOTING HEALTH LITERACY (R21)

NIH: Office of the Director

Description:
A total of nine institutes and offices of the National Institutes of Health invite proposals for the understanding and promoting health literacy (R21) programme. The goal of this R21 funding opportunity announcement is to encourage methodological, intervention and dissemination research for understanding and promoting health literacy. Health literacy is defined as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.

This call will use the NIH R21 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-130, which uses the R01 grant mechanism, and PAR-13-131, which uses the R03 grant mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Direct costs are limited to US$275,000 over two years with no more than US$200,000 available in any year. PAR-13-132 (replaces PAR-10-135).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on
every 16 February, 16 June and 16 October until 8 May 2016.

Posted date: 04 Mar 13

Award type: Directed grants to institutions, research groups etc

Award amount max: $275,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Public Health; Public Health, Health Services & Primary Care; Health & Safety Education & Instruction; Patient Care & Education; Clinical Medicine; Health Promotion; Health Systems; Primary Care; Health Education

Contact Details

OBSSR
NIH
31 Centre Drive, Room B1C19
Bethesda, MD 20814
Tel: +1 301 401 0116
Email: elwoodwi@od.nih.gov

---

**DRUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R21)**

**NIH: National Institute of Mental Health**

**Description:**
The National Institute of Mental Health, the National Institute on Aging, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute on Drug Abuse invite applications for their drug discovery for nervous system disorders funding opportunity. This R21 funding opportunity announcement encourages research grant applications directed toward the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders. The goal is to advance new, innovative and effective therapies for the prevention and treatment of nervous system disorders. Studies aimed at the development and testing of compounds for novel targets are encouraged, however projects designed for target identification are not covered under this announcement.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

This FOA will use the R21 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-13-048, that solicits applications under the R01 mechanism. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to US$275,000 direct costs over a two-year period, with no more than US$200,000 in direct costs allowed in any single year. PAR-13-049 (replaces PAR-10-002).

**Closing date: 16 Feb 16**

**Deadline information:** Applications due by 5pm local time of applicant institution.

Posted date: 19 Dec 12
A compilation of the Research Services of the Office of Research, Innovation & Development (ORID)

Issue 24: Volume 1b – Grants from NIH (January – March, 2016)

Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-049

Eligibility profile
Country of applicant institution: Any

Disciplines
Diagnostic Sciences; Neurobiology; Clinical Chemistry; Central Nervous System; Clinical Medicine; Neuroendocrinology; Toxicology; Muscle Diseases; Biochemical Markers; Neuroscience; Disease Models; Electrophysiology; Immunological & Bioassay Methods; Weapons of Mass Destruction; Human Biological Sciences; Cellular Interactions; Pharmacokinetics; Neuroanatomy; Stress, Psychological; Chemistry; Neuropharmacology; Psychology; Pharmacogenomics; General Practice; Neuroimaging; Pharmacotherapy; Medicinal Chemistry; Methods of Drug Delivery; Endocrine & Neuroendocrine Cancers; Clinical Pharmacy & Pharmacology; Neurosurgery; Prosthetic & Orthotic Devices; Neurology; Neurotransmitters; Neuropsychology; Pharmaceutical Drugs; Biological Sciences; Screening of Drugs & Agents; Pharmacy & Pharmacology; Drug Design; Neurostimulation

Contact Details
NIMH
6001 Executive Boulevard, Room 7189
Rockville, MD 20852
Tel: +1 301 443 5288
Email: jdrisco1@mail.nih.gov

FUNCTIONAL GENETICS, EPIGENETICS AND NON-CODING RNAs IN DRUG ADDICTION (R21)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its functional genetics, epigenetics and non-coding RNAs in drug addiction (R21) programme. This R21 funding opportunity announcement encourages basic functional genomic research in two areas: functional validation to determine which candidate genes or variants have an authentic role in addictive processes, and detailed elucidation of the molecular pathways and processes modulated by candidate genes or variants, particularly for those genes with an unanticipated role in addiction.

This FOA will use the R21 exploratory/developmental research grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-014, which encourages applications under the R01 research project grant mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Applications budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.
Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Ref: PA-14-013 (reissue of PA-11-034).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation, every 16 February, 16 June and 16 October until 8 January 2017.
Posted date: 06 Dec 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-14-013

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Computer Science & Informatics; Public Health, Health Services & Primary Care; Neuroimaging; Biochemical Markers; Ribonucleic Acid, RNA; Diagnostic Sciences; Genomics; Biological Sciences; Primary Care; Bioinformatics; Disease Models; Molecular Genetics; Epigenetics; Behavioural Medicine; Addiction; Neurotransmitters; Psychology; Pharmacokinetics; Immunological & Bioassay Methods; Proteomics & Molecular Interactions; Health Informatics; Drug & Substance Abuse; Electrophysiology; Physiology; Biological Markers & Sensor Mechanisms

Contact Details
----------------------------------------------
NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 435 1020
Email: satterleej@nida.nih.gov

INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R21)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its international research collaboration on drug abuse and addiction research (R01) research opportunity announcement. This announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US.

Special opportunities include access to unusual talent, resources, populations or environmental conditions in other countries that will speed scientific discovery. Projects must have relevance to the mission of NIDA and where feasible, should address NIDA’s scientific priority areas. These include: linkages between HIV/Aids and drug abuse; prevention, initiation and treatment of nicotine and tobacco use; the neuroscience of marijuana and cannabinoids; the effect of changes in laws and policies on marijuana and its impact.

This funding opportunity uses the NIH exploratory research project grant (R21) mechanism and runs in parallel with two of
identical scientific scope, PA-15-141 and PA-15-142 which respectively solicit applications under the NIH small grant programme (R03) mechanism and the NIH research project grant (R01) mechanism.

Research must be conducted by US investigators in collaboration with non-US based investigators. Projects must include significant contributions of resources by each participant. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to US$275,000 with a maximum of US$200,000 in indirect costs per year. The maximum project period is two years.

Ref: PA-15-143 (reissue of PA-12-041).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 May 2015 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 May 2018.
Posted date: 18 Mar 15

INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R03)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its international research collaboration on drug abuse and addiction research (R03) research opportunity announcement. This announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US.

Award type: Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration
Award amount max: $275,000
Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275245

Eligibility profile
Country of applicant institution: Any

Disciplines
Smoking & Tobacco; Drug & Substance Abuse; Alcoholism

Contact Details
National Institute on Drug Abuse
NSC BG Room 4274
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6480
Email: ipdirector@nida.nih.gov

Special opportunities include access to unusual talent, resources, populations or environmental conditions in other countries that will speed scientific discovery. Projects must have relevance to the mission of NIDA and where feasible should address NIDA’s scientific priority areas. Priority areas include: linkages between HIV/AIDS and drug abuse; prevention, initiation and treatment of nicotine and tobacco use; the neuroscience of marijuana and cannabinoids; and the effect of
changes in laws and policies on marijuana and its impact.

This funding opportunity uses the NIH small grant programme (R03) mechanism and runs in parallel with two of identical scientific scope, PA-15-142 and PA-15-143, which respectively solicit applications under the NIH research project grant programme (R01) mechanism and the NIH exploratory/developmental grant (R21) mechanism.

Research must be conducted by US investigators in collaboration with non-US based investigators. Projects must include significant contributions of resources by each participant. US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited US$50,000 per year over a maximum project period of two years.

Ref: PA-15-141 (reissue of PA-12-042).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 May 2018.
Posted date: 18 Mar 15
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $100,000

Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275228

Eligibility profile
Country of applicant institution: Any
Disciplines
Alcoholism; Drug & Substance Abuse; Smoking & Tobacco

Contact Details
National Institute on Drug Abuse
NSC BG Room 4274
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 6480
Email: ipdirector@nida.nih.gov

EUROSCIENCE RESEARCH ON DRUG ABUSE (R21)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its neuroscience research on drug abuse (R21) grants. This R21 funding opportunity announcement aims to understand the neurobiological mechanisms underlying drug abuse and addiction, with emphasis on changes that occur during chronic drug use, withdrawal and relapse. In vivo and in vitro model systems, as well as human studies, are appropriate.

This FOA will use the NIH exploratory/developmental (R21) award
mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-338, which encourages applications under the R01 research project grant mechanism, and PA-13-336, which encourages applications under the R03 small grant programme mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in any year. Public and private, non-profit and for-profit, and domestic and foreign organisations are eligible. PA-13-337 (replaces PA-10-269).

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 January 2017.
Posted date: 27 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

- Behavioural Medicine
- Diagnostic Sciences
- Allied Health Professions
- Addiction
- Primary Care
- Public Health
- Health Services & Primary Care
- Physiology
- Cognitive & Behavioural Therapies
- Psychology
- Drug & Substance Abuse
- Neuroscience
- Neurobiology
- Social Work & Social Policy
- Pharmacy & Pharmacology
- Biological Sciences

**Contact Details**

Division of Basic Neuroscience and Behavioral Research
NIDA
Neuroscience Center
6001 Executive Blvd, Rm 4282, MSC 9555
Bethesda, MD 20892-9555
Tel: +1 301 435 1317
Email: npilotte@nih.gov

---

**NEUROSCIENCE RESEARCH ON DRUG ABUSE (R03)**

*NIH: National Institute on Drug Abuse*

**Description:**

The National Institute on Drug Abuse invites applications for its neuroscience research on drug abuse (R03) grants. This R03 funding opportunity announcement aims to understand the neurobiological mechanisms underlying drug abuse and addiction, with emphasis on changes that occur during chronic drug use, withdrawal and relapse. In vivo and in vitro model systems, as well as human studies, are appropriate.

This FOA will use the NIH small research grant (R03) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-337, which encourages applications under the R21 exploratory/developmental grant mechanism, and PA-13-338, which encourages applications under the R01 research project grant mechanism. Direct costs are worth a maximum of US$100,000 over two years, with no more than US$50,000 in any year. Public and private, non-profit and for-profit, and
domestic and foreign organisations are eligible. PA-13-336 (replaces PA-10-270).

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 January 2017.
Posted date: 27 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Biological Sciences; Neuroscience; Psychology; Allied Health Professions; Behavioural Medicine; Physiology; Diagnostic Sciences; Cognitive & Behavioural Therapies; Drug & Substance Abuse; Neurobiology; Primary Care; Pharmacy & Pharmacology; Addiction; Public Health, Health Services & Primary Care; Social Work & Social Policy

Contact Details
----------------------------------------------
Division of Basic Neuroscience and Behavioral Research
NIDA
Neuroscience Center
6001 Executive Blvd, Rm 4282, MSC 9555
Bethesda, MD 20892-9555
Tel: +1 301 435 1317
Email: npilotte@nih.gov

**ALCOHOL USE DISORDERS: TREATMENT, SERVICES AND RECOVERY RESEARCH (R03)**
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its alcohol use disorders: treatment, services and recovery research (R03) programme. This R03 funding opportunity announcement supports research on behavioural and pharmacological treatment for alcohol use disorders; organisational, financial and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; or the phenomenon of recovery from alcohol use disorders.

Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. The total project period may not exceed two years. Direct costs are limited to US$100,000 over a two-year period, with no more than US$50,000 in direct costs allowed in any single year. This programme will use the NIH R03 grant mechanism and runs in parallel with two programmes of identical scientific scope: PA-13-160, which solicits applications under the R01 mechanism, and PA-13-162, which solicits applications under the R21 mechanism. PA-13-161 (replaces PA-10-101)

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 May 2016.
DEVELOPMENT OF ANIMAL MODELS AND RELATED BIOLOGICAL MATERIALS FOR RESEARCH (R21)
NIH: Office of the Director

Description:
The NIH Office of the Director invites applications for its development of animal models and related biological materials for research programme (R21).

This R21 announcement solicits proposals to develop, characterise or improve animal models for human disease, or to improve diagnosis and control diseases of laboratory animals that may interfere with research. Topics include:

- genetically-modified animals and preservation of important disease models;
- fundamental biology of animal model systems;
- disease biomarkers;
- genetically encoded reporters;
- biological molecule interactive and functional networks;
- animal models for human rare disease conditions;
- complementary approaches to use of animal models; animal diseases.

Domestic and foreign for-profit and non-profit organisations and public or private institutions may apply.

Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

PA-13-145 (replaces PA-10-138).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm applicant’s local time, 16 February, 16 June and 16 October until 8 May 2016.
Posted date: 20 Mar 13
Award type: Directed grants to institutions, research groups etc
Issue 24: Volume 1b – Grants from NIH (January – March, 2016)

Award amount max: $275,000
Application form: http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Genetics & Systems Biology; Animal Physiology; Clinical Medicine; Disease Models; Philosophy; Embryonic Stem Cells; Diagnostic Sciences; Stem Cell Genomics; Primary Care; Public Health, Health Services & Primary Care; Immunisation Programmes & Vaccination; Gene Therapy; Computer Simulation & Modelling; Animal Parasites & Pathogens; Stem Cell; Medical Genetics; Induced Pluripotent Stem Cells; Computer Science & Informatics; Animal Breeding; Veterinary Medicine; Bioinformatics; Ethology; Biological Sciences; Stem Cell Therapy; Ethical Use of Technology; Laboratory Animals; Regenerative Medicine; Genetically Modified & Transgenic Animals; Research Ethics & Misconduct

Contact Details
-------------------------------
DCM/ORIP/Division of Programme Coordination, Planning and Strategic Initiatives
Office of the Director
NIH
6701 Democracy Boulevard
Bethesda MD 20892-4874
Tel: +1 301 435 0744
Fax: +1 301 480 3819
Email: oleg.mirchnitchenko@nih.gov

BEHAVIOURAL AND SOCIAL SCIENCE RESEARCH ON UNDERSTANDING AND REDUCING HEALTH DISPARITIES (R21)
NIH: Office of the Director

Description:
Participating institutes and centres of the National Institutes of Health invite applications for behavioural and social science research on understanding and reducing health disparities (R21) grants. This R21 funding opportunity announcement supports behavioural and social science research on the causes and solutions to health and disabilities disparities in the US population. Emphasis is placed on research in and among three broad areas of action:

- public policy;
- healthcare;
- disease and disability prevention.

Particular attention is given to reducing health gaps among groups. Proposals that use an interdisciplinary approach, investigate multiple levels of analysis, incorporate a life-course perspective, or employ innovative methods such as system science or community-based participatory research are particularly encouraged.

This FOA will utilise the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PAR13-292, which solicits applications under the R01 mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with
no more than US$200,000 in direct costs allowed in any single year.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-288 (replaces PAR-10-137)

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 16 February, 16 June and 16 October until 8 September 2016.
Posted date: 05 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile

Country of applicant institution: Any

**Disciplines**

Public Health, Health Services & Primary Care; Behavioural Medicine; Health Systems; Disadvantaged & Minority Groups; Preventive Medicine; Health Disparities; Clinical Medicine; Care for Disabled People; Sociology; Population Studies, Medical; Allied Health Professions; Primary Care; Economic & Social Environment; Public Health; Psychology; Medical Sociology; Social Work & Social Policy; Rural Health; Health Systems Policy

**Contact Details**

OBSSR
31 Center Drive
Building 31, Room B1C19
Bethesda, MD 20892-2027
Tel: +1 301 451 4286
Email: michael.spittel@mail.nih.gov

---

**NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R03)**

NIH: National Institute on Alcohol Abuse and Alcoholism

**Description:**
The National Institute on Alcohol Abuse and Alcoholism and the Office of Dietary Supplements invite applications for their nutrition and alcohol-related health outcomes (R03) grants. This R03 funding opportunity announcement supports research to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this R01 funding opportunity announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease.

This FOA will use the small grant programme (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-359 and PA-13-361, which use the R01 research project grant and the R21 exploratory/developmental grant mechanisms, respectively. Budgets for direct costs of limited to US$50,000 per year over a maximum two year project period. Domestic and foreign for-profit and non-profit organisations and public or private
institutions are eligible to apply. PA-13-360 (replaces PA-10-240).

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 January 2017.
Posted date: 24 Sep 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-360

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Pathophysiology; Public Health, Health Services & Primary Care; Disease Models; Addiction; Alcoholism; Clinical Medicine; Cognitive Processes; Preventive Medicine; General Practice; Allied Health Professions; Psychology; Primary Care; Nutrition & Dietetics; Epidemiology

Contact Details
----------------------------------------------
Division of Epidemiology and Prevention Research
NIAAA
5635 Fishers Lane, Room 2081, MSC 9304
Bethesda, MD 20892-9304
Tel: +1 301 594 6231
Fax: +1 301 443 8614
Email: rbrreslow@mail.nih.gov

UTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R21)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism and the Office of Dietary Supplements invite applications for their nutrition and alcohol-related health outcomes (R21) grants. This R21 funding opportunity announcement supports research to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this R01 funding opportunity announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease.

This FOA will use the exploratory/developmental research grant (R21) mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-359 and PA-13-360, which use the R01 research project grant and the R03 small grant programme mechanisms, respectively. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-361 (replaces PA-10-241).

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 January 2017.

Posted date: 24 Sep 13

Award type: Directed grants to institutions, research groups etc

Award amount max: $275,000

Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-361

Eligibility profile
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Country of applicant institution: Any

Disciplines
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Addiction; Allied Health Professions; Cognitive Processes; Clinical Medicine; Nutrition & Dietetics; Primary Care; Preventive Medicine; Psychology; General Practice; Public Health, Health Services & Primary Care; Epidemiology; Alcoholism; Disease Models; Pathophysiology

Contact Details
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Division of Epidemiology and Prevention Research
NIAAA
5635 Fishers Lane, Room 2081, MSC 9304
Bethesda, MD 20892-9304
Tel: +1 301 594 6231
Fax: +1 301 443 8614
Email: rbreslow@mail.nih.gov

SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its screening and brief interventions in underage and young adult populations (R21) funding opportunity announcement. This announcement encourages research on screening and brief interventions to prevent or reduce alcohol use and alcohol related harms among underage and young adult populations. The R21 exploratory/developmental grant supports investigation of novel scientific ideas, new model systems, tools or technologies that have the potential for significant impact on biomedical or biobehavioural research.

This FOA will utilise the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-295 and PA-15-296, that solicit applications under the small research grant (R01) and exploratory/developmental (R03) award mechanisms, respectively.

Application budgets are limited to US$275,000 and the maximum project period is two years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-15-294 (replaces PA-12-030).

Closing date: 16 Feb 16

Deadline information: Applications due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October, until 8 May, 2018.
SCREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R03)

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its screening and brief alcohol interventions in underage and young adult populations funding opportunity announcement. This R03 funding announcement encourages research on screening and brief interventions to prevent and reduce alcohol use and alcohol related harms among underage and young adult populations.

This FOA will utilise the NIH small research grant (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-295 and PA-15-294, that solicit applications under the R21 and R01 mechanisms, respectively. Application budgets are up to US$50,000 per year in direct costs under a maximum project duration of up to two years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-15-296 (replaces PA-12-029).

Closing date: 16 Feb 16

Deadline information: Applications due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 May, 2018.

Posted date: 13 Jul 15

Award type: Directed grants to institutions, research groups etc

Award amount max: $100,000

Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-029

Eligibility profile

Country of applicant institution: Any

Disciplines

Screening of Drugs & Agents; Alcoholism

Contact Details

Tel: +1 301 402 9389
Email: shirleym@mail.nih.gov

CREENING AND BRIEF ALCOHOL INTERVENTIONS IN UNDERAGE AND YOUNG ADULT POPULATIONS (R03)

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its screening and brief alcohol interventions in underage and young adult populations funding opportunity announcement. This R03 funding announcement encourages research on screening and brief interventions to prevent and reduce alcohol use and alcohol related harms among underage and young adult populations.

This FOA will utilise the NIH small research grant (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-295 and PA-15-294, that solicit applications under the R21 and R01 mechanisms, respectively. Application budgets are up to US$50,000 per year in direct costs under a maximum project duration of up to two years. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-15-296 (replaces PA-12-029).

Closing date: 16 Feb 16

Deadline information: Applications due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 May, 2018.

Posted date: 13 Jul 15

Award type: Directed grants to institutions, research groups etc

Award amount max: $100,000

Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-029

Eligibility profile

Country of applicant institution: Any

Disciplines

Screening of Drugs & Agents; Alcoholism

Contact Details

Tel: +1 301 402 9389
Email: shirleym@mail.nih.gov
ENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R03)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their gene-environment interplay in substance use disorders (R03) funding opportunity announcement.

This announcement seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course and outcomes of substance and alcohol use disorders. Collaborations to combine data and enhance power are strongly encouraged. Proposals are expected to focus on the interplay of genetics and environment.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

This FOA uses the small grant programme (R03) and runs in parallel with two FOAs of identical scientific scope, PA-15-110, which solicits applications under the research project (R01) grant mechanism and PA-15-112, which solicits applications under the exploratory/developmental (R21) grant mechanism.

Direct costs are limited to US$50,000 per year with a maximum project period of two years.


Closing date: 16 Feb 16

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2017.

Posted date: 06 Feb 15

Award type: Directed grants to institutions, research groups etc

Award amount max: $100,000

Website:

Application form:

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse; Alcoholism; Medical Genetics

Contact Details

NIDA
NSC BG Room 5150
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 402 1908
Email: nw46w@nih.gov
GENE-ENVIRONMENT INTERPLAY IN SUBSTANCE USE DISORDERS (R21)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their gene-environment interplay in substance use disorders (R21) funding opportunity announcement.

This announcement seeks to stimulate and expand research on the interplay of genetic and environmental factors in the genesis, course and outcomes of substance and alcohol use disorders.

Proposals are expected to focus on the interplay of genetics and environment. Collaborations to combine data and enhance power are strongly encouraged.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

This FOA uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-110, which solicits applications under the research project (R01) grant mechanism and PA-15-111, which solicits applications under the small grant programme (R03) mechanism.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PA-15-112 (replaces PA-11-236).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2017.
Posted date: 06 Feb 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Award amount min: -
Award budget total: -

Eligibility profile
Country of applicant institution: Any
Disciplines
Medical Genetics; Drug & Substance Abuse; Alcoholism
Contact Details
NIDA
NSC BG Room 5150
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 402 1908
Email: nw46w@nih.gov
NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH SMALL GRANT PROGRAMME FOR NEW INVESTIGATORS (R03)
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its small grant programme for new investigators (R03). This R03 funding opportunity announcement supports pilot and developmental research with the intention of facilitating subsequent submission of an Individual research project grant (R01) application.

Budgets for direct costs of up to US$150,000 over a two-year period may be requested. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-348 (replaces PAR-10-275).

Closing date: 16 Feb 16
Deadline information: Submissions due by 5pm proposers’s local time, every 16 February, 16 June and 16 October until 8 September 2016.
Posted date: 12 Sep 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $150,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Craniofacial Disorders; Oral Medicine; Dental Health & Hygiene; Oral & Maxillofacial Surgery; Dentistry

EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R21)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its epidemiology and prevention in alcohol research grants. The goal of this R21 funding opportunity is to encourage the submission of investigator-initiated research grant applications to support research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of under-age drinking, alcohol-related harms, and alcohol use disorders. This mechanism will support investigation of novel scientific ideas or new model systems, tools or technologies that have the potential for significant impact on biomedical or biobehavioural research.

This funding opportunity announcement will utilise the NIH exploratory/developmental (R21) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-190, which solicits applications under the R01 research project grant mechanism,
A compilation of the Research Services of the Office of Research, Innovation & Development (ORID)

Issue 24: Volume 1b – Grants from NIH (January – March, 2016)

and PA-14-189, which solicits applications under the R03 small grant programme mechanism.

Direct costs are limited to US$275,000 over a maximum period of two years, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-14-188 (replaces PA-11-018).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation every 16 June, 16 November and 16 March until 8 September 2017.
Posted date: 28 Apr 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: -
Website:
http://grants.nih.gov/grants/guide/announcements/PA-14-188.html

Alcohol Use Disorders: Treatment, Services and Recovery Research (R21)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its alcohol use disorders: treatment, services and recovery research (R21) programme. This R21 funding opportunity announcement supports research on behavioural and pharmacological treatment for alcohol use disorders; organisational, financial and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; or the phenomenon of recovery from alcohol use disorders.

Applications will be accepted from domestic and foreign for-profit or non-profit organisations and public or private institutions. The total project period may not exceed two years. Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year. This programme will use the NIH exploratory/developmental (R21)

Application form:
http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Preventive Medicine; Alcoholism; Behavioural Medicine; Population Studies, Medical; Sociology; Allied Health Professions; Psychology; Addiction; Biomedical Engineering; Epidemiology; Public Health, Health Services & Primary Care; Economic & Social Environment; Medical Sociology; Patient Care & Education

Contact Details
NIHAA
Building 5635FL, Room 2083
5635 Fishers Lane
Rockville MD 20852
Tel: +1 301 402 6328
Email: mscott@mail.nih.gov
grant mechanism and runs in parallel with two programs of identical scientific scope: PA-13-160, which solicits applications under the R01 mechanism, and PA-13-161, which solicits applications under the R03 mechanism. PA-13-162 (replaces PA-10-102)

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 May 2016.
Posted date: 02 Apr 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000


---

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Primary Care; Health Systems, Administration; Public Health, Health Services & Primary Care; Experimental Psychology; Pharmacy & Pharmacology; General Practice; Drug & Substance Abuse; Allied Health Professions; Alcoholism; Cognitive & Behavioural Therapies; Psychology

**Contact Details**

NIAAA
6000 Executive Boulevard
Bethesda, MD 20892-7003
Tel: +1 301 443 0788
Email: falkde@mail.nih.gov

---

**Epidemiology of Drug Abuse (R03)**

NIH: National Institute on Drug Abuse

**Description:**
The National Institute on Drug Abuse invites applications for its epidemiology of drug abuse grants. This R03 funding opportunity announcement supports projects that enhance understanding of the nature, extent, distribution, aetiology, comorbidities and consequences of drug use, abuse and addiction across individuals, families, communities, and diverse population groups. Projects should aim to fill knowledge gaps related to changing patterns in drug use, associated factors and consequences in populations, including, but not limited to:

- individual, familial, and environmental factors associated with drug use;
- interplay of factors that exacerbate or mitigate risk for drug initiation, addiction, desistence, recovery, and relapse;
- co-occurring psychiatric conditions, behaviours and associated problems;
- indicators and mechanisms of risk, vulnerability, and health disparities among and between sub-populations;
- developmental and life course trajectories related to the aetiology and natural history of drug use;
- need for, access to, and utilisation of drug abuse prevention and treatment
services, and the social, community, and organisational factors that influence intervention development, availability, and effectiveness.

- public health impacts of the attitudes, availability, behaviours, and products, resulting from the shifting marijuana policy environment.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. This funding opportunity announcement uses the NIH small research grant (R03) award mechanism and runs in parallel with opportunities of identical scientific scope: PA-15-001, which solicits applications under the NIH exploratory and developmental grant (R21) mechanism, and PA-15-003, which solicits applications under the NIH research project grant (R01) mechanism.

Funding is worth up to US$50,000 per year for a maximum project period of two years.


Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2017.
Posted date: 06 Oct 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Website:

Application form:

Eligibility profile
Country of applicant institution: Any

Disciplines
Drug & Substance Abuse; Addiction; Compulsive Behaviour; Equal Educational Opportunity; Health Systems, Risk Management; Social Exclusion & Isolation; Public Health; Education; Aetiology; Social Work & Social Policy; Epidemiology; Prognosis & Natural History of Disease; Health Psychology; Sexual Risk Taking; Social Psychology; Poverty in Developing Countries; Social Aspects of Mental Health; Psychology; Public Health, Health Services & Primary Care; Primary Care

Contact Details
DESPR
National Institute on Drug Abuse, NIH/DHHS
6001 Executive Boulevard, Room 5185, MSC 9589
Bethesda, MD 20892-9589
Tel: +1 301 443 6504
Email: lopezmar@nida.nih.gov
Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its secondary analyses of existing alcohol epidemiology data (R03) grants. These R03 grants support investigator-initiated research projects that either analyse previously collected data in order to address key issues that have emerged from recent findings in alcohol epidemiology and prevention research, or develop new analytic techniques for conducting studies in alcohol epidemiology and prevention research. The goal is to enhance understanding of patterns of alcohol consumption and the epidemiology of alcohol-related problems.

This funding opportunity announcement uses the small grant programme (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-338 that encourages applications under the research project grant (R01) mechanism and PA-14-336 that encourages applications under the exploratory/developmental (R21) mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Grants are worth up to US$50,000 per year for direct costs over a maximum period of two years.
Ref: PA-14-337 (replaces PA-11-309).

Closing date: 16 Feb 16
Deadline information: New applications are invited between 24 September and 5pm local time of applicant organisation, 24 October 2014. After this, applications are invited on every 16 February, 16 June and 16 October until 8 September 2017.

Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-337.html


Eligibility profile
Country of applicant institution: Any

Disciplines
Population Studies, Medical; Epidemiology; Data Analysis; Economic & Social Environment; Alcoholism; Social Work & Social Policy; Ethnic Groups; Allied Health Professions; Aetiology; Diagnostic Sciences; Traumatology, Accidents & Injury; Public Health, Health Services & Primary Care; Primary Care

Contact Details
NIAAA
6000 Executive Boulevard
Willco Building
Bethesda, MD 20892-7003
Tel: +1 301 443 0633
Email: zhaw@mail.nih.gov
EHAVIOURAL OR SOCIAL INTERVENTION CLINICAL PLANNING GRANT (R34)
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its NIDCR behavioural or social intervention clinical planning grant (R34). These R34 grants support activities that include, but are not limited to:

• the development of the behavioural or social intervention manual and procedures for training interventionists;
• development of the clinical protocol that will guide a subsequent clinical trial;
• the tools for data management, participant safety and operational oversight;
• other activities to prepare for a subsequent clinical trial.

R34 applications preparing for a behavioural or social intervention study may involve human subjects as part of small-scale testing of the feasibility and acceptability of the interventions, measures, methods and training approaches.

Eligible applicants include domestic and foreign public or private institutions and non-profit or for-profit organisations.

Funding is worth up to US$150,000 for a period of maximum of one year.

PAR-14-342 (replaces PAR-11-338)

Closing date: 16 Feb 16

Deadline information: Applications open on 21 October 2014 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2017.

Posted date: 22 Sep 14

Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants

Award amount max: $150,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Biochemical Markers; Dental Health & Hygiene; Biological Markers & Sensor Mechanisms; Diagnostic Sciences; Drug Design; Clinical Medicine; Dentistry; Clinical Chemistry; Oral Medicine

Contact Details

National Institute of Dental and Craniofacial Research
1DEM, Room 634, MSC 4878
6701 Democracy Boulevard
Bethesda, MD 20892-4878
Tel: +1 301 594 4814
Email: dclark2@nidcr.nih.gov
RESEARCH TO ADVANCE VACCINE SAFETY (R21)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases, and Centres for Disease Control and Prevention invite applications for their research to advance vaccine safety (R21) funding opportunity announcement. This announcement supports research that will contribute to the overall understanding of vaccine safety. Studies should address scientific areas potentially relevant to vaccine safety such as:

- physiological and immunological responses to vaccines and vaccine components;
- how genetic variations affect immune or physiological responses that may impact vaccine safety;
- identification of risk factors biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines;
- creation or evaluation of statistical methodologies for analysing data on vaccine safety, including data available from existing data sources such as passive reporting systems;
- the application of genomic or molecular technologies to improve knowledge of vaccine safety.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-312, which solicits applications under the NIH research project grant (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Direct costs are limited to US$275,000 over a two-year period, and no more than US$200,000 may be requested in any year.

Ref: PA-15-313 (replaces PA-12-038)

Closing date: 16 Feb 16
Deadline information: Applications open on 16 September, 2015 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2018.
Posted date: 29 Jul 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: -

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Immunology; Immunisation Programmes & Vaccination

Contact Details
---------------------------------------------------------------
Tel: +1 240 627 3322
Email: bmulach@niaid.nih.gov
**MECHANISMS OF ALCOHOL AND NICOTINE CO-DEPENDENCE (R21)**

NIH: National Institute on Alcohol Abuse and Alcoholism

**Description:**
The National Institute on Alcohol Abuse and Alcoholism invites applications for its mechanisms of alcohol and nicotine co-dependence (R21) grants. This R21 funding opportunity announcement will support studies of neurobiological and behavioural mechanisms contributing to concurrent alcohol and nicotine co-addiction.

This FOA will use the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-194, which encourages applications under the R01 research project grants mechanism. Application budgets are limited to US$275,000 over a two-year period, with no more than US$200,000 in any year. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PA-13-193 (PA-09-098).

**Closing date:** 16 Feb 16
**Deadline information:** Deadlines by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2016.
**Posted date:** 15 Apr 13

**Award type:** Directed grants to institutions, research groups etc
**Award amount max:** $275,000
**Award amount min:** -
**Award budget total:** -
**Application form:** http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-193

**Eligibility profile**
Country of applicant institution: Any

**Disciplines**
Allied Health Professions; Primary Care; Biological Sciences; Alcoholism; Public Health, Health Services & Primary Care; Smoking & Tobacco; Biochemistry & Molecular Biology; Neurobiology; Behavioural Medicine; Psychology

**Contact Details**
Tel: +1 301 443 7600
Email: igrakalic@mail.nih.gov

---

**PILOT AND FEASIBILITY STUDIES IN PREPARATION FOR DRUG AND ALCOHOL ABUSE PREVENTION TRIALS (R34)**

NIH: National Institute on Drug Abuse

**Description:**
The National Institute on Drug Abuse and the National institute on Alcohol Abuse and Alcoholism invite applications for their pilot and feasibility studies in preparation for drug and alcohol abuse prevention trials (R34) funding opportunity announcement. This announcement supports pilot and feasibility
testing of innovative new, revised or adapted prevention intervention approaches to achieve the following: prevent or delay the initiation and onset of drug and alcohol use, the progression to problem use or alcohol and other substance use disorder; reduce drinking and driving, deaths related to impaired driving and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings. It also supports pre-trial feasibility testing for prevention services and systems research. Of particular interest are prevention interventions targeting the healthcare system.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$450,000 in direct costs, with up to US$225,000 in direct costs per year. The maximum project period is three years.

Ref: PA-15-177 (reissue of PA-12-171).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 May 2018.

ENAL FUNCTION AND CHRONIC KIDNEY DISEASE IN AGEING (R21)
NIH: National Institute on Aging

Description:
The National Institute on Aging invites grant applications for renal function and chronic kidney disease in ageing. This R21 funding opportunity announcement funds basic, clinical and translational research on chronic kidney disease and its consequences in ageing and in older persons. Applications should focus on:

- biology and pathophysiology of CKD in animal models;
- aetiology and pathophysiology of CKD in older adults;

Posted date: 08 Apr 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $450,000
Award amount min: -
Award budget total: -

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Alcoholism; Drug & Substance Abuse; HIV/AIDS; Preventive Medicine

Contact Details
----------------------------------------------
NIDA NSC BG Room 5166
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 8892
Email: lloydj2@nida.nih.gov
• epidemiology and risk factors for the development of CKD with advancing age;
• diagnosis, medical management and clinical outcomes of CKD in this population.

This funding opportunity announcement will use the exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-211, which encourages applications under the NIH research project grant (R01) mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in any year. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PA-12-210 (replaces PA-09-166).

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 January 2016.
Posted date: 14 Jun 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-210.html

PAIN IN AGEING (R21)
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications under its pain in ageing programme. This funding opportunity announcement encourages exploratory and developmental research grant (R21) applications from institutions and organisations that propose to study pain from an ageing perspective, including studies of older populations, studies of age differences and age-related changes in pain processes and experiences, and studies of pain treatment and management in older adults. This FOA particularly encourages studies on:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-210

Eligibility profile
Country of applicant institution: Any

Disciplines
Epidemiology; Aetiology; Osteoporosis & Other Bone Diseases; Clinical Medicine; Blood Diseases; Medical & Diagnostic Tests; HIV/Aids; Geriatrics & Gerontology; Biological Markers & Sensor Mechanisms; Public Health, Health Services & Primary Care; Nephrology & Kidneys; Primary Care; Hormones & Endocrinology; Pathophysiology; Translational Medicine

Contact Details
Division of Geriatrics and Clinical Gerontology
National Institute on Aging
7201 Wisconsin Avenue
Gateway Building, Room 3C307
Bethesda, MD 20892
Tel: +1 301 496 6761
Email: susan.zieman@nih.gov
• mechanisms and predictors of pain experience in ageing;
• development and evaluation of pain assessment tools for older adults or older model organisms;
• development and evaluation of pain management strategies in older adults, with particular attention to the challenges associated with treating pain in patients with multiple morbidities.

This FOA will use the NIH exploratory/developmental research grant (R21) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-058, that encourages applications under the research project grant (R01) grant mechanism, and PA-13-060, that encourages applications under the R03 small research grants mechanism. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organizations. PA-13-059 (replaces PA-09-194)

Closing date: 16 Feb 16
Deadline information: Applications are due every February 16, June 16 and October 16 until 8 January 2016.

PAIN IN AGEING (R03)
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications under its pain in ageing programme. This funding opportunity announcement encourages small grant (R03) applications from institutions and
organisations that propose to study pain from an ageing perspective, including studies of older populations, studies of age differences and age-related changes in pain processes and experiences, and studies of pain treatment and management in older adults. This FOA particularly encourages studies on:

- mechanisms and predictors of pain experience in ageing;
- development and evaluation of pain assessment tools for older adults or older model organisms;
- development and evaluation of pain management strategies in older adults, with particular attention to the challenges associated with treating pain in patients with multiple morbidities.

This FOA will use the NIH R03 small research grants award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-058, that encourages applications under the R21 exploratory/developmental grant mechanism, and PA-13-059, that encourages applications under the research project grant (R01) mechanism. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Direct costs are limited to US$50,000 per year for a maximum of US$100,000 direct costs over a two-year project period. The maximum project period is two years. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PA-13-060 (replaces PA-09-195)

Closing date: 16 Feb 16
Deadline information: Applications are due every February 16, June 16 and October 16 until 8 January 2016.
Posted date: 27 Dec 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-060

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Chronic Pain; Primary Care; Human Physiology; Biochemistry & Molecular Biology; Radiology & Medical Imaging; Biological Sciences; Psychology; Pain Management; Public Health, Health Services & Primary Care; Behavioural Medicine; Biochemical Markers; Psychology of Ageing; Clinical Medicine; Geriatrics & Gerontology

Contact Details
----------------------------------------------
NIA
Building 31, Room 5C27
31 Center Drive, MSC 2292
Bethesda, MD 20892
Tel: +1 301 496 9350
Fax: chenw@nia.nih.gov
BEHAVIOURAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R34)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the Office of Behavioral and Social Sciences Research invite applications for their behavioural and integrative treatment development (R34) grants. The aim of this R34 programme is to develop and test behavioural and integrative treatments for drug and alcohol abuse and dependence. Research will test efficacy, conduct clinical trials, examine mechanisms of behaviour change, determine dose-response, optimise combinations, or ascertain best sequencing of behavioural, combined, sequential, or integrated behavioural and pharmacological treatments in the following circumstances:

- drug abuse treatment interventions in diverse settings;
- drug abuse treatment and adherence interventions for use in primary care;
- drug abuse treatment and adherence interventions that use technologies to boost effects and increase implementability;
- interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment;
- interventions to promote adherence to drug abuse treatment, HIV and addiction medications;
- interventions to treat chronic pain.

Research of interest includes but is not limited to Stage II and Stage III efficacy research.

This funding opportunity announcement will use the R34 award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-079, which solicits applications under the R01 research project grant mechanism.

Direct costs are limited to US$450,000 over three years, with no more than US$225,000 in direct costs allowed in any single year. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. PA-13-078 (replaces PA-10-013).

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 January 2016.
Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-078

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Primary Care; Medical Sociology; Cognitive Processes; Psychology; Public Health, Health Services & Primary Care; Molecular Genetics; Allied Health Professions; Neurobiology; Biological Sciences; Neuroscience; Drug & Substance Abuse; Sociology; Cognitive & Behavioural Therapies; Alcoholism; Physiology; Behavioural Medicine; Population Studies, Medical; Counselling & Therapy; Mental Illness; General Practice
EI CLINICAL STUDY PLANNING GRANT PROGRAMME (R34)
NIH: National Eye Institute

Description:
The National Eye Institute invites applications for its clinical study planning grant programme (R34). This R34 funding opportunity announcement will facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed manual of procedures (MOP) for a large-scale clinical trial or epidemiologic study. Funding may support the development of an MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential.

Direct costs are limited to US$150,000 per year and projects may not exceed two years. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PAR-13-073 (replaces PAR-10-017).

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 January 2016.
Posted date: 09 Jan 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $300,000

Award amount min: -
Award budget total: -

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-073

Eligibility profile
Country of applicant institution: Any

Disciplines
Epidemiology; Eye Diseases; Sensory Systems; Diagnostic Sciences; Vision Science; Drug Design

Contact Details
Division Extramural Research
NEI
5635 Fishers Lane, Suite 1300, MSC 9300
Bethesda, MD 20892-9300
Tel: +1 301 451 2020
Fax: +1 301 402 0528
Email: everettd@mail.nih.gov
**Description:**
The National Institute of Dental and Craniofacial Research invites proposals for its small research grants for data analysis and statistical methodology applied to genome-wide data. This R03 funding opportunity announcement will support meritorious research projects that involve secondary data analyses or development of statistical methodology using existing genome-wide data, relevant to human dental or craniofacial conditions or traits. Development of statistical methodology appropriate for analysing genome-wide data, relevant to human dental or craniofacial conditions or traits, may also be proposed.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

Up to US$200,000 is available per year for direct costs, given that the total project budget does not exceed US$300,000 over a maximum project period of two years. PAR-13-044 (replaces PAR-10-041).

**Closing date:** 16 Feb 16
**Deadline information:** Applications due by 5pm local time of applicant organisation on deadline dates. Deadlines on: 16 February 2016, 16 June 2016, 16 October 2016, and repeated annually.
SELECTED TOPICS IN TRANSFUSION MEDICINE (R21)

NIH: National Heart, Lung and Blood Institute

Description:
The National Heart, Lung and Blood Institute invites applications for its selected topics in transfusion medicine (R21) programme. This R21 funding opportunity announcement will study topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Specifically, research focused on improving blood donor health, the safety and availability of blood products and improving the practice of transfusion medicine is critical to public health. Research designed to better understand the determinants of transfusion-associated adverse events and how to best minimise transfusion risks is also important. Research is also needed to maintain an adequate blood supply by minimising risks associated with the donation process and developing enhanced recruitment and retention programmes.

This FOA will use the NIH exploratory/developmental R21 grant mechanism and runs in parallel with an FOA of identical scope, PAR-13-026, that encourages applications under the R01 mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,00 in direct costs allowed in any single year. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PAR-13-025 (replaces PAR-10-033).

Closing date: 16 Feb 16
Deadline information: Applications due every 16 February and 16 October until 8 January 2017.
Posted date: 26 Nov 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine; Blood, Blood Products & Transfusions

Contact Details

Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Rockledge II, MSC 7950
6701 Rockledge Drive
Bethesda, MD 20892-7950
Tel: +1 301 435 0065
Fax: +1 301 480 0867
Email: zousn@nhlbi.nih.gov
HOME AND FAMILY BASED APPROACHES FOR THE PREVENTION OR MANAGEMENT OF OVERWEIGHT OR OBESITY IN EARLY CHILDHOOD (R21)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases, the National Heart, Lung and Blood Institute, the Office of Behavioral and Social Sciences Research and the Office of Disease Prevention invite R21 applications for their home and family based approaches for the prevention or management of overweight or obesity in early childhood programme. This R21 is for applications for exploratory pilot or feasibility studies or small clinical trials that test novel home or family based interventions for the prevention or management of overweight in infancy and early childhood. Tested interventions can use behavioural, environmental or other relevant approaches. Applications should focus on infants and young children and emphasise the role of home environment and the influence of family members and parents within that environment. The direct goal of this initiative is to fund research that will advance knowledge for innovative approaches to the prevention and management of overweight in children less than six years of age, with potential future translation to applications either in the home or linked to community settings.

This FOA will utilise the R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-153, that encourages applications under the R01 mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PA-13-154 (replaces PA-10-128).

Closing date: 16 Feb 16
Posted date: 25 Mar 13
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-154

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Primary Care; Public Health, Health Services & Primary Care; Nutrition & Dietetics; Paediatrics; Social Work & Social Policy; Obesity; Maternal Health; Social Programmes; Child Protection & Welfare

Contact Details
-----------------------------------------------
Division of Digestive Diseases and Nutrition
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Room 673
Bethesda, MD 20892-5450
Tel: +1 301 451 8354
Fax:+1 301 480 8300
Email: robert.kuczmarski@nih.gov

572 | A compilation of the Research Services of the Office of Research, Innovation & Development (ORID)
RESEARCH ON HEARING HEALTHCARE (R21)
NIH: National Institute on Deafness and Other Communication Disorders

Description:
The National Institute on Deafness and Other Communication Disorders invites applications for its research on hearing healthcare (R21) grants. This R21 funding opportunity announcement supports research leading to accessible and affordable hearing healthcare. The overarching emphasis is on the acquisition of knowledge that can be rapidly translated into new or enhanced approaches for access, assessment or interventions in order to deliver better hearing healthcare outcomes. Applications should seek quality approaches that are effective, affordable and deliverable to those who need them as well as implementable and sustainable in settings beyond the research environment.

This funding opportunity announcement will use the R21 exploratory/developmental research grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-091, which encourages applications under the R01 research project grant mechanism.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any single year.

Ref: PA-14-090 (replaces PA-10-254).

Closing date: 16 Feb 16

Deadline information: Applications due by 5pm proposer’s local time, every 16 February, 16 June and 16 October until 8 May 2017.

Posted date: 06 Feb 14

Award type: Directed grants to institutions, research groups etc

Award amount max: $275,000

Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-090.html

Application form: http://www.grants.gov/web/grants/applicant-packages/download-application-package.html#download=true&oppNum=PA-14-090

Eligibility profile

Country of applicant institution: Any

Disciplines

Health Economics; Clinical Decision-making & Analysis; Health Systems Policy; Social Work & Social Policy; Health Systems; Health Systems, Consumer Choice; Quality of Care; Standards of Care; Sensory Systems; Hearing & Otology; Economics & Econometrics; Access to Health Care

Contact Details

NIDCD
6120 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 402 3458
Email: donahuea@nidcd.nih.gov
EUROBIOLOGY OF MIGRAINE (R21)
NIH: National Institute of Neurological Disorders and Stroke

Description:
A total of five institutes and offices of the NIH invite applications for their neurobiology of migraine grants. These R01 grants support research elucidating the mechanisms underlying migraine; expanding our current knowledge of the role of genetic, physiological, biopsychosocial and environmental influences in migraine susceptibility and progression; and exploring new therapeutic targets and therapies for acute migraine management and longer term prevention.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

This FOA utilises the R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-068, that encourages applications under the R01 mechanism. Applicants may request support for up to two years. The combined budget for direct costs for this period may not exceed US$275,000. No more than US$200,000 may be requested in any single year.

Ref: PA-14-069 (replaces PA-10-259).
Closing date: 16 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 16 February, 16 June and 16 October until 8 May 2017.
Posted date: 14 Jan 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-00-069.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Biological Sciences; Physiology; Human Biological Sciences; Neurobiology; Headaches; Neurology

Contact Details
Tel: +1 301 451 4460
Email: porterl@ninds.nih.gov

EARLY-CAREER AWARD IN CHEMISTRY OF DRUG ABUSE AND ADDICTION (R21/R33)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its early-career award in chemistry of drug abuse and addiction (R21/R33). This R21/R33 funding opportunity announcement seeks to facilitate the entry of new-to-NIH investigators into basic chemistry research applied to drug abuse and addiction.

Direct costs are limited to US$250,000 over a R21 two-year period, with a maximum of
US$200,000 allowed in any single year. The R33 award phase will be limited to US$250,000 in direct costs per year. The total project period for an application submitted in response to this funding opportunity may not exceed four years. Awards will support milestone driven exploratory/feasibility proof of concept studies (R21 phase, up to two years), with possible rapid transition to expedited development (R33 phase, up to three years, depending upon the requested period for the R21 phase). Eligible organisations include domestic and foreign public and private non-profit organisations and for-profit organisations. PAR-13-350 (replaces PAS-10-274).

Closing date: 16 Feb 16
Deadline information: Submissions due by 5pm proposers’s local time, every 16 February, 16 June and 16 October until 8 September 2016.
Posted date: 12 Sep 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $1,000,000
Award amount min: -
Award budget total: -


Eligibility profile
Country of applicant institution: Any

Disciplines
Addiction; Biological Sciences; Public Health, Health Services & Primary Care; Clinical Chemistry; Psychology; Primary Care; Alcoholism; Neurobiology; Drug & Substance Abuse

Contact Details
Division of Basic Neuroscience and Behavioral Research
NIDA
6001 Executive Boulevard
Bethesda, MD 20892-9555
Tel: +1 301 443 9800
Email: boughk@mail.nih.gov

STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R03)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its studies in neonatal resuscitation (R03) grants. These R03 grants support collaborative research projects on a wide range of topics related to neonatal resuscitation.

Projects should help develop strategies to deliver highest quality of healthcare to newborn infants and children with utmost safety and effectiveness. Projects may relate to the epidemiology of various domains of medical errors and consequent patient harm, assessing the factors at various levels that contribute to such errors, and intervention strategies at individual, systems and institutional-levels to help reduce and eliminate medical errors.
Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This funding opportunity utilises the R03 mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-350 that encourages applications under the R01 research project grant mechanism and PA-14-349 that encourages applications under the R21 exploratory or developmental grant mechanism.

Application budgets are limited to US$50,000 in direct costs per year over a maximum period of two years.

Ref: PA-14-351 (replaces PAR-11-223).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation on 16 February, 16 June and 16 October until 8 January 2018.
Posted date: 29 Sep 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Website:
Application form:
http://www.grants.gov/web/grants/applicant-package.html#download=true&oppNum=PA-14-351

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Paediatrics; Respiratory Medicine; Cardiology; Foetal Health & Prenatal Development; Neonatal Disorders; Obstetrics & Gynaecology; Allied Health Professions; Clinical Medicine

Contact Details
----------------------------------------------
NICHHD
Building 31, Room 2A32
MSC 2425
31 Center Drive
Bethesda, MD 20892-2425
Email: +1 301 435 6873
Email: kosomari@mail.nih.gov

STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R21)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its studies in neonatal resuscitation (R21) grants. These R21 grants support collaborative research projects on a wide range of topics related to neonatal resuscitation.

Projects should help develop strategies to deliver highest quality of healthcare to newborn infants and children with utmost safety and effectiveness. Projects may relate to the epidemiology of various domains of medical errors and consequent patient harm, assessing the factors at various levels that contribute to such errors, and intervention strategies at individual, systems and
institutional-levels to help reduce and eliminate medical errors.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This funding opportunity uses the R21 exploratory and developmental grant mechanism, and runs in parallel with two opportunities of identical scientific scope: PA-14-351, which solicits applications under the R03 small grant programme mechanism, and PA-14-350, which solicits applications under the R01 research project grant mechanism.

Application budgets are limited to US$275,000 over a maximum of two years, and no more than US$200,000 may be requested in a single year.

Ref: PA-14-349 (replaces PAR-11-224).

Closing date: 16 Feb 16
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organisation on every 16 February, 16 June and 16 October until 8 January 2018.
Posted date: 29 Sep 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration

Award amount max: $275,000
Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-350.html
Application form: http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
*****************************************************************************
Country of applicant institution: Any

Disciplines
*****************************************************************************
Neonatal Disorders; Allied Health Professions; Clinical Medicine; Obstetrics & Gynaecology; Paediatrics; Respiratory Medicine; Foetal Health & Prenatal Development; Cardiology

Contact Details
*****************************************************************************
NIH: National Institute of Child Health and Human Development
Building 31, Room 2A32
MSC 2425
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 435 6873
Email: kosomari@mail.nih.gov

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL, AND PAEDIATRIC CARE (R21)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for its patient safety in the context of perinatal, neonatal, and paediatric care (R21) grants. The purpose of this R21 funding opportunity announcement is to encourage a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and paediatric care both in routine hospital settings and in the intensive care units. The FOA welcomes applications related
to the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems and institutional levels to help reduce and eliminate medical errors. It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness.

This FOA will utilise the R21 mechanism and runs in parallel with two FOAs of identical scientific scope, PAR-14-312 that encourages applications under the R01 research grant programme mechanism and PAR-14-313 that encourages applications under the R03 small grant programme mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are limited to direct costs of up $275,000 over a two-year project period and no more than $200,000 may be requested in any one year.

Ref: PA-14-311 (replaces PAR-11-227).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2017.
Posted date: 07 Aug 14

Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-311.html
Application form: http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-311

Eligibility profile
Country of applicant institution: Any

Disciplines
Midwifery; Maternal Health; Paediatrics; Family Health; Pregnancy & Birth; Public Health, Health Services & Primary Care; Clinical Medicine; Women’s Health; Epidemiology; General Practice; Nursing; Primary Care; Neonatal Disorders; Patient Care & Education; Obstetrics & Gynaecology; Quality of Care; Paediatric Nursing

Contact Details
NIH: National Institute of Child Health and Human Development
Building 31, Room 2A32
MSC 2425
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 435 6873
Email: kosomari@mail.nih.gov

PATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R21)
NIH: National Cancer Institute

Description:
The National Cancer Institute and the National Institute of Environmental Health Sciences invite applications for their spatial uncertainty: data, modeling and communication (R21) grants. This R21
A compilation of the Research Services of the Office of Research, Innovation & Development (ORID)

S

PATIAL UNCERTAINTY: DATA, MODELLING AND COMMUNICATION (R03)
NIH: National Cancer Institute

Description:
The National Cancer Institute and the National Institute of Environmental Health Sciences invite applications for their spatial uncertainty: data, modelling and communication (R03) grants. This R03 funding opportunity announcement supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualise the nature and consequences of spatial uncertainty.

Award amount max: $275,000

Eligibility profile
Country of applicant institution: Any
Disciplines
Public Health, Health Services & Primary Care; Informatics & Big Data; Bioinformatics; Preventive Medicine; Demography; Social Work & Social Policy; Health Informatics; Primary Care; Computer Science & Informatics; Libraries & Information Science; Epidemiology; Population Studies, Medical; Health Systems, Risk Management; Disease Control; Prognosis & Natural History of Disease

Contact Details
NCI
6116 Executive Boulevard, Room 504
Bethesda, MD 20852
Tel: +1 240 276 6851
Email: li.zhu@nih.gov

Funding opportunity announcement supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualise the nature and consequences of spatial uncertainty.

This FOA uses the NIH exploratory and developmental grant (R21) mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-010 and PA-15-011, that solicit applications under the research project grant (R01) award and the small grant (R03) award mechanisms, respectively. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Funding is worth up to US$275,000 over a maximum two-year project period.


Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation, every 16 February, 16 June and 16 October until 8 January 2018.
Posted date: 13 Oct 14
Award type: Directed grants to institutions, research groups etc
This FOA uses the NIH small grant (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-009 and PA-15-010, that solicit applications under the exploratory and developmental grant (R21) and the research project grant (R01) award mechanisms, respectively. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Funding is worth up to US$50,000 per year over a maximum two-year project period.


Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation, every 16 February, 16 June and 16 October until 8 January 2018.
Posted date: 13 Oct 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000


Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Demography; Informatics & Big Data; Primary Care; Preventive Medicine; Public Health, Health Services & Primary Care; Prognosis & Natural History of Disease; Libraries & Information Science; Epidemiology; Social Work & Social Policy; Computer Science & Informatics; Population Studies, Medical; Health Systems, Risk Management; Disease Control; Bioinformatics; Health Informatics

Contact Details
----------------------------------------------
NCI
6116 Executive Boulevard, Room 504
Bethesda, MD 20852
Tel: +1 240 276 6851
Fax: li.zhu@nih.gov

EGAL, ETHICAL AND SOCIAL IMPLICATIONS OF GENOMIC RESEARCH EXPLORATORY/DEVELOPMENTAL RESEARCH PROGRAMME (R21)
NIH: National Human Genome Research Institute

Description:
A total of eight participating institutes and centres of the National Institutes of Health invite applications for their ethical, legal and social implications of genomic research exploratory/developmental research programme. The purpose of this R21 funding opportunity is to study the ethical, legal and social implications of human genome research. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

The specific areas of interest for this FOA are:

- genomic research;
- genomic health care;
- broader societal issues;
• legal, regulatory and public policy issues.

This FOA will use the NIH exploratory/developmental research programme (R21) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-277 that encourages applications under the small grant programme (R03) mechanism PA-14-276 that encourages applications under the regular research grant (R01) mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are limited to no more than US$275,000 in direct costs for up to two years, with no more than US$200,000 in direct costs in a single year.

Ref: PA-14-278 (replaces PA-11-251).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2017.
Posted date: 11 Jul 14
Award type: Directed grants for individual investigators
Award amount max: $275,000

Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-278.html
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Professional Ethics; Public Health & Medical Law; Biological Sciences; Medical Sociology; Sociology; Diagnostic Sciences; Medical Genetics; Genomics; Medical & Health Ethics; Philosophy; Law; Human Genome; Primary Care; Public Health, Health Services & Primary Care; Cancer Genetics; Research Ethics & Misconduct; Ethical Use of Technology

Contact Details
National Human Genome Research Institute
National Institutes of Health
Building 31, Room 4B09
31 Center Drive MSC 2152
9000 Rockville Pike
Bethesda MD 20892 2152
Tel: +1 301 402 4997
Email: jb40m@nih.gov

REGNANCY IN WOMEN WITH DISABILITIES (R21)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Development invites applications for its pregnancy in women with disabilities (R21) grants. The purpose of this R21 funding opportunity announcement is to encourage research investigating the incidence, course and outcomes of pregnancy among women with disabilities. Areas of interest also include studies to inform preconceptional and antenatal counselling and strategies for
addressing barriers to prenatal care, and management of pregnancy, the puerperium, and the transition to parenthood in order to optimise outcomes for women with physical, intellectual and developmental, or sensory disabilities and their families. Applicants are encouraged to include women with disabilities and members of the community in the design and conduct of their research.

This FOA will utilise the NIH exploratory/developmental grant (R21) award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-355 that solicits applications under the research project grant (R01) mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US$275,000 over a two-year project period. No more than US$200,000 may be requested in any single year.

Ref: PAR-14-354 (replaces PAR-11-259).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 January 2017.
Posted date: 02 Oct 14

Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile

Country of applicant institution: Any

Disciplines

Allied Health Professions; Women’s Health; Clinical Medicine; Public Health, Health Services & Primary Care; Reproductive Medicine; Obstetrics & Gynaecology; Primary Care; Neonatal Disorders; Family Health; Reproduction & Fertility; Care for Disabled People; Pregnancy & Birth; Diagnostic Sciences; Sociology; Maternal Health

Contact Details

NICHD
Building 31, Room 2A32
MSC 2425
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 435 7909
Email: higginsr@mail.nih.gov

MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R21)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its molecular and cellular substrates of complex brain disorders (R21) grants. This funding opportunity announcement uses the R21 mechanism to encourage new research activities directed toward the discovery of the impact of
alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. By using the R21 activity code, this funding opportunity seeks to foster the introduction of novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential to advance research at the interface between cellular and molecular mechanisms and that address gaps in understanding the biological mechanisms behind putative disease associated processes with the goal of accelerating progress in emerging research areas relevant to complex brain disorders.

This FOA uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-309 that encourages applications under the NIH research project (R01) grant mechanism. Direct costs are limited to US$275,000 over a two year period, with no more than US$200,000 in direct costs in any one year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PAR-14-310 (replaces PAR-11-300).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2017.

Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-310.html
Application form: http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PAR-14-310

Eligibility profile
-------------------------------------------------------------
Country of applicant institution: Any

Disciplines
-------------------------------------------------------------
Cell & Developmental Biology; Neurobiology; Endocrine & Neuroendocrine Cancers; Neuroendocrinology; Public Health, Health Services & Primary Care; Intellectual Disabilities; Cognitive Processes; Psychology; Pharmacy & Pharmacology; Neuropharmacology; Nucleus & Organelles; Diagnostic Sciences; Neuroanatomy; Biochemistry & Molecular Biology; Electrophysiology; Muscle Diseases; Primary Care; Mental Illness; Neurology; Central Nervous System; Allied Health Professions; Biological Sciences; Neuroscience; Clinical Medicine

Contact Details
-------------------------------------------------------------
NIMH
6001 Executive Blvd
Room 8184 MSC 9663
Bethesda, Maryland 20892
Tel: +1 301 443 5288
Email: casanuma@mail.nih.gov
DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R03)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and the Office of Rare Diseases invite applications for the development of appropriate formulations and paediatric drug delivery systems (R03) grants. This R03 funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Development and testing of novel paediatric drug delivery systems is also part of this initiative. This FOA also encourages development of novel drug delivery systems in the paediatric population. Investigators are encouraged to explore approaches and concepts new to the area of paediatric formulation development, testing and use of newly developed techniques superior to the ones currently used in the field.

This funding opportunity announcement will use the NIH research project R03 grant mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-325, which solicits applications under the research project grant (R01) mechanism and PAR-13-326, which solicits applications under the exploratory/developmental research grant award (R21) mechanism.

Application budgets are limited to US$100,000 over a two-year project period, with no more than US$50,000 in direct costs per year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-344 (replaces PAR-11-302).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 16 February, 16 June and 16 October until 8 September 2016.
Posted date: 05 Sep 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-344

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Allied Health Professions; Pharmacy & Pharmacology; Methods of Drug Delivery; Drug Design; Diagnostic Sciences; Clinical Medicine; Paediatrics

Contact Details
---------------------------------------------------------------
NICHD
Obstetric and Paediatric Pharmacology and Therapeutics Branch
6100 Executive Boulevard, Room 4A01C, MSC 7510
Bethesda, MD 20852
Tel: +1 301 496 5589
Email: gg65m@nih.gov
DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R21)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

**Description:**
The National Institute of Child Health and the National Institute on Deafness and Other Communication Disorders invite applications for the development of appropriate formulations and paediatric drug delivery systems (R21) grants. This R21 funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Development and testing of novel paediatric drug delivery systems is also part of this initiative.

This funding opportunity announcement will use the NIH research project R21 grant mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-325, which solicits applications under the research project grant (R01) mechanism and PAR-13-344, which solicits applications under the small grant award (R03) mechanism.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs per year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-326 (replaces PAR-11-303)

**Closing date: 16 Feb 16**
**Deadline information: Applications due by 5pm proposer’s local time, every 16 February, 16 June and 16 October until 8 September 2016.**
**Posted date: 05 Sep 13**
**Award type: Directed grants to institutions, research groups etc**
**Award amount max: $275,000**
**Application form:** [http://apply07.grants.gov/apply/GetGrantFro mFedgrants?opportunity=PAR-13-326](http://apply07.grants.gov/apply/GetGrantFro mFedgrants?opportunity=PAR-13-326)

**Eligibility profile**
----------------------------------------------
Country of applicant institution: Any

**Disciplines**
----------------------------------------------
Paediatrics; Pharmacy & Pharmacology; Drug Design; Methods of Drug Delivery; Diagnostic Sciences; Allied Health Professions; Clinical Medicine

**Contact Details**
----------------------------------------------
NICHD
Obstetric and Paediatric Pharmacology and Therapeutics Branch
6100 Executive Boulevard, ROom 4A01C, MSC 7510
Bethesda, MD 20852
Tel: +1 301 496 5589
Email: gg65m@nih.gov
SYSTEMS SCIENCE AND HEALTH IN BEHAVIOURAL AND SOCIAL SCIENCES (R21)

NIH: Office of the Director

Description:
A total of 11 participating institutes of the National Institutes for Health invite applications for their systems science and health in the behavioural and social sciences (R21) grants. This R21 funding opportunity announcement seeks to increase the breadth and scope of topics that can be addressed with systems science methodologies. This FOA calls for research projects that are applied or basic in nature, including methodological and measurement development, have a human behavioural or social science focus and employ methodologies suited to addressing the complexity inherent in behavioural and social phenomena, referred to as systems science methodologies. Additionally, this FOA seeks to promote interdisciplinary collaboration among health researchers and experts in computational approaches to further the development of modelling- and simulation-based systems science methodologies and their application to important public health challenges. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. This funding opportunity announcement uses the NIH exploratory/developmental R21 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-15-048 that solicits applications under the research project grant award (R01) mechanism. Application budgets are limited to US$275,000 over the two-year R21 period, with no more than US$200,000 in any year. The maximum project period is two years.


Closing date: 16 Feb 16
Deadline information: Applications are invited between 16 January and 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 January 2018.
Posted date: 24 Nov 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000


Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Social Sciences; Research Methods in Sociology; Behavioural Studies & Social Problems

Contact Details
----------------------------------------------
NCI
BG 9609 Room 3E602
9609 Medical Centre DR
Rockville MD 20850
Tel: +1 301 402 1146
Email: wireley@mail.nih.gov
HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIOURS IN CHILDREN AND ADOLESCENTS (R21)

NIH: National Institute of Nursing Research

Description:
A total of two institutes and offices of the NIH invite applications for their healthy habits: timing for developing sustainable healthy behaviours in children and adolescents (R21) grants. This R21 funding opportunity announcement encourages applications that employ innovative research to identify mechanisms of influence and promote positive sustainable health behaviour in children and youth up to the age of 21. Applications to promote positive health behaviour should target social and cultural factors, including schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and mass media. Topics to be addressed in this announcement include:

- effective, sustainable processes for influencing young people to make healthy behaviour choices;
- identification of the appropriate stage of influence for learning sustainable lifelong health behaviours;
- the role of technology and new media in promoting healthy behaviour;
- identification of factors that support healthy behaviour development in vulnerable populations, identification of barriers to healthy behaviours;
- identification of mechanisms and mediators that are common to the development of a range of habitual health behaviours.

Given the many factors involved in developing sustainable health behaviours, applications from multidisciplinary teams are strongly encouraged. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PA-14-176 (Reissue of PA-11-329).

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 May 2017.
Posted date: 22 Apr 14
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile
--------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------
Primary Care; Health Psychology; Social Psychology; Maternal Health; Child Development; Psychology; Communication Studies; Media Studies; Social Aspects of Mental Health; Child Protection & Welfare; Group Dynamics & Collective Behaviour; Education; Food Science; Sociology; Social Behaviour & Attitudes; Public Health; Health Services & Primary Care; Popular Culture; Behavioural Medicine; Medical Education; Health Education; Social Work & Social Policy; Communication & Media Studies; Adolescent Paediatrics; Behavioural Studies & Social Problems; Malnutrition; Public Health; Mental Health; Computer, Internet & Mobile Gaming; Social Programmes; Health Promotion; Children’s Literature; Dentistry
IOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R21)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for its biomarkers: bridging paediatric and adult therapeutics (R21) grants. This R21 funding opportunity announcement invites applications that propose adapting adult biomarkers to children. This would include the application and validation of biomarkers developed in adults to paediatric diagnosis, prognosis, and estimation of disease progression, toxicity and response to therapy. Projects supported will be confined to those biomarkers that correlate with a clinical observation, have been extensively studied in adults, and for which there is solid evidence that they have paediatric applications. Discovery of new biomarkers for use in new drug development or in preclinical studies are not part of this FOA.

This funding opportunity announcement will use the NIH exploratory/developmental research grant award (R21) mechanism and runs in parallel with two FOAs of identical scientific scope: PAR-13-299, which solicits applications under the small grants programme (R03) mechanism and PAR-13-296, which solicits applications under the research project grant (R01) mechanism.

Direct costs are limited to US$275,000 over two years, with no more than US$200,000 in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-295 (replaces PAR-11-324).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 16 February, 16 June and 16 October until 8 September 2016.
Posted date: 02 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Clinical Medicine; Drug Design; Medical Instrumentation; Medical & Diagnostic Tests; Biochemical Markers; Biological Markers & Sensor Mechanisms; Diagnostic Sciences; Paediatrics

Contact Details
Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R03)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for its biomarkers: bridging paediatric and adult therapeutics (R03) grants. This R03 funding opportunity announcement invites applications that propose adapting adult biomarkers to children. This would include the application and validation of biomarkers developed in adults to paediatric diagnosis, prognosis, and estimation of disease progression, toxicity and response to therapy. Projects supported will be confined to those biomarkers that correlate with a clinical observation, have been extensively studied in adults, and for which there is solid evidence that they have paediatric applications. Discovery of new biomarkers for use in new drug development or in preclinical studies are not part of this FOA.

This funding opportunity announcement will use the NIH small grants programme (R03) mechanism and runs in parallel with two FOAs of identical scientific scope: PA-13-296, which solicits applications under the research project grants (R01) mechanism and PA-13-295, which solicits applications under the exploratory/developmental grant (R21) mechanism. Applicants may request up to US$50,000 per year in direct costs for a maximum of two years.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-299 (replaces PAR-11-323).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 16 February, 16 June and 16 October until 8 September 2016.
Posted date: 02 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Drug Design; Biochemical Markers; Clinical Medicine; Medical & Diagnostic Tests; Paediatrics; Diagnostic Sciences; Biological Markers & Sensor Mechanisms; Medical Instrumentation

Contact Details
Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
HEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R21)

NIH: National Institute of Nursing Research

Description:
A total of two institutes and offices of the NIH invite applications for their mHealth tools for individuals with chronic conditions to promote effective patient-provider communication, adherence to treatment and self-management (R21) grants. The purpose of this R21 funding opportunity announcement is to stimulate research utilising mobile health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases in underserved populations.

This funding opportunity announcement will utilise the NIH research project grant R21 mechanism and runs in parallel with another FOA of identical scientific scope: PA-14-180 that solicits applications under the research project grant (R01) funding mechanism. The combined budget for direct costs for the two year project period may not exceed US$275,000 and no more than US$200,000 may be requested in any single year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Ref: PA-14-181 (Reissue of PA-11-332).

Closing date: 16 Feb 16

Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 May 2017.
Posted date: 23 Apr 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Chronic Care; Computer Science & Informatics; Assistive Technology; Patient Care & Education; 5G, Wireless & Mobile Networks; Social Work & Social Policy; Medical & Diagnostic Tests; Rural Health; Pharmaceutical Drugs; Social Programmes; Clinical Medicine; Health Economics; Public Health, Health Services & Primary Care; Primary Care

Contact Details
----------------------------------------------
Tel: +1 301 594 5971
Email: mccloskd@mail.nih.gov
THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R03)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of eight institutes and offices of the National Institutes of Health invite applications for their health of sexual and gender minority populations (R03) funding opportunity announcement. This announcement encourages research that describes the biological, clinical, behavioural and social processes that affect the health and development of sexual and gender minority populations and individuals, as well as their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that enhance the health and development of these populations. The research must focus on clearly defined health outcomes. The following types of research are prioritised:

- basic social and behavioural science studies addressing the processes involved as individuals discover, uncover, address or adapt to their sexual orientation and claim or do not claim identity as SGM, and how these processes affect the mental and physical health of the individual;
- research leading to interventions to ameliorate health disparities in SGM populations;
- large-scale design, implementation and evaluation of preventive or treatment interventions addressing health issues in SGM populations;
- research on how family structures and processes—including both families of origin and families of choice—affect the health of SGM individuals and their family members, including whether and how being raised in a family headed by SGM individuals affects the health, development and well-being of children.

This funding opportunity uses the NIH small grant programme (R03) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-261 and PA-15-263, which solicit applications under the NIH research project (R01) grant mechanism and the NIH research project (R01) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to US$100,000 over a two-year project period, with no more than US$50,000 in direct costs allowed in any year.

Ref: PA-15-262 (reissue of PA-12-112).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 September 2015 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 May 2018.
Posted date: 19 May 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Gender Roles & Sexuality; Health of Minority Groups; Lesbian, Gay, Bisexual & Transgender Studies

Contact Details
----------------------------------------------
Eunice Kennedy Shriver NICHD
BG 6100 Room 8B05L
6100 Executive Boulevard
Rockville MD 20852
Tel: +1 301 435 6981
Email: newcomes@nih.gov

THE HEALTH OF SEXUAL AND GENDER MINORITY POPULATIONS (R21)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of nine institutes and offices of the National Institutes of Health invite applications for their health of sexual and gender minority populations (R21) funding opportunity announcement. This announcement encourages research that describes the biological, clinical, behavioural and social processes that affect the health and development of sexual and gender minority populations and individuals, as well as their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that enhance the health and development of these populations. The research must focus on clearly defined health outcomes. The following types of research are prioritised:

- basic social and behavioural science studies addressing the processes involved as individuals discover, uncover, address or adapt to their sexual orientation and claim or do not claim identity as SGM, and how these processes affect the mental and physical health of the individual;
- research leading to interventions to ameliorate health disparities in SGM populations;
- large-scale design, implementation and evaluation of preventive or treatment interventions addressing health issues in SGM populations;
- research on how family structures and processes-including both families of origin and families of choice-affect the health of SGM individuals and their family members, including whether and how being raised in a family headed by SGM individuals affects the health, development and wellbeing of children.

This funding opportunity uses the NIH research project (R01) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-261 and PA-15-262, which solicit applications under the NIH research project (R01) grant mechanism and the NIH small grant programme (R03) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.
Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any year.

Ref: PA-15-263 (reissue of PA-12-113).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 September 2015 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 May 2018.
Posted date: 19 May 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Award amount min: -
Award budget total: -

Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276657

Eligibility profile
Country of applicant institution: Any
Disciplines
Health of Minority Groups; Gender Roles & Sexuality; Lesbian, Gay, Bisexual & Transgender Studies

Contact Details
Eunice Kennedy Shriver NICHD
BG 6100 Room 8B05L
6100 Executive Boulevard
Rockville MD 20852
Tel: +1 301 435 6981
Email: newcomes@nih.gov

PILOT HEALTH SERVICES AND ECONOMIC RESEARCH ON THE TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R34)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite applications for their pilot health services and economic research on the treatment of drug, alcohol and tobacco abuse (R34) funding opportunity announcement. This announcement encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials into the quality, effectiveness, affordability and utilisation of drug, tobacco or alcohol use disorder treatments.

This funding opportunity uses the NIH planning (R34) grant mechanism and runs in parallel with several of identical scientific scope, PA-15-251, PA-15-252 and PA-15-253 which solicit applications under the NIH research project (R01), the NIH small grant programme (R03) and the NIH exploratory/developmental (R21) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$450,000 in direct costs with up to US$225,000 in direct costs per year.

The maximum project period is three years.
ENVIRONMENTAL EXPOSURES AND HEALTH: EXPLORATION OF NON-TRADITIONAL SETTINGS (R21)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research and the National Institute of Environmental Health Research invite applications for their environmental exposures and health: exploration of non-traditional settings (R21) grants. The purpose of this R21 funding opportunity announcement is to encourage interdisciplinary research aimed at promoting health, limiting symptoms and disease, and reducing health disparities in children and older adults living or spending time in non-traditional settings. These settings result in exposure to environmental pollutants and toxins that result in health risks, symptoms and other health conditions including lower respiratory diseases, chronic obstructive pulmonary disease and cardiovascular diseases. Risk identification and symptom management include prevention and behaviour changes and actions to maintain health and prevent disease with an emphasis on the individual, family and community which will advance nursing science.

This funding opportunity announcement will use the NIH exploratory/developmental grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope: PA-12-133 that solicits applications under the research project grant (R01) mechanism. Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-12-134.

Closing date: 16 Feb 16
Deadline information: Deadline: every 16 February, 16 June and 16 October until 8 January 2016.
Posted date: 26 Mar 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-134.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-134

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Cardiovascular Diseases; Chronic Care; Primary Care; Health Disparities; Nursing; Environmental Medicine; Economic & Social Environment; Environmental & Occupational Health & Safety; Public Health, Health Services & Primary Care; Preventive Medicine; Medicine & Health; Clinical Medicine; Respiratory Medicine

PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS: EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R21)
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its physical activity and weight control interventions among cancer survivors: effects on biomarkers of prognosis and survival (R21) grants. This R21 funding opportunity announcement encourages transdisciplinary and translational research that will identify specific biological or biobehavioural pathways through which physical activity or weight control may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin or glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available. Biomarkers may include but are not limited to intervention-induced changes in sex hormones, insulin-like growth factors or their binding proteins, leptin and other adipokines, immunologic or inflammatory factors, oxidative stress and DNA damage or repair capacity, angiogenesis, or prostaglandins.

This FOA will use the exploratory/developmental (R21) grant mechanism, and runs in parallel with an FOA of identical scientific scope, PA-15-311, which solicits applications under the research project grant (R01) mechanism.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions.

Ref: PA-15-310 (replaces PAR-12-229).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 September 2015 and are due by 5pm local
time of applicant organisation every 16 February, 16 June and 16 October until until 8 September 2018.
Posted date: 27 Jul 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile

Country of applicant institution: Any
Disciplines
Obesity; Cancer Studies & Oncology; Cancer Diagnosis

Contact Details
Tel: +1 240 276 6782
Email: pernafm@mail.nih.gov

UNCONVENTIONAL ROLES OF ETHANOL METABOLISING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R21)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its unconventional roles of ethanol metabolising enzymes, metabolites and cofactors in health and disease (R21) funding opportunity announcement. This announcement provides support for integrated, innovative research on the novel and unconventional contributions of ethanol metabolising pathways, their metabolites, cofactors and interactions with synergising biological pathways in the development of alcohol-induced diseases and end organ injuries.

The aim is to generate data that leads to breakthroughs in identification and understanding of key cellular and molecular components in the initiation, progression and maintenance of the diverse medical disorders caused by excessive or long term alcohol consumption. The generated knowledge should enable clinicians to improve disease outcomes and consequently, public health. Research areas include the following: ethanol and NAD+; ethanol and acetate; ethanol and SAM; ethanol and zinc; endogenous substrates and functions of alcohol metabolising pathways - regulation of growth, development and disease.

This announcement uses the R21 exploratory or developmental research grant mechanism and runs in parallel with one of identical scientific scope, PA-15-058, which encourages applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Grants cover direct costs up to a maximum of US$275,000 over a maximum period of two years. No more than US$200,000 may be requested in any single year.

Ref: PA-15-057 (reissue of PA-12-234).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 16
EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R21)

NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its examination of survivorship care planning efficacy and impact (R21) funding opportunity announcement. This announcement aims to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy, with the goal to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors. Specifically, this call aims to stimulate research that will:

- develop and test metrics for evaluating the impact of survivorship care planning;
- evaluate the impact of survivorship care planning on cancer survivors morbidity, self-management and adherence to care recommendations, utilisation of follow-up care;
- evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organisations implementing the care planning;
- identify models and processes of care that promote effective survivorship care planning.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-012, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.
Application budgets are limited to US$275,000 per year for a maximum project period of two years. No more than US$200,000 may be requested in any single year.

Ref: PA-16-011 (replaces PA-12-274).

Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2016 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 January 2019.
Posted date: 26 Oct 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: -

Website:

Eligibility profile
Country of applicant institution: Any

Disciplines
Cancer Studies & Oncology; Rehabilitation Engineering; Emotional Rehabilitation; Quality of Care; Life Expectancy & Quality of Life

Contact Details
Tel: +1 240 276 6947
Email: taplins@mail.nih.gov

EFFECTS OF IN UTERO ALCOHOL EXPOSURE ON ADULT HEALTH AND DISEASE
(R21)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its effects of in utero alcohol exposure on adult health and disease (R21) grants. This R01 funding opportunity announcement will support novel research on how prenatal alcohol exposure may contribute to the aetiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease concept which suggest that foetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adulthood disease. The goal of this FOA is to stimulate a broad range of research to:

- investigate the biological, cellular and molecular mechanisms by which prenatal alcohol exposure may impact disease outcomes later in life;
- identify biomarkers associated with gestational alcohol exposure that may predict adult disease susceptibility in exposed offspring.

Studies supported by this FOA will provide fundamental insights into a possible foetal-basis to adult disease that is influenced by maternal alcohol use.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-291, that solicits
applications under the R01 research project grant mechanism. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PA-12-291.

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 May 2016.
Posted date: 01 Oct 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: -
Application form: [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-292](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-292)

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Reproduction & Fertility; Child Development; Pregnancy & Birth; Cell & Developmental Biology; Aetiology; Growth & Growth Factors; Medicine & Health; Alcoholism; Disease Models; Psychology; Biochemistry & Molecular Biology; Reproductive Medicine; Cognitive Processes; Biological Sciences; Foetal Health & Prenatal Development; Diagnostic Sciences

**Contact Details**

Division of Metabolism and Health Effects
NIAAA
5635 Flishers Lane, Room 2120
Bethesda, MD 20892-7003
Tel: +1 301 443 7351
Email: duntyw@mail.nih.gov

**EPIGENETIC INHERITANCE AND TRANSGENERATIONAL EFFECTS OF ALCOHOL (R21)**

NIH: National Institute on Alcohol Abuse and Alcoholism

**Description:**
The National Institute on Alcohol Abuse and Alcoholism invites applications for its epigenetic inheritance and transgenerational effects of alcohol (R21) grants. This R21 funding opportunity announcement will support research proposing to conduct mechanistic studies in human and animal models on alcohol-induced transgenerational effects and the role of epigenetic inheritance in these effects.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-003, that solicits applications under the R01 research project grant mechanism. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Eligible applicants include domestic and foreign non-profit or for-profit organisations and public or private institutions. PA-13-004.

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 May 2016.
Posted date: 04 Oct 12
**Award type:** Directed grants to institutions, research groups etc  
**Award amount max:** $275,000  
**Award amount min:** -  
**Award budget total:** -  
**Website:**  
**Application form:**  

**Eligibility profile**  
Country of applicant institution: Any

---

### Disciplines

- Quantitative Genetics
- Reproduction & Fertility
- Pharmaceutical Drugs
- Epigenetics
- Biological Sciences
- Alcoholism
- Diagnostic Sciences
- Reproductive Medicine

---

**Contact Details**

- Division of Neuroscience and Behavior  
- NIAAA  
- 6000 Executive Boulevard  
- Bethesda, MD 20892-7003  
- Tel: +1 301 594 6228  
- Email: reillymt@mail.nih.gov

---

**HARK TANK COMPETITION AWARD**

**Epilepsy Foundation**

**Description:**

The Epilepsy Foundation invites letters of intent for its shark tank competition award. This will be awarded to support the development and commercialisation of an important new product, technology or therapeutic concept to help people with epilepsy. Proposed novel concepts may be:

- a drug or device treatment that stops a seizure;
- a system that helps patients manage their treatment or their epilepsy;
- a device that prevents personal injury from a seizure;
- any other concept that could improve the lives of people with epilepsy potentially in the near future.

There are no specific background or experience requirements, and applicants may reside in any country.

Up to six proposals will be chosen to be presented to the judging panel at the AEDD conference. All finalists are eligible for a travel stipend to attend the conference and free conference registration. The winner will receive a cash prize of up to US$200,000.

**Closing date:** 16 Feb 16 (Forecast)  
**Deadline information:** Call has not yet been announced by funder, but this is the approximate deadline we expect. Letters of intent due by 11.59pm ET. This call is repeated once a year.  
**Posted date:** 13 Jan 15  
**Award type:** Prizes, Technology innovation/development, Innovation grants  
**Award amount max:** $200,000  
**Award budget total:** $200,000  
**Website:**  

---

**Eligibility profile**  
Country of applicant institution: Any
**OLID ORGAN TRANSPLANTATION: OLDER DONORS AND RECIPIENTS (R03)**

**NIH: National Institute on Aging**

**Description:**
The National Institute on Aging invites applications for its solid organ transplantation: older donors and recipients (R03) grants. This R03 funding opportunity announcement will support basic, clinical translational, epidemiological and outcomes research on solid organ transplant in older persons. Research may focus on, but is not limited to, the following:

- appropriate selection of older SOT donors and recipients;
- improved management of older SOT recipients;
- immunology and immunosuppression pertaining to older SOT patients;
- healthcare disparities, utilisation and costs of SOT in older patients.

Supported research is expected to enhance knowledge of immunobiology in ageing and transplantation, and to provide evidence-based guidance to improve access to transplantation, organ allocation and utilisation, graft survival, and short- and long-term outcomes of SOT in older persons.

Application budgets are limited to US$100,000 over a two-year project period, with no more than US$50,000 in direct costs allowed in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PA-13-037.

**Closing date:** 16 Feb 16

**Deadline information:** Applications due every 16 February, 16 June and 16 October until 8 January 2016.

**Posted date:** 07 Dec 12

**Award type:** Directed grants to institutions, research groups etc

**Award amount max:** $100,000


**Application form:** [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-037](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-037)

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Geriatrics & Gerontology; Transplantation Immunology; Immunology; Health Economics; Diagnostic Sciences; Clinical Medicine; Access to Health Care; Organ Transplantation; Immunotherapy; Economics
SOLID ORGAN TRANSPLANTATION: OLDER DONORS AND RECIPIENTS (R21)

NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its solid organ transplantation: older donors and recipients (R21) grants. This R21 funding opportunity announcement will support basic, clinical translational, epidemiological and outcomes research on solid organ transplant in older persons. Research may focus on, but is not limited to, the following:

- appropriate selection of older SOT donors and recipients;
- improved management of older SOT recipients;
- immunology and immunosuppression pertaining to older SOT patients;
- healthcare disparities, utilisation and costs of SOT in older patients.

Supported research is expected to enhance knowledge of immunobiology in ageing and transplantation, and to provide evidence-based guidance to improve access to transplantation, organ allocation and utilisation, graft survival, and short- and long-term outcomes of SOT in older persons.

This FOA will use the R21 exploratory/developmental research grant mechanism and runs in parallel with two FOAs of identical scope, PA-13-037, which uses the R01 research project grant mechanism.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PA-13-038.

Closing date: 16 Feb 16
Deadline information: Applications due every 16 February, 16 June and 16 October until 8 January 2016.
Posted date: 07 Dec 12
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-038

Eligibility profile
Country of applicant institution: Any

Disciplines

- & Econometrics; Accounting & Finance;
- Medical Effectiveness & Patient Outcomes
DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R03)

NIH: National Institute of Mental Health

Description:
A total of nine participating institutes and centres of the National Institutes of Health invite applications for their dissemination and implementation research in health (R03) grants. This R03 funding opportunity announcement encourages investigators to submit applications that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures, and strategies to disseminate and implement research-tested health behaviour change interventions, evidence-based prevention, early detection, diagnostic, treatment and management, and quality of life improvement services, and data monitoring and surveillance reporting tools into public health and clinical practice settings that focus on patient outcomes.

This FOA will use the R03 small grant programme mechanism, and runs in parallel with two FOAs of identical scientific scope, PAR-13-055, which encourages applications under the research project grant mechanism, and PAR-13-054, which encourages applications under the R21 exploratory/developmental award mechanism.

Direct costs are limited to US$100,000 over a two-year period, with no more than US$50,000 in direct costs allowed in any single year. Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. PAR-13-056 (replaces PAR-10-039).

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 January 2016.
Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-056

Eligibility profile
Country of applicant institution: Any

Disciplines
Health Systems; Psychiatry; Economic & Social Environment; Public Health, Health Economics; Medical Effectiveness & Patient Outcomes; Clinical Medicine; Health Disparities; Immunology; Organ Transplantation

Contact Details
NIA
7201 Wisconsin Avenue, Room 3C307
Bethesda, MD 20814
Tel: +1 301 496 6761
Email: susan.zieman@nih.gov
DIFFERENTIATION AND INTEGRATION OF STEM CELLS (EMBRYONIC AND INDUCED-PLURIPOTENT) INTO DEVELOPING OR DAMAGED TISSUES (R21)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Development invites applications for its differentiation and integration of stem cells (embryonic and induced-pluripotent) into developing or damaged tissues (R21) grants. This R21 funding opportunity announcement aims to promote in vivo studies of stem cells in animals models and humans to better understand how stem cells function within developing or damaged tissues. The areas of emphasis would include systematically profiling and cataloguing changes at genetic and epigenetic levels that take place in stem cells and their microenvironment. The study intends to gain in-depth knowledge of the mechanisms involved in:

- progressive differentiation of embryonic stem cells into embryonic lineages, progenitor cells and specialised cell types;
- adult stem cells or progenitor calls during tissue regeneration and wound healing;
- induced pluripotent stem cells at the site of injury during stem cell therapy.

This FOA will use the R21 exploratory/developmental research grant mechanism and runs in parallel with an FOA of identical scope, PAR-13-094, which uses the R01 research project grant mechanism.

Application budgets are limited to US$275000 over a two-year project period, with no more than US$200,000 in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-13-095.

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 September 2016.
Posted date: 29 Jan 13
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-095
Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Molecular Genetics; Embryonic Stem Cells; Primary Care; Cancer Genetics; Genetics & Systems Biology; Gene Therapy; Physiology; Induced Pluripotent Stem Cells; Human Biological Sciences; Medical Genetics; Stem Cell Genomics; Stem Cell Therapy; Stem Cell; Clinical Medicine; Regenerative Medicine; Tissue Culture; Nursing; Wound Healing; Epigenetics; Biological Sciences; Diagnostic Sciences; Public Health, Health Services & Primary Care; Pharmacotherapy; Pharmacy & Pharmacology

Contact Details
----------------------------------------------
Developmental Biology and Structural Variation Branch
NICHD
Building 31
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 435 6886
Email: mukhopam@mail.nih.gov

School Nutrition and Physical Activity Policies, Obesogenic Behaviours and Weight Outcomes (R21)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of four institutes and offices of the National Institutes of Health invites applications for their school nutrition and physical activity policies, obesogenic behaviours and weight outcomes (R21) grants. The objectives of this R21 funding opportunity announcement are to understand how school-related policies impact the school and home environment, promote positive nutrition and physical activity behaviours and decrease childhood obesity. Applications should propose to:

• foster multidisciplinary research that will evaluate how policies can influence school physical activity and nutrition environments, youths’ obesogenic behaviours and weight outcomes;
• understand how schools are implementing these policies and examine multi-level influences on adoption and implementation at various levels;
• understand the synergistic or counteractive effect of school nutrition and physical activity policies on the home and community environment and body weight.

This FOA will use the R21 exploratory/developmental research grant mechanism and runs in parallel with two FOAs of identical scope, PAR-13-099, which uses the R03 small grant programme mechanism, and PAR-13-100, which uses the R01 research project grant mechanism.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-13-098.

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 May 2016.
Posted date: 04 Feb 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: -

Eligibility profile

Country of applicant institution: Any

### Disciplines

Diagnostic Sciences; Schools Policy & Politics; Physical & Sports Education; Psychology; Nutrition & Dietetics; Sports & Exercise Studies; Behavioural Medicine; Obesity; Primary Care; Social Work & Social Policy; Human Nutrient Requirements; Public Health, Health Services & Primary Care; Education; Health Education

### Contact Details

NICHD
6100 Executive Boulevard, Room 4B05
Rockville, MD 20852
Tel: +1 301 435 6888
Email: espositl@mail.nih.gov

---

**SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIOURS AND WEIGHT OUTCOMES (R03)**

**NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

**Description:**
A total of three institutes and offices of the National Institutes of Health invites applications for their school nutrition and physical activity policies, obesogenic behaviours and weight outcomes (R03) grants.

The objectives of this R03 funding opportunity announcement are to understand how school-related policies impact the school and home environment, promote positive nutrition and physical activity behaviours and decrease childhood obesity. Applications should propose to:

- foster multidisciplinary research that will evaluate how policies can influence school physical activity and nutrition environments, youths’ obesogenic behaviours and weight outcomes;
- understand how schools are implementing these policies and examine multi-level influences on adoption and implementation at various levels;
- understand the synergistic or counteractive effect of school nutrition and physical activity policies on the home and community environment and body weight.

This FOA will use the R03 small grant programme mechanism and runs in parallel with two FOAs of identical scope, PAR-13-098, which uses the R21 exploratory/developmental research grant mechanism, and PAR-13-100, which uses the R01 research project grant mechanism.
Application budgets are limited to US$50,000 per year over a two-year project period. Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public or private institutions. PAR-13-099.

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 May 2016.
Posted date: 04 Feb 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Award amount min: -
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-099

Eligibility profile

Country of applicant institution: Any

Disciplines

Physical & Sports Education; Education; Nutrition & Dietetics; Psychology; Health Education; Human Nutrient Requirements; Social Work & Social Policy; Sports & Exercise Studies; Obesity; Diagnostic Sciences; Behavioural Medicine; Schools Policy & Politics; Public Health, Health Services & Primary Care; Primary Care

Contact Details

NICHD
6100 Executive Boulevard, Room 4B05
Rockville, MD 20852
Tel: +1 301 435 6888
Email: espositl@mail.nih.gov

Improvement of Animal Models for Stem-Cell-Based Regenerative Medicine (R21)

NIH: Office of the Director

Description:
The NIH Office of Research Infrastructure Programs, the National Heart, Lung and Blood Institute and the National Institute of Dental and Craniofacial Research invite applications for their improvement of animal models for stem-cell-based regenerative medicine (R21) grants. This R21 funding opportunity announcement aims to characterise animal stem cells and improve existing and create new animal models for human disease conditions. This initiative focuses on the following areas:

- comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems;
- development of new technologies for stem cell characterisation and transplantation;
- improvement of animal disease models for stem-cell-based therapeutic applications.

This FOA will use the R21 exploratory/developmental award mechanism, and runs in parallel with an FOA of identical scientific scope, PAR-13-114, which encourages applications under the R01 research project grant mechanism.
Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. Application budgets are limited to US$275,000 over a two-year period, with no more than US$200,000 in any year. PAR-13-115.

Closing date: 16 Feb 16
Deadline information: Applications due every 16 February, 16 June and 16 October until 8 May 2016.
Posted date: 12 Feb 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Disease Control; Induced Pluripotent Stem Cells; Pharmacotherapy; Physiology; Diagnostic Sciences; Public Health, Health Services & Primary Care; Nursing; Biological Sciences; Preventive Medicine; Stem Cell; Pharmacy & Pharmacology; Regenerative Medicine; Animal Models; General Practice; Stem Cell Genomics; Primary Care; Clinical Medicine; Stem Cell Therapy; Embryonic Stem Cells

Contact Details
----------------------------------------------
Division of Comparative Medicine
ORIP
Division of Programme Coordination, Planning and Strategic Initiatives
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 435 0744
Fax: +1 301 480 3819
Email: oleg.mirochnitchenko@nih.gov

R
EGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R21)
NIH: National Institute on Aging

Description:
The National Institute on Aging invites R21 applications for its regional and international differences in health and longevity at older ages grants.

Applications are sought from organisations proposing to advance knowledge on the reasons behind the divergent trends that have been observed in health and longevity at older ages, both across industrialised nations and across geographical areas in the United States. This FOA will utilise the R21 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

The combined budget for direct costs may not exceed US$275,000 over two years. no more than US$200,000 per year may be requested.

PA-13-124.

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, 16 February, 16
Regional and International Differences in Health and Longevity at Older Ages (R03)
NIH: National Institute on Aging

Description:
The National Institute on Aging invites R03 applications for its regional and international differences in health and longevity at older ages grants.

Applications are sought from organisations proposing to advance knowledge on the reasons behind the divergent trends that have been observed in health and longevity at older ages, both across industrialised nations and across geographical areas in the United States.

This FOA will utilise the R03 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

The combined budget for direct costs may not exceed US$100,000 over two years, no more than US$50,000 per year may be requested.

PA-13-123.

Closing date: 16 Feb 16

Eligibility profile
-------------------------------------------------------------
Country of applicant institution: Any

Disciplines
-------------------------------------------------------------
Population Studies, Medical; Psychology; Geriatrics & Gerontology; International Health; Primary Care; Health Disparities; Psychology of Ageing; Social & Income Inequality; Life Expectancy & Quality of Life;
CUTE KIDNEY INJURY IN OLDER ADULTS (R03)

NIH: National Institute on Aging

Description:
The National Institute on Aging invites R03 applications for its acute kidney injury in older adults grants.

Applications should propose basic, clinical, translational and outcomes research on kidney injury in older adults. Applications may focus on: the epidemiology, etiology and risk factors for AKI in older adults; pathophysiology of AKI in the ageing kidney and its impact on chronic kidney disease (CKD) and other organ disease; early detection, diagnosis and monitoring of AKI; prevention, treatment and management strategies of AKI in older patients with the goal of improving short- and long-term outcomes, including morbidity, mortality, progression of CKD, functional independence and quality of life.

This programme announcement will utilise the R03 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

Funding for direct costs may not exceed US$100,000 over two years, and no more than US$50,000 may be requested in any single year.

PA-13-142.

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 16 February, 16 June and 16 October until 8 May 2016.
Posted date: 15 Mar 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Nephrology & Kidneys; Public Health, Health Services & Primary Care; Geriatrics & Gerontology; Prosthetic & Orthotic Devices; Diagnostic Sciences; Primary Care; Diabetes; Clinical Medicine; Traumatology, Accidents & Injury

Contact Details
Tel: +1 301 496 6761
Email: susan.zieman@nih.gov
CUTE KIDNEY INJURY IN OLDER ADULTS (R21)
NIH: National Institute on Aging

Description:
The National Institute on Aging invites R21 applications for its acute kidney injury in older adults grants.

Applications should propose basic, clinical, translational and outcomes research on kidney injury in older adults. Applications may focus on: the epidemiology, etiology and risk factors for AKI in older adults; pathophysiology of AKI in the ageing kidney and its impact on chronic kidney disease (CKD) and other organ disease; early detection, diagnosis and monitoring of AKI; prevention, treatment and management strategies of AKI in older patients with the goal of improving short- and long-term outcomes, including morbidity, mortality, progression of CKD, functional independence and quality of life.

This programme announcement will utilise the R21 award mechanism. Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

Funding for direct costs may not exceed US$275,000 over two years, and no more than US$200,000 may be requested in any single year.

PA-13-143.

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 16 February, 16 June and 16 October until 8 May 2016.
Posted date: 15 Mar 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-13-143.html
Application form:

Eligibility profile
Country of applicant institution: Any

Disciplines
Diagnostic Sciences; Primary Care; Traumatology, Accidents & Injury; Geriatrics & Gerontology; Nephrology & Kidneys; Diabetes; Clinical Medicine; Public Health, Health Services & Primary Care; Prosthetic & Orthotic Devices

Contact Details
Tel: +1 301 496 6761
Email: susan.zieman@nih.gov
IDCR SMALL RESEARCH GRANTS FOR SECONDARY ANALYSIS OF FACEBASE DATA (R03)

NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its small research grants for secondary analysis of FaceBase data (R03). This R03 funding opportunity announcement will support research projects that conduct secondary data analyses of the FaceBase Consortium datasets relevant to craniofacial development, human craniofacial conditions or traits, and animal models of those conditions. Informatics projects that integrate data from multiple FaceBase datasets are particularly encouraged.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. Direct costs are limited to US$300,000 over two years, with no more than US$200,000 in any year. PAR-13-178.

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 16 February, 16 June and 16 October until 8 September 2016.
Posted date: 03 Apr 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $300,000

Award amount min: -
Award budget total: -
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-178

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Oral & Maxillofacial Surgery; Biological Sciences; Physiology; Restorative Dentistry; Osteoporosis & Other Bone Diseases; Oral Medicine; Animal Models; Dentistry; Diagnostic Sciences; Craniofacial Disorders; Plastic & Reconstructive Surgery; Bone Cancers

Contact Details
-----------------------------------------------
NIDCR
45 Center Drive, MSC 6400
Bethesda, MD 20892-6400
Tel: +1 301 594 3977
Email: scholnis@nidcr.nih.gov
RESEARCH GRANTS USING THE RESOURCES FROM THE OSTEOARTHRITIS INITIATIVE (R21)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Center for Complementary and Alternative Medicine and the National Institute on Aging invite applications for their research grants using the resources from the osteoarthritis initiative (R21). This R21 funding opportunity announcement encourages research focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community.

Domestic and foreign public and private non-profit organisations and for-profit organisations may apply.

Direct costs may not exceed US$275,000 over a two-year project period, with no more than US$200,000 in any year. PA-13-237.

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 June, 16 October and 16 February until 8 January 2016.

Posted date: 03 Jun 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Osteoporosis & Other Bone Diseases; Rheumatology & Arthritis; Clinical Medicine; Diagnostic Sciences; Bone Cancers

Contact Details
----------------------------------------------
NIAMS
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 594 3511
Email: lester1@mail.nih.gov

RESEARCH TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R03)
NIH: National Institute on Aging

Description:
A total of six institutes of the NIH invite applications for grants for research to characterise and reduce stigma to improve health. This R03 funding opportunity announcement encourages research grant applications to characterise the role of stigma in health, life course development, and ageing, both in the US and globally, and to test interventions to prevent or reduce the impact of stigma at the individual, community, healthcare system, and policy levels. The goal is to promote research
addressing the health-related aspects of stigma, including the aetiology and perpetuation of it; its impact on physical and mental health, well-being, life course development, and ageing; its influence on health behaviours and on use, access to, and quality of received healthcare services; its contribution to health disparities affecting vulnerable demographic groups; and intervention strategies to reduce health-related stigma or the negative health and life course developmental impacts of stigma.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

This funding opportunity uses the R03 small grant programme mechanism and runs in parallel with two of identical scientific scope, PA-13-246, which solicits applications under the NIH exploratory/developmental grant mechanism, and PA-13-248, which uses the R03 research project grant mechanism.

The combined budget for direct costs over the two-year maximum period may not exceed US$100,000. No more than US$50,000 in direct costs may be requested in any single year. PA-13-247.

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September, 2016.

Posted date: 17 Jun 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $50,000

Eligibility profile
Country of applicant institution: Any
Disciplines
Social Work & Social Policy; Economic & Social Environment; Health Systems, Administration; Psychology; Mental Health; Primary Care; Psychology of Ageing; Sociology; Public Health, Health Services & Primary Care; Geriatrics & Gerontology; Behavioural Medicine; Medical Sociology; Social Services Delivery; Health Disparities; Education; Allied Health Professions; Health Education

Contact Details
NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: +1 301 402 4156
Email: nielsenli@nia.nih.gov

RESEARCH TO CHARACTERISE AND REDUCE STIGMA TO IMPROVE HEALTH (R21)
NIH: National Institute on Aging

Description:
A total of six institutes of the NIH invite applications for grants for research to characterise and reduce stigma to improve health. This R21 funding opportunity announcement encourages research grant
applications to characterise the role of stigma in health, life course development, and ageing, both in the US and globally, and to test interventions to prevent or reduce the impact of stigma at the individual, community, healthcare system, and policy levels. The goal is to promote research addressing the health-related aspects of stigma, including the aetiology and perpetuation of it; its impact on physical and mental health, well-being, life course development, and ageing; its influence on health behaviours and on use, access to, and quality of received healthcare services; its contribution to health disparities affecting vulnerable demographic groups; and intervention strategies to reduce health-related stigma or the negative health and life course developmental impacts of stigma.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

This funding opportunity uses the R21 exploratory/developmental research grant mechanism, and runs in parallel with two of identical scope, PA-13-248, which solicits applications under the R01 research project grant mechanism, and PA-13-247, which uses the R03 small grant mechanism.

The combined budget for direct costs over the two-year maximum period may not exceed US$275,000. No more than US$200,000 in direct costs may be requested in any single year. PA-13-246.

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September, 2016.
Posted date: 17 Jun 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: -

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Economic & Social Environment; Public Health, Health Services & Primary Care; Health Education; Sociology; Allied Health Professions; Psychology of Ageing; Health Systems, Administration; Mental Health; Primary Care; Medical Sociology; Psychology; Health Disparities; Geriatrics & Gerontology; Social Services Delivery; Social Work & Social Policy; Behavioural Medicine; Education

Contact Details
----------------------------------------------
NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: +1 301 402 4156
Email: nielsenli@nia.nih.gov
SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R21)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its secondary analyses of alcohol and chronic disease (R21) grants. This R21 funding opportunity announcement aims to support secondary analyses of alcohol related to chronic disease aetiology and epidemiology. The goal of this programme is to facilitate cost-effective exploratory or novel studies that break new ground or extend previous discoveries towards new directions or applications.

This funding opportunity announcement will use the NIH exploratory/development research grant (R21) mechanism and runs in parallel with two FOA of identical scientific scope, PA-13-261, which solicits applications under the R03 small grant programme mechanism, and PA-13-260, which solicits applications under the R01 research project grant mechanism.

Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Domestic and foreign for-profit and nonprofit organisations and public or private institutions may apply.

Closing date: 16 Feb 16

Deadline information: Applications due by 5pm every 16 February, 16 June and 16 October until 8 September 2016.
Posted date: 09 Jul 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-251

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Public Health, Health Services & Primary Care; Epidemiology; Aetiology; Alcoholism; Chronic Care; Clinical Medicine; Primary Care

Contact Details
----------------------------------------------
NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 594 6231
Email: rbreslow@mail.nih.gov

SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R03)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its secondary analyses of alcohol and chronic disease (R03) grants. This R03 funding opportunity announcement aims to support secondary analyses of alcohol related to chronic disease aetiology and epidemiology. The goal of this programme is to facilitate cost-effective exploratory or novel studies that break new ground or extend previous discoveries towards new directions or applications.

This funding opportunity announcement will use the NIH exploratory/development research grant (R03) mechanism and runs in parallel with two FOA of identical scientific scope, PA-13-261, which solicits applications under the R03 small grant programme mechanism, and PA-13-260, which solicits applications under the R01 research project grant mechanism.

Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Domestic and foreign for-profit and nonprofit organisations and public or private institutions may apply.

Closing date: 16 Feb 16

Deadline information: Applications due by 5pm every 16 February, 16 June and 16 October until 8 September 2016.
Posted date: 09 Jul 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-251

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Public Health, Health Services & Primary Care; Epidemiology; Aetiology; Alcoholism; Chronic Care; Clinical Medicine; Primary Care

Contact Details
----------------------------------------------
NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 594 6231
Email: rbreslow@mail.nih.gov
secondary analyses of alcohol related to chronic disease aetiology and epidemiology. The goal of this programme is to facilitate innovative yet cost-effective research using previously collected data.

This funding opportunity announcement will use the NIH small grant programme (R03) mechanism and runs in parallel with two FOA of identical scientific scope, PA-13-260, which solicits applications under the R01 research project grant mechanism, and PA-13-251, which solicits applications under the R21 exploratory/developmental research grant mechanism.

Direct costs are limited to US$100,000 over a two-year project period, with no more than US$50,000 in any year. Domestic and foreign for-profit and nonprofit organisations and public or private institutions may apply. PA-13-260.

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 September 2016.
Posted date: 09 Jul 13

Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-261

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Alcoholism; Clinical Medicine; Chronic Care; Aetiology; Primary Care; Public Health, Health Services & Primary Care; Epidemiology

Contact Details
----------------------------------------------
NIAA
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 594 6231
Email: rbreslow@mail.nih.gov

IMPLICATIONS OF NEW DIGITAL MEDIA USE FOR UNDERAGE DRINKING, DRINKING-RELATED BEHAVIOURS AND PREVENTION RESEARCH (R21)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its implications of new digital media use for underage drinking, drinking-related behaviours and prevention research (R21) grants. This R21 funding opportunity announcement aims to investigate whether, and how, having involvement in new digital media use, particularly social media and social networking sites, may influence adolescent alcohol use and drinking patterns, as well as drinking-related problems. The FOA also encourages studies exploring the ways new digital media may be use as platforms for preventative interventions aimed at underage drinking and related problems.

This funding opportunity announcement will use the NIH exploratory/developmental research grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-262, which solicits applications...
under the R01 research project grant mechanism.

Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Domestic and foreign for-profit and non-profit organisations and public or private institutions may apply. PA-13-263.

Closing date: 16 Feb 16
Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 September 2016.
Posted date: 09 Jul 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-263

Eligibility profile
----------------------------------------------------------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------------------------------------------------------------------------------
Communication & Media Studies; Alcoholism; Communication Studies; Business & Management Studies; Public Health, Health Services & Primary Care; Networking Protocols; Primary Care; Social Networks; Sociology; Media Studies; Social Behaviour & Attitudes

Contact Details
----------------------------------------------------------------------------------------------------------------------
NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 443 8820
Email: rfreeman@mail.nih.gov

THE ROLE OF THE CYTOSKELETON IN CELLULAR AGEING (R21/R33)
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its role of the cytoskeleton in cellular ageing (R21/R33) grants. This R21/R33 funding opportunity announcement aims to stimulate the development of innovative research strategies to increase understanding of the molecular and cellular changes in the cytoskeleton that occur during the ageing process. Applications considering the effect of age on factors such as cytoskeleton structure and function, the impact of the cytoskeleton on intracellular organelle interactions, and the signalling or regulatory molecules controlling cellular architecture are encouraged. There is also interest in studying the role of the cytoskeleton in nuclear-cytoplasmic communications and in spatio-temporal relationships during the ageing process and in age-related diseases.

The total project period for the combined R21/R33 application submitted in response to this FOA may not exceed five years and total direct costs are limited to $1.18 million. The R21 phase may not exceed two years or $275,000 in direct costs. The R33 phase may not exceed three years or $900,000 in direct costs.
Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PAR-13-301.

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 5 February, 5 June and 5 October until 8 September 2016.
Posted date: 02 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $1,175,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-301

Eligibility profile
Country of applicant institution: Any

Disciplines
Cell Physiology & Metabolism; Geriatrics & Gerontology; Cell & Developmental Biology; Diagnostic Sciences; Biochemistry & Molecular Biology; Biological Sciences

Contact Details
NIA
7201 Wisconsin Avenue
Bethesda, MD 20814
Email: +1 301 496 6428
Fax: jvelazqu@mail.nih.gov

DEVELOPMENTAL PHARMACOLOGY AND TOXICOLOGY: ROLE OF ONTOGENY (R03)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development, the National Institute of Environmental Health Sciences and the National Institute of General Medical Sciences invite applications for funding concerning the role of ontogeny in developmental pharmacology and toxicology. This R03 funding opportunity announcement encourages grant applications from institutions or organisations that propose multidisciplinary, investigator-initiated basic and translational research in developmental pharmacology and toxicology. Particular emphasis should be placed on the role of ontogeny on drug metabolising enzymes, transporters, receptors and signalling pathways across developmental periods from foetal life to adolescence affecting drug action and toxicity.

This funding opportunity uses the NIH R03 small grant mechanism and runs in parallel with two of identical scientific scope, PAR-13-306, which solicits applications under the R01 research project grant mechanism and PAR-13-308, which solicits applications under the R21 exploratory/developmental grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

Total project periods may not exceed two years; the combined budget for direct costs may not exceed US$100,000 for this period. No more than US$50,000 may be requested in any single year. PAR-13-307.
DEVELOPMENTAL PHARMACOLOGY AND TOXICOLOGY: ROLE OF ONTOGENY (R21)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development, the National Institute of Environmental Health Sciences and the National Institute of General Medical Sciences invite applications for funding concerning the role of ontogeny in developmental pharmacology and toxicology. This R21 funding opportunity announcement encourages grant applications from institutions or organisations that propose multidisciplinary, investigator-initiated basic and translational research in developmental pharmacology and toxicology. Particular emphasis should be placed on the role of ontogeny on drug metabolising enzymes, transporters, receptors and signalling pathways across developmental periods from foetal life to adolescence affecting drug action and toxicity.

This funding opportunity uses the R21 small grant mechanism and runs in parallel with two of identical scientific scope, PAR-13-306, which solicits applications under the R01 research project grant mechanism and PAR-13-307, which solicits applications under the R03 small grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

Total project periods may not exceed two years; the combined budget for direct costs may not exceed US$275,000 for this period. No more than US$200,000 may be requested in any single year. PAR-13-308

Closing date: 16 Feb 16
Deadline information:
Posted date: 08 Aug 13
MECHANISMS OF ALCOHOL AND STIMULANT CO-ADDICTION (R21)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their mechanisms of alcohol and stimulant co-addiction (R21) grants. This R21 funding opportunity announcement promotes research on neurobiological and behavioural mechanisms that might explain how alcohol and stimulants interact at genetic, epigenetic, cellular, neurocircuitry and behavioural levels to promote co-addiction.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PAR-13-339, which solicits applications under the R01 research project grant mechanism. Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. PA-13-340.

Closing date: 16 Feb 16
Deadline information: Deadlines every 5 February, 5 June and 5 October until 8 January 2017.
Posted date: 29 Aug 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFro\nFedgrants?opportunity=PA-13-340

Eligibility profile
Country of applicant institution: Any

Disciplines
Pharmacokinetics; Clinical Pharmacy & Pharmacology; Chemistry; Toxicology; Foetal Health & Prenatal Development; Pharmacy & Pharmacology

Contact Details
NICHD
MSC 2425
31 Center Drive
Bethesda, MD 20892-2425
Tel: +1 301 496 5589
Email: gg65m@mail.nih.gov
ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R21)
NIH: National Institute on Aging

Description:
The National Institute on Aging and the National Center for Complementary and Alternative Medicine invite applications for their grants for advancing the science of geriatric palliative care. This R21 funding opportunity announcement encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasises studies in a variety of settings including ambulatory care, hospitals, assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programmes. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients’ disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with two of identical scientific scope: PA-13-356, which solicits applications under the R03 small grant programme mechanism, and PA-13-354, which solicits applications under the R01 research project grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The total project period may not exceed two years; the combined budget for direct costs over this period may not exceed US$275,000. No more than US$200,000 may be requested in any single year. PA-13-355.

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Posted date: 20 Sep 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Clinical Medicine; Clinical Pharmacy & Pharmacology; Pain Management; Health Systems; Chronic Pain; Public Health, Health Services & Primary Care; Hospitalisation; Geriatrics & Gerontology; Geriatric Nursing; Pharmacy & Pharmacology; Nursing; Hospice & Palliative Care; Pharmaceutical Drugs; Palliative Nursing; Primary Care

Contact Details
----------------------------------------------
NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: +1 301 496 6761
Email: basil.eldadah@nih.gov

ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R03)
NIH: National Institute on Aging

Description:
The National Institute on Aging and the National Center for Complementary and Alternative Medicine invite applications for their grants for advancing the science of geriatric palliative care. This R03 funding opportunity announcement encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasises studies in a variety of settings including ambulatory care, hospitals, assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programmes. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients' disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.

This FOA uses the R03 small grant programme mechanism and runs in parallel with two of identical scientific scope: PA-13-354, which solicits applications under the R01 research project grant mechanism, and PA-13-355, which solicits applications under the R21 exploratory/developmental grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The total project period may not exceed two years; direct costs are limited to US$50,000 per year. PA-13-356.

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Posted date: 20 Sep 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Secondary Data Analyses to Explore the National Institute of Mental Health Research Domain Criteria (R03)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its call for secondary data analyses to explore its research domain criteria (R03). This R03 funding opportunity announcement aims to expedite the work of assessing the validity of research domain criteria project constructs and to stimulate new hypotheses and pilot data for future RDoC projects. Databases that include measure that align with RDoC constructs and include more than one unit of analysis are optimal.

Domestic and foreign for-profit or non-profit organisations and public or private institutions may apply. The combined budget for direct costs over the two-year project period may not exceed US$100,000. No more than US$50,000 in direct costs may be requested in any single year.

Ref: PAR-14-008.

Posted date: 25 Nov 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-008.html


Eligibility profile
Country of applicant institution: Any

Disciplines
Psychobiology; Neuroscience; Mental Health; Data Analysis; Medical Genetics; Cancer Genetics; Diagnostic Sciences; Psychology

Contact Details
NIMH
6001 Executive Boulevard
EUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R21)

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its grants on neuroimmune signalling and function in substance abuse disorders (R21). This R21 funding opportunity announcement aims to examine the molecular, cellular, circuit and behavioural responses to neuroimmune signalling within the central nervous system. Research should pertain to the initiation, escalation and maintenance of the neurological consequences resulting from substance use disorders and to abstinence, withdrawal and relapse. The goal is to determine the extent to which neuroimmune responses contribute to or protect against the risk and consequences of SUDs.

This FOA will use the R21 exploratory/developmental research grant mechanism, and runs in parallel with an FOA of identical scientific scope, PA-14-084, which encourages applications under the R01 research project grant mechanism.

US and foreign for-profit or non-profit organisations and public or private institutions may apply. Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Ref: PAR-14-083.

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposers’s local time, every 16

February, 16 June and 16 October until 8 May 2017.
Posted date: 05 Feb 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-083.html
Application form: http://www.grants.gov/web/grants/applicantpackage.html#download=true&oppNum=P A-14-083

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Pathology; Cell & Developmental Biology; Diagnostic Sciences; Primary Care; Cytopathology; Ethology; Behavioural Medicine; Biochemistry & Molecular Biology; Public Health, Health Services & Primary Care; Biological Sciences; Psychology; Neuroscience; Drug & Substance Abuse

Contact Details
-----------------------------------------------
NIDA
6001 Executive Boulevard
Bethesda, MD 20892-9561
Tel: +1 301 443 3205
Email: rsorense@mail.nih.gov
SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R03)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its call on synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R03). This R03 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies.

This FOA uses the R03 small grant programme grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-105 and PA-14-106 which use the R21 exploratory/developmental and R01 research project grant mechanisms respectively.

The combined budget for direct costs for the maximum two year project period may not exceed US$100,000. No more than US$50,000 in direct costs may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.
Ref: PA-14-014.

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 16 February, 16 June and 16 October until 8 May 2017.
Posted date: 21 Feb 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-104.html

Application form: http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-104

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Public Health, Health Services & Primary Care; Primary Care; General Practice; Pharmacokinetics; Clinical Medicine; Behavioural Medicine; Diagnostic Sciences; Drug Design; Drug & Substance Abuse; Chemistry; Psychology; Methods of Drug Delivery

Contact Details
-----------------------------------------------
Tel: +1 301 435 1304
Email: rrapaka@nida.nih.gov
SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R21)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its call on synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R21). This R21 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with two FOAs of identical scientific scope, PAR-14-104 and PAR-14-106 which use the R03 small grant and R01 research project grant mechanisms respectively.

The combined budget for direct costs for the maximum two year project period may not exceed US$275,000. No more than US$200,000 may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.
Ref: PAR-14-105.

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time, every 16 February, 16 June and 16 October until 8 May 2017.
Posted date: 21 Feb 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-105.html

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Chemistry; Diagnostic Sciences; Drug & Substance Abuse; General Practice; Drug Design; Public Health, Health Services & Primary Care; Methods of Drug Delivery; Clinical Medicine; Pharmacokinetics; Behavioural Medicine; Primary Care; Psychology

Contact Details
---------------------------------------------------------------
Tel: +1 301 435 1304
Email: rrrapaka@nida.nih.gov
**FAMILY-CENTRED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R21)**

NIH: National Institute of Nursing Research

**Description:**
The National Institute of Nursing Research invites applications for its call on family-centred self-management of chronic conditions (R21). This R21 funding opportunity announcement seeks to build on the science of family-centred self-management in chronic conditions.

This FOA uses the R21 exploratory/developmental research grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-112, which uses the R01 research project grant mechanism.

Foreign or US for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-14-113.

**Closing date:** 16 Feb 16

**Deadline information:** Applications due by 5pm proposer’s local time every 16 February, 16 June and 16 October until 8 May 2017.

**Posted date:** 25 Feb 14

**Award type:** Directed grants to institutions, research groups etc


**Eligibility profile**

- Country of applicant institution: Any

**Disciplines**

- Chronic Care; Public Health, Health Services & Primary Care; Social Work & Social Policy; Primary Care; Social Programmes; Community Health Services

**Contact Details**

- Tel: +1 301 594 5970
- Email: husk@mail.nih.gov

**ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R21)**

NIH: National Institute on Alcohol Abuse and Alcoholism

**Description:**
The National Institute on Alcohol Abuse and Alcoholism invites applications for its alcohol-induced effects on tissue injury and repair (R21) grants. This R21 funding opportunity announcement supports the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. The NIAAA is especially interested in integrative research that elucidates alcohol’s effects on complex mechanisms of injury and repair that are either common or specific to each organ system. The call also encourages the study of alcohol’s effect on stem cells, embryonic development and regeneration, as well as the...
studies on molecular and cellular actions of moderate alcohol consumption.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-123, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PA-14-124.

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time every 16 February, 16 June and 16 October until 8 May 2017.
Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Prevention and Treatment of Substance Using Populations with or At Risk for Hepatitis C Virus (R34)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its grants on the prevention and treatment of substance using populations with or at risk for hepatitis C virus (R34). This R34 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing infections more effectively. This FOA supports the initial development of a clinical trial or research project focused on HCV for at-risk substance using populations, including those with or at risk for HIV.

This FOA uses the R34 planning grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-136 and PA-14-137, which use the R21 exploratory/developmental grant mechanism and the R01 research project grant mechanisms respectively.
The combined budget for direct costs for the maximum three year project period may not exceed US$450,000. No more than US$225,000 may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.
Ref: PA-14-135

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time every 16 February, 16 June and 16 October until 8 May 2017.
Posted date: 04 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $450,000
Website:
Application form:
http://www.grants.gov/web/grants/applicants/download-application-

Prevention and Treatment of Substance Using Populations With or At Risk for Hepatitis C Virus (R21)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its grants on the prevention and treatment of substance using populations with or at risk for hepatitis C virus (R21). This R21 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing infections more effectively. This FOA supports the initial development of a clinical trial or research project focused on HCV for at-risk substance using populations, including those with or at risk for HIV.

This FOA uses the R21 exploratory/developmental grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-135 and PA-14-137, which use the R34 planning grant mechanism and the R01 research project grant mechanisms respectively.

The combined budget for direct costs for the maximum two year project period may not exceed US$275,000. No more than US$200,000 may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organisations and public and private organisations.
EUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R21)

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its grants on neuroimmune mechanisms of alcohol-related disorders (R21). This R21 funding opportunity announcement seeks studies to address the role of neuroimmune modulation in response to and in the neuroadaptation of the brain to acute and chronic alcohol exposure, and alcohol dependence and withdrawal. The goal is to achieve fundamental insights of neuroimmune mechanisms underlying brain functional and behavioural changes induced by alcohol.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-139 which uses the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PA-14-138.

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time every 16 February, 16 June and 16 October until 8 May 2017.
Posted date: 04 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:

Application form:
http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-138

Eligibility profile
------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
------------------------------------------------------------------
Clinical Medicine; Neurology; Neuroscience; Neurobiology; Endocrine & Neuroendocrine Cancers; Neuroendocrinology; Psychology; Ethology; Diagnostic Sciences; Neuropsychology; Behavioural Medicine; Immunology; Alcoholism; Biological Sciences

Contact Details
------------------------------------------------------------------
NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: +1 301 443 1678
Email: changhai.cui@nih.gov

COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R21)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for its community partnerships to advance research (R21). This R21 funding opportunity announcement encourages researchers to partner with communities using community engaged research methodologies that will enhance relationships leading to better interventions and positive health outcomes.

This funding opportunity announcement will use the NIH R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-142, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Ref: PAR-14-141.

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time every 16 February, 16 June and 16 October until 8 May 2017.
Posted date: 05 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Award amount min: -
Award budget total: -
Website:
Application form:
http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-141
Eligibility profile

Country of applicant institution: Any

Disciplines

Medical Research of Selected Fields; Public Health, Health Services & Primary Care; Medical Effectiveness & Patient Outcomes; Nursing; Biomedical Engineering; Pharmaceutical Drugs; Clinical Medicine; Translational Medicine; Primary Care

Contact Details

NINR
National Institutes of Health
31 Center Drive, Room 5B10
Bethesda MD 20892-2178
Tel: +1 301 594 5971
Email: mccloskd@mail.nih.gov

E

STABLISHING BEHAVIOURAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R21)

NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its grants on establishing behavioural and social measures for causal pathway research in dental, oral and craniofacial health (R21). This R21 funding opportunity announcement aims to establish measures of specific behavioural or social phenomena to test causal hypotheses about behavioural and social contributors to dental, oral or craniofacial diseases. This announcement encourages the development and testing of two types of measures:

- measures of the health behaviours, social interactions, community characteristics, built environments, targeted by behavioural or social interventions to improve oral health;
- measures of the hypothesised moderators and mediators of a behavioural or social intervention's effect.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-143, which uses the R01 research project grant mechanism.

US and foreign for-profit and non-profit organisations and public or private institutions may apply.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Ref: PAR-14-144.

Closing date: 16 Feb 16

Deadline information: Applications due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 May 2017.

Posted date: 06 Mar 14

Award type: Directed grants to institutions, research groups etc

Award amount max: $275,000

Website:
http://grants.nih.gov/grants/guide/pa-files/PAR-14-144.html

Application form:
http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PAR-14-144
Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Public Health, Health Services & Primary Care; Restorative Dentistry; Oral & Maxillofacial Surgery; Dentistry; Medical Education; Special Needs Dentistry; Preventive Dentistry; Paediatric Dentistry; Oral Medicine; Craniofacial Disorders; Primary Care; Behavioural Medicine; Dental Health & Hygiene; Psychology

Contact Details
----------------------------------------------
NIDCR
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: +1 301 451 3888
Email: riddleme@mail.nih.gov

TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R21)
NIH: National Institute on Aging

Description:
The National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering invite applications for their call on translational research to help older adults maintain their health and independence in the community (R21). This R21 funding opportunity announcement supports translational research collaborations between academic research centres and community-based organisations with expertise in serving or engaging older adults to develop tools, techniques, programmes or policies to respond to the needs of the ageing population.

This FOA uses the R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-161, which solicits applications under the R01 research project grant mechanism.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.
Ref: PAR-14-159 (replaces PAR-11-124).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm proposer’s local time every 16 February, 16 June and 16 October until 8 May 2017.
Posted date: 21 Mar 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-159.html


Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Psychology; Psychology of Ageing; Social Work & Social Policy; Access to Health Care; Accessibility for Disabled People; Health Systems Policy; Home Health Care Services; Social Programmes; Geriatrics & Gerontology; Public Health, Health Services & Primary Care; Primary Care

Contact Details
----------------------------------------------
NIA
7201 Wisconsin Avenue
Bethesda, MD 20814
Tel: +1 301 402 4156
Email: kingjo@nia.nih.gov

EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R21)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its call on the effects of cannabis use and cannabinoids on the developing brain (R21). This R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans.

This FOA uses the R21 exploratory and developmental grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-163 and PA-14-164, which use the R01 research project grant mechanism and the R03 small research grant mechanism respectively.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.
Ref: PA-14-162.

Closing date: 16 Feb 16

Deadline information: Applications due by 5pm proposer’s local time every 16 February, 16 June and 16 October until 8 May 2017.
Posted date: 27 Mar 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:

Application form:
http://www.grants.gov/web/grants/applicant s/download-application-package.html#download=true?oppNum=PA-14-162

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Psychology; Drug & Substance Abuse; Public Health, Health Services & Primary Care; Cognitive Processes; Pharmacokinetics; Neuroscience; Diagnostic Sciences; Primary Care; Central Nervous System; Neurology
**EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R03)**
NIH: National Institute on Drug Abuse

**Description:**
The National Institute on Drug Abuse invites applications for its call on the effects of cannabis use and cannabinoids on the developing brain (R03). This R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans.

This FOA uses the R03 small research grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-162 and PA-14-163, which use the R21 exploratory/developmental grant mechanism and the R01 research project grant mechanism respectively.

US and foreign for-profit or non-profit organisations and public or private institutions may apply.

Direct costs are limited to US$100,000 over a two-year project period, with no more than US$50,000 in any year.

Ref: PA-14-164.

**Closing date:** 16 Feb 16
**Deadline information:** Applications due by 5pm proposer’s local time every 16 February, 16 June and 16 October until 8 May 2017.

**Posted date:** 27 Mar 14
**Award type:** Directed grants to institutions, research groups etc
**Award amount max:** $100,000


**Eligibility profile**
----------------------------------------------
Country of applicant institution: Any

**Disciplines**
----------------------------------------------
Neurology; Pharmacokinetics; Primary Care; Public Health, Health Services & Primary Care; Neuroscience; Psychology; Diagnostic Sciences; Drug & Substance Abuse; Central Nervous System; Cognitive Processes

**Contact Details**
----------------------------------------------
NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: +1 301 435 4649
Email: wudy@mail.nih.gov
ADVANCING RESEARCH IN VOICE DISORDERS (R21)
NIH: National Institute on Deafness and other Communication Disorders

Description:
The National Institute on Deafness and Other Communication Disorders invites applications for its advancing research in voice disorders (R21) grants. The purpose of this R21 funding opportunity is to focus on advancing the scientific knowledge of the human larynx and human voice production in health and disease and optimal ways to prevent, evaluate, diagnose and clinically manage voice disorders. This is to support the development of novel ideas, technologies, or methodologies at an early stage of development which have the potential to break new ground or extend toward new directions or applications. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply. The combined budget for direct costs for the two year project period may not exceed US$275,000. No more than US$200,000 may be requested in any single year. The total project period may not exceed two years.

Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-235.html

Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Speech & Language Therapy; Clinical Medicine; Physiology; Allied Health Professions; Primary Care; Public Health, Health Services & Primary Care; Speech Pathology & Disorders; Prosthetic & Orthotic Devices

Contact Details
NIDCD
Division of Extramural Research
Executive Plaza South, Room 400C
6120 Executive Boulevard, MSC 7180
Rockville, MD 20892-7180
Tel: +1 301 496 5061
Email: shekiml@nidcd.nih.gov

HIGH THROUGHPUT SCREENING (HTS) TO DISCOVER CHEMICAL PROBES (R21)
NIH: National Institutes of Health

Description:
The National Institutes of Health invite applications for its high throughput screening (HTS) to discover chemical probes (R21). This R21 funding opportunity aims to encourage investigators to form collaborations with an...
established academic, nonprofit, or commercial high throughput screening facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. The call intends to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH Institutes; discovery or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease targets and processes. Discovery research will mainly support HTS implementation and hit validation.

Any higher education institution, non-profit organisation, for-profit organisation, businesses, governments and foreign institutions may apply.

Funding covers the total direct costs of US$275,000 over a R21 two-year period for each award, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PAR-14-283 (replaces PAR-12-058).

Closing date: 16 Feb 16
Deadline information: Applications open on 5 September 2014 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2017.

February, 16 June and 16 October until 8 September 2017.
Posted date: 18 Jul 14
Award type: Directed grants to institutions, research groups etc, Publish, edit, translate, disseminate, Networking/collaboration
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-283.html
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile

Country of applicant institution: Any

Disciplines

In Vitro Biology; Animal Models; Biological Sciences; Pathogenesis; Tissue Culture; Analytical Chemistry; Chemistry; Chemotherapy; Physiology; Diagnostic Sciences; Biochemistry & Molecular Biology; Medicinal Chemistry; Molecular Probes; Drug Resistance

Contact Details

NIH
6701 Rockledge Drive, Room 1040 - MSC 7710
Bethesda, MD 20892-7710
Tel: +1 301 435 0714
Email: grantsinfo@nih.gov

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R03)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institutes of Health invites applications for their patient safety in the context of perinatal, neonatal and paediatric care programme. This R03 funding opportunity announcement encourages collaborative research projects related to patient safety in the context of perinatal, neonatal and paediatric care both in routine
hospital settings and in the intensive care units. Proposals may address:

- the epidemiology of errors and adverse events in neonatal and paediatric care hospital units;
- medication errors;
- diagnostic errors;
- procedure-related errors;
- human factor and fatigue;
- promotion of a safety culture;
- other working conditions and systems issues;
- risk reduction and disclosure practices.

Eligibility is unrestricted. This funding opportunity uses the NIH small grant (R03) mechanism and runs in parallel with one of identical scientific scope, PA-14-312, which solicits applications under the NIH research project grant (R01) mechanism.

Funding is worth up to US$50,000 per year for a maximum project period of two years. Ref: PA-14-313 (replaces PAR-11-226).

Closing date: 16 Feb 16
Deadline information: Applications are invited from 16 September 2014 and are due by 5pm local time of applicant organisation.
Posted date: 07 Aug 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $100,000
Website:

Application form:
http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-313

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Medical Research of Selected Fields; Paediatric Nursing; Allied Health Professions; Medical Effectiveness & Patient Outcomes; Medical & Diagnostic Tests; Health Systems, Risk Management; Standards of Care; Psychology; Hospitalisation; Quality of Care; Patient Care & Education; Safety & Accident Investigation; Paediatrics; Health Psychology; Law; Nursing; Clinical Decision-making & Analysis; Health Informatics; Neonatal Disorders; Medical Informatics & Telemedicine; Maternal Health; Public Health & Medical Law; Health Professions; Pregnancy & Birth; Primary Care; Business & Management Studies; Public Health, Health Services & Primary Care

Contact Details
----------------------------------------------
NIH
Pregnancy and Perinatology Branch
Eunice Kennedy Shriver National Institute of Child and Human Development
6100 Executive Blvd, 4B03D
Bethesda MD 20892
Tel: +1 301 435 6873
Fax: +1 301 496 3790
Email: kosomari@mail.nih.gov
SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R21)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its secondary analyses of existing alcohol epidemiology data (R21) grants. These R21 grants support investigator-initiated research projects that either analyse previously collected data in order to address key issues that have emerged from recent findings in alcohol epidemiology and prevention research, or develop new analytic techniques for conducting studies in alcohol epidemiology and prevention research. The goal is to enhance understanding of patterns of alcohol consumption and the epidemiology of alcohol-related problems.

This funding opportunity announcement uses the NIH exploratory/developmental research grant (R21) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-338 that encourages applications under the research project grant (R01) mechanism and PA-14-337 that encourages applications under the small grant programme (R03) mechanism.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Grants are worth up to US$275,000 in direct costs over a maximum period of two years. No more than US$200,000 may be requested in any single year. Ref: PA-14-336.

Closing date: 16 Feb 16
Posted date: 10 Sep 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
---------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------
Primary Care; Economic & Social Environment; Psychology; Addiction; Aetiology; Traumatology, Accidents & Injury; Public Health, Health Services & Primary Care; Clinical Medicine; Education; Behavioural Studies & Social Problems; Chronic Care; Epidemiology; Alcoholism; Allied Health Professions

Contact Details
---------------------------------------------------
NIAAA
6000 Executive Boulevard
Willco Building
Bethesda, MD 20892-7003
Tel: +1 301 443 0633
Fax: +1 301 443 6077
Email: zhaw@mail.nih.gov
SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R21)
NIH: National Institute of Nursing Research

Description:
A total of three participating institutes and centres of the National Institutes of Health invite applications for their self-management for health in chronic conditions (R21) grants. These R21 grants support research in self-management focused across conditions. Projects should address the Institute of Medicine’s recommendation for crosscutting, coordinated public health actions for living well with chronic illness, by describing an initiative that focuses on self-management as a mainstream science in order to reduce the burden of chronic illnesses or conditions.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

This FOA will use the NIH exploratory and developmental grant (R21) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-344 that encourages applications under the research project grant(R01) mechanism and PA-14-345 that encourages applications under the academic research enhancement award (R15) mechanism.

The combined budget for direct costs for the two-year project period may not exceed US$275,000. No more than US$200,000 in direct costs may be requested in any single year. The maximum project period is two years.
Ref: PA-14-343.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation on every 16 February, 16 June and 16 October until 8 January 2018.

Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-343.html
Application form: http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-343

Eligibility profile
Country of applicant institution: Any

Disciplines
Public Health, Health Services & Primary Care; Quality of Care; Health Systems Policy; Medical Informatics & Telemedicine; Clinical Medicine; Primary Care; General Practice; Economic & Social Environment; Health Systems; Chronic Care; Clinical Decision-making & Analysis; Health Informatics; Libraries & Information Science; Access to Health Care; Medical Effectiveness & Patient Outcomes; Disease Control; Standards of Care; Social Work & Social Policy; Home Health Care Services

Contact Details
NINR
NIH
31 Center Drive, Room 5B10
Bethesda MD 20892-2178
Tel: +1 301 594 5970
Email: hussk@mail.nih.gov
NIH: National Institute of Dental and Craniofacial Research

IDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY PLANNING GRANT (R34)

Description:
The National Institute of Dental and Craniofacial Research invites applications for its NIDCR clinical trial or biomarker clinical validation study planning grant (R34) call. This R34 call for funding supports activities to develop a draft clinical protocol, the clinical investigators brochure, tools for data and quality management, safety and operational oversight plans, recruitment and retention strategies, a study team and other essential documents.

US and foreign for-profit and non-profit organisations and public and private organisations may apply. This funding opportunity uses the NIH planning grant (R34) mechanism and runs in parallel with two opportunities of identical scientific scope, PAR-14-342, which solicits applications under the same mechanism (R34) and PAR-11-339, which solicits applications under the NIH research project cooperative agreement (U01) mechanism.

Direct costs may not exceed US$150,000 over a period of one year.

Ref: PAR-14-346 (replaces PAR-11-338).

Closing date: 16 Feb 16
Deadline information: Applications due by 5pm applicant’s local time every 16
February, 16 June and 16 October until 8 September 2017.

Posted date: 22 Sep 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $150,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-346.html
Application form: http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Oral Medicine; Drug Design; Biochemical Markers; Diagnostic Sciences; Public Health, Health Services & Primary Care; Craniofacial Disorders; Biological Markers & Sensor Mechanisms; Dental Health & Hygiene; Clinical Medicine; Dentistry

Contact Details
----------------------------------------------
NIH NIDCR
Public Information and Liaison Branch
45 Center Drive, MSC 6400
Bethesda MD 20892-6400
Tel: +1 301 435 7908
Email: jatkinso@mail.nih.gov
Description:
The National Institute of Dental and Craniofacial Research and the National Institute of Biomedical Imaging and Bioengineering invite applications for their biology of the temporomandibular joint in health and disease (R21) grants. This R21 funding opportunity encourages research that advances understanding of the temporomandibular joint in health and disease, and aims to stimulate research focused on the biology of joint function and the tissues that make up the joint. Focus areas include:

- bone;
- muscle;
- cartilaginous and ligamentous tissues;
- vascularisation and innervation;
- models;
- measurement of joint health, disease and functions.

This funding opportunity uses the NIH research project (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-14-358, which solicits applications under the NIH exploratory and developmental grant (R01) mechanism. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

Funding is worth up to US$275,000 over two years, and projects may request no more than US$200,000 per year.

Ref: PA-14-359.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation, every 16 February, 16 June and 16 October until 8 September 2017.

Posted date: 06 Oct 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:
Application form:
http://www.grants.gov/web/grants/applicantpackage.html#download=true?oppNum=PA-14-359

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Primary Care; Muscle Diseases; Connective Tissue; Osteoporosis & Other Bone Diseases; Public Health, Health Services & Primary Care; Movement Disorders; Physiology; Musculoskeletal System; Clinical Medicine; Diagnostic Sciences; Human Biological Sciences; Orthopaedic Surgery; Bone Cancers; Cardiology; Disease Models

Contact Details
---------------------------------------------------------------
NIH: National Institute of Dental and Craniofacial Research
Public Information and Liaison Branch
45 Center Drive, MSC 6400
Bethesda MD 20892-6400
Tel: +1 301 594 9898
Email: jasonwan@mail.nih.gov
BIOBEHAVIOURAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R21)

NIH: National Institutes of Health

Description:
The National Institutes of Health, under the National Institute of Nursing Research and the National Institute on Aging, invite applications for their biobehavioural and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia grants. These R21 grants aim to stimulate clinical research focused on biobehavioural or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment, or disease or age-related cognitive decline. Particular interest is on the following:

- interventions that can be implemented in community settings by the affected individual, informal caregivers or others in the community;
- research to inform the development of the type of interventions identified above;
- research that examines underlying mechanisms and biomarkers associated with response to interventions.

This funding opportunity uses the R21 exploratory or developmental grant mechanism that seeks to foster the introduction of novel scientific ideas, model systems, tools, agents, targets and technologies that have the potential to substantially advance biomedical research. The opportunity runs in parallel with two opportunities of identical scientific scope; PA-15-017, which solicits applications under the R01 research project grant mechanism, and PA-15-016, which solicits applications under the R15 academic research enhancement award mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

Grants cover direct costs up to a maximum of US$275,000 over a period of up to two years.

Ref: PA-15-015.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation on every 16 February, 16 June and 16 October until 8 January 2018. Deadlines on: 16 February 2016, 16 June 2016, 16 October 2016, and repeated annually.

Posted date: 15 Oct 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $275,000
Application form: http://grants.nih.gov/grants/guide/ApplyButonSplash.cfm

Eligibility profile
-----------------------------
Country of applicant institution: Any

Disciplines
-----------------------------
Neurology; Diagnostic Sciences; Medical Effectiveness & Patient Outcomes; Primary Care; Clinical Medicine; General Practice; Cognitive Processes; Alzheimer’s Disease & Senile Dementia; Health Economics; Public
Research on Eosinophil Associated Disorders (R21)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases, the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Diabetes and Digestive and Kidney Diseases invite applications for their research on eosinophil associated disorders grants. These R21 grants encourage research aimed at elucidating the pathophysiology of eosinophil-associated disorders and clarifying the cellular and molecular mechanisms underlying the role of eosinophil leukocytes in these conditions. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these studies.

This funding opportunity uses the R21 exploratory or developmental research grant mechanism and runs in parallel with one of identical scientific scope, PA-15-027, which solicits applications under the R01 research project grant mechanism.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US$275,000 for direct costs. No more than US$200,000 may be requested in any single year. The maximum project period is two years. Ref: PA-15-028.

Closing date: 16 Feb 16
Deadline information: Applications are invited between 16 January and 5pm local time of applicant organisation on every 16 February, 16 June and 16 October until 8 May 2018. Deadlines on: 16 February 2016, 16 June 2016, 16 October 2016, and repeated annually.
Posted date: 12 Nov 14
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award budget total: -

Eligibility profile

Country of applicant institution: Any

Disciplines

Pathology; Cell & Developmental Biology; Biological Markers & Sensor Mechanisms;
DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R03)
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its diabetes and cardiovascular disease in older adults (R03) grants.

These R03 grants encourage basic, clinical and epidemiological outcomes research on the impact of age on the development of, diagnosis and management of diabetes and cardiovascular disease complications in older persons or animal models. Research supported by this initiative is expected to elucidate the role of ageing mechanisms that underlie the increased vulnerability of older adults to DM and its CVD complications and to provide evidence-based guidance to improve more appropriate diagnostic criteria, risk stratification and intervention recommendations to prevent the onset, or improve short- and long-term outcomes, of DM and CVD in older persons.

This funding opportunity uses the R03 small grant programme mechanism and runs in parallel with two of identical scientific scope, PA-15-037, which solicits applications under the R01 research project grant mechanism and PA-15-038, which solicits applications under the R21 exploratory and developmental research grant mechanism. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US$100,000 for direct costs over a maximum project period of two years. No more than US$50,000 may be requested in any single year.

Ref: PA-15-039.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 January 2018.

Posted date: 20 Nov 14
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Website:
Application form:

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Cardiovascular Diseases; Diabetes; Geriatrics & Gerontology

Contact Details
----------------------------------------------
GWY BG Room 3C307
7201 Wisconsin Avenue
Bethesda MD 20814
Tel: +1 301 496 6761
Email: susan.zieman@nih.gov

DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R21)
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its diabetes and cardiovascular disease in older adults (R21) grants.

These R21 grants encourage basic, clinical and epidemiological outcomes research on the impact of age on the development of, diagnosis and management of diabetes and cardiovascular disease complications in older persons or animal models. Research supported by this initiative is expected to elucidate the role of ageing mechanisms that underlie the increased vulnerability of older adults to DM and its CVD complications and to provide evidence-based guidance to improve more appropriate diagnostic criteria, risk stratification and intervention recommendations to prevent the onset, or improve short- and long-term outcomes, of DM and CVD in older persons.

This funding opportunity uses the R21 exploratory and developmental research grant mechanism and runs in parallel with two of identical scientific scope, PA-15-037, which solicits applications under the R01 research project grant mechanism and PA-15-039, which solicits applications under the R03 small grant programme mechanism. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Application budgets are limited to US$275,000 for direct costs over a maximum project period of two years. No more than US$200,000 may be requested in any single year.

Ref: PA-15-038.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 January 2018.
Posted date: 20 Nov 14
Award type: Directed grants for individual investigators, Innovation grants
Award amount max: $275,000


Eligibility profile
----------------------------------------------
Country of applicant institution: Any
INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): PHARMACODYNAMICS AND IN VIVO EFFICACY STUDIES FOR SMALL MOLECULES AND BIOLOGICS/BIOTECHNOLOGY PRODUCTS (R21/R33)

NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its innovation grants to nurture initial translational efforts (IGNITE): pharmacodynamics and in vivo efficacy studies for small molecules and biologics or biotechnology products (R21/R33) funding opportunity announcement. This announcement provides funding to conduct pharmacodynamics, pharmacokinetics and in vivo efficacy studies to demonstrate that proposed therapeutic agents have sufficient biological activity to warrant further development to treat neurological disorders. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity uses the NIH phased innovation award (R21/R33) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-070, which also solicits applications under the NIH phased innovation award (R21/R33) grant mechanism.

Application budgets are limited to US$750,000 over the maximum combined project period of three years, with a maximum of US$250,000 for the R21 phase and US$500,000 for the R33 phase. The R21 and R33 cannot be awarded in the same fiscal year.

Ref: PAR-15-071.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 January 2018.
Posted date: 15 Dec 14
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $750,000

Eligibility profile
Country of applicant institution: Any
INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): ASSAY DEVELOPMENT AND THERAPEUTIC AGENT IDENTIFICATION AND CHARACTERISATION TO SUPPORT THERAPEUTIC DISCOVERY (R21/R33)

NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its innovation grants to nurture initial translational efforts (IGNITE): assay development and therapeutic agent identification and characterisation to support therapeutic discovery (R21/R33) funding opportunity announcement. This announcement encourages research to develop in vitro or ex vivo assays and conduct iterative screening efforts to identify and characterise potential therapeutic agents for neurological disorders.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This FOA uses the NIH phased innovation award (R21/R33) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-071, which also solicits applications under the NIH phased innovation award (R21/R33) grant mechanism.

Application budgets are limited to US$750,000 over the maximum combined project period of three years, with a maximum of US$250,000 for the R21 phase and US$500,000 for the R33 phase. The R21 and R33 cannot be awarded in the same fiscal year.

Ref: PAR-15-070.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 January 2018.
Posted date: 15 Dec 14
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $750,000


Eligibility profile
Country of applicant institution: Any
Disciplines
Neurology
Contact Details
NSC BG Room 2106
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 496 1779
Email: amir.tamiz@nih.gov
PREVENTION RESEARCH IN MID-LIFE ADULTS (R21)
NIH: National Institute of Nursing Research

Description:
The National Institute on Nursing Research and the National Institute on Ageing invite applications for their prevention research in mid-life adults (R21) funding opportunity announcement. This announcement encourages research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimise health and wellness as individuals age and prevent illness and disability in later years. This FOA particularly encourages interventions that can be delivered in multiple settings. Studies in disparate groups, such as African American, Native American and Hispanic populations who have a greater prevalence of illness related to multiple chronic conditions, are especially needed. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-098, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The combined application budget is limited to US$275,000 in direct costs over a two-year period. No more than US$200,000 may be requested in any single year.

Ref: PA-15-097.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 May 2015 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 May 2018.
Posted date: 23 Jan 15
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Geriatric Nursing; Preventive Medicine; Geriatrics & Gerontology; Health of Minority Groups

Contact Details
NINR
BG 1Dem Room 717
6701 Democracy Boulevard
Bethesda MD 20817
Tel: +1 301 594 2154
Email: mary.roary@nih.gov
REDUCTIONS IN ILLICIT DRUG USE AND FUNCTIONAL OUTCOMES (R21/R33)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its reductions in illicit drug use and functional outcomes (R21/R33) funding opportunity announcement. This announcement encourages research that determines whether reductions in illicit drug use are associated with positive changes in health-related and other functional outcomes in individuals with substance use disorders. Functional outcomes include, for example, reductions in morbidity, mortality, criminal justice involvement and overall healthcare expenditures.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

This FOA provides up to US$275,000 for direct costs for up to two years for research planning activities and feasibility studies (R21 phase). This may be followed by transition to expanded research support (R33 phase), for which up to US$1.5 million is available to cover direct costs for up to three years. The transition to the R33 phase will be determined by NIH programme evaluation of successful achievement of the milestones set for the R21 phase.

Ref: PA-15-099.

Closing date: 16 Feb 16

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2017.

Posted date: 26 Jan 15

Award type: Directed grants to institutions, research groups etc

Award budget total: -


Eligibility profile
Country of applicant institution: Any
Disciplines
Smoking & Tobacco; Drug & Substance Abuse; Alcoholism; Health Promotion

Contact Details
NSC BG Room 4131
6001 Exectutive Boulevard
Rockville MD 20852
Tel: +1 301 443 8639
Email: imontoya@mail.nih.gov
NOVEL BIOMARKERS FOR THE DEVELOPMENT OF HIV INCIDENCE ASSAYS WITH IMPROVED SPECIFICITY (R21)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its HIV incidence assays with improved specificity (R21) funding opportunity announcement. This announcement supports projects that seek to develop novel biomarkers and improved HIV incidence assays and algorithms, with increased specificity for distinguishing incident from chronic HIV infections.

Biomarkers may be based on evolution of specific viral parameters or host responses in the first year after HIV infection. Additionally, method development for using the biomarkers to identify incident cases in a highly accurate, cost effective assay, may be supported.

This funding opportunity uses the exploratory and developmental research (R21) grant mechanism that supports early and conceptual stages of such projects. The opportunity runs in parallel with an announcement of identical scientific scope, PA-15-105, which solicits applications under the research project (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to US$275,000 in direct costs over a maximum period of two years.
Ref: PA-15-106.

Closing date: 16 Feb 16

Deadline information: Applications open on 7 April 2015 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 January 2018.
Posted date: 30 Jan 15
Award type: Research calls for business, Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: $275,000


Eligibility profile
-------------------------------
Country of applicant institution: Any

Disciplines
-------------------------------
Biological Markers & Sensor Mechanisms; Biochemical Markers; HIV/AIDS; Infection Agents & Pathogens

Contact Details
-------------------------------
NIAID
Building 5601FL
Room 8C29
5601 Fishers Lane
Rockville MD 20852
Tel: +1 240 292 4809
Email: usharma@niaid.nih.gov
EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R03)
NIH: National Cancer Institute

Description:
The National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Environmental Health Sciences invite applications for their early-life factors and cancer development in later life (R03) funding opportunity announcement. This announcement stimulates research focused on the role of early-life factors in cancer development in later life. A better understanding is sought in the following areas:

- early-life factors that are associated with later cancer development, with early-life including maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and adult years;
- how early-life factors mediate biological processes relevant to carcinogenesis;
- whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies.

This announcement uses the R03 small grant programme mechanism, which supports pilot or feasibility studies, secondary analysis of existing data, small and self-contained research projects, the development of research methodology or the development of new research technology. The announcement also runs on parallel with two announcements of identical scientific scope; PA-15-126, which uses the R01 research project grant mechanism, and PA-15-125, which uses the R21 exploratory or developmental research grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. The principal investigator should attend an NCI-sponsored two-day meeting, generally held every second year in the Washington DC area.

Awards are worth up to US$100,000 each in direct costs over a maximum period of two years.


Closing date: 16 Feb 16
Deadline information: Applications open on 16 May 2015 and are due by 5pm local time of applicant organisation on every 16 February, 16 June and 16 October until 8 January 2018. Deadlines on: 16 February 2016, 16 June 2016, 16 October 2016, and repeated annually.
Posted date: 27 Feb 15
Award type: Technology innovation/development, Research calls for business, Directed grants to institutions, research groups etc, Innovation grants, Academic-Industry links, Networking/collaboration
Award amount max: $100,000
Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=274816

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Cancer Studies & Oncology
EARLY-LIFE FACTORS AND CANCER DEVELOPMENT LATER IN LIFE (R21)

NIH: National Cancer Institute

Description:
The National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Environmental Health Sciences invite applications for their early-life factors and cancer development in later life (R21) funding opportunity announcement. This announcement stimulates research focused on the role of early-life factors in cancer development in later life. A better understanding is sought in the following areas:

- early-life factors that are associated with later cancer development, with early-life including maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and adult years;
- how early-life factors mediate biological processes relevant to carcinogenesis;
- whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies.

This announcement uses the R21 exploratory or developmental grant mechanism and runs on parallel with two announcements of identical scientific scope; PA-15-126, which uses the R01 research project grant mechanism, and PA-15-124, which uses the R03 small grant programme mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply. The principal investigator should attend an NCI-sponsored two-day meeting, generally held every second year in the Washington DC area.

Awards are worth up to US$275,000 each in direct costs over a maximum period of two years.

Ref: PA-15-125.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 May 2015 and are due by 5pm local time of applicant organisation on every 16 February, 16 June and 16 October until 8 January 2018. Deadlines on: 16 February 2016, 16 June 2016, 16 October 2016, and repeated annually.
Posted date: 27 Feb 15
Award type: Research calls for business, Directed grants to institutions, research groups etc, Academic-Industry links, Networking/collaboration
Award amount max: $275,000
Award amount min: -
Award budget total: -
Application form:
http://www.grants.gov/view-opportunity.html?dpp=1&oppId=274785

Eligibility profile
--------------------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------------------------------------------
Cancer Studies & Oncology

FUNCTIONAL WELLNESS IN HIV – MAXIMISING THE TREATMENT CASCADE (R21)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research and the Office of Behavioral and Social Sciences Research invite applications for their functional wellness in HIV – maximising the treatment cascade (R21) funding opportunity announcement. This announcement encourages the development of HIV interventions that target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV. Projects should include strategies and interventions that aim to:

- improve functional wellness and increase quality of life in HIV positive individuals;
- determine barriers and facilitators to entering and maintaining HIV care;
- validate the construct of functional wellness;
- develop and test methods to improve entrance and continuance in HIV care.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-133, which solicits applications under the NIH research project (R01) grant mechanism.

The combined budget for direct costs over the two-year project period may not exceed US$275,000, with no more than US$200,000 requested in any single year. The maximum project period is two years.
Ref: PA-15-134.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 May 2015 and are due by 5pm local time of applicant organisation every 16 June, 16 October and 16 February until 8 May 2018.
Posted date: 06 Mar 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:
PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN KIDNEY DISEASES (R21)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its pilot and feasibility clinical research grants in kidney diseases (R21) funding opportunity announcement. This announcement supports small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney diseases research.

Studies should address important clinical and translational questions that are potentially of high clinical and public health impact.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-162, which also solicits applications under the R21 mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs with a maximum of US$200,00 in direct costs per year. The maximum project period is two years.


Closing date: 16 Feb 16
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organisation on every 16 February, 16 June and 16 October until 8 May 2018.
Posted date: 30 Mar 15
Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000

Application form:
http://www.grants.gov/web/grants/applicant
s/download-application-package.html#search=true&oppNum=PAR-15-161

Eligibility profile
Country of applicant institution: Any
MMUNE SYSTEM PLASTICITY IN THE PATHOGENESIS AND TREATMENT OF
COMPLEX DENTAL, ORAL, AND CRANIOFACIAL DISEASES (R21)
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its immune system plasticity in the pathogenesis and treatment of complex dental, oral, and craniofacial diseases (R21) funding opportunity announcement. This announcement supports contemporary, systematic research to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral and craniofacial diseases as well as to develop novel tools and technologies to treat and prevent disease based on precise modulation of the immune system. Plasticity, for the purposes of this initiative, is defined as the ability of the immune system to undergo changes in both characteristics and functions in response to the environment.

Clinical trials are not supported.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-192, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs with up to US$200,000 in direct costs per year.

The maximum project period is two years.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 September 2015 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2018.
Posted date: 29 Apr 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Website:

Application form:
http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276222

Eligibility profile
Country of applicant institution: Any

Disciplines
Endodontics; Restorative Dentistry; Periodontics; Craniofacial Disorders; Oral Medicine; Preventive Dentistry; Dental Health
STUDIES AT PERIVIABLE GESTATION (R03)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its studies at periviable gestation (R03) funding opportunity announcement. This announcement supports research that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants. The scope of this FOA includes the following areas:

- knowledge gaps in obstetrical care practices at periviable gestations;
- knowledge gaps in neonatal care at periviable gestations;
- research needs concerning family counseling.

This funding opportunity uses the NIH small grant programme (R03) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-198, which solicits applications under the NIH exploratory or developmental (R21) grant mechanism and PA-15-200, which solicits applications under the NIH research project (R01) grant mechanism.

Application budgets are limited to a total of US$100,000 in direct costs with up to US$50,000 in direct costs per year.

The maximum project period is two years.
Ref: PA-15-199.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October, until 8 September 2018.
Posted date: 05 May 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276312

Eligibility profile
Country of applicant institution: Any

Disciplines
 Foetal Health & Prenatal Development; Family & Relationships Counselling; Pregnancy & Birth; Obstetrics & Gynaecology
S

TUDIES AT PERIVIABLE GESTATION (R21)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its studies at periviable gestation (R21) funding opportunity announcement. This announcement supports research that will provide an evidence base to guide therapies and treatment at periviable gestational age for both mothers and their infants. The scope of this FOA includes the following areas:

- knowledge gaps in obstetrical care practices at periviable gestations;
- knowledge gaps in neonatal care at periviable gestations;
- research needs concerning family counseling.

This funding opportunity uses the NIH exploratory or developmental (R21) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-199, which solicits applications under the NIH small grant programme (R03) grant mechanism and PA-15-200, which solicits applications under the NIH research project ((R01) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs with up to US$200,000 in direct costs per year.

The maximum project period is two years.


Closing date: 16 Feb 16
Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October, until 8 September 2018.

Posted date: 05 May 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276320

Eligibility profile

Country of applicant institution: Any

Disciplines

Pregnancy & Birth; Obstetrics & Gynaecology; Foetal Health & Prenatal Development; Family & Relationships Counselling
HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R03)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its human studies to evaluate promising medications to treat alcohol use disorder (R03) funding opportunity announcement. This announcement encourages applications that use human laboratory paradigms or clinical trials to evaluate the safety and efficacy of novel or repurposed compounds, that bind to new targets, for treatment of alcohol use disorder or AUD with a comorbid post-traumatic stress disorder.

This funding opportunity uses the NIH small grant programme (R03) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-256 and PA-15-254, which solicit applications under the NIH research project (R01) grant mechanism and the NIH exploratory/developmental (R21) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$100,000 in direct costs with up to US$50,000 in direct costs per year.

The maximum project period is two years. Ref: PA-15-255.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 May 2018.
Posted date: 14 May 15
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award amount max: $100,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Alcoholism; Post Traumatic Stress Disorder

Contact Details
BG 5635FL Room 2041
5635 Fishers Lane
Rockville MD 20852
Tel: +1 301 443 0636
Email: rlitten@mail.nih.gov
HUMAN STUDIES TO EVALUATE PROMISING MEDICATIONS TO TREAT ALCOHOL USE DISORDER (R21)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its human studies to evaluate promising medications to treat alcohol use disorder (R21) funding opportunity announcement. This announcement encourages applications that use human laboratory paradigms or clinical trials to evaluate the safety and efficacy of novel or repurposed compounds, that bind to new targets, for treatment of alcohol use disorder or AUD with a comorbid post-traumatic stress disorder.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with two announcements of identical scientific scope, PA-15-255 and PA-15-256, which solicit applications under the NIH small grant programme (R03) grant mechanism and the NIH research project (R01) grant mechanism respectively.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are limited to a total of US$275,000 in direct costs with up to US$200,000 in direct costs per year.

The maximum project period is two years.
Ref: PA-15-254.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 May 2018.
Posted date: 14 May 15
Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Application form: http://www.grants.gov/view-opportunity.html?dpp=1&oppId=276516

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Alcoholism; Post Traumatic Stress Disorder

Contact Details
-----------------------------------------------
BG 5635FL Room 2041
5635 Fishers Lane
Rockville MD 20852
Tel: +1 301 443 0636
Email: rlitten@mail.nih.gov
PILOT SERVICES RESEARCH GRANTS NOT INVOLVING INTERVENTIONS (R34)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health (NIMH) invites participants for its pilot services research grants that are not involving interventions (R34). This R34 call aims to encourage pilot research consistent with NIMH priorities for services research studies that are not immediate precursors to the development and testing of services interventions. These areas include:

- studies to identify mutable factors that impact access, utilisation, quality, financing, outcomes including disparities in outcomes, or scalability of mental health services, which may serve as targets in future intervention development;
- development and testing of new research tools, measures, or methods;
- testing of the feasibility of integrating existing data sets to understand factors affecting access, quality or outcomes of care.

Higher education institutions, for-profit organisations, non-profit organisation, governments, independent school districts, public housing authorities, native American tribal organisations, faith-based or community-based organisations, regional organisations and non-domestic entities may apply for this call.

Direct costs are limited to US$450,000 over the project period, with no more than US$225,000 in direct costs allowed in any one year.

Ref: PAR-15-323.

Closing date: 16 Feb 16
Deadline information: Applications are invited between 16 September 2015 and are due by 5pm local time of applicant organisation, every 16 October, 16 February and 16 June until 8 September 2018.
Posted date: 07 Aug 15
Award type: Research calls for business, Directed grants for individual investigators, Directed grants to institutions, research groups etc, Academic-Industry links
Award amount max: $450,000
Application form: [https://sam.gov/](https://sam.gov/)

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Mental Health; Health Systems

Contact Details
----------------------------------------------
Tel: +1 301 443 8811
Email: djuliano@mail.nih.gov
END-OF-LIFE AND PALLIATIVE NEEDS OF ADOLESCENTS AND YOUNG ADULTS WITH SERIOUS ILLNESSES (R21)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research, the National Cancer institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Office of Research on Women’s Health invite applications for their end-of-life and palliative needs of adolescents and young adults with serious illnesses (R21) funding opportunity announcement. This announcement aims to foster research on the unique perspectives, needs, wishes and decision-making processes of adolescents and young adults with serious, advanced illnesses. This also supports research focused on specific end-of-life and palliative care models that support the physical, psychological, spiritual and social needs of AYA with serious illness as well as their families and caregivers. The objective is to encourage clinical studies aimed at:

- increasing this knowledge base;
- the development of AYA-appropriate measurement tools;
- the design, testing and evaluation of AYA-specific EOLPC models of care and interventions that positively impact health related quality of life for AYA with serious illness and their family and caregivers.

This funding opportunity uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-15-324, which solicits applications under the NIH research project (R01) grant mechanism.

US and foreign for-profit, non-profit and public and private organisations may apply.

Application budgets may not exceed US$275,000 over the maximum project period of two years. No more than US$200,000 may be requested in any single year.

Ref: PA-15-325.

Closing date: 16 Feb 16
Deadline information: Applications open 16 January, 2016 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 January, 2019.
Posted date: 10 Aug 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Hospice & Palliative Care; Adolescent Paediatrics; Palliative Nursing; Child & Adolescent Psychiatry; Youth & Adolescents

Contact Details
----------------------------------------------
Tel: +1 301 594 8911
Email: lynn.adams@nih.gov
PERSONALISED STRATEGIES TO MANAGE SYMPTOMS OF CHRONIC ILLNESS (R21)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for its personalised strategies to manage symptoms of chronic illness (R21) funding opportunity announcement. This announcement aims to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life in persons with chronic illness through increasing knowledge of the biological mechanisms of symptoms and promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms. The research objectives are to:

- examine complex adaptive symptoms related to bio-behavioural and environmental interactions that underlie symptom evolution to include change over time;
- identify and validate novel biomarkers and other patient risk factors to assess individual susceptibility to physical, cognitive and affective symptoms and serve as surrogate endpoints for evaluating clinical benefit of targeted interventions;
- develop computer-simulated dynamic models that result in strategies to address individual heterogeneity related symptoms, clusters and patterns;
- develop and test targeted scalable interventions to prevent and mitigate symptoms and clusters to include examination of omics and genetic factors that predict response to interventions;
- examine large databases and electronic health records to discover new biologic, clinical, psychosocial, behavioural and economic factors related to symptom burden and health-related quality of life experienced by persons with chronic illness and new patterns and trends that may translate to targeted interventions.

This funding opportunity uses the NIH exploratory and developmental research (R21) grant mechanism and runs in parallel with two of identical scientific scope, PA-16-007 and PA-16-006, which solicits applications under the NIH research (R01) project grant mechanism and the NIH academic research (R15) enhancement award.

US and foreign for-profit and non-profit organisations and public and private organisations may apply. Interdisciplinary collaborations that include nurse scientists in the team are strongly encouraged.

Application budgets are limited to US$275,000 for the maximum project period of two years. No more than US$200,000 may be requested in any single year.

Ref: PA-16-008.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2016 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 January 2019. Deadlines on: 16 February 2016, 16 June 2016, 16 October 2016, and repeated annually.
Posted date: 19 Oct 15
Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration
Award amount max: $275,000
INNOVATIVE QUESTIONS IN SYMPTOM SCIENCE AND GENOMICS (R21)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for its innovative questions in symptom science and genomics (R21) funding opportunity announcement. This announcement seeks to optimise innovation, insight and cutting edge conceptual and technological breakthroughs by catalysing research that emanates from the identified questions in symptom and genomic nursing science. These innovative questions are reflective of broad domains from which more specific novel hypotheses or problems to be solved can be derived.

Application budgets are limited to US$275,000 and no more than US$200,000 may be requested in any single year. The maximum project period is two years.

Ref: PA-16-023.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2016 and due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 January 2019.

Posted date: 02 Nov 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-16-023.html

Eligibility profile
Country of applicant institution: Any
Disciplines
Genomics; Nursing; Diagnostic Sciences
APPLYING METABOLOMICS TO DRIVE BIOMARKER DISCOVERY IN SYMPTOM SCIENCE (R21)
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research and the National Center for Complementary and Integrative Health invite applications for their applying metabolomics to drive biomarker discovery in symptom science (R21) funding opportunity announcement. This announcement encourages applications on biomarker discovery that utilise metabolomics approaches to advance the understanding, assessment and management of symptoms. Research objectives include:

- identification of biomarkers of symptoms, including fatigue, impaired sleep, pain, nausea, dyspnea and cognitive impairment using metabolomic approaches;
- application of metabolite profiling and biomarker discovery tools to discriminate symptomatic from asymptomatic individuals, differing symptoms and varying symptoms experienced by individuals with similar conditions or illnesses;
- influence of particular metabolite profiles in combination with genetic variants on symptom risk, management and response to treatment;
- assessment of biomarkers as gleaned from metabolomic approaches to facilitate personalised health strategies for symptom management.

This funding opportunity announcement focuses on both preclinical and clinical research.

This funding opportunity uses the NIH exploratory or developmental research (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-030, which solicits applications under the NIH research project (R01) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

The combined budget for direct costs excluding consortia facilities and administration costs for the maximum two year project period is US$275,000. No more than US$200,000 in direct costs may be requested in any single year.

Ref: PA-16-029.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2016 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 January 2019.
Posted date: 04 Nov 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $275,000
Website:
ADVANCING UNDERSTANDING, PREVENTION AND MANAGEMENT OF INFECTIONS TRANSMITTED FROM WOMEN TO THEIR INFANTS (R21)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its advancing understanding, prevention and management of infections transmitted from women to their infants (R21) funding opportunity announcement. This announcement supports research that will increase scientific understanding of and treatments for high-priority perinatal infections. The aim is to stimulate investigations including translational, epidemiologic and clinical studies and trials that improve the understanding, prevention and clinical outcomes of non-HIV infections transmitted from women to their offspring during pregnancy, labour and delivery and breast-feeding.

This funding opportunity uses the NIH exploratory or developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-16-032, which solicits applications under the NIH research project (R01) grant mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are limited to US$275,000 in direct costs for the maximum project period of two years. No more than US$200,000 may be requested in any single year.

Ref: PA-16-031.

Closing date: 16 Feb 16
Deadline information: Applications open on 16 January 2016 and are due by 5pm local time of applicant organisation every 16 February, 16 June and 16 October until 8 September 2019.
Posted date: 06 Nov 15
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-16-031.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Infectious Diseases; Foetal Health & Prenatal Development; Pregnancy & Birth; Infant Paediatrics; Disease Control
UTILISING THE PLCO BIOSPECIMENS RESOURCE TO BRIDGE GAPS IN CANCER AETIOLOGY AND EARLY-DETECTION RESEARCH (U01)

NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its utilising the PLCO biospecimens resource to bridge gaps in cancer aetiology and early-detection research (U01) funding opportunity announcement. This announcement seeks to advance research in cancer aetiology and early-detection biomarkers, using the advantages of the unique biorepository resources of the NCI-sponsored prostate, lung, colorectal and ovarian cancer screening trial. The repository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from trial participants and a one-time collection of buccal cells from the control arm participants.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

Application budgets are not limited, but need to reflect actual needs of the project. The maximum project period is five years.


Closing date: 17 Feb 16

Deadline information: Applications open on 17 January 2016 and are due by 5pm local time of applicant organisation on deadline dates.

Posted date: 15 Jul 15

Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc

Award amount max: -

Award amount min: -

Award budget total: -


Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-036

Eligibility profile

Country of applicant institution: Any

Disciplines

Biological Markers & Sensor Mechanisms;
Lung Cancer; Cancer Diagnosis; Aetiology;
Prostate & Testicular Cancers; Ovarian & Cervical Cancers; Colorectal, Pancreatic & Stomach Cancers

Contact Details

Tel: +1 240 276 7013
Fax: +1 240 276 7848
Email: zhucla@mail.nih.gov
EXPLORATORY CLINICAL TRIALS OF NOVEL INTERVENTIONS FOR MENTAL DISORDERS (R61/R33)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its exploratory clinical trials of novel interventions for mental disorders (R61/R33) funding opportunity announcement. This announcement supports the efficient pilot testing of novel interventions for mental disorders in children and adults, through an experimental therapeutics approach. Trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the intervention. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of the intervention’s engagement of the therapeutic target, possibly followed by up to three years of support (R33 phase) for studies to replicate target engagement and relate change in the intervention target to functional or clinical effects.

This FOA uses the NIH phased innovation award (R61/R33) grant mechanism and runs in parallel with the following FOAs with a similar scientific scope:

- RFA-MH-16-410, which solicits applications under the NIH clinical trial planning (R34) grant mechanism.
- RFA-MH-16-410, which solicits applications under the NIH exploratory/developmental grants phase II (R33) mechanism;
- RFA-MH-16-420 and RFA-MH-16-425, which solicit applications under the NIH research project (R01) grant mechanism;
- RFA-MH-16-415, which solicits applications under the NIH collaborative research project (R01) grant mechanism;
- RFA-MH-16-410, which solicits applications under the NIH clinical trial planning (R34) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget is US$4 million in fiscal year 2016 and US$4m in fiscal year 2017, to fund five to 10 awards per year. Project budgets are not limited, but should reflect the actual needs of the proposed project. The maximum funding period of the combined R61 and R33 phases is five years.


Closing date: 17 Feb 16
Deadline information: Applications open on 27 June and are due by 5pm local time of applicant organisation on 27 July and 14 October 2015 and on 17 February, 15 June and 14 October 2016.
Posted date: 26 May 15
Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants
Award budget total: -

Application form: http://www.grants.gov/web/grants/applicant
download-application-package.html#search=true&oppNum=RFA-MH-16-406

Eligibility profile

Country of applicant institution: Any
Disciplines
----------------------------------------------
Mental Illness; Mental Health

Contact Details
----------------------------------------------
NSC BG Room 7173
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 3633
Email: awagner@mail.nih.gov

EXPLORATORY CLINICAL TRIALS OF NOVEL INTERVENTIONS FOR MENTAL DISORDERS (R33)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its exploratory clinical trials of novel interventions for mental disorders (R33) funding opportunity announcement. This announcement supports the efficient pilot testing of novel interventions for mental disorders in children and adults, through an experimental therapeutics approach. Trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the intervention.

This FOA uses the NIH exploratory/developmental grants phase II (R33) mechanism and runs in parallel with FOA’s with a similar scientific scope, RFA-MH-16-405, which solicits applications under the NIH phased innovation (R21/R33) grant mechanism, RFA-MH-16-420 and RFA-MH-16-425, which solicit applications under the NIH research project (R01) grant mechanism, RFA-MH-16-415, which solicits applications under the NIH collaborative research project (R01) grant mechanism and RFA-MH-16-410, which solicits applications under the NIH clinical trial planning (R34) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget is US$2 million in fiscal year 2016 and US$2m in fiscal year 2017, to fund three to six awards per year. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is three years.


Closing date: 17 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on 14 October 2015, and 17 February, 15 June and 14 October 2016.
Posted date: 31 Mar 15
Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants
Award budget total: $4,000,000
Website:

Application form:
http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275509

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
**Clinical Trials to Test the Effectiveness of Treatment, Preventive and Services Interventions (R01)**

*NIH: National Institute of Mental Health*

**Description:**
The National Institute of Mental Health invites applications for its clinical trials to test the effectiveness of treatment, preventive and services interventions (R01) funding opportunity announcement. This announcement supports investigator-initiated clinical trials to establish the effectiveness of hypotheses regarding moderators, mediators and mechanisms of action of these interventions.

Applications may include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial, device-based, rehabilitative and combination interventions to prevent or treat mental illness. Given the focus on practice-relevant questions in community and practice settings, collaborations between academic researchers and clinical or community practice partners or networks are expected.

This FOA uses the NIH research project (R01) grant mechanism and runs in parallel with FOA’s with a similar scientific scope, RFA-MH-16-405, which solicits applications under the NIH phased innovation (R21/R33) grant mechanism, RFA-MH-16-425, which solicits applications under the NIH research project (R01) grant mechanism, RFA-MH-16-415, which solicits applications under the NIH collaborative research project (R01) grant mechanism, and RFA-MH-16-410, which solicits applications under the NIH clinical trial planning (R34) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget is US$6.5 million in fiscal year 2016 and US$6.5m in fiscal year 2017, to fund seven to ten awards per year. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years; however, projects with a duration of up to four years are strongly encouraged.


**Closing date:** 17 Feb 16

**Deadline information:** Applications due by 5pm local time of applicant organisation on 14 October 2015, and 17 February, 15 June and 14 October 2016.

**Posted date:** 31 Mar 15

**Award type:** Clinical trials, Directed grants to institutions, research groups etc

**Award budget total:** $13,000,000


**Application form:** [http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275515](http://www.grants.gov/view-opportunity.html?dpp=1&oppId=275515)
CLINICAL TRIALS TO TEST THE EFFECTIVENESS OF TREATMENT, PREVENTIVE AND SERVICES INTERVENTIONS (COLLABORATIVE R01)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its clinical trials to test the effectiveness of treatment, preventive and services interventions (collaborative R01) funding opportunity announcement. This announcement supports investigator-initiated clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators and mechanisms of action of these interventions. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA should be used when two or more sites are needed to complete the study.

This FOA uses the NIH the collaborative research project (R01) grant mechanism and runs in parallel with FOAs with a similar scientific scope, RFA-MH-16-400, which solicits applications under the NIH exploratory/developmental grants phase II (R33) mechanism, RFA-MH-16-405, which solicits applications under the NIH phased innovation (R21/R33) grant mechanism, RFA-MH-16-420 and RFA-MH-16-425, which solicit applications under the NIH research project (R01) grant mechanism and RFA-MH-16-410, which solicits applications under the NIH clinical trial planning (R34) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget is US$6.5 million in fiscal year 2016 and US$6.5m in fiscal year 2017, to fund seven to 10 awards per year. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years; however, projects with a duration of up to four years are strongly encouraged.


Closing date: 17 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on 14 October 2015, and 17 February, 15 June and 14 October 2016.
Posted date: 01 Apr 15
Award type: Clinical trials, Directed grants to institutions, research groups etc, Innovation grants, Networking/collaboration Award budget total: $13,000,000
PILOT EFFECTIVENESS TRIALS FOR TREATMENT, PREVENTIVE AND SERVICES INTERVENTIONS (R34)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its pilot effectiveness studies and services research (R34) funding opportunity announcement. This announcement supports effectiveness research on interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings and innovative services research directions that require preliminary testing or development.

Applications should provide resources for evaluating the feasibility, tolerability, acceptability and safety of approaches to improve mental health and modify risk factors, and for obtaining the preliminary data needed as a prerequisite to a larger-scale intervention trial or a large-scale services study.

This FOA uses the NIH planning (R34) grant mechanism and runs in parallel with FOA’s with a similar scientific scope, RFA-MH-16-400, which solicits applications under the NIH exploratory/developmental (R33) grant mechanism, RFA-MH-16-425 and RFA-MH-16-420, which solicit applications under the NIH research project (R01) grant mechanism, RFA-MH-16-415, which solicits applications under the NIH collaborative research project (R01) grant mechanism and RFA-MH-16-405, which solicits applications under the NIH phased innovation award (R21/R33) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget is US$4 million in fiscal year 2016 and US$4m in fiscal year 2017, to fund 12 to 16 awards per year. Direct costs are limited to US$450,000 over the three-year R34 project period, with no more than US$225,000 in any year.


Closing date: 17 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on 14 October 2015, and 17 February, 15 June and 14 October 2016.
CONFIRMATORY EFFICACY CLINICAL TRIALS OF NON-PHARMACOLOGICAL INTERVENTIONS FOR MENTAL DISORDERS (R01)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its confirmatory efficacy clinical trials of non-pharmacological interventions for mental disorders (R01) funding opportunity announcement. This announcement supports confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Trials must be designed so that results will provide information of high scientific utility and will support future decisions about further development or effectiveness testing of a targeted, scaled-up intervention.

This FOA uses the NIH research project (R01) grant mechanism and runs in parallel with FOA’s with a similar scientific scope, RFA-MH-16-405, which solicits applications under the NIH phased innovation (R21/R33) grant mechanism, RFA-MH-16-420, which solicits applications under the NIH research project (R01) grant mechanism, RFA-MH-16-415, which solicits applications under the NIH collaborative research project (R01) grant mechanism, RFA-MH-16-400, which solicits applications under the NIH exploratory/developmental grants phase II mechanism, and RFA-MH-16-410, which solicits applications under the NIH clinical trial planning (R34) grant mechanism.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget is US$4 million in fiscal year 2016 and US$4m in fiscal year 2017, to fund up to four awards per year. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years; however, projects with a duration of up to four years are strongly encouraged.

Closing date: 17 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation on 14 October 2015, and 17 February, 15 June and 14 October 2016.
Posted date: 31 Mar 15
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award budget total: $8,000,000
Application form: http://www.grants.gov/web/grants/applicant

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Mental Health; Mental Illness
Contact Details
----------------------------------------------
Tel: +1 301 443 9233
Email: sarah.morris@nih.gov

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its mechanisms underlying the contribution of type 1 diabetes risk-associated variants (DP3) funding opportunity announcement. This announcement enables institutions or organisations to undertake projects to characterise the genetic variations in human genomic regions that have been putatively associated with T1D and conduct follow-up functional studies of particular genetic variants. Potential research areas include the following:

- human studies;
- comparison of wild type and gene variant functions;
- identification of causal genes or genetic variants;
- non-coding RNAs and regulatory elements;
- epigenetics and epigenomics;
- systems-level approaches.

Eligible applicants include for-profit or non-profit organisations and public or private institutions around the world.

NIDDK intends to commit approximately US$15 million to fund roughly four to five awards in fiscal year 2016. The application budget is limited to a maximum of US$600,000 direct costs, excluding subcontracts, over a maximum period of five years.

Ref: RFA-DK-15-025.

Closing date: 17 Feb 16
Deadline information: Applications are invited between 17 January and 5pm local time of applicant organisation, 17 February 2016.
Posted date: 08 Jul 15
CLINICAL TRIAL READINESS FOR RARE NEUROLOGICAL AND NEUROMUSCULAR DISEASES (U01)

NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its clinical trail readiness for rare neurological and neuromuscular diseases (U01) funding opportunity announcement. This announcement supports clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers or by characterising cohorts of relevant patients. The goal is to accelerate the initiation of clinical trials for rare diseases and to increase the likelihood of success in those trials. The studies supported through this call should be clinical observational studies, and no intervention studies are allowed.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

Application budgets are not limited but need to reflect the actual needs of the proposes project. The maximum project period is five years.

Ref: PAR-16-020.

Closing date: 18 Feb 16
Deadline information: Applications open on 18 January 2016 and due by 5pm local time of applicant organisation, 18 February and 18 August 2016, 17 February and 17 August 2017, and 15 February and 17 August 2018.
Posted date: 30 Oct 15
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-16-020.html

Eligibility profile
Country of applicant institution: Any
Disciplines
Neurology; Preventive Medicine; Muscle Diseases
INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS – DEVELOPMENT AND VALIDATION OF MODEL SYSTEMS AND PHARMACODYNAMIC MARKERS TO FACILITATE THE DISCOVERY OF NEUROTHERAPEUTICS (R21/R33)

NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke and the National Institute on Drug Abuse invite applications for their innovation grants to nurture initial translational efforts – development and validation of model systems and pharmacodynamic markers to facilitate the discovery of neurotherapeutics (R21/R33) funding opportunity announcement. This announcement aims to develop and validate animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. The goal is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, testing paradigms and endpoints that will be utilised to facilitate the development of neurotherapeutics. Applications that have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings are sought after.

This funding opportunity uses the NIH phased innovation (R21/R33) award mechanism and runs in parallel with two of identical scientific scope, PAR-15-070 and PAR-15-071, which solicit applications under the same mechanism.

Eligible applicants include US and foreign for-profit or non-profit organisations and public or private institutions.

NINDS intends to commit up to US$750,000 per year to fund nine awards in fiscal years 2016 to 2018. Direct costs are limited to US$250,000 per year regardless of grant phase. The project period is limited to three years, with no more than two years in either phase.

Ref: RFA-NS-16-013.

Closing date: 18 Feb 16
Deadline information: Applications are due by 5pm local time of applicant organisation on 18 February, 21 June and 18 October 2016, and 21 February, 21 June and 18 October 2017.
Posted date: 04 Nov 15
Award type: Directed grants to institutions, research groups etc, Innovation grants
Award amount max: $750,000
Award amount min: -
Award budget total: $2,250,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
MALL GRANTS PROGRAMME FOR CANCER RESEARCH (R03)

NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its small grants programme for cancer research (R03). This R03 funding opportunity announcement supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology and development of new research technology.

This funding opportunity will use the small grant programme (R03) mechanism, and runs in parallel with an FOA of identical scientific scope, PAR-13-146, which solicits applications under the exploratory/developmental (R21) award mechanism.

Applicants may request direct costs of up to US$50,000 per year over a two-year project period. Domestic and foreign for-profit or non-profit organisations and public or private institutions are eligible to apply.

Ref: PAR-14-007 (replaces PAR-12-144).

Closing date: 26 Feb 16
Deadline information: Applications due by 5pm local time of applicant organisation.

Posted date: 22 Nov 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-007.html

Application form: http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PAR-14-007

Eligibility profile
Country of applicant institution: Any

Disciplines
Project Management & Resource Allocation; Colorectal, Pancreatic & Stomach Cancers; Data Analysis; Cancer Immunology; Diagnostic Sciences; Leukaemia & Other Blood Cancers; Oncology Nursing; Human Biological Sciences; Cancer Studies & Oncology; Ovarian & Cervical Cancers; Nursing; Economics & Econometrics; Cancer Cell Biology; Lung Cancer; Carcinogenesis; Breast Cancer; Physiology; Clinical Medicine; Molecularly Targeted Therapy; Prostate & Testicular Cancers; Primary Care; Computer Science & Informatics; Non-cancerous...
Tumours; Melanoma & Other Skin Cancers; Brain Cancer; Medical Research of Selected Fields

Contact Details

----------------------------------------------
NCI
6120 Executive Boulevard
Bethesda, MD 20892-7150
Tel: +1 301 496 7800

ICKLE CELL DISEASE IN SUB-SAHARAN AFRICA: DATA COORDINATING CENTRE

NIH: National Heart, Lung and Blood Institute

Description:
The National Heart, Lung and Blood Institute invites applications for its sickle cell disease in sub-Saharan Africa: data coordinating centre (U24) funding opportunity announcement. This announcement seeks applications that propose to develop a sickle cell disease in sub-Saharan Africa data coordinating centre that will support the activities of the SCD in SSA collaborative consortium. Applications that propose a comprehensive plan to provide overall project coordination, administration, data management and biostatistical support are of high interest.

This funding opportunity uses the NIH research project (U24) resource-related research projects – cooperative agreements mechanism and runs in parallel with one of identical scientific scope, RFA-HL-17-006 using the same mechanism.

Eligible applicants include African for-profit or non-profit organisations and public or private institutions.

The NHLBI intends to commit up to total costs of US$853,200 for fiscal year 2017, US$972,000 for fiscal year 2018, US$900,000 in FY2019 and US$740,000 in FY2020. The maximum project period is four years.

Ref: RFA-HL-17-007.

Closing date: 26 Feb 16
Deadline information: Applications open on 26 January and are due by 5pm local time of applicant organisation on 26 February 2016.
Posted date: 02 Sep 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-17-007.html

Eligibility profile

Country of applicant institution: All African Nations

Disciplines

Blood Diseases

Contact Details

Tel: +1 301 435 0080
Email: norma.lerner@nih.gov
ICKLE CELL DISEASE IN SUB-SAHARAN AFRICA: COLLABORATIVE CONSORTIUM (U24)  
NIH: National Heart, Lung and Blood Institute

Description:
The National Heart, Lung and Blood Institute invites applications for its sickle cell disease in sub-Saharan Africa: collaborative consortium (U24) funding opportunity announcement. This announcement solicits applications that propose to develop a sickle cell disease in sub-Saharan Africa collaborative consortium. The collaborative consortium will be responsible for developing an infrastructure upon which a future SCD in SSA research network can be built, comprised of a consortium hub and at least two collaborating sites located in SSA countries separate from that of the applicant institution. This programme is intended to establish an SCD resource that can be shared across the collaborative consortium to enhance future research endeavours. Applications that propose a feasible plan for developing a sickle hemoglobinopathy database that can facilitate patient tracking and serve as a backbone for future SCD in SSA research network operations are of high programmatic interest.

This funding opportunity uses the NIH research project (U24) resource-related research projects – cooperative agreements mechanism and runs in parallel with one of identical scientific scope, RFA-HL-17-007, using the same mechanism.

Eligible applicants include foreign sub-Saharan African for-profit or non-profit organisations and public or private institutions.


Ref: RFA-HL-17-006.

Closing date: 27 Feb 16
Deadline information: Applications open on 26 January and are due by 5pm local time of applicant organisation on 26 February 2016.
Posted date: 02 Sep 15
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award amount max: -
Award amount min: -
Award budget total: -

Eligibility profile
--------------------------------------------------------
Country of applicant institution: Sub-Saharan Africa

Disciplines
--------------------------------------------------------
Blood Diseases

Contact Details
--------------------------------------------------------
Tel: +01 301 435 0080
Email: norma.lerner@nih.gov
IDENTIFICATION OF GENETIC AND GENOMIC VARIANTS BY NEXT-GEN SEQUENCING IN NON-HUMAN ANIMAL MODELS (U01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its identification of genetic and genomic variants by next-gen sequencing in non-human animal models (U01) funding opportunity announcement. This announcement aims to identify gene variants of traits associated with addiction and substance abuse in selectively bred, and outbred non-human animal models using methodologies of next gen-sequencing, mapping and genotyping.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. Applicants requesting US$500,000 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application.

Ref: PAR-15-120 (reissue of PAR-14-010).

Closing date: 01 Mar 16
Deadline information: Applications open on 30 May and are due by 5pm local time of applicant organisation on 30 June and 20 October 2015, 1 March, 30 June and 20 October 2016, 1 March, 30 June and 20 October 2017 and 1 March 2018.
ROLE OF THE MICROFLORA IN THE AETIOLOGY OF GASTROINTESTINAL CANCER (R01)

NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its role of the microflora in the aetiology of gastrointestinal cancer grants. This funding opportunity aims to support innovative multidisciplinary R01 research projects that will advance mechanistic understanding of microflora influences on gastrointestinal carcinogenesis. An additional goal of this programme is to encourage collaborative efforts between scientists currently engaged in gastrointestinal cancer research with those in scientific disciplines that may not otherwise apply their expertise to study cancer aetiology and prevention.

Investigators from the disciplines of microbiology, microbial ecology, molecular biology, immunology, nutrition sciences, bioinformatics and computational sciences are particularly encouraged to apply. Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed five years.

Ref: PAR-14-242 (replaces PAR-12-140).

Closing date: 03 Mar 16
Deadline information: Applications due by 5pm local time of applicant organisation on every 4 November and 3 March until 4 March 2017.

Posted date: 04 Jun 14
Award type: Directed grants to institutions, research groups etc
Award amount max: -
Award amount min: -
Award budget total: -
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Gastroenterology; Microbiology; Diagnostic Sciences; Aetiology; Biochemistry & Molecular Biology; Cancer Immunology; Immunology; Clinical Medicine; Cancer Studies & Oncology; Inflammation; Carcinogenesis; Biological Sciences; Cancer Cell Biology

Contact Details
----------------------------------------------
NIH: National Cancer Institute
6116 Executive Boulevard
Suite 300
Bethesda, MD 20892-8322
Tel: +1 240 276 6227
Email: daschnep@mail.nih.gov
IMPACT OF THE USE OF GLUCOSE MONITORING AND CONTROL TECHNOLOGIES ON HEALTH OUTCOMES AND QUALITY OF LIFE IN OLDER ADULTS WITH TYPE 1 DIABETES (T1D) (DP3)

NIH: National Institutes of Health

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for its impact of the use of glucose monitoring and control technologies on health outcomes and quality of life in older adults with type 1 diabetes (T1D) (DP3) research award. This announcement encourages applications from organisations proposing clinical studies of the use of current and emerging technologies for monitoring of blood glucose and insulin administration in older adults with T1D. Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions. Research should seek to develop information addressing efficacy, safety, quality of life and cost when these devices are used in older adults with T1D to identify strategies to improve management of T1D in this segment of the population. This announcement solicits well-designed, prospective studies to determine whether higher frequency of self-monitoring of blood glucose, use of continuous glucose monitors and or combination of sensing and insulin delivery devices in an open or closed loop system may contribute to better outcomes in older adults with T1D. The NIDDK intends to commit US$10 million in fiscal year 2016 to fund three to five awards. The maximum direct costs for each award are US$2.5m over a maximum period of five years.

Ref: RFA-DK-15-028.

Closing date: 03 Mar 16
Deadline information: Applications are invited between 3 February and 5pm local time of applicant organisation, 3 March 2016.
Posted date: 28 Sep 15
Award type: Directed grants to institutions, research groups etc
Award amount max: $2,500,000
Award amount min: -
Award budget total: $10,000,000
Website:

Eligibility profile

Country of applicant institution: Any

Disciplines

Diabetes

Contact Details

Tel: +1 301 594 4724
Email: arreazag@mail.nih.gov

RESEARCH USING BIOSAMPLES AND SUBJECTS FROM TYPE 1 DIABETES CLINICAL STUDIES - COMPLICATIONS (DP3)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its research using biosamples and subjects from type 1 diabetes clinical studies - complications (DP3) funding
opportunity announcement. This announcement supports collaborative projects using subjects and their samples from clinical studies of type 1 diabetes to better understand the pathogenesis of diabetes complications in humans and to develop biomarkers for the evaluation of new therapeutics for diabetes complications. The aim is to accelerate the pace of scientific research towards prevention and treatment of the complications of type 1 diabetes by providing opportunities to utilise resources from clinical studies on type 1 diabetes.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

The NIDDK intends to commit US$5 million in fiscal year 2016 to fund three to five awards. Application budgets are limited to US$1m in direct costs for the maximum project period of three years. Facilities and administration costs to be determined at the time of the award.

Ref: RFA-DK-15-019.

Closing date: 03 Mar 16
Deadline information: Applications are invited between 3 February and 5pm local time of applicant organisation, 3 March 2016.
Posted date: 09 Oct 15
Award type: Directed grants for individual investigators, Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: $5,000,000

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Preventive Medicine; Diabetes

Contact Details
---------------------------------------------------------------
Tel: +1 301 435 2996
Email: jonester@mail.nih.gov

PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R01)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institutes of Health invites applications for their patient safety in the context of perinatal, neonatal and paediatric care programme. This R01 funding opportunity announcement encourages collaborative research projects related to patient safety in the context of perinatal, neonatal and paediatric care both in routine hospital settings and in the intensive care units. Proposals may address:

- the epidemiology of errors and adverse events in neonatal and paediatric care hospital units;
- medication errors;
- diagnostic errors;
- procedure-related errors;
- human factor and fatigue;
- promotion of a safety culture;
- other working conditions and systems issues;
- risk reduction and disclosure practices.
Eligibility is unrestricted. This funding opportunity uses the NIH research project grant (R01) mechanism and runs in parallel with one of identical scientific scope, PA-14-313, which solicits applications under the NIH small grant (R03) mechanism.

Applicants requesting US$500,000 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. The total project period may not exceed five years.

Ref: NIH PA-14-312 (replaces PAR-11-225).

Closing date: 05 Mar 16
Deadline information: Applications are invited from 5 September 2014 and are due by 5pm local time of applicant organisation.
Posted date: 07 Aug 14
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-312.html
Application form: http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-312

Eligibility profile

Disciplines

Country of applicant institution: Any
Psychology; Paediatrics; Nursing; Standards of Care; Patient Care & Education; Law; Medical Research of Selected Fields; Medical & Diagnostic Tests; Safety & Accident Investigation; Health Psychology; Medical Effectiveness & Patient Outcomes; Hospitalisation; Public Health, Health Services & Primary Care; Allied Health Professions; Quality of Care; Paediatric Nursing; Business & Management Studies; Maternal Health; Health Informatics; Neonatal Disorders; Clinical Decision-making & Analysis; Health Systems, Risk Management; Medical Informatics & Telemedicine; Public Health & Medical Law; Primary Care; Pregnancy & Birth; Health Professions

Contact Details

NIH
Pregnancy and Perinatology Branch
Eunice Kennedy Shriver National Institute of Child and Human Development
6100 Executive Blvd, 4B03D
Bethesda MD 20892
Tel: +1 301 435 6873
Fax: +1 301 496 3790
Email: kosomari@mail.nih.gov

INTEGRATED PRECLINICAL AND CLINICAL AIDS VACCINE DEVELOPMENT PROGRAMME (U19)  
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its integrated preclinical and clinical Aids vaccine development programme (U19) funding opportunity announcement. This announcement aims to facilitate the translation of sufficiently advanced, innovative and promising vaccine candidates into early clinical testing.
The programme enables a multidisciplinary team of investigators to complete all steps necessary from down-selection of a vaccine candidate through Committee for Medicinal Products for Human Use manufacture, testing and product release, and into clinical trials.

Awards provide the critical resources to allow the advancement of vaccine concepts to clinical trials within the project period of the award. However, funds for conducting the clinical studies are not provided and applicants are encouraged to collaborate with NIAID-supported clinical networks, or to develop other relationships to support the clinical studies. Preclinical research applications alone are not sufficient for this announcement.

US and foreign for-profit and non-profit organisations and public and private organisations may apply.

NIH intends to commit approximately US$2.8 million in fiscal year 2017 to fund one to two awards. Application budgets are expected to be between US$1.5m and US$2.5m per year. The maximum project period is five years. Investigators are expected to begin clinical studies by the end of the award.


Closing date: 09 Mar 16
Posted date: 17 Aug 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -

Eligibility profile

Country of applicant institution: Any
Disciplines
Immunisation Programmes & Vaccination; Preventive Medicine; HIV/Aids

Contact Details
Tel: +1 301 435 3749
Email: mpensiero@niaid.nih.gov

ADVANCED CLINICAL TRIALS TO TEST ARTIFICIAL PANCREAS DEVICE SYSTEMS IN TYPE 1 DIABETES (UC4)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its advanced clinical trials to test artificial pancreas device systems in type 1 diabetes (UC4) funding opportunity announcement. The purpose of this announcement is to support the conduct of advanced clinical trials designed to test the outpatient clinical safety and efficacy of artificial pancreas device systems in type 1 diabetes with the objective of improving glycemic control, reducing acute and chronic complications, and improving quality of life. Trials should generate data able to satisfy safety and efficacy requirements by regulatory agencies regarding the clinical testing of AP device systems. Any clinical trial
proposed must meet the following criteria:

- it must be supported by strong clinical preliminary data that justifies pursuing the trial;
- the trial must have a well-defined and clinically important outcome demonstrating improvement of management of type 1 diabetes;
- it must include a clinical diabetes measure;
- it should have a well justified choice of comparator therapy;
- it may also have improvement of quality of life and measurement of psychosocial impact as important outcomes using validated metrics;
- a target population of patients with type 1 diabetes is required;
- the study should be performed in the actual use, real-world environment and by the intended use population;
- the study should be conducted with an advanced AP-device system for which approval may be sought and should be designed to demonstrate the safety and effectiveness of the complete system in the intended use population;
- it should include a data management unit with experience in processing continuous glucose monitoring and artificial pancreas data.

Domestic and foreign for-profit and non-profit organisations and public or private institutions are eligible to apply.

NIDDK intends to commit up to US$20 million in fiscal year 2016 to fund one to three awards. The application budget is limited to a maximum of US$16m direct costs for the entire project period of five years excluding subcontracts. Budgets are expected to vary depending on the actual needs of the proposed project.

Ref: RFA-DK-16-008 (replaces RFA-DK-14-024).

Closing date: 09 Mar 16
Deadline information: Applications open on 9 February and are due by 5pm local time of applicant organisation on 9 March 2016.
Posted date: 03 Sep 15
Award type: Clinical trials, Directed grants to institutions, research groups etc
Award amount max: $16,000,000
Award amount min: -
Award budget total: $20,000,000
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-16-008.html
Application form:

Eligibility profile

Country of applicant institution: Any

Disciplines

Chronic Care; Nephrology & Kidneys; Diabetes; Pathophysiology; Hormones & Endocrinology; Gastroenterology; Medical Devices

Contact Details

Tel: +1 301 594 4724
Email: arreazag@mail.nih.gov
EXPLORATION OF THE ROLES OF BROWN AND BEIGE ADIPOSE TISSUE IN HUMANS (R01)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its exploration of the roles of brown and beige adipose tissue in humans (R01) funding opportunity announcement. This announcement is intended for investigations of the biological functions of brown and beige adipose tissue in humans, other than heat production and maintenance of body temperature, and to explore their impact on human health.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions as well as higher education institutions.

NIDDK intends to commit up to US$2 million in the fiscal year 2016 to fund three to six awards. Application budgets are not limited. The maximum project period is three years.

Ref: RFA-DK-15-031.

Closing date: 09 Mar 16

Deadline information: Applications open on 9 February and are due by 5pm local time of applicant organisation, 9 March 2016.
Posted date: 30 Jun 15
Award type: Directed grants to institutions, research groups etc
Award budget total: -
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-15-031.html#_Section_II._Award_1

Eligibility profile
Country of applicant institution: Any

Disciplines
Tissue Culture; Connective Tissue; Tissue Engineering

Contact Details
Tel: +1 301 594 7689
Email: haftc@mail.nih.gov

INTEGRATIVE NEUROSCIENCE INITIATIVE ON ALCOHOLISM (INIA) CONSORTIA (COLLABORATIVE U01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its integrative neuroscience initiative on alcoholism consortia (collaborative U01) funding opportunity announcement. This FOA solicits collaborative research projects applications to participate in two consortia under the Integrative Neuroscience Initiative on Alcoholism (INIA). Continuing support is sought for integrated, multidisciplinary, collaborative research projects studying neuronal mechanisms of excessive alcohol intake associated with alcohol dependence. One focus of the initiative will be to examine brain immune signaling mechanisms
promoting and controlling excessive alcohol consumption. A second focus will be to examine enduring consequences of stress challenges on adaptations in brain circuitry leading to excessive drinking and to altered stress responsiveness. An additional emphasis to be promoted within this initiative is the identification of drugable genomic targets to lay the foundations for new treatments for alcohol dependence. As in prior years, projects supported under this initiative are expected to integrate approaches at the molecular, cellular, synaptic, physiological and behavioural level of analysis.

Any individuals with the skills, knowledge and resources necessary to carry out the proposed research as programme directors or principal investigators is invited to work with his or her organisation to develop an application. Research projects should be collaborative and highly integrated within each INIA consortium. Eligible applicants include both domestic and foreign public and private institutions as well as non-profit and for-profit organisations.

An amount of US$9.2 million in the financial year 2017 is committed for this FOA and companion FOAs. On this, US$5.8m is to be committed for a consortium focused on neuroimmune mechanisms and US$3.4m for a consortium focused on stress and alcohol dependence. The maximum project period is five years.

Ref: RFA-AA-16-004.

Closing date: 10 Mar 16
Deadline information: Applications open on 10 February and are due by 5pm local time of applicant organisation on 10 March 2016.
Posted date: 28 Sep 15
Award type: Directed grants to institutions, research groups etc,
Networking/collaboration
Award budget total: -
Website: 
Application form: http://grants.nih.gov/grants/guide/redirect.htm?id=11128

Eligibility profile
Country of applicant institution: Any
Disciplines
Alcoholism; Neuroscience

Contact Details
National Institute on Alcohol Abuse and Alcoholism
Tel: +1 301 594 6382
Email: megli@mail.nih.gov

INTEGRATIVE NEUROSCIENCE INITIATIVE ON ALCOHOLISM CONSORTIA (COLLABORATIVE U01)  
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its integrative neuroscience initiative on alcoholism consortia (collaborative U01) funding opportunity announcement. This announcement supports integrated, multidisciplinary, collaborative research projects studying neuronal mechanisms of excessive alcohol intake associated with alcohol dependence. This initiative focuses on examining brain immune signalling
mechanisms promoting and controlling excessive alcohol consumption as well as examining enduring consequences of stress challenges on adaptations in brain circuitry leading to excessive drinking and to altered stress responsiveness. This FOA solicits co-operative agreements to participate in two consortia under the Integrative Neuroscience Initiative on Alcoholism. Projects should be collaborative.

This funding opportunity uses the NIH research project (U01) co-operative agreements mechanism and runs in parallel with two of identical scientific scope, RFA-AA-16-005 and RFA-AA-16-006, which solicits applications under the NIH resource-related research (U24) project mechanism.

Eligible applicants include domestic and foreign for-profit or non-profit organisations and public or private institutions.

NIAAA intends to commit US$9.2 million in fiscal year 2017 for this FOA and companion FOAs RFA-AA-16-005 and RFA-AA-16-006. Of this US$9.2m, US$5.8m is to be committed for a consortium focused on neuroimmune mechanisms and US$3.4m for a consortium focused on stress and alcohol dependence. NIAAA expects to fund up to 15 applications.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: RFA-AA-16-004

Closing date: 10 Mar 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Posted date: 22 Sep 15
Award type: Directed grants to institutions, research groups etc,
Networking/collaboration
Award budget total: $9,200,000
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-AA-16-004.html

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Stress, Psychological; Alcoholism

Contact Details
---------------------------------------------------------------
Tel: +1 301 594 6382
Email: megli@mail.nih.gov

CELL IMMUNOLOGY PROGRAMME FOR HIV-1 VACCINE DEVELOPMENT (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its B cell immunology programme for HIV-1 vaccine development (R01) funding opportunity announcement. This announcement supports basic and preclinical research and the analysis of clinical samples to identify and evaluate parameters critical for programming desired B cell functions.

The objective is to encourage multidisciplinary teams to explore and exploit emerging knowledge about the complexities and developmental plasticity of B cells, at vaccine priming and at response recall, that
are associated with the induction of potent and durable adaptive immune responses against HIV-1. Applications submitted in response must propose hypothesis-driven research with the goal of defining biological mechanisms of immune response. Novel approaches based on recently identified molecular markers or pathways of immunological relevance are especially encouraged.

US and foreign for-profit and non-profit organisations and public or private institutions may apply.

NIAID intends to commit US$2 million in fiscal year 2017 to fund two to three awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: RFA-AI-15-055.

Closing date: 17 Mar 16
Deadline information: Applications are invited between 17 February and 5pm local time of applicant organisation, 17 March 2016.

Post date: 22 Oct 15
Award type: Directed grants to institutions, research groups etc, Networking/collaboration
Award budget total: $2,000,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Preventive Medicine; Immunisation Programmes & Vaccination; HIV/AIDS; Humoral Immunity & Immunochemistry

Contact Details
----------------------------------------------
Tel: +1 240 292 6130
Email: amalaspina@niaid.nih.gov

GRAND OPPORTUNITY IN MEDICATIONS DEVELOPMENT FOR SUBSTANCE-USE DISORDERS (U01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its grand opportunity in medications development for substance-use disorders (U01). This U01 funding opportunity announcement will support a diverse array of preclinical and clinical projects to accelerate the development of medication for the treatment of substance-use disorders. The goal is to fund medication studies that will have a high impact and quickly yield the necessary results to advance medications closer to approval by the US Food and Drug Administration. The aim is to enable critical medications development studies that would not be possible using traditional means.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

The NIH intends to commit US$10 million to fund two to three awards in fiscal year 2013. Application budgets are limited to US$5m a year over a three-year period. PAR-13-270
Closing date: 28 Mar 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Posted date: 12 Jul 13
Award type: Directed grants to institutions, research groups etc
Award amount max: $15,000,000

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-270

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Primary Care; Pharmacy & Pharmacology; Clinical Medicine; Drug Design; Clinical Pharmacy & Pharmacology; Diagnostic Sciences; Human Biological Sciences; Pharmaceutical Drugs; Drug & Substance Abuse; Public Health, Health Services & Primary Care

Contact Details
----------------------------------------------
Division of Pharmacotherapies and Medical Consequences of Drug Abuse
NIDA
NIH
9000 Rockville Pike
Bethesda, MD 20892
Tel: +1 301 443 8639
Email: imontoya@mail.nih.gov

TRATEGIC ALLIANCES FOR MEDICATIONS DEVELOPMENT TO TREAT SUBSTANCE USE DISORDERS (R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its strategic alliances for medications development to treat substance use disorders (R01). The purpose of this R01 funding opportunity announcement is to support research that advances compounds towards US Food and Drug Administration approval by leveraging NIDA funds with the strengths and resources of outside organisations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations and small businesses. Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project.

Applications may be submitted by foreign or domestic for-profit and non-profit organisations and public and private organisations.

Application budgets for direct costs may be up to $3 million per year, but need to reflect the actual needs of the proposed project. The maximum period of support is three years.

PAR-13-334 (Reissue of PAS-12-122).

Closing date: 28 Mar 16
Deadline information: Applications due by 5pm local time of applicant organisation.
Deadlines on: 27 March 2014, 28 July 2014, 27
FAST-TRACK DEVELOPMENT OF MEDICATIONS TO TREAT CANNABIS USE DISORDERS (UG3/UH3)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its fast-track development of medications to treat cannabis use disorders (UG3/UH3) funding opportunity announcement. This announcement aims to accelerate the discovery and development of medications to treat cannabis use disorders. Studies should focus on the following topics:

- new chemical entities;
- already-marketed pharmacotherapies
- biologics, for example immunotherapies such as vaccines and antibodies, enzymes and gene therapies;
- combinations of medication or new delivery devices and technologies.

The UG3/UH3 phase innovation awards cooperative agreement involves two phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the two-year period. The UH3 is to provide funding for three years to a project that successfully completed the milestones set in the UG3. Investigators responding to this FOA must address both UG3 and UH3 phases.

US and foreign for-profit and non-profit organisations and public and private organisations are eligible to apply.

The total budget of US$3 million for fiscal year 2016 funds three awards. Application budgets are limited to US$1m in directs costs per year. The maximum project period is two years for the UG3 phase and three years for the UH3 phase.


Closing date: 28 Mar 16
Posted date: 28 May 15
Award type: Directed grants to institutions, research groups etc, Academic-Industry links
Award amount max: $1,000,000
Award amount min: -
Award budget total: -

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Drug Design; Methods of Drug Delivery; Drug & Substance Abuse

**Contact Details**

NSC BG Room 4131
6001 Executive Boulevard
Rockville MD 20852
Tel: +1 301 443 8639
Email: imontoya@mail.nih.gov